

Contents

CONTRIBUTORS	vii
PREFACE	ix

Organometallic Complexes of Boron, Silicon, and Phosphorus Analogues of Azoles

ALEXANDER P. SADIMENKO

I. Introduction	2
II. Complexes of Di- and Triborolyl Ligands	3
III. Complexes of Thiaborolyl Ligands	19
IV. Complexes of Azaborolyl Ligands	21
V. Complexes of Silicon Analogues of Imidazol-2-ylidenes	24
VI. Complexes of Azaphospholes	26
VII. Complexes of Di- and Triphospholes and Corresponding Phosphorus-Antimony Ligands	30
VIII. Complexes of Pentaphospholes	43
IX. Miscellaneous	47
X. Conclusions	48
References	49

Heterocyclic Mesomeric Betaines and Analogs in Natural Product Chemistry. Betainic Alkaloids and Nucleobases

ANDREAS SCHMIDT

I. Introduction	68
II. Mesomeric Betaines	79
III. Zwitterionic Alkaloids	138
IV. Conclusions	155
References	156

Recent Development in the Chemistry of Pyrido-oxazines, Pyrido-thiazines, Pyrido-diazines and Their Benzologs.

Part 2

ISTVÁN HERMECZ

I. Introduction	175
II. Pyrido[2,1- <i>b</i>][1,3]oxazines and Their Benzologs	177

III. Pyrido[2,1- <i>b</i>][1,3]thiazines and Their Benzo Derivatives	190
IV. Pyrido[1,2- <i>a</i>]pyrimidine	195
V. Benzologs of Pyrido[1,2- <i>a</i>]pyrimidine	259
References	266
 Cumulative Index of Authors, Volumes 1–85	 287
Cumulative Index of Titles, Volumes 1–85	303
Cumulative Subject Index, Volumes 81–85	317

Contributors

Numbers in parantheses indicate the pages on which the author's contributions begin.

István Hermecz (173), Chinoin Pharmaceutical and Chemical Works, Ltd., Research Center, Budapest, Hungary

Alexander P. Sadimenko (1), Department of Chemistry, University of Fort Hare, 6 Chatham Road, Baysville, East London 5241, Republic of South Africa

Andreas Schmidt (67), Technical University of Clausthal, Institute of Organic Chemistry, Leibnizstrasse 6, D-38678 Clausthal-Zellerfeld, Germany

Preface

Volume 85 of *Advances in Heterocyclic Chemistry* comprises three chapters and indexes.

The first chapter covers organometallic complexes of boron, silicon, and phosphorus analogs of azoles. This chapter continues the series by A. P. Sadimenko (Fort Hare, South Africa) in which he is treating comprehensively organometallic complexes of heterocyclic compounds. So far, he has covered, in the volumes of AHC indicated, complexes of the following heterocycles:

Thiophenes and furans in volume 77.

Pyrroles, indoles, carbazoles, phospholes, siloles and boroles in volume 79.

Pyrazoles in volume 80.

Pyrazolyl borates in volume 81.

Poly heteroatom azoles other than pyrazole in volume 83.

Taken together, these chapters and those which will follow provide an unparalleled picture of the highly important organometallic complexes of heterocycles which span an enormous diversity of structure.

The second chapter (A. Schmidt, Clausthal, Germany) provides a concise review of heterocyclic mesomeric betaines and their analogs as found in natural products. Finally, I. Hermecz (Budapest, Hungary) provides part two of his survey of pyrido-oxazines, pyrido-thiazines, pyrido-diazines and their benzologs. This encompasses a large variety of heterocycles, many of which are of increasing importance because of their physiological activity. Much of this material has not been reviewed for decades and the subject has advanced enormously in this period.

As an index volume, volume 85 of *Advances in Heterocyclic Chemistry* also includes cumulative indexes of authors and titles of chapters in volumes 1 through 85, together with a cumulative subject index for volumes 81 to 85. Previous cumulative subject indexes have appeared in volumes 60, 70, 75 and 80.

ALAN R. KATRITZKY
Department of Chemistry
University of Florida
Gainesville, Florida

Organometallic Complexes of Boron, Silicon, and Phosphorus Analogues of Azoles

ALEXANDER P. SADIMENKO

*Department of Chemistry, University of Fort Hare, 6 Chatham Road,
Baysville, East London 5241, Republic of South Africa*

I. Introduction	2
II. Complexes of Di- and Triborolyl Ligands	3
A. Iron Group	3
B. Cobalt Group	7
1. Sandwiches and Triple-deckers	7
2. Multidecker Compounds	11
C. Nickel Group	18
III. Complexes of Thiaborolyl Ligands	19
IV. Complexes of Azaborolyl Ligands	21
V. Complexes of Silicon Analogues of Imidazol-2-ylidenes	24
VI. Complexes of Azaphospholes	26
VII. Complexes of Di- and Triphospholes and Corresponding Phosphorus-Antimony Ligands	30
A. Non-Transition Elements	30
B. Chromium and Manganese Groups	31
C. Iron Group	33
D. Cobalt Group	39
E. Nickel Group	41
F. Rare-Earth Elements	43
VIII. Complexes of Pentaphospholes	43
IX. Miscellaneous	47
X. Conclusions	48
References	49

Abbreviations

Ad	adamantyl
Alk	alkyl
AN	acetonitrile
Bu	butyl
CDT	cyclodecatriene
cod	cyclooctadiene-1,5
COE	cyclooctene
Cp	cyclopentadienyl

Cp*	pentamethylcyclopentadienyl
Cy	cyclohexyl
DME	dimethoxyethane
DMF	dimethylformamide
Et	ethyl
Me	methyl
Mes	mesityl
nbd	2,5-norbornadiene
Np	neopentyl
pip	piperidino
OTf ⁻	triflate
Ph	phenyl
Pr	propyl
py	pyridine
TCNE	tetracyanoethylene
TCNQ	7,7,8,8-tetracyano- <i>p</i> -quinodimethane
THF	tetrahydrofuran
TMEDA	tetramethylethylenediamine
TMP	2,2,6,6-tetramethylpiperidine

I. Introduction

Following the forgoing reviews of the classical five-membered heteroaromatic ligands (five-membered monoheterocycles (01AHC(78)1, 01AHC(79)115) and azoles (01AHC(80)157, 01AHC(81)167, 02AHC(83)117, 02AHC(84)191), an analysis is now presented of the trends in the coordination chemistry of azole analogues where nitrogen is replaced by another element. The reason for this is the frequent strikingly different behavior of these compounds as ligands in organometallic complexes. This difference is especially well manifested on comparison of azoles with P,N-ligands as well as with di-, tri-, and pentaphospholes. However, we start our discussion with five-membered heterocycles containing two or three boron heteroatoms (di- and triborolyls), and continue with B,S- and B,N-combinations (thiaborolyls and azaborolyls, respectively), which most often act as the η^5 -donors and form extended multidecker complexes of interest for materials chemistry. For the di- and triborolyl systems we have had to exclude capped and proton-bridged carboranes because of space problems. This exclusion can be justified by the fact that these compounds have been well reviewed as shown in the references below.

Azaphospholes and especially di-, tri- and pentaphospholyl systems offer a wide variety of coordination modes that frequently cannot be found in

azole chemistry. Similarity is found in carbene complexes of the azol-2-ylidene type but in the other respects there is a sharp contrast in the ligand behavior, the reasons for which still deserve detailed theoretical analysis.


II. Complexes of Di- and Triborolyl Ligands

A. IRON GROUP


The di- and triborolyl ligands not only have a clear tendency to form η^5 -coordination but are also able to bind metals from both sides of the heteroring to yield stable multidecker complexes (72SCI462, 75MI1, 76JA3219, 79CCR(28)47, 81IC863, 82MI1, 83AICR55, 85AGE943, 87PAC847, 87PAC947, 90IC516, 91MI1, 91PAC369, 92CRV251, 92MI3, 92OM2397, 93ADOC187, 93CB1587, 93CRV1081, 93JA6143, 93JCLS297, 94MI1, 94MI2, 95CCR(143)71, 95MI1, 95MI2, 95OM4668, 96AOC209, 99JOM(581)1, 99JOM(581)13, 00CCR(200)773). Thus, the $\text{Et}_2\text{C}_2\text{B}_3\text{H}_3^{4-}$ ligand is electronically similar to the cyclopentadienyl anion (88MI1). One of their remarkable features is the stabilization of oxidation states such as iron(III) and ruthenium(III) in the metal arene derivatives (82MI2, 89OM1580, 91OM3545, 92JA5214, 94JA9359).

The triple-decker complex **2** [$\text{ML}_n = \text{M}'\text{L}'_n = \text{Fe}(\eta^5\text{-Cp})$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$] is assumed to be formed via an intermediate sandwich **1** [$\text{ML}_n = \text{Fe}(\eta^5\text{-Cp})$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$] (83OM1666). These two species follow simultaneously from the corresponding 2,3-dihydro-1,3-diborole and $[(\eta^5\text{-Cp})\text{Fe}(\eta^4\text{-cod})]$ (94AGE203, 96CEJ487). 2,3-Dihydro-1,3-diboroles containing the bulkier *iso*-propyl groups when treated with sodium hydride and then $[(\eta^5\text{-Cp})\text{FeCl}]$ gave only the analogue of sandwich **2** containing *i*-Pr-groups instead of Et in the 4 and 5 positions of the heteroring. The corresponding diborolene ligand reacts simultaneously with $[(\eta^5\text{-Cp})\text{Fe}(\text{CO})_2]_2$ and $[(\eta^5\text{-Cp})\text{Co}(\text{CO})_2]$ and the diamagnetic triple-decker 30-valence electron species **2** [$\text{ML}_n = \text{Fe}(\eta^5\text{-Cp})$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Me}$, $\text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp})$] acts analogously (77AGE857). Similar ruthenium complexes **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $\text{R}^1 = \text{R}^3 = \text{Et}$, $\text{R}^2 = \text{Me}$, $\text{R}^4 = \text{R}^5 = i\text{-Pr}$, $\text{R}^2 = \text{Et}$] result from various 2,3-dihydro-1,3-diboroles, sodium hydride, and $[(\eta^5\text{-Cp}^*)\text{RuCl}]$. When 2,3-dihydro-4,5-diethyl-1,3-borole reacts with *tert*-butyl lithium followed by $[(\eta^5\text{-Cp}^*)\text{RuCl}]$, sandwich **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $\text{R}^1 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$, $\text{R}^3 = t\text{-Bu}$] is the product having an unusually folded diborolyl ring (78ZN(B)1410, 94ZN(B)315). 2,3-Dihydro-pentamethyl- and -1,2,3-trimethyl-4,5-diethyl-1,3-diboroles react with sodium hydride and $[(\eta^5\text{-Cp}^*)\text{RuCl}]$ to give the triple-decker compounds **2** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $\text{M}'\text{L}'_n = \text{RuH}(\eta^5\text{-Cp}^*)$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Me}$;


$R^1 = R^3 = R^4 = R^5 = \text{Et}$, $R^2 = \text{Me}$]. Sandwiches **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $R^1 = \text{Et}$, $R^2 = R^3 = R^4 = R^5 = \text{Me}$; $R^1 = R^3 = R^4 = R^5 = \text{Et}$, $R^2 = t\text{-Bu}$] react with carbon monoxide to give **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)(\text{CO})$, $R^1 = \text{Et}$, $R^2 = R^3 = R^4 = R^5 = \text{Me}$; $R^1 = R^3 = R^4 = R^5 = \text{Et}$, $R^2 = t\text{-Bu}$].



The range of the ruthenium sandwiches, their derivatives and stacking products was subsequently extended (99EJIC1685). Thus, some 2,3-dihydro-1,3-diboroles react first with methyllithium and then with $[(\eta^5\text{-Cp}^*)\text{RuCl}]_4$ or $[(\eta^5\text{-C}_5\text{Me}_4\text{Et})\text{RuCl}]_4$ to yield a set of sandwiches **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $\text{Ru}(\eta^5\text{-C}_5\text{Me}_4\text{Et})$, $R^1 = R^2 = R^3 = R^4 = R^5 = \text{Me}$; $\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $R^1 = R^2 = R^3 = \text{Me}$, $R^4 = R^5 = \text{Et}$; $\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $R^1 = R^3 = \text{CH}_2\text{SiMe}_3$, $R^2 = R^4 = R^5 = \text{Me}$; $\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $\text{Ru}(\eta^5\text{-C}_5\text{Me}_4\text{Et})$, $R^1 = R^3 = R^4 = R^5 = \text{Me}$, $R^2 = \text{Et}$]. Similar to the aforementioned reaction with carbon monoxide, sandwiches **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $R^1 = R^4 = R^5 = \text{Et}$, $R^2 = R^3 = \text{Me}$; $R^1 = R^4 = R^5 = \text{Me}$, $R^2 = R^3 = \text{Et}$] add *tert*-butyl isocyanide to give **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)(\text{CNBu}^t)$, $R^1 = R^4 = R^5 = \text{Et}$, $R^2 = R^3 = \text{Me}$; $R^1 = R^4 = R^5 = \text{Me}$, $R^2 = R^3 = \text{Et}$]. Addition of molecular hydrogen can proceed in several directions-towards dihydrogen, $\text{Ru}(\text{H}_2)$, and two types of the dihydride products, $\text{Ru}(\text{H})_2$ and RuH , BH . Existing data favor the $\text{Ru}(\text{H})_2$ series **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)(\text{H})_2$, $R^1 = R^4 = R^5 = \text{Et}$, $R^2 = R^3 = \text{Me}$; $R^1 = R^4 = R^5 = \text{Me}$, $R^2 = R^3 = \text{Et}$]. Products **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)(\text{H})_2$, $R^1 = R^4 = R^5 = \text{Et}$, $R^2 = R^3 = \text{Me}$; $R^1 = R^4 = R^5 = \text{Me}$, $R^2 = R^3 = \text{Et}$] oxidatively add $\text{BH}_3 \cdot \text{THF}$. In this process, reductive elimination of H_2 and rearrangement to *closo*- RuC_3B_3 ruthenacarboranes take place. Sandwich **1** [$\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*)$, $R^1 = R^2 = R^3 = R^4 = R^5 = \text{Me}$] also reacts with $[(\eta^2\text{-C}_2\text{H}_4)_2\text{RhCl}]$ to give the tetranuclear product **3** formulated as a pentadecker species with two central bridging chlorine atoms.




Displacement of cyclooctatetraene from $[(\eta^6\text{-C}_8\text{H}_{10})\text{Fe}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_4)]^-$ in the presence of $[(\eta^5\text{-Cp})\text{Co}(\text{CO})_2]$ gives the iron-cobalt triple-decker species of composition $[(\eta^5\text{-Cp})\text{Fe}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_3)\text{Co}(\eta^5\text{-Cp})]$ (74IC1138, 89JA4776). Complex **4** [$\text{ML}_n = \text{Ru}(\text{CO})_3$, $\text{R}^1 = \text{R}^3 = \text{H}$; $\text{R}^2 = \text{Cl}$, $\text{R}^4 = \text{R}^5 = \text{Et}$] can be prepared as the result of interaction of the dianions $[(\eta^5\text{-Cp}^*)\text{Co}(\eta^5\text{-Et}_2\text{C}_2\text{B}_3\text{H}_2\text{Cl})]^{2-}$ and $[(\text{OC})_3\text{RuCl}_2]_2$. With phenyl lithium and subsequent alkylation with Me_3OBF_4 , species **4** [$\text{ML}_n = \text{Ru}(\text{CO})_3$, $\text{R}^1 = \text{R}^3 = \text{H}$; $\text{R}^2 = \text{Cl}$, $\text{R}^4 = \text{R}^5 = \text{Et}$] is derivatized and gives the Fischer type methoxycarbene compound **5** (92JA8733). *Nido*- $[(\eta^6\text{-cymene})\text{Ru}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_5)]$ is deprotonated with *tert*-butyl lithium in two steps—to the mono- and then the dianion, and the latter reacts with $[(\eta^6\text{-cymene})\text{RuCl}_2]$ to yield the triple-decker **6** [$\text{ML}_n = \text{M}'\text{L}'_n = \text{Ru}(\eta^6\text{-cymene})$; $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$; $\text{R}^4 = \text{R}^5 = \text{Et}$] (89JA4776). The other triple-decker, **6** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$, $\text{M}'\text{L}'_n = \text{Ru}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = \text{R}^5 = \text{Et}$], follows from the reaction of the aforementioned monoanion with sodium cyclopentadienyl and cobalt(II) chloride. Treatment of **6** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$, $\text{M}'\text{L}'_n = \text{Ru}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = \text{R}^5 = \text{Et}$] with ruthenium(III) chloride gives the product of substitution at the triborolyl heterocycle, **6** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$, $\text{M}'\text{L}'_n = \text{Ru}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{H}$, $\text{R}^3 = \text{Cl}$, $\text{R}^4 = \text{R}^5 = \text{Et}$]. The ruthenium-containing starting dianion also reacts with $[(\eta^6\text{-cymene})\text{OsCl}_2]$ to give the corresponding triple-decker **6** [$\text{ML}_n = \text{Os}(\eta^6\text{-cymene})$, $\text{M}'\text{L}'_n = \text{Ru}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = \text{R}^5 = \text{Et}$], which on further interaction with osmium(II) chloride gives the substitution product **6** [$\text{ML}_n = \text{Os}(\eta^6\text{-cymene})$, $\text{M}'\text{L}'_n = \text{Ru}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{H}$, $\text{R}^3 = \text{Cl}$, $\text{R}^4 = \text{R}^5 = \text{Et}$]. *Nido*- $[(\eta^5\text{-Cp})\text{Co}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_5)]$ can also be deprotonated in two steps with *tert*-butyl lithium, and further give the cobalt-osmium triple-decker **6** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$, $\text{M}'\text{L}'_n = \text{Os}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = \text{R}^5 = \text{Et}$] together with some **6** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$, $\text{M}'\text{L}'_n = \text{Os}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{H}$, $\text{R}^3 = \text{Cl}$, $\text{R}^4 = \text{R}^5 = \text{Et}$].




The ruthenium starting materials of composition *nido*- $[(\eta^6\text{-MeC}_6\text{H}_4\text{Pr-}i)\text{Ru}(2,3\text{-Et}_2\text{C}_2\text{B}_3\text{H}_4\text{-5-R})]$ ($\text{R} = \text{Me}, \text{Cl}$) with *tert*-butyl lithium and then


cobalt(II) chloride give the tetradeccker species **7** [$ML_n = M''L''_n = Ru(\eta^6\text{-cymene})$; $M' = CoH$; $R^1 = R^3 = H$; $R^2 = R^{2'} = Me, Cl$; $R^4 = R^5 = Et$] but the methyl derivative could not be isolated (95OM3683). In moist air they are readily converted to a series **7** [$ML_n = M''L''_n = Ru(\eta^6\text{-cymene})$; $M' = Co$; $R^1 = R^3 = H$; $R^2 = R^{2'} = Me, Cl$; $R^2 = Me, R^{2'} = Et$; $R^2 = Cl, R^{2'} = H$; $R^4 = R^5 = Et$]. The methyl-containing starting material after a similar sequence of transformations but with nickel chloride gives the nickel analogue of **7** [$ML_n = M''L''_n = Ru(\eta^6\text{-cymene})$; $M' = Ni$, $R^1 = R^3 = H$; $R^2 = R^{2'} = Me$; $R^4 = R^5 = Et$].



The reaction of $C_5Me_4(C_6H_4)_n(C_5Me_4)$ ($n=1, 2$) with $[(\eta^6\text{-cymene})Ru(Et_2C_2B_3H_4)]^-$ in the presence of cobalt(II) chloride gives **8** ($n=2, 3$) (89JA4784). The reaction of $[C_5H_4-C_5H_4]^{2-}$ with $[(\eta^6\text{-cymene})Ru(Et_2C_2B_3H_4)]$ and $CoCl_2$ forms **9**.



In the complexes of 1,3-boroles containing the unsaturated substituents ([89CB633](#), [90CB2273](#), [94CB2393](#)), the coordination mode is η^5 in the case of iron tricarbonyl complexes **10** and **11** ($R = H, Me$).




B. COBALT GROUP

1. Sandwiches and Triple-deckers

Generally, precursors of the triple- and multiple-deckers are the metallocarboranes of composition $[LM(C_2B_3H_5)]$ where $LM = (\eta^5\text{-Cp})Co$, $(\eta^5\text{-Cp}^*)Co$, $(\eta^6\text{-arene})Fe$, and $(\eta^6\text{-arene})Ru$ ([89OM2492](#), [90OM1171](#), [90OM1177](#), [92OM2404](#)). They are subject to the so-called re-capitation reactions ([96IC6703](#), [97IC3602](#)). Another opportunity is the product of interaction of 1,3,4,5-tetraethyldiborole with $[Co_2(CO)_8]$, $[HCo(CO)_4]$, or $[(\eta^3\text{-C}_3\text{H}_5)Co(CO)_3]$, which leads to the sandwich **1** [$ML_n = Co(CO)_3$, $R^1 = R^2 = R^3 = Me$, $R^4 = R^5 = Et$] ([85AGE248](#), [85CB401](#), [87JOM\(324\)57](#)). Reaction of thallium cyclopentadienyl with $[(\eta^5\text{-1,3,4,5-tetramethyl-2,3-dihydro-1H-1,3-diborolene})cobalt(\eta^5\text{-cyclopentadienyl})]$ gives neutral complexes **2** [$ML_n = Tl(\eta^5\text{-Cp})$, $M'L'_n = Co(\eta^5\text{-Cp})$, $R^1 = R^2 = R^3 = R^4 = R^5 = Me$] ([85AGE71](#), [87JOM\(324\)57](#)).

2,3-Dihydro-1,3-diborole derivatives react with $[(C_2H_4)_2RhCl]_2$ to yield the dimers **12** ($R^1 = R^2 = Me$, $R^3 = MeCH_2$; $R^1 = Et$, $R^2 = R^3 = Me$; $R^1 = Me$, $R^2 = t\text{-Bu}$, $R^3 = Me$) ([98JOM\(571\)107](#), [01JOM\(619\)7](#)). The product undergoes dehydrohalogenation in benzene or toluene in the presence of methyl lithium to yield species **13** ($R^1 = R^2 = Me$, $R^3 = MeCH_2$, $R^4 = H$; $R^1 = Et$, $R^2 = R^3 = Me$, $R^4 = Me$, H ; $R^1 = Me$, $R^2 = t\text{-Bu}$, $R^3 = R^4 = Me$). 1,3,4,5-Tetramethyl-2,3-dihydro-1,3-diborole interacts with *tert*-butyl lithium, methyl lithium, or potassium hydride, and $[(C_2H_4)_2RhCl]_2$ in toluene to yield **13** ($R^1 = Me$, $R^2 = t\text{-Bu}$, $R^3 = R^4 = H$). Dimer **12** ($R^1 = Et$, $R^2 = R^3 = Me$) in the presence of naphthalene in THF and *tert*-butyl lithium gives **14** ($R^1 = Et$, $R^2 = R^3 = Me$). Pure 1,3-diborolyl sandwich **15** ($R^1 = Me$, $R^2 = t\text{-Bu}$, $R^3 = Me$) can be prepared from **13** ($R^1 = Me$, $R^2 = t\text{-Bu}$, $R^3 = R^4 = Me$), methyl lithium and the 1,3-diborole ligand ([01JOM\(619\)7](#)). The by-product of this reaction is the triple-decker species

16 ($R^1 = \text{Me}$, $R^2 = t\text{-Bu}$, $R^3 = \text{Me}$). Dimeric compound **12** ($R^1 = \text{Me}$, $R^2 = t\text{-Bu}$, $R^3 = \text{Me}$) experiences cleavage of the chlorine bridges under the action of sodium cyclopentadienyl or lithium pentamethylcyclopentadienyl and gives sandwiches **17** ($R^1 = \text{Me}$, $R^2 = t\text{-Bu}$, $R^3 = \text{Me}$) with rhodium(I) center and **18** ($R^1 = \text{Me}$, $R^2 = t\text{-Bu}$, $R^3 = \text{Me}$) with rhodium(III) center, respectively.




The reactions of the Group VIII di- and triborolyl or carboranes sandwiches are directed basically to their extension to multidecker derivatives.

Anionic carborane complex $[(\eta^5\text{-Cp}^*)\text{Co}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_4)]^-$ with $[\text{Mo}(\text{CO})_4\text{Cl}(\mu\text{-Cl})_2]$ gives triple-decker and tetradecker species **6** [$\text{ML}_n = \text{Mo}(\text{CO})_4$, $\text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp}^*)$, $R^1 = R^2 = R^3 = \text{H}$, $R^4 = R^5 = \text{Et}$] and **7** [$\text{ML}_n = \text{M}''\text{L}''_n = \text{Co}(\eta^5\text{-Cp}^*)$, $\text{M}' = \text{Mo}(\text{CO})_2$, $R^1 = R^2 = R^3 = \text{H}$, $R^4 = R^5 = \text{Et}$], respectively (98IC102). The tetradecker derivative of the same kind as **7** is known for the diboroles and can be formulated as $[(\eta^5\text{-Cp})\text{Co}(\text{Et}_2\text{HC}_3\text{B}_2\text{Me}_2)_2\text{Sn}$ (83OM1899). Compound **7** [$\text{ML}_n = \text{M}''\text{L}''_n = \text{Co}(\eta^5\text{-Cp}^*)$, $\text{M}' = \text{Mo}(\text{CO})_2$, $R^1 = R^2 = R^3 = \text{H}$, $R^4 = R^5 = \text{Et}$] is the only product of interaction of $[(\eta^5\text{-Cp}^*)\text{Co}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_4)]^-$ and $[\text{Mo}(\text{CO})_4\text{Br}(\mu\text{-Br})_2]$ but

the triple-decker species is not formed (98IC102). The reaction of the same cobalt precursor with $[\text{W}(\text{CO})_4\text{Br}(\mu\text{-Br})]_2$ gives the tungsten analogue of **6** $[\text{ML}_n = \text{W}(\text{CO})_4, \text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp}^*), \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}, \text{R}^4 = \text{R}^5 = \text{Et}]$. Complex **6** $[\text{ML}_n = \text{Mo}(\text{CO})_4, \text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp}^*), \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}, \text{R}^4 = \text{R}^5 = \text{Et}]$ with phenyl lithium in the presence of trimethyloxonium tetrafluoroborate in toluene gives **6** $[\text{ML}_n = \text{Mo}(\text{CO})_4, \text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp}^*), \text{R}^1 = \text{PhCH}_2, \text{R}^2 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}]$.

Nido- $[(\eta^5\text{-Cp}^*)\text{Co}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_4)]^-$ and Cp^*TaCl_4 , Cp^*TaCl_4 , and Cp^*NbCl_4 yield the triple-deckers **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{MXX}'(\eta^5\text{-C}_5\text{R}_5)$ ($\text{M} = \text{Ta}, \text{R} = \text{H}, \text{Me}, \text{X} = \text{X}' = \text{Cl}; \text{M} = \text{Nb}, \text{R} = \text{H}, \text{X} = \text{X}' = \text{Cl}; \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$ as the main products (95OM3014). With an alkylating or arylating agent, complex **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{MXX}'(\eta^5\text{-C}_5\text{R}_5)$ ($\text{M} = \text{Ta}, \text{R} = \text{H}, \text{X} = \text{X}' = \text{Cl}; \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$ undergoes the following transformations: with Me_2Zn or AlMe_3 —to **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{MXX}'(\eta^5\text{-C}_5\text{R}_5)$ ($\text{M} = \text{Ta}, \text{R} = \text{H}, \text{X} = \text{Me}, \text{X}' = \text{Cl}; \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$, MeLi or MeMgBr —to **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{MXX}'(\eta^5\text{-C}_5\text{R}_5)$ ($\text{M} = \text{Ta}, \text{R} = \text{H}, \text{X} = \text{X}' = \text{Me}; \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$, with $\text{Zn}(\text{CH}_2\text{Ph})_2$ —to **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{MXX}'(\eta^5\text{-C}_5\text{R}_5)$ ($\text{M} = \text{Ta}, \text{R} = \text{H}, \text{X} = \text{PhCH}_2, \text{X}' = \text{Cl}; \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$, with PhCH_2MgBr —to **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{MXX}'(\eta^5\text{-C}_5\text{R}_5)$ ($\text{M} = \text{Ta}, \text{R} = \text{H}, \text{X} = \text{X}' = \text{PhCH}_2; \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$, with $\text{Np}_2\text{Mg} \cdot \text{dioxane}$ —to **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{MXX}'(\eta^5\text{-C}_5\text{R}_5)$ ($\text{M} = \text{Ta}, \text{R} = \text{H}, \text{X} = t\text{-BuCH}_2, \text{X}' = \text{Cl}; \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$, and with NpLi —to **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{MXX}'(\eta^5\text{-C}_5\text{R}_5)$ ($\text{M} = \text{Ta}, \text{R} = \text{H}, \text{X} = \text{X}' = t\text{-BuCH}_2, \text{X}' = \text{Cl}; \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$. Treatment of **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*), \text{M}'\text{L}'_n = \text{TaCl}_2(\eta^5\text{-Cp}), \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}; \text{R}^4 = \text{R}^5 = \text{Et}]$ with *N*-bromo- or *N*-iodosuccinimide gives **6** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*); \text{M}'\text{L}'_n = \text{TaCl}_2(\eta^5\text{-Cp}); \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{Cl}, \text{Br}; \text{R}^4 = \text{R}^5 = \text{Et}]$ (00OM2200).

Reaction of the anionic sandwich **19** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp}^*), \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}, \text{R}^4 = \text{R}^5 = \text{Et}]$ as its lithium salt with $[(\eta^5\text{-Cp}^*\text{RuCl})_4]$ gives the triple-decker **6** $[\text{ML}_n = \text{Ru}(\eta^5\text{-Cp}^*), \text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp}^*), \text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}, \text{R}^4 = \text{R}^5 = \text{Et}]$ (97JOM(536)115).




Similar triple-decker complexes are known, e.g., $[(\eta^6\text{-}p\text{-MeC}_6\text{H}_4\text{CHMe}_2)\text{Ru}(\eta^5\text{-Et}_2\text{C}_2\text{B}_3\text{H}_3)\text{Ru}(\eta^6\text{-}p\text{-MeC}_6\text{H}_4\text{CHMe}_2)]$ and $[(\eta^5\text{-Cp})\text{Co}(\eta^5\text{-Et}_2\text{C}_2\text{B}_3\text{H}_3)]$

$\text{Ru}(\eta^6\text{-}p\text{-MeC}_6\text{H}_4\text{CHMe}_2)]^+$, and their redox properties were studied by electrochemical techniques (79JA3399, 90JEAC139, 92JA9846, 99IC93). Species **6** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$, $\text{M}'\text{L}'_n = \text{Ru}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = \text{R}^5 = \text{Et}$] and **6** [$\text{ML}_n = \text{M}'\text{L}'_n = \text{Ru}(\eta^6\text{-cymene})$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = \text{R}^5 = \text{Et}$] are fully delocalized (92JA9846). However, this is not the case for the triple-decker species **6** [$\text{ML}_n = \text{Fe}(\eta^5\text{-Cp})$, $\text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp})$, $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{H}$, $\text{R}^4 = \text{R}^5 = \text{Et}$] (92JA5214, 94IC4211, 95IC2058).

Nido- $[(\eta^5\text{-Cp}^*)\text{Co}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_4\text{-5-R})]$ ($\text{R} = \text{H}$, Cl , Br) undergo bridge-deprotonation with *n*-butyl lithium, and then react with $[(\eta^5\text{-Cp}^*)\text{FeCl}]_2$ in THF in the presence of air to give triple-deckers **6** [$\text{ML}_n = \text{Fe}(\eta^5\text{-Cp}^*)$; $\text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp}^*)$; $\text{R}^1 = \text{R}^3 = \text{H}$; $\text{R}^2 = \text{H}$, Cl , Br , $\text{R}^4 = \text{R}^5 = \text{Et}$] (95IC2058). They contain iron in the formal oxidation state of +3. The same assignment of the iron oxidation number is valid for $[(\eta^5\text{-Cp})\text{Co}(\text{Et}_2\text{MeC}_3\text{B}_2\text{Et}_2)\text{Fe}(\text{Et}_2\text{C}_2\text{B}_4\text{H}_4)]$ (89OM1300).

The cobalt anionic sandwich complex **20** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$] (82AGE148, 83OM1666) reacts with *nido*-6-Me-5,6,9- $\text{C}_3\text{B}_7\text{H}_9^-$ anions in the presence of $\text{FeCl}_2 \cdot \text{THF}$, CoCl_2 , or $\text{NiBr}_2 \cdot \text{DME}$ to give the triple-deckers **2** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$; $\text{M}'\text{L}'_n = \text{Fe}(\eta^6\text{-5-Me-2,3,5-C}_3\text{B}_7\text{H}_9)$, $\text{Co}(\eta^6\text{-2-Me-2,3,5-C}_3\text{B}_7\text{H}_9)$, $\text{Ni}(\eta^4\text{-8-Me-7,8,10-C}_3\text{B}_7\text{H}_9)$; $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$; $\text{R}^2 = \text{Me}$] (95OM1911). In the latter case the $\eta^6 \rightarrow \eta^4$ cage distortion takes place. Other known triple-deckers include **2** [$\text{ML}_n = \text{Co}(\eta^5\text{-Cp})$; $\text{M}'\text{L}'_n = \text{Fe}(\eta^5\text{-Cp})$, $\text{Co}(\eta^5\text{-Cp})$, $\text{Ni}(\eta^5\text{-Cp})$; $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$; $\text{R}^2 = \text{Me}$] (83JA2582).

**20**

A series of cobalt neutral and charged triple-deckers was prepared as early as in 1973 when $[(\eta^5\text{-Cp})\text{Co}(\eta^5\text{-C}_2\text{B}_3\text{H}_5)\text{Co}(\eta^5\text{-Cp})]$ was first synthesized (73JA3046). The end rings in the triple-deckers may include cyclopentadienyl, pentamethylcyclopentadienyl, arene and hetarene (e.g. pyrrolyl and phospholyl groups) (91OM2631). Bromination of the sandwich $[(\eta^5\text{-Cp})\text{Co}(\eta^5\text{-C}_2\text{Et}_2\text{B}_3\text{H}_3)\text{Co}(\eta^5\text{-Cp})]$ by N-bromosuccinimide occurs at three boron atoms and gives $[(\eta^5\text{-Cp})\text{Co}(\eta^5\text{-C}_2\text{Et}_2\text{B}_3\text{Br}_3)\text{Co}(\eta^5\text{-Cp})]$ (95OM4661).

The cobalt analogues **6** [$\text{ML}_n = \text{M}'\text{L}'_n = \text{Co}(\eta^5\text{-Cp}^*)$; $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{Me}$, $\text{R}^2 = \text{Cl}$, Me] are prepared from the corresponding capped precursors $[(\eta^5\text{-Cp}^*)\text{Co}(\text{Me}_2\text{C}_2\text{B}_3\text{H}_2\text{-4,5,6-Me}_3)]$ and $[(\eta^5\text{-Cp}^*)\text{Co}(\text{Me}_2\text{C}_2\text{B}_3\text{H}_3\text{-4,6-Me}_2\text{-5-Cl})]$, respectively, as a result of the sequence of lithiation (*n*-BuLi) and reaction with $[(\eta^5\text{-Cp}^*)\text{CoCl}]_2$ (81JA1399, 92IC3904). A similar approach

provides the triple-decker complexes **6** [$ML_n = M'L'_n = Co(\eta^5-Cp^*)$; $R^1 = R^2 = R^3 = H$, $R^4 = R^5 = H$, $SiMe_3$].

Sandwich *nido*- $[(\eta^5-Cp^*)Ir(2,3-Et_2C_2B_3H_5)]$ on bridge-deprotonation with *n*-butyl lithium, and further treatment with $[(\eta^5-Cp^*)IrCl_2]_2$ leads to the triple-decker species **6** [$ML_n = M'L'_n = Ir(\eta^5-Cp^*)$, $R^1 = R^2 = H$, $R^3 = Cl$, $R^4 = R^5 = Et$] (96IC7027). The heterobimetallic cobalt-iridium analogue **6** [$ML_n = Ir(\eta^5-Cp^*)$, $M'L'_n = Co(\eta^5-Cp^*)$, $R^1 = R^2 = H$, $R^3 = Cl$, $R^4 = R^5 = Et$] follows from the anionic *nido*- $[(\eta^5-Cp^*)Co(Et_2C_2B_3H_4)]^-$ and $[(\eta^5-Cp^*)IrCl_2]_2$.

A group of studies is devoted to cases where a carborane ligand serves as the terminal chain of triple-deckers. Complexes **2** [$ML_n = Co(\eta^5-Cp)$; $M'L'_n = M(MeC_3B_7H_9)$ ($M = Fe, Co, Ni$); $R^1 = R^3 = R^4 = R^5 = Et$; $R^2 = Me$] (95OM1911), **2** [$ML_n = Co(\eta^5-Cp)$; $M'L'_n = M(Et_2C_2B_4H_4)$ ($M = Co, Ni$); $R^1 = R^3 = R^4 = R^5 = Et$; $R^2 = Me$] (90IC5157), **2** [$ML_n = Co(\eta^5-Cp)$; $M'L'_n = M(nido-C_2B_9H_{11})$ ($M = Co, Ni$); $R^1 = R^3 = R^4 = R^5 = Et$; $R^2 = Me$] ($M = Co, Ni$) (93JCS(D)1783) serve as examples. Deprotonation of the complex $[(\eta^5-Cp)Co\{\eta^5-(EtC)_2(EtB)_2CHMe\}]$ (83OM1666) gives the anionic sandwich **20** [$ML_n = Co(\eta^5-Cp)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$], which further reacts with cobalt(II) chloride and *nido*-4,5- $C_2B_6H_5^-$ to yield the triple-decker **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Co(2,3-C_2B_5H_9)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] (96CB213). In a similar reaction where *arachno*-4,5- $C_2B_2H_{12}^-$ participates, the triple-decker **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Co(6,9-C_2B_7H_9)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] is formed. On heating, **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Co(6,9-C_2B_7H_9)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] isomerizes to **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Co(1,6-C_2B_7H_9)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] and at higher temperatures to **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Co(1,10-C_2B_7H_9)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$]. If $RhCl_2$ is used in this reaction, the product is **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Rh(1,6-C_2B_7H_9)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$].

Interaction of the lithium salt of $[(\eta^5-Cp)Co(\eta^5-(EtC)_2(EtB)_2(CMe))]^-$ (83OM1666) with the boranyl $B_9H_{14}^-$ and cobalt(II) chloride gives the triple-decker species **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Co(B_9H_{13})$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] (97CB329). If in a similar reaction *arachno*- $C_8^+SB_9H_{12}^-$ is used, the diamagnetic triple-decker complex **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Co(SB_9H_9)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] results. The product is **2** [$ML_n = Co(\eta^5-Cp)$, $M'L'_n = Co(6,8-S_2B_6H_8)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] when *arachno*-6,8- $S_2B_7H_8^-$ is one of the reactants.

2. Multidecker Compounds

When species *nido*- $[(\eta^5-Cp^*)Co(Et_2C_2B_3H_4-5-X)]$ ($X = Me, Cl$) are deprotonated with *n*-butyl lithium and then reacted with iron(II) chloride,

they give after work-up on alumina, tetradeccker complexes **7** [$ML_n = Co(\eta^5-Cp)$; $M = FeH$; $M''L''_n = Co(\eta^5-Cp^*)$; $R^1 = R^3 = H$; $R^2 = H, Cl, Me$; $R^4 = R^5 = Et$]. Here the iron site is in the oxidation state +3 (95IC6509).



Sandwich *nido*- $[(\eta^5-Cp^*)Ir(2,3-Et_2C_2B_3H_4-5-Cl)]$ appeared to be a starting material for various rhodium-containing tetradeccker compounds. Thus, first reacting with *n*-butyl lithium and then with $[Rh(AN)_3Cl_3]$, the iridium sandwich yields complex **7** [$ML_n = M''L''_n = Ir(\eta^5-Cp^*)$, $M' = RhH$, $R^1 = R^3 = H$, $R^2 = Cl$, $R^4 = R^5 = Et$] separated from a mixture of various products. Joint application of two anionic sandwiches *nido*- $[(\eta^5-Cp^*)Ir(2,3-Et_2C_2B_3H_4-5-Cl)]^-$ and *nido*- $[(\eta^5-Cp^*)Co(Et_2C_2B_3H_3Cl)]^-$ in their reaction with *n*-butyl lithium and then $[Rh(AN)_3Cl_3]$ allows the preparation of a mixture of tetradeccker compounds **7** [$ML_n = M''L''_n = Ir(\eta^5-Cp^*)$, $M' = RhH$, $R^1 = R^3 = H$, $R^2 = Cl$, $R^4 = R^5 = Et$], **7** [$ML_n = Co(\eta^5-Cp^*)$, $M' = RhH$, $M''L''_n = Ir(\eta^5-Cp^*)$, $R^1 = R^3 = H$, $R^2 = Cl$, $R^4 = R^5 = Et$], **7** [$ML_n = M''L''_n = Co(\eta^5-Cp^*)$, $M' = RhH$, $R^1 = R^3 = H$, $R^2 = Cl$, $R^4 = R^5 = Et$] (96IC7027).

Reaction of monoanion $[(Et_2C_2B_3H_4)Co(\eta^5-C_2Et_2CMeB_2Et_2)Co(\eta^5-Cp)]^-$ with $[(\eta^5-Cp^*)CoCl]_2$ gives the tetradeccker species **7** [$ML_n = M''L''_n = Co(\eta^5-Cp^*)$; $M' = Co$; $R^1 = R^2 = H$; $R^3 = H, Cl$; $R^4 = R^5 = Et$, $R^{2'} = R^{3'} = R^{4'} = R^{5'} = Et$; $R^{2'} = Me$] (90IC5164). This and two subsequent species contain two different triborolyl ligands, and substituents bearing the $Co(\eta^5-Cp^*)$ moiety labeled as $R^{n'}$ ($n = 1-5$). Preliminary deprotonation of the same anion with $LiHBEt_3$ and treatment of the resultant dianion with $[(\eta^5-Cp^*)RhCl_2]_2$ or $[(\eta^6-cymene)RuCl_2]$ gives the heteronuclear tetradeccker species **7** [$ML_n = Rh(\eta^5-Cp)$; $M' = Co$; $M''L''_n = Co(\eta^5-Cp^*)$; $R^1 = R^2 = H$; $R^3 = H, Cl$; $R^4 = R^5 = Et$, $R^{1'} = R^{3'} = R^{4'} = R^{5'} = Et$; $R^{2'} = Me$] and **7** [$ML_n = Ru(\eta^6-cymene)$; $M' = Co$; $M''L''_n = Co(\eta^5-Cp^*)$; $R^1 = R^2 = H$; $R^3 = H, Cl$; $R^4 = R^5 = Et$, $R^{1'} = R^{3'} = R^{4'} = R^{5'} = Et$; $R^{2'} = Me$], respectively.

With a capped cobalt precursor, the sequence of lithiation and transition-metal stacking with nickel(II) bromide gives the cobalt nickel tetradeccker **7** [$ML_n = M''L''_n = Co(\eta^5-Cp^*)$, $M' = Ni$, $R^1 = R^3 = H$, $R^2 = R^4 = R^5 = Me$] (92IC3904). This complex as well as tetradeccker species **7** [$ML_n = M''L''_n = Co(\eta^5-Cp^*)$; $M' = Co$; $R^1 = H$; $R^2 = Me, COMe, Cl, Br, I, CH_2C \equiv CBut'$; $R^3 = H, Cl$; $R^4 = R^5 = Et$] and **7** [$ML_n = M''L''_n = Co(\eta^5-Cp^*)$; $M' = Ni$; $R^1 = H$; $R^2 = Me, COMe, Cl, Br, I, CH_2C \equiv CBut'$; $R^3 = H, Cl$; $R^4 = R^5 = Et$] are characterized by an extended electron delocalization (93OM4452, 93OM4459).

The carborane anionic sandwiches *nido*- $[(\eta^5-Cp^*)Co(RR'C_2B_3H_3X)]$ ($X = H, Cl, Br, I, Me, COMe, CH_2C \equiv CMe$; $R, R' = Alk, H$) upon reaction with *n*-butyl lithium and then metal salts experience stacking and formation of the tetradeccker heterometallic species **7** [$ML_n = M''L''_n = Co(\eta^5-Cp^*)$; $M' = Co, Ni, Ru$; $R^1 = R^3 = H$; $R^2 = Me, COMe, H, Cl, Br, I, CH_2C \equiv CMe$; $R^4 = R^5 = H, Me, Et$] (92IC5202, 93JA6143, 93OM4452, 93OM4459).


The anionic sandwich $[(\eta^5\text{-Cp})\text{Co}(\eta^5\text{-Et}_2\text{MeC}_3\text{B}_2\text{Et}_2)]^-$ when reacted with $[(\eta^5\text{-C}_9\text{H}_7)\text{Fe}(\text{Et}_2\text{C}_4\text{B}_4\text{H}_4)]^-$ in the presence of nickel(II) bromide gives the tetradeccker **21** (83JOM(257)275, 90IC5157, 91JA3061). In a similar reaction with $[(\eta^5\text{-Cp}^*)\text{Fe}(\text{Et}_2\text{C}_2\text{B}_4\text{H}_4)]$, potassium, and nickel(II) bromide, **22** $[\text{ML}_n = \text{M}''\text{L}'' = \text{Co}(\eta^5\text{-Cp})]$; $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$; $\text{R}^1' = \text{R}^2' = \text{R}^3' = \text{H}$; $\text{R}^4' = \text{R}^5' = \text{Et}$] is formed. Again for the mixed-ligand species, the labeling of one of the heterocycles is $\text{R}^{n'}$ ($n = 1-5$).

**21****22**

1,3,4,5-Tetraethyl-1*H*-2,3-dihydro-2-methyl-1,3-diborole and $[(\eta^5\text{-Cp})\text{Co}(\eta^2\text{-C}_2\text{H}_4)_2]$ give the neutral sandwich $[(\eta^5\text{-Cp})\text{Co}(\text{C}_3\text{B}_2\text{HMeEt}_4)]$ (85ZN(B) 326), which can be deprotonated with *n*-butyl lithium in THF to give the anionic sandwich **20** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp})]$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$] (93JCS(D)1783). The latter reacts with the carborane dianion $[7,8\text{-C}_2\text{B}_9\text{H}_{11}]^{2-}$ and bis(pentane-2,4-dionato)nickel(II) to yield a mixture of species **22** $[\text{ML}_n = \text{M}''\text{L}'' = \text{Co}(\eta^5\text{-Cp})]$, $\text{M}' = \text{Ni}$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$], **2** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp})]$, $\text{M}'\text{L}' = \text{Ni}(7,8\text{-C}_2\text{B}_9\text{H}_{11})$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$], **2** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp})]$, $\text{M}'\text{L}' = \text{Co}(7,8\text{-C}_2\text{B}_9\text{H}_{11})$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$] Complex **22** $[\text{ML}_n = \text{M}''\text{L}'' = \text{Co}(\eta^5\text{-Cp})]$, $\text{M}' = \text{Ni}$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$] can alternatively be prepared from the cobalt anionic sandwich **20** $[\text{ML}_n = \text{Co}(\eta^5\text{-Cp})]$, $\text{R}^1 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Et}$, $\text{R}^2 = \text{Me}$] and $[(\eta^5\text{-Cp})\text{Ni}(\text{CO})_2]$ (82AGE149). A series of tetradeccker species can be made using this route, including $[(\eta^5\text{-Cp})\text{Co}(\text{C}_2\text{B}_3\text{R}_5)]_2\text{M}$ ($\text{M} = \text{Cr}, \text{Mn}, \text{Fe}, \text{Co}, \text{Ni}, \text{Cu}, \text{Zn}$). The electronic characteristics of these complexes predicted quantum-mechanically (90JA722) correlate well with experimental data.


The B(5)-acetyl complex $[(\eta^5\text{-Cp}^*)\text{Co}(\text{Et}_2\text{C}_2\text{B}_3\text{H}_4\text{-5-COMe})]$ (91JA680) can be deprotonated with *n*-butyl lithium and then react with nickel(II) bromide to yield the tetradeccker **7** $(\text{ML}_n = \text{M}'\text{L}' = \text{Co}(\eta^5\text{-Cp}^*))$, $\text{M}' = \text{Ni}$, $\text{R}^1 = \text{R}^3 = \text{H}$, $\text{R}^2 = \text{COMe}$, $\text{R}^4 = \text{R}^5 = \text{Et}$] (91JA681). In this complex, cobalt has the oxidation state of +3 and nickel of +4. The pentadecker $[(\eta^5\text{-Cp})_2\text{Co}_2\text{Ni}_2(\eta^5\text{-Et}_2\text{MeC}_3\text{B}_2\text{Et})_3]$ (82AGE453) was prepared and the existence of the corresponding Co_2Ni_3 hexadecker was postulated (85ZN(B)167).

Interaction of the carborane sandwiches of composition $[(\eta^5\text{-RR}'\text{C}_2\text{B}_3\text{H}_3\text{X})\text{Co}(\eta^5\text{-Cp}^*)]$ ($\text{R}=\text{Me}$, Et , SiMe_3 ; $\text{X}=\text{H}$, Cl , Br , I , Me , COMe , $\text{CH}_2\text{C}\equiv\text{CMe}$) with *n*-butyl lithium followed by Co^{2+} , CoH^+ , Ni^{2+} , Ru^{2+} gives the tetradeccker species **7** ($\text{ML}_n=\text{M}''\text{L}_n'=\text{Co}(\eta^5\text{-Cp}^*)$; $\text{M}'=\text{Co}^{\text{IV}}$, $\text{Co}^{\text{III}}\text{H}$, Ni^{IV} , Ru^{IV} ; $\text{R}^1=\text{R}^3=\text{H}$; $\text{R}^2=\text{H}$, Cl , Br , I , Me , COMe , $\text{CH}_2\text{C}\equiv\text{CMe}$; $\text{R}^4=\text{R}^5=\text{Et}$, SiMe_3) (92IC5202, 93JA6143, 93OM4452, 93OM4459). The iron-centered tetradeccker species are more difficult to isolate (93IC2156). In a series of reactions of triple-decker compounds, $[(\eta^5\text{-Cp}^*)\text{Co}(\text{Et}_2\text{C}_2\text{B}_2\text{H}_2\text{BMe})\text{CoH}(\eta^5\text{-C}_2\text{Et}_2\text{B}_3\text{H}_4)]$ with sodium hydride, then air, followed by *n*-butyl lithium, and finally cobalt(II) chloride or platinum(II) bromide, three hexadeccker complexes **23** ($\text{ML}_n=\text{M}_1\text{L}_{n1}=\text{Co}(\eta^5\text{-Cp}^*)$; $\text{M}'=\text{Co}$, $\text{M}''=\text{Co}$, CoH , Pt ; $\text{M}'''=\text{CoH}$; $\text{R}^1=\text{R}^3=\text{H}$; $\text{R}^2=\text{Me}$; $\text{R}^4=\text{R}^5=\text{Et}$) were synthesized (94JA2687). In a similar manner, pentadeccker species **24** ($\text{ML}_n=\text{M}_1\text{L}_{n1}=\text{Co}(\eta^5\text{-Cp}^*)$; $\text{M}'=\text{Co}$, CoH , Pt ; $\text{M}''=\text{CoH}$; $\text{R}^1=\text{R}^3=\text{H}$; $\text{R}^2=\text{Me}$; $\text{R}^4=\text{R}^5=\text{Et}$) follow from $[(\eta^5\text{-Et}_2\text{C}_2\text{B}_3\text{H}_3\text{Me})\text{Co}(\eta^5\text{-Cp}^*)]$ and $[(\eta^5\text{-Et}_2\text{C}_2\text{B}_3\text{H}_3\text{Me})\text{Co}(\eta^5\text{-Cp}^*)]$ in the presence of M^{2+} and air. Such a synthetic approach may lead to polymers similar to the nickel-diborolyl sandwich polymer having semiconducting properties (86AGE105, 87SM757, 88PAC1345, 93ZN(B)1512).




The dianionic triple-decker species **25** in the presence of cobalt(II) and nickel(II) salts, molecular oxygen, and $[(\eta^5\text{-Cp}^*)\text{Co}(\text{C}_2\text{Et}_2\text{BHX})]^-$ ($\text{X}=\text{H}$,


Me) give the pentadecker species **24** ($ML_n = M_1L_{n1} = Co(\eta^5-Cp^*)$; $M' = Co^{IV}$, Ni^{IV} ; $M'' = CoH$; $R^1 = R^3 = H$; $R^2 = Me$; $R^4 = R^5 = Et$], while cobalt(II) and platinum(II) salts in the presence of molecular oxygen yield the hexadecker complexes **23** ($ML_n = M_1L_{n1} = Co(\eta^5-Cp^*)$; $M' = Co$, CoH ; $M'' = Co^{IV}$, Ni^{IV} ; $M''' = CoH$; $R^1 = R^3 = H$; $R^2 = Me$; $R^4 = R^5 = Et$] (95JA12218, 95JA12227).

**25**

Nido- $[(\eta^5-Cp^*)Co(Et_2C_2B_3H_4-5-Me)]$ can be deprotonated with *n*-butyl lithium and then allowed to react with cobalt(II) chloride to yield a mixture of triple-deckers **6** ($ML_n = Co^{III}(\eta^5-Cp^*)$, $M'L'_n = M(Et_2C_4B_4H_4)$ ($M = Co^{III}H$, Co^{IV}); $R^1 = R^3 = H$; $R^2 = Me$, $R^4 = R^5 = Et$] (94JA2687). In moist TMEDA, they are converted to diamagnetic species **6** ($ML_n = Co^{III}(\eta^5-Cp^*)$, $M'L'_n = Co^{III}H(Et_2C_2B_3H_5)$, $R^1 = R^3 = H$; $R^2 = Me$, $R^4 = R^5 = Et$], which can be deprotonated at the $Co^{III}H$ site to give the anionic diamagnetic compound **26**. The latter in air gives the paramagnetic Co^{III}/Co^{IV} derivative **6** ($ML_n = Co^{III}(\eta^5-Cp^*)$, $M'L'_n = Co^{IV}(Et_2C_2B_3H_5)$, $R^1 = R^3 = H$; $R^2 = Me$, $R^4 = R^5 = Et$). When **6** ($ML_n = Co^{III}(\eta^5-Cp^*)$, $M'L'_n = Co^{IV}(Et_2C_2B_3H_5)$, $R^1 = R^3 = H$; $R^2 = Me$, $R^4 = R^5 = Et$) is deprotonated with *n*-butyl lithium and then treated with cobalt(II) chloride, paramagnetic hexadeckers **23** ($ML_n = M_1L_{n1} = Co(\eta^5-Cp^*)$; $M' = CoH$, Co ; $M'' = Co$; $M''' = CoH$; $R^1 = R^3 = H$; $R^2 = Me$; $R^4 = R^5 = Et$) are formed.





**26**

Thermolysis of **22** [$ML_n = M''L''_n = Ni(\eta^3\text{-allyl})$, $M' = Ni$, $R^1 = R^3 = Me$, $R^3 = H$, $R^4 = R^5 = Et$] and **27** ($R = Et$, $R' = Me$, $R'' = H$) gives **28** ($R = Et$, $R' = Me$, $R'' = H$), **2** [$ML_n = M'L'_n = Co(\eta^5\text{-Cp})$, $R^1 = R^3 = Me$, $R^2 = H$, $R^4 = R^5 = Et$], and **22** [$ML_n = M''L''_n = Co(\eta^5\text{-Cp})$, $M' = Ni$, $R^1 = R^3 = Me$, $R^2 = H$, $R^4 = R^5 = Et$]. The same reaction of **22** [$ML_n = M''L''_n = Ni(\eta^3\text{-allyl})$, $M' = Ni$, $R^1 = R^3 = Me$, $R^3 = H$, $R^4 = R^5 = Et$] and **27** ($R = R' = Et$, $R'' = Me$) yields an analogue of **28** ($R = R' = Et$, $R'' = Me$) and species **29** ($R = R' = Et$, $R'' = Me$) (*87JOM*(324)57). An alternative way to complex **28** ($R = R' = Et$, $R'' = Me$) containing diboroly rings with two different substituent sets uses the reaction of **2** [$ML_n = Ni(\eta^3\text{-allyl})$, $M'L'_n = Co(\eta^5\text{-Cp})$, $R^1 = R^3 = Me$, $R^2 = H$, $R^4 = R^5 = Et$] and **30** ($R = Me$). Two rings surrounding the nickel atoms have methyl groups and two others carrying ethyl groups.



Linked sandwich systems are of considerable practical interest (*97MI1*). Thus (*93JA6143*) the interaction of $[(\eta^5\text{-Et}_2\text{C}_2\text{B}_3\text{H}_4\text{Cl})Co(\eta^5\text{-C}_5\text{H}_4\text{C}_6\text{H}_4\text{C}_5\text{H}_4)Co(\eta^5\text{-Et}_2\text{C}_2\text{B}_3\text{H}_4\text{Cl})]$ with *n*-butyl lithium and then cobalt(II) or nickel(II) chloride gives a kind of tetradecker-linked complex **31** ($M = Co$, Ni), which on further interaction with *n*-butyl lithium and MCl_2 ($M = Co$, Ni) gives **32** ($M = Co$, Ni) with a potential to form oligomers. The derivatives based on $(C_5H_4)_2$ or fulvalene units **33** ($M = Co$, Ni) can also be made by a similar synthetic approach and lead to higher oligomers. Here the xylyl-bridged bis(triple-decker) species **34** may be mentioned. It is made from $p\text{-}[(\eta^5\text{-Cp}^*)Co((SiMe_3)(C_2B_3H_5)CH_2)_2C_6H_4]$ through the steps of

lithiation by *n*-butyl lithium and further reaction with $[(\eta^5\text{-Cp}^*)\text{CoCl}]_2$ (91IC2836, 92IC3897).




C. NICKEL GROUP

Sandwich **1** [$ML_n = Ni(\eta^5-Cp)$, $R^1 = R^2 = R^3 = R^4 = R^5 = Me$] with $[(\eta^5-Cp)_2M]$ ($M = Co, Ni$) forms the triple-decker species **2** [$ML_n = Ni(\eta^5-Cp)$; $M'L'_n = Co(\eta^5-Cp)$, $Ni(\eta^5-Cp)$; $R^1 = R^2 = R^3 = R^4 = R^5 = Me$] (81JOM(215)255). Similar nickel sandwiches and triple-deckers are known (77AGE468, 78ZN(B)1410, 81JOM(207)343). The latter can be reduced to the anionic species using metallic potassium (81JOM(208)137).


Alkyl-2,3-dihydrodiboroles on treatment with bis(η^3 -allyl)- or bis(η^3 -methylallyl)nickel give the tetradecar complexes **2** [$ML_n = M'L'_n = Ni(\eta^3$ -allyl), $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] (86JOM(305)199). The following mixed carborane-diborole nickel complexes are known: sandwich **1** [$ML_n = Ni(nido-2,3,5-R_6C_3B_3)$ ($R = Me, Et$); $R^1 = R^3 = R^4 = R^5 = Et$; $R^2 = Me$] and triple-deckers **2** [$ML_n = M'L'_n = Ni(nido-2,3,5-R_6C_3B_3)$ ($R = Me, Et$); $R^1 = R^3 = R^4 = R^5 = Et$; $R^2 = Me$] and **2** [$ML_n = Ni(nido-2,3,5-R_6C_3B_3)$ ($R = Me, Et$); $M'L'_n = Ni(\eta^5-Cp)$; $R^1 = R^3 = R^4 = R^5 = Et$; $R^2 = Me$] (84AGE965, 86AGE1099, 88OM2316). Species μ - η^5 : η^5 -(2-benzyl-1,3,4,5-tetramethyl-2,3-dihydro-1,3-diborolyl)(η^3 -allyl)(η^4 -1,5-hexadiene)dinickel and μ - η^5 : η^5 -[2-(2,4,6-trimethylbenzyl)-1,3,4,5-tetramethyl-2,3-dihydro-1,3-diborolyl](η^3 -allyl)(η^4 -1,5-hexadiene)dinickel serve as representative triple-decker complexes (01ZN(B)73).

Reaction of bis(η^5 -2,3-dihydro-1,3-diborolyl)platinum with $[(\eta^5-Cp)Fe(C_8H_{12})]$ gives the tetradecar complex **22** [$ML_n = Ni(\eta^5-Cp)$, $M' = Pt$, $M''L''_n = Fe(\eta^5-Cp)$, $R^1 = R^3 = R^4 = R^5 = Et$, $R^2 = Me$] (87JOM(318)157). Sandwich **35** (84ZN(B)50) and $[(\eta^5-Cp)Co(C_2H_4)_2]$ give the triple-decker **36** (87JOM(324)57). The list of tetradecar species also includes $[(\eta^5-Cp)M(C_3B_2R_5)]_2Pt$ ($M = Fe, Ni$) (85CB729).




Simultaneous coordination of the type η^5 : η^2 , via the heteroring and saturated substituent, makes the $Ni(\eta^4$ -cod) complexes **37** and **38** different

from the similar tricarbonyliron derivatives **10** and **11** (89CB633, 90CB2273, 94CB2393).




III. Complexes of Thiaborolyl Ligands


Benzo-1,3-thiaborolide (98OM2379) and N,N-di-*iso*-propyl-3-amino-1,3-thiaborolide (99OM1821) are interesting ligands. The latter reacts with $[(\eta^5\text{-Cp}^*)\text{RuCl}]_4$ or $[(\eta^5\text{-Cp}^*)\text{ZrCl}_3]$ to yield sandwiches **39** ($\text{M} = \text{Ru}, \text{ZrCl}_2$) (99OM1821). 1,2-Benzothiaborole enters similar complex forming processes to yield **40** ($\text{M} = \text{Ru}, \text{ZrCl}_2$) (00OM4681).




The lithium salt of 2-(di-*iso*-propylamino)-1,2-thiaborolide with $[(\eta^5\text{-Cp}^*)\text{RuCl}]_4$ or $[(\eta^5\text{-Cp}^*)\text{ZrCl}_3]$ yields sandwiches similar to **39** ($\text{M} = \text{Ru}, \text{ZrCl}_2$) (00OM4935). The same anionic ligand enters a sequence of reactions with dimethylchlorosilane, lithium cyclopentadienyl, lithium di-*iso*-propylamide, and zirconium(IV) chloride to give sandwich **41**.




1,2,5-Benzothiadiaborolene with $[\text{Fe}_2(\text{CO})_9]$ and $[\text{Fe}_3(\text{CO})_{12}]$ forms species **42**, where the annulated benzene ring is not delocalized and behaves like the cyclohexatriene system (75AGE262).



The B–S five-membered heterocycles attract occasional attention of chemists since the mid 1970s (77JOM(131)1, 86CB971). 1,2,5-Thiadiborolene with $[\text{Mn}_2(\text{CO})_{10}]$ forms the diamagnetic complex **43** [$\text{ML}_n = \text{M}'\text{L}'_n = \text{M}_n(\text{CO})_3$] (76AGE434). 3,4-Diethyl-2,5-dimethyl-1,2,5-thiadiborolene also reacts with $[(\eta^5\text{-Cp})\text{Fe}(\text{CO})_2]_2$ and gives the triple-decker species **43** [$\text{ML}_n = \text{M}'\text{L}'_n = \text{Fe}(\eta^5\text{-Cp})$] (76AGE779). With $[\text{Co}_2(\text{CO})_8]$, the triple-decker complex with three thiadiborolyl chains, **44**, results (77AGE333). Also $[(\eta^5\text{-C}_2\text{Et}_2\text{B}_2\text{Me}_2\text{S})_2\text{Ni}]$ is known (76ZN(B)803).




Complex **45** is formed on thermolysis of $[(\eta^5\text{-Cp})\text{Co}(\text{CO})_2]$ and thiadiborole (87JOM(324)57). The bis(thiadiborole)iron carbonyl complex is known (85JOM(282)297). Triple-deckers of composition $[(\eta^5\text{-Cp})\text{Fe}(\text{C}_2\text{B}_2\text{SR}_4)]_2\text{M}$ ($\text{M} = \text{Fe}, \text{Co}$) (80AGE746) and $[(\text{C}_2\text{B}_2\text{SR}_4)\text{Co}(\text{C}_2\text{B}_2\text{SR}_4)]_2\text{Fe}$ (79AGE949) are also representatives of 1,2,5-thiadiborolyl organometallic chemistry. 1,2,5-Thiadiborolene reacts with $[(\eta^5\text{-Cp})\text{Fe}(\text{C}_8\text{H}_{12})]_2\text{Zn}$ to yield the trinuclear complex **46** (80AGE746). Further interaction of the latter gives sandwich **47** (88JOM(343)78), which is the starting material for the tetradecker species **48** ($\text{M} = \text{Fe}, \text{Co}$) made by stacking with iron(II) or cobalt(II) chloride. In the case of iron(II) chloride the process is complicated and gives **44** [$\text{ML}_n = \text{M}'\text{L}'_n = \text{Fe}(\eta^5\text{-Cp})$] together with **48** ($\text{M} = \text{Fe}$) and $[(\eta^5\text{-Cp})\text{Fe}(\text{H})(\eta^5\text{-Et}_2\text{C}_2\text{B}_2(\text{Me}_2)\text{S})]$. The latter contains the $\text{Fe-H}\cdots\text{B}$ three-center two-electron bond.



IV. Complexes of Azaborolyl Ligands


2,3-Dihydro-1*H*-1,3,2-diazaboroles (90IC4421) form stable adducts with 1,3-dialkyl-4,5-dimethylimidazol-2-ylidenes (alkyl = Me, *i*-Pr) of a carbene type (97CB705, 98EJIC1145, 99EJIC491, 00OM2891, 01OM5248). This property is also typical for 3,4-dihydro-2*H*-1,2,4,3-triazaboroles (99EJIC1193).

Another aspect of this problem is the existence of heterocyclic carbenes containing a low-valent gallium center, **49** (95JA5421, 98EJIC305, 99JA9758, 01JCS(D)3459). 1,4-Bis(2,6-di-*iso*-propylphenyl)-1,4-diazabuta-1,3-diene and 1,4-bis(2,6-diethylphenyl)-1,4-diazabuta-1,3-diene with $[(\eta^5\text{-Cp}^*)\text{Ga}]$ yield **50** (R = 2,6-di-*iso*-propylphenyl-, 2,6-diethylphenyl-) (01OM1965, 01OM5492). 1,4-Di-*tert*-butyl-1,4-diazabuta-1,3-diene in these conditions produces compound **51** perhaps through intermediate **50** (R = *t*-Bu). Some developments with aluminum (01OM3367) and indium (02OM1167) ligands open a perspective to the study of organometallic adducts.




Complex $[\text{Sn}(\eta^5\text{-N}(\text{Bu}^t)\text{B}(\text{Me})\text{C}(\text{Me})(\text{CH})_2)_2]$ is known (85AGE602). Bis(1,2-azaborolyl)complexes of various metals represent the η^5 -coordinated sandwiches (80AGE54, 80CB2348, 80JOM(193)83, 82CB3830, 83CB951, 83ZN(B)485, 83ZN(B)1094, 84CB1052, 84ZN(B)1082, 85CIC17, 87OM435, 88AGE952, 89JOM(375)21, 00OL2089). 1,2-Azaborolyls are prospective ligands in the sense that they are isoelectronic with cyclopentadienyl.

The lithium salt of 2-methyl-1-trimethylsilyl-1,2-azaborolynyl with iron(II) and cobalt(II) bromides gives sandwiches **52** ($M = \text{Fe, Co}$, $R = \text{SiMe}_3$) (82CB732). Lithium 1-*tert*-butyl-2-methyl-1,2-azaborolynyl reacts with iron(II) and cobalt(II) bromide to yield sandwiches **52** ($M = \text{Fe, Co}$, $R = t\text{-Bu}$) and with titanium(IV) bromide to give **52** ($M = \text{TiBr}_2$, $R = t\text{-Bu}$) (82CB3830). Neutral 2-methyl-1-trimethylsilyl- Δ^3 -1,2-azaboroline with vanadium in a vapor-phase synthesis gives sandwich **52** ($M = \text{V}$, $R = \text{SiMe}_3$). Sandwich **52** ($M = \text{Fe}$, $R = \text{SiMe}_3$) (80JOM(193)83, 81CB1297, 82AGE68, 82CB3830) can be lithiated at the nitrogen heteroatom using $\text{Li}(\text{TMP})$ to yield **52** ($M = \text{Fe}$, $R = \text{Li}$) (83CB951). The latter with *tert*-butanol gives **52** ($M = \text{Fe}$, $R = \text{H}$) and **52** ($M = \text{Fe}$, $R = \text{Me, Et}$) with methyl iodide or ethyl bromide. Species **53** [$R = \text{Cl}$, $\text{ML}_n = \text{Fe}(\text{CO})_2\text{I}$] follows from the corresponding B-chloroboracycle with iron pentacarbonyl and then molecular iodine (02AGE174). Further interaction of the product with thallium (η^5 -cyclopentadienyl) gives **53** [$R = \text{Cl}$, $\text{ML}_n = \text{Fe}(\eta^5\text{-Cp})$]. Complex **53** [$R = \text{Me}$, $\text{ML}_n = \text{Co}(\text{CO})_2$] undergoes photolysis with ethylene to give **53** [$R = \text{Me}$, $\text{ML}_n = \text{Co}(\text{C}_2\text{H}_4)_2$] (90ZN(B)1235). With 2-butyne, diphenylethyne, 3-hexyne, and 4-octyne, the species **53** [$R = \text{Me}$, $\text{ML}_n = \text{Co}(\text{C}_2\text{H}_4)_2$] forms two types of compounds: the products of cyclotrimerization-the 1,3-cyclohexadiene sandwiches **54** with $R = \text{Me, Ph, Et, and } n\text{-Pr}$, respectively (92OM1789, 95JOM(492)185), and the products of cyclodimerization-the cyclobutadiene sandwiches **55** ($R = \text{Ph, Et, } n\text{-Pr}$) for diphenylethyne, 3-hexyne, and 4-octyne (95JOM(492)185). Note that 2-butyne forms only the cyclotrimerized complex **54** ($R = \text{Me}$). Complex **56** is the product of interaction of 1-*tert*-butyl-3-methyl-2-phenyl- Δ^3 -azaboroline and $[\text{Fe}(\text{CO})_5]$ (80AGE54).




Oxidation of the borazole complexes $[(\eta^5\text{-C}_3\text{H}_3\text{B}(\text{Me})\text{NR})_2\text{Co}]$ ($\text{R} = \text{Me}$, $t\text{-Bu}$, SiMe_3) by iodine leads to $[(\eta^5\text{-C}_3\text{H}_3\text{B}(\text{Me})\text{NR})_2\text{Co}]_n$ ($n = 3\text{--}5$). The hexafluorophosphate salts are obtained by oxidation using ferricinium hexafluorophosphate (83JOM(256)225, 86JOM(305)1).

1-*tert*-Butyl-2-methyl-1,2-azaborolynyl ligand in the nickel complex **57** reveals the properties of a three- rather than a five-electron donor (86JOM(305)199).




1,2-Dihydro[1,3,2]diazaborolo[1,5-*a*]pyridines are useful as well (01JCS(D)378). They are interesting $\eta^5\text{-}(\pi\text{-})$ ligands (85CB2418, 91AGE1015, 96MI4), and form $\text{Cr}(\text{CO})_3$ complexes (77AGE249, 81CB495).


An interesting case of the benzannulated B, N complex is species **58** ($\text{X} = \text{Cl}$) (00AGE948), prepared from $[(\text{OC})\text{Os}(\text{PPh}_3)_2\text{Cl}(\text{BCl}_2)]$ and 8-aminoquinoline. It reacts with tetra-*n*-butyl ammonium iodide and forms **58** ($\text{X} = \text{I}$).




A series of 1,3,2-diazaboroles in a thermal substitution reaction with $[\text{Cr}(\text{CO})_3(\text{AN})_3]$ forms the $\eta^5\text{-coordinated}$ complexes **59** ($\text{R} = \text{R}' = \text{Me}$, Et , $i\text{-Pr}$; $\text{R} = \text{Me}$, $\text{R}' = \text{Et}$) (90IC4421). The corresponding dimeric ligand in this reaction yields complex **60** where only one heteroring is $\eta^5\text{-coordinated}$.



Interaction of iron(II) chloride with the lithium salt of $R_4B_2N_3^-$ ($R = Me, Et$) gives sandwiches **61** ($R = Me, Et$) ([67ZAAC1](#), [96MI4](#)), resembling in electronic properties those of ferrocene ([99ICA\(288\)17](#)). The π - (η^5 -) complex stems from the further complex-formation of **61** ($R = Me, Et$) with mercury(II) salts via the unsubstituted nitrogen atom.










4,5-Dimethyl-1,2,2,3-tetramethyl- Δ^3 -1,2,5-azasilaboroline with $[Fe_2(CO)_9]$ gives sandwich **62** and sandwich **63** ([82AGE207](#), [82CB738](#)) with $[(\eta^5-Cp)Co(C_2H_4)_2]$. With $[Ni(CDT)]$ or in a vapor phase with metallic nickel, sandwich **64** ($M = Ni$) is formed. The vapor-phase synthesis with iron gives **64** ($M = Fe$). In all these sandwiches, **62–64**, the η^4 -coordination of the heterocyclic ligand is realized.



V. Complexes of Silicon Analogues of Imidazol-2-ylidenes

Silicon analogues of imidazol-2-ylidenes are stable as the parent compounds and are characterized to some extent by aromatic stabilization ([96JCS\(D\)1475](#), [00JCS\(CC\)1427](#), [02JOM\(643\)272](#)). The synthesis, structure, and properties of the silicon ([94JA2691](#), [94JA6641](#), [94JA10813](#), [94JCS\(CC\)33](#), [94JCS\(D\)2405](#), [96JCS\(CC\)2657](#), [96MI1](#), [96PAC785](#), [98EJIC1067](#), [98JA12714](#), [98OM2352](#), [00ACR704](#), [00OM4726](#)) and germanium ([92AGE1485](#), [98AX\(C\)1830](#)) analogues have been studied. 1,3-Di-*tert*-butyl-1,3,2-diazasilol-2-ylidene reacts with $[(\eta^6-Mes)Cr(CO)_3]$, $[Fe_2(CO)_9]$, and $[Ni(CO)_4]$ to yield stable carbene complexes ([94JCS\(CC\)33](#), [96MI3](#), [96PAC785](#)). The same ligand with $[(\eta^5-Cp)_2MH_2]$ ($M = Mo, W$) gives **65**


(M = Mo, W) (99OM2615), which results from the insertion of the ligand into the M–H bond. Interaction with $[(\eta^5\text{-Cp})_2\text{Mo}(\text{PEt}_3)]$ in a typical ligand substitution reaction is followed by the formation of carbene complex **66**. The product can add water to yield **67**. Photochemical reaction with $[\text{M}(\text{CO})_6]$ (M = Cr, Mo, W) gives the bis-carbene complexes *trans*- $[\text{M}(\text{CO})_4\text{L}_2]$ (M = Cr, Mo, W) (01JOM(636)17). With $[\text{Fe}_2(\text{CO})_9]$ in THF, the product is $[\text{LFe}(\text{CO})_5]$, while with $[\text{Ru}_3(\text{CO})_{12}]$ in THF $[\text{L}_2\text{Ru}(\text{CO})_3]$ is formed. The data show that the M–Si bond in these species is weaker than the M–C bond in the corresponding imidazol-2-ylidene complexes in accordance with theoretical calculations (98OM5801). 1,3-Di-*tert*-butyl-1,3,2-diazasilol-2-ylidene with $[(\{\text{Cy}_2\text{P}(\text{CH}_2)_4\text{PCy}_2\}\text{ClRu}(\mu\text{-Cl})_3\text{Ru}\{\text{Cy}_2\text{P}(\text{CH}_2)_4\text{PCy}_2\}(\text{N}_2)]$ gives the $\eta^1(\text{Si})$ -coordinated species **68** (02OM534). Other illustrative examples with a bulkier ligand include complexes **69**, **70** (98OM5599), and **71** (00OM3263).




VI. Complexes of Azaphospholes

Conjugative stabilization of the phosphorus lone pair in the P- and also the As-analogue of benzimidazole with the π -system is less than in the parent benzimidazole (89JOM(373)49, 89JOM(373)57). In a series of 1,3-azaphospholes, 1,2,4-diazaphospholes, and 1,2,3,4-triazaphospholes, aromatic stability increases with the number of the nitrogen atoms in the heteroring (89MI1, 90MI3, 92JA9080, 92JCP623, 94TOC307, 95JMS(T)55, 96MI2, 96MI3, 96PSS109, 01CRV1229, 01CRV3549). The same trends can be noted for the arsenic analogues of azaphospholes (95JMS57). In the analogues of imidazol-2-ylidene the reaction site, the carbene carbon atom, is replaced by a phosphorus-chlorine grouping (96TL9025, 99EJIC41), or by P-R groups (00CEJ3414, 00EJIC369, 00EJIC2425, 01JOM(617)737).


2H-1,2-Azaphosphole complexes containing the $\eta^1(\text{P})$ -coordinated site can be obtained by thermolysis of the corresponding 2H-azaphosphirene $\text{W}(\text{CO})_5$ species **72** ($\text{R} = p\text{-MeOC}_6\text{H}_4$, Ph, $p\text{-F}_3\text{C-C}_6\text{H}_4$) in dimethylacetylene dicarboxylate (95JCS(CC)2113, 97AGE1492, 97ZAAC1897, 98CEJ1542, 98EJIC2005, 99JCS(CC)2127, 99OM5627, 00EJIC1253, 00JCS(D)2495, 00OM475). The products of thermolysis are **73** ($\text{R} = p\text{-MeOC}_6\text{H}_4$, Ph, $p\text{-F}_3\text{C-C}_6\text{H}_4$). Nitrilium phosphane ylide complexes **74** ($\text{R} = \text{Ph}$, Me_2N) in dimethylaminonitrile ($\text{R} = \text{Ph}$) or benzonitrile ($\text{R} = \text{Me}_2\text{N}$) give the $\eta^1(\text{P})$ -coordinated 2H-1,3,2-diazaphosphole species **75** by 1,3-dipolar cycloaddition (97JCS(CC)2317, 98JCS(CC)1529). The product has a planar heteroring where the double bonds are localized. The 2H-azaphosphirene complex bearing the pentamethylcyclopentadienyl substituent at the phosphorus atom adds dimethyl acetylenedicarboxylate in benzonitrile at elevated temperature to give complex **76**, which undergoes further [4+2] cycloaddition of the acetylene derivative with elimination C_5Me_5 to yield **77** (99EJIC1567). Complexes similar to **76** have instead of a phenyl group a piperidino moiety. Instead of a cyclopentadienyl substituent there are Me or Ph groups attached (00AGE3686). Complexes of type **72** [$\text{R} = \text{Ph}$, instead of $\text{W}(\text{CO})_5$ - $\text{M}(\text{CO})_5$, $\text{M} = \text{Cr}$, Mo , W] react with 1-piperidinonitrile and TCNE to yield in toluene **78** ($\text{M} = \text{W}$; $\text{R} = 1\text{-piperidino}$) and yield **78** ($\text{M} = \text{Cr}$, Mo , W) (00CEJ3997) without solvent. With TCNE in benzo- or acetonitrile, the tungsten precursor gives **78** ($\text{M} = \text{W}$; $\text{R} = \text{Ph}$, Me). A similar synthetic approach to the complexes of 2H-1,2,3-azadiphospholes was applied (00JCS(CC)1659). Thermolysis of complexes **79** ($\text{R} = \text{Me}$, Ph) with 1-piperidino carbonitrile gives 2H-1,3,2- (**80**; $\text{R} = \text{Me}$, Ph) and 2H-1,4,2-diazazaphosphole (**81**; $\text{R} = \text{Me}$, Ph) complexes with the $\eta^1(\text{P})$ -coordination mode (01EJIC3175).




Benzonitrile with $[(\eta^1\text{-Cp}^*)\text{P}\{\text{W}(\text{CO})_5\}_2]$ gives **82**, the result of migration of the phosphorus atom, insertion of the nitrile moiety into the P–C bond and further C–H bond activation ([01AGE3413](#)).




The 1,2-azaphosphole $\eta^1(\text{P})$ -coordinated complexes **83** and **84** follow from the corresponding ligand and $[(\eta^3\text{-allyl})\text{NiCl}]_2$ and $[(1,5,9\text{-cyclododecatriene})\text{Ni}]$, respectively ([98ICA\(270\)273](#)).




2-phosphaindolizine **94** that follows from the ligand and $[(\text{THF})\text{Cr}(\text{CO})_5]$ (**98EJIC1079**).



4-(Bis(dimethylaminotrimethylsilyl)imino)(phosphorano)-2,5-dimethyl-2*H*-1,2,3-diazaphosphole (**99IC1971**) with $[(\eta^5\text{-Cp}^*)\text{TiCl}_3]$ forms a complex with an exocyclic mode of coordination, **95** (**99IC2791**). This mode is also observed in $[(\eta^5\text{-Cp})\text{Ru}(\text{PPh}_3)(\text{L})\text{Cl}]$, the product of the interaction of 4-(difluorophosphino)-2,5-dimethyl-2*H*-1,2,3-diazaphosphole (L) and $[(\eta^5\text{-Cp})\text{Ru}(\text{PPh}_3)_2\text{Cl}]$ (**99OM3306**). The same ligand with $[(\eta^5\text{-Cp}^*)\text{RhCl}_2]_2$ gives the monosubstituted complex **96** and with $[(\eta^5\text{-Cp})\text{Rh}(\text{CO})_2]$ the disubstituted product **97** is formed. Although this type of coordination prevails (**80JOM(185)53**), exocyclic coordination is not excluded (**83JOM(256)375**, **88IC2612**).




2*H*-Azaphosphirene complexes **98** ($\text{X} = \text{H}, \text{Me}, \text{OMe}, \text{NMe}_2$) with benzonitrile in the presence of ferrocenium hexafluorophosphate give rise to the 2*H*-1,2,4-diazaphosphole species **99** ($\text{X} = \text{H}, \text{Me}, \text{OMe}, \text{NMe}_2$) with the $\eta^1(\text{P})$ -coordination mode (**02JOM(643)253**). 1,2,4-Diazaphospholide ligand (L) in the species $[(\eta^5\text{-Cp})\text{Fe}(\text{CO})_2\text{L}]$ is $\eta^1(\text{N})$ -coordinated (**95OM581**).




VII. Complexes of Di- and Triphospholes and Corresponding Phosphorus-Antimony Ligands

A. NON-TRANSITION ELEMENTS

In a manner similar to that of phospholes, di-, tri-, and pentaphospholes (84CJC341, 86AGE644, 86JCS(CC)737, 87JCS(CC)844, 87JOM(323)C35, 92JOC3694, 96IC4690, 96JPC6194, 96JPC13447, 98AGE1083, 00AGE1029, 00AGE2307) as well as their arsenic and antimony analogues (81AGE33) reveal a tendency to form η^5 -coordination, the products being highly reactive (80PAC1443, 87JOM(334)C35, 87MI1, 88CB443, 88CRV1327, 89POL2407, 90AGE534, 90CRV169, 90CRV191, 90MI1, 90MI2, 90MI3, 90PAC423, 90ZC41, 90ZC55, 91CB1159, 91OM2835, 92CCR(120)259, 92MI1, 93CI(L)404, 94CCR(137)1, 95CCR(145)201, 96ADOC325, 98ADOC1, 98CCR(178)771, 98CSR319, 98MI1, 99ACR751, 01EJIC891). Nevertheless, their electronic characteristics contrast to those of the cyclopentadienyl analogues (83OM1008, 89POL1135, 90IC879). In particular, the P_3C_2 ring containing two *tert*-butyl substituents at carbon atoms is more electron-withdrawing than the cyclopentadienyl counterpart (97JOM(529)375). The di- and triphospholyl anions typically include $C_3-t-Bu_3P_2^-$ and $C_2-t-Bu_2P_3^-$ (92JOM(430)C10, 93JOM(453)C16, 93POL1383, 94JCS(CC)489, 95JCS(CC)1659) and differently substituted derivatives (91JOM(415)C15, 92POL601). The anion of $P_2SbC_2Bu_2^-$ forms simple salts with lithium compounds (97JOM(527)291, 00OM1713). However, with potassium compounds, distinct complexes are formed (00OM219, 01JOM(622)61). Thus (01JOM(622)61), $KSb(SiMe_3)_2$ when reacted with $(Me_3Si)P=C(Bu^t)(OSiMe_3)$ in DME gives sandwich **100**. With tetravalent silicon and germanium compounds, SiI_4 or GeI_4 (00JCS(CC)879) and $SiMe_2Cl_2$ (01JOM(622)61), potassium complexes form the silicon- or germanium-containing cage compounds.




The vapor phase synthesis of sandwiches **101** and **102** involves the co-condensation of *tert*-butyl phosphaethyne and metallic indium vapor (99OM793, 00JCS(D)1715). The thallium derivative has the composition $[\text{Tl}(\mu\text{-}\eta^5\text{:}\eta^5\text{-1,2,4-P}_3\text{C}_2\text{Bu}_2^t)]$ (99JCS(CC)1731, 00JCS(D)1013, 00JCS(D)1507, 00JCS(D)3534) or $[\text{Tl}(\mu\text{-}\eta^5\text{:}\eta^5\text{-1,4,2-P}_2\text{SbC}_2\text{Bu}_2^t)]_\infty$ (98OM3826). Species $[(\eta^5\text{-Cp}^*)\text{M}(\eta^5\text{-P}_2\text{SbC}_2\text{Bu}_2^t)]$ ($\text{M} = \text{Sn}, \text{Pb}$) can be prepared similarly (99JCS(D)4057, 00JCS(CC)2027). The anion $\text{P}_3\text{C}_2\text{Bu}_2^{t-}$ with PbCl_2 forms the sandwich **103**, while the antimony analogue $\text{P}_2\text{SbC}_2\text{Bu}_2^{t-}$ in this reaction (as in the reaction with FeCl_2 (97JCS(CC)305)) gives the product of oxidative coupling in the form of the cage compound $\text{P}_4\text{Sb}_2\text{C}_4\text{Bu}_4^t$ (99JCS(D)2627). In a similar synthetic procedure, $\text{P}_3\text{C}_2\text{Bu}_2^{t-}$ with PbCl_2 but in the presence of $[(\eta^5\text{-Cp}^*)\text{Li}]$ gives the mixed sandwich **104** ($\text{E} = \text{P}$). The antimony analogue **104** ($\text{E} = \text{Sb}$) can be prepared from the relevant anion and $[(\eta^5\text{-Cp}^*)\text{PbCl}]$ but it is contaminated with **104** ($\text{E} = \text{P}$). In the reaction with $\text{E}(\text{S}_2\text{CNEt}_2)_2$ ($\text{E} = \text{Se}, \text{Te}$), the anion of 1,4,2- $\text{P}_2\text{SbC}_2\text{Bu}_2^t$ gives 1,4,2- $\text{P}_2\text{EC}_2\text{Bu}_2^t$ ($\text{E} = \text{Se}, \text{Te}$) (99TL3815).




B. CHROMIUM AND MANGANESE GROUPS

Sandwich $[\text{Cr}(\eta^5\text{-P}_3\text{C}_2\text{-}t\text{-Bu}_2)_2]$ is known and its structure is unequivocal (88JOM(356)C1). The η^5 -coordination is also realized in $[(\eta^5\text{-P}_2\text{C}_3\text{-}t\text{-Bu}_3)\text{Mo}(\eta^3\text{-indenyl})(\text{CO})_2]$ (90JCS(CC)472).


Complex **105** in an atmosphere of carbon monoxide experiences rearrangement to **106**, which through C-H activation gives the final product **107** with η^4 -coordination of the 3,4-diphosphacyclopentadienone ligand (97JCS(CC)1539).



A 1,3,4-triposphole complex is prepared in the thermally induced regio-specific insertion of (*i*-Pr)(Me₃Si)N–C≡P into the phosphorus–phosphorus bond of species **108** to yield **109** (01AGE2471).




1-Triphenylstannyl-3,5-di(*tert*-butyl)-1,2,4-triposphole and [Mn(CO)₅Br] give the triphosphacymantrene **110** (99PSS725, 00AGE2087). The rhenium analogue is known (01JCS(D)1726). Further reaction of **110** with [Cr(CO)₅(THF)] gives the $\eta^5:\eta^1$ complex **111**. The same starting ligand with [Mn(NSiMe₃)₂] yields sandwich **112**.




C. IRON GROUP

Lithium 1,2-diphospholide with $[(\eta^6\text{-}p\text{-Me}_2\text{C}_6\text{H}_4)\text{Fe}(\eta^5\text{-Cp})](\text{PF}_6)$ gives sandwich **113** (95AGE590). Similarly, lithium 1,3-diphospholides with $[(\eta^6\text{-C}_6\text{H}_6)\text{Fe}(\eta^5\text{-Cp})]$ give sandwiches **114** ($\text{R} = \text{Me}, \text{Et}$), and with $[(\eta^6\text{-1,4-xylylene})\text{Fe}](\text{PF}_6)_2$ -1,1',3,3'-tetraphosphaferrocenes **115** ($\text{R}^1 = \text{R}^2 = \text{Me}, \text{Et}$; $\text{R}^1 = \text{Me}, \text{R}^2 = t\text{-Bu}$) (92POL601). 2-Diphenylphosphino-4,5-diphenyl-1,3-diphospholide reacts with $[(\eta^5\text{-Cp})\text{Fe}(\eta^6\text{-Me}_2\text{C}_6\text{H}_4)](\text{PF}_6)$ to yield sandwich **116**, which retains the ligating properties and further reacts with $[\text{W}(\text{CO})_5(\text{THF})]$ to yield the $\eta^5:\eta^1$ coordinated species **117** (97JOM(529)69). Reaction of $\text{K}(\text{THF})(\text{P}_2\text{C}_3\text{Bu}')_3$ with iron(II) chloride in THF gives sandwich **118** (01JCS(D)1013).








A mixture of the sodium salts of $\text{P}_2\text{C}_3\text{-}t\text{-Bu}_3^-$ and $\text{P}_3\text{C}_2\text{-}t\text{-Bu}_2^-$ with $[(\eta^4\text{-cod})\text{RuCl}_2]_n$ gives the sandwich **119**, while with $[(\eta^6\text{-C}_6\text{H}_6)\text{RuCl}_2(\text{PPh}_3)]$, the derivative **120** is formed (93JOM(462)319).








Reaction of $[(\eta^5\text{-1,3-}t\text{-Bu}_2\text{C}_5\text{H}_3)(\text{OC})_2\text{Fe-P}(\text{SiMe}_3)\text{P}=\text{C}(\text{SiMe}_3)_2]$ with $[(\text{cyclooctene})\text{Cr}(\text{CO})_5]$ yields the sandwich having the $\eta^5:\eta^1$ coordination

mode, **121** among other products (95CB665). Thermolysis of the product in toluene in the presence of $[\text{Fe}_2(\text{CO})_9]$ provides the pure η^5 -product, **122**, which on photolysis with $\text{Fe}(\text{CO})_5$ in *n*-pentane gives another representative of the $\eta^5:\eta^1$ group, **123**. Refluxing **121** in *n*-pentane in excess $[\text{Fe}_2(\text{CO})_9]$ gives the species with the side-on-coordination of one of the iron sites, **124**. The starting complex **121** also reacts with $[\text{Ni}(\text{CO})_4]$ and at room temperature produces the $\eta^5:\eta^1$ complex **125**. The other complex with the mixed $\eta^5:\eta^1$ coordination is $[(\eta^5\text{-P}_2\text{C}_3\text{-}t\text{-Bu}_3)\text{Fe}(\eta^5\text{-P}_3\text{C}_2\text{-}t\text{-Bu}_2)\text{W}(\text{CO})_5]$ (92JOM(430) C10). The cyclization reaction between $[(\eta^5\text{-}t\text{-BuC}_5\text{H}_4)(\text{OC})_2\text{Fe-P}(\text{SiMe}_3)\text{-P}=\text{C}(\text{SiMe}_3)_2]$ and $[(\text{COE})\text{Cr}(\text{CO})_5]$ gives **126** ($\text{M}=\text{Cr}$; $\text{R}^2=t\text{-Bu}$, $\text{R}^1=\text{R}^3=\text{R}^4=\text{R}^5=\text{H}$) (96ZAAC543). In a similar way, derivatives **126** ($\text{M}=\text{Cr}$; $\text{R}^1=\text{R}^2=\text{R}^3=\text{R}^4=\text{R}^5=\text{Me}$) (91JCS(CC)1293, 93OM731) and **126** ($\text{M}=\text{Cr}$; $\text{R}^2=\text{R}^5=t\text{-Bu}$, $\text{R}^1=\text{R}^3=\text{R}^4=\text{H}$) (95CB665) can be prepared. If the reaction is started with $(\text{Me}_3\text{Si})_2\text{P-P}=\text{C}(\text{SiMe}_3)_2$ and $[(\eta^5\text{-}t\text{-BuC}_5\text{H}_4)\text{Fe}(\text{CO})_2\text{Br}]$, the η^5 -coordinated diphosphaferrocene **127** ($\text{R}^2=t\text{-Bu}$, $\text{R}^1=\text{R}^3=\text{R}^4=\text{R}^5=\text{H}$) results; this can form the $\eta^5:\eta^1$ species **126** ($\text{M}=\text{Cr}$; $\text{R}^2=t\text{-Bu}$, $\text{R}^1=\text{R}^3=\text{R}^4=\text{R}^5=\text{H}$) on interaction with $[(\text{COE})\text{Cr}(\text{CO})_5]$ (96ZAAC543). This synthetic route for the diphosphole sandwiches can be used for **127** ($\text{R}^1=\text{R}^2=\text{R}^3=\text{R}^4=\text{R}^5=\text{H}$) (91JCS(CC)1659). A similar sandwich **127** ($\text{R}^2=\text{R}^5=t\text{-Bu}$, $\text{R}^1=\text{R}^3=\text{R}^4=\text{H}$) photolyzes with $[\text{M}(\text{CO})_6]$ ($\text{M}=\text{Mo}$, W) to yield the $\eta^5:\eta^1$ coordinated products **126** ($\text{M}=\text{Mo}$, W ; $\text{R}^2=\text{R}^5=t\text{-Bu}$, $\text{R}^1=\text{R}^3=\text{R}^4=\text{H}$) (96ZAAC543). Photolysis with $[(\eta^5\text{-MeC}_5\text{H}_4)\text{Mn}(\text{CO})_3]$ gives the $\eta^5:\eta^1$ product **128**. Reaction with $[\text{Co}_2(\text{CO})_8]$ in turn gives the trinuclear species **129**.







Sandwiches $[\text{Fe}(\eta^5\text{-C}_3\text{Et}_2\text{HPAs})_2]$ (93BSCF521), $[\text{Fe}(\eta^5\text{-P}_3\text{C}_2\text{-}t\text{-Bu}_2)_2]$ (87JCS(CC)1146, 97CCCC309, 99CEJ3143, 99JOM(584)87) and the $\eta^5:\eta^1$ coordinated species $[(\eta^5\text{-Cp})\text{Fe}(\eta^5\text{-C}_2\text{-}t\text{-Bu}_2\text{AsP}_2)\text{W}(\text{CO})_5]$ (94JOM(480)45) are known. Sandwiches **130** (87JCS(CC)1146), **131** (87JCS(CC)1146, 94JOM(479)C28), and **132** (88JOM(340)C37, 93JOM(453)C16) possess remarkable properties as ligands (88CRV1327, 91E49, 93CI(L)404, 96JOM(572)141). Among the illustrations of the P-coordinated species are **133** ($n = 5$, $M = \text{W}$; $n = 4$, $M = \text{Fe}$), **134** (92JOM(430)C10), and **135** ($n = 5$, $M = \text{Cr}$, W ; $n = 4$, $M = \text{Fe}$; $n = 2$, $M = \text{Ni}$) (93POL1383). In the case of $M = \text{Ni}$, the product **136** is also possible. Mixed sandwich **131** with $[\text{N}(n\text{-Bu})_4][\text{Ir}_4(\text{CO})_{11}\text{Br}]$ in the presence of AgSbF_6 gives **137**, and species **132** gives an identical product **138**, which is in isomeric equilibrium with **139** (96JCS(CC)441). Further reaction of **138** with $[\text{N}(n\text{-Bu})_4][\text{Ir}_4(\text{CO})_{11}\text{Br}]$ in the presence of AgSbF_6 is unique and gives the sterically crowded complex **140**, in which two phosphorus sites are engaged in coordination. Sandwich **132** reacts with $[(\eta^5\text{-Cp}^*)\text{Rh}(\text{CO})_2]$ to yield the edge-coordinated triphosphaferrocene, **141** (99JOM(584)87).




Triphospholyl anions $C_2-t-Bu_2PEE'^-$ ($E = E' = P$; $E = As, E' = P$; $E = P, E' = As$) (93PSS45, 96JCS(CC)1591, 97JCS(D)4321, 97JOM(527)291) form the ruthenium cyclopentadienyl sandwiches (95JOM(490)155). A mixture of the sodium salts of $P_2C_3-t-Bu_3^-$ and $P_3C_2-t-Bu_2^-$ reacts with $[RuCl_2(PPh_3)_3]$ to give the mixed sandwich **142** (95JOM(490)155). The lithium salt of $P_3C_2-t-Bu_2^-$ under similar conditions gives the symmetrical sandwich **143**. The same mixture of sodium salts but with $[(\eta^5-Cp)RuCl(PPh_3)_2]$ gives sandwich **144** ($R = H$) and with $[(\eta^5-Cp^*)RuCl(\eta^4-nbd)]$ sandwich **144** ($R = Me$).




With $[(\eta^5-Cp^*)Ru(AN)_3](PF_6)$, they first form sandwiches **145** ($E = E' = P$; $E = As, E' = P$; $E = P, E' = As$), and then in the presence of excess ruthenium precursor, they yield the cationic triple-deckers **146** ($E = E' = P$; $E = As, E' = P$; $E = P, E' = As$) (95OM4382). The iron sandwiches **147** ($E = E' = P$; $E = As, E' = P$; $E = P, E' = As$) however react with $[(\eta^5-Cp^*)Ru(AN)_3](PF_6)$ differently, giving the $\eta^5:\eta^1$ species **148** ($E = E' = P$; $E = As, E' = P$; $E = P, E' = As$). The latter are transformed to triple-deckers **149** ($E = E' = P$; $E = As, E' = P$; $E = P, E' = As$) only on further refluxing in nitromethane. The pentamethylcyclopentadienyl analogues of **147** ($E = E' = P$; $E = As, E' = P$; $E = P, E' = As$) react with $[(\eta^5-Cp^*)Ru(AN)_3](PF_6)$ straightforwardly and yield the triple-decker analogues of **149** ($E = E' = P$; $E = As, E' = P$; $E = P, E' = As$), where the iron site is η^5 -bonded to the Cp^* framework.




A mixture of 1,4,2-diphosphastibolyl and 1,2,4-triphospholyl anions with $[\text{RuCl}_2(\text{PPh}_3)_3]$ give an isomeric mixture of antimony-containing sandwiches **150** and **151** as well as sandwich **152** (97JCS(D)2183). In the same conditions FeCl_2 produces sandwich **153** only. If $[(\eta^5\text{-C}_5\text{R}_5)\text{Ru}(\text{AN})_3](\text{PF}_6)$ ($\text{R} = \text{H}, \text{Me}$) are used as organometallic precursors, the products are **154** ($\text{R} = \text{H}, \text{Me}$), which react further with $[\text{W}(\text{CO})_5(\text{THF})]$ to yield the $\eta^5:\eta^1$ coordinated species **155** ($\text{R} = \text{Me}$). The same chain of transformations takes place with FeCl_2 in the presence of lithium pentamethylcyclopentadienyl (**156**) and then $[\text{W}(\text{CO})_5(\text{THF})]$ (**157**). In excess $[(\eta^5\text{-Cp}^*)\text{Ru}(\text{AN})_3](\text{PF}_6)$, the triple-decker **158** results.



The 1,2,4-triphosphole ligand, $\text{P}_3\text{C}_2\text{Bu}^t\text{CH}(\text{SiMe}_3)_3$, displaces naphthalene from $[(\eta^4\text{-cod})\text{Ru}(\eta^6\text{-C}_{10}\text{H}_8)]$ to yield **159** (95JCS(CC)1661, 96JCS(CC)2751). Further treatment with carbon monoxide gives the dicarbonyl species **160**, the product of displacement of $\eta^4\text{-cod}$ (99JOM (584)58). The latter easily reacts with water followed by **161**.




1,2,3-Triphenylphospholyl ligands are quite rare ([94BSCF397](#)). The reaction between $[(\eta^5\text{-}1,2,3\text{-Bu}_3^t\text{C}_5\text{H}_2)(\text{OC})_2\text{Fe}(\mu\text{-}\eta^1\text{-P}_4)\text{Fe}(\text{CO})_2(\eta^5\text{-}1,2,3\text{-Bu}_3^t\text{C}_5\text{H}_2)]$ or $[(\eta^5\text{-Pr}_5^i\text{C}_5)(\text{OC})_2\text{Fe}(\mu\text{-}\eta^1\text{-P}_4)\text{Fe}(\text{CO})_2(\eta^5\text{-Pr}_5^i\text{C}_5)]$ with diphenylacetylene gives sandwiches **162** ($\text{R}^1 = \text{R}^2 = \text{R}^4 = \text{Bu}^t$, $\text{R}^3 = \text{R}^5 = \text{H}$; $\text{R}^1 = \text{R}^2 = \text{R}^3 = \text{R}^4 = \text{R}^5 = \text{Pr}^i$) ([00AGE1426](#)).




D. COBALT GROUP


Sandwiches of the cobalt group are known, e.g., the one with the mixed coordination mode, **163**, prepared from the corresponding 1,2,4-triphenylphosphole anion and cobalt(II) chloride ([88JCS\(CC\)819](#)), as well as the mixed-ligand species $[(\eta^5\text{-P}_3\text{C}_2\text{-}t\text{-Bu}_2)\text{Rh}(\eta^4\text{-cod})]$ ([88JCS\(CC\)1615](#)). Species $[(\eta^5\text{-Cp})\text{RhH}(\eta^1\text{-P}_3\text{C}_2\text{-}t\text{-Bu}_2)(\text{PPh}_3)]$ is not a frequent representative of the η^1 -coordination of the triphenylphospholyl ring ([93JOM\(462\)319](#)). A mixture of the sodium salts of $\text{C}_3\text{-}t\text{-Bu}_3\text{P}_2^-$ and $\text{C}_2\text{-}t\text{-Bu}_2\text{P}_3^-$ with $[(\eta^4\text{-cod})\text{RhCl}]_2$ and $[(\eta^4\text{-hexadiene})\text{RhCl}]$ gives products of type **164**, while $[(\eta^5\text{-Cp}^*)\text{RhCl}_2(\text{PPh}_3)]$ gives the P-coordinated complex **165**. Complex $[(\eta^5\text{-P}_3\text{C}_2\text{-}t\text{-Bu}_2)\text{Rh}(\eta^4\text{-cod})]$ results from a mixture of the same lithium salts and $[(\eta^4\text{-cod})\text{RhCl}]_2$ ([88JCS\(CC\)1475](#)).




2,4-Diphosphastibolyl anion reacts with $[(\eta^4\text{-cod})\text{MCl}_2]$ to give **166** ($\text{M} = \text{Rh}, \text{Ir}$) (97JOM(534)89). The same salt mixed with lithium cyclopentadienyl and CoCl_2 gives a mixture of two sandwiches **167** and **168**.



1-Triphenylstannyl-3,5-di(*tert*-butyl)-1,2,4-triphosphole with $\text{Co}_2(\text{CO})_8$ gives the η^5 -coordinated species **169** (01OM2905). The latter enters into photochemical CO-substitution reactions with triethyl- and triphenylphosphine; one carbonyl ligand is substituted. With cyclohexylcyanide, however, a mixture of two substitution products is formed, with one and two CO ligands being substituted by CN-Cy groups, respectively.




The metal-vapor technique was applied to cobalt atoms and $t\text{-BuC}\equiv\text{P}$ (01JOM(635)212). The mixture of products that resulted includes the mixed-ligand sandwiches **170** and **171**. Further interaction of complex **170** with $[\text{W}(\text{CO})_5(\text{THF})]$ leads to the coordination of the $\text{W}(\text{CO})_5$ -group via the phosphorus heteroatom of the four-membered ring to yield **172**.




E. NICKEL GROUP


In the nickel group, it is interesting to mention the mixed sandwich $[(\eta^5\text{-P}_3\text{C}_2\text{-}t\text{-Bu}_2)\text{Ni}(\eta^5\text{-P}_2\text{C}_3\text{-}t\text{-Bu}_3)]$ (89JOM(373)C17). There are also the representatives of the $\eta^1(\text{P})$ -coordinated complexes, $[\text{MCl}(\text{P}_3\text{C}_2\text{-}t\text{-Bu}_2)(\text{PEt}_3)]$ ($\text{M}=\text{Pd}, \text{Pt}$) (89JNC353, 93JOM(461)237), *trans*- $[\text{PtCl}_2(\text{PEt}_3)\{\text{P}_3\text{C}_2\text{-}t\text{-Bu}_2\text{CH}(\text{SiMe}_3)_2\}]$ (95JCS(CC)1661). In the latter case, the coordination is via the P^3 -center. A unique case of $\eta^5:\eta^2$ coordination is known (97JCS(CC)1739). The η^2 -coordination represents the rare edge mode, **173**. In the species $[\text{Ni}(\text{P}_2\text{C}_3\text{Bu}_3)_2]$, the $\eta^5:\eta^3$ coordination mode is realized (95JOM(487)C21).




1-Trimethylstannyl-3,5-di-*tert*-butyl-1,2,4-triphosphole with $[(\text{Ph}_3\text{P})_2\text{NiCl}_2]$ gives sandwich **174** (00OM4283). However, the same ligand with $[(\text{Ph}_3\text{P})_2\text{Ni}(\text{NO})\text{Cl}]$ gives the exo-bidentate species **175** with a very rare coordination mode for this type of ligands (98ZAAC399). At elevated temperatures the triphenylphosphine ligands are eliminated and the η^5 -coordinated species **176** is formed in solution (00OM4283). This conclusion is based on solution data. Indirect confirmation of this possibility is found in the reaction between **176** and $[\text{W}(\text{CO})_5(\text{THF})]$ to yield the $\eta^5:\eta^1$ coordinated complex **177**.



The metal-vapor synthesis, involving co-condensation of nickel vapors, $t\text{-BuC}\equiv\text{P}$, and 1,2,4-triphospholyl system leads to the mixed-ligand species **178** (94AGE2330).




Anions $[C_2R_2P_3]^-$ ($R = t\text{-Bu, Ad}$) on interaction with $cis\text{-}[MCl_2(PEt_3)_2]$ give the *trans*-species **179** ($X = Cl$; $M = Pd, Pt$; $R = t\text{-Bu, Ad}$; $R' = Et$) (88JCS(CC)1615). From $cis\text{-}[PtI_2(PPh_3)_2]$, species **179** ($X = I$; $M = Pt$; $R = t\text{-Bu, Ad}$; $R' = Ph$) result. Excess $C_2(t\text{-Bu})_2P_3^-$ when acting on **179** ($X = Cl$; $M = Pd, Pt$; $R = t\text{-Bu}$; $R' = Et$) gives species **180** ($M = Pd, Pt$). The other $\eta^1(P)$ -coordinated species are known (90JCS(CC)317). Thus, treatment of the lithium salt of $P_3C_2Bu_2^-$ with $[M(CO)_6]$ ($M = Cr, Mo, W$) gives complexes **181** ($M = Cr, Mo, W$). At elevated temperatures the reaction of **181** ($M = Cr, Mo, W$) gives the $\eta^5:\eta^1$ coordinated species **182** ($M = Cr, Mo, W$). Treatment of **181** ($M = Cr, Mo, W$) with $[PtCl_2(PEt_3)_2]$ gives **183** ($M = Cr, Mo, W$). The latter undergo further transformation followed by the elimination of $[M(CO)_5(PEt_3)]$ to yield the dimeric clusters **184** ($M = Cr, Mo, W$). The $\eta^1(P)$ -donor function is revealed in the compounds $[M(\eta^1-P_3C_2Bu_2)_2(py)_n]$ ($M = Zn, n = 2$; $M = Cd, n = 3$) (01JOM(633)143).



F. RARE-EARTH ELEMENTS

The thallium salt of 2,3-di-*tert*-butyl-1,2,4-triposphole with $[(\eta^5\text{-Cp}^*)_2\text{Sm}(\text{THF})_2]$ gives the η^2 -coordinated species **185**, which to a certain degree is similar to the 1,2,4-tripospholyl and pyrazolyl ligands (98JCS(CC)797, 99MSF136, 00OM1713). Thallium 2,3-di-*tert*-butyl-1,4,2-diphosphastibolyl with metallic ytterbium in the presence of the lithium salt of the same anion gives the species **186** with the mixed $\eta^5:\eta^2$ coordination mode. The reaction of the potassium salt of 1,2,4-tripospholyl with MI_3 ($\text{M} = \text{Sc}, \text{Y}, \text{U}$) gives the neutral species **187** ($\text{M} = \text{Sc}, \text{Y}, \text{U}$) with the same coordination unit. Compound $t\text{-BuC}\equiv\text{P}$ reacts with scandium atoms to yield the triple-decker species **188** (97JCS(CC)481). Metal-vapor synthesis also allowed the formation of mixed ligand triple-decker scandium species **189** (96JA7630).




VIII. Complexes of Pentaphospholes


Interaction of P_4 and sodium in diglyme or P_4 and MPH_2 ($\text{M} = \text{Li}, \text{Na}$) in THF in the presence of 18-crown-6 gives $[\text{M}(\eta^5\text{-P}_5)]$ ($\text{M} = \text{Li}, \text{Na}$) (85CPL352, 87ZAAC87, 89AGE485, 89CB2121, 89ZN(B)381). $[\text{K}(\eta^5\text{-P}_5)]$ is also known (91AGE580).

Pentaphosphacyclopentadienyl rings manifest their ability to undergo η^5 -coordination with the chromium tricarbonyl moiety, **190** (91AGE580). Chromium(0) also forms triple-decker **191**, where the equivalent P–P distances are unequivocal (85AGE351, 85AGE924, 86AGE363, 88OM1561,

89JA2030). The triple-deckers with $\text{Cr}(\eta^5\text{-Cp})$ and $\text{Cr}(\eta^5\text{-1,3-di-tert-butyl cyclopentadienyl})$ units follow from $[(\eta^5\text{-Cp}')\text{Cr}(\text{CO})_2]_2$ (Cp' is Cp^* or 1,3-di-*tert*-butyl cyclopentadienyl) and P_4 in xylene (86AGE363). The other example is the triple-decker species $[(\eta^5\text{-Cp}^*)\text{Cr}(\mu\text{-}\eta^5\text{:}\eta^5\text{-P}_5)\text{Cr}(\eta^5\text{-Cp}^*)]$ (94JCS(CC)163). The arsenic analogue $[(\eta^5\text{-Cp})\text{Cr}(\mu\text{-}\eta^5\text{:}\eta^5\text{-As}_5)\text{Cr}(\eta^5\text{-Cp})]$ follows from gray arsenic as the reactant (91OM875). The structure of the triple-decker $[(\eta^5\text{-Cp})\text{Mo}(\text{As}_5)\text{Mo}(\eta^5\text{-Cp})]$ is better described in terms of the $\mu\text{-}\eta^4$, $\eta^1\text{:}\eta^4$, η^1 coordination mode (82JA4727). The cyclopentadienyl analogue of **191** can be prepared by prolonged treatment of $[(\eta^5\text{-Cp})\text{Cr}(\text{CO})_3]_2$ with P_4 (89JCS(D)1951, 90JCS(D)977, 93OM888). Additionally, from the same reaction **192** can be prepared (00EJIC2585). $[(\eta^5\text{-Cp})(\text{OC})_2\text{Cr}(\mu\text{-}\eta^2\text{-P}_2)]$ with $[(\eta^4\text{-nbd})\text{Mo}(\text{CO})_4]$ leads to the isolation of product **193**. Moreover, the pentaarsacyclopentadienyl-containing triple-deckers containing $\text{Cr}(\eta^5\text{-1,3-di-tert-butyl cyclopentadienyl})$ (89JOM(361)C11), $\text{Cr}(\eta^5\text{-Cp}^*)$ (90CB3), and $\text{Mo}(\eta^5\text{-Cp})$ (82JA4727) exist. The latter is the product of the interaction of $[(\eta^5\text{-Cp})\text{Mo}(\text{CO})_3]_2$ and $(\text{MeAs})_5$ and is formulated as $[\{(\eta^5\text{-Cp})\text{Mo}\}_2(\mu\text{-}\eta^4\text{-As}_5)]$, the molybdenum(II) complex.



Species $[(\eta^5\text{-Cp})\text{Cr}(\text{CO})_2(\mu\text{-}\eta^2\text{-P}_2)(\text{OC})_2\text{Cr}(\eta^5\text{-Cp})]$ reacts with LiBEt_3H to yield a mixture of products and among them is the $\eta^5\text{:}\eta^2$ coordinated complex **194** (99OM2833). The crystal structure of **194** however suggests that the central ring is split into the allylic P_3 framework and P_2 moiety. Some similar developments are known (93JOM(447)259, 94PSS257, 00JCS(D)1135).




194

The reaction of $t\text{-Bu}_4\text{Sb}_4$ with $[(\eta^5\text{-}1,2,4\text{-}t\text{-Bu}_3\text{C}_5\text{H}_2)\text{Mo}(\text{CO})_3\text{Me}]$ is unusual in the sense that along with the expected triple-decker species $[(\eta^5\text{-}1,2,4\text{-}t\text{-Bu}_3\text{C}_5\text{H}_2)\text{Mo}(\mu, \eta^5\text{-Sb}_5)\text{Mo}(\eta^5\text{-}1,2,4\text{-}t\text{-Bu}_3\text{C}_5\text{H}_2)]$ it gives $[(\eta^5\text{-}1,2,4\text{-}t\text{-Bu}_3\text{C}_5\text{H}_2)\text{Mo}(\mu, \eta^5\text{-Sb}_5)\text{Mo}(\eta^5\text{-}1,4\text{-}t\text{-Bu}_2\text{-}2\text{-MeC}_5\text{H}_2)]$ with replacement of one of the *tert*-butyl groups with a methyl in the second product (00AGE4148).

The potassium complex $[(\eta^5\text{-P}_5)\text{K}]$ with $[\text{Mn}(\text{CO})_5\text{Br}]$ in DMF gives the product of metathesis, $[(\eta^5\text{-P}_5)\text{Mn}(\text{CO})_3]$ (91AGE580).




Interaction of $[\text{Cr}(\text{CO})_5\text{PCl}_3]$ with $\text{K}[(\eta^5\text{-}1,3\text{-}t\text{-Bu}_2\text{C}_5\text{H}_3)\text{Fe}(\text{CO})_2]$ at -78°C in THF gives the classical sandwich **195** (93AGE593, 97CB1299).




195

Thermolysis of $[(\eta^5\text{-Cp}^*)\text{Fe}(\text{CO})_2]$ with white phosphorus (P_4) gives sandwiches $[(\eta^5\text{-Cp}^*)\text{Fe}(\eta^5\text{-P}_5)]$ (87AGE59). The electrochemical properties of this sandwich are remarkable and may be interpreted in terms of the two possible coupling processes, involving **196** and **197** (99OM1827) separately. This type of reaction for white phosphorus (P_4) and $[(\eta^6\text{-C}_5\text{Me}_4\text{R})\text{Fe}(\text{CO})_2]_2$ or $[(\eta^5\text{-C}_5\text{Me}_4\text{R})\text{Ru}(\text{CO})_2\text{Br}]$ gives mixed sandwiches $[(\eta^5\text{-P}_5)\text{M}(\eta^5\text{-C}_5\text{Me}_4\text{R})]$ ($\text{M} = \text{Fe}$, $\text{R} = \text{Me}$, Et ; $\text{M} = \text{Ru}$, $\text{R} = \text{Me}$, Et) (88CB935). Thermolysis of sandwiches **198** ($\text{M} = \text{Fe}$; $\text{E} = \text{P}$, As) with $[(\eta^5\text{-Cp}^*)\text{M}(\text{CO})_2]_2$ ($\text{M} = \text{Ru}$, Os) appears to be a reaction involving the transfer of the $\eta^5\text{-E}_5$ ($\text{E} = \text{P}$, As) ligands in the case of $\text{M} = \text{Ru}$ and the $\eta^5\text{-P}_5$ ligand in the case of $\text{M} = \text{Os}$ to yield sandwiches **198** ($\text{M} = \text{Ru}$, $\text{E} = \text{P}$, As ; $\text{M} = \text{Os}$, $\text{E} = \text{P}$) (95CB71). Sandwiches **198** ($\text{M} = \text{Fe}$; $\text{E} = \text{P}$, As) (89ACS458, 90JOM(387)C21, 91JOM(409)C15, 94AGE1110, 95CB635, 96PSS133, 96ZAAC1478, 00EJC2451) serve as the ligands. There are cases of further η^1 -coordination followed by the relevant $\eta^5\text{:}\eta^1$ species (90AGE1104).

With $[\text{Cr}(\text{CO})_5(\text{THF})]$, the $\eta^5:\eta^1:\eta^1$ species **199** is formed, while with $[\eta^5\text{-Cp}]\text{Mn}(\text{CO})_2(\text{THF})$, even **200** becomes possible (89CB2049). Reaction of **198** ($\text{M} = \text{Fe}$; $\text{E} = \text{P}$, As) with the dimers $[(\eta^5\text{-Cp}^*)\text{M}(\text{CO})]_2$ ($\text{M} = \text{Rh}$, Ir) gives rise to the $\eta^5:\eta^2$ species **201** ($\text{E} = \text{P}$, As; $\text{M} = \text{Rh}$, Ir) with the so-called side-on coordination of the rhodium or iridium fragment (95AGE1321). Another interesting example in this respect is $[(\eta^5\text{-C}_5\text{H}_4\text{Et})\text{Fe}(\text{P}_5)\text{Co}(\text{CO})(\eta^5\text{-C}_5\text{H}_4\text{Et})\{\text{Co}_2(\eta^5\text{-C}_5\text{H}_4\text{Et})(\mu\text{-CO})\}]$, where the coordination mode of the P_5 ring is $\mu\text{-}\eta^5:\eta^2:\eta^2:\eta^1$ (98CEJ1910). Attempts to obtain the full sandwich of iron containing two pentaphosphacyclopentadienyl rings have so far been unsuccessful (88AGE280, 91AGE580). This might be the product of an interaction of pentaphosphacyclopentadienyl lithium with iron(II) chloride, although there is no rigorous structural confirmation (88AGE280). There are cases where the central $\eta^5\text{-P}_5$ ligand is cleaved (94AGE1110, 97JOM(529)379), for example, in the reaction of $[(\eta^5\text{-Cp}^*)\text{Fe}(\eta^5\text{-P}_5)]$ with $[(\eta^5\text{-Cp}^*)\text{Ta}(\text{CO})_4]$ followed by the splitting of one of the P–P bonds.




Sandwiches $[(\eta^5\text{-Cp}^*)\text{Fe}(\eta^5\text{-E}_5)]$ ($\text{E} = \text{P}, \text{As}$) serve as the starting materials for the triple-deckers **202** ($\text{E} = \text{P}, \text{As}$) that follow from their reaction with $[(\text{OC})_3\text{Mo}(\text{AN})_3]$ (92MI2). The stacking reaction of $[(\eta^5\text{-E}_5)\text{M}(\eta^5\text{-Cp}^*)]$ ($\text{E} = \text{P}, \text{As}$; $\text{M} = \text{Fe}, \text{Ru}$) with $[\text{M}'(\text{CO})_3(\text{AN})_3]$ ($\text{M} = \text{Cr}, \text{Mo}, \text{W}$) also gives triple-deckers **202** (92CB1011).




IX. Miscellaneous

There is some information on the analogues of azoles, which do not fall under any of the above considered ligands. These data are quite scattered and non-systematic but deserve mentioning because of their potential value.


Dilithium octaphenyltetraphosphafulvalene with $[(\eta^5\text{-Cp})\text{Fe}(\eta^6\text{-1,4-Me}_2\text{C}_6\text{H}_4)(\text{PF}_6)]$ gives the η^5 -coordinated species **203**, which is unstable with respect to oxidants but can be stabilized by reacting with $[(\eta^4\text{-nbd})\text{Cr}(\text{CO})_4]$ (92AGE1031). The latter affords the chelate complex **204**.



1,2,4-Selenadiphosphole and 1,2,4-telluradiphosphole form the $\eta^1(\text{P})$ coordinated complexes **205** ($\text{M} = \text{Cr}, \text{W}$; $\text{E} = \text{Se}$; $\text{M} = \text{W}$, $\text{E} = \text{Te}$) with $[\text{M}(\text{CO})_5(\text{THF})]$ (99JOM(580)156).



Complexes with heterocycles containing two sulfur heteroatoms may be of interest in materials chemistry (95IC4979, 98CEJ1714, 98JCS(D)483). One such ligand is dianionic 4,5-disulfanyl-1,3-dithiole-2-thionate (99OM1834). The interaction of the disodium salt of this ligand with $[\text{Me}_2\text{C}(\eta^5\text{-C}_5\text{H}_4)_2\text{MCl}_2]$ ($\text{M} = \text{Mo}, \text{W}$) gives products **206** ($\text{M} = \text{Mo}, \text{W}$) with a rare dithiolene coordination. Further oxidation of the complexes obtained with TCNQF_4 gives $[\mathbf{1}]_2(\text{TCNQF}_4)$ with a highly organized layered structure. Protonation of $[\text{W}(\text{CO})_5(\text{PPh}_2)(\text{CS}_2\text{CHRC}\equiv\text{CR}')]]$ ($\text{R} = \text{H}, \text{R}' = \text{CH}, \text{N}$; $\text{R} = \text{Me}, \text{R}' = \text{N}$) with tetrafluoroboric acid gives 1,3-dithiolium tungsten complexes **207** ($\text{R} = \text{H}, \text{R}' = \text{Me}, \text{NH}_2$; $\text{R} = \text{Me}, \text{R}' = \text{NH}_2$) (01OM2604). Interaction of the product **207** ($\text{R} = \text{H}, \text{R}' = \text{NH}_2$) with Ph_3CBF_4 gives **207** ($\text{R} = \text{H}, \text{R}' = \text{NHCPH}_3$).



Another interesting aromatic anion **208**, which is well within the group of cyclopentadienyl and pentaphospholyl species, is a possible ligand (01AGE3173).



X. Conclusions

1. The di- and triborolyl ligands tend to η^5 -coordination in sandwich-forming reactions. There is a clear-cut tendency for stacking processes followed by the formation of multidecker species and often stabilization of the unusual oxidation states of the transition metals. The route to the linked sandwich and multidecker complexes is attractive for materials chemistry. Thia- and azaborolyl organometallic chemistry follows the same trends, although in the azaborolyl complexes the η^3 -rather than η^5 -coordination is sometimes realized. Moreover, coordination via the boron atom is known. In the B, N, Si-heterocycles, the heteroring is η^4 -coordinated.

2. Silicon analogues of imidazole-2-ylidenes are stable carbenes that form adducts where the metal-silicon bond is relatively weaker than that between metal and carbon atoms.
3. Azaphospholes where heteroaromaticity is regarded as appreciable, however, act mainly as $\eta^1(\text{P})$ ligands, and often the P-donor carries two coordinated organometallic moieties.
4. Di- and triphospholyl ligands are in sharp contrast with the corresponding azoles tending basically to the η^5 -mode. Although there are cases of η^4 - or $\eta^1(\text{P})$ -coordination, the trend is striking, sandwich ions based on the P_2 and P_3 heterorings possess notable reactivity leading to numerous $\eta^5:\eta^1(\text{P})$ cases along with the $\eta^5:\eta^2$ side-on coordination of the complicated organometallic molecules, and variety of $\eta^5:\eta^1:\eta^1$ coordinations. One such combination resembles endo-bidentate coordination in pyrazole chemistry, which however requires preliminary η^5 -sandwich formation. Finally, stacking reactions followed by triple-decker complexes appear possible.
5. Pentaphospholyl organometallic chemistry is in development again in sharp contrast to that of N_5 , which is still considered by theoreticians as a possible ligand. The main trend is η^5 -sandwich-formation and further stacking reactions although sometimes the islands as donor sites ($\eta^3:\eta^2$ instead of η^5) are postulated and the cases of cleavage of the η^5 -ligand exist. As for di- and triphospholyl ligands, the reactivity of sandwiches and multideckers is remarkable and cases of $\eta^5:\eta^1$ and $\eta^5:\eta^2$ (side-on) mixed coordination are typical.
6. Some ligands by being analogues of azoles (condensed diphospholyls, SeP , TeP , SS , and S_2N_3) are occasionally examined but no systematic study of their organometallic chemistry exists.

REFERENCES

- | | |
|----------|--|
| 67ZAAC1 | H. Noth and W. Regnet, <i>Z. Anorg. Allg. Chem.</i> , 352 , 1 (1967). |
| 72SCI462 | M. F. Hawthorne and G. B. Dunks, <i>Science</i> , 178 , 462 (1972). |
| 73JA3046 | D. C. Beer, V. R. Miller, L. G. Sneddon, R. N. Grimes, N. Mathew, and G. J. Palenik, <i>J. Am. Chem. Soc.</i> , 95 , 3046 (1973). |
| 74IC1138 | R. N. Grimes, D. C. Beer, L. G. Sneddon, V. R. Miller, and R. Weiss, <i>Inorg. Chem.</i> , 13 , 1138 (1974). |
| 75AGE262 | W. Siebert, G. Augustin, R. Full, C. Kruger, and Y. H. Tsay, <i>Angew. Chem., Int. Ed. Engl.</i> , 14 , 262 (1975). |
| 75MI1 | G. B. Dunks and M. F. Hawthorne, in "Boron Hydride Chemistry" (E. L. Muetterties, ed.), Chapter 1, Academic Press, New York (1975). |
| 76AGE434 | W. Siebert and K. Kinberger, <i>Angew. Chem. Int. Ed. Engl.</i> , 15 , 434 (1975). |

- 76AGE779 W. Siebert, T. Renk, K. Kinberger, H. Bochmann, and C. Kruger, *Angew. Chem. Int. Ed. Engl.*, **15**, 779 (1976).
- 76JA3219 J. W. Lauher, M. Elian, R. H. Summerville, and R. Hoffmann, *J. Am. Chem. Soc.*, **98**, 3219 (1976).
- 76ZN(B)803 W. Siebert, R. Full, C. Kruger, and Y. H. Tsay, *Z. Naturforsch.*, **B21**, 803 (1976).
- 77AGE249 G. Schmid and J. Schulze, *Angew. Chem., Int. Ed. Engl.*, **16**, 249 (1977).
- 77AGE333 W. Siebert and W. Rothermel, *Angew. Chem., Int. Ed. Engl.*, **16**, 333 (1977).
- 77AGE468 W. Siebert and M. Bochmann, *Angew. Chem., Int. Ed. Engl.*, **16**, 468 (1977).
- 77AGE857 W. Siebert and M. Bochmann, *Angew. Chem., Int. Ed. Engl.*, **16**, 857 (1977).
- 77JOM(131)1 W. Siebert, R. Full, J. Edwin, K. Kinberger, and C. Kruger, *J. Organomet. Chem.*, **131**, 1 (1977).
- 78TL441 K. Issleib, R. Vollmer, H. Oehme, and H. Meyer, *Tetrahedron Lett.*, 441 (1978).
- 78ZN(B)1410 W. Siebert, M. Bochmann, J. Edwin, C. Kruger, and Y. H. Tsay, *Z. Naturforsch.*, **B33**, 1410 (1978).
- 79AGE949 W. Siebert, W. Rothermel, C. Bohle, C. Kruger, and D. G. Bauer, *Angew. Chem., Int. Ed. Engl.*, **24**, 949 (1985).
- 79CCR(28)47 R. N. Grimes, *Coord. Chem. Rev.*, **28**, 47 (1979).
- 79JA3399 D. E. Brennan and W. E. Geiger, *J. Am. Chem. Soc.*, **101**, 3399 (1979).
- 80AGE54 J. Schulze and G. Schmid, *Angew. Chem., Int. Ed. Engl.*, **19**, 54 (1980).
- 80AGE746 W. Siebert, C. Bohle, and C. Kruger, *Angew. Chem., Int. Ed. Engl.*, **19**, 746 (1980).
- 80CB2348 J. Schulze, R. Boese, and G. Schmid, *Chem. Ber.*, **113**, 2348 (1980).
- 80JOM(185)53 J. H. Weinmaier, A. Tautz, A. Schmidpeter, and S. Pohl, *J. Organomet. Chem.*, **185**, 53 (1980).
- 80JOM(193)83 J. Schulze and G. Schmid, *J. Organomet. Chem.*, **193**, 83 (1980).
- 80PAC1443 B. M. Gimarc and N. Trinajtic, *Pure Appl. Chem.*, **52**, 1443 (1980).
- 81AGE33 H. G. Schoering, *Angew. Chem., Int. Ed. Engl.*, **20**, 33 (1981).
- 81CB495 J. Schulze and G. Schmid, *Chem. Ber.*, **114**, 495 (1981).
- 81CB1297 J. Schulze, R. Boese, and G. Schmid, *Chem. Ber.*, **114**, 1297 (1981).
- 81IC863 D. C. Finster and R. N. Grimes, *Inorg. Chem.*, **20**, 863 (1981).
- 81JA1399 D. C. Finster, E. Sinn, and R. N. Grimes, *J. Am. Chem. Soc.*, **103**, 1399 (1981).
- 81JOM(207)343 G. Marr and B. W. Rockett, *J. Organomet. Chem.*, **207**, 343 (1981).
- 81JOM(208)137 F. H. Kohler, U. Zenneck, J. Edwin, and W. Siebert, *J. Organomet. Chem.*, **208**, 137 (1981).
- 81JOM(215)255 J. Edwin, W. Siebert, and C. Kruger, *J. Organomet. Chem.*, **215**, 255 (1981).
- 81ZAAC22 K. Issleib and R. Vollmer, *Z. Anorg. Allg. Chem.*, **481**, 22 (1981).
- 82AGE68 S. Amirkhalili, U. Hohner, and G. Schmid, *Angew. Chem., Int. Ed. Engl.*, **21**, 68 (1982).
- 82AGE148 W. Siebert, J. Edwin, and H. Pritzkow, *Angew. Chem., Int. Ed. Engl.*, **21**, 148 (1982).
- 82AGE149 W. Siebert, J. Edwin, H. Wadepohl, and H. Pritzkow, *Angew. Chem., Int. Ed. Engl.*, **21**, 149 (1982).

- 82AGE207 G. Koster and G. Seidel, *Angew. Chem., Int. Ed. Engl.*, **21**, 207 (1982).
- 82AGE453 M. W. Whitely, H. Pritzkow, U. Zenneck, and W. Siebert, *Angew. Chem., Int. Ed. Engl.*, **21**, 453 (1982).
- 82CB732 S. Amirkhalili, R. Boese, U. Hohner, D. Kampmann, G. Schmid, and P. Rademacher, *Chem. Ber.*, **115**, 732 (1982).
- 82CB738 R. Kostner, G. Seidel, S. Amirkhalili, R. Boese, and G. Schmid, *Chem. Ber.*, **115**, 738 (1982).
- 82CB3830 G. Schmid, S. Amirkhalili, U. Hohner, D. Kampmann, and R. Boese, *Chem. Ber.*, **115**, 3830 (1982).
- 82JA4727 A. L. Rheingold, M. J. Foley, and P. J. Sullivan, *J. Am. Chem. Soc.*, **104**, 4727 (1982).
- 82MI1 R. N. Grimes, in “*Comprehensive Organometallic Chemistry*” (G. Wilkinson, F. G. A. Stone, and E. W. Abel, eds.), Chapter 5.5, Pergamon Press, Oxford, England (1982).
- 82MI2 W. E. Geiger, in “*Metal Interactions with Boron Clusters*” (R. N. Grimes, ed.), Chapter 6, Plenum Press, (1982).
- 82PS259 F. Nief, C. Charrier, F. Mathey, and M. Simalty, *Phosphorus Sulfur*, **12**, 259 (1982).
- 82TL3643 J. Heinicke and A. Tzschach, *Tetrahedron Lett.*, **23**, 3643 (1982).
- 83AICR55 R. N. Grimes, *Adv. Inorg. Chem. Radiochem.*, **26**, 55 (1983).
- 83CB951 G. Schmid, U. Hohner, D. Kampmann, D. Zaika, and R. Boese, *Chem. Ber.*, **116**, 951 (1983).
- 83JA2582 J. Edwin, M. Bochmann, M. C. Bohm, D. E. Brennan, W. E. Geiger, C. Kruger, J. Pebler, W. Siebert, W. Swiridoff, H. Wadepohl, J. Weiss, and U. Zenneck, *J. Am. Chem. Soc.*, **105**, 2582 (1983).
- 83JOM(256)225 G. Schmid, U. Hohner, D. Kampmann, D. Zaika, and R. Boese, *J. Organomet. Chem.*, **256**, 225 (1983).
- 83JOM(256)375 J. G. Kraajkamp, G. van Koten, K. Vrieze, D. M. Grove, E. A. Klop, A. L. Spek, and A. Schmidpeter, *J. Organomet. Chem.*, **256**, 375 (1983).
- 83JOM(257)275 B. W. Rockett and G. Marr, *J. Organomet. Chem.*, **257**, 275 (1983).
- 83OM1008 N. M. Kostic and R. F. Fenske, *Organometallics*, **2**, 1008 (1983).
- 83OM1666 J. Edwin, M. C. Bohm, N. Chester, D. M. Hoffman, R. Hoffmann, H. Pritzkow, W. Siebert, K. Stumpf, and H. Wadepohl, *Organometallics*, **2**, 1666 (1983).
- 83OM1899 H. Wadepohl, H. Pritzkow, and W. Siebert, *Organometallics*, **2**, 1899 (1983).
- 83ZN(B)485 G. Schmid and R. Boese, *Z. Naturforsch.*, **B38**, 485 (1983).
- 83ZN(B)1094 G. Schmid, U. Hohner, and D. Kampmann, *Z. Naturforsch.*, **B38**, 1094 (1983).
- 84AGE965 T. Kuhlmann, H. Pritzkow, U. Zenneck, and W. Siebert, *Angew. Chem., Int. Ed. Engl.*, **23**, 965 (1984).
- 84CB1052 G. Schmid, U. Kampmann, U. Hohner, D. Blaser, and R. Boese, *Chem. Ber.*, **117**, 1052 (1984).
- 84CJC341 N. C. Baird, *Can. J. Chem.*, **62**, 341 (1984).
- 84ZN(B)50 H. Wadepohl and W. Siebert, *Z. Naturforsch.*, **B39**, 50 (1984).
- 84ZN(B)1082 G. Schmid, O. Boltsch, D. Blaser, and R. Boese, *Z. Naturforsch.*, **B39**, 1082 (1984).
- 85AGE71 K. Stumpf, H. Pritzkow, and W. Siebert, *Angew. Chem., Int. Ed. Engl.*, **24**, 71 (1985).

- 85AGE248 H. Bonnemann, *Angew. Chem., Int. Ed. Engl.*, **24**, 248 (1985).
- 85AGE351 O. J. Scherer, H. Sitzmann, and G. Wolmershauser, *Angew. Chem., Int. Ed. Engl.*, **24**, 351 (1985).
- 85AGE602 G. Schmid, D. Zaika, and R. Boese, *Angew. Chem., Int. Ed. Engl.*, **24**, 602 (1985).
- 85AGE924 O. J. Scherer, *Angew. Chem., Int. Ed. Engl.*, **24**, 924 (1985).
- 85AGE943 W. Siebert, *Angew. Chem., Int. Ed. Engl.*, **24**, 943 (1985).
- 85CB401 M. Bochmann, K. Geilich, and W. Siebert, *Chem. Ber.*, **118**, 401 (1985).
- 85CB729 H. Wadepohl, H. Pritzkow, and W. Siebert, *Chem. Ber.*, **118**, 729 (1985).
- 85CB2418 G. Schmid, D. Kampmann, W. Meyer, R. Boese, P. Paetsold, and K. Delpy, *Chem. Ber.*, **118**, 2418 (1985).
- 85CIC17 G. Schmid, *Commun. Inorg. Chem.*, **4**, 17 (1985).
- 85CPL352 J. T. Snodgrass, J. V. Coe, C. B. Freidhoff, K. M. Mc Hugh, and K. H. Bowen, *Chem. Phys. Lett.*, **122**, 352 (1985).
- 85JOM(282)297 J. Edwin, W. Siebert, and C. Kruger, *J. Organomet. Chem.*, **282**, 297 (1985).
- 85ZN(B)167 T. Kuhlmann and W. Siebert, *Z. Naturforsch.*, **B40**, 167 (1985).
- 85ZN(B)326 W. Siebert, U. Enderand, and W. Herter, *Z. Naturforsch.*, **B40**, 326 (1985).
- 86AGE105 T. Kuhlmann, S. Roth, J. Roziere, and W. Siebert, *Angew. Chem., Int. Ed. Engl.*, **25**, 105 (1986).
- 86AGE363 O. J. Scherer, J. Schwalb, G. Wolmershauser, W. Kaim, and G. Ross, *Angew. Chem., Int. Ed. Engl.*, **25**, 363 (1986).
- 86AGE644 P. Binger, R. Milczarek, R. Mynott, M. Regitz, and W. Rosch, *Angew. Chem., Int. Ed. Engl.*, **25**, 644 (1986).
- 86AGE1099 J. Zwecker, H. Pritzkow, U. Zenneck, and W. Siebert, *Angew. Chem., Int. Ed. Engl.*, **25**, 1099 (1986).
- 86CB971 U. Zenneck, L. Saber, H. Pritzkow, and W. Siebert, *Chem. Ber.*, **119**, 971 (1986).
- 86JCS(CC)737 P. B. Hitchcock, M. J. Maah, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 737 (1986).
- 86JOM(305)1 J. T. Mague, *J. Organomet. Chem.*, **305**, 1 (1986).
- 86JOM(305)199 B. W. Rockett and G. Marr, *J. Organomet. Chem.*, **305**, 199 (1986).
- 86ZAAC336 G. Becker, W. Massa, O. Mundt, R. E. Schmidt, and C. Witthauer, *Z. Anorg. Allg. Chem.*, **540/541**, 336 (1986).
- 87AGE59 O. J. Scherer and T. Bruck, *Angew. Chem., Int. Ed. Engl.*, **26**, 59 (1987).
- 87JCS(CC)844 P. B. Hitchcock, M. J. Maah, J. F. Nixon, and C. Woodward, *J. Chem. Soc., Chem. Commun.*, 844 (1987).
- 87JCS(CC)1146 R. Bartsch, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 1146 (1987).
- 87JOM(318)157 R. C. Kerber, *J. Organomet. Chem.*, **318**, 157 (1987).
- 87JOM(319)49 S. Kersch, B. Wrackmeyer, A. Willhalm, and A. Schmidpeter, *J. Organomet. Chem.*, **319**, 49 (1987).
- 87JOM(323)C35 P. Binger, R. Milczarek, R. Mynott, and M. Regitz, *J. Organomet. Chem.*, **323**, C35 (1987).
- 87JOM(324)57 J. T. Mague, *J. Organomet. Chem.*, **324**, 57 (1987).
- 87JOM(334)C35 M. Dreiss, D. Hu, H. Pritzkow, H. Schaufele, U. Zenneck, M. Regitz, and W. Rosch, *J. Organomet. Chem.*, **334**, C35 (1987).

- 87MI1 I. Haiduc and D. B. Sowerby, in *"The Chemistry of Inorganic Homocyclic and Heterocycles"* (I. Haiduc and D. B. Sowerby, eds.), Vol. 1, p. 1, Academic Press, London (1987).
- 87OM435 G. Schmid, O. Boltsch, and R. Boese, *Organometallics*, **6**, 435 (1987).
- 87PAC847 R. N. Grimes, *Pure Appl. Chem.*, **59**, 847 (1987).
- 87PAC947 W. Siebert, *Pure Appl. Chem.*, **59**, 947 (1987).
- 87SM757 T. Kuhlmann, S. Roth, J. Roziere, W. Siebert, and U. Zenneck, *Synth. Met.*, **19**, 757 (1987).
- 87ZAAC87 M. Baudler, D. Duster, and D. Ouzounis, *Z. Anorg. Allg. Chem.*, **544**, 87 (1987).
- 88AGE280 M. Baudler, S. Akpapoglou, D. Ouzounis, F. Wasgestian, B. Meinigke, H. Budzikiewicz, and H. Munster, *Angew. Chem., Int. Ed. Engl.*, **27**, 280 (1988).
- 88AGE952 G. Schmid, W. Meyer-Zaika, R. Boese, and R. Augart, *Angew. Chem., Int. Ed. Engl.*, **27**, 952 (1988).
- 88CB443 O. J. Scherer, J. Schwalb, H. Swarowsky, G. Wolmershauser, W. Kaim, and R. Gross, *Chem. Ber.*, **121**, 443 (1988).
- 88CB935 O. J. Scherer, T. Bruck, and G. Wolmershauser, *Chem. Ber.*, **121**, 935 (1988).
- 88CRV1327 J. F. Nixon, *Chem. Rev.*, **88**, 1327 (1988).
- 88IC2612 J. G. Kraajkamp, D. M. Grove, G. van Koten, and A. Semidpeter, *Inorg. Chem.*, **27**, 2612 (1988).
- 88JCS(CC)819 R. Bartsch, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 819 (1988).
- 88JCS(CC)1475 R. Bartsch, P. B. Hitchcock, T. J. Madden, M. F. Meidine, J. F. Nixon, and H. Wang, *J. Chem. Soc., Chem. Commun.*, 1475 (1988).
- 88JCS(CC)1615 R. Bartsch, D. Carmichael, P. B. Hitchcock, M. F. Meidine, J. F. Nixon, and G. J. D. Sillett, *J. Chem. Soc., Chem. Commun.*, 1615 (1988).
- 88JOM(340)C37 R. Bartsch, P. B. Hitchcock, and J. F. Nixon, *J. Organomet. Chem.*, **340**, C37 (1988).
- 88JOM(343)78 R. C. Kerber, *J. Organomet. Chem.*, **343**, 78 (1988).
- 88JOM(356)C1 R. Bartsch, P. B. Hitchcock, and J. F. Nixon, *J. Organomet. Chem.*, **356**, C1 (1988).
- 88MI1 R. N. Grimes, in *"Advances in Boron and the Boranes"* (J. F. Liebman, A. Greenberg, and R. E. Williams, eds.), p. 235, VCH Publishers, New York (1988).
- 88OM1561 E. D. Jemmis and A. C. Reddy, *Organometallics*, **7**, 1561 (1988).
- 88OM2316 J. Zwecker, T. Kuhlmann, H. Pritzkow, W. Siebert, and U. Zenneck, *Organometallics*, **7**, 2316 (1988).
- 88PAC1345 W. Siebert, *Pure Appl. Chem.*, **60**, 1345 (1988).
- 89ACS458 R. Blom, T. Bruck, and O. J. Scherer, *Acta Chem. Scand.*, **43**, 458 (1989).
- 89AGE485 T. P. Hamilton and H. F. Schaeffer, *Angew. Chem., Int. Ed. Engl.*, **28**, 485 (1989).
- 89CB633 G. Brodt and W. Siebert, *Chem. Ber.*, **122**, 633 (1989).
- 89CB2049 O. J. Scherer, T. Bruck, and G. Wolmershauser, *Chem. Ber.*, **122**, 2049 (1989).
- 89CB2121 R. Janoschek, *Chem. Ber.*, **122**, 2121 (1989).
- 89JA2030 W. Tremel, R. Hoffmann, and M. Kertesz, *J. Am. Chem. Soc.*, **111**, 2030 (1989).

- 89JA4776 J. H. Davis, E. Sinn, and R. N. Grimes, *J. Am. Chem. Soc.*, **111**, 4776 (1989).
- 89JA4784 J. H. Davis, E. Sinn, and R. N. Grimes, *J. Am. Chem. Soc.*, **111**, 4784 (1989).
- 89JCS(D)1951 L. Y. Goh, C. K. Chu, R. C. S. Wong, and T. W. Hambley, *J. Chem. Soc. Dalton Trans.*, 1989 (1951).
- 89JOM(361)C11 O. J. Scherer, W. Wiedemann, and G. Wolmershauser, *J. Organomet. Chem.*, **361**, C11 (1989).
- 89JOM(373)C17 R. Bartsch, P. B. Hitchcock, and J. F. Nixon, *J. Organomet. Chem.*, **373**, C17 (1989).
- 89JOM(373)49 L. Nyulaszi, G. Csonka, J. Reffy, T. Veszpremi, and J. Heinicke, *J. Organomet. Chem.*, **373**, 49 (1989).
- 89JOM(373)57 L. Nyulaszi, G. Csonka, J. Reffy, T. Veszpremi, and J. Heinicke, *J. Organomet. Chem.*, **373**, 57 (1989).
- 89JOM(375)21 G. Schmid and T. Rohling, *J. Organomet. Chem.*, **375**, 21 (1989).
- 89MI1 A. Schmidpeter and K. Karaghiosoff, in "Rings, Clusters and Polymers of Main Group and Transition Elements" (H. W. Roesky, ed.), Elsevier, Amsterdam (1989).
- 89NJC353 P. B. Hitchcock, J. F. Nixon, and G. J. D. Sillett, *Nouv. J. Chim.*, **13**, 353 (1989).
- 89OM1300 M. D. Attwood, K. K. Fonda, R. N. Grimes, G. Brodt, D. Hu, U. Zenenck, and W. Siebert, *Organometallics*, **8**, 1300 (1989).
- 89OM1580 J. M. Merkert, W. E. Geiger, J. H. Davis, M. D. Attwood, and R. N. Grimes, *Organometallics*, **8**, 1580 (1989).
- 89POL1135 M. C. Kerins, N. J. Fitzpatrick, and M. T. Nguyen, *Polyhedron*, **8**, 1135 (1989).
- 89OM2492 K. J. Chase and R. N. Grimes, *Organometallics*, **8**, 2492 (1989).
- 89POL2407 R. Bartsch and J. F. Nixon, *Polyhedron*, **8**, 2407 (1989).
- 89ZN(B)381 M. Baudler and D. Ouzounis, *Z. Naturforsch.*, **B44**, 381 (1989).
- 90AGE534 N. Maigrot, L. Ricard, C. Charrier, and F. Mathey, *Angew. Chem., Int. Ed. Engl.*, **29**, 534 (1990).
- 90AGE1104 O. J. Scherer, *Angew. Chem., Int. Ed. Engl.*, **29**, 1104 (1990).
- 90CB3 O. J. Scherer, W. Wiedemann, and G. Wolmershauser, *Chem. Ber.*, **123**, 3 (1990).
- 90CB2273 A. Fessenbecker, H. Schulz, H. Pritzkow, and W. Siebert, *Chem. Ber.*, **123**, 2273 (1990).
- 90CRV169 A. J. Di Maio and A. L. Rheingold, *Chem. Rev.*, **90**, 169 (1990).
- 90CRV191 M. Regitz, *Chem. Rev.*, **90**, 191 (1990).
- 90IC516 A. Fessenbecker, M. D. Attwood, R. N. Grimes, M. Stephan, H. Pritzkow, U. Zenneck, and W. Siebert, *Inorg. Chem.*, **29**, 516 (1990).
- 90IC879 J. A. Chamizo, M. Ruiz-Mazon, R. Salcedo, and R. A. Toscano, *Inorg. Chem.*, **29**, 879 (1990).
- 90IC4421 G. Schmid, M. Polk, and R. Boese, *Inorg. Chem.*, **29**, 4421 (1990).
- 90IC5157 A. Fessenbecker, M. D. Attwood, R. F. Bryan, R. N. Grimes, M. K. Woode, M. Stephan, U. Zenneck, and W. Siebert, *Inorg. Chem.*, **29**, 5157 (1990).
- 90IC5164 A. Fessenbecker, M. D. Attwood, R. N. Grimes, M. Stephan, H. Pritzkow, U. Zenneck, and W. Siebert, *Inorg. Chem.*, **29**, 5164 (1990).

- 90JA722 E. D. Jemmis and A. C. Reddy, *J. Am. Chem. Soc.*, **112**, 722 (1990).
- 90JCS(CC)317 P. B. Hitchcock, M. F. Meidine, J. F. Nixon, and G. J. D. Sillett, *J. Chem. Soc., Chem. Commun.*, 317 (1990).
- 90JCS(CC)472 R. Bartsch, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 472 (1990).
- 90JCS(D)977 L. Y. Goh, R. C. S. Wong, C. K. Chu, and T. W. Hambley, *J. Chem. Soc., Dalton Trans.*, 977 (1990).
- 90JEAC139 L. Michels and W. Schmikler, *J. Electroanal. Chem. Interfacial Electrochem.*, **295**, 139 (1990).
- 90JOM(382)53 K. Issleib, H. Schmidt, and E. Leissring, *J. Organomet. Chem.*, **382**, 53 (1990).
- 90JOM(387)C21 O. J. Scherer, C. Blath, and G. Wolmershauser, *J. Organomet. Chem.*, **387**, C21 (1990).
- 90MI1 O. J. Scherer, in "Multiple Bonds and Low Coordination in Phosphorus Chemistry" (M. Regitz and O. J. Scherer, eds.), p. 112, Georg Thieme Verlag, Stuttgart (1990).
- 90MI2 G. Markl, in "Multiple Bonds and Low Coordination in Phosphorus Chemistry" (M. Regitz and J. Scherer, eds.), p. 220, Georg Thieme Verlag, Stuttgart (1990).
- 90MI3 A. Schmidpeter and K. Karaghiosoff, in "Multiple Bonds and Low Coordination in Phosphorus Chemistry" (M. Regitz and O. J. Scherer, eds.), p. 258, Georg Thieme Verlag, Stuttgart (1990).
- 90OM1171 J. H. Davis, M. E. Attwood, and R. N. Grimes, *Organometallics*, **9**, 1171 (1990).
- 90OM1177 M. E. Attwood and R. N. Grimes, *Organometallics*, **9**, 1177 (1990).
- 90PAC423 B. M. Gimarc, *Pure Appl. Chem.*, **62**, 423 (1990).
- 90ZC41 M. Scheer and E. Herrmann, *Z. Chem.*, **30**, 41 (1990).
- 90ZC55 M. Scheer and E. Herrmann, *Z. Chem.*, **30**, 55 (1990).
- 90ZN(B)1235 G. Schmid, A. K. Boutrid, and E. M. Kreuzer, *Z. Naturforsch.*, **B45**, 1235 (1990).
- 91AGE580 M. Baudler and T. Etzbach, *Angew. Chem., Int. Ed. Engl.*, **30**, 580 (1991).
- 91AGE1015 G. Schmid, J. Lehr, M. Polk, and R. Boese, *Angew. Chem., Int. Ed. Engl.*, **30**, 1015 (1991).
- 91CB475 R. K. Bansal, K. Karaghiosoff, N. Gupta, A. Schmidpeter, and C. Spindler, *Chem. Ber.*, **124**, 475 (1991).
- 91CB1159 M. Baudler and T. Edzbach, *Chem. Ber.*, **124**, 1159 (1991).
- 91E49 J. F. Nixon, *Endeavor*, **15**, 49 (1991).
- 91IC2836 M. A. Benvenuto and R. N. Grimes, *Inorg. Chem.*, **30**, 2836 (1991).
- 91JA680 K. W. Piepgrass, J. H. Davis, M. Sabat, and R. N. Grimes, *J. Am. Chem. Soc.*, **113**, 680 (1991).
- 91JA681 K. W. Piepgrass, J. H. Davis, M. Sabat, and R. N. Grimes, *J. Am. Chem. Soc.*, **113**, 681 (1991).
- 91JA3061 A. Fessenbecker, M. Stephan, R. N. Grimes, H. Pritzkow, U. Zenneck, and W. Siebert, *J. Am. Chem. Soc.*, **113**, 3061 (1991).
- 91JCS(CC)1293 L. Weber, R. Kirchhoff, R. Boese, and H. G. Stammer, *J. Chem. Soc., Chem. Commun.*, 1293 (1991).
- 91JCS(CC)1659 E. Niecke and D. Schmidt, *J. Chem. Soc., Chem. Commun.*, 1659 (1991).
- 91JOM(409)C15 O. J. Scherer, C. Blath, G. Heckmann, and G. Wolmershauser, *J. Organomet. Chem.*, **409**, C15 (1991).

- 91JOM(415)C15
91MI1 R. Bartsch and J. F. Nixon, *J. Organomet. Chem.*, **415**, C15 (1991).
R. N. Grimes, in "Electron-Deficient Boron and Carbon Clusters" (G. A. Olah, K. Wade, and R. E. Williams, eds.), p. 261, John Wiley and Sons, New York (1991).
- 91OM875 L. Y. Goh, R. C. S. Wong, W. H. Yip, and T. C. W. Mak, *Organometallics*, **10**, 875 (1991).
- 91OM2631 K. J. Chase, R. F. Ryan, M. K. Woods, and R. N. Grimes, *Organometallics*, **10**, 2631 (1991).
- 91OM2835 M. L. Sierra, N. Maigrot, C. Charrier, L. Ricard, and F. Mathey, *Organometallics*, **10**, 2835 (1991).
- 91OM3545 J. M. Merkert, W. E. Geiger, M. D. Attwood, and R. N. Grimes, *Organometallics*, **10**, 3545 (1991).
- 91PAC369 R. N. Grimes, *Pure Appl. Chem.*, **63**, 369 (1991).
- 92AGE1031 N. Maigrot, L. Ricard, C. Charrier, and F. Mathey, *Angew. Chem., Int. Ed. Engl.*, **31**, 1031 (1992).
- 92AGE1485 W. A. Herrmann, M. K. Denk, J. Behm, W. Scherer, F. R. Kilngan, H. Bock, B. Solouki, and M. Wagner, *Angew. Chem., Int. Ed. Engl.*, **31**, 1485 (1992).
- 92CB1011 B. Rink, O. J. Scherer, G. Heckmann, and G. Wolmershauser, *Chem. Ber.*, **125**, 1011 (1992).
- 92CCR(120)259 M. Di Vaira and P. Stoppioni, *Coord. Chem. Rev.*, **120**, 259 (1992).
- 92CRV251 R. N. Grimes, *Chem. Rev.*, **92**, 251 (1992).
- 92IC3897 M. A. Benvenuto and R. N. Grimes, *Inorg. Chem.*, **31**, 3897 (1992).
- 92IC3904 M. A. Benvenuto, M. Sabat, and R. N. Grimes, *Inorg. Chem.*, **31**, 3904 (1992).
- 92IC5202 K. W. Pieprgrass, X. Meng, M. Holscher, M. Sabat, and R. N. Grimes, *Inorg. Chem.*, **31**, 5202 (1992).
- 92JA5214 M. Stephan, J. H. Davis, X. Meng, K. P. Chase, J. Hauss, U. Zenneck, H. Pritzkow, W. Siebert, and R. N. Grimes, *J. Am. Chem. Soc.*, **114**, 5214 (1992).
- 92JA8733 K. E. Stockman, M. Sabat, M. G. Finn, and R. N. Grimes, *J. Am. Chem. Soc.*, **114**, 8733 (1992).
- 92JA9080 L. Nyulaszi, T. Veszpremi, J. Reffy, B. Burkhardt, and M. Regitz, *J. Am. Chem. Soc.*, **114**, 9080 (1992).
- 92JA9846 J. M. Merkert, J. H. Davis, W. E. Geiger, and R. N. Grimes, *J. Am. Chem. Soc.*, **114**, 9846 (1992).
- 92JOC3694 E. J. P. Malar, *J. Org. Chem.*, **57**, 3694 (1992).
- 92JOM(430)C10 R. Bartsch, A. Gelessus, P. B. Hitchcock, and J. F. Nixon, *J. Organomet. Chem.*, **430**, C10 (1992).
- 92JCP623 T. Veszpremi, L. Nyulaszi, J. Reffy, and J. Heinicke, *J. Chem. Phys.*, **96**, 623 (1992).
- 92MI1 B. M. Gimarc and L. E. Starr, in "The Chemistry of Inorganic Ring Systems" (R. Streudel, ed.), Vol. 14, p. 429, Elsevier, Amsterdam, 1992.
- 92MI2 O. J. Scherer, C. Blath, J. Braun, B. Hobel, K. Pfeiffer, B. Rink, H. Slodzyk, P. Walther, B. Werner, and R. Winter, in "The Chemistry of Inorganic Ring Systems" (R. Streudel, ed.), Vol. 14, p. 429, Elsevier, Amsterdam, 1992.
- 92MI3 R. N. Grimes, in "Inorganometallic Chemistry" (T. P. Fehlner, ed.), Plenum Press, New York (1992).
- 92OM1789 G. Schmid and M. Schutz, *Organometallics*, **11**, 1789 (1992).

- 92OM2397 K. W. Piepgrass and R. N. Grimes, *Organometallics*, **11**, 2397 (1992).
92OM2404 K. W. Piepgrass, M. Sabat, and R. N. Grimes, *Organometallics*, **11**, 2404 (1992).
92POL601 N. Maigrot, M. L. Sierra, C. Charrier, L. Ricard, and F. Mathey, *Polyhedron*, **11**, 601 (1992).
93ADOC187 W. Siebert, *Adv. Organomet. Chem.*, **35**, 187 (1993).
93AGE593 M. Scheer, G. Friedrich, and K. Schuster, *Angew. Chem., Int. Ed. Engl.*, **32**, 593 (1993).
93BSCF521 M. L. Sierra, C. Charrier, L. Ricard, and F. Mathey, *Bull. Soc. Chim. France*, **130**, 521 (1993).
93CB1587 W. Siebert, W. Herter, H. Schulz, S. Huck, H. Pritzkow, L. Zhu, and O. Eisenstein, *Chem. Ber.*, **126**, 1587 (1993).
93CI(L)404 J. F. Nixon, *Chem. Ind.*, 404 (1993).
93CRV1081 A. K. Saxena and N. S. Hosmane, *Chem. Rev.*, **93**, 1081 (1993).
93IC2156 K. W. Piepgrass, M. A. Curtis, X. Wang, X. Meng, M. Sabat, and R. N. Grimes, *Inorg. Chem.*, **32**, 2156 (1993).
93JA6143 X. Meng, M. Sabat, and R. N. Grimes, *J. Am. Chem. Soc.*, **115**, 6143 (1993).
93JCLS297 N. S. Hosmane and J. A. Maguire, *J. Cluster Sci.*, **4**, 297 (1993).
93JCS(D)1783 J. M. Forward, D. M. P. Mingos, W. Siebert, J. Hauss, and H. R. Powell, *J. Chem. Soc., Dalton Trans.*, 1783 (1993).
93JOM(447)259 M. Scheer, M. Dargatz, and P. G. Jones, *J. Organomet. Chem.*, **447**, 259 (1993).
93JOM(453)C16 C. Muller, R. Bartsch, A. Fischer, and P. G. Jones, *J. Organomet. Chem.*, **453**, C16 (1993).
93JOM(461)237 J. F. Nixon and G. J. D. Sillett, *J. Organomet. Chem.*, **461**, 237 (1993).
93JOM(462)319 P. B. Hitchcock, R. M. Matos, and J. F. Nixon, *J. Organomet. Chem.*, **462**, 319 (1993).
93JPC4011 L. Nyulaszi, T. Veszpremi, and J. Reffy, *J. Phys. Chem.*, **97**, 4011 (1993).
93OM731 L. Weber, R. Kirchhoff, R. Boese, H. G. Stammer, and B. Neumann, *Organometallics*, **12**, 731 (1993).
93OM888 L. Y. Goh, R. C. S. Wong, and E. Sinn, *Organometallics*, **12**, 888 (1993).
93OM4452 J. R. Pipal and R. N. Grimes, *Organometallics*, **12**, 4452 (1993).
93OM4459 J. R. Pipal and R. N. Grimes, *Organometallics*, **12**, 4459 (1993).
93POL1383 C. Muller, R. Bartsch, A. Fischer, and P. J. Jones, *Polyhedron*, **12**, 1383 (1993).
93PSS45 R. Bartsch, P. B. Hitchcock, J. A. Johnson, R. M. Matos, and J. F. Nixon, *Phosphorus, Sulfur, Silicon, Relat. Elem.*, **77**, 45 (1993).
93ZN(B)1512 U. Fenner, T. Kuhlmann, G. Brodt, J. Roziere, and W. Siebert, *Z. Naturforsch.*, **B48**, 1512 (1993).
94AGE203 W. Siebert, R. Hettrich, and H. Pritzkow, *Angew. Chem., Int. Ed. Engl.*, **33**, 203 (1994).
94AGE1110 M. Detzel, T. Mohr, O. J. Scherer, and G. Wolmershauser, *Angew. Chem., Int. Ed. Engl.*, **33**, 1110 (1994).
94AGE2330 A. G. Avent, F. G. N. Cloke, K. R. Flower, P. B. Hitchcock, J. F. Nixon, and D. M. Vickers, *Angew. Chem., Int. Ed. Engl.*, **33**, 2330 (1994).
94BSCF397 N. Maigrot, M. Sierra, C. Charrier, and F. Mathey, *Bull. Soc. Chim. France*, **131**, 397 (1994).

- 94CB2393 B. Gangnus, A. Fessenbecker, H. Pritzkow, and W. Siebert, *Chem. Ber.*, **127**, 2393 (1994).
- 94CCR(137)1 F. Mathey, *Coord. Chem. Rev.*, **137**, 1 (1994).
- 94IC4211 M. Stephan, J. Hauss, U. Zenenck, W. Siebert, and R. N. Grimes, *Inorg. Chem.*, **33**, 4211 (1994).
- 94JA2687 X. Wang, M. Sabat, and R. N. Grimes, *J. Am. Chem. Soc.*, **116**, 2687 (1994).
- 94JA2691 M. K. Denk, R. Lennon, R. Hayashi, R. West, A. Haaland, A. V. Belyakov, H. P. Verne, M. Wagner, and N. Metzler, *J. Am. Chem. Soc.*, **116**, 2691 (1994).
- 94JA6641 A. J. Arduengo, H. Bock, H. Chen, M. K. Denk, D. A. Dixon, J. C. Green, W. A. Herrmann, N. L. Jones, M. Wagner, and R. West, *J. Am. Chem. Soc.*, **116**, 6641 (1994).
- 94JA10813 M. K. Denk, R. K. Hayashi, and R. West, *J. Am. Chem. Soc.*, **116**, 10813 (1994).
- 94JA9359 T. T. Chin, S. R. Lovelace, W. E. Geiger, C. M. Davis, and R. N. Grimes, *J. Am. Chem. Soc.*, **116**, 9359 (1994).
- 94JCS(CC)33 M. K. Denk, R. K. Hayashi, and R. West, *J. Chem. Soc., Chem. Commun.*, 33 (1994).
- 94JCS(CC)163 A. K. Hughes, V. J. Murphy, and D. O'Hare, *J. Chem. Soc., Chem. Commun.*, 163 (1994).
- 94JCS(CC)489 F. G. N. Cloke, K. R. Flower, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 489 (1994).
- 94JCS(D)2405 M. K. Denk, J. C. Green, N. Metzler, and M. Wagner, *J. Chem. Soc., Dalton Trans.*, 2405 (1994).
- 94JOM(479)C28 P. Binger and G. Glaser, *J. Organomet. Chem.*, **479**, C28 (1994).
- 94JOM(480)45 S. Al-Juaid, P. B. Hitchcock, J. A. Johnson, and J. F. Nixon, *J. Organomet. Chem.*, **480**, 45 (1994).
- 94MI1 R. N. Grimes, in "Current Topics in the Chemistry of Boron" (G. W. Kabalka, ed.), p. 269, Royal Society of Chemistry, Cambridge, England (1994).
- 94MI2 W. Siebert, in "Current Topics in the Chemistry of Boron" (G. W. Kabalka, ed.), p. 269, Royal Society of Chemistry, Cambridge, England (1994).
- 94PSS257 M. Scheer and U. Becker, *Phosphorus Sulfur Silicon, Relat. Elem.*, **93-94**, 257 (1994).
- 94T7675 R. K. Bansal, K. Karaghiosoff, and A. Schmidpeter, *Tetrahedron*, **50**, 7675 (1994).
- 94TOC307 J. Heinicke, *Trends Organomet. Chem.*, **1**, 307 (1994).
- 94ZN(B)315 U. Fenner, H. Pritzkow, and W. Siebert, *Z. Naturforsch.*, **B49**, 315 (1994).
- 95AGE590 N. Maigrot, N. Avarvari, C. Charrier, and F. Mathey, *Angew. Chem., Int. Ed. Engl.*, **34**, 590 (1995).
- 95AGE1321 M. Detzel, G. Friedrich, O. J. Scherer, and G. Wolmershauser, *Angew. Chem., Int. Ed. Engl.*, **34**, 1321 (1995).
- 95CB71 B. Rink, O. J. Scherer, and G. Wolmershauser, *Chem. Ber.*, **128**, 71 (1995).
- 95CB259 D. Gudat, M. Nieger, and M. Schrott, *Chem. Ber.*, **128**, 259 (1995).
- 95CB635 O. J. Scherer, G. Berg, and G. Wolmershauser, *Chem. Ber.*, **128**, 635 (1995).

- 95CB665 L. Weber, O. Sommer, H. G. Stammer, B. Neumann, and U. Kolle, *Chem. Ber.*, **128**, 665 (1995).
- 95CCR(143)71 R. N. Grimes, *Coord. Chem. Rev.*, **143**, 71 (1995).
- 95CCR(145)201 J. F. Nixon, *Coord. Chem. Rev.*, **145**, 201 (1995).
- 95IC2058 M. Stephan, P. Muller, U. Zenneck, H. Pritzkow, W. Siebert, and R. N. Grimes, *Inorg. Chem.*, **34**, 2058 (1995).
- 95IC4979 M. Fourmigue, C. Lenoir, C. Coulon, F. Guyon, and J. Amaudrut, *Inorg. Chem.*, **34**, 4979 (1995).
- 95IC6509 X. Wang, M. Sabat, and R. N. Grimes, *Inorg. Chem.*, **34**, 6509 (1995).
- 95JA5421 D. S. Brown, A. Decken, and A. H. Cowley, *J. Am. Chem. Soc.*, **117**, 5421 (1995).
- 95JA12218 X. Wang, M. Sabat, and R. N. Grimes, *J. Am. Chem. Soc.*, **117**, 12,218 (1995).
- 95JA12227 X. Wang, M. Sabat, and R. N. Grimes, *J. Am. Chem. Soc.*, **117**, 12,227 (1995).
- 95JCS(CC)1541 D. Gudat, M. Schrott, and M. Nieger, *J. Chem. Soc., Chem. Commun.*, 1541 (1995).
- 95JCS(CC)1659 F. G. N. Cloke, K. R. Flower, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 1659 (1995).
- 95JCS(CC)1661 V. Caliman, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 1661 (1995).
- 95JCS(CC)2113 A. Ostrowski, J. Jeske, and P. G. Jones, *J. Chem. Soc., Chem. Commun.*, 2113 (1995).
- 95JMS57 L. Nyulaszi and T. Veszpremi, *J. Mol. Struct.*, **347**, 57 (1995).
- 95JMS(T)55 L. Nyulaszi, P. Varnai, and T. Veszpremi, *J. Mol. Struct. (THEOCHEM)*, **358**, 55 (1995).
- 95JOM(487)C21 F. G. N. Cloke, K. R. Flower, C. Jones, R. M. Matos, and J. F. Nixon, *J. Organomet. Chem.*, **487**, C21 (1995).
- 95JOM(490)155 P. B. Hitchcock, J. F. Nixon, and R. M. Matos, *J. Organomet. Chem.*, **490**, 155 (1995).
- 95JOM(492)185 G. Schmid and M. Schutz, *J. Organomet. Chem.*, **492**, 185 (1995).
- 95MI1 G. E. Herberich, in "Comprehensive Organometallic Chemistry II" (E. Abel, F. G. A. Stone, and G. Wilkinson, eds.), Chapter 5, Vol. 1, Pergamon Press, Oxford, England (1995).
- 95MI2 R. N. Grimes, in "Comprehensive Organometallic Chemistry II" (E. Abel, F. G. A. Stone, and G. Wilkinson, eds.), Chapter 9, Vol. 1, Pergamon Press, Oxford, England (1995).
- 95OM581 L. Weber, O. Kaminski, H. G. Stammer, and B. Neumann, *Organometallics*, **14**, 581 (1995).
- 95OM1911 W. Weinmann, A. Wolf, H. Pritzkow, W. Siebert, B. A. Barnum, P. J. Carroll, and L. G. Sneddon, *Organometallics*, **14**, 1995 (1995).
- 95OM3014 K. E. Stockman, K. L. Houseknecht, E. A. Boring, M. Sabat, M. G. Finn, and R. N. Grimes, *Organometallics*, **14**, 3014 (1995).
- 95OM3683 P. Greiwe, M. Sabat, and R. N. Grimes, *Organometallics*, **14**, 3683 (1995).
- 95OM4382 P. B. Hitchcock, J. A. Johnson, and J. F. Nixon, *Organometallics*, **14**, 4382 (1995).
- 95OM4661 K. E. Stockman, D. L. Garrett, and R. N. Grimes, *Organometallics*, **14**, 4661 (1995).
- 95OM4668 X. Wang, M. Sabat, and R. N. Grimes, *Organometallics*, **14**, 4668 (1995).

- 96ADOC325 A. J. Ashe, *Adv. Organomet. Chem.*, **39**, 325 (1996).
96AOC209 R. N. Grimes, *Appl. Organomet. Chem.*, **10**, 209 (1996).
96CB213 W. Weinmann, F. Metzner, H. Pritzkow, W. Siebert, and L. Sneddon, *Chem. Ber.*, **129**, 213 (1996).
96CB337 D. Gudat, M. Schrott, V. Bajorat, M. Nieger, S. Kotila, R. Fleischer, and D. Stalke, *Chem. Ber.*, **129**, 337 (1996).
96CEJ487 R. Hettrich, M. Kaschke, H. Wadepohl, W. Herrmann, M. Stephan, H. Pritzkow, W. Siebert, I. Hyla-Kryspin, and R. Gleiter, *Chem. Eur. J.*, **2**, 487 (1996).
96IC4690 L. Nyulaszi, *Inorg. Chem.*, **35**, 4690 (1996).
96IC6703 M. A. Curtis, M. Sabat, and R. N. Grimes, *Inorg. Chem.*, **35**, 6703 (1996).
96IC7027 D. A. Franz, E. J. Houser, M. Sabat, and R. N. Grimes, *Inorg. Chem.*, **35**, 7027 (1996).
96JA7630 P. L. Arnold, F. G. N. Cloke, P. B. Hitchcock, and J. F. Nixon, *J. Am. Chem. Soc.*, **118**, 7630 (1996).
96JCS(CC)441 M. H. A. Benvenutti, P. B. Hitchcock, J. F. Nixon, and M. D. Vargas, *J. Chem. Soc., Chem. Commun.*, 441 (1996).
96JCS(CC)1591 M. D. Francis, D. E. Hibbs, M. B. Hursthouse, C. Jones, and K. M. A. Malik, *J. Chem. Soc., Chem. Commun.*, 1591 (1996).
96JCS(CC)2657 N. Metzler and M. K. Denk, *J. Chem. Soc., Chem. Commun.*, 2657 (1996).
96JCS(CC)2751 P. B. Hitchcock, J. F. Nixon, and N. Sakaraya, *J. Chem. Soc., Chem. Commun.*, 2751 (1996).
96JCS(D)1475 P. Blakeman, B. Gehrhus, J. C. Green, J. Heinicke, M. F. Lappert, M. Kindermann, and T. Veszpremi, *J. Chem. Soc., Dalton Trans.*, 1475 (1996).
96JOM(572)141 C. Muller, R. Bartsch, A. Fischer, P. G. Jones, and R. Schmutzler, *J. Organomet. Chem.*, **572**, 141 (1996).
96JPC6194 L. Nyulaszi, *J. Phys. Chem.*, **100**, 6194 (1996).
96JPC13447 M. N. Glukhovtsev, A. Dransfeld, and P. R. Schleyer, *J. Phys. Chem.*, **96**, 13,447 (1996).
96MI1 M. Denk, R. J. West, R. K. Hayashi, Y. Apeloig, R. Pauncz, and M. Karni, in "Organosilicon Chemistry: From Molecules to Materials" (N. Auner and J. Weis, eds.), p. 251, VCH, Weinheim, (1996).
96MI2 A. Schmidpeter, in "Comprehensive Heterocyclic Chemistry II" (A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, eds.), Vol. 3, p. 709, Pergamon, Oxford (1996).
96MI3 A. Schmidpeter, in "Comprehensive Heterocyclic Chemistry II" (A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, eds.), Vol. 4, p. 772, Pergamon, Oxford (1996).
96MI4 G. Schmid, in "Comprehensive Heterocyclic Chemistry II" (A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, eds.), Vol. 1, p. 740, Pergamon, Oxford (1996).
96PAC785 R. West and M. Denk, *Pure Appl. Chem.*, **68**, 785 (1996).
96PSS109 L. Nyulaszi and T. Veszpremi, *Phosphorus, Sulfur, Silicon, Relat. Elem.*, **109-110**, 109 (1996).
96PSS133 O. J. Scherer, M. Detzel, G. Berg, J. Braun, H. Edinger, T. Mohr, G. Schwarz, P. Walther, and G. Wolmershauser, *Phosphorus, Sulfur, Silicon, Relat. Elem.*, **109-110**, 133 (1996).

- 96TL9025 M. K. Denk, S. Gupta, and R. Ramachandran, *Tetrahedron Lett.*, 9025 (1996).
- 96ZAAC543 L. Weber, O. Sommer, H. G. Stammer, and B. Neumann, *Z. Anorg. Allg. Chem.*, **622**, 543 (1996).
- 96ZAAC1478 G. Friedrich, O. J. Scherer, and G. Wolmershauser, *Z. Anorg. Allg. Chem.*, **622**, 1478 (1996).
- 97AGE1492 R. Streubel, H. Wilkens, A. Ostrowski, C. Neumann, F. Ruthe, and P. G. Jones, *Angew. Chem., Int. Ed. Engl.*, **36**, 1492 (1997).
- 97CB329 W. Weinmann, H. Pritzkow, W. Siebert, and L. G. Sneddon, *Chem. Ber.*, **130**, 329 (1997).
- 97CB705 L. Weber, E. Dobbert, H. G. Stammer, B. Neumann, R. Boese, and D. Blaser, *Chem. Ber.*, **130**, 705 (1997).
- 97CB1299 M. Scheer, K. Schuster, A. Krug, and H. Hartung, *Chem. Ber.*, **130**, 1299 (1997).
- 97IC1476 D. Gudat, M. Nieger, and M. Schrott, *Inorg. Chem.*, **36**, 1476 (1997).
- 97IC3602 M. A. Curtis, T. Muller, V. Beez, H. Pritzkow, W. Siebert, and R. N. Grimes, *Inorg. Chem.*, **36**, 3602 (1997).
- 97CCCC309 D. Bohm, F. Heinemann, D. Hu, S. Kummer, and U. Zenneck, *Collect. Czech. Chem. Commun.*, **62**, 309 (1997).
- 97JCS(CC)305 S. J. Black, M. D. Francis, and C. Jones, *J. Chem. Soc., Chem. Commun.*, 305 (1997).
- 97JCS(CC)481 P. L. Arnold, F. G. N. Cloke, and P. B. Hitchcock, *J. Chem. Soc., Chem. Commun.*, 481 (1997).
- 97JCS(CC)1539 M. H. A. Benvenutti, P. B. Hitchcock, J. L. Kiplinger, J. F. Nixon, and T. G. Richmond, *J. Chem. Soc., Chem. Commun.*, 1539 (1997).
- 97JCS(CC)1739 V. Caliman, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 1739 (1997).
- 97JCS(CC)2317 H. Wilkens, J. Jeske, P. G. Jones, and R. Streubel, *J. Chem. Soc., Chem. Commun.*, 2317 (1997).
- 97JCS(D)2183 S. J. Black, M. D. Francis, and C. Jones, *J. Chem. Soc., Dalton Trans.*, 2183 (1997).
- 97JCS(D)4321 S. J. Black, D. E. Hibbs, M. B. Hursthouse, C. Jones, K. M. A. Malik, and R. C. Thomas, *J. Chem. Soc., Dalton Trans.*, 4321 (1997).
- 97JOM(527)291 M. D. Francis, D. E. Hibbs, M. B. Hursthouse, C. Jones, and K. M. A. Malik, *J. Organomet. Chem.*, **527**, 291 (1997).
- 97JOM(529)69 C. Charrier, N. Maignot, and F. Mathey, *J. Organomet. Chem.*, **529**, 69 (1997).
- 97JOM(529)375 R. Bartsch, S. Datsenko, N. V. Ignatiev, C. Muller, J. F. Nixon, and C. J. Pickett, *J. Organomet. Chem.*, **529**, 375 (1997).
- 97JOM(529)379 O. J. Scherer, T. Mohr, and G. Wolmershauser, *J. Organomet. Chem.*, **529**, 379 (1997).
- 97JOM(534)89 S. J. Black and C. Jones, *J. Organomet. Chem.*, **534**, 89 (1997).
- 97JOM(536)115 E. J. Houser, M. A. Curtis, M. Sabat, and R. N. Grimes, *J. Organomet. Chem.*, **536-537**, 115 (1997).
- 97MI1 R. N. Grimes, in "Advances in Boron Chemistry" (W. Siebert, ed.), p. 321, Royal Soc. Chem., Cambridge (1997).
- 97ZAAC1897 A. Ostrowski, J. Jeske, F. Ruthe, P. G. Jones, and R. Streubel, *Z. Anorg. Allg. Chem.*, **623**, 2001 (1997).
- 98AGE1083 F. G. N. Cloke, P. B. Hitchcock, P. Hunnabell, J. F. Nixon, L. Nyulaszi, E. Niecke, and V. Thelen, *Angew. Chem., Int. Ed. Engl.*, **37**, 1083 (1998).

- 98ADOC1 K. H. Whitmire, *Adv. Organomet. Chem.*, **42**, 1 (1998).
- 98AX(C)1830 M. K. Denk, M. Khan, A. J. Lough, and K. Shuchi, *Acta Cryst.*, **C54**, 12,830 (1998).
- 98CCR(178)771 P. Le Floch and F. Mathey, *Coord. Chem. Rev.*, **178–180**, 771 (1998).
- 98CEJ1542 H. Wilkens, F. Ruthe, P. G. Jones, and R. Streubel, *Chem. Eur. J.*, **4**, 1542 (1998).
- 98CEJ1714 M. Fourmigue, B. Domercq, I. V. Jourdain, P. Molinie, F. Guyon, and J. Amaudrut, *Chem. Eur. J.*, **4**, 1714 (1998).
- 98CEJ1910 O. J. Scherer, S. Weigel, and G. Wolmershauser, *Chem. Eur. J.*, **4**, 1998 (1910).
- 98CSR319 J. F. Nixon, *Chem. Soc. Rev.*, **27**, 319 (1998).
- 98EJIC305 A. Sundermann, M. Reiher, and W. W. Schoeller, *Eur. J. Inorg. Chem.*, 305 (1998).
- 98EJIC1067 M. K. Denk, K. Hatano, and A. J. Lough, *Eur. J. Inorg. Chem.*, 1067 (1998).
- 98EJIC1079 N. Gupta, C. B. Jain, J. Heinicke, R. K. Bansal, and P. G. Jones, *Eur. J. Inorg. Chem.*, 1079 (1998).
- 98EJIC1145 L. Weber, E. Dobbert, R. Boese, M. T. Kirchner, and D. Blaser, *Eur. J. Inorg. Chem.*, 1145 (1998).
- 98EJIC2005 R. Streubel, U. Rohde, J. Jeske, F. Ruthe, and P. G. Jones, *Eur. J. Inorg. Chem.*, 2005 (1998).
- 98IC102 M. A. Curtis, E. J. Houser, M. Sabat, and R. N. Grimes, *Inorg. Chem.*, **37**, 102 (1998).
- 98ICA(270)273 K. Angermund, A. Eckerle, J. Monkiewicz, C. Kruger, and G. Wilke, *Inorg. Chim. Acta*, **270**, 273 (1998).
- 98JA12714 M. Haaf, A. Schmiedl, T. A. Schmedake, R. A. Powell, A. J. Millevolte, M. K. Denk, and R. West, *J. Am. Chem. Soc.*, **120**, 12,714 (1998).
- 98JCS(CC)797 P. L. Arnold, F. G. N. Cloke, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 797 (1998).
- 98JCS(CC)1529 H. Wilkens, F. Ruthe, P. G. Jones, and R. Streubel, *J. Chem. Soc., Chem. Commun.*, 1529 (1998).
- 98JCS(D)483 I. V. Jourdain, M. Fourmigue, F. Guyon, and J. Amaudrut, *J. Chem. Soc., Dalton Trans.*, 483 (1998).
- 98JOM(571)107 S. Huck, A. Ginsberg, H. Pritzkow, and W. Siebert, *J. Organomet. Chem.*, **571**, 107 (1998).
- 98MI1 K. B. Dillon, F. Mathey, and J. F. Nixon, in “*Phosphorus: the Carbon Copy*”, Wiley, New York (1998).
- 98OM2352 S. Urquhart, A. P. Hitchcock, and M. K. Denk, *Organometallics*, **17**, 2352 (1998).
- 98OM2379 A. J. Ashe, X. Fang, and J. W. Kampf, *Organometallics*, **17**, 2379 (1998).
- 98OM3826 M. D. Francis, C. Jones, G. B. Deacon, E. E. Delbridge, and P. C. Junk, *Organometallics*, **17**, 3826 (1998).
- 98OM5599 B. Gehrhuis, P. B. Hitchcock, M. F. Lappert, and H. Maciejewski, *Organometallics*, **17**, 5599 (1998).
- 98OM5801 C. Boehme and G. Frenking, *Organometallics*, **17**, 5801 (1998).
- 98ZAAC399 M. Scheer and J. Krug, *Z. Anorg. Allg. Chem.*, **624**, 399 (1998).
- 99ACR751 O. J. Scherer, *Acc. Chem. Res.*, **32**, 751 (1999).
- 99CEJ3143 A. Elvers, F. W. Heinemann, B. Wrackmeyer, and U. Zenneck, *Chem. Eur. J.*, **5**, 3143 (1999).

- 99EJIC41 M. K. Denk, S. Gupta, and A. J. Lough, *Eur. J. Inorg. Chem.*, 41 (1999).
- 99EJIC491 L. Weber, E. Dobbert, H. G. Stammer, B. Neumann, R. Boese, and D. Blaser, *Eur. J. Inorg. Chem.*, 491 (1999).
- 99EJIC1193 L. Weber, M. Schnieder, H. G. Stammer, B. Neumann, and W. W. Schoeller, *Eur. J. Inorg. Chem.*, 1193 (1999).
- 99EJIC1567 R. Streubel, H. Wilkens, U. Rohde, A. Ostrowski, J. Jeske, F. Ruthe, and P. G. Jones, *Eur. J. Inorg. Chem.*, 1567 (1999).
- 99EJIC1685 T. Muller, M. Kaschke, M. Strauch, A. Ginsberg, H. Pritzkow, and W. Siebert, *Eur. J. Inorg. Chem.*, 1685 (1999).
- 99IC93 T. T. Chin, R. N. Grimes, and W. E. Geiger, *Inorg. Chem.*, **38**, 93 (1999).
- 99IC1971 R. G. Cavell and M. D. Mikoluk, *Inorg. Chem.*, **38**, 1999 (1971).
- 99IC2791 M. D. Mikoluk, R. McDonald, and R. G. Cavell, *Inorg. Chem.*, **38**, 2791 (1999).
- 99ICA(288)17 A. J. Bridgeman and J. Rothery, *Inorg. Chim. Acta*, **288**, 17 (1999).
- 99JA9758 E. S. Schmidt, A. Jokisch, and H. Schmidbaur, *J. Am. Chem. Soc.*, **121**, 9758 (1999).
- 99JCS(CC)1731 F. G. N. Cloke, J. R. Hanks, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 1731 (1999).
- 99JCS(CC)2127 R. Streubel, H. Wilkens, F. Ruthe, and P. G. Jones, *J. Chem. Soc., Chem. Commun.*, 2127 (1999).
- 99JCS(D)2627 D. E. Hibbs, M. B. Hursthouse, C. Jones, and R. C. Thomas, *J. Chem. Soc., Dalton Trans.*, 2627 (1999).
- 99JCS(D)4057 J. J. Durkin, M. D. Francis, P. B. Hitchcock, C. Jones, and J. F. Nixon, *J. Chem. Soc., Dalton Trans.*, 4057 (1999).
- 99JOM(577)337 C. B. Jain, D. C. Sharma, N. Gupta, J. Heinicke, and R. K. Bansal, *J. Organomet. Chem.*, **577**, 337 (1999).
- 99JOM(580)156 M. D. Francis, D. E. Hibbs, P. B. Hitchcock, M. B. Hursthouse, C. Jones, T. Mackewitz, J. F. Nixon, L. Nyulaszi, M. Regitz, N. Sakarya, *J. Organomet. Chem.*, **580**, 156 (1999).
- 99JOM(581)1 R. N. Grimes, *J. Organomet. Chem.*, **581**, 1 (1999).
- 99JOM(581)13 N. S. Hosmane, *J. Organomet. Chem.*, **581**, 13 (1999).
- 99JOM(584)58 G. K. B. Clentsmith, P. B. Hitchcock, J. F. Nixon, and N. Sakaraya, *J. Organomet. Chem.*, **584**, 58 (1999).
- 99JOM(584)87 C. S. J. Callaghan, P. B. Hitchcock, and J. F. Nixon, *J. Organomet. Chem.*, **584**, 87 (1999).
- 99MSF136 J. E. Cosgriff, G. B. Deacon, E. E. Delbridge, C. Jones, B. W. Skelton, and A. H. White, *Mater. Sci. Forum*, **315–317**, 136 (1999).
- 99OM793 C. Callaghan, G. K. B. Clentsmith, F. G. N. Cloke, P. B. Hitchcock, J. F. Nixon, and D. M. Vickers, *Organometallics*, **18**, 793 (1999).
- 99OM1821 A. J. Ashe, X. Fang, and J. W. Kampf, *Organometallics*, **18**, 1999 (1821).
- 99OM1827 R. F. Winter and W. E. Geiger, *Organometallics*, **18**, 1999 (1827).
- 99OM1834 I. V. Jourdain, M. Fourmigue, F. Guyon, and J. Amaudrut, *Organometallics*, **18**, 1999 (1834).
- 99OM2615 S. H. A. Petri, D. Eikenberg, B. Neumann, H. G. Stammer, and P. Jutzi, *Organometallics*, **18**, 2615 (1999).
- 99OM2833 P. Sekar, M. Scheer, A. Voigt, and R. Kirmse, *Organometallics*, **18**, 2833 (2001).

- 99OM3306 M. D. Mikoluk, R. McDonald, and R. G. Cavell, *Organometallics*, **18**, 3306 (1999).
- 99OM5627 H. Wilkens, A. Ostrowski, J. Jeske, F. Ruthe, P. G. Jones, and R. Streubel, *Organometallics*, **18**, 5627 (1999).
- 99PSS725 A. Elvers, F. W. Heinemann, S. Kummer, B. Wrackmeyer, M. Zeller, and U. Zenneck, *Phosphorus, Sulfur, Silicon, Relat. Elem.*, **144–145**, 725 (1999).
- 99TL3815 M. D. Francis, C. Jones, and C. P. Morley, *Tetrahedron Lett.*, **40**, 3815 (1999).
- 99ZN(B)1244 D. Gudat, A. W. Holderberg, N. Korber, M. Nieger, and M. Schrott, *Z. Naturforsch.*, **B54**, 1244 (1999).
- 00ACR704 M. Haaf, T. A. Schmedake, and R. West, *Acc. Chem. Res.*, **33**, 704 (2000).
- 00AGE948 C. J. Irvine, C. E. F. Ricard, W. R. Roper, A. Williamson, and L. L. Wright, *Angew. Chem., Int. Ed. Engl.*, **39**, 948 (2000).
- 00AGE1029 O. J. Scherer, *Angew. Chem., Int. Ed. Engl.*, **39**, 1029 (2000).
- 00AGE1426 O. J. Scherer, T. Hilt, and G. Wolmershauser, *Angew. Chem., Int. Ed. Engl.*, **39**, 1426 (2000).
- 00AGE2087 T. Clark, A. Elvers, F. W. Heinemann, M. Hennemann, M. Zeller, and U. Zenneck, *Angew. Chem., Int. Ed. Engl.*, **39**, 2087 (2000).
- 00AGE2307 F. E. Hahn, L. Wittenbecher, D. Le Van, R. Frohlich, and B. Wibbeling, *Angew. Chem., Int. Ed. Engl.*, **39**, 2307 (2000).
- 00AGE3686 R. Streubel, U. Schiemann, P. G. Jones, N. H. T. Huy, and F. Mathey, *Angew. Chem., Int. Ed. Engl.*, **39**, 3686 (2000).
- 00AGE4148 H. J. Breunig, N. Burford, and R. Rosler, *Angew. Chem., Int. Ed. Engl.*, **39**, 4148 (2000).
- 00CCR(200)773 R. N. Grimes, *Coord. Chem. Rev.*, **200–202**, 773 (2000).
- 00CEJ3997 R. Streubel, H. Wilkens, and P. G. Jones, *Chem. Eur. J.*, **6**, 3997 (2000).
- 00CEJ3414 D. Gudat, A. Haghverdi, H. Hupfer, and M. Nieger, *Chem. Eur. J.*, **6**, 3414 (2000).
- 00EJIC369 W. W. Schoeller, *Eur. J. Inorg. Chem.*, 369 (2000).
- 00EJIC1253 R. Streubel, R. Priemer, F. Ruthe, and P. G. Jones, *Eur. J. Inorg. Chem.*, 1253 (2000).
- 00EJIC2425 L. Weber, *Eur. J. Inorg. Chem.*, 2425 (2000).
- 00EJIC2451 R. H. Herber and O. J. Scherer, *Eur. J. Inorg. Chem.*, 2451 (2000).
- 00EJIC2585 P. Sekar, S. Umbarkar, M. Scheer, A. Voigt, and R. Kirmse, *Eur. J. Inorg. Chem.*, 2585 (2000).
- 00JCS(CC)879 A. G. Avent, F. G. N. Cloke, M. D. Francis, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 879 (2000).
- 00JCS(CC)1427 B. Gehrhuis, P. B. Hitchcock, M. F. Lappert, and J. C. Sloodweg, *J. Chem. Soc., Chem. Commun.*, 1427 (2000).
- 00JCS(CC)1637 D. Gudat, S. Hap, L. Szarvan, and M. Nieger, *J. Chem. Soc., Chem. Commun.*, 1637 (2000).
- 00JCS(CC)2027 M. D. Francis, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Chem. Commun.*, 2027 (2000).
- 00JCS(D)1013 R. Bartsch, F. G. N. Cloke, J. C. Green, R. M. Matos, J. F. Nixon, R. J. Suffolk, J. L. Suter, and D. J. Wilson, *J. Chem. Soc., Dalton Trans.*, 1013 (2000).
- 00JCS(D)1135 S. Umbarkar, P. Sekar, and M. Scheer, *J. Chem. Soc., Dalton Trans.*, 1135 (2000).

- 00JCS(D)1507 S. B. Clendenning, J. C. Green, and J. F. Nixon, *J. Chem. Soc., Dalton Trans.*, 1507 (2000).
- 00JCS(CC)1659 F. G. N. Cloke, P. B. Hitchcock, U. Schlemann, R. Streubel, J. F. Nixon, and D. J. Wilson, *J. Chem. Soc., Chem. Commun.*, 1659 (2000).
- 00JCS(D)1715 G. K. B. Clentsmith, F. G. N. Cloke, M. D. Francis, J. C. Green, P. B. Hitchcock, J. F. Nixon, J. L. Suter, and D. M. Vickers, *J. Chem. Soc., Dalton Trans.*, 1715 (2000).
- 00JCS(D)2495 R. Streubel, C. Neumann, and P. G. Jones, *J. Chem. Soc., Dalton Trans.*, 2495 (2000).
- 00JCS(D)3534 F. G. N. Cloke, J. C. Green, J. R. Hanks, J. F. Nixon, and J. L. Suter, *J. Chem. Soc., Dalton Trans.*, 3534 (2000).
- 00OL2089 A. J. Ashe and X. Fang, *Org. Lett.*, 2089 (2000).
- 00OM219 F. G. N. Cloke, P. B. Hitchcock, J. F. Nixon, and D. J. Wilson, *Organometallics*, **19**, 219 (2000).
- 00OM475 R. Streubel, U. Schiemann, N. Hoffmann, Y. Schiemann, P. G. Jones, and D. Gudat, *Organometallics*, **19**, 475 (2000).
- 00OM1713 G. B. Deacon, E. E. Delbridge, G. D. Falton, D. E. Hibbs, C. Jones, M. B. Hursthouse, B. W. Skelton, and A. H. White, *Organometallics*, **19**, 1713 (2000).
- 00OM2200 K. E. Stockman, E. A. Boring, S. M. G. Finn, and R. N. Grimes, *Organometallics*, **19**, 2200 (2000).
- 00OM2891 L. Weber, H. B. Wartig, H. G. Stammeler, A. Stammeler, and B. Neumann, *Organometallics*, **19**, 2891 (2000).
- 00OM3263 T. A. Schmedake, M. Haaf, B. J. Paradise, D. R. Powell, and R. West, *Organometallics*, **19**, 3263 (2000).
- 00OM4283 F. W. Heinemann, H. Pritzkow, M. Zeller, and U. Zenneck, *Organometallics*, **19**, 4283 (2000).
- 00OM4681 A. J. Ashe, J. W. Kampf, and M. Schiesher, *Organometallics*, **19**, 4681 (2000).
- 00OM4726 J. M. Dysard and T. D. Tiley, *Organometallics*, **19**, 4726 (2000).
- 00OM4935 A. J. Ashe, X. Fang, and J. W. Kampf, *Organometallics*, **19**, 4935 (2000).
- 01AGE2471 R. Streubel, U. Schiemann, P. G. Jones, J. Grunenberg, H. M. Scheibel, and D. Gudat, *Angew. Chem., Int. Ed. Engl.*, **40**, 2471 (2001).
- 01AGE3173 S. Herler, P. Mayer, H. Noth, A. Schulz, M. Suter, and M. Vogt, *Angew. Chem., Int. Ed. Engl.*, **40**, 3173 (2001).
- 01AGE3413 M. Schiffer and M. Scheer, *Angew. Chem., Int. Ed. Engl.*, **40**, 3413 (2001).
- 01AHC(78)1 A. P. Sadimenko, *Adv. Heterocycl. Chem.*, **78**, 1 (2001).
- 01AHC(79)115 A. P. Sadimenko, *Adv. Heterocycl. Chem.*, **79**, 115 (2001).
- 01AHC(80)157 A. P. Sadimenko, *Adv. Heterocycl. Chem.*, **80**, 157 (2001).
- 01AHC(81)167 A. P. Sadimenko, *Adv. Heterocycl. Chem.*, **81**, 167 (2001).
- 01CRV1229 L. Nyulaszi, *Chem. Rev.*, **101**, 1229 (2001).
- 01CRV3549 R. K. Bansal and J. Heinicke, *Chem. Rev.*, **101**, 3549 (2001).
- 01EJIC891 F. Nief, *Eur. J. Inorg. Chem.*, 891 (2001).
- 01EJIC2563 J. Heinicke, A. Surana, N. Peulecke, R. K. Bansal, A. Murso, and D. Stalke, *Eur. J. Inorg. Chem.*, 2563 (2001).
- 01EJIC3175 R. Streubel, U. Schiemann, N. H. T. Huy, and F. Mathey, *Eur. J. Inorg. Chem.*, 3175 (2001).
- 01JCR3549 R. K. Bansal and J. Heinicke, *J. Chem. Res.*, **101**, 3549 (2001).

- 01JCS(D)378 L. Weber, M. Schneider, R. Boese, and D. Blaser, *J. Chem. Soc., Dalton Trans.*, 378 (2001).
- 01JCS(D)1013 R. Bartsch, F. G. N. Cloke, J. C. Green, R. M. Matos, J. F. Nixon, R. J. Suffolk, J. L. Suter, and D. J. Wilson, *J. Chem. Soc., Dalton Trans.*, 1013 (2001).
- 01JCS(D)1726 M. Al-Ktaifani, J. C. Green, P. B. Hitchcock, and J. F. Nixon, *J. Chem. Soc., Dalton Trans.*, 1726 (2001).
- 01JCS(D)3459 L. Weber, M. Schmieder, and P. Lonnecke, *J. Chem. Soc., Dalton Trans.*, 3459 (2001).
- 01JMS(T)189 T. Veszpremi, J. Matrai, J. Heinicke, and M. K. Hindermann, *J. Mol. Struct. THEOCHEM*, **538**, 189 (2001).
- 01JOM(617)737 M. K. Denk and J. M. Rodenzo, *J. Organomet. Chem.*, **617**, 737 (2001).
- 01JOM(619)7 A. Ginsberg, H. Pritzkow, and W. Siebert, *J. Organomet. Chem.*, **619**, 7 (2001).
- 01JOM(622)61 C. Jones and R. C. Thomas, *J. Organomet. Chem.*, **622**, 61 (2001).
- 01JOM(633)143 M. M. Al-Ktaifani, M. D. Francis, P. B. Hitchcock, and J. F. Nixon, *J. Organomet. Chem.*, **633**, 143 (2001).
- 01JOM(635)212 F. G. N. Cloke, P. B. Hitchcock, J. F. Nixon, and D. M. Vickers, *J. Organomet. Chem.*, **635**, 212 (2001).
- 01JOM(636)17 T. A. Schmedake, M. Haaf, B. J. Paradise, A. J. Millevolte, D. R. Powell, and R. West, *J. Organomet. Chem.*, **636**, 17 (2001).
- 01OM1965 T. Pott, P. Jutzi, B. Neumann, and H. G. Stammer, *Organometallics*, **20**, 2001 (1965).
- 01OM2604 K. H. Yih, G. H. Lee, and Y. Wang, *Organometallics*, **20**, 2604 (2001).
- 01OM2905 F. W. Heinemann, H. Pritzkow, M. Zeller, and U. Zenneck, *Organometallics*, **20**, 2905 (2001).
- 01OM3367 A. V. Korolev, F. Delpech, S. Dagorne, I. A. Guzei, and R. F. Jordan, *Organometallics*, **20**, 3367 (2001).
- 01OM5248 I. Weber, H. B. Wartig, H. G. Stammer, and B. Neumann, *Organometallics*, **20**, 5248 (2001).
- 01OM5492 T. Pott, P. Jutzi, W. W. Schoeller, A. Stammer, and H. G. Stammer, *Organometallics*, **20**, 5492 (2001).
- 01ZN(B)73 W. Siebert, S. Huck, and H. Pritzkow, *Z. Naturforsch.*, **B56**, 73 (2001).
- 02AGE174 S. Y. Liu, M. M. C. Lo, and G. C. Fu, *Angew. Chem., Int. Ed. Engl.*, **41**, 174 (2002).
- 02AHC(83)117 A. P. Sadimenko, *Adv. Heterocycl. Chem.*, **83**, 117 (2002).
- 02JOM(643)253 C. Neumann, E. Ionescu, U. Schiemann, M. Schlenker, M. Bode, F. Ruthe, P. G. Jones, and R. Streubel, *J. Organomet. Chem.*, **643–644**, 253 (2002).
- 02JOM(643)272 X. Cai, B. Gehrhus, P. B. Hitchcock, M. F. Lappert, and J. C. Slootweg, *J. Organomet. Chem.*, **643–644**, 272 (2002).
- 02JOM(646)113 A. Surana, S. Singh, R. K. Bansal, N. Peulecke, A. Spannenberg, and J. Heinicke, *J. Organomet. Chem.*, **646**, 113 (2002).
- 02OM534 D. Amoroso, M. Haaf, G. P. A. Yap, R. West, and D. E. Fogg, *Organometallics*, **21**, 534 (2002).
- 02OM912 J. Heinicke, K. Steinhäuser, N. Peulecke, A. Spannenberg, P. Mayer, and K. Karaghiosoff, *Organometallics*, **21**, 912 (2002).
- 02OM1167 F. Delpech, I. A. Guzei, and R. F. Jordan, *Organometallics*, **21**, 1167 (2002).
- 03AHC(84)191 A. P. Sadimenko, *Adv. Heterocycl. Chem.*, **84**, 191 (2003).

Heterocyclic Mesomeric Betaines and Analogs in Natural Product Chemistry. Betainic Alkaloids and Nucleobases

ANDREAS SCHMIDT¹

*Technical University of Clausthal, Institute of Organic Chemistry,
Leibnizstrasse 6, D-38678 Clausthal-Zellerfeld, Germany*

I. Introduction	68
A. The Terms “Zwitterion” and “Mesomeric Betaine”	68
B. Classification and Characteristic Features of Heterocyclic Mesomeric Betaines	73
II. Mesomeric Betaines	79
A. Conjugated Mesomeric Betaines	79
1. Pyridinium-olates	79
2. Pyridinium-phenolates	83
3. Isoquinolinium-olates	84
4. 3-Oxo-pyrido[1,2- <i>c</i>]pyrimidinium-4-olate	98
5. Phenanthridinium-olates	99
6. Isoquino[3,2- <i>a</i>]isoquinolinium-olates	103
7. Benzo[<i>c</i>]phenanthridinium-olates	107
8. Dibenzo[<i>de,g</i>]quinolinium-olates	108
9. Purines	116
B. Heterocyclic Conjugated N-oxides	119
1. Pyridine-N-oxides	119
2. Pyrazine-N-oxides	120
3. Phenazine-N-oxides	122
4. β -Carboline-N-oxides	122
5. Quinoline-N-oxides	123
6. Purine-N-oxides	124
C. Cross-conjugated Heterocyclic Mesomeric Betaines	124
1. Pyridinium-3-carboxylates	124
2. Imidazolium-4-carboxylates	129
3. Pyrido[2,1- <i>a</i>]isoquinoline-3-carboxylic Acids	130
D. Pseudo-cross-conjugated Heterocyclic Mesomeric Betaines	131
1. Pyridinium-2-carboxylates	131
2. Isoquinolinium-2-carboxylates	133
3. 2-Immoniummethyl-benzoylate	133
4. Indazolium-11-carboxylates	134

¹Tel./fax: +49-5323-723861.

5. Indolo[2,3- <i>a</i>]quinolizinium-carboxylates	135
6. Phenazinium-1-carboxylates	138
III. Zwitterionic Alkaloids	138
A. 2-Substituted Isoquinolinones	138
B. 1,2-Dihydroindazol-4-one	140
C. Phenazin-1-ones (Pyocyanines)	141
D. Phenanthridin-1-one	142
E. Indole Derivatives	142
F. Benzo[<i>c</i>]phenanthridinones	154
G. Dibenzo[<i>de,g</i>]quinoline-5,7-dione	155
IV. Conclusions	155
References	156

I. Introduction

A. THE TERMS “ZWITTERION” AND “MESOMERIC BETAINÉ”

In principle, the relationship between positive and negative charges in molecules can be simplified and categorized as shown in Fig. 1 (99JOC9499). In salts **I**, positive and negative charges are localized on discrete cations and anions, whereas the charges on zwitterions and mesomeric betaines are in the same molecule. An interrupted conjugation between the charged parts of the molecule, for example by one or more sp^3 -hybridized carbon atoms, results in zwitterions **II**. Polyheterocyclic molecules, however, can form zwitterionic ground states as shown in **III**, in which both the negative and the positive charges are delocalized within a common π -electron system, although at least one uncharged covalent structure can be drawn (93JOC6976, 93H1055, 91TL4473). As a consequence of the weighted average of all the canonical formulae highly polar entities are formed. In contrast to these kinds of zwitterions, mesomeric betaines **IV** are neutral compounds that can *exclusively* be formulated as dipolar structures, in which the positive and negative charges are delocalized within a common π -electron system. They possess an *even* number of positive and negative charges and no uncharged covalent structure can be drawn (85T2239). Betaines with an *odd* number of charges form a distinct class of compounds (98JOC4636, 98H865, 99H2119, 00MI2, 01H827, 02JHC949, 02OL1375).

Representatives of all these distinct categories of charged or charge-separated species have been isolated from natural sources. Salts of cationic alkaloids are widespread in nature, among them pyridinium, quinolinium, and isoquinolinium alkaloids. Examples of monocationic alkaloids are Cryptaustoline (**1**) (*Cryptocarya*) and the antitumor active Avicine (**2**)






Fig. 1

(93P1449, 85CPB4139) shown in Scheme 1. The former mentioned alkaloid has a sp^3 hybridized quaternary nitrogen atom and is an ammonium salt. Alkaloid **2** is a heteroarene salt as it has a quaternary sp^2 hybridized nitrogen atom. There are a number of highly biologically active natural products which bear more than one charge. Tubacurarine (**3**) and Cyclostelletamine (**4**) (94TL3967, 96T10849) are examples of dicationic alkaloids, whereas the oligomeric pyridinium-alkaloid **5** is a multicationic species (93JOC5925).



Scheme 1

Negatively charged alkaloids are rare. The isolation of the zinc salt Clathridin (**6**) (Scheme 2) from the marine sponge *Clathrina clathrus* was reported in 1990 (90T4387). Other examples are bis(isonaamidinato) A Zinc




Scheme 2

(II) and G from *Leucetta* species (95HCA1178) and zinc containing alkaloids from *Leucetta* cf. *chacosensis* (98JNP384). Magnesidine (7) ($n=0, 1$) is produced by the marine bacterium *Pseudomonas magnesorubra* (74TL983) and *Vibrio gazogenes*.

The combination of positive and negative charges within the same molecule causes a more complicated situation, which obviously has not been well-defined to date. A quite large number of pyrrolizidine alkaloids are related to Otonecine (8) (Scheme 3). Spectroscopic investigations show that these alkaloids exist in the nonionized form in CDCl_3 , and in the zwitterionic form in D_2O (00JNP857, 71TL3421). The dipolar structure is the result of an intramolecular interaction between a nucleophilic and an electrophilic center.


In contrast to this, the zwitterion Aplidiamin (9), which was isolated from *Ascidiae* living in the Ningaloo Reef, exists predominantly as an inner salt in which the positive and negative charges are separated by a sp^3 -hybridized carbon atom (97TL941, 92TL2597). Javacarboline (10) from *Picrasma javanica* (94H1413), which is used in folk medicine as febrifuge and as a substitute for quinine (73MI2), as well as the class of plant dyes called Betalaines (11) (Betanidine, Betanine) are also zwitterionic. The charge separation, however, is not due to a neutralization of acidic and basic functional groups within the same molecule, but to deprotonation of a carboxylic acid function adjacent to a quaternary nitrogen atom. As evidenced by HH-COSY, HSQC and HMBC experiments as well as X-ray crystallography, Javacarboline (10) has a protonated indole-nitrogen atom and a deprotonated carboxy group which form a hydrogen bond in the solid state (94H1413). Interestingly, racemization of the *L*-tryptophan derived zwitterionic alkaloid occurs via a 1,2-dihydropyridinium derivative. Dehydrobufotenine (12) and Bufothionine (13), which are components of the toxin producing skin glands of toads (*Bufo*nidae, *Hylidae*), are deprotonated at the hydroxy group and sulfonic acid group to form zwitterions, respectively. In 12 and 13, the positive charge is localized outside the π -electron system.



Scheme 3

A large number of alkaloids contains the indolo[2,3-*a*]quinolizine structure increment **14** (88MI2) (Scheme 4). They are found as zwitterions with an anionic indole ring or as salts depending on their base properties (90BCJ2498). The dipolar ground state arises from deprotonation, but the positive and the resulting negative charge are delocalized within a common π -electron system which can therefore be referred to as “conjugated zwitterion”. The deprotonated species can be represented by several dipolar structures and *one* neutral covalent canonical formula **14B**. The zwitterionic ground state is evidenced by its colored nature, high permanent dipole moments in the ground state and by the pH dependent UV–VIS spectra (25JCS1604, 53JA3361). The alkaloid Nigellidine (**15**) (*Nigella sativa*), which belongs to the extremely rare class of indazole alkaloids, is another example of this type of zwitterion (95TL1993). The positive and negative charges are in mutual conjugation and several dipolar structures, but only one neutral canonical formula, can be drawn. Evidently, the latter two mentioned species are related to heterocyclic mesomeric betaines and will be treated in Section III.

In contrast to the alkaloids mentioned so far, heterocyclic mesomeric betaines are defined as neutral conjugated molecules which can be represented *only* by dipolar structures in which both the negative and the positive charges are delocalized within the π -electron system (38JCS824, 85T2239). The first heterocyclic mesomeric betaine was prepared unknowingly by Emil Fischer (1882LA316). The real structure remained unknown



Scheme 4

until 1969 (69JCS(CC)1356, 69JCS(CC)1240, 70JA1965) when it was formulated as the mesoion tetrazoliumthiolate which is the valence tautomer of the originally proposed structure. For decades the nomenclature as well as the adequate representation of these structures were controversial (55CIL521). This is exemplified by the flood of acronyms such as mesoion (49JCS307, 55CIL910), ylide, paraion (80JA3971), sydnone (46JCS591, 64CRV129), münchnone (64AG185, 70CB2581), mesoionic $4n\pi$ -heterocycle (80ZN1002, 83H23), mesoionic malonyl heterocycle, inner salt, and anhydro compound. In addition, the symbols ψ and \pm were used for the dipolar representation of these compounds. After the first systematizations of heterocyclic N-oxides and N-ylides by Katritzky (71MI2), Ochiai (67MI2), Johnson and Petrovanu (66MI1, 76MI1), heterocyclic mesomeric betaines were classified in 1977 by Ramsden on the basis of their type of conjugation (77JCS(CC)109). The first comprehensive classification was published eight years later by Ollis, Stanforth and Ramsden (85T2239). All mesomeric betaines can be divided into four major classes, conjugated (CMB), cross-conjugated (CCMB), pseudo-cross-conjugated (PCCMB) heterocyclic mesomeric betaines, and conjugated heterocyclic N-ylides, the later are closely related to CMB. Today, the term mesoion is exclusively restricted to five-membered conjugated heterocyclic mesomeric betaines and thus includes the well-known sydnones, münchnones and derivatives (55CIL521, 85T2239). It has been demonstrated that these four major classes can be subdivided into four additional categories on the basis of their isoconjugate relationships to odd/even, alternant/nonalternant hydrocarbon




Fig. 2

anions/dianions, respectively. In summary, at least 16 distinct classes of heterocyclic mesomeric betaines can be differentiated (85T2239) which is exemplified in Fig. 2. The chemistry of mesoionic heterocycles of type A and B (02CHE681, 76AHC1, 79MI4, 82T2965), heteropentalenes (77T3203, 84CHEC1027, 77MI3, 77H1319, 78AHC183, 75ACR139, 78JOC3893), and conjugated mesomeric betaines isoconjugate with alternant hydrocarbon atoms (80AHC1) have been reviewed.


B. CLASSIFICATION AND CHARACTERISTIC FEATURES OF HETEROCYCLIC MESOMERIC BETAINES

This review demonstrates that representatives of all four major classes of heterocyclic mesomeric betaines were isolated from natural sources. The profound differences in the electronic structures of these distinct classes can be realized by a closer look at the canonical formulae, the frontier orbital profile, the isoconjugate relationships, physico-organic properties, and the

chemical behavior. As examples, four heterocyclic mesomeric betaines are presented in [Scheme 5](#) which are alkaloids or substructures of alkaloids. For conjugated mesomeric betaines (CMB) such as 1-methylpyridinium-3-olate (**16**) (cf. [Section II.A.1](#)), common atoms for either positive and negative charges exist in the canonical formulae. The charges are in mutual conjugation. X-ray single crystal structure analyzes show that all bonds in conjugated mesomeric betaines have double bond character ([82T2965](#), [76AHC1](#), [85T2239](#)). The same is true for heterocyclic conjugated N-ylides and relatives for which Malloapeltine (**17**) is an example (cf. [Section II.B.1](#)). They form a distinct major class, because they can satisfactorily be represented by 1,2-dipolar structures. The delocalization of the negative charge is much more important for the N-ylide stability than the delocalization of the positive charge (Kröhnke's rule) ([76MII](#)). In 1-methylpyridinium-3-carboxylate (**18**) (the alkaloid Trigollenine, cf. [Section II.C.1](#)), however, the charges are *exclusively* delocalized in separated parts of the molecule which is characteristic for cross-conjugated mesomeric betaines. No common atoms for the delocalization of the positive and negative charge exist. Pseudo-cross-conjugated heterocyclic mesomeric betaines (PCCMB) are hybrids between conjugated and cross-conjugated mesomeric betaines. As revealed by the canonical formulae of 1-methylpyridinium-2-carboxylate (**19**) (the alkaloid Homarine, cf. [Section II.D.1](#)), common atoms for the delocalization of the negative and positive charges exist. The mutual conjugation, however, involves electron sextet structures without internal electron octet stabilization. If the true structure of a molecule is to be a weighted average of its canonical formulae, there is only a very small contribution of these electron sextet structures to the overall electronic structure. Thus, the charges are effectively, but not exclusively, delocalized in separated parts of the common π -electron system. For this phenomenon the term "pseudo-cross-conjugation" was defined ([85T2239](#)).


In CCMB and PCCMB the negative partial structure is joined to the negative increment through an unstarred position. This bond is called a *union* in the sense defined by Dewar ([69MI3](#), [75MI2](#)): union is a process in which two conjugated molecules combine in such a way that their two π -electron systems unite into a larger one ([85T2239](#)). For the case of **18** and **19**, the anionic part is isoconjugate with the propenyl anion as shown in [Scheme 6](#).

Single crystal X-ray analyzes confirm the concept of cross-conjugation. The cationic and anionic segments of, e.g., 6-oxopyrimidinium-4-olate are unambiguously separated by single bonds without π -contributions. Delocalization and double bond character can be observed exclusively in the charge-separated segments ([81JHC881](#)).



Scheme 5

The type of conjugation is also reflected in the frontier orbital profile, the charge distribution, and the permanent dipole moments. The results of semiempirical calculations on 1-methylpyridinium-3-olate (**16**), Malloapeltine (**17**), Trigollenine (**18**), and Homarine (**19**) are presented in [Scheme 7](#). Characteristically for the class of conjugated mesomeric betaines, the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) are distributed over the entire molecule as exemplified for 1-methylpyridinium-3-olate. It was shown that 90% of the




Scheme 6

charge density is located at the active positions of the HOMO (76JCS(P1)2296). The same is true for the N-ylide Malloapeltine, which is also a conjugated system. In contrast to this, the frontier orbitals of the cross-conjugated and the pseudo-cross-conjugated mesomeric betaines are located in separated parts of the π -electron system. The HOMOs of the CCMB Trigollenine and the PCCMB Homarine are essentially located at the oxygen atoms of the carboxy group, whereas the LUMOs are located in the pyridinium rings, respectively. For cross-conjugation and pseudo-cross-conjugation, the pyridinium ring is joined to the anionic partial structure by a union (69MI3, 75MI2) through a nodal position of the HOMO. Thus, the positive and negative charges are separated by an inactive position of the HOMO, which causes their isolation (88JOC2889). Consequently, the permanent dipole moments of cross-conjugated mesomeric betaines in the ground state are by far the largest as presented in Scheme 7 in correct size and direction. The zwitterionic ground state of betaines and zwitterions can be demonstrated by the effect of negative solvatochromism and Hammett correlations. Thus, all UV absorption maxima shift to shorter wavelengths with increasing solvent polarity, characterized, e.g., by the E_T^N scale by Reichardt (83LA721), or by the Z scale defined by Kosower (62MI1). This is mainly due to the decreased permanent dipole moment (Scheme 7) as a consequence of charge neutralization on HOMO–LUMO excitation (76LA125). Thus, in betainic molecules the electronic excitation is facilitated by nonpolar solvents. In addition, the zwitterionic ground state is furthermore supported by means of Hammett correlations in a specific example of a linear free energy relationship (79AG119). The spectroscopic Hammett equation may be expressed as follows:

$$(E_{T,R} - E_{T,0})/2.303 RT = \sigma \rho_A$$


where $E_{T,R}$ and $E_{T,0}$ are the transition energies of the substituted and the reference compound (e.g., R = H), σ is the Hammett constant (73JMC1207,



Scheme 7

58JOC420, 53CRV191), R is the gas constant, T is the temperature, and ρ_A ("absorption constant") is the slope of the line. According to this equation, the energy differences $E_{T,R} - E_{T,0}$ are a linear function of the σ_m and σ_p constants. The substituents R^2 and R^3 in zwitterions gave negative slopes ρ_A , thus indicating an increasing charge density at the substituted ring atoms during excitation.

There are specific associations of various types of dipoles with the four major classes of heterocyclic mesomeric betaines, which have implications in providing a rational foundation for correlating the chemical reactions of these compounds (85T2239). Eight dipole types, systematically generated by *union* of the heterocations $H_2C=X^+-H$ with carbanions and the heterosystem $\ddot{Y}-H$, or their vinylogs can easily be identified by an inspection of the canonical formulae of a heterocyclic mesomeric betaine. The nitrile-ylide moiety, characteristic for conjugated mesomeric



Scheme 8

betaines, is present in **16** (Scheme 8). The nitrile oxide is found in the conjugated N-oxide Malloapeltine (**17**). The characteristic dipole types for CCMB and PCCMB can also easily be identified in Trigollenine (**18**) and Homarine (**19**). The complete list of dipole types for the identification of mesomeric betaines can be found in the literature (85T2239). Cross-conjugated heterocyclic mesomeric betaines undergo predominantly 1,4-dipolar cycloadditions and cycloreactions, which in some cases are thermodynamically driven by a charge neutralization (82H1083, 84H358, 83H1367, 83M227).

The isoconjugate relationships are presented in Scheme 8. 1-Methylpyridinium-3-olate (**16**) is isoconjugate with the benzyl anion, which is an odd alternant hydrocarbon anion. The terms odd and even refer to the total number of atoms, which form the conjugated molecule. The skeletal atoms of alternant hydrocarbons can be divided into two sets (starred and unstarred) in such a way that no atoms of like parity are directly bonded. The number of starred atoms is either identical or larger than the number of unstarred positions. All five-membered rings must therefore be nonalternant. The isoconjugate relationship defines 1-methylpyridinium-3-olate (**16**) as member of class 1, i.e., as a conjugated heterocyclic mesomeric betaine isoconjugate with odd alternant hydrocarbon anions (Fig. 2). Likewise, Malloapeltine (**17**) is a heterocyclic mesomeric betaine of class 5, i.e., a conjugated mesomeric N-ylide isoconjugate with odd alternant hydrocarbon anions. The cross-conjugated

Trigollenine (**18**) and the pseudo-cross-conjugated Homarine (**19**) are isoconjugate with the isopropenylbenzene anion, which is an odd alternant hydrocarbon anion. Therefore, these betaines belong to class 9 and 13, respectively.


It was interesting to know which classes of heterocyclic mesomeric betaines are found in nature and to see whether there are any preferred types of conjugation. This review seeks to give an overview about isolation, characterization, known spectroscopic and chemical properties, and total syntheses of alkaloids and nucleobases, which are heterocyclic mesomeric betaines. For the sake of clarity in this review, alkaloids are categorized according to their largest cyclic π -conjugated system. Some interesting total syntheses of alkaloids via mesomeric betaines as reactive intermediates have been described. Thus, Ipalbidine, δ -Coniceine and Septicine were prepared by Padwa and coworkers employing the rhodium-catalyzed isomünchnone generation followed by 1,3-dipolar cycloaddition ([97JOC438](#), [99OL83](#), [99JOC8648](#)). Intramolecular cycloadditions of isomünchnones were applied to prepare Vallesamidine ([95JOC2704](#)), Erythrinane homologues ([94JOC5518](#)), Lycopodine ([97JOC78](#)), the frog alkaloid Pumiliotoxine C ([97TL1505](#)), and Onychine ([00JOC2368](#)). 1,3-Cycloaddition chemistry of isothiomiünchnones was applied to synthesize Alloyohimbane and Tetrahydropapaverine ([98TL4757](#), [00JOC2684](#)). Likewise, an approach to Lysergic acid was reported ([95JOC2704](#)). As this paper is restricted to naturally occurring betainic alkaloids and nucleobases, these highly interesting aspects of the chemistry of heterocyclic mesomeric betaines are beyond the scope of this review.

II. Mesomeric Betaines

A. CONJUGATED MESOMERIC BETAINES

1. *Pyridinium-olates*

3-Hydroxypyridine is an alkaloid by itself and was isolated from the African tree *Entandophragma cylindricum* (Sapele) ([71MI1](#)). It is furthermore the structure element of the antifungal antibiotics UK-2A and UK-3A which were isolated from *Streptomyces* species ([96JAN639](#), [96JAN1226](#)) and whose total syntheses were described recently ([98T12745](#)). In general, 3-hydroxypyridine has been shown by ultraviolet spectroscopy to exist equally as neutral and betainic tautomers ([63AHC353](#)) in solvents of high dielectric constant ([55JA2431](#)). From the pD dependence of the ^{13}C NMR



Scheme 9

chemical shifts it can be concluded that neutral and betainic tautomer are present in nearly equal amounts in aqueous solution at any pD (79MI2). On the basis of NMR studies betainic structures for the vitamins B₆ Pyridoxamine (20) (PM) and Pyridoxaminephosphate (21) (PMP) in neutral aqueous solutions have been proposed (79MI2) (Scheme 9). A particular feature of the change of the UV spectrum with solvent is the appearance of a band at long wavelengths in aqueous solutions, which does not exist in alcohol. The intensity of this band, which is due to the absorption of the betainic species alone, is a measure of the tautomeric equilibrium. The tautomeric constant of 3-hydroxypyridine $k_t = [\text{betaine}]/[\text{neutral form}]$ is 1.27. The pK_a of the OH group of 3-hydroxypyridine was determined potentiometrically in water at 20 °C to be 8.54–8.67, and of the N⁺–H group 4.69–4.86 (92CJC1635). The hydroxy group of 3-hydroxy-1-methylpyridine has a $pK_a = 4.96$, determined under similar conditions (56JCS1294). 1-Methylpyridinium-3-olate (16) has absorption maxima λ_{max} at 320 nm in water, at 328 nm in EtOH, and at 356 nm in dioxane (59JCS1247), thus exhibiting the effect of negative solvatochromism, which is characteristic for betainic ground states (cf. Scheme 7). Pyridinium-3-olates proved to be photostable compounds in water (79JCS(P1)2535), although the valence-tautomerized aziridine derivative, 6-azabicyclo[3.1.0]hexene, was identified, depending on the substitution pattern of the starting material (76JCS(P1)2338). These aziridines play key roles in the chemistry of Berberine derivatives (cf. 54).

¹³C, ¹⁴N and ¹H NMR data of 3-hydroxy-1-methylpyridinium iodide have been reported (71HCA229). The chemical shift differences $\Delta\delta$ of substituted *N*-methylpyridinium iodides are mainly due to a


Table I. NMR CHEMICAL SHIFTS OF 1-METHYL-3-HYDROXYPYRIDINIUM IODIDE AND FP₁ **26a**

Atom	16 · HI			16	FP ₁ 26a	
	¹ H NMR ^a	¹³ C NMR ^b	¹³ C NMR ^c	¹ H NMR ^d	¹ H NMR ^e	¹³ C NMR ^e
2	8.03, d, <i>J</i> = 1.9 Hz	134.58	136.05	7.37, s	8.50, dd, <i>J</i> = 2/1 Hz	133.5
3	—	157.36	167.62	—	—	158.8
4	7.50, d, <i>J</i> = 8.7 Hz	132.73	134.57	7.12, m	7.94, ddd, <i>J</i> = 9/2/1 Hz	132.8
5	7.65, dd, <i>J</i> = 5.6/8.7 Hz	129.59	128.66	7.17, m	7.88, dd, <i>J</i> = 9/6 Hz	129.3
6	8.00, d, <i>J</i> = 5.9 Hz	138.01	130.32	7.18, m	8.48, dt, <i>J</i> = 6/1 Hz	136.2

^aIn DMSO-*d*₆.^bIn D₂O at pD 2.^cIn D₂O at pD 8.^dIn CDCl₃.^eIn CD₃OD.

charge transfer from the substituent through the π -electron system of the heteroaromatic ring to the *N*-methyl group. The $^1J_{\text{CH}}$ coupling constant of the *N*-methyl group increases with decreasing nitrogen charge density. It is interesting to note that in contrast to CDCl₃ the ^1H and ^{13}C NMR values determined in D₂O shift considerably to lower field with increasing concentration, whereas the ^{14}N resonance frequencies remain unchanged. An association constant of 2.3 in water was reported for 3-hydroxy-1-methylpyridinium iodide (56JA2537), so that the formation of ion pairs is probably the reason for this observation. Table I presents the ^{13}C NMR chemical shifts determined in D₂O at pD 2 and pD 8. Other reported values are slightly different (76JA8237). The peak assignment of C-4 and C-5 were assigned from the coupling constants (79MI2) and contrasted to literature values (73OMR551).

Although derivatives of 1-alkylpyridinium-3-olates are well-known in heterocyclic chemistry, seemingly only few representatives of this betainic system exist in nature. Deoxypyridinoline (**25**) (R = H) and Pyridinoline (R = OH) are cross-links of the mature form of collagen and were isolated from bones (96MI1) (Scheme 10). They are biochemical markers of collagen turnover correlated with biochemical diseases such as osteoporosis, bone cancer and arthropathies (96MI2, 97MI1). Deoxypyridinoline was synthesized starting from the bromo ketone **22** and the protected




Scheme 10

L-lysine **23** to give the rather unstable amine **24** which was cyclized to a protected deoxypyridinoline. Hydrogenolysis followed by treatment with TFA finally gave the target molecule as a white crystalline monotrifluoroacetate monohydrate ([99JCS\(CC\)559](#)). On protonation of the betaine the 1H NMR resonance frequencies of the α -pyridinium hydrogen atoms shift from $\delta = 7.57$ and 7.48 [CD_3OD] to $\delta = 8.69$ and 8.62 [D_2O], respectively.

1-Substituted 3-hydroxy-pyridines were identified in a new series of fungal toxins known as Fumonisin (**26**) after acidic work-up with 0.1% formic acid ([Scheme 11](#)). These toxins are produced by several species of *Fusaria*, most notably *F. moniliforme*. Characteristically for 3-hydroxy pyridinium salts, the UV spectra of the new compounds show a UV maximum at 289 nm in 0.1 N HCl with a shift to 322 nm under basic conditions (0.1 N NaOH) ([96JNP970](#)). In general, fumosinines, which are found in corn and corn products ([93MI1](#), [93MI2](#)) and cause a variety of diseases ([90MI1](#), [91MI1](#)), possess an aminopolyol eicosane backbone and two tricarballic acid esters ([88JCS\(CC\)743](#)). The NMR data presented in [Table I](#) are in accordance with the isolation of FP_1 in protonated form.

In the course of studies directed towards the structure elucidation of Rotundine from *Stephania rotunda* LOUREIO, the β -piperidone **28**, which is available starting from the keto ester **27**, was treated with mercuric acetate in 10% acetic acid solution. Basification yields the betaine **29** as colorless prisms ([Scheme 12](#)).




26a: FP₁: R¹ = R² = OH


26b: FP₂: R¹ = OH, R² = H

26c: FP₃: R¹ = H, R² = OH

Scheme 11



Scheme 12



Scheme 13

2. Pyridinium-phenolates


An unusual phenolic alkaloid **30** was isolated as pyridinium chloride from the leaves of *Punica granatum* (94P1175) (Scheme 13). As an aqueous solution of this compound has pH 4.5, this alkaloid exists as a mixture of cation **30** and mesomeric betaine **31** (02UPI1). It is interesting to note that deprotonation of the 2-hydroxy group resulted in a conjugated mesomeric betaine **31A**, whereas the formation of a 4-olate group gave a cross-conjugated mesomeric betaine **31B**. Mesomeric betaines that are interconvertible between two classes are rare (99H237). On addition of

hydrochloric acid to the aqueous solution, the color changes from yellow (pH 4–5) to green yellow (pH 1–3) and on addition of aqueous sodium hydroxide the color changes to red (pH 8). At higher pH, decomposition via pericyclic ring cleavage to amino pentadienals accompanied by a color change to brown (pH 10) and finally reddish black (pH 11) is observable by ^1H NMR spectroscopy. The mesomeric betaine either produced from the cation with Amberlite IRA-410 or with sodium carbonate is negatively solvatochromic. The UV absorption maxima λ_{max} shift from 505 nm in chloroform (E_{T}^{N} 0.259) to 400 nm in water (E_{T}^{N} 1.000) (02UPI1). By means of HH-COSY experiments the unambiguous assignments of the hydroxy groups resonance frequencies were possible. A ^1H NMR titration of **30** with 1,8-bis(dimethylamino)naphthalene (DMAN, proton sponge) clearly showed that in $\text{DMSO}-d_6$ the 4-hydroxy group is the more acidic one. At higher ratios of the base, a rapid equilibrium between CMB and CCMB is observable.


This compound had already been prepared by treatment of hydroquinone with pyridine and iodine (1901G256) or bromine (80IJC(B)718), or by vigorous reaction between benzoyl chloride, quinone, pyridine and copper (31CB1045) before it was identified as a natural product. Furthermore, a reaction of *p*-quinone with pyridine in the presence of water and hexachlorocyclotriphosphazatriene was described (70MI2). The formate and acetate were synthesized on reaction of *p*-benzoquinone with pyridine in the presence of formic acid and acetic acid, respectively (37CB2339). On deprotonation with sodium carbonate, the betaine forms (37LA51). The inolizine Ipohardine (**32**), the aromatic derivative of Ipalbidine, is an *Ipomoea* alkaloid isolated from *Ipomoea violacea*. The seeds of this plant are used as hallucinogens (79JCR(S)1, 86JOC3915). It is mentioned here, because of the structural relationship to **31B**, although deprotonation resulted in a cross-conjugated mesomeric betaine.

3. Isoquinolinium-olates

2-Substituted isoquinolinium-olates are isoconjugate with the methylnaphthalene anion as shown in Scheme 14. Joining negative structure elements—the olate function—to unstarred positions of the isoconjugate



Scheme 14



Scheme 15

heteroaromatic of the naphthalene anion results in heterocyclic mesomeric betaines. In all other cases covalent structures can be drawn.

Thus, *N*-alkylated isoquinolinium-4-, 5- and 7-olates **33**, **34** and **35** are mesomeric betaines, whereas the corresponding 1-, 3-, 6- and 8-derivatives **36–39** are lactams or ketones which may or may not adopt zwitterionic ground states (Scheme 15). The main question in view of heterocyclic mesomeric betaines in nature is whether the isoquinolinium derivatives exist as cationic species possessing a hydroxy group, or as betainic species with an olate function. The UV spectra of a wide range of *N*-heteroaromatic hydroxy compounds have been measured and it was found that tautomerism to the betainic forms is general amongst the nonalkylated monoaza hydroxy compounds. The concentration of the betainic form increases with conjugation between the oxygen and the nitrogen atoms and with the addition of fused benzene rings. By a comparison of the hydroxy compounds with the corresponding *N*-methyl derivatives it was concluded that the compounds with a hydroxy group α or γ to the ring-nitrogen atom tautomerize predominantly to the amide form in organic and aqueous solutions. The compounds with hydroxy groups neither in an α nor in a γ -position show a change of spectrum on changing the solvent from an organic solvent to an aqueous solution. The changes are due to the displacement of a single equilibrium process as the absorption curves taken in continuously changing solvent mixtures of alcohol–water or


dioxane–water show a single set of isosbestic points. The conclusion is, the betainic and the neutral forms exist in equilibrium in solvents of high dielectric constant.

In general, the *N*-methyl derivative of a given compound absorbs at longer wavelengths than the *O*-methyl derivative. The intensity of a band which appears in aqueous solutions beyond the maximum absorption in alcohol and which is due to the absorption of the betainic species alone, is a measure of the tautomeric equilibrium. The pK_a value of the 2-methyl-hydroxyisoquinolinium chlorides increase in the order 4-hydroxy (4.93), 8-hydroxy (5.81), 6-hydroxy (6.02), 5-hydroxy (6.90), and 7-hydroxy (7.09 in water at 25 °C, respectively) (57JCS5010). Thus, 2-methyl-4-hydroxyisoquinolinium chloride is the strongest acid. The UV spectra of 2-methyl-isoquinolinium-5-olate (**34**) and 2-methyl-isoquinolinium-8-olate (**39**) were also presented (61BCJ533) and the formation of a quinoid structure of 2-methyl-isoquinolinium-6-olate (**38**) can also be detected by means of UV-spectroscopy.


a. Isoquinolinium-4-olates. Isoquinolinium-4-olate **33**, a structure element of some betainic alkaloids, was prepared as hygroscopic yellow needles on ion-exchange of 4-hydroxy-2-methylisoquinolinium iodide with Amberlite IRA-401 (72JCS(P1)2054). Under slightly basic conditions at pH 8.5, 4-hydroxy-2-methylisoquinolinium iodide has absorption maxima at $\lambda_{\max} = 364$ (9660), 320 (3670), and 248 nm (9180). The tautomeric constants $k_t = [\text{Betaine}]/[\text{neutral form}]$ of unsubstituted 4-hydroxyisoquinoline is 3.76 (57JCS5010, 58JCS674).

The alkaloids isolated from natural sources or derived by simple reactions from natural material possess the isoquinolinium-4-olate moiety as a partial structure of larger conjugated ring systems. In some alkaloids, the 3-position is substituted by an indole, forming the indolo[2',3':3,4]pyrido[1,2-*b*]isoquinolinium-14-olate ring system **40** (Scheme 16). Others possess the isoquino[3,2-*a*]isoquinolinium-13-olate ring system **41**. This substitution pattern enlarges the delocalization of the positive as well as of the negative charge. The ring system **40** is isoconjugate with the 2-(1*H*-inden-2-yl)-1-methyl-naphthalene dianion, which is an even nonalternant hydrocarbon dianion, so that these alkaloids belong to class 4. The ring system **41** is isoconjugate with the 1-methyl-2-phenyl-naphthalene anion and the 5-methyl-benzo[*a*]anthracene anion which are odd alternant hydrocarbon anions, respectively. They are therefore natural representatives of class 1 of heterocyclic mesomeric betaines.

Neooxygambirtannine (**43**) shown in Scheme 17 is an example of a heterocyclic mesomeric betaine belonging to class 4. This alkaloid, which is red in color, was found in Gambir and is a tanning material produced by




Scheme 16



Scheme 17

evaporation of the aqueous extract of leaves and stems of the south-east Asian Rubiaceae *Uncaria gambier* (67T3129). Betaine **43**, which apparently is an oxidation product of Gambirtannine (**42**), is easily formed from Gambirtannine on alumina, when a hexane-acetone mixture is used as eluent. It is an isomer of Oxogambirtannine (**45**) and resembles Neoxyberberine (**52**), whose UV spectrum is quite similar. It is interesting to note that the indolic NH of **43** was unambiguously confirmed by a ^1H NMR resonance frequency at $\delta = 11.62$ ppm which is not exchangeable




Scheme 19

prepared in 1911 ([11JCS1690](#), [65CB2566](#)). Treatment of Berberine (**49**) with acetone anion results in the formation of ketone **50** (“Berberine acetone”, 8-acetyldihydroberberine), a crystalline solid, which on oxidation with potassium permanganate yields Neooxyberberine-acetone (**51**) and Neooxyberberine (**52**) ([73TL2795](#)). The mesomeric betaine **52** is available in pure form by reaction of **50** with osmium tetroxide. Protonation gives the corresponding phenol ([66JPJ534](#)) and treatment with iodomethane and iodoethane yields the 13-methoxy and 13-ethoxy derivative, respectively ([76CCC3654](#)). The UV absorption maxima are as follows: λ_{max} (MeOH) = 236 (4.48), 258 sh (4.24), 312 (4.05), 365 (4.02), 444 (4.16) nm ([84CPB2230](#)). Neooxyberberine (**52**) has antimalarial ([88JMC1084](#)) and antimicrobial activities ([98MI1](#)). ^1H NMR data are presented in [Table II](#) ([84CPB2230](#)). The peak assignments for 11-*H* and 12-*H* are obviously incorrect in the original literature.


Dihydroberberine (**53**) is converted by irradiation in the presence of oxygen and Rose Bengal in 80% yield into Neooxyberberine (**52**) ([Scheme 20](#)). Applying the same reaction conditions without sensitizer yielded Berberine ([77H953](#)). Alternatively, reaction of dihydroberberine with *m*-chloroperbenzoic acid gave Neooxyberberine ([75JOC644](#)). The betaine can be used to synthesize a spirobenzylisoquinoline and methoxyberberal ([77H1981](#)).

Table II. NMR CHEMICAL SHIFTS OF NEOOXYBERBERINE **52** AND THE 8-METHOXYBERBERINEPHENOLBETAIN **58**

Atom	¹ H NMR ^a	
	52	58
1	9.01, s	8.80, s
4	6.65, s	6.58, s
5	3.03, t, <i>J</i> = 6 Hz	2.90, t, <i>J</i> = 6 Hz
6	4.38, t, <i>J</i> = 6 Hz	4.58, t, <i>J</i> = 6 Hz
8	7.76, s	3.90, s (OMe) ^b
9	4.02, s (OMe) ^b	4.02, s (OMe) ^b
10	4.05, s (OMe) ^b	4.02, s (OMe) ^b
11	7.39, d, <i>J</i> = 9 Hz	7.40, d, <i>J</i> = 9 Hz
12	8.37, d, <i>J</i> = 9 Hz	8.42, d, <i>J</i> = 9 Hz
–OCH ₂ O–	5.97, s	5.91, s

^aIn CDCl₃.^bPeak assignments exchangeable.**Scheme 20**


On irradiation of Neooxyberberine derivatives in methanol through a Pyrex filter in a stream of nitrogen 8,14-cycloberbines **54** were formed in 70% yield (Scheme 21). The ring system is unexpectedly stable as conrotatory ring cleavage of the aziridine is thermally disallowed. Irradiation without Pyrex filter yielded the orange-colored starting material in 55% yield through a photochemically allowed disrotatory ring opening (84CPB2230). Ethyl chloroformate in benzene converts **54** into spirobenzylisoquinoline **55** (R = H, 70% yield), methylidene-spiroisoquinoline (R = Me, 100%), a mixture of *E*- and *Z*-ethylidene-spiroisoquinoline and an oxazolidinone derivative (R = Et). Methylation of the unsubstituted derivative gave the benzindenoazepine **57** in 60% yield, whereas the methyl- and ethyl derivative were converted into spiro compounds similar to **55** and **56** (*N*-methyl instead of *N*-COOEt).



Scheme 21

The orange colored 8-methoxy derivative of Neoxyberberine (**58**) (8,9,10-trimethoxy-5,13a-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolium-13-olate, “8-Methoxyberberinephenolbetaine”) was formed on ferricyanide oxidation of Berberine (**49**) and subsequent treatment with methanolic hydrogen chloride (76JA6714). The 8-ethoxy derivative was prepared similarly (79JOC4337). The UV absorption maxima λ_{max} in EtOH ($\log \epsilon$) of **58** were found at 235 (4.22), 262 (4.15), 317 (4.13), 362 (3.92), 377 (4.12), 464 (4.13) nm (83CPB947) and are in good agreement with a structure related to **52**. The ^1H NMR values are presented in Table II (77H895). Reported NMR data in the literature are obviously incorrect.

Scheme 22 presents the synthetic potential of this mesomeric betaine. The alkaloid Ophiocarpine (**59**) was formed from the betaine on reduction with sodium borohydride. Treatment of the betaine with wet diethylether, a solvent in which it is only slightly soluble, resulted in the formation of the dehydronorhydrastine methyl ester **60** in 80% yield. Methyl anhydroberberilate (**63**) was formed in a two-step-procedure on treatment of the betaine **58** with acetic anhydride in pyridine. The resulting 13-acetoxyoxoberberine (**62**), which was formed in 95% yield, gave the target alkaloid on addition of methanolic potassium hydroxide (79JOC4337). Irradiation of the betaine effects a valence isomerization to give an aziridine derivative as an intermediate, which undergoes ring




Scheme 22


cleavage to the spiro compound **61**. This is a model compound for spirobenzyloisoquinoline alkaloids (84CPB2230).

In contrast to the reaction of the betaine **58** in wet diethylether, wet THF, in which the betaine is better soluble, gives the methyl isoanhydroberberilate **64** in 71% yield. The mechanism seemingly involves an unusual carbon to nitrogen acyl migration as shown in Scheme 23. Hydration and air oxidation of the betaine to the peroxide leads to the formation of an aziridine intermediate and loss of a hydroxide anion (77TL3787).

Irradiation of Berberine (**49**) (400W high-pressure Hg lamp, Pyrex filter) in methanol in the presence of Rose Bengal and sodium methoxide in a stream of oxygen gave the methoxy derivative **65** in 59% yield (Scheme 24). Recrystallization from methanol gave the orange-colored 8-methoxyberberinephenolbetaine (**58**) in quantitative yield. A possible mechanism for this transformation involving the initial attack of methoxide ion on a 8-methoxydihydroberberine, and reaction of the resulting enamine moiety with singlet oxygen to form an oxetane was discussed (83CPB947). Here, betaine formation is a consequence of aromatization. The phenolbetaine was converted into racemic Ophiocarpine (**59**) as shown in Scheme 24 (77H895). Betainic azaberbinones were also described (70JCS(CC)1601, 87H1841).




Scheme 23



Scheme 24


b. Isoquinolinium-7-olates. 2-Methyl-7-hydroxyisoquinolinium iodide (**66**) in methanol exists as a mixture of neutral and cationic species, as evidenced by a complex absorption of seven peaks in the UV spectra (**61BCJ533**) (Scheme 25). In general, formation of a phenolate group causes a red shift which is enlarged by protonation of the nitrogen atom. The shift for the π_1 -band is the largest. As UV spectroscopy is an important method for the detection of betaines, the characteristic features are mentioned here. The absorption maxima of 2-methyl-7-hydroxyisoquinolinium iodide in

**Scheme 25****Scheme 26**

methanol/0.1 N HCl are found at λ_{\max} ($\log \epsilon$) = 217 (4.48), 243 (4.71), 280/367 (3.72/3.54), whereas in methanolic 0.1 N NaOH the maxima are observable at λ_{\max} ($\log \epsilon$) = 217 (4.39), 265 (4.64), 308/424 (3.86/3.38), corresponding to π_3 , π_2/π_1 , respectively. Obviously, bathochromic shifts are characteristic for betaine formation from salts.

On heating Papaverinium chloride (**66**) beyond its melting point for some minutes a separable mixture of Protopapaverinium betaine (**67**) and Norpapaverinium chloride (**68**) was formed (Scheme 26). The dipolar 6,7-dihydroxyisoquinolinium **67** can form a conjugated mesomeric betaine (7-olate form) or a zwitterionic species (6-olate) (cf. Section III). It can be converted into its methyl derivative by methyl iodide in a sealed tube. The reduction gave Codamine (**69**), Pseudolaudanine (**70**) and Argemonine (**71**). By this work the structure of Argemonine, first isolated from the desert poppy *Argemone hispida* (44MI1), was elucidated (66TL1177).

Dehydrodiscretamine (**72**), Thalifedine (**73**), Thalidastine (**74**), Fissisaine (**75**), Stepharine (**76**), and Dehydrocorydalmine (**77**) are additional examples of alkaloids, which possess the 7-hydroxy-isoquinoline moiety which on deprotonation yields conjugated mesomeric betaines (Scheme 27). In either case, the π -electron system is extended by substitution




- 72: $R^1 = \text{OMe}, R^2 = \text{OH}, R^3 = R^4 = \text{H}$
 73: $R^1-R^2 = -\text{O}-\text{CH}_2-\text{O}-, R^3 = R^4 = \text{H}$
 74: $R^1-R^2 = -\text{O}-\text{CH}_2-\text{O}-, R^3 = \text{H}, R^4 = \text{OH}$
 75: $R^1 = R^2 = \text{OMe}, R^3 = \text{OH}, R^4 = \text{H}$
 76: $R^1 = \text{OH}, R^2 = \text{OMe}, R^3 = R^4 = \text{H}$
 77: $R^1 = R^2 = \text{OMe}, R^3 = R^4 = \text{H}$

Scheme 27

of the 3-position by an additional aromatic substituent. These six alkaloids represent members of class 1 of mesomeric betaines as they are conjugated heterocyclic mesomeric betaines isoconjugate with the 2-methyl-6-phenyl-naphthalene anion, which is an odd, alternant hydrocarbon anion.

The protoberberine alkaloids Dehydrodiscretamine (72), Fissisaine (75), and Columbamine (not a mesomeric betaine) were found in the twigs of the Chinese and Vietnamese climbing shrub *Fissistigma balansae* in 1998 (98P367). Extraction was performed with 3% HCl, but final purification was accomplished by column chromatography using chloroform, methanol, and ammonia (100 : 5 : 1). In the spectra of Fissisaine (75), seemingly, no OH-group was observed in the ^1H NMR spectra, however, the authors report a band at 3400 cm^{-1} in the IR spectrum for the hydroxyl group. On addition of alkali the typical bathochromic shifts of phenolic berberine-type betainic alkaloids are observable (72MI1). As no anion is described in the original literature, the existence of these alkaloids as betaines or salts in the natural material remains unanswered. Dehydrodiscretamine (72), however, was isolated earlier as an orange colored chloride (*Corydalis tashiroi* MAKINO) (81MI2). On investigating the natural products contained in *Thalictrum foliolosum* DC., a herb indigenous to the temperate Himalayas which is used for the treatment of flatulence, jaundice and visceral obstructions, 11 alkaloids were isolated (83P2607), among them Dehydrodiscretamine (72), Thalifendine (73), Thalidastine (74). The alkaloids were isolated as chlorides after treatment with the anion exchange resin in its Cl^- form (83P2607). The formation of a betainic species from Dehydrodiscretamine (72) displays a characteristic bathochromic shift on addition of base, although deprotonation of the 6-hydroxy group would result in the formation of a



Scheme 28

neutral structure (cf. Section III.A). Thus, UV absorption maxima λ_{\max} (MeOH) ($\log \epsilon$) of **72** were found at 434 (3.60), 346 (4.29), 273 (4.26), 263 sh (4.25), 237 sh (4.22) nm, whereas maxima were found in a mixture of methanol and sodium hydroxide at 505 (3.60), 386 (4.50), 302 sh (4.10), 278 (4.23), 255 (4.20) 235 sh (4.14) nm. Thalifendin (**73**) had already been described as a yellow phenolic alkaloid from *Thalictrum fendleri* (65TL3595) and *Thalictrum minus* var. *adiantifolium* (69MI1) before it was isolated from other species. Thalidastine chloride (**74**) was first isolated from *Thalictrum fendleri* (65TL3825). A similar bathochromic shift of the UV absorption maxima were observed on addition of base [λ_{\max} (MeOH) ($\log \epsilon$) = 425 (3.36), 350 (4.02), 273 (4.09), 231 (4.15) nm; λ_{\max} (MeOH+KOH) = 476, 378, 290] which is due to the formation of a conjugated mesomeric betaine. Stepharanine (**76**) was identified in *Stephania glabra* (67JOC3253, 80MI2, 82JNP407) and in extracts of the roots of *Tinospora capillipes*. It was isolated as an iodide after anion exchange. Methylation with dimethylsulfate gave palmatine chloride. An additional alkaloid of this series is Dehydrocorydalmine (**77**) (*Stephania glabra*).

The isoquinolinium-7-olate moiety is also part of a macrocyclic system in the orange-colored Fenfangjines D (**79**) (Scheme 28). The Fenfangjines D (**79**), H (**80**), and I (**81**) were identified in methanolic extracts of the roots of *Stephania tetrandra* (Fen-fang-ji) on plant monitoring of the inhibitory activity on angiotensine I converting enzyme (ACE). The Chinese traditional medicine Fen-fang-ji is demonstrated to have antiinflammatory, antiallergic, and hypotensive effects. Fangchinoline (**78**) was converted into Fenfangjine D (**79**) on treatment with manganese dioxide (88H1149). Fenfangjine H (**80**) and I (**81**), which are cleaved structures of Fenfangjine D (88H1149), showed hydroxyl groups at 3408 and 3412 cm^{-1} , respectively, in the IR spectra, so that the protonated form was formulated as a hydroxide salt. However, no aromatic OH group of Fenfangjine H and I were detected in ^1H NMR in CDCl_3 and no elemental analyzes were presented to confirm


Table III. NMR CHEMICAL SHIFTS OF THE ISOQUINOLINIUM MOIETY OF DEHYDRODISCRETAMINE **72**, STEPHARIDINE **76**, AND THE FENFANGJINES **D 79**, **H 80**, AND **I 81** (ISOQUINOLINE NUMBERING)

	72^a	76^b	79^c	80^c	81^c
Atom	¹ H NMR	¹ H NMR	¹ H NMR	¹ H NMR ¹³ C NMR	¹ H NMR ¹³ C NMR
1	9.50, s	> 9.00 ^d	—	8.59, s	134.7
3	—	—	7.86, d, <i>J</i> = 6.6 Hz	7.42, d, <i>J</i> = 6.4 Hz	126.8
4	8.53, s	8.50, s	7.75, d, <i>J</i> = 6.6 Hz	7.40, d, <i>J</i> = 6.4 Hz	121.8
4a	—	—	—	—	126.8
5	7.93, m	7.93, m	6.53, s	6.81, s	100.8
6	7.93, m	7.93, m	—	—	165.6
7	—	—	—	—	158.6
8	—	—	—	—	132.4
8a	—	—	—	—	122.1


^aAs chloride in a mixture of CDCl₃, CD₃OD, TFA.^bAs iodide in TFA.^cIn CDCl₃.^dSpectrum terminated at $\delta = 9.00$.

the existence of an anion (98H311). In addition, a comparison of the chemical shifts with the series of NMR experiments published for the alkaloid PO-3 (**129**, Section II.A.8) strongly hint at a mesomeric betaine instead of a cationic species. This is furthermore confirmed by a comparison of the resonance frequencies of the Fenfangjines **80** and **81**, Dehydrodiscretamine (**72**), and Stepharanine (**76**) are presented in Table III. The spectra of **72** and **76** were determined in the presence of TFA so that the cationic species were measured. Thus, Table III presents a ¹H NMR spectroscopic comparison between cationic and betainic molecules. The signals of the Fenfangjines appear considerably upfield and unambiguously prove the existence of mesomeric betaines. A considerable upfield shift of all the protons of the isoquinoline moiety is obviously characteristic for betaine formation.

Leptopinine **82** possesses the 3,4-dihydro-isoquinolin-7-ol moiety without further conjugation and was isolated as yellow powder from *Hypocoum leptocarpum* after several extractions with hydrochloric acid so that this alkaloid was finally isolated as a chloride (Scheme 29). The formation of a mesomeric betaine from this dihydroisoquinoline derivative is unlikely because on addition of base no significant changes of the UV spectra were observed (99P339). A similar structure is Pycnarrhine (*Pycnarrhena longifolia*), which was isolated as a hydroxide (81P323).

**82**


Scheme 29

**83:** R = OMe**84:** R = H


Scheme 30

4. 3-Oxo-pyrido[1,2-c]pyrimidin-4-olate

Circumdatin A (**83**) and B (**84**) were isolated as red–orange solids from a culture of the fungus *Aspergillus ochraceus* (99JOC1689) (Scheme 30). These highly unusual structures belong to the class of benzodiazepine alkaloids and represented the first betainic naturally occurring benzodiazepines. The structure proposals are based on $^1\text{J}_{\text{CC}}$ -INEPT2-INADEQUATE in combination with $^1\text{J}_{\text{CC}}$ -HMBC-INADEQUATE experiments. The UV absorption maxima λ_{max} of Circumdatin A in ethanol were found at 357 (3.30), 290 (shoulder, 3.33), 238 (shoulder, 3.84), and of Circumdatin B at 358 (2.76), 284 (shoulder, 2.73). The ^1H and ^{13}C NMR data of the isolated alkaloids are presented in the original literature. The parent 3-oxo-pyrido[1,2-c]pyrimidin-4-olate moiety, however, seemingly is without precedent in the chemistry of heterocyclic mesomeric betaines so that the unambiguous structure elucidation of Circumdatin A and B still await confirmation by a total synthesis or at least by the preparation of model compounds for spectroscopic comparison (02UPI2). Recently, an interesting N-oxide was isolated from this fungus (01JAN911).



Scheme 31




Scheme 32

5. Phenanthridinium-olates

8-*O*-Demethylvasconine (**85**) (9-methoxy-5-methyl-phenanthridin-8-olate) presented in [Scheme 31](#) was found in *Crinum kirkii* ([95P1291](#)) (Amaryllidaceae). Although published as cation, no information about the anion of this alkaloid is given. Its relationship to other alkaloids of this class, however, makes a betainic structure more than likely and this is confirmed by a comparison of the ^1H NMR data of **85** with the cationic and betainic alkaloids presented in [Table III](#). This betaine is isoconjugate with the 2-methylphenanthrene anion and thus defined the alkaloid as a member of class 1 (odd alternant hydrocarbon anions). Whereas substitution of the isoconjugate phenanthridinium moiety at the 1-position with an anionic fragment results in zwitterions (cf. [Section III.D](#)), the phenanthridinium-2-olate is a mesomeric betaine.

The betainic structure of the pyrrolophenanthridinium alkaloid Ungerimine (**87**) (*Amaryllidaceae*) ([86P2399](#)) is unambiguous ([Scheme 32](#)). The parent 1-methyl-quinolinium-6-olate moiety has been known since 1891 ([1891JPR522](#)). It was first identified in *Ungernia minor* in 1965 ([65MI1](#), [96MI3](#), [92P2139](#), [70MI1](#)), but was already synthesized as early as 1955 ([55JA5885](#)): A dark red compound was obtained on oxidation of the alkaloid Lycoporine (**86**) by selenium dioxide, *t*-butyl hypochlorite, pyridine perbromide hydrobromide, or *N*-bromosuccinimide, to which the structure of Ungerimine was assigned. In the protonated form the $\text{p}K_{\text{a}}$ value is 7.15 in



Scheme 33


water at 20 °C. As expected, the UV absorption maxima of Ungerimine shift bathochromically on addition of base. Thus, λ_{max} values were found at 360 and 258 nm in methanol plus 0.1 M HCl, and at 408 and 262 nm in methanol plus 0.1 M NaOH.

Later, Ungerimine (**87**) was isolated from *Crinum americanum* (86P2399), *Crinum asiaticum*, and *Zephyranthes flava*. It has aroused considerable interest due to its anti-cancer activities (97MI2, 89MI1, 88MI2, 87MI1, 83MI1, 81MI1, 80MI1, 78JMC199) especially against human ovarian and stomach cancers (97MI3, 82MI1). In general, this class of alkaloids attracted considerable attention due to its anti-leukemia (78JMC199) and other pharmacological activities (91TL65, 90TL1523).

The first total synthesis of **87** was published in 1990 (90TL1523). 5-Hydroxyindole (**88**) was mesylated and then reduced with sodium cyanoborohydride to give an indoline which was brominated to afford the bromoindoline **89** in good yield (Scheme 33). Cross-coupling with *ortho*-formyl boronic acid under Suzuki conditions, followed by air oxidation of the resulting cyclized product, followed by reduction of the lactam formed with excess Red-Al gave the target compound **87**.

In 1991, another total synthesis of **87** was described (91TL65). Starting from the indoline **90**, amidation with benzo[1,3]dioxole-5-carbonyl chloride gave the precursor **91** for a radical cyclization which is the key step of the synthesis (Scheme 34). On treatment with potassium carbonate and benzyl triethylammonium chloride in DMSO at elevated temperatures a nitrophenyl radical is formed which is quenched by reaction with an adjacent phenyl group. The resulting 1:1 mixture of **92** and **93** was separated by fractional crystallization to give 27% of pure **92**. Diazotization, phenol formation to **94**, subsequent reduction of the amide function to **95** and oxidation gave the target compound Ungerimine (**87**).


Criabetaïne (**100**) was isolated from *Crinum asiaticum* (98MI2, 90P805, 86P1975, 86JCR(S)112, 56JA4145). Syntheses of Ungerimine and




Scheme 34

Criasbetaine were published in 2000 (00JOC3227). Starting from 5-benzyloxyindole (96), reduction to the corresponding indoline, protection as a *t*-BOC carbamate and deprotection using hydrogen and palladium catalyst gave the starting material 1-BOC-5-hydroxyindoline (Scheme 35). Protection as *tert*-butyldimethylsilyl (TBDMS) ether to 97, the lithiation—transmetalation—Ziegler–Ullmann coupling sequence with the iodoarylimine 98 was applied to result in the formation of 99. Refluxing trifluoroacetic acid over a period of 16 h promoted the BOC removal, cyclization-dehydration, a desilylation sequence to Criasbetaine (100) which was finally obtained as a trifluoroacetate. A similar reaction sequence led to Ungerimine (87).

In 1956, the alkaloid Methylpseudolycorine (101) isolated from the King Alfred daffodil (*Narcissus pseudonarcissus* L.) was oxidized to the pale yellow chloride with selenium dioxide (Scheme 36). Conversion into the betaine was accomplished by aqueous ammonia to give yellow prisms of the trihydrate of Criasbetaine (100) (56JA4145, 56JA4151). The UV absorption




Scheme 35




Scheme 36

maxima are shifted to higher wavelengths on conversion of the cationic species **102** into the betaine.

Another 2-oxyphenanthridinium betaine-type alkaloid is Zefbetaine (**103**), isolated from the Egyptian sea lily *Pancratium maritimum* L. as an amorphous pale yellow solid (92P2139). It was first isolated from the lily *Zephyranthes flava* (86P1975), however, the reported structure proved to be incorrect. Its UV spectrum in MeOH shows absorption maxima at 409, 372, 262 nm, which is indicative of the existence of a betainic species. Zefbetaine became red when sprayed with Fast Red Salt B, a reagent for polyvalent phenols, and gave positive results when tested with 1% aqueous iron(III) chloride. The structure of Zefbetaine was established by means of ¹H NOE difference spectra as well as chemical synthesis. Thus, on treatment of **104** with selenium dioxide Zefbetaine (**103**) was formed in good yield (Scheme 37). On the other hand, oxidation of



Scheme 37



Scheme 38


Sternbergine (**105**) from *Sternbergia lutea* Ker Gawl ([84JNP1003](#)) resulted in the formation of an isomeric species called *iso*-Zefbetaine (**106**). The ^1H NMR values of Zefbetaine shift downfield on changing the solvent from CD_3OD to $\text{CD}_3\text{OD}-\text{CD}_3\text{CO}_2\text{D}=3:1$ which is also indicative of a betainic species.

6. *Isoquino[3,2-a]isoquinolinium-olates*


Mineral acids convert Thalidastine (**74**) into Deoxythalidastine (**107**) ([60JA1145](#), [61JOC2231](#), [62JOC2213](#)) which after deprotonation is isoconjugate with the 9-methyl-benzo[*a*]anthracene anion ([Scheme 38](#)).

Similarly, photooxidation of dihydrocoralyne (**108**) in hot methanol at pH 8, subsequent addition of sodium methoxide and additional irradiation yielded 6,7-dimethoxyisoquinolone and 3-methyl-3,5,6-trimethoxyphthalide via the betainic intermediate **109** ([77H45](#)) ([Scheme 39](#)). It was demonstrated earlier that dihydrocoralyne is oxidized to this betaine in quantitative yields under physiological conditions ([76H153](#)). The autooxidative degradation of the mesomeric betaine was rationalized by the addition of singlet oxygen.

The coralyne salt **110** was reduced to **111**, a 5,6-dehydro analogue of dihydroberberine ([Scheme 40](#)). A solution of **111** in hot ethanol kept in the dark resulted in the almost quantitative formation of the coralyne-13-olate **109** as orange needles by autooxidation. No anion was found by elemental analysis. Treatment of **109** in ethanol with 10% hydrochloric acid resulted in



Scheme 39



Scheme 40

the formation of 13-hydroxy-2,3,10,11-tetramethoxydibenzo[*a,g*]quinolizinium chloride, which was isolated as yellow needles. As evidenced by the UV spectra, this salt is in equilibrium with the betainic form in alcohols. This is confirmed by a methylation of **109**, which was accomplished by methyl iodide to give yellow needles of 13-methoxycoralayne iodide (**112**). On methylation the absorption maximum of the betaine at $\lambda_{\max} = 466\text{--}470\text{ nm}$ disappears. UV and ^1H NMR spectroscopic comparisons of the betainic and the methylated cationic molecule are given in [Tables IV and V](#), respectively ([80JCS\(P1\)911](#)). On methylation of the 13-olate function, the resonance frequencies of 4-*H*, 5-*H*, 6-*H*, and 9-*H* shift considerably to lower field, whereas the signals of 1-*H* and 12-*H* shift upfield. The shift difference $\Delta\delta$ of 6-*H* is the largest (-1.04 ppm).

Norcoralayne (**113**) was reduced with zinc in acetic acid and 1% hydrochlorid acid in 88% yield to give the 13-hydroxy-norcoralynium

Table IV. NMR SPECTROSCOPIC COMPARISON BETWEEN CORALYNE-13-OLATE **109**, 13-METHOXY DERIVATIVE **112**, AND THE ALKALOID **117**

Atom	109^a	112^b	117^c	
	¹ H NMR	¹ H NMR	¹ H NMR	¹³ C NMR
1	10.83	8.97	8.15	107.9
2	4.17 (OMe)	4.13 (OMe)	—	154.3
3	4.22 (OMe)	4.18 (OMe)	6.82	113.4
4	6.96 ^c	7.57 ^c	7.38	113.0
4a	—	—	—	136.6 ^d
5	7.14, d, <i>J</i> = 9 Hz	7.90, d, <i>J</i> = 8 Hz	8.17	118.3
6	7.82, d, <i>J</i> = 9 Hz	8.86, d, <i>J</i> = 8 Hz	8.45	137.2
8	2.80 (Me)	2.50 (Me)	9.39	138.6
8a	—	—	—	122.2
9	6.83 ^c	7.57 ^c	7.66	106.6
10	3.98	3.96 (OMe)	—	152.5
11	3.98	3.96 (OMe)	7.19	119.4
12	8.17	7.81 ^c	7.72	114.0
12a	—	—	—	131.7 ^d
13	—	4.00 (OMe)	—	188.7
14	—	—	—	115.5
14a	—	—	—	131.4 ^d

^aIn DMSO-*d*₆.
^bIn CDCl₃.
^cIn acetone-*d*₆.
^dPeak assignments exchangeable.


Table V. UV SPECTRA OF CORALYNE-13-OLATE **109**, ITS HYDROCHLORIDE SALT **109** · HCl, AND ITS METHOXY DERIVATIVE **112**

	λ_{max} [nm] (log ϵ)
109^a	466 (4.15), 439 (4.09), 411 (4.00), 323 (4.24), 288 (4.37)
109 · HCl ^b	470 (3.39), 442 (4.01), 419 (3.88), 367 (3.45), 330 (4.26), 314 (4.22), 304 (4.22)
112^b	436 (3.98), 414 (3.83), 390 (3.51), 367 (3.54), 331 (4.28), 316 (4.37), 305 (4.34)


^aIn MeOH.
^bIn EtOH, from 80JCS(P1)911.

phenolbetaine (**115**) after the addition of *m*-chloroperbenzoic acid to a degassed solution of **114** in the presence of triethylamine (Scheme 41). A photochemical conversion of the partially reduced species to the betaine failed. Instead, the formation of the starting material was observed (77H959).

Despite of ¹H-¹H-COSY, ¹H-¹H-NOESY, and ¹H-¹³C-COSY experiments the position of the second hydroxy group of an amorphous red



Scheme 41



Scheme 42


alkaloid and its glycosyl derivative isolated from *Aristolochia arcuata silvestris* could not unambiguously be elucidated so that the two possible structures **116** and **117** were published (Scheme 42). As the compounds are presumably related to 8-benzylberberine and benzyloisoquinoline alkaloids isolated from *Aristolochia* species, the authors suggest L-tyrosine and 4-hydroxybenzaldehyde as biosynthetic precursors. From this viewpoint the 7-hydroxyisoquinoline moiety **117** is the more likely structure (95P991).

As the alkaloid was extracted with hexane, acetone, and ethanol, subjected to column chromatography, acidified (AcOH) and then neutralized (NaOH), the cationic form was formulated as a hydroxide salt. However, only two OH groups were detectable on ^1H NMR spectroscopy. Only slight differences were found in the UV spectra taken in methanol [λ_{max} ($\log \epsilon$) = 218 (4.68), 302 (4.39), 394 (4.08) nm] and methanol+NaOH [λ_{max} ($\log \epsilon$) = 228 (4.66), 310 (4.39) nm]. Three tautomeric forms can be formulated which are shown in [Scheme 42](#). Two of them possess the isoquinolium-7-olate moiety. The ^1H NMR data are presented in [Table IV](#). They indeed unambiguously resemble the cationic species **112**.

7. Benzo[c]phenanthridinium-olates

Benzo[c]phenanthridine alkaloids are widespread in Papaveraceae, Fumariaceae, and Rutaceae. Fagaridine (**118**), the structure of which had to be revised, is a derivative of the unknown 5-methyl-benzo[c]phenanthridine-8-olate (**119**) which is isoconjugate with the 2-methyl-chrysene anion ([Scheme 43](#)). Thus, Fagaridine is a member of class 1 of conjugated heterocyclic mesomeric betaines, which are isoconjugate with odd alternant hydrocarbon anions.

The benzophenanthridine alkaloid Fagaridine, to which originally the structure **120** was assigned, was first isolated from the roots of *Fagara xanthoxyloides* in 1973 ([73P2315](#)), an African plant, which is used to combat diarrhoea, enteritis, and to treat wounds. Later it was identified in *Fagara tessmannii* ([79MI1](#)) and "Prickly Ash", i.e., *Zanthoxylum tsihanimposa* ([77MI2](#)), *Z. xanthoxyloides* ([86MI1](#), [86JNP715](#)), *Z. rigidifolium*



Scheme 43


(86PHA747), and *Z. lepreurii* (87MI2). Fagaridine (called “Isfagaridine” in the original paper) was identified in the methanol extract of the southern Chinese climbing shrub *Zanthoxylum nitidum* and proved to be a strong inhibitor of topoisomerase I-mediated DNA relaxation. It stabilizes the covalent binary complex between the enzyme and the DNA (93JOC5025). Significant antitumor activities were reported in 1989 (89CA718). The hydrogen sulfate dihydrate of Fagaridine, coded NK109 (99JNP864), has undergone evaluation in clinical trials in Japan.

The originally proposed structure **120** (now called “Isfagaridine”) is no mesomeric betaine, but can adopt a zwitterionic or keto form. According to the elemental analysis published in 1973, it was isolated as a phenolic hydroxide. The phenolic group was identified with FeCl_3 and by a broad band at 3420 cm^{-1} in the IR spectrum. As elucidated by Nakanishi and Suzuki in 1998 (98JNP1263), the spectroscopic data of Fagaridine (**119**) and Isfagaridine (**120**) are very similar, except for the UV absorption maxima. The $\text{p}K_a$ value of the originally proposed structure is 5.3 so that the purple keto form is therefore the preferable form in dilute solution. The charged species is yellow. The revised structure of Fagaridine has been proven by a total synthesis (98JNP1263). The synthesis starts from 2,3-dihydroxybenzaldehyde, which was treated with methyl iodide in the presence of lithium carbonate to yield selectively 3-hydroxy-2-methoxybenzaldehyde (Scheme 44). Bromination and subsequent benzylation gave 3-(benzyloxy)-6-bromo-2-methoxybenzaldehyde (**121**). Condensation with the amine followed by reduction of the resulting Schiff base resulted in the formation of the key intermediate **122**, which was subjected to a radical cyclization. Subsequent aromatization with manganese dioxide, *N*-methylation with methyl 2-nitrobenzenesulfonate in toluene and debenylation gave Fagaridine (**119**) as a hydrochloride.


The synthesis leading to the originally proposed structure **120** starts from Oxchelerythrine (**124**) as shown in Scheme 45 (85CPB1763). The structure is not identical to the naturally occurring compounds and obviously does not occur in nature.

8. *Dibenzo[de,g]quinolinium-olates*


The oxoaporphine alkaloids Teliglazine (**126**), Corunnine (**127**), Nandazurine (**128**), PO-3 (**129**), *N*-Methyliriodendronine (**130**), and *N,O*-Dimethyliriodendronine (**131**) contain the 6-methyl-7-oxo-dibenzo[de,g]quinolinium-1-olate ring system **125** which is isoconjugate with the 1-methyl-7-methylene-7H-benzo[de]anthracene anion (Scheme 46). Therefore, these alkaloids belong to class 1, i.e., heterocyclic mesomeric betaines isoconjugate with odd alternant hydrocarbon anions. Another



Scheme 44



Scheme 45



Scheme 46

mesomeric form, the 1-oxo-7-olate, can be formulated with this ring system. On protonation, however, the 1-hydroxy derivative is formed (97JNP1328).


The chemistry of oxoaporphines has been reviewed in 1972 (72MI2). They are most probably derived in plants by oxidation of the corresponding aporphines. Teliglazine (**126**) was identified in *Telitoxicum glaziovii* (97JNP1328). Under acidic conditions, protonation at C(1) occurs, yielding the corresponding cation. On protonation, the color changes from green (neutral and basic conditions) to pink (acidic). All attempts to methylate, silylate, or acetylate Teliglazine failed due to the missing phenol group. A synthetic sample of Teliglazine was obtained on treatment of *O*-methylmoschatoline with excess MeI in acetone at room temperature for 18 h. The UV absorption maxima λ_{max} of Teliglazine in ethanol were determined at 246 (shoulder, 3.24), 318 (3.43), 430 (2.53), and 648 (2.55) nm, whereas the protonated form exhibits absorption maxima λ_{max} (EtOH+0.1 M HCl) at 248 (3.31), 294 (3.29), 316 (shoulder, 3.06), 378 (2.59), 520 (2.47). ^1H and ^{13}C NMR data are given in Table VI. The broadening of the resonance frequencies of 4-H and 5-H at 7.88 and 8.14 ppm, respectively, is indicative of a quaternary nitrogen atom. The ^{13}C NMR data were recorded through the ^1H -detected inverse HMQC and HMBC correlation data. The resonance frequency of C-1 could not be detected.

Corunnine (**127**) (73JCS(CC)915) was isolated as violet needles in the course of studies of Spanish Papaveraceae, i.e., *Glaucium flavum* Cr. var. *vestitum* (71TL3093). The UV absorption maxima λ_{max} of Corunnine are very similar in ethanol and hydroxide solutions and were found at

Table VI. NMR CHEMICAL SHIFTS OF TELIGLAZINE **126**, PO-3 PRECURSORS **143** AND **144**, PO-3 **129**, AND NANDAZURINE **128**

Atom	126^a		143^a	144^a	129^b	128
	¹ H NMR	¹³ C NMR	¹ H NMR	¹ H NMR	¹ H NMR	¹ H NMR ^d
1	—	n.d.	4.00 (OMe) ^c	4.02 (OMe) ^c	—	—
2	4.34, s (OMe)	152.3/60.9	4.08 (OMe) ^c	4.27 (OMe) ^c	3.86 (OMe) ^c	3.93 (OMe)
3	4.11, s (OMe)	143.7/61.5	7.13, s	7.89, s	7.14, s	7.14
3a	—	117.0	—	—	—	—
4	8.14, br d, <i>J</i> =4.6 Hz	117.2	7.74, d, <i>J</i> =5.2 Hz	8.90, d, <i>J</i> =5.8 Hz	7.93, m	7.96
5	7.88, br d, <i>J</i> =4.6 Hz	134.8	8.81, d, <i>J</i> =5.2 Hz	9.22, d, <i>J</i> =5.8 Hz	8.40, d, <i>J</i> =5.5 Hz	8.14
N(6)–Me	4.87, br s	51.2	—	4.82, s	4.65, s	4.50
6a	—	135.1	—	—	—	—
7	—	177.0	—	—	—	—
7a	—	130.1	—	—	—	—
8	8.48, dd, <i>J</i> =8.3/1.5 Hz	126.6	7.29, d, <i>J</i> =7.9 Hz	7.39, d, <i>J</i> =8 Hz	7.93, m	7.40
9	7.42, ddd, <i>J</i> =8.3/6.9/1.5 Hz	124.3	7.55, t, <i>J</i> =7.9 Hz	7.65, t, <i>J</i> =8 Hz	7.2–7.5	—
10	7.79, ddd, <i>J</i> =8.3/6.9/1.5 Hz	134.1	8.10, d, <i>J</i> =7.9 Hz	7.90, d, <i>J</i> =8 Hz	7.2–7.5	—
11	10.03	126.5	3.73 (OMe) ^c	3.88 (OMe) ^c	3.94 (OMe) ^c	8.32
11a	—	136.9	—	—	—	—
11b	—	105.6	—	—	—	—

^aIn CDCl₃.^bIn DMSO-*d*₆.^cPeak assignments exchangeable.^dIn TFA-d.




Scheme 47


258 (4.13), 325 (4.32), 400 (3.54), 440 (3.42, sh), 630 (3.35) nm. On addition of acids, they hypsochromically shift to 256 (4.23), 295 (4.14), and 385 (3.75) nm. An oxidative photocyclization is the key step of its total synthesis, which is shown in [Scheme 47](#). Starting from the *o*-iodoaldehyde **132** and the Reissert compound **133**, the precursor molecule for the photocyclization **134** was prepared. The authors explain the high yield of this step by the formation of the insoluble tetracycle **135** and its removal from the photolysis medium before being subjected to further photochemical transformations. Standard reactions converted **135** into Corunnine (**127**).

Oxidation of the alkaloid Glaucin (**136**) resulted in the formation of a yellow alkaloid **137**, which seemingly is contained in *Glaucium flavum* var. *vestitum* ([Scheme 48](#)). Addition of methyl iodide converted this compound via a methylation/ether cleavage sequence into Corunnine (**127**) and small amounts of Pontevedrine (**138**) which is not a mesomeric betaine ([71TL3093](#)).

Bischler–Napieralski reaction of **139** to a 3,4-dihydroisoquinoline, oxidation, dehydrogenation and reduction of the nitro to the amino function gave **140** which was subjected to a Pschorr reaction ([Scheme 49](#)). Quaternization was accomplished by methyl iodide to furnish the isoquinolininium salt **141** which underwent an ether cleavage on heating a solid sample or benzene or DMF solution to Corunnine (**127**) ([73TL3617](#)).




Scheme 48




Scheme 49

Nandazurine (**128**) was isolated from *Nandina domestica* in 1927 as a blue solid ([30BCJ348](#)). It is green in neutral or basic solvents, but yellow in acids and was also identified in *Coprydalis bulbosa* ([81MI3](#)). The structure elucidation was reported ([74MI3](#), [74E518](#)). The synthesis of Nandazurine was accomplished under identical reaction conditions as described for Coruninne (**127**) ([73JCS\(CC\)915](#)). When oxonantenine (**142**) was heated to its melting point, Nandazurine was obtained ([Scheme 50](#)).

The Apomorphine-derived alkaloid PO-3 (**129**) was isolated as violet needles after crystallization from acetone and ether from *Papaver orientale* ([66MI2](#)), but was not found in the green solutions of autoxidized apomorphine hydrochloride ([62M941](#), [68HCA683](#)) ([Scheme 51](#)). No anion was detected by elemental analysis. The pK_a of PO-3 is 3.88 ± 0.02 in 50% ethanol. The IR spectrum displays no carbonyl absorption between 1650 and 1700 cm^{-1} ([69MI2](#)). The UV absorption maxima of PO-3 are in agreement with the formulation of a mesomeric betaine: $[\lambda_{\max}(\text{EtOH}) = 310$



Scheme 50





Scheme 51

(3.7), 430 (3.7), 645 (4.5) nm (values approximated from chart)]. In comparison to the nonbetainic alkaloids Cassamedine, Thalycinine, Hernandonine, Imenine, the absorption band at 645 nm seems to be diagnostic for a betainic ground-state. Table VI presents a comparison between a neutral precursor **143**, the *N*-methylated cationic molecule **144** (CDCl_3) (Scheme 51), and the betainic PO-3 (**69MI2**). On methylation of **143** to **144**, the resonance frequencies especially of 3-H ($\Delta\delta = -0.76$ ppm), 4-H ($\Delta\delta = -1.16$ ppm) and 5-H ($\Delta\delta = -0.41$ ppm) shift considerably to lower field. On betaine formation to PO-3 **129**, the chemical shift of 3-H remains virtually unchanged in comparison to **143**, 4-H shifts downfield ($\Delta\delta = -0.19$ ppm), and 5-H shifts upfield ($\Delta\delta = +0.41$ ppm).


On oxidation, Isothebaine (**145**) forms 6a,7-Didehydroisothebaine (**146**) as well as PO-3 **129**, which can be protonated to give a red substance. Both alkaloid gives Isothebain on reduction (**69MI2**) (Scheme 52).

The aporphinoid alkaloid PO-3 (**129**) was also prepared by intermolecular benzyne cycloaddition between 1-methylene isoquinolines **148** and arynes derived from **147** (Scheme 53). The alkaloid was finally isolated by means of preparative thin layer chromatography (**91JOC2984**).

Bio-assay guided fractionation of the methanolic extract of the African climbing shrub *Stephania dinklagei* contains six bioactive alkaloids, among



them *N*-Methyliriodendronine (**130**) and *N,O*-Dimethyliriodendronine (**131**). The stems of this plant are used to treat infertility of women and impotence of men; the stems are reported to possess vermifuge, analgesic, and sedative effects. *N*-Methyliriodendronine proved to be active against *Leishmania donovani* amastigotes (00MI1). 2-*N,O*-Dimethyliriodendronine (**131**) was also identified as a blue solid on treatment of Liriodenine methiodide (**150**) with basic alumina (80JPS1180, 76TL601) (Scheme 54). Alternatively, it was obtained as dark green needles on treatment of Liriodendronine (**151**) isolated from *Liriodendron tulipifera* with dimethyl-sulfate in alkaline solution. The intense absorption maximum λ_{max} at 311 nm indicated that the structure is similar to the oxaphorphine zwitterions like Corunnine. The absorption bands at 1628 and 1581 cm^{-1} correspond to carbonyl groups of the Corunnine type (77P2015). The UV absorption maxima of 2-*O,N*-Dimethyliriodendronine at 247 (4.03), 311 (4.29), 420 (3.46), 585 (3.44), 602 (3.44) in methanol do not change on addition of 0.005 N NaOH (77P2015). On protonation with 0.005 N HCl, however, the




Scheme 54

UV spectrum changes dramatically. The salt causes maxima at 251 (4.16), 286 (4.16), 387 (3.56), and 473 (3.37) nm. ^1H NMR data for a sample in CF_3COOD were presented. It is interesting to note that the nonmethylated derivatives of **130** and **131** are present in solution above pH 6.5 as betaines, forming a protonated pyridine ring and an olate group (91MI3).

Some unnatural analogs have been synthesized and their antifungal activities have been examined (91MI3).

9. Purines


The alkaloid Herbipoline was first isolated from the giant silica sponge (*Geodia gigas*) and proved to be 7-methylguanine (**152**) (58AG80, 59CB566). This betainic purine and its derivatives were identified later as 7-methylguanosine (**153**) (m^7G) (61BBA198), 2,7-dimethylguanosine (**154**) ($\text{m}^{2,7}\text{G}$), and 2,2,7-trimethylguanosine (**155**) ($\text{m}^{2,2,7}\text{G}$) in distinct types of RNA such as *ribosomal*-RNA (89MI4, 68BBA63, 85MI3, 78JBC1101, 79MI3), *archaea*-, *bacterial*-, *eucaryotic-transfer*-RNA (61BBA198, 62JCS5281), *sn*- (69NAT1365, 91MI2, 82NAT684), *viral*- (76NAT264, 80BBR102) and *messenger*-RNA (90MI2, 83MI3) (Scheme 55). These compounds undergo nonstandard base-pairings such as $\text{m}^7\text{G}=\text{G}\equiv\text{C}$ (76NAR181, 78MI1), and unusual π -stacking interactions such as the intercalation of adenine into m^7G and G to stabilize the tertiary structures of RNA (74MI2). 7-Methylguanosine forms the 5'-capping structure **156** of eucaryotic messenger-RNA and is joined to the RNA through a unique triphosphate bridge $\text{Gp}(5'-5)\text{ppN}$. The enzyme guanylyl transferase adds the 7-methylguanosine. This capping structure is essential for ribosomal binding of the mRNAs and it protects the mRNAs from degradation by 5'-exonucleases. The cap-structure seems to be involved in several aspects of pre-mRNA and mRNA metabolism, in most cases related to identifying the 5'-end of the RNA. The cap-structure binds two cap binding proteins in the nucleus to form a cap binding complex which influences the splicing of the pre-mRNA. Furthermore, it may be involved in the transport of the



Scheme 55

pre-mRNA to the cytoplasm. The cap-structure, which is bound by a translation initiation factor in the cytoplasm, is important for the initiation of translation. The crystal structures of the m^7GTP and m^7GpppA initiation factor complexes have been reported. Compound **156** is sandwiched between two aromatic side chains of tryptophane. Two hydrogen bonds between the NH of m^7G and the carboxy group of glutamic acid stabilize the stacking interaction (02BJ539).


The synthesis of **152** was described (67MI3). All four compounds Herbipoline **152**, m^7G **153**, $m^{2,7}G$ **154**, and $m^{2,2,7}G$ **155** belong to the class of conjugated mesomeric betaines. The positive and negative charges are in mutual conjugation and are not restricted to separate parts of the π -electron system of the molecule. Correspondingly, the canonical formulae display common atoms such as C(8) for either charge which is presented in Scheme 56. This is the result of the π -connection of the negative to the positive fragment through an “active” atom, i.e., a starred position of the isoconjugated benzyl anion of the pyrimidin-4-olate moiety **157**. The 7-methylguanines **152–155** are members of class 4 of mesomeric betaines due to their isoconjugate equivalency with an even nonalternant



Scheme 56

hydrocarbon dianion. Semiempirical as well as *ab initio* calculations on 7,9-dimethylguanine (**152**) were performed (02JCS(P1)982). The HOMO [IP(PM3)=+8.19 eV] of the planar 7,9-dimethylguanine is essentially located at N(1), N(3), C(5) and O(13) of the pyrimidine moiety and in the imidazole ring, whereas the LUMO [IP(PM3)=+0.92 eV] has its largest coefficients at N(7), C(8), and N(9) in the imidazole ring and at C(5) of the pyrimidine. The calculated permanent dipole moment of 7,9-dimethylguanine is 10.80 D [RHF6-31g(d)] which is presented—in addition to the net atomic charges—in Scheme 56.

The pK_a value of 7,9-dimethylguanine is 7.19 (61LA167) so that it exists as 1:1 mixture of cationic and betainic species at pH 7. This is the condition for self-complementarity and this was indeed confirmed by ESI mass spectrometry and ^1H NMR spectroscopy (96AG1321). Dimerization occurs between the acid and its conjugated base through three hydrogen bonds and the structure of the dimer with iodine as the anion has been elucidated by an X-ray analysis (89MI2). Similarly, N7-guanosines and guanines are self-complementary as presented in Scheme 57 (80JA5418, 82IC3216, 81JA5691, 95JCS(D)3767). 7-Methylguanosine ($m^7\text{G}$) is hepatotoxic and mutagenic (95JCS(P2)839, 97MI4), and has been identified in the liver of animals after exposure to strong carcinogens such as alkylating agents or hydrazine (80NAT596, 57CIL633, 60BJ478). Some model compounds of $m^7\text{G}$ (02JCS(P1)982, 02H2231, 02CL222, 01BCJ2379, 01CL348) and other



Scheme 57


nucleobases (97JOC3910, 99JOC9499) were synthesized in order to study the dependence of the type of conjugation on the base pairing properties.

B. HETEROCYCLIC CONJUGATED N-OXIDES

Relatively few heteroaromatic N-oxides occur in nature. The chemistry of compounds that contain the oxidized peptide bond (the so-called hydroxamic acids) and their role in iron metabolism have been reviewed (67SC1443). Another review deals with the natural occurrence of N-oxides (68MI1).

1. Pyridine-N-oxides

The N-oxide Malloapeltine (**17**) was extracted from the roots of *Mallotus apelta* (98P2193), which have been widely used for the treatment of chronic hepatitis in traditional Chinese medicine. Extracts of this plant containing Malloapeltine have significant anti-HIV activity (89CPB1810). The antibacterial alkaloids Piericidine B₁ N-oxide (**158a**) (91JAN1283) and Piericidine B₅ N-oxide (**158b**) (93JAN564) are phosphatidylinositol turn-over inhibitors and were isolated as pale yellow oils from *Streptomyces* species (Scheme 58). Reduction of **158a** with zinc powder in acetic acid gives Piericidin B₁ (91JAN1283). The UV absorption maxima of Piericidin B₁ N-oxide in methanol are seemingly not very sensitive toward the addition of 0.1 N HCl or 0.1 N NaOH. A bathochromic shift of 8–9 nm from $\lambda_{\max} = 267$ nm is observable in either case, all other absorptions remain virtually unchanged (91JAN1283). Orellanine (**159**) (79TL1931) was first isolated from the mushroom *Cortinarius orellanus* (59MI2). Some syntheses (02T309, 93T8373, 88HCA957, 87E462, 87LA857, 86T1475, 85TL4903) and a study on the chirality of Orellanine derivatives have been described (02H137). The bis-pyridinium-N-oxide (**160**) and Cortamidine Oxide (**161**) were isolated from *Cortinarius* species (01JNP342). All N-oxides presented in Scheme 58 are conjugated heterocyclic ylides isoconjugate with the



Scheme 58


benzyl anion, which is an odd alternant hydrocarbon anion. The betaines **17** and **158–161** are therefore members of class 5.

2. Pyrazine-N-oxides


In 1943, Aspergillilic acid (**162**) (6-*s*-butyl-2-hydroxy-3-isobutylpyrazine 1-oxide) was isolated from *Aspergillus flavus* (43MI1, 44JBC359, 47JBC321, 49JCS(S)126, 49JCS127, 51JCS2679). The tautomeric form of the aromatic N-oxide **162A** is a mesomeric betaine whereas a neutral covalent structure can be drawn for the olate structure **162B** (Scheme 59). It has antibiotic activity, but its toxicity prevented therapeutic use. Additional examples of aromatic N-oxides from fungi are hydroxyaspergillilic acid (**163**) (*Aspergillus flavus*) (43MI2, 58JBC785), mutaaspergillilic acid (**164**) (*Aspergillus oryzae*) (61MI1), neohydroxyaspergillilic acid (**165**) and 3-hydroxy-2,5-diisobutylpyrazine 4-oxide (**166**) (*Aspergillus sclerotiorum*) (58MI2, 64JCS1507). Pulcherrimine is an iron(III) complex of pulcherrimic acid (**167**) (*Candida albicans*) (56JCS4133). Whereas the N-oxides **163–166** belong to class 5, **167** is isoconjugate with the *p*-xylene dianion, which is even and alternant (class 7).

Emeheteron (Scheme 60), to which the structure **168** was originally assigned, was isolated from a culture filtrate of the fungus *Emericella heterothallica* (88P3022) and the basidiomycetes *Albatrellus confluens* (01HCA259). The structure **169** was finally proven by a total synthesis, which is shown in Scheme 61 (90H1655).


DL-Phenylalanin anhydride (**171**), readily available by heating DL-phenylalanine (**170**) in ethylene glycol, was treated with a mixture of




Scheme 59



Scheme 60



Scheme 61



Scheme 62


phosphoryl chloride and phosphorus pentachloride in a sealed tube to give a mixture of two chlorinated pyrazines **172** and **173** (Scheme 61). Nucleophilic substitution on **172** then resulted in the methoxy derivative **174**, which was oxidized with permaleic acid (PMA) to yield the N-oxide **175**. Subsequent acetylation, which presumably formed 6-(α -acetoxybenzyl)-3-benzyl-5-methoxypyrazine as a by-product in 55% yield, gave 2-acetoxy-3,6-dibenzyl-5-methoxypyrazine which was hydrolyzed to the hydroxy compound **176** by potassium carbonate. Benzylation and oxidation by PMA gave an N-oxide, which was then hydrogenated to yield Emeheterone (**169**). As the IR spectrum displays a band at 1640 cm^{-1} , Emeheterone is supposed to exist predominantly in the pyrazinone form **169B**.

3. Phenazine-N-oxides

Iodinine (**177**) (1,6-phenazindiol-5,10-dioxide) was the first aromatic N-oxide found in nature (*Chromobacterium iodinum*) (Scheme 62). It is a bis-N-oxide with antibacterial activity against gram-positive bacteria and forms a violet crystalline solid (39CA6383). Myxin (**178**) is the corresponding monomethylether from *Pseudomonas* sp. and displays additional activity against gram-negative bacteria. Methylation of Iodinine with dimethyl sulfate in the presence of alkali produced Myxin as the major product (67TL715). Care must be taken as the substance may explode on attempts to dry it. The biosynthesis follows the Shikimi-acid pathway (74TL4201). These compounds are described as aromatic molecules so that the classification as members of class 7 of heterocyclic mesomeric betaines is acceptable. The corresponding olate tautomer, however, represent a conjugated mesomeric betaine of class 3.

4. β -Carboline-N-oxides

The cytotoxic 9-methoxycanthin-6-one N-oxide (**179A**) was isolated from the branches of *Picrolemma granatensis* (92P2499) (Scheme 63). It is




Scheme 63

isoconjugate with the 2,5-dimethyl-1-*o*-tolyl-naphthalene anion and thus represents a member of class 5 of heterocyclic mesomeric betaines. The canonical formula **179B** signifies the close relationship between the class of N-ylides and conjugated mesomeric betaines as positive as well as negative charges are delocalized over the entire molecule and common atoms for either charge exist. In addition to 9-hydroxycanthine-6-one N-oxide (**180**) it was also found in the roots of the Indonesian small jungle tree *Eurycoma longifolia* which are used as a traditional medicine for the treatment of dysentery, glandular swelling, persistent fever, and tertian malaria (**91JNP1360**). In the search for the biologically active substances of *Brucea Mollis* var. *tonkinensis*, which is an important drug in Chinese folk medicine and is used as a remedy for malaria and other parasitic diseases, 11-hydroxycanthin-6-one-N-oxide (**94P1543**) (**182**) was identified together with its derivative **181** which was found earlier (**76CPBI532**). On formation of the N-oxide **179B** from its nonoxidized derivative, the ^{13}C NMR signals in CDCl_3 the α/α' - and γ -positions of the pyridine moiety shift approximately 10 and 7.5 ppm to higher field, respectively (**91JNP1360**). Likewise, signals for the α - and β -hydrogen atoms shift upfield in ^1H NMR spectroscopy. The chemical shift differences are 0.15 and 0.43 ppm, respectively (**94P1543**).

5. Quinoline-N-oxides

Quinoline-N-oxides were found in the myxobacterium *Stigmatella aurantiaca* which is a source of the aurachins, i.e., quinoline alkaloids with a sesquiterpenoid substituent. There are noteworthy structural variations between the members of the family (Scheme 64). The following Scheme presents Aurachin A (**183**), and B (**184**), F (**185**), G (**186**), H (**187**), and I (**188**) (**89GEP3520229**). Aurachin A and B display antibacterial and weakly antifungal properties (**87JAN258**). Certain Aurachins inhibit photosynthetic electron transport by binding to quinone receptor sites in respiratory oxidases (**95B1076**). They also belong to class 5.



Scheme 64



Scheme 65

6. Purine-N-oxides

The conjugated mesomeric betaine guanine-7-oxide (**189**), isolated from natural sources ([85JAN572](#), [85JAN972](#), [85JAN977](#), [85JAN1440](#)), displays antitumor ([87MI3](#)), antimicrobial, and antiviral activities ([85JAN1581](#), [86JAN1291](#)). It is isoconjugate with the odd and nonalternant 3-methyl-4-methylene-4H-indene anion and belongs therefore to class 6 of heterocyclic mesomeric betaines ([Scheme 65](#)).


C. CROSS-CONJUGATED HETEROCYCLIC MESOMERIC BETAINES

1. Pyridinium-3-carboxylates

The alkaloid Trigollenine (**18**), *N*-methyl nicotinate, was first identified in 1885 in *Trigonella foenum graecum* ([1885CB2521](#)). A comparison of its properties with the first synthetic sample, which was prepared by Hantzsch ([1886CB32](#)), led to its structure elucidation ([1887CB2840](#), [1887MI](#)). Trigollenine is wide-spread in nature. It was isolated from various plants such as lianas of *Gnetum parvifolium* ([99JAN1025](#)), *Aeschynomene indica* ([99H927](#), [95P817](#)), *Nothapodytes foetida* ([95P383](#)), the seeds of


Pisum sativum (84P1837, 09ZPC174, 1894CB769, 1891ZPC145), Alfalfa (59CJC1043), *Acanthus montanus* (88P2581) and *illicifolius* (80PJC2089), *Abrus precatorius* (71P195), *Pseudolmedia laevis* and *laevigata* (91P3285), *Desmodium triflorum* (71P3312), *Calyx nicacensis* (61ZPC197), *Quisqualis fructus* (75MI1), *Arion empiricorum* (60ZPC212), *Cassia occidentalis* (70P429), potatoes (*Solanum tuberosum*) (04MI), and coffee beans (*Coffea arabica* and *Coffea liberica*) (31JPC11, 10LA242), *Astragalus wootoni* (42JOC389), *Mappia foetida* (75IJC758) the roots of *Dictamnus albus* (30MI), and sugar-beet juices (60MI1). Especially, Trigollenine has been detected in many gymnosperms, several monocotyledonous and dicotyledonous plants (79P105). Trigollenine was also identified in animals (42JBC357, 67MI1) such as dogs (12MI, 26JB163) and sea urchins (31JPC11). The tail muscle of the western rock lobster *Panulirus cygnus* George contains Trigollenine as well as human urine after its ingestion (81AJC787). Trigollenine was identified as a cell proliferation regulating factor (78JA7759) and it has been shown to promote cell arrest in G2 of certain plants (74MI1). The plant hormone Trigollenine is synthesized in the leaves of *Pisum sativum* and *Glycine max*, and is translocated to the pods and seeds during fruit maturation (97P1037). Plants, when exposed to excess salt, accumulate osmoregulators such as Trigollenine to prevent water loss (97P1037). Trigollenine forms charge-transfer-complexes with FMNH_2 . Benesi-Hildebrand plots revealed the existence of 1:1 complexes in phosphate buffer solution (66BBA459). Trigollenine is usually the most abundant molecule in pyridine metabolism for the biosynthesis of NAD. Thus, this alkaloid may have a regulatory role in NAD biosynthesis as well as in cell proliferation (73MI1, 57JA4246, 82P1201). Trigollenine has been shown not to arise from tryptophane (59JBC93, 55CJC405) and the methyl group at the nitrogen atom obviously arises by transfer from *S*-adenosylmethionine (60JBC2981).

An X-ray single crystal structure analysis was performed. The unit cell contains a pair of molecules of the betaine and two molecules of water (81AJC787). The bond length between the methyl group and the pyridine nitrogen atom was determined to be 148.0(5) pm while the bond length between C(3) and the carboxy carbon is 152.8(5) pm. Thus, they are single bonds without π -contribution. The two carbon-oxygen bonds of the carboxy group were found to be 123.5(4) and 125.3(4) pm long, respectively. The UV absorption maxima λ_{max} in water were found at 264 (2700), 207 (4300). The ^1H NMR data at 400 MHz in D_2O are as follows. The resonance frequency of 2-*H* appears at $\delta = 9.10$ ppm (s, br), whereas 6-*H* is observable at $\delta = 8.80$ (d, $J = 6$ Hz). The signals of 4-*H* and 5-*H*, respectively, appear at $\delta = 8.83$ (d, $J = 8$ Hz) and 8.06 ppm (95P817). The methyl group gives a resonance frequency at $\delta = 4.42$ ppm.



Scheme 66

Hantzsch's synthesis (1886) begins with the deprotonation of nicotinic acid (**190**) with potassium hydroxide, evaporation to dryness and proceeds with the addition of methyl iodide at 150°C for several hours (Scheme 66). Treatment with silver chloride and silver oxide gave *N*-methyl nicotinate monohydrate as long needles, which loses one molecule of water on heating at 100°C . In 1900, Meyer prepared Trigollenine (**18**) similarly by treatment of 3-carboxy-1-methylpyridinium iodide with silver oxide in water (1900M913, 1903M195, 05M537). Starting from nicotinic acid ethyl ester, treatment with methyl iodide in a sealed tube for 3 h at 100°C , followed by the addition of silver oxide and hydrogen sulfide to remove excess silver ions gave also Trigollenine (44CB362). Saponification can alternatively be accomplished using an anion exchange resin (Dowex, OH^- form) (84P1225, 56JA4896, 61JOC1318). Pyrolysis of nicotinic acid methyl ester also results in the formation of Trigollenine (55JPC670). Treatment of chinolinic acid (**192**) with methyl iodide in methanol gave carbon dioxide and Trigollenine; no reaction was observed under the same reaction conditions in pure MeI (1901M361). Cocondensation of *N*-methylpyrrol (**193**) with carbon and carbon dioxide at 77 K in a standard carbon arc reactor in which atomic carbon is generated by striking an arc between two high purity graphite electrodes, followed by the addition of HCl and methanol resulted in the formation of 1-methyl pyridine and *N*-methylpyridinium-3-carboxylic acid (97JA5091) which can be deprotonated to give Trigollenine. On heating to 100°C over a period of several hours chinolinic acid anhydride **196** and methyl iodide form the corresponding pyridinium salt **195** which was converted into the colorless betaine with hot water in 80% yield. Heating in



Scheme 67

methanol under reflux gives Trigollenine (**18**) in quantitative yield. When the pyridinium salt **197** was kept at room temperature with sodium methoxide in methanol, ready cleavage of the side chain occurred, giving sodium nicotinate methiodide as a monohydrate (76JCS(P1)315). Pictet and coworkers describe two syntheses of Trigollenine starting from nicotine (**198**). Methylation of nicotine to the pyridinium iodide with methyl iodide, followed by its conversion to the hydroxide with silver oxide in water, oxidation with potassium permanganate to the *N*-methyl nicotinic acid hydroxide and subsequent deprotonation with silver oxide yielded Trigollenine as colorless needles (1897CB2117). In a later publication, the formation of nicotinic acid from nicotine was described. Esterification followed by aminolysis and methylation yielded the *N*-methylnicotinamide (**199**), which gave Trigollenine on treatment with silver oxide (1898MI).

Späth and Bobenberg described a synthesis of Trigollenine starting from manihot alkaloid (**200**), which was methylated at the side chain on reaction with formaldehyde and formic acid in a sealed tube to form **201** (Scheme 67). Hydrogen iodide protonates at the aliphatic nitrogen atom at 0 °C, whereas subsequent reaction with methyl iodide quaternized the pyridine nitrogen to give the *N*-methyl manihotin derivative **202**. Subsequent treatment with silver chloride, silver permanganate, silver oxide, and H₂S to remove excess silver cations yielded Trigollenine (**18**) (44CB362).

In *Dioscorea hispida*, Trigollenine is incorporated into the isoquinuclidine moiety of the alkaloid Dioscorine (**208**), as proved by a feeding experiment with [methyl-¹⁴C, 2-²H, ³H]trigollenine (88P3793). These results are consistent with the hypothesis for the biosynthesis of Dioscorine (**208**), Dumetorine and Dihydrodioscorine, which is presented in Scheme 68.

In the rosary pea *Abrus precatorius* L. Trigollenine as well as its gallic acid ester Precatorine (**209**) is found (71P195) (Scheme 69). 1-Carboxymethylnicotinic acid (**210**) was isolated as a colorless solid from the marine sponge *Anthosigmella* cf. *raromicrosclera* as a cysteine protease inhibitor (98JNP671). This compound was first synthesized in 1991. The sodium



salt was identified by the $m/z=204$ amu ($M^+ + H^+$) and $m/z=182$ ($M^+ - Na + H^+$) in FAB mass spectrometry. The alkaloid can easily be prepared on reaction of nicotinic acid with iodoacetic acid in DMF, followed by preparative HPLC on an Amide-80 column in a mixture of acetonitrile and methanol and ammonium formate buffer. The 1H and ^{13}C NMR data are as follows (98JNP671). In contrast to the 1H NMR values of Trigollenine, the resonance frequency of 2-*H* appears at $\delta=8.72$ ppm, while 4-*H* and 5-*H* were detected at $\delta=8.80$ and 8.02 ppm, respectively. The signal of 6-*H* at $\delta=9.00$ ppm forms a broad singlet. The coupling constants are $^3J_{4-5}=8.1$ Hz, $^3J_{5-6}=5.8$ Hz. In ^{13}C NMR spectroscopy, C-2, C-3, C-4, C-5, and C-6 appear at $\delta=146.8, 168.5, 137.6, 147.0, 128.3$, and 146.0 ppm, respectively. The carboxy carbon atom at C(3) of the pyridinium moiety gives a signal at $\delta=168.5$ ppm, while the second

COOH group causes a signal at $\delta = 171.5$ ppm. The methylene group appears at $\delta = 64.2$ ppm.


In 1998, Pyridinebetaine A (**211**) and Pyridinebetaine B (**212**) were isolated from the caribbean sponge *Agelas dispar* Duchassaing and Michelotti 1860 (98JNP1171) and *Agelas conifera*, *clathrodes* and *longissima*, respectively (97BMC2283) (Scheme 69). The former mentioned species exhibited antibacterial activities against gram-positive bacteria. Pyridinebetaine A can easily be prepared on treatment of sodium nicotinate with oxirane in water at pH 7–11 (59JBC889).

2. Imidazolium-4-carboxylates

Norzooanemonine (**213**) (1,3-dimethylimidazolium-4-carboxylate), which may be regarded as a nor-derivative of zooanemonine (**214**), was isolated from the marine sponges *Pseudopterogorgia americana* and *Cacospongia scalaris* as a metamorphosis-inducing compound (73T3135). In addition, it was identified together with Trigollenine (**18**), which is presumably a primary metabolite, in the coralline demosponge *Astrosclera willeyana* Lister 1900 living in the Great Barrier Reef (97TL3883). This animal, termed a living fossil, is a representative of the Palaeozoic and Mesozoic reef building sponges, which demonstrates the biological role of these mesomeric betaines over the last 220 million years. It is isoconjugated with the 1-isopropenyl-cyclopenta-1,3-diene dianion which is an even nonalternant hydrocarbon dianion. Thus, norzooanemonine belongs to class 12 of heterocyclic mesomeric betaines. The NMR resonance frequencies are presented in Table VII (94T13583). Note the chemical shift differences on changing the solvent. Characteristic for the proton exchange of the 2-position of dimethylimidazolium in D₂O, the signal at $\delta = 8.63$ ppm rapidly disappears on addition of ammonia vapor. Prominent peaks in the FAB mass spectra were found at $m/z = 141$ amu which

Table VII. NMR CHEMICAL SHIFTS OF NORZOOANEMONINE **213**

Atom	¹ H NMR (in D ₂ O)	¹ H NMR (in DMSO- <i>d</i> ₆)	¹³ C NMR (in DMSO- <i>d</i> ₆)
2	8.63, s	9.22, s	140.0
4	—	—	125.9
5	7.69, s	8.27, s	128.5
COO [−]	—	—	169.8
N(1)–Me	3.87	3.84	36.0
N(3)–Me	3.99	3.98	35.8




Scheme 70


corresponds to the molecular peak, and at 97 amu which is the molecular mass minus carbon dioxide. Norzooanemonine is biogenetically related to 1,7,9-trimethylhypoxanthinium (**215**) (*Jaspis* sp.). The IR spectrum of Norzooanemonine displays a strong carboxylate ion absorption at 1640 cm^{-1} which shifted to 1710 cm^{-1} on protonation with HCl. The syntheses of Norzooanemonine can easily be accomplished by dimethyl sulfate methylation of imidazole-4-carboxylic acid using controlled amounts of NaOH to keep the pH below 9 (Scheme 70).

3. Pyrido[2,1-a]isoquinoline-3-carboxylic acids

It is interesting to note that the 7,12-dihydro-2-methyl-6H-indolo[2,3-a]quinolizinium chloride (**216**) (R = acetal) can be deprotonated to give the orange-yellow zwitterion **217**, whereas the vinyllog amide **218** is formed when R = COMe (Scheme 71). This substitution pattern gives rise to the



Scheme 71

**220****Scheme 72**

formation of the β -enamino carbonyl chromophor. Oxidation of **216** gives the cross-conjugated mesomeric betaine **219**, but no zwitterionic species, which would result on deprotonation of the hydroxy group (88LA1111). This observation is similar to the chemistry of Neoxygambirtannine (**43**), the indolic NH of which was unambiguously proved by NMR spectroscopy.


Oxidation of berberine (**49**) with hot dilute nitric acid yields berberidic acid (**220**) (58MI1) which can form a cross-conjugated and a pseudo-cross-conjugated mesomeric betaine on deprotonation as shown in Scheme 72.

D. PSEUDO-CROSS-CONJUGATED HETEROCYCLIC MESOMERIC BETAINES


1. *Pyridinium-2-carboxylates*

As outlined in Section I, in contrast to 1-methylpyridinium-3-carboxylate the isomeric 2- and 4-carboxylates belong to the class of PCCMB. As they are isoconjugate with the isopropenyl benzene anion (an odd alterant hydrocarbon anion), they are members of class 13 of heterocyclic mesomeric betaines. 1-Methylpyridinium-2-carboxylate (**19**) is called Homarine (33ZPC105) and was isolated from the muscles of lobsters *Homa homerus* (33ZPC45), shells *Arca noae* (33ZPC33), and *Arbatia pustulosa* (24MI), and in the groups of invertebrates *Cnidaria* (Jellyfish, sea anemones, corals), *Porifera*, *Arthropoda* and *Echinodermata* (01MI). Homarine was described as a defense or deterrent compound of *Cnidaria* (58MI3, 89MI3). It presumably affects pattern formation in *Hydractinia* (87MI4) and functions as an osmoregulator (60MI2, 95MI1) and transmethylation agent has been discussed (82JBC11971). Homarin (**19**) was obtained on methylation of picolinic acid in the presence of barium hydroxide (33ZPC105) (Scheme 73).

The ^{13}C NMR data in D_2O at pD 9 are as follows. The carbon atom of the carboxy group appears at $\delta = 165.4$ ppm, and C-2 at $\delta = 152.5$ ppm.




Scheme 73



Scheme 74

The resonance frequencies of C-3 and C-5 appear at $\delta=127.4$ and 126.6 ppm. The atoms C-4 and C-6 give signals at $\delta=147.7$ and 146.7 ppm in ^{13}C NMR spectroscopy (76JA8237). On saponification of the 2-carboethoxy substituent to the 2-carboxylate group, 3-H and 5-H shift 0.15 and 0.18 ppm to upper field, respectively (82JOC498). The carboxy group can be detected at 1640 cm^{-1} in IR spectroscopy (70LA64).

1-Substituted pyridinium-2-carboxylates lose carbon dioxide at 60°C in dipolar aprotic solvents such as *N*-methylpyrrolidone, acetonitrile or benzonitrile to form an intermediate nucleophilic carbene **222** which can be trapped by electrophiles (Scheme 74). In protic solvents, pyridine forms (82JOC498). In aprotic solvents, aldehydes give alcohols like **223** (70LA43, 70LA64), sulfur gives pyridine-2-thiones **224**, carbon disulfide gives dithioacids **225** (83SI49), azides gives triazenes **226**, and diazonium ions give azo compounds **227**. The decarboxylation of quinoline-2-carboxylic acid at elevated temperatures (Hammick reaction) gave rise to the postulation of nucleophilic carbenes as highly reactive intermediates (37JCS1724). It is noteworthy that considerably higher temperatures are necessary to



Scheme 75

decarboxylate cross-conjugated mesomeric betaines such as Trigollenine (**18**) (70LA64).

Pyridine-2-carboxylic acid is a structure element of the macrocycle 1,6-bis-deacetyllevonine (*Euonymus europaeus*) (02CPB199).

2. Isoquinolinium-2-carboxylates


1-Methylisoquinolinium 2-carboxylate (**230**), originally prepared by Quast (70LA64), was recently identified as a defensive betaine from *Photuris versicolor* fireflies (99JNP378). It is a pseudo-cross-conjugated mesomeric betaine isoconjugate to the odd alternant hydrocarbon 2-isopropenyl-naphthalene anion which is an odd alternant hydrocarbon anion. This compound therefore is a member of class 13, which is very rare. The UV absorption maxima λ_{max} (methanol) were found at 235 (4.35), 320 (shoulder, 3.97), and 326 (3.99) nm. This compound undergoes similar reactions as Homarine **19** (Scheme 75). The NMR data are presented in Table VIII.

3. 2-Immoniummethyl-benzoylate

Shihunine (**233**) (Scheme 76) was isolated from orchids *Dendrobium lohohense* (64CPB749), *Dendrobium pierardii* (71ACSA721), *Dendrobium lohohense* Tang and Wang (68CPB1014) which are used to prepare the Chinese drug Shi-Hu (64CPB749). The ^1H NMR spectra reveal that this

Table VIII. NMR CHEMICAL SHIFTS OF **230**


Atom	^1H NMR	^{13}C NMR
2	—	155.5
3	7.91	119.4
4	9.07	148.0
4a	—	128.6
5	8.31	130.4
6	7.99	129.7
7	8.24	136.7
8	8.40	118.4
8a	—	138.3
N(1)-Me	4.54	41.2
COO ⁻	—	166.6

**Scheme 76**


alkaloid forms a racemic phthalide structure in nonpolar solvents, whereas the pseudo-cross-conjugated form is adopted in methanol or water ([71ACSA721](#)). Total syntheses have been described ([75T499](#), [65MI4](#)) and the biosynthesis was examined ([73JCS\(CC\)522](#)). In its betainic form it is isoconjugate with the 1-isopropenyl-2-vinyl-benzene anion, which is an odd alternant hydrocarbon anion.

4. Indazolium-11-carboxylates

The alkaloid Nigellicine proved to be the pyridazino[1,2-*a*]indazolium-11-carboxylate (**234**) and forms yellow crystals (**Scheme 77**). It was isolated from the widely distributed herbaceous plant *Nigella sativa* L., which is used as a spice and for the treatment of various diseases ([85TL2759](#)). The structure was determined by an X-ray crystal structure analysis. The carboxylate bond distances are essentially equal (123.3 and 125.6 pm). An intramolecular hydrogen bond was found between the carboxylate oxygen atom and the hydroxy group. In mass spectrometry, the molecular peak was found at $m/z = 246$ (20) and the base peak at $m/z = 202$ which corresponds



Scheme 77




Scheme 78

to a decarboxylated species. The hydroxy group appears at 3405 cm^{-1} in an IR spectrum and additional absorptions were found at 1670 and 1650 cm^{-1} which correspond to $-\text{CH}=\text{N}$ and $\text{C}=\text{O}$ groups. The carboxylate group is detectable at 1406 cm^{-1} . The parent heterocyclic system is isoconjugate with the 3-isopropenyl-1H-indene dianion as shown in [Scheme 77](#). Pyridaziniumcarboxylates are negatively solvatochromic ([02UPI3](#)).

5. *Indolo[2,3-a]quinolizinium-carboxylates*

Quaternization of harman (**235**) with ethyl bromoacetate, followed by cyclization of the pyridinium salt **236** with 1,2-cyclohexane-dione in refluxing ethanol yielded an ester which on hydrolysis gave the pseudo-cross-conjugated mesomeric betaine **237**. Decarboxylation resulted in the formation of the alkaloid Sempervirine (**238**). The PCCMB **237** is isoconjugate with the 11*H*-benzo[*a*]fluorene anion—an odd nonalternant hydrocarbon anion—and belongs to class 14 of heterocyclic mesomeric betaines ([Scheme 78](#)).




Scheme 79


The alkaloid Flavocarpine (**244**) was isolated from the tropical plant *Pleiocarpa mutica* (62JA3393). It contains a quinolizinium-2-carboxylate, which is also known synthetically (64JCS3225). A synthesis (Scheme 79) was published by Büchi and coworkers. Starting from 3-ethylpyridine-N-oxide (**239**), methylation followed by cyanation in the γ -position yielded **240**, which was N-oxidized again by hydrogen peroxide to give **241**. Chlorination gave a mixture of the chloropyridine **242** and its isomer, which was separated by distillation. Hydrolysis to the amide and subsequent Ban-cyclization with tryptophyl bromide gave the desired tetracyclic system **243** in low yield. Aromatization and hydrolysis afforded flavocarpine (**244**) as the hydrochloride. Decarboxylation (Cu, quinoline, reflux, 20 min, 26%) gave the zwitterionic alkaloid Flavopereirine (62JA3393) (cf. Section III).

The pyridine-N-oxide **245** was converted into the cyanopyridine **246** and its isomer (Scheme 80). Grignard reaction, Fischer's indole synthesis, and N-protection gave a pyridinyl indole **247**. Selenium dioxide selectively oxidized the methyl group to give the isonicotinic acid. The synthesis of Flavocarpine (**244**) was finally accomplished by a set of standard reactions as outlined in Scheme 80 (87TL5259).


The des-ethyl derivative **251** of Flavopereirine was prepared similarly starting from 2-chloro isonicotinic acid methyl ester **250** (Scheme 81). The resulting hydrochloride was converted into the pseudo-cross-conjugated



Scheme 80




Scheme 81



Scheme 82

mesomeric betaine by treatment with Amberlite IR-4B in water (68CPB549).

Vincarpin and Dihydrovincarpin are two additional examples of pseudo-cross-conjugated mesomeric betaines. They were isolated from *Vinca major elegantissima* (76TL4887) (Scheme 82).



Scheme 83

6. Phenazinium-1-carboxylates


Aeruginosine A (**254**) (69JCS(C)2514) and B (**255**) (61MI2), shown in Scheme 83, are metabolites of the pyocyanine producing *Pseudomonas aeruginosa*. They are isoconjugate with the odd alternant 1-isopropenyl-anthracene anion (class 13).

III. Zwitterionic Alkaloids


A. 2-SUBSTITUTED ISOQUINOLINONES

As already mentioned in Section II.A.3, substitution of the 4-, 5-, and 7-position of the isoquinolinium ring with negatively charged substituents results in conjugated mesomeric betaines. In contrast, substitution of the 1-, 3-, 6-, and 8-positions gives rise to the formulation of zwitterionic structures as well as at least one neutral canonical formula so that these compounds do not belong to the class of heterocyclic mesomeric betaines. The 1-hydroxy-isoquinolinium moiety was identified in an alkaloid named 8-Hydroxypseudocoptisine chloride (**256**). It was isolated from the roots of *Thalictrum przewalskii* after treatment with 5% hydrochloric acid, extraction and basification with ammonia to pH 9–10. The existence of the hydroxy group was unambiguously proved (98MI3). Deprotonation of **256** resulted in the 2-substituted 2*H*-isoquinolin-1-one form **257**, which was not reported in the original paper (Scheme 84).

As shown in Scheme 26, Papaverine hydrochloride yields a separable mixture of Protopapaverine (**67**) and the salt norpapaverinium chloride (**68**) when heated slightly beyond its melting point for several minutes. Molecule **67** can exist as conjugated mesomeric betaine **67A** (7-hydroxy form) or as 2-substituted-2*H*-isoquinolin-6-one **67B** (6-hydroxy form) (66TL1177). Similar structures were described as zwitterionic pentacyclic




Scheme 84




Scheme 85

homopro-aporphines. Thus, Regelinone (**259**) and Isoregelinone (**260**) from *Colchicum kesselringii* (85M11) both possess the isoquinolinium-6-olate increment (Scheme 85). The corresponding protonated species 6-hydroxy-isoquinolinium has a pK_a of 6.02 (57JCS5010). In contrast to this, Regecoline (**261**), Isoregecoline (**262**) (85M11) as well as the dimeric protoberberine alkaloid Bisjathrorrhizine dichloride (**263**) (*Jathrorrhiza palmata*) (72JCS(P1)327) have 2,3-dihydroisoquinoline rings. Whereas **261** and **262** were isolated as zwitterions, **263** was identified as a dichloride.

The 8-hydroxyisoquinoline moiety is present in the following alkaloids. Casadinium chloride (**264**) (9-desmethyldihydrocorydaline) gives a stable and characterizable betaine on treatment with sodium hydroxide (76TL1595) (Scheme 86). It was found in *Ceratocarpus*



Scheme 86




Scheme 87

heterocarpa. A bathochromic shift of the UV absorption maxima of the chloride of **264** is observable on addition of base (93P559).

The papaver alkaloid Narcotoline (**265**) can be converted into the yellow colored Cotarnoline (**267**) on hydrolysis which adopts a zwitterionic ground state (56MI1, 57MI1) (Scheme 87). The corresponding dihydro derivative was also identified in nature. The UV spectrum of the zwitterionic Tarkonine (**268**), which forms red crystals from acetone, is shifted bathochromically in comparison to the chloride. Tarkonine is a very weak base ($\text{p}K_{\text{b}} = 9.58$), which is well in accord with the formation of an inner salt, and Cotarnoline (**267**) is a stronger base than Tarkonine (**268**) ($\text{p}K_{\text{b}} = 9.15$). The $\text{p}K_{\text{s}}$ values are larger than 13 (66MI3). The methylated derivative of Narcotoline is Narcotine (**266**).

B. 1,2-DIHYDROINDAZOL-4-ONE

The indazole alkaloid Nigellidine (**269**) (Scheme 88) which was described as a zwitterion, was detected in the seeds of *Nigella sativa* L. (Ranunculaceae) (95TL1993), which is an erect annual plant found in South Asia and is widely cultivated. The seeds are commonly believed to have carminative, stimulatory and diaphoretic properties (75PHA2759). An X-ray single crystal analysis was performed on the methyl chloride. It is




269

Scheme 88


structurally related to Nigellidine (234) (cf. Scheme 77) which is a pseudo-cross-conjugated mesomeric betaine.

C. PHENAZIN-1-ONES (PYOCYANINES)

Pyocyanine (275) (cyanomycine, 5-methylphenazinium-1-olate), known for decades, is a dark-blue pigment with antibiotic activity (94MI1) which was isolated in 1972 from *Pseudomonas aeruginosa* (72JCS(P1)622), *Streptomyces cyanoflavus*, and *Bacillus pyocyaneus* (Scheme 89). It is structurally related to the heteroaromatic N-oxides Aeruginosine A (254) and Iodinine (177) (cf. Sections II.B.3 and II.B.6, respectively). Photo-oxidation of the quaternary salt 271 in hydrochloric acid gave Pyocyanine (275) in low yield together with 9-hydroxy- and 6-hydroxyphenazine-1-carboxylic acid and other by-products. This finding suggests a mechanism



Scheme 89



Scheme 90


via the formation of a 1,4-endoperoxide with singlet oxygen (70TL4101). It has been shown that 1-hydroxyphenazine is not precursor of Pyocyanine (59MI1). Tracer experiments, however, have shown that phenazine-1-carboxylic acid and its 5-methyl betaine are incorporated into pyocyanine by *Ps. aeruginosa* by decarboxylative hydroxylation (72JCS(P1)622).

D. PHENANTHRIDIN-1-ONE

Oxidation of Pluviine (276), isolated from *Narcissus pseudonarcissus*, *Narcissus incomparabilis*, and *Lycoris radiata* Herb., with benzophenone and potassium *tert*-butoxide yielded a red phenol-betaine 277 from which one neutral covalent form can be drawn (Scheme 90). The betaine has absorption maxima λ_{\max} (log ϵ) in a buffer at pH 10 at 240 (4.49), 325 (4.46), 360 (3.58), 380 (3.27), and 490 (3.26) nm. In dilute HCl, a salt is formed [λ_{\max} = 260 (4.57), 295 (4.39), 340 (3.76), 355 (3.84), 400 (3.62) nm] (57CB363). The oxidation of the alkaloid Caranine gives a similar betaine, the 1,3-dioxolo derivative 278 (56CIL348).

E. INDOLE DERIVATIVES


More than 1500 indole alkaloids are known today, among them β -carbolines and indolo[2,3-*a*]quinolizines which form by far the largest collection of interesting zwitterionic species in nature (88MI1). An excellent review dealing with this class of compounds appeared in 1988 so that only some representative results of the last two decades are mentioned here. The β -carboline ring is composed of a π -deficient pyridine ring fused to a π -excessive indole moiety. 1-Methyl-9*H*-pyrido[3,4-*b*]indole (235) (Harman, Passiflorine, Aribine, Loturine) is the structural element of numerous alkaloids from *Passiflora incarnata* and other Passifloraceae and Rubiaceae (Scheme 91). The formation of zwitterionic species in the β -carboline series on treatment of the quarternary pyridinium salts with bases is well-documented. On deprotonation, a characteristic shift of the UV



Scheme 91

absorption maxima to longer wavelengths is observed (68JOC3985). Thus, the *N*-methylated Harman (279), a cationic species, has UV absorption maxima in aqueous solution at $\lambda_{\max} = 248$ (4.40), 303 (4.17), and 366 (3.35) nm and a fluorescence emission at $\lambda_{\max} = 437$ nm. The zwitterionic form 280—called Melinonine F (83MI4, 86MI2, 85MI2) and isolated from the stem bark of *Strychnos mellodora* S. MOORE (99P1171)—has UV absorption maxima at $\lambda_{\max} = 272$ (4.20), 321 (3.82), and 357 (3.25) and a fluorescence emission maximum at $\lambda_{\max} = 511$ nm (93JCS(P2)99). Dihydroharmalol (281) (4,9-dihydro-1-methyl-3H-pyrido[3,4-*b*]indol-7-ol) is a fluorescent alkaloid which is of considerable pharmacological interest as a hallucinogen. According to UV measurements, it exists at pH 10.2 as a mixture of the neutral ($\lambda_{\max} = 340$ nm) and the zwitterionic forms ($\lambda_{\max} = 431$ nm), and it is likely that the anionic and cationic species are also present. Obviously, the bathochromic shift is characteristic for the betainic form. From the fluorescence spectra it can be concluded that the zwitterionic species with the absorption maximum λ_{\max} at 530 nm is present in the pH range between 6 and 12. No fluorescence of the neutral form of harmalol was detected in aqueous solutions. From the pK_a data it was concluded that the hydroxy group of harmalol is more acidic and the pyridine nitrogen atom is more basic in the excited singlet state S_1 in comparison to the ground states (84MI3, 61BCJ533). Normelinonine F (282) (83MI2) (2-methylnorharman-hydrochloride) was also identified in plants. Recently, the brominated alkaloids 2-Methyleudistomin D and J were isolated from *Eudistoma gilboverde* (01JNP1454). They represent the simplest structures of this class of alkaloids.


Scheme 92 proves that the β -carboline moiety is widespread in nature. Thus, 3,4,5,6-Tetrahydro-18,19-dihydrocorynantheol (283), 10-(Methoxy-3,4,5,6-tetrahydro-18,19-dihydrocorynantheol (284), the initially postulated structure 3,4,5,6-Tetrahydrochroproposine (285) (cf. Scheme 96),




Scheme 92

10-Methoxy-3,4,5,6-tetradehydrocorynantheol (**286**), 3,4,5,6,18,19-Hexadehydroochroposinine (**287**), 3,4,5,6-Tetradehydrositsirikine (**288**), Alstonine (**289**), the no-name-alkaloid (**290**) (*Mitragna speciosa*) ([98T8433](#)), 3,4,5,6-Tetradehydropalicoside (**291**) and its methylester which were isolated recently from *Strychnos mellodora* ([99P1171](#)), Serpentine (**292**), and Serpentinine (**293**) are known representatives of this class of alkaloids.

This ring system is also contained in Serpenticine (**294**), Schoberidine (**295**), and Ophiorine (**296**) ([Scheme 93](#)). Picrasidine F (**297**) was identified as a hydrochloride in *Picrasma quassioides* and its structure was elucidated by an X-ray structure analysis ([86CPB3228](#)). Bleekerine (**298**) is an additional example. 3',4',5',6'-Tetradehydro-longicaudatine (**299**) was identified in 1998 in *Strychnos usambarensis* collected from the Ivory Coast. The roots are the main ingredients of African arrow poisons. The absorption maxima were found at $\lambda_{\max} = 204, 255, 308,$ and 367 nm in acidic as well as neutral solutions, thus suggesting a β -carbolinium chromophore. A bathochromic shift was observed on deprotonation, due to the formation of a zwitterionic species ([98P1263](#)).




Scheme 93



Scheme 94

3,4,5,6-Tetrahydromitragynine (**302**) (Scheme 94) was extracted from the tropical plant *Mitragyna speciosa* (Rubiaceae), found in Thailand and the Malay Peninsula. The leaves are traditionally used as a stimulant, which is illegal now due to the narcotism of the plant. For structure and absolute stereochemistry elucidation the orange alkaloid was semisynthetically prepared from Mitragynine (**300**), which was treated with *t*-butylhypochlorite in the presence of triethylamine to give **301**. Ethanolic HCl and DDQ for aromatization converted **301** into the alkaloid **302** (98T8433).

The β -carboline alkaloid Chrysotricine (**306**) was identified in the Rubiacea species *Hedyotis chrysotricha* and proved to inhibit the growth of HL-60 cells *in vitro* (97P1119). The form **306A** was established by an X-ray single crystal analysis and the CDCl_3 NMR spectra are consistent with this structure (Scheme 95). However, the spectra taken in CD_3OD display additional CH groups at $\delta = 86.4$ and 3.78 ppm, respectively, which are




Scheme 95

in accord with the tautomeric structure **306B**. The racemate of this alkaloid and its diastereomer were prepared as outlined in [Scheme 95 \(00M383\)](#). Pictet–Spengler reaction of tryptamine (**303**) with **304** resulted in the formation of the tetrahydrocarboline **305** as mixture of four diastereoisomers. Dehydrogenation to the β -carboline, deacetylation with base, quaterization with dimethylsulfate and subsequent deprotonation with potassium hydroxide led to racemic Chrysotricine (**306**) and its diastereomer.

In 1983, a zwitterionic indolo[2,3-*a*]quinolizinium alkaloid was detected in the trunk bark of *Aspidosperma marcgravianum* Woodson. The assigned structure of 3,4,5,6-Tetradehydro-17-hydroxycorynanium (**285**) was deduced on the basis of spectroscopic methods and a semisynthetic sample prepared from corynan-17-ol ([83JNP694](#)) ([Scheme 96](#)). In 1993 a total synthesis was attempted. Selective reduction of the lactam ester **308** prepared from **307** gave a lactam alcohol, which was acylated to give **309**. Bischler–Napieralski cyclization followed by hydrolysis yielded a tetracyclic alcohol **310**, which was isolated as a perchlorate salt. Aromatization was accomplished using palladium black and maleic acid in boiling water. The anhydronium base **285** was finally obtained after treatment with sodium hydroxide. The NMR spectra of the reaction product and the alkaloid isolated from the natural source as well as the signs of the specific rotation, however, were not identical.


Total syntheses of racemic Melinonine E (**316**) and Strychnoxanthine (**317**) were performed using a radical cyclization process as the key step ([98JOC968](#)). Melinonine E was first isolated from the bark of *Strychnos melinoniana* in 1957 ([57HCA1167](#)), but structure elucidation was not carried




Scheme 96

out before 1984 (84HCA455). Strychnoxanthine was found in the bark of *Strychnos gossweileri* (84MI1). Reductive amination of the protected 1,4-cyclohexanedione with tryptamine yielded **311**, which was trichloroacetylated and hydrolyzed to give **312** (Scheme 97). For the purpose of the one carbon homologation the cyanohydrine was produced by treatment of **312** with trimethylsilyl cyanide and zinc iodide, followed by the hydrolysis of the intermediary O-silylcyanohydrine. Phosphorus oxychloride converted the cyanohydrine into the nitrile **313**. On treatment with tris(trimethylsilyl) silane (TTMSS) as the radical mediator cyclization to the 2-azabicyclo[3.3.1]nonane **314** took place. A sequence consisting of Bischler–Napieralski reaction and NaBH_4 reduction gave a 3-H β relative configuration and a trans C/D ring quinolizidine moiety. Epimerization of C-20 was partially accomplished by LDA and subsequent quenching with hydrochloric acid at -78°C . Reduction of the nitrile to the imine, hydrolysis to the aldehyde and reduction gave the common precursor **315**. The target compounds were finally obtained as shown in Scheme 97.

Mitrasulgynine (**318**) (*Mitragyna speciosa*) (98T8433) and 3,4,5,6-Tetradehydro- β -yohimbine (**319**) possess the 2,3-dihydro β -carboline moiety. The asymmetric bisindole alkaloid Strychnocrysine (**320**) was isolated as an orange solid from *Strychnos nux-vomica* (98JNP139). The UV spectrum is not modified in alkali and no NH of the indole ring is detectable by NMR spectroscopy. The closely related structures 5',6'-Dehydroguiaflavine and 5',6'-Dehydroguiachrysine were recently identified in *Strychnos guianensis* (01P619) (Scheme 98).




Scheme 97




Scheme 98

The parent skeleton of the alkaloids containing the indolo[2,3-*a*]quinolizinium ring system **321** was examined spectroscopically (Scheme 99). On conversion to the deprotonated form **322** in CD_3OD , all resonance frequencies shift to higher field and this tendency is particularly



Scheme 99




Scheme 100

remarkable for the C ring protons. An additional upfield shift is observed in $CD_3OD/NaOD$, whereas the reverse is the case for the solvent systems CD_3OD/D_2O and CD_3OD/DCl . The authors postulate an equilibrium between the uncharged and protonated forms in protic solvents (93T1879).

Indolopyridocoline (323), Flavopereirine (324) (Melinonine G), Flavocoryline (325), Flavocorynanthrone (326), and Sempervirine (327) are examples of this class of compounds (Scheme 100). Afrocurarine (328) was identified in *Strychnos usambarensis* (84MI2). Guianensine (329) (*Strychnos guianensis*) has a zwitterionic bis-indole structure with the negative and positive charges separated by interrupted conjugation. On treatment with alkali, a bathochromic shift of the UV absorption maxima is observable, suggesting an anhydronium moiety (95P1557).

The key step of an interesting synthesis of Sempervirine (327) is a triazine Diels–Alder annulation reaction with an enamine (88T3195). 1-(Phenylsulfonyl)indole 330 was converted to a ketone by a set of standard reactions followed by the selenium dioxide oxidation of the resulting acetyl group to the ketoaldehyde 332 (Scheme 101). Methylthiosemicarbazide hydroiodide reacted with 332 to the triazine 333 in 83% yield. As Diels–Alder reactions with 1-pyrrolidinocyclohexene failed, 333 was first oxidized




Scheme 101

to the corresponding sulfone triazine. Cycloaddition to the pyridine sulfone **334** was then accomplished in 45% yield for the two steps. Sodium amalgam under carefully controlled conditions caused a complete desulfonylation without reduction of the pyridine ring. Treatment of the sulfonylated species **335** with butyl lithium followed by quenching with bromoacetaldehyde provided the indoloquinolizinium bromide **336**, which on alkaline hydrolysis yielded the zwitterionic Sempervirine (**327**).


The iodocyclization of 1,4-dihydropyridines was used as the key step for the formal total synthesis of Sempervirine (**327**) as shown in [Scheme 102 \(99JOC2997\)](#).

Total syntheses of Flavopereirine (**324**) and 5,6-Dihydroflavopereirine (**346**) were performed as presented in [Scheme 103 \(96H1365\)](#). Palladium-catalyzed reaction of iodoaniline **340** with propargyl methyl ether gave alkyne **341**, which was subsequently hydrated to ketone **342** by slowly adding it to refluxing methanol containing catalytic amounts of mercuric sulfate. Acylation, low-valent titanium mediated indole formation with titanium graphite gave **345**. Bromination was accomplished by boron tribromide. Cyclization yielded 5,6-dihydroflavopereirine (**346**), which was finally aromatized with DDQ to give Flavopereirine (**324**). The perchlorate was finally converted into the free base ([95T773](#)).

An interesting observation has been described in [Section II.C.3 \(Scheme 70\)](#). 7,12-Dihydro-2-methyl-6*H*-indolo[2,3-*a*]quinolizinium chloride (**214**) can be deprotonated to give the orange-yellow zwitterion **215** or the vinylog amide **216** depending on the substitution pattern ([Scheme 104](#)).




Scheme 102




Scheme 103

Oxidation yields the cross-conjugated mesomeric betaine **217**, but no zwitterionic species, which would result by deprotonation of the indole NH group (88LA1111). The corresponding 5,6-unsaturated indole, however, gave the zwitterion. The same publication describes a total synthesis of Flavoserpentine.




Scheme 104




Scheme 105

The yellow colored, sparsely soluble 5-ethyl-2-methyl-11*H*-pyrido[3,4-*a*]carbazolium **347** isolated from *Aspidosperma gilbertii* exists as a hydroxide after filtration of the corresponding iodide over basic aluminum oxide. A short synthesis was described (80CB3245). The Pyrido[3,4-*a*]carbazole ring system is present in the alkaloid AG-1, whereas Cryptolepine (**348**) possesses the indolo[3,2-*b*]quinoline moiety (65MI1).

A heteroaromatic pentacycle is found in Fascaplysin (**353**) (Scheme 105). This bis-indole alkaloid is an antimicrobial and cytotoxic red pigment from the Fijian sponge *Fascaplysinopsis Bergquist* sp. It inhibits the growth of microbes and displays activity against mouse leukemia *in vitro*. A broad exchangeable resonance frequency at $\delta = 11.5$ ppm suggested the existence of an N-H functionality. In the X-ray single crystal analysis, the chloride is in close contact (210 pm) to the N-H group (88JOC3276). At least three total syntheses were performed. Suzuki's Palladium-catalyzed cross-coupling of **349** with 3-fluoro-4-iodopyridine followed by regioselective metalation of the resulting **350** and treatment of the lithio derivative with 2-fluorobenzaldehyde gave the trisubstituted pyridine **351**. Oxidation and subsequent cyclization with pyridinium chloride at



Scheme 106




Scheme 107

170°C gave the dark red alkaloid **353** as chloride ([93TL7917](#)). The overall yield is 76%.


Another total synthesis used the rich chemistry of iminophosphoranes ([95AHC159](#)). The β -(3-indolyl)vinyl iminophosphorane **354** underwent an aza-Wittig/electrocyclic ring closure reaction to give the carboline **355** which was hydrolyzed with lithium hydroxide ([Scheme 106](#)). A selective reduction, deprotection, decarboxylation and diazotation followed by ring closure gave Fascaplysine (**353**) ([94TL8851](#)).

Another synthesis of Fascaplysine was reported by Gribble ([90TL2381](#)) and is presented in [Scheme 107](#). The diindole **357** was available starting from indole **356**, which was first converted into 3-indolylglyoxylyl chloride. Reaction with 1-indolylsodium followed by a reduction of the resulting keto amide gave **357**. Trifluoroacetic acid at room temperature gave the cyclized products **358** and **359** in a 10:1 ratio, which were oxidized without separation to give the fully aromatic pentacycle. Final oxidation yielded Fascaplysine (**353**).


The indoloquinolizidine alkaloid Villagorgin B (**360**) was isolated from the Gorgonian *Villagorgia rubra* collected in New Caledonia ([Scheme 108](#)). The positive charge of the molecule was deduced from the chemical shifts of the C-6 and C-5 ethylene bridge. However, only one NH group was detectable in ¹H NMR in DMSO-*d*₆ ([93TL7773](#)). Additional heteroaromatic




360




361




362



363




364




365

Scheme 108




366

Al-isopropoxide,
cyclohexanone



367




368

Scheme 109

pentacyclic systems are in 6,12-dihydroindolo[2,3-*a*]quinolizines present in Alstoniline (**361**) and Orouparine (**362**) from which Euxylophorine A (**363**) (68TL4865, 83MI5) has an additional keto group. The interesting molecule Polyervinine (**364**) was detected in *Ervatamia polyneura* (95P953). It possesses a quinoniminium chromophore (**365**), which was confirmed by a spectroscopic comparison with the dark red pigment adrenochrome.

F. BENZO[*c*]PHENANTHRIDINONES

Hydroxysanguinarinebetaine (**367**) is formed on Oppenauer oxidation of Chelidonine (**366**) as a red compound (65MI2) (Scheme 109). Deprotonation of the benzo[*c*]phenanthridine alkaloid Fagaronine (93T10305), which is known to inhibit various reverse transcriptases (77MI1), resulted in the

**369****Scheme 110**

formation of a molecule **368** from which neutral as well as zwitterionic canonical formulae can be drawn. A total synthesis of Fagaronine has been described ([02TL5323](#)).

G. DIBENZO[*de,g*]QUINOLINE-5,7-DIONE

Pontevodrine (**369**) is a red compound from Papaveraceae ([71TL3093](#)). The UV–VIS absorption maxima λ_{\max} in ethanol were found at 245 (4.59), 312 (4.28), 325 (4.39), and 470 (4.01) nm. On addition of acid or alkali no changes were observable. A zwitterionic structure was proposed on the basis of the NMR data ([Scheme 110](#)).

IV. Conclusions

This review, which cannot be comprehensive because the reports describing these interesting classes of natural products are scattered throughout the literature, demonstrates that conjugated heterocyclic mesomeric betaines (CMB) including their subdivision of N-ylides form by far the largest group of mesomeric betaines in nature. Most of the betainic alkaloids and nucleobases described here are isoconjugate with odd alternant hydrocarbon anions and are therefore members of the classes 1 (CMB), 5 (N-ylides), 9 (CCMB), and 13 (PCCMB), respectively. The classes 4, 7, and 16 are also relatively populated whereas representatives of some classes seemingly have not yet been isolated from natural materials. It is interesting to note that mesomeric betaines of class 1 and 4 (which include mesoions such as sydnones and münchnones) are well-known in heterocyclic chemistry and numerous compounds have been synthesized to date. The same is true for the class of N-ylides. Cross-conjugated mesomeric betaines, which belong to the classes 9 and 12, are extremely rare in synthetic

heterocyclic chemistry. It is astonishing, therefore, that the former mentioned class obviously occurs relatively often in nature. Little information about pseudo-cross-conjugated heterocyclic mesomeric betaines has been collected to date. In comparison to their synthetic analogs, they were relatively frequently isolated from natural materials. No representatives of PCCMB belonging to class 16 were known when the classification of heterocyclic mesomeric betaines was published in 1985 (85T2239). This review presents six alkaloids (234, 237, 244, 251, 252, 253), which belong to that class.

Acknowledgments

This work is dedicated to Prof. Heinrich Wamhoff who initiated my interest in heterocyclic chemistry. My former and current coworkers and students Thorsten Mordhorst, Tobias Habeck, Abbas Gholipour Shilabin, Lars Merkel, Wibke Dempwolf, Nikoloz Kobakhidze, Dr. Dirk Albrecht, and scientific partners Markus Rugen, Dr. Markus Karl Kindermann, Dr. Martin Nieger, and Prof. Pirjo Vainiotalo is gratefully acknowledged for their encouraged experimental, theoretical, or spectroscopic work in the field of heterocyclic mesomeric betaines, alkaloids, modified nucleobases, and zwitterions. The Deutsche Forschungsgemeinschaft DFG and the Fonds der Chemischen Industrie FCI is gratefully acknowledged for their financial support.

REFERENCES

- | | |
|------------|---|
| 1882LA316 | E. Fischer and E. Besthorn, <i>Ann.</i> , 212 , 316 (1882). |
| 1885CB2521 | E. Jahns, <i>Chem. Ber.</i> , 18 , 2518 (1885). |
| 1886CB32 | A. Hantzsch, <i>Chem. Ber.</i> , 19 , 32 (1886). |
| 1887CB2840 | E. Jahns, <i>Chem. Ber.</i> , 20 , 2840 (1887). |
| 1887MI | E. Jahns, <i>Arch. Pharm.</i> , 225 , 992 (1887). |
| 1891JPR522 | A. Claus and H. Howitz, <i>J. Prakt. Chem.</i> , 43 , 522 (1891). |
| 1891ZPC145 | E. Schulze, <i>Hoppe-Seyler's Z. Physiol. Chem.</i> , 15 , 145 (1891). |
| 1894CB769 | E. Schulze, <i>Frankfurt Chem. Ber.</i> , 27 , 769 (1894). |
| 1897CB2117 | A. Pictet and P. Genequand, <i>Chem. Ber.</i> , 30 , 2117 (1897). |
| 1898MI | A. Pictet and G. Sussdorf, <i>Chem. Zentralbl. GE</i> , 69 (I), 677 (1898). |
| 1900M913 | H. Meyer, <i>Monatsh. Chem.</i> , 21 , 913 (1900). |
| 1901G256 | G. Ortoleva and G. di Stefano, <i>Gazz. Chim. Ital.</i> , 31 (II), 256 (1901). |
| 1901M361 | A. Kirpal, <i>Monatsh. Chem.</i> , 22 , 361 (1901). |
| 1903M195 | H. Meyer, <i>Monatsh. Chem.</i> , 24 , 195 (1903). |
| 04MI | E. Schulze, <i>L. V. St.</i> , 59 , 340 (1904). |
| 05M537 | R. Turnau, <i>Monatsh. Chem.</i> , 26 , 537 (1905). |
| 09ZPC174 | E. Schulze, <i>Hoppe-Seyler's Z. Physiol. Chem.</i> , 60 , 174 (1909). |

- 10LA242 K. Gorter, *Justus Liebigs Ann. Chem.*, **372**, 237 (1910).
11JCS1690 J. Pyman, *J. Chem. Soc.*, **99**, 1690 (1911).
12MI D. Ackermann, *Z. Biol.*, **59**, 17 (1912).
24MI F. Holtz, F. Kutscher, and F. Thielmann, *Z. Biol.*, **81**, 57 (1924).
25JCS1604 J. W. Armit and R. Robinson, *J. Chem. Soc.*, **127**, 1604 (1925).
26JB163 Y. Komori and Y. Sendju, *J. Biochem.*, **6**, 163 (1926).
30BCJ348 Z. Kitasato, C. Sone, and H. Shishido, *Bull. Chem. Soc. Jpn.*, **5**, 348 (1930).
30MI H. Thoms and C. Dambergis, *Arch. Pharm.*, **268**, 39 (1930).
31CB1045 E. Koenigs and H. Greiner, *Chem. Ber.*, **64**, 1045 (1931).
31JPC11 A. Heiduschka and R. Brüchner, *J. Prakt. Chem.*, **130**, 11 (1931).
33ZPC33 F. Kutscher and D. Ackermann, *Z. Physiol. Chem.*, **221**, 33 (1933).
33ZPC45 F. A. Hoppe-Seyler, *Z. Physiol. Chem.*, **221**, 45 (1933).
33ZPC105 F. A. Hoppe-Seyler, *Z. Physiol. Chem.*, **222**, 105 (1933).
37CB2339 E. Buchta, *Chem. Ber.*, **70**, 2339 (1937).
37LA51 O. Diels and R. Kassebart, *Liebigs Ann. Chem.*, **530**, 51 (1937).
37JCS1724 P. Dyson and D. L. Hammick, *J. Chem. Soc.*, 1724 (1937).
38JCS824 A. Schönberg, *J. Chem. Soc.*, 910 (1938).
39CA6383 J. G. Davies, *Zentr. Bakteriolog. Parasitenk.*, Abt. II, **100**, 273 (1939) [*CA* **33**, 6383 (1939)].
42JBC357 P. Handler and W. J. Dean, *J. Biol. Chem.*, **146**, 357 (1942).
42JOC389 W. S. Knowles and R. C. Elderfield, *J. Org. Chem.*, **7**, 389 (1942).
43MI1 E. C. White and H. H. Hill, *J. Bacteriol.*, **45**, 433 (1943).
43MI2 G. T. Menzel, O. Wintersteiner, and G. Rake, *J. Bacteriol.*, **46**, 109 (1943).
44CB362 E. Späth and G. Bobenberger, *Chem. Ber.*, **77**, 362 (1944).
44JBC359 J. D. Dutcher and O. Wintersteiner, *J. Biol. Chem.*, **155**, 359 (1944).
44MI1 T. O. Soine and O. Gisvold, *J. Am. Pharm. Assoc. Sci. Ed.*, **33**, 185 (1944).
46JCS591 R. A. Eade and J. C. Earl, *J. Chem. Soc.*, 591 (1946).
47JBC321 J. D. Dutcher, *J. Biol. Chem.*, **171**, 321 (1947).
49JCS(S)126 G. Dunn, J. J. Gallagher, G. T. Newbold, and F. S. Spring, *J. Chem. Soc.*, (Supplement) 126 (1949).
49JCS127 G. Dunn, J. J. Gallagher, G. T. Newbold, and F. S. Spring, *J. Chem. Soc.*, 127 (1949).
49JCS307 W. Baker, W. D. Ollis, and V. D. Poole, *J. Chem. Soc.*, 307 (1949).
51JCS2679 G. T. Newbold, W. Sharp, and F. S. Spring, *J. Chem. Soc.*, 2679 (1951).
53CRV191 H. H. Jaffé, *Chem. Rev.*, **53**, 191 (1953).
53JA3361 B. Witkop, *J. Am. Chem. Soc.*, **75**, 3361 (1953).
55CIL521 A. R. Katritzky, *Chem. Ind.*, 521 (1955).
55CIL910 W. Baker and W. D. Ollis, *Chem. Ind. (London)*, 910 (1955).
55CJC405 E. Leete, L. Marion, and I. D. Spenser, *Can. J. Chem.*, **33**, 405 (1955).
55JA2431 D. E. Metzler and E. E. Snell, *J. Amer. Chem. Soc.*, **77**, 2431 (1955).
55JA5885 H. M. Fales, E. W. Warnhoff, and W. C. Wildman, *J. Am. Chem. Soc.*, **77**, 5885 (1955).
55JPC670 M. L. Black, *J. Phys. Chem.*, **59**, 670 (1955).
56CIL348 E. W. Warnhoff and W. C. Wildman, *Chem. Ind.*, 348 (1956).
56JA2537 E. M. Kosower and J. C. Burbach, *J. Am. Chem. Soc.*, **65**, 2537 (1956).

- 56JA4145 H. M. Fales, L. D. Giuffrida, and W. C. Wildman, *J. Am. Chem. Soc.*, **78**, 4145 (1956).
- 56JA4151 H. M. Fales and W. C. Wildman, *J. Am. Chem. Soc.*, **78**, 4151 (1956).
- 56JA4896 R. W. Green and H. K. Tong, *J. Am. Chem. Soc.*, **78**, 4896 (1956).
- 56JCS1294 A. Albert and J. N. Phillips, *Chem. Soc.*, 1294 (1956).
- 56JCS4133 A. H. Cook and C. A. Slater, *J. Chem. Soc.*, 4133 (1956).
- 56MI1 S. Pfeiffer and F. Weiß, *Arch. Pharm.*, **289**, 24 (1956).
- 57CB363 H.-G. Boit, H. Ehmke, S. Uyeo, and H. Yajima, *Chem. Ber.*, **90**, 363 (1957).
- 57CIL633 P. D. Lawley and C. A. Wallick, *Chem. Ind.*, 633 (1957).
- 57HCA1167 E. Bächli, C. Vamvacas, H. Schmid, and P. Karrer, *Helv. Chim. Acta*, **40**, 1167 (1957).
- 57JA4246 J. Preiss and P. Handler, *J. Am. Chem. Soc.*, **79**, 4246 (1957).
- 57JCS5010 S. F. Mason, *J. Chem. Soc.*, 5010 (1957).
- 57MI1 S. Pfeifer, *Arch. Pharm.*, **290**, 261 (1957).
- 58AG80 D. Ackermann, *Angew. Chem.*, **70**, 80 (1958).
- 58JBC785 J. D. Dutcher, *J. Biol. Chem.*, **232**, 785 (1958).
- 58JCS674 S. F. Mason, *J. Chem. Soc.*, 674 (1958).
- 58JOC420 D. H. McDaniel and H. C. Brown, *J. Org. Chem.*, **23**, 420 (1958).
- 58MI1 A. Resplandy, *C.R. Acad. Sci., Ser. C*, **247**, 2nd Sem., 2428 (1958).
- 58MI2 U. Weiss, F. Strelitz, H. Flon, and I.N. Asheshov, *Arch. Biochem. Biophys.*, **74**, 150 (1958) [*CA* **52**, 9311 (1958)].
- 58MI3 J. H. Welsh and P. B. Prock, *Biol. Bull.*, **114**, 551 (1958).
- 59CB566 H. Brederick, G. Kupsch, and H. Wieland, *Ber.*, **92**, 566 (1959).
- 59CJC1043 A. V. Robertson and L. Marion, *Can. J. Chem.*, **37**, 1043 (1959).
- 59JBC889 H. G. Windmueller, C. J. Ackerman, H. A. Bakerman, and O. Mickelsen, *J. Biol. Chem.*, **234**, 889 (1959).
- 59JBC93 R. U. Byerrum, et al., *J. Biol. Chem.*, **234**, 93 (1959).
- 59JCS1247 S. F. Mason, *J. Chem. Soc.*, 1247 (1959).
- 59MI1 L. H. Frank and R. D. DeMoss, *J. Bacteriol.*, **77**, 776 (1959).
- 59MI2 S. Grzymala, *Mykol. Mitteilungsblatt*, **3**, 1 (1959).
- 60BJ478 P. Brookes and P. D. Lawley, *Biochem. J.*, **77**, 478 (1960).
- 60JA1145 C. K. Bradsher and N. L. Dutta, *J. Am. Chem. Soc.*, **82**, 1145 (1960).
- 60JBC2981 J. G. Joshi and P. Handler, *J. Biol. Chem.*, **235**, 2981 (1960).
- 60MI1 A. Carruthers, J. F. T. Oldfield, and H. J. Teague, *Analyst (London)*, **85**, 272 (1960).
- 60MI2 E. L. Gasteiger, P. C. Haake, and J. A. Gergen, *Ann. N.Y. Acad. Sci.*, **90**, 622 (1960).
- 60ZPC212 D. Ackermann and H. G. Menssen, *Hoppe-Seyler's Z. Physiol. Chem.*, **318**, 212 (1960).
- 61BBA198 D. B. Dunn, *Biochim. Biophys. Acta*, **46**, 198 (1961).
- 61BCJ533 K. Nakanishi, M. Ohashi, S. Kumasaki, and H. Koike, *Bull. Chem. Soc. Jpn.*, **34**, 533 (1961).
- 61JOC1318 E. M. Kosower and J. W. Patton, *J. Org. Chem.*, **26**, 1318 (1961).
- 61JOC2231 C. K. Bradsher and N. L. Dutta, *J. Org. Chem.*, **26**, 2231 (1961).
- 61LA167 W. Pfeleiderer, *Liebigs Ann. Chem.*, **647**, 167 (1961).
- 61MI1 S. Nakamura, *Agr. Biol. Chem. (Tokyo)*, **25**, 74 and 658 (1961).
- 61MI2 R. B. Herbert and F. G. Holliman, *South African Ind. Chem.*, **15**, 233 (1961).

- 61ZPC197 D. Ackermann and R. Pant, *Hoppe-Seyler's Z. Physiol. Chem.*, **326**, 197 (1961).
- 62JA3393 G. Büchi, R. E. Manning, and F. A. Hochstein, *J. Am. Chem. Soc.*, **84**, 3393 (1962).
- 62JCS5281 J. A. Haines, C. B. Reese, and L. Todd, *J. Chem. Soc.*, 5281 (1962).
- 62JOC2213 C. K. Bradsher and N. L. Dutta, *J. Org. Chem.*, **27**, 2213 (1962).
- 62M941 H. Gries, *Monatsh. Chem.*, **93**, 941 (1962).
- 62MI1 E. M. Kosower, in "An Introduction to Physical Organic Chemistry", Wiley, New York (1962).
- 63AHC353 A. R. Katritzky and J. M. Lagowski, *Adv. Heterocycl. Chem.*, **1**, 353 (1963).
- 64AG185 R. Huisgen, H. Gotthardt, H. O. Bayer, and F. C. Schäfer, *Angew. Chem.*, **76**, 185 (1964); *Angew. Chem. Int. Ed. Engl.*, **3**, 136 (1964).
- 64CPB749 Y. Inubishi, Y. Tsuda, T. Konita, and S. Matsumoto, *Chem. Pharm. Bull.*, **12**, 749 (1964).
- 64CRV129 F. H. C. Stewart, *Chem. Rev.*, **64**, 129 (1964).
- 64JCS1507 R. G. Micetich and J. C. MacDonald, *J. Chem. Soc.*, 1507 (1964).
- 64JCS3225 R. M. Acheson and D. M. Goodall, *J. Chem. Soc.*, 3225 (1964).
- 65CB2566 C. Schöpf and M. Schweickert, *Chem. Ber.*, **98**, 2566 (1965).
- 65MI1 M. Normatov, K. A. Abduazimiv, and S. Y. Yunusov, *Uzb. Khim. Zh.*, **9**, **25** (1965) [*CA* **63**, 7061 (1965)].
- 65MI2 E. Seoane, *Anales Real Soc. Espan. Fis. Quim., Ser. B*, **61**, 755 (1965) [*CA* **63**, 16,395 (1965)].
- 65MI3 J. E. Saxton, in "The Alkaloids" (R. H. F. Manske, ed.), Vol. VIII, pp. 19–21, Academic Press, New York, NY (1965).
- 65MI4 T. Onaka, *Yakugaku Zasshi*, **85**, 839 (1965) [*CA* **63**, 18,183 (1965)].
- 65TL3595 M. Shamma, M. A. Greenberg, and B. S. Dudock, *Tetrahedron Lett.*, **40**, 3595 (1965).
- 65TL3825 M. Shamma and B. S. Dudock, *Tetrahedron Lett.*, **43**, 3825 (1965).
- 66BBA459 T. Sakurai and H. Hosoya, *Biochim. Biophys. Acta*, **112**, 459 (1966).
- 66JPJ534 J. Isawa and S. Naruto, *J. Pharm. Soc. Jpn.*, **86**, 534 (1966).
- 66MI1 A. W. Johnson, in "Ylid Chemistry", Academic Press, New York (1966).
- 66MI2 V. Preininger and F. Santavý, *Acta Univ. Olomuc., Fac. Med.*, **43**, 5 (1966) [*CA* **67**, 54,290 (1967)].
- 66MI3 B. Göber and S. Pfeifer, *Arch. Pharm.*, **299**, 196 (1966).
- 66TL1177 F. R. Stermitz and J. N. Seiber, *Tetrahedron Lett.*, **11**, 1177 (1966).
- 67JOC3253 R. W. Doskotch, M. Y. Malik, and J. L. Beal, *J. Org. Chem.*, **32**, 3253 (1967).
- 67MI1 J. R. Bears, *Comp. Biochem. Physiol.*, **21**, 11 (1967).
- 67MI2 E. Ochiai, in "Aromatic Amine Oxides", Elsevier, Amsterdam (1967).
- 67MI3 T. Okano, S. Goya, and T. Kaizu, *Yakugaku Zasshi*, **87**, 469 (1967) [*CA* **67**, 73,582 (1967)].
- 67SC1443 J. B. Niellands, *Science*, **156**, 1443 (1967).
- 67T3129 L. Merlini, R. Mondelli, G. Nasini, and M. Hesse, *Tetrahedron*, **23**, 3129 (1967).
- 67TL715 M. Weigle, and W. Leimgruber, *Tetrahedron Lett.*, **8**, 715 (1967).
- 68BBA63 L. A. Isaksson and J. H. Phillipps, *Biochim. Biophys. Acta*, **115**, 63 (1968).
- 68CPB549 Y. Ban and T. Kimura, *Chem. Pharm. Bull. Japan*, **16**, 549 (1968).

- 68CPB1014 Y. Inubushi, Y. Tsuda, T. Konita, and S. Matsumoto, *Chem. Pharm. Bull. Tokyo*, **16**, 1014 (1968).
- 68HCA683 H. H. A. Linde and M. S. Ragab, *Helv. Chim. Acta*, **51**, 683 (1968).
- 68JOC3985 K. T. Potts and G. S. Mattingly, *J. Org. Chem.*, **33**, 3985 (1968).
- 68MI1 G. B. Brown, *Progr. Nucleic Acid Res. Mol. Biol.*, **8**, 209 (1968).
- 68TL4865 L. Canonica, B. Danieli, P. Manitto, G. Russo, and G. Ferrari, *Tetrahedron Lett.*, 4865 (1968).
- 69JCS(C)2514 F. G. Holliman, *J. Chem. Soc. (C)*, 2514 (1969).
- 69JCS(CC)1240 Y. Kushi and Q. Fernando, *Chem. Commun.*, 1240 (1969).
- 69JCS(CC)1356 R. S. Ramakrishna and H.M.N.H. Irving, *Chem. Commun.*, 1356 (1969).
- 69MI1 R. W. Doskotch, P. L. Schiff, and J. L. Beal, *Lloydia*, **32**, 29 (1969).
- 69MI2 V. Preininger, J. Hrbek, Jr., Z. Samek, and F. Santavy, *Arch. Pharm.*, **302**(11), 808 (1969).
- 69MI3 M. J. S. Dewar, in "The Molecular Orbital Theory of Organic Chemistry", McGraw-Hill, New York (1969).
- 69NAT1365 A. G. Saponara and M. D. Enger, *Nature*, **223**, 1365 (1969).
- 70CB2581 H. O. Bayer, R. Huisgen, R. Knorr, and F. C. Schäfer, *Chem. Ber.*, **103**, 2581 (1970).
- 70JA1965 Y. Kushi and Q. Fernando, *J. Am. Chem. Soc.*, **92**, 1970 (1965).
- 70JCS(CC)1601 M. P. Cava, M. J. Mitchell, and D. T. Hill, *J. Chem. Soc., Chem. Commun.*, 1601 (1970).
- 70LA43 H. Quast and E. Schmitt, *Liebigs Ann. Chem.*, **732**, 43 (1970).
- 70LA64 H. Quast and E. Schmitt, *Justus Liebigs Ann. Chem.*, **732**, 64 (1970).
- 70MI1 K. Allayarov, A. Abdusamatov, and S. Y. Yunusov, *Khim. Prir. Soedin.*, **6**, 143 (1970) [*CA* **73**, 6971 (1970)].
- 70MI2 Z. B. Kiro and B. Stepanov, *Tr. Mosk. Khim.-Tekhnol. Inst.*, **66**, 154 (1970) [*CA* **75**, 88,453 (1975)].
- 70P429 S. Ghosal, *Phytochemistry*, **9**, 429 (1970).
- 70TL4101 M. E. Flood, R. B. Herbert, and F. G. Holliman, *Tetrahedron Lett.*, **47**, 4101 (1970).
- 71ACSA721 M. Elander, L. Gawell, and K. Lander, *Acta Chem. Scand.*, **25**, 721 (1971).
- 71HCA229 F. W. Wehrli, W. Giger, and W. Simon, *Helv. Chim. Acta*, **54**, 229 (1971).
- 71MI1 R. G. Chavarria, *An. Assoc. Quim. Argent.*, **59**, 371 (1971) [*CA* **77**, 58,771 (1972)].
- 71MI2 A. R. Katritzky and J. M. Lagowski, in "The Chemistry of Heterocyclic N-Oxides", Academic Press, New York (1971).
- 71P195 S. Ghosal and S. K. Dutta, *Phytochemistry*, **10**, 195 (1971).
- 71P3312 S. Ghosal, R. S. Srivastava, P. K. Banerjee, and S. K. Dutta, *Phytochemistry*, **10**, 3312 (1971).
- 71TL3093 I. Ribas, J. Sueiras, and L. Castedo, *Tetrahedron Lett.*, **33**, 3093 (1971).
- 71TL3421 K. B. Birnbaum, A. Klásek, P. Sedmera, G. Snatzke, L. F. Johnson, and F. Santavy, *Tetrahedron Lett.*, 3421 (1971).
- 72JCS(P1)327 M. L. Carvalhas, *J. Chem. Soc., Perkin Trans. 1*, 327 (1972).
- 72JCS(P1)622 M. E. Flood, R. B. Herberts, and F. G. Holliman, *J. Chem. Soc., Perkin Trans. 1*, 622 (1972).
- 72JCS(P1)2054 N. Dennis, A. R. Katritzky, and Y. Takeuchi, *J. Chem. Soc., Perkin Trans. 1*, 2054 (1972).

- 72MI1 M. Shamma, in *"The Isoquinoline Alkaloids, Chemistry and Pharmacology"*, pp. 194–314, Academic Press, New York (1972).
- 72MI2 M. Shamma, in *"The Isoquinoline Alkaloids, Chemistry and Pharmacology"*, p. 245, Academic Press, New York (1972).
- 73JCS(CC)522 E. Leete and G. B. Bodem, *Chem. Commun.*, 522 (1973).
- 73JCS(CC)915 S. M. Kupchan and P. F. O'Brien, *J. Chem. Soc., Chem. Commun.*, 915 (1973).
- 73JMC1207 C. Hansch, A. Leo, S. H. Unger, K. H. Kim, D. Nikaitani, and E. J. Lien, *J. Med. Chem.*, **16**, 1207 (1973).
- 73MI1 H. R. Godavari and E. R. Waygood, *Can. J. Botany*, **48**, 2267 (1973).
- 73MI2 T. C. White, in *"Tree Flora of Malaya"*, Vol. II, p. 351, Longman (1973).
- 73OMR551 U. Vögeli and W. von Philipsborn, *Org. Mag. Res.*, **5**, 551 (1973).
- 73P2315 F. G. Torto, I. A. Mensah, and I. Baxter, *Phytochemistry*, **12**, 2315 (1973).
- 73T3135 A. J. Weinheimer, E. K. Metzner, and M. L. Mole, Jr., *Tetrahedron*, **29**, 3135 (1973).
- 73TL2795 B. Nalliah, R. H. F. Manske, R. Rodrigo, and D. B. MacLean, *Tetrahedron Lett.*, **29**, 2795 (1973).
- 73TL3617 I. Ribas, S. Sáa, and L. Castedo, *Tetrahedron Lett.*, 3617 (1973).
- 74E518 J. Kunitomo, M. Juichi, Y. Yoshikawa, and H. Chikamatsu, *Experientia*, **29**, 518 (1973).
- 74MI1 L. S. Evans and J. van't Hof, *Exp. Cell Res.*, **87**, 259 (1974).
- 74MI2 A. Klug, J. Ladner, and J. D. Robertus, *J. Mol. Biol.*, **89**, 511 (1974).
- 74MI3 J. Kunitomo, M. Juichi, Y. Yoshikawa, and H. Chikamatsu, *Yakugaku Zasshi*, **94**, 97 (1974) [*CA* **80**, 108,725 (1974)].
- 74TL983 H. Kohl, S. V. Bhat, J. R. Patell, N. M. Ghandi, J. Nazareth, P. V. Divekar, N. J. de Souza, H. G. Berscheid, and H.-W. Fehllhaber, *Tetrahedron Lett.*, **12**, 983 (1974).
- 74TL4201 R. H. Herbert, F. G. Holliman, and J. B. Sheridan, *Tetrahedron Lett.*, 4201 (1974).
- 75ACR139 M. P. Cava and M. V. Lakshmikantham, *Acc. Chem. Res.*, **8**, 139 (1978).
- 75IJC758 J. S. Aggarwal and R. P. Rastogi, *Indian J. Chem.*, **13**, 758 (1975).
- 75JOC644 P. W. Jeffs and J. D. Scharver, *J. Org. Chem.*, **40**, 644 (1975).
- 75MI1 T. Takemoto, N. Takagi, T. Nakajima, and K. Koike, *Yakugaku Zasshi*, **95**, 176 (1975) [*CA* **82**, 152,211 (1975)].
- 75MI2 M. J. S. Dewar and R. C. Dougherty, in *"The PMO Theory of Organic Chemistry"*, Plenum Press, New York (1975).
- 75PHA2759 T. S. El-Alfy, H. M. El-Fataty, and M. A. Toama, *Pharmazie*, **26**, 2759 (1975).
- 75T499 E. Breuer and S. Zbaida, *Tetrahedron*, **31**, 499 (1975).
- 76AHC1 W. D. Ollis and C. A. Ramsden, *Adv. Heterocycl. Chem.*, **19**, 1 (1976).
- 76CCC3654 S. Pavelka and J. Kovar, *Collect. Czech. Chem. Commun.*, **41**, 3654 (1976).
- 76CPB1532 T. Ohmoto, R. Tanaka, and T. Nikaido, *Chem. Pharm. Bull.*, **24**, 1532 (1976).
- 76H153 J. Imai and Y. Kondo, *Heterocycles*, **5**, 153 (1976).
- 76JA6714 J. L. Moniot and M. Shamma, *J. Am. Chem. Soc.*, **98**, 6714 (1976).
- 76JA8237 J. M. Liesch, D. S. Millington, R. C. Pandey, and K. L. Rinehart, Jr., *J. Am. Chem. Soc.*, **98**, 8237 (1976).

- 76JCS(P1)315 A. S. Afridi, A. R. Katritzky, and C. A. Ramsden, *J. Chem. Soc., Perkin Trans. I*, 315 (1976).
- 76JCS(P1)2296 N. Dennis, B. Ibrahim, and A. R. Katritzky, *J. Chem. Soc., Perkin Trans. I*, 2296 (1976).
- 76JCS(P1)2338 N. Dennis, A. R. Katritzky, and H. Wilde, *J. Chem. Soc., Perkin Trans. I*, 2338 (1976).
- 76LA125 C. Reichardt and R. Müller, *Liebigs Ann. Chem.*, **11**, 125 (1976).
- 76MI1 I. Zugravesku and M. Petrovanu, in "*N-Ylide Chemistry*", McGraw Hill, New York (1976).
- 76NAR181 S.-H. Kim, *Prog. Nucl. Acid. Res. Mol. Biol.*, **17**, 181 (1976).
- 76NAT264 C. C. Hsu-Chen and D. T. Dubin, *Nature*, **264**, 190 (1976).
- 76TL601 J. M. Sad, M. J. Mitchell, and M. P. Cava, *Tetrahedron Lett.*, 601 (1976).
- 76TL1595 S. Naruto, H. Mizuta, J. Nakano, and H. Nishimura, *Tetrahedron Lett.*, **19**, 1595 (1976).
- 76TL4887 E. Ali, V. S. Giri, and S. C. Pakrashi, *Tetrahedron Lett.*, 4887 (1976).
- 77H45 Y. Kondo, H. Inoue, and J. Imai, *Heterocycles*, **7**, 45 (1977).
- 77H895 M. Hanaoka, C. Mukai, and Y. Arata, *Heterocycles*, **6**, 895 (1977).
- 77H953 Y. Kondo, H. Inoue, and J. Imai, *Heterocycles*, **6**, 953 (1977).
- 77H959 J. Imai and Y. Kondo, *Heterocycles*, **6**, 959 (1977).
- 77H1319 H. Volz and H. Kowarsch, *Heterocycles*, **7**, 1319 (1977).
- 77H1981 M. Hanaoka and C. Mukai, *Heterocycles*, **6**, 1977 (1981).
- 77IJC(B)183 A. Chatterjee and S. Mukhopadhyay, *Ind. J. Chem.*, **15B**, 183 (1977).
- 77JCS(CC109) C. A. Ramsden, *J. Chem. Soc., Chem. Commun.*, 109 (1977).
- 77MI1 V. S. Sethi, *Ann. N.Y. Acad. Sci.*, **284**, 508 (1977).
- 77MI2 N. Decaudain, N. Kunesch, and J. Poisson, *Ann. Pharm. Fr.*, **35**, 521 (1977).
- 77MI3 K. T. Potts, in "*Special Topics in Heterocyclic Chemistry*" (A. Weissberger and E. C. Taylor, eds.), p. 317, Wiley, New York (1977).
- 77P2015 P. D. Senter and C.-L. Chen, *Phytochemistry*, **16**, 2015 (1977).
- 77T3203 C. A. Ramsden, *Tetrahedron*, **33**, 3203 (1977).
- 77TL3787 J. L. Moniot, H. Abd el Rahman, and M. Shamma, *Tetrahedron Lett.*, **43**, 3787 (1977).
- 78AHC183 J. Elguero, R. M. Claramunt, and A. J. H. Summers, *Adv. Heterocycl. Chem.*, **22**, 183 (1978).
- 78JA7759 D. G. Lynn, K. Nakanishi, and S. L. Patt, *J. Amer. Chem. Soc.*, **10**, 7759 (1978).
- 78JBC1101 G. Thomas, J. Gordon, and H. Rogg, *J. Biol. Chem.*, **253**, 1101 (1978).
- 78JMC199 R. K. Y. Zee-Cheng, S.-J. Yan, and C. C. Cheng, *J. Med. Chem.*, **21**, 199 (1978).
- 78JOC3893 R. Gleiter, R. Bartetzko, G. Brähler, and H. Bock, *J. Org. Chem.*, **43**, 3893 (1978).
- 78MI1 J. L. Sussman, S. R. Holbrook, R. Wade Warrant, G. M. Church, and S.-H. Kim, *J. Mol. Biol.*, **123**, 607 (1978).
- 79AG119 C. Reichardt, *Angew. Chem.*, **91**, 119 (1979).
- 79JCR(S)1 S. H. Hedges and R. B. Herbert, *J. Chem. Res. (S)*, 1 (1979).
- 79JCS(P1)2535 A. R. Katritzky, S. I. Bayyuk, N. Dennis, G. Musumarra, and E.-U. Würthwein, *J. Chem. Soc., Perkin Trans. I*, 2535 (1979).
- 79JOC4337 J. L. Moniot and M. Shamma, *J. Org. Chem.*, **44**, 4337 (1979).

- 79MI1 I. A. Mensah and E. A. Sofowora, *Planta Med.*, **35**, 94 (1979).
- 79MI2 T. S. Viswanathan and T. J. Swift, *Bioorg. Chem.*, **8**, 191 (1979).
- 79MI3 J. P. Cecchini and R. Miassod, *Eur. J. Biochem.*, **98**, 203 (1979).
- 79MI4 C. A. Ramsden, in "Comprehensive Organic Chemistry" (D. H. R. Barton and W. D. Ollis, eds.), Vol. 4, p. 1171, Pergamon Press, Oxford (1979).
- 79P105 U. Willeke, V. Heeger, M. Meise, H. Newman, I. Schindelmeiser, K. Vordemfelde, and W. Barz, *Phytochemistry*, **18**, 105 (1979).
- 79TL1931 W. Z. Antkowiak and W. P. Gessner, *Tetrahedron Lett.*, 1979 (1931).
- 80AHC1 C. A. Ramsden, *Adv. Heterocycl. Chem.*, **26**, 1 (1980).
- 80BBR102 L. Osorio-Almeida, P. Guillemaut, G. Keith, J. Canady, and J. H. Weil, *Biochem. Biophys. Res. Commun.*, **92**, 102 (1980).
- 80CB3245 E. Conde Miranda, C. H. Brieskorn, and S. Blechert, *Chem. Ber.*, **113**, 3245 (1980).
- 80JC(B)718 M. L. Jain, R. P. Soni, and J. P. Saxena, *Indian J. Chem.*, **19B**, 718 (1980).
- 80JA3971 K. T. Potts, S. Kanemasa, and G. Zvilichovsky, *J. Am. Chem. Soc.*, **102**, 3971 (1980).
- 80JA5418 R. Faggiani, C. J. L. Lock, and B. Lippert, *J. Am. Chem. Soc.*, **102**, 5418 (1980).
- 80JCS(P1)911 Y. Kondo, J. Imai, and H. Inoue, *J. Chem. Soc. Perkin I*, 911 (1980).
- 80JPS1180 C. D. Hufford, A. S. Sharma, and B. O. Oguntimein, *J. Pharm. Sci.*, **69**, 1180 (1980).
- 80MI1 E. Furusawa, H. Irie, D. Combs, and W. C. Wildman, *Chemotherapy (Basel)*, **26**, 28 (1980).
- 80MI2 A. Patra, A. Ghosh, and A. K. Mitra, *Planta Med.*, **40**, 333 (1980).
- 80NAT596 R. F. Newbold, W. Warren, A. S. C. Medcalf, and J. Amos, *Nature*, **283**, 596 (1980).
- 80PJC2089 P. K. Minocha and K. P. Tiwari, *Pol. J. Chem.*, **54**, 2089 (1980).
- 80ZN1002 W. Friedrichsen, *Z. Naturforsch.*, **35B**, 1002 (1980).
- 81AJC787 J. R. Cannon, J. S. Edmonds, K. A. Francesconi, C. L. Raston, J. B. Saunders, B. W. Skelton, and A. H. White, *Aust. J. Chem.*, **34**, 787 (1981).
- 81JA5691 B. Lippert, *J. Am. Chem. Soc.*, **103**, 5691 (1981).
- 81JHC881 C. Kratky and T. Kappe, *J. Heterocycl. Chem.*, **18**, 881 (1981).
- 81MI1 B. Xu, *Trends Pharmacol. Sci.*, **2**, 271 (1981).
- 81MI2 C. Tani, N. Nagakura, S. Saeki, and M. T. Kao, *Planta Med.*, **41**, 403 (1981).
- 81MI3 H. G. Kiryakov, E. Iskrenova, B. Kuzmanov, and L. Estatieva, *Planta Med.*, **43**, 51 (1981).
- 81P323 J. Siwon, R. Verpoorte, T. Van Beek, H. Meerburg, and A. Baerhiem Svendsen, *Phytochemistry*, **20**, 323 (1981).
- 82H1083 W. Friedrichsen, T. Kappe, and A. Böttcher, *Heterocycles*, **19**, 1083 (1982).
- 82IC3216 R. Faggiani, B. Lippert, C. J. L. Lock, and R. A. Speranzini, *Inorg. Chem.*, **21**, 3216 (1982).
- 82JBC11971 J. C. Netherton and S. Gurin, *J. Biol. Chem.*, **257**, 11,971 (1982).
- 82JNP407 D. S. Bhakuni and S. Gupta, *J. Nat. Prod.*, **45**, 407 (1982).
- 82JOC498 A. R. Katritzky, R. Awartani, and R. C. Patel, *J. Org. Chem.*, **47**, 498 (1982).

- 82MI1 Z.-Y. Wenig, Z.-Y. Wang, and X.-M. Yan, *Acta Pharm. Sin.*, **17**, 744 (1982) [*CA* **98**, 89,710 (1983)].
- 82NAT684 Y. Kuchino, M. Ihara, Y. Yabusaki, and S. Nishimura, *Nature*, **298**, 684 (1982).
- 82P1201 W. A. Tramontano, C. H. Hartnett, D. G. Lynn, and L. S. Evans, *Phytochemistry*, **21**, 1201 (1982).
- 82T2965 C. G. Newton and C. A. Ramsden, *Tetrahedron*, **38**, 2965 (1982).
- 83H23 W. Friedrichsen, *Heterocycles*, **20**, 23 (1983).
- 83H1367 T. Kappe and D. Pocivalnik, *Heterocycles*, **20**, 1367 (1983).
- 83JNP694 G. M. T. Robert, A. Ahond, C. Poupat, P. Potier, C. Jollès, A. Jousselin, and H. Jacquemin, *J. Nat. Prod.*, **46**, 694 (1983).
- 83LA721 C. Reichardt and E. Harbusch-Görnert, *Liebigs Ann. Chem.*, 721 (1983).
- 83M227 T. Kappe, Y. Ravai, and W. Stadlbauer, *Monatsh. Chem.*, **114**, 227 (1983).
- 83MI1 C. C. Huang, C. S. Han, X. F. Yue, C. M. Shen, S. W. Wang, F. G. Wu, and B. Xu, *J. Natl. Cancer Inst.*, **71**, 841 (1983).
- 83MI2 M. Caprasse, C. Coune, and L. Angenot, *J. Pharm. Belg.*, **38**, 135 (1983).
- 83MI3 G. Dirheimer, in “*Modified Nucleosides and Cancer*” (G. Glass, ed.), pp. 15–46, Springer-Verlag, Berlin, Heidelberg (1983).
- 83MI4 R. Basseleer, J. M. Marnette, P. Wiliquet, M. C. DePauw-Gillet, M. Caprasse, and L. Angenot, *Planta Med.*, **49**, 158 (1983).
- 83MI5 J. Bergman, in “*The Alkaloids*” (A. Brossi, ed.), Vol. 21, Chapter 2, Academic Press, New York, NY (1983).
- 83P2607 S. K. Chattopadhyay, A. B. Ray, D. J. Slatkin, and P. L. Schiff, Jr., *Phytochemistry*, **22**, 2607 (1983).
- 83S149 A. R. Katritzky and H. M. Faid-Allah, *Synthesis*, 149 (1983).
- 84CHEC1027 C. A. Ramsden, in “*Comprehensive Heterocyclic Chemistry*” (A. R. Katritzky and C. W. Rees, eds.), Vol. 6, p. 1017, Pergamon Press, Oxford (1984).
- 84CPB2230 M. Hanaoka, C. Mukai, K. Nagami, K. Okajima, and S. Yasuda, *Chem. Pharm. Bull.*, **32**, 2230 (1984).
- 84H358 T. Kappe, *Heterocycles*, **21**, 358 (1984).
- 84HCA455 R. P. Borris, A. Guggisberg, and M. Hesse, *Helv. Chim. Acta*, **67**, 455 (1984).
- 84JNP1003 A. Evidente, I. Iasiello, and G. Randazzo, *J. Nat. Prod.*, **47**, 1003 (1984).
- 84MI1 C. Coune, D. Tavernier, M. Caprasse, and L. Angenot, *Planta Med.*, **50**, 93 (1984).
- 84MI2 M. Caprasse, L. Angenot, D. Tavernier, and M. J. O. Anteunis, *Planta Med.*, **50**, 131 (1984).
- 84MI3 F. T. Vert, I. Z. Sánchez, and A. O. Torrent, *J. Photochem.*, **26**, 285 (1984).
- 84P1225 D. G. Lynn, D. H. Lewis, W. A. Tramontano, and L. S. Evans, *Phytochemistry*, **23**, 1225 (1984).
- 84P1837 L. S. Evans and W. A. Tramontano, *Phytochemistry*, **23**, 1984 (1983).
- 85CPB1763 M. Hanaoka, H. Yamagishi, and C. Mukai, *Chem. Pharm. Bull.*, **33**, 1763 (1985).
- 85CPB4139 H. Ishii, Y.-I. Ichikawa, E. Kawanabe, M. Ishikawa, and T. Ishikawa, *Chem. Pharm. Bull.*, **33**, 4139 (1985).

- 85JAN1440 M. Nishii, J. Inagaki, F. Nohara, K. Isono, H. Kusakabe, K. Kobayashi, T. Sakurai, S. Koshimura, S. K. Sethi, J. A. McCloskey, *J. Antibiot.*, **38**, 1440 (1985).
- 85JAN572 C. Hokanson, J. C. French, and N. K. Dally, *J. Antibiot.*, **38**, 572 (1985).
- 85JAN972 M. Kitahara, K. Ishii, Y. Kumada, T. Shiraishi, T. Furuta, T. Miwa, H. Kawaharada, and K. Watanabe, *J. Antibiot.*, **38**, 972 (1985).
- 85JAN977 M. Kitahara, K. Ishii, H. Kawaharada, K. Watanabe, T. Suga, T. Hirata, and S. Nakamura, *J. Antibiot.*, **38**, 977 (1985).
- 85JAN1581 M. Hasobe, M. Saneyoshi, and K. Isono, *J. Antibiot.*, **38**, 1581 (1985).
- 85MI1 M. K. Yusupov, B. Chommadov, and A. M. Usmanov, *Khim. Prir. Soedin.*, **808** (1985) [*CA* **105**, 187,562 (1986)].
- 85MI2 R. Bassler, D. Clermont, J. M. Marmette, M. Caprasse, M. Tits, and L. Angenot, *Ann. Pharm. Fr.*, **43**, 83 (1985).
- 85MI3 V. S. Zueva, A. S. Mankin, A. A. Bogdanov, D. L. Thurlow, and R. A. Zimmermann, *FEBS Lett.*, **188**, 233 (1985).
- 85T2239 W. D. Ollis, S. P. Stanforth, and C. A. Ramsden, *Tetrahedron*, **41**, 2239 (1985).
- 85TL2759 Atta-ur Rahman, S. Malik, H. Cun-heng, and J. Clardy, *Tetrahedron Lett.*, **26**, 2759 (1985).
- 85TL4903 E. V. Dehmlow and H. J. Schulz, *Tetrahedron Lett.*, **26**, 4903 (1985).
- 86CPB3228 M. Koike, T. Ohmoto, and K. Ogata, *Chem. Pharm. Bull. Japan*, **34**, 3228 (1986).
- 86JAN1291 M. Hasobe, M. Saneyoshi, and K. Isono, *J. Antibiot.*, **39**, 1291 (1986).
- 86JCR(S)112 S. Ghosal, Y. Kumar, S. K. Singh, and A. Kumar, *J. Chem. Res. Synop.*, **3**, 112 (1986).
- 86JNP715 S. K. Adesina, *J. Nat. Prod.*, **49**, 715 (1986).
- 86JOC3915 S. J. Danishefsky and C. Vogel, *J. Org. Chem.*, **51**, 3915 (1986).
- 86MI1 S. K. Adesina and D. D. Akinwusi, *High Resolut. Chromatogr. Chromatogr. Commun.*, **9**, 412 (1986).
- 86MI2 M. Beljanski, *Oncology*, **43**, 198 (1986).
- 86P1975 S. Ghosal, S. K. Singh, and R. S. Srivastava, *Phytochemistry*, **25**, 1986 (1975).
- 86P2399 A. A. Ali, H. M. Sayed, O. M. Abdallah, and W. Steglich, *Phytochemistry*, **25**, 2399 (1986).
- 86PHA747 S. K. Adesina, O. A. Olatunji, and D. D. Akinwusi, *Pharmazie*, **41**, 747 (1986).
- 86T1475 M. Tiecco, M. Tingoli, L. Testaferri, D. Chianelli, and E. Wenkert, *Tetrahedron*, **42**, 1475 (1986).
- 87E462 M. Tiecco, M. Tingoli, L. Testaferri, D. Chianelli, and E. Wenkert, *Experientia*, **43**, 462 (1987).
- 87H1841 Y. Ahmad, T. Begum, I. H. Qureshi, Atta-ur-Rahman, K. Zaman, X. Changfu, and J. Clardy, *Heterocycles*, **26**, 1841 (1987).
- 87JAN258 B. Kunze, G. Höfle, and H. Reichenbach, *J. Antibiot.*, **40**, 258 (1987).
- 87LA857 E. V. Dehmlow and H. J. Schulz, *Liebigs Ann. Chemie*, 857 (1987).
- 87MI1 X. Wang, W. Yu, Z. Shen, J. Yang, and B. Xu, *Zhongguo Yaoli Xuebue*, **8**, 86 (1987) [*CA* **106**, 95,753 (1987)].
- 87MI2 S. K. Adesina, *Fitoterapia*, **58**, 123 (1987).
- 87MI3 R. C. Jackson, T. J. Boritzki, J. A. Besserer, K. L. Hamelhele, J. L. Shillis, W. R. Leopold, and D. W. Fry, *Adv. Enzyme Regul.*, **26**, 301 (1987).

- 87MI4 S. Berking, *Development*, **99**, 211 (1987).
- 87TL5259 G. W. Gribble and D. A. Johnson, *Tetrahedron Lett.*, 5259 (1987).
- 88HI149 T. Ogino, T. Sato, H. Sasaki, M. Chin, and H. Mitsuhashi, *Heterocycles*, **27**, 1149 (1988).
- 88HCA957 H.-A. Hasseberg and H. Gerlach, *Helv. Chim. Acta*, **71**, 957 (1988).
- 88JCS(CC)743 S. C. Bezuidenhout, W. C. A. Gelderblom, C. P. Gorst-Allman, R. M. Horak, W. F. O. Marasas, G. Spiteller, and R. Vleggaar, *J. Chem. Soc., Chem. Commun.*, 743 (1988).
- 88JMC1084 J. L. Vennerstrom and D. L. Klayman, *J. Med. Chem.*, **31**, 1084 (1988).
- 88JOC2889 K. T. Potts, P. M. Murphy, and W. R. Kuehnling, *J. Org. Chem.*, **53**, 2889 (1988).
- 88JOC3276 D. M. Roll, C. M. Ireland, H. S. M. Lu, and J. Clardy, *J. Org. Chem.*, **53**, 3276 (1988).
- 88LA1111 H.-J. Teuber, R. Quintanilla-Licea, and T. Raabe, *Liebigs Ann. Chem.*, 1111 (1988).
- 88MI1 G. W. Gribble, in "Studies in Natural Products Chemistry", Vol. 1, p. 123, *Stereoselective Synthesis, Part A*, Elsevier, Amsterdam (1988).
- 88MI2 Y. Wu, C. Yu, S. Zhang, and Z. Su, S. Jiang, *Shanghai Yixue*, **11**, 683 (1988) [*CA* **111**, 17,263 (1989)].
- 88P2581 H. F. W. Jensen, S. R. Jensen, and B. J. Nielsen, *Phytochemistry*, **27**, 2581 (1988).
- 88P3022 N. Kawahara, K. Nozawa, S. Nakajimia, and K.-I. Kawai, *Phytochemistry*, **27**, 3022 (1988).
- 88P3793 E. Leete and R. H. Michelson, *Phytochemistry*, **27**, 3793 (1988).
- 88T3195 G. W. Gribble, T. C. Barden, and D. A. Johnson, *Tetrahedron*, **44**, 3195 (1988).
- 89CA718 M. Hanaoka, H. Ekimoto, M. F. Kobayashi, Y. Irie, and K. Takahashi, *Eur. Pat Appl.* EP 432,630 [*CA* **116**, 718 (1992)].
- 89CPB1810 O. Katsuhiko, N. Hideo, and Z.-M. Meng, *Chem. Pharm. Bull.*, **37**, 1989 (1810).
- 89GEP3520229 H. Augustiniak, K. Gerth, G. Hoefle, H. Irschik, R. Jansen, B. Kunze, H. Reichenbach, H. Steinmetz, W. Trowitsch-Kienast, Ger. Offen. DE 3,520,229 [*CA* **110**, 73,858 (1989)].
- 89MI1 H. M. He and Z. Y. Wenig, *Yaoxue Xuebo*, **24**, 302 (1989) [*CA* **111**, 108,492 (1989)].
- 89MI2 K. Tomita, *Yakugaku Zasshi*, **109**, 439 (1989).
- 89MI3 A. R. Davis, N. M. Targett, O. J. McConnell, and C. M. Young, *Bioorg. Marine Chem.*, **3**, 85 (1989).
- 89MI4 C. W. Gehrke and K. C. Kuo, *J. Chromatogr.*, **471**, 3 (1989).
- 90BCJ2498 J. L. Aihara, H. Ichikawa, H. Tokiwa, and Y. Okumura, *Bull. Chem. Soc. Jpn.*, **63**, 2498 (1990).
- 90HI1655 A. Ohta, A. Kojima, and Y. Aoyagi, *Heterocycles*, **31**, 1655 (1990).
- 90MI1 L. R. Harrison, B. M. Colvin, J. T. Greene, L. E. Newman, and J. R. Cole, *J. Vet. Diagn. Invest.*, **2**, 217 (1990).
- 90MI2 R. Liou and T. Blumenthal, *Mol. Cell Biol.*, **10**, 1764 (1990).
- 90P805 S. Ghosal, S. K. Singh, and S. G. Unnikrishnan, *Phytochemistry*, **29**, 805 (1990).
- 90T4387 P. Ciminiello, E. Fattorusso, A. Mangoni, B. Di Blasio, and V. Pavone, *Tetrahedron*, **46**, 4387 (1990).
- 90TL1523 M. A. Siddiqui and V. Snieckus, *Tetrahedron Lett.*, **31**, 1523 (1990).

- 90TL2381 B. Pelcman and G. W. Gribble, *Tetrahedron Lett.*, **31**, 2381 (1990).
- 91JAN1283 H. Nishioka, T. Sawa, K. Isshiki, and Y. Takahashi, *J. Antibiot.*, **44**, 1283 (1991).
- 91JNP1360 L. B. S. Kardono, C. K. Angerhofer, S. Tsauri, K. Padmawintana, J. M. Pezzuto, and A. D. Kinghorn, *J. Nat. Prod.*, **54**, 1360 (1991).
- 91JOC2984 N. Atanes, L. Catedo, E. Guitián, C. Saá, J. M. Saá, and R. Suau, *J. Org. Chem.*, **56**, 2984 (1991).
- 91MI1 W. C. A. Gelderblom, N. P. J. Kriek, W. F. O. Marasas, and P. G. Thiel, *Carcinogenesis*, **12**, 1247 (1991).
- 91MI2 C. G. Edmons, P. F. Crain, R. Gupta, T. Hashizume, C. H. Hocart, J. A. Kowalak, S. C. Pomerantz, K. O. Stetter, and J. A. McCloskey, *J. Bacteriol.*, **173**, 3138 (1991).
- 91MI3 V. Pabuccuoglu, M. D. Rozwadowska, A. Brossi, A. Clark, C. D. Hufford, C. George, and J. L. Flippen-Anderson, *Arch. Pharm.*, **324**, 29 (1991).
- 91P3285 T. Shrestla and N. G. Bisset, *Phytochemistry*, **30**, 3285 (1991).
- 91TL65 U. Lauk, D. Dürst, and D. W. Fischer, *Tetrahedron Lett.*, **32**, 65 (1991).
- 91TL4473 H. Wamhoff, A. Schmidt, and M. Nieger, *Tetrahedron Lett.*, 4473 (1991).
- 92CJC1635 S. B. Asensio, E. Lopez-Cantarero, and J. Llor, *Can. J. Chem.*, **70**, 1635 (1992).
- 92P2139 A. H. Abou-Donia, A. A. Abib, A. S. El Din, A. Evidente, M. Gaber, and A. Scopa, *Phytochemistry*, **31**, 2139 (1992).
- 92P2499 E. Rodrigues Fo, J. B. Fernandes, P. C. Vieira, and M.F.D.G.F. Da Silva, *Phytochemistry*, **31**, 2499 (1992).
- 92TL2597 M. Tsuda, H. Shigemori, M. Ishibashi, and J. Kobayashi, *Tetrahedron Lett.*, **33**, 2597 (1992).
- 93H1055 H. Wamhoff and A. Schmidt, *Heterocycles*, **35**, 1055 (1993).
- 93JAN564 H. Nishioka, T. Sawa, Y. Takahashi, H. Naganawa, M. Hamada, and T. Takeuchi, *J. Antibiot.*, **46**, 564 (1993).
- 93JCS(P2)99 M. Balón, J. Hidalgo, P. Guardado, M. A. Munoz, and C. Carmona, *J. Chem. Soc., Perkin Trans. 2*, 99 (1993).
- 93JOC5025 S.-D. Fang, L.-K. Wang, and S. M. Hecht, *J. Org. Chem.*, **58**, 5025 (1993).
- 93JOC5925 M. T. Davies-Coleman and D. Faulkner, *J. Org. Chem.*, **58**, 5925 (1993).
- 93JOC6976 H. Wamhoff and A. Schmidt, *J. Org. Chem.*, **58**, 6976 (1993).
- 93MI1 P. A. Murphy, L. G. Rice, and P. F. Ross, *J. Agric. Food Chem.*, **41**, 263 (1993).
- 93MI2 E. C. Hopmans and P. A. Murphy, *J. Agric. Food Chem.*, **41**, 165 (1993).
- 93P559 R. Suau, M. V. Silva, and M. Valpuesta, *Phytochemistry*, **34**, 559 (1993).
- 93P1449 I.-S. Chen, I.-L. Tdai, S.-J. Wu, W.-S. Sheen, T. Ishikawa, and H. Ishii, *Phytochemistry*, **34**, 1449 (1993).
- 93T1879 T. Fujii, M. Ohba, and T. Ohashi, *Tetrahedron*, **49**, 1993 (1879).
- 93T8373 F. Trécourt, M. Mallet, O. Mongin, B. Gervais, and G. Quéguiner, *Tetrahedron*, **49**, 8373 (1993).
- 93T10305 Y. L. Janin and E. Bisagni, *Tetrahedron*, **49**, 10,305 (1993).
- 93TL7773 A. Espada, C. Jiménez, C. Debitus, and R. Riguera, *Tetrahedron Lett.*, **34**, 7773 (1993).

- 93TL7917 P. Roca, F. Marsais, A. Godard, and G. Quéguiner, *Tetrahedron Lett.*, **34**, 7917 (1993).
- 94H1413 K. Koike, T. Ohmoto, A. Uchida, and I. Oonishi, *Heterocycles*, **38**, 1413 (1994).
- 94JOC5518 J. P. Marino, Jr., M. H. Osterhout, A. T. Price, M. A. Semones, and A. Padwa, *J. Org. Chem.*, **59**, 5518 (1994).
- 94MI1 F. A. Badria and W. A. El-Naggar, *Sci. Pharm.*, **62**, 355 (1994).
- 94P1175 M. A. M. Nawwar, S. A. M. Hussein, and I. Merfort, *Phytochemistry*, **37**, 1175 (1994).
- 94P1543 Y. Ouyang, K. Koike, and T. Ohmoto, *Phytochemistry*, **36**, 1543 (1994).
- 94T13583 S. Tsukamoto, H. Kato, H. Hirota, and N. Fusetani, *Tetrahedron*, **50**, 13,583 (1994).
- 94TL3967 N. Fusetani, N. Asai, and S. Matsunaga, *Tetrahedron Lett.*, **23**, 3967 (1994).
- 94TL8851 P. Molina, P. M. Fresneda, S. Garcia-Zafra, and P. Almendros, *Tetrahedron Lett.*, **35**, 8851 (1994).
- 95AHC159 H. Wamhoff, G. Richardt, and S. Stölben, *Adv. Heterocycl. Chem.*, **64**, 159 (1995).
- 95B1076 B. Meunier, S. A. Magdwick, E. Reil, W. Oettmeier, and P. R. Rich, *Biochemistry*, **34**, 1076 (1995).
- 95HCA1178 I. Mancini, G. Guella, C. Debitus, and F. Pietra, *Helv. Chim. Acta*, **78**, 1178 (1995).
- 95JCS(D)3767 G. Schröder, B. Lippert, M. Sabat, C. J. L. Lock, R. Faggiani, B. Song, and H. Sigel, *J. Chem. Soc., Dalton Trans.*, 3767 (1995).
- 95JCS(P2)839 D. Venkateswarlu and R. H. D. Lyngdoh, *J. Chem. Soc., Perkin Trans. 2*, 839 (1995).
- 95JOC2704 J. P. Marino, Jr., M. H. Osterhout, and A. Padwa, *J. Org. Chem.*, **60**, 2704 (1995).
- 95MI1 H. Nishitani, S. Kikushi, K. Okumura, and H. Taguchi, *Arch. Biochim. Biophys.*, **322**, 327 (1995).
- 95P383 T.-S. Wu, Y.-L. Leu, H.-C. Hsu, L.-F. Ou, and C.-C. Chen, *Phytochemistry*, **39**, 383 (1995).
- 95P817 M. Ueda, M. Niwa, and S. Yamamura, *Phytochemistry*, **39**, 817 (1995).
- 95P953 P. Clivio, D. Guillaume, J. Vercauteren, B. Richard, J.-M. Nuzillard, M. Zèches-Hanrot, and L. le Men-Olivier, *Phytochemistry*, **40**, 953 (1995).
- 95P991 L. Y. Watanabe and L. M. X. Lopes, *Phytochemistry*, **40**, 991 (1995).
- 95P1291 J. Bastida, C. Codina, P. Peeters, M. Rubiralta, M. Orozco, F. J. Luque, and S. C. Chhabra, *Phytochemistry*, **40**, 1291 (1995).
- 95P1557 J. Quetin-Leclercq, G. Llabres, R. Warin, M.-L. Belem-Pinheiro, H. Mavar-Manga, and L. Angenot, *Phytochemistry*, **40**, 1557 (1995).
- 95T773 A. Fürstner and A. Ernst, *Tetrahedron*, **51**, 773 (1995).
- 95TL1993 Atta-ur Rahman, S. Malik, S. S. Hasan, M. I. Choudhary, C.-Z. Ni, and J. Clardy, *Tetrahedron Lett.*, **36**, 1993 (1995).
- 96AG1321 S. Metzger and B. Lippert, *Angew. Chem.*, **108**, 1321 (1996); *Angew. Chem., Int. Ed. Engl.*, **35**, 1228 (1996).
- 96H1365 M. Lounasmaa, P. Hanhinen, and S. Lipponen, *Heterocycles*, **43**, 1365 (1996).
- 96JAN639 M. Ueckl, K. Abe, M. Hanafi, K. Shibata, T. Tanaka, and M. Taniguchi, *J. Antibiot.*, **49**, 639 (1996).

- 96JAN1226 M. Hanafi, K. Shibata, M. Ueckl, and M. Taniguchi, *J. Antibiot.*, **49**, 1226 (1996).
- 96JNP970 S. M. Musser, M. L. Gay, E. P. Mazzola, and R. D. Plattner, *J. Nat. Prod.*, **59**, 970 (1996).
- 96MI1 S. P. Robins, A. Duncan, N. Wilson, and B. J. Evans, *Clin. Chem.*, **42**, 1621 (1996).
- 96MI2 I. T. James, A. J. Walne, and D. Perrett, *Ann. Clin. Biochem.*, **33**, 397 (1996).
- 96MI3 J. Bastida, C. Codina, C. L. Porras, and L. Paiz, *Planta Med.*, **62**, 74 (1996).
- 96T10849 H. Anan, N. Seki, O. Noshiro, K. Hona, K. Yasumuro, T. Ozasa, and N. Fusetani, *Tetrahedron*, **52**, 10,849 (1996).
- 97BMC2283 F. Cafieri, R. Carnuccio, E. Fattorusso, O. Taglialatela-Scafati, and T. Vallefuoco, *Bioorg. Med. Chem. Lett.*, **7**, 2283 (1997).
- 97JA5091 W. Pan and P. B. Shevlin, *J. Am. Chem. Soc.*, **119**, 5091 (1997).
- 97JNP1328 M. D. Menachery, H. M. Mandell, S. A. DeSaw, N. A. DeAntonio, A. J. Freyer, and L. B. Killmer, *J. Nat. Prod.*, **60**, 1328 (1997).
- 97JOC78 A. Padwa, M. A. Brodney, J. P. Marino, Jr., and S. M. Sheehan, *J. Org. Chem.*, **62**, 78 (1997).
- 97JOC438 S. M. Sheehan and A. Padwa, *J. Org. Chem.*, **62**, 438 (1997).
- 97JOC3910 A. Schmidt and M. K. Kindermann, *J. Org. Chem.*, **63**, 3910 (1997).
- 97MI1 R. H. Christenson, *Clin. Biochem.*, **30**, 573 (1997).
- 97MI2 B. Xu and X.-W. Wang, *Drugs Future*, **22**, 123 (1997).
- 97MI3 J. Chen, K. Chen, H. Jiang, M. Lin, and R. Ji, *Prog. Nat. Sci.*, **7**, 329 (1997).
- 97MI4 D. Venkateswarlu and R. H. D. Lyngdoh, *THEOCHEM*, **393**, 151 (1997).
- 97P1037 W. A. Tramontano and D. Jouve, *Phytochemistry*, **44**, 1037 (1997).
- 97P1119 J.-N. Peng, X.-Z. Feng, Q.-T. Zheng, and X.-T. Liang, *Phytochemistry*, **46**, 1119 (1997).
- 97TL941 H. Kang and W. Fenical, *Tetrahedron Lett.*, **38**, 941 (1997).
- 97TL1505 J. T. Kuethe and A. Padwa, *Tetrahedron Lett.*, **38**, 1505 (1997).
- 97TL3883 T. Jahn, G. M. König, A. D. Wright, G. Wörheide, and J. Reitner, *Tetrahedron Lett.*, **38**, 3883 (1997).
- 98H311 T. Ogino, T. Katsuhara, T. Sato, H. Sasaki, M. Okada, and M. Maruno, *Heterocycles*, **48**, 311 (1998).
- 98H865 A. Schmidt, *Heterocycles*, **48**, 865 (1998).
- 98JNP139 R. G. Biala, M. Tits, J. Penelle, M. Frédérich, V. Brandt, C. Prospéri, G. Llabrès, and L. Angenot, *J. Nat. Prod.*, **61**, 139 (1998).
- 98JNP384 X. Fu, F. J. Schmitz, R. S. Tanner, and M. Kelly-Borges, *J. Nat. Prod.*, **61**, 384 (1998).
- 98JNP671 S. Matsunaga, T. Kamimura, and N. Fusetani, *J. Nat. Prod.*, **61**, 671 (1998).
- 98JNP1171 F. Cafieri, E. Fattorusso, and O. Taglialatela-Scafati, *J. Nat. Prod.*, **61**, 1171 (1998).
- 98JNP1263 T. Nakanishi and M. Suzuki, *J. Nat. Prod.*, **61**, 1263 (1998).
- 98JOC968 J. Quirante, C. Escolano, A. Merino, and J. Bonjoch, *J. Org. Chem.*, **63**, 968 (1998).
- 98JOC4636 A. Schmidt and M. K. Kindermann, *J. Org. Chem.*, **63**, 4636 (1997).
- 98MI1 K. Isawa, H. Nanba, D.-U. Lee, and S.-I. Kang, *Planta Med.*, **64**, 748 (1998).

- 98MI2 C. K. Tran, *Tap Chi Duoc Hoc*, **7**, 11 (1998) [*CA* **130**, 158,320 (1999)].
- 98MI3 G.-L. Zhang, G. Rücker, E. Breitmaier, R. Mayer, and C. Steinbeck, *Planta Med.*, **64**, 165 (1998).
- 98P367 Y.-C. Chia, F.-R. Chang, C.-M. Li, and Y.-C. Wu, *Phytochemistry*, **48**, 367 (1998).
- 98P1263 M. Frédérich, J. Quetin-Leclercq, R. G. Biala, V. Brandt, J. Penelle, M. Tits, and L. Angenot, *Phytochemistry*, **48**, 1263 (1998).
- 98P2193 X.-F. Cheng, Z.-M. Meng, and Z.-L. Chen, *Phytochemistry*, **49**, 2193 (1998).
- 98T8433 H. Takayama, M. Kurihara, M. Kitajima, I. M. Said, and N. Aimi, *Tetrahedron*, **54**, 8433 (1998).
- 98T12745 M. Shimono, N. Kamei, T. Shibata, K. Inoguchi, N. Itoh, T. Ikari, and H. Senda, *Tetrahedron*, **54**, 12,745 (1998).
- 98TL4757 T. M. Heidelbaugh, B. Liu, and A. Padwa, *Tetrahedron Lett.*, **39**, 4757 (1998).
- 99H237 A. Schmidt, M. K. Kindermann, and M. Nieger, *Heterocycles*, **51**, 237 (1999).
- 99H927 M. Ueda and S. Yamamur, *Heterocycles*, **51**, 927 (1999).
- 99H2119 A. Schmidt and M. Nieger, *Heterocycles*, **51**, 2119 (1999).
- 99JAN1025) Q. Xu and M. Lin, *J. Nat. Prod.*, **62**, 1025 (1999).
- 99JCS(CC)559 P. Allevi, A. Longo, and M. Anastasia, *J. Chem. Soc., Chem. Commun.*, 559 (1999).
- 99JNP378 A. Gonzáles, F. Schroeder, J. Meinwald, and T. Eisner, *J. Nat. Prod.*, **62**, 378 (1999).
- 99JNP864 T. Nakanishi, M. Suzuki, A. Saimoto, and T. Kabasawa, *J. Nat. Prod.*, **62**, 864 (1999).
- 99JOC1689 L. Rahbaek, J. Breinhold, J. C. Frisvad, and C. Christophersen, *J. Org. Chem.*, **64**, 1689 (1999).
- 99JOC2997 R. Lavilla, O. Coll, M. Nicolàs, B. A. Sufi, J. Torrents, and J. Bosch, *Eur. J. Org. Chem.*, 2997 (1999).
- 99JOC8648 A. Padwa, S. M. Sheehan, and C. S. Straub, *J. Org. Chem.*, **64**, 8648 (1999).
- 99JOC9499 A. Schmidt, M. K. Kindermann, P. Vainiotalo, and M. Nieger, *J. Org. Chem.*, **64**, 9499 (1999).
- 99OL83 C. S. Straub and A. Padwa, *Org. Lett.*, **1**, 83 (1999).
- 99P339 Y. Zhou, G. Zhang, and B. Li, *Phytochemistry*, **50**, 339 (1999).
- 99P1171 V. Brandt, M. Tits, A. Geerlings, M. Frederich, J. Penelle, C. Delaude, R. Verpoorte, and L. Angenot, *Phytochemistry*, **51**, 1171 (1999).
- 00JNP857 G. Lin, P. Rose, K. B. Chatson, E. M. Hawes, X. G. Zhao, and Z. T. Wang, *J. Nat. Prod.*, **63**, 857 (2000).
- 00JOC2368 A. Padwa, T. M. Heidelbaugh, and J. T. Kuethe, *J. Org. Chem.*, **65**, 2368 (2000).
- 00JOC2684 A. Padwa, L. S. Beall, T. M. Heidelbaugh, B. Liu, and S. M. Sheehan, *J. Org. Chem.*, **65**, 2684 (2000).
- 00JOC3227 L. M. Stark, X.-F. Lin, and L. A. Flippin, *J. Org. Chem.*, **65**, 3227 (2000).
- 00M383 S. Mahboobi, M. Koller, and D. Schollmeyer, *Monatsh. Chem.*, **131**, 383 (2000).
- 00MI1 M. Del Rayo Camacho, G. C. Kirby, D. C. Warhurst, S. L. Croft, and J. D. Phillipson, *Planta Med.*, **66**, 478 (2000).

- 00MI2 M. Mäkinen, A. Schmidt, and P. Vainiotalo, *Eur. J. Mass Spectrom.*, **6**, 259 (2000).
- 01BCJ2379 A. Schmidt and M. K. Kindermann, *Bull. Chem. Soc.*, **74**, 2379 (2001).
- 01CL348 A. Schmidt and M. K. Kindermann, *Chem. Lett.*, 348 (2001).
- 01H827 A. Schmidt and M. Nieger, *Heterocycles*, **55**, 827 (2001).
- 01JAN911 Y. Sugie, H. Hirai, T. Inagaki, M. Ishiguro, Y.-J. Kim, Y. Kojima, T. Sakakibara, S. Sakemi, A. Sugiura, Y. Suzuki, L. Brennan, J. Duignan, L.-H. Huang, J. Sutcliffe, N. Kojima, *J. Antibiot.*, **54**, 911 (2001).
- 01JNP342 G. M. Nicholas, J. W. Blunt, and M. H. G. Munro, *J. Nat. Prod.*, **64**, 342 (2001).
- 01JNP1454 M. A. Rashid, K. R. Gustafson, and M. R. Boyd, *J. Nat. Prod.*, **64**, 1454 (2001).
- 01MI P. Polychronopoulos, P. Magiatis, A.-L. Skaltsounis, F. Tillequin, E. Vardala-Theodorou, and A. Tsarbopoulos, *Nat. Prod. Lett.*, **15**(6), 411 (2001).
- 01P619 J. Penelle, P. Christen, J. Mogló, M. Tits, V. Brandt, M. Frédérich, and L. Angenot, *Phytochemistry*, **58**, 619 (2001).
- 02BJ539 K. Tomoo, X. Shen, K. Okabe, Y. Nozoe, S. Fukuhara, S. Morino, T. Ishida, T. Taniguchi, H. Hasegawa, A. Tetrashima, M. Sasaki, Y. Katsuya, K. Kitamura, H. Miyoshi, M. Ishikawa, K.-I. Miura, *Biochem. J.*, **362**, 539 (2002).
- 02CHE681 G. W. Gribble, in “*The Chemistry of Heterocyclic Compounds*, Vol. 59: *Synthetic Applications of 1,3-dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products*”, (A. Padwa and W. H. Pearson, eds.), p. 681, Wiley, New York (2002).
- 02CL222 A. Schmidt and N. Kobakhidze, *Chem. Lett.*, 222 (2002).
- 02CPB199 C. Descoins, Jr., I. L. Bazzocchi, and A. G. Ravelo, *Chem. Pharm. Bull.*, **50**, 199 (2002).
- 02H137 R. Antkowiak, W. Z. Antkowiak, and B. Nowak-Wydra, *Heterocycles*, **58**, 137 (2002).
- 02H2231 A. Schmidt and N. Kobakhidze, *Heterocycles*, **57**, 2231 (2002).
- 01HCA259 D. Zhi-Hui, D. Ze-Jun, and L. Ji-Kai, *Helv. Chim. Acta*, **84**, 259 (2001).
- 02JCS(P1)982 A. Schmidt, N. Kobakhidze, and M. K. Kindermann, *J. Chem. Soc., Perkin Trans. 1*, 982 (2002).
- 02JHC949 A. Schmidt, *J. Heterocycl. Chem.*, **39**, 949 (2002).
- 02OL1375 A. Schmidt, T. Mordhorst, and T. Habeck, *Org. Lett.*, **4**, 1375 (2002).
- 02T309 F. Mongin, F. Trécourt, O. Mongin, and G. Quéguiner, *Tetrahedron*, **58**, 309 (2002).
- 02TL5323 M. Treus, J. C. Estévez, L. Castedo, and R. J. Estévez, *Tetrahedron Lett.*, **43**, 5323 (2002).
- 02UPII A. Schmidt and M. Mordhorst, unpublished (2002).
- 02UPI2 A. Schmidt and A. Gholipour Shilabin, unpublished (2002).
- 03JOC5977 A. Schmidt, T. Habeck, M. K. Kindermann, and M. Nieger, *J. Org. Chem.*, **68**, 5977 (2003).

Recent Development in the Chemistry of Pyrido-oxazines, Pyrido-thiazines, Pyrido-diazines and Their Benzologs. Part 2

ISTVÁN HERMECZ

*Chinoin Pharmaceutical and Chemical Works, Ltd., Research Center,
Budapest, Hungary*

I. Introduction	175
II. Pyrido[2,1- <i>b</i>][1,3]oxazines and Their Benzologs	177
A. Structure	177
1. Theoretical Calculations	177
2. NMR Spectroscopy	179
3. X-ray Investigations	180
B. Reactivity	181
1. Ring Opening	181
2. Reactivity of Ring Carbon Atoms	182
3. Reactivity of Substituents Attached to a Ring Carbon Atom	183
4. Miscellaneous	183
C. Synthesis	184
1. By Formation of One Bond β to the Bridgehead Nitrogen	
Atom [6+0 (β)]	184
2. By Formation of One Bond γ to the Bridgehead Nitrogen	
Atom [6+0 (γ)]	186
3. By Formation of Two Bonds from [5+1] Atom Fragments	188
4. By formation of Two Bonds from [4+2] and [3+3] Atom Fragments	188
5. Miscellaneous	188
D. Applications and Important Compounds	189
III. Pyrido[2,1- <i>b</i>][1,3]thiazines and Their Benzo Derivatives	190
A. Structure	190
1. Theoretical Calculations	190
2. ^1H NMR Spectroscopy	190
B. Reactivity	191
1. Ring Opening	191
2. Hydrogenation, Reduction	191
3. Oxidation	191
4. Reactivity of Substituents Attached to Ring Carbon Atoms	192
5. Ring Transformation	192
6. Miscellaneous	193
C. Synthesis	193
1. By Formation of One Bond β to the Bridgehead Nitrogen	
Atom [6+0 (β)]	193

2. By Formation of One Bond γ to the Bridgehead Nitrogen Atom [6+0 (γ)]	193
3. By Formation of Two Bonds from [3+3] Atom Fragments	194
4. Rearrangement	194
5. Miscellaneous	195
IV. Pyrido[1,2- <i>a</i>]pyrimidine	195
A. Structure	195
1. Thermodynamic Aspects	195
2. Theoretical Calculations	196
3. UV Spectroscopy	197
4. IR Spectroscopy	197
5. NMR Spectroscopy	198
6. Mass Spectrometry	200
7. X-ray Investigations	200
B. Reactivity	202
1. Ring Opening	202
2. Hydrogenation, Reduction	203
3. Oxidation	204
4. Reactivity of Ring Nitrogen Atoms	205
5. Reactivity of Ring Carbon Atoms	205
6. Reactivity of the Substituents Attached to a Ring Nitrogen Atom	209
7. Reactivity of the Substituent Attached to a Ring Carbon Atom	209
8. Reactions Leading to Polycondensed Ring System	220
9. Ring Transformations	229
10. Miscellaneous	233
C. Synthesis	234
1. By Formation of One Bond α to the Bridgehead Nitrogen Atom [6+0 (α)]	234
2. By Formation of One Bond β to the Bridgehead Nitrogen Atom [6+0 (β)]	238
3. By Formation of Two Bonds from [5+1] Atom Fragments	239
4. By Formation of Two Bonds from [4+2] Atom Fragments	240
5. By Formation of Two Bonds from [3+3] Atom Fragments	241
6. By Formation of Three Bonds from [3+2+1] Atom Fragments	249
7. Rearrangement	250
8. Miscellaneous	251
D. Applications and Important Compounds	254
V. Benzologs of Pyrido[1,2- <i>a</i>]pyrimidine	259
A. Structure	259
1. Thermodynamic Aspects	259
2. Circular Dichroism	259
3. Theoretical Calculations	259
4. Infrared Spectroscopy	259
5. NMR Spectroscopy	260
6. X-ray Investigations	260
B. Reactivity	260
1. Hydrogenation	260
2. Oxidation	260
3. Reactivity of Ring Carbon Atoms	261
4. Reactivity of Substituents Attached to Ring Carbon Atoms	261

5. Miscellaneous	261
C. Synthesis	262
1. By Formation of One Bond α to the Bridgehead Nitrogen	
Atom [6+0 (α)]	262
2. By Formation of One Bond β to the Bridgehead Nitrogen	
Atom [6+0 (β)]	262
3. By Formation of Two Bonds from [5+1] Atom Fragments	263
4. By Formation of Two Bonds from [4+2] Atom Fragments	263
5. By Formation of Two Bonds from [3+3] Atom Fragments	264
6. Ring Transformation	264
7. Miscellaneous	265
D. Applications and Important Compounds	265
References	266


I. Introduction

This review is the second part of a survey on the recent developments in the chemistry of pyrido-oxazines, pyrido-thiazines, pyrido-diazines and their benzologs. The first part was published recently (03AHC(84)219), and the second part covers the ring systems depicted in Scheme 1. The chemistry of the bicyclic 6–6 system containing one ring junction nitrogen and one extra heteroatom and their benzologs was reviewed in 1996 (96CHC-II(8)563). The early articles on pyrido[1,2-*a*]pyrimidines (61HC(15-2)1141), pyrido[2,1-*b*]quinazolines (61HC(15-2)1153) and pyrimido[1,2-*a*]quinoline (61HC(15-2)1160) were covered by Mosby's book in 1961.

A review in 1986 dealt with pyrido[2,1-*b*]quinazolines among others (86AHC(39)281). The chemistry of pyrido[2,1-*b*][1,3]oxazines, pyrido[2,1-*b*][1,3]thiazines and their benzologs (Scheme 1) was summarized in 1999 (99AHC(72)225), and that of pyrido[1,2-*a*]pyrimidines in 1995 (95AHC(63)103), in 1994 (94KGS579), and in 1983 (83AHC(33)241, 85MI1). The chemistry of the benzologs of pyrido[1,2-*a*]pyrimidines was surveyed in 1999 (99AHC(73)178).

This chapter covers the primary chemical literature of bicyclic 6–6 systems containing one ring junction nitrogen and one extra heteroatom and their benzologs contained in *Chemical Abstract* Chemical Substance Indexes up to Volume 135 from Volume 127 for pyrido[2,1-*b*][1,3]oxazines, pyrido[2,1-*b*][1,3]thiazines and their benzologs; from Volume 120 for pyrido[1,2-*a*]pyrimidines, and from Volume 127 for its benzologs. In Scheme 1 the names of ring systems are in bold; they were treated in papers and patents during the above indicated period.


The perhydropyrido[2,1-*b*][1,3]oxazine skeleton is a constituent part of macrocyclic xestospongine/araguspongine and aragupetrosine alkaloids



Scheme 1

isolated from different marine sponges. Many microorganisms growing under iron deficient conditions produce Fe^{3+} complexing agents, so-called siderophores (among them pseudobactins, pyoverdins, isopyoverdins, and azoverdins), which consist of three distinct substructural parts: a heterocyclic unit, which may be (1*S*)-8,9-dihydroxy-5-amino-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-1-carboxylic acid (**1**), its 7-sulfonic acid **2**, 5, 6-dihydro derivatives **3**, and (3*S*)-8,9-dihydroxy-5-amino-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-3-carboxylic acid (**4**) chromophore; a peptide chain (containing both L- and D-amino acids) bound to the carboxylic group of pyrimido[1,2-*a*]quinoline moiety; and a dicarboxylic acid (amide) connected to a 5-amino group of a pyrimido[1,2-*a*]quinoline part (Scheme 2). 6,7,8,9-Tetrahydro-11*H*-pyrido[2,1-*a*]quinazoline (**5**) and its 11-oxo derivative **6** were isolated from *Mackinlaya subulata* and *M. macrosciadia*.

More than a dozen representatives of the pyrido[1,2-*a*]pyrimidine ring system were introduced into human therapy. Pemirolast (**7**) is applied as an orally active antiallergic-asthmatic agent, and its derivative, AS-35 (**8**) is under development for treating allergic disorders. Pirenperone (**9**) is a selective serotonin-2 (5-HT₂) and D-LSD antagonist, metrenperone (**10**) is also a selective 5-HT₂ antagonist, applied in the veterinary field. Risperidone



Scheme 2

(11) became a block-buster as an atypical antipsychotic drug in recent years. Its active metabolite, paliperidone (12) is under preclinical investigations. Ocaperidone (13) exhibits both D₂-dopaminergic and 5-HT₂ serotonergic antagonist activities, lusaperidone (14) is in a development phase as an antidepressant, seganserine (15) is a specific 5HT₂ antagonist, and ramastine (16) is an antihistaminic compound (Scheme 3).

The pharmacological activities of other derivatives of these ring systems are examined intensively. Whereas other representatives of the above ring systems are patented as photographic sensitizers, catalysts for curing polyisocyanates, or dyes for acrylic nylon, polyester filters, and photographic material.


In the following sections structure, thermodynamic aspects, theoretical calculations, spectroscopic properties, reactions, syntheses, and more briefly, utilization of the representatives of these ring systems are discussed.

II. Pyrido[2,1-*b*][1,3]oxazines and Their Benzologs

A. STRUCTURE


1. Theoretical Calculations

Molecular mechanics calculations with the molecular mechanics force field program were performed to compare thermodynamic stability among araguspongine B (17) (containing two *cis*-fused perhydropyrido[2,1-*b*][1,3]oxazine bicycles), araguspongine D (18) (containing two *trans*-fused perhydropyrido[2,1-*b*][1,3]oxazine bicycles), and araguspongine E (19)



Scheme 3


(containing one *cis*-, and one *trans*-fused perhydropyrido[2,1-*b*][1,3]oxazine bicycles). The total energies of araguspongines B (17) and *E* (19) indicate 1.37 and 0.60 kcal/mol of unstability compared to that of araguspongine D (18), respectively (98H(47)195).




Theoretical calculations (B3LYP/6-31G*) were reported for geometries (bond lengths and bond angles) and ^{13}C chemical shifts of 3-methyl- and 3-phenyl-4-hydroxy-2-oxo-2H-pyrido[2,1-*b*][1,3]oxazinium inner salts (00JCS(P2)2096).

2. NMR Spectroscopy

^1H and ^{13}C NMR data for araguspongines B (17), D (18), and E (19) were assigned from a detailed analysis by 2D NMR (COSY, C–H COSY HMBC, and COLOC experiments). Araguspongine B (17) and D (18) have C_2 symmetry as only 14 carbon signals appear in their ^{13}C NMR spectra. NOE correlation and coupling constant showed that the 2,9-disubstituted perhydropyrido[2,1-*b*][1,3]oxazine moiety of araguspongine B (17) has a *cis*-decaline-like conformation, while that of araguspongine D (18) has a *trans*-decaline-like conformation (98H(47)195). On the basis of these results the C(9) stereochemistry of araguspongines B (17) and E (19) was revised.




In D_2O (7*R*)-7 α ,8 β ,9 α -trihydroxy- (20) (99T6759) and (7*R*)-7 α ,8 β ,9 β -trihydroxyperhydropyrido[2,1-*b*][1,3]oxazines (22) (99T14251) exist as an 88:12 and a 45:55 mixture of α and β anomers, respectively. α -Anomer 20 adopts a *cis*-fused ring junction containing the anomeric oxygen atom axial to the piperidine ring due to a strong *endo*-anomeric effect. The coupling constants of the averaged conformations 22 and 23 could be determined at 60 °C. α and β -Anomers 20, 22, 23 and 21, 24, respectively were characterized by ^1H and ^{13}C NMR data.



Scheme 4

Reaction of 3-amino-1-propanol and 5-bromo-5-deoxy-D-furanosyl bromide (25) in D_2O was monitored by 1H NMR (Scheme 4). The α -anomer of trihydroxypyrido[2,1-*b*]-[1,3]oxazine 26 formed 20 times faster, but the β -anomer 27 was more stable ($K_{\alpha/\beta} \approx 7.3$). The faster formation of the α -anomer is a consequence of a kinetic anomeric effect that destabilizes the transition state for equatorial *N*-alkylation and formation of the β -anomer 27 (00JOC889).



On the basis of coupling constants for 4a-H (9.3 and 13.6 Hz) and a $\Delta_{ax,eq}$ value for the C(1)H₂ methylene group (1.1 ppm), *trans* ring junction was assigned in 8-nitro-1,2,3,4,4a,6-hexahydropyrido[1,2-*a*][3,1]benzoxazine (28) (98ZN(B)37).

3. X-ray Investigations

The solid state structure of 3-methyl- and 3-phenyl-4-hydroxy-2-oxo-2H-pyrido[2,1-*b*]-[1,3]oxazinium inner salts were established by X-ray diffraction analysis (00JCS(P2)2096). The “amide type” N(5)–C(4)O bonds are


unusually long (148.7 pm); they are long N–C single bonds showing no sign of an amide type conjugation. The C(4)=O group tilted towards the ring N(5) atom with an O–C(4)–N(5) angle of 114° – 116° (instead of 120°), and the C(2)=O group tilted just as much towards O(1) [O–C(2)–N(1) 112° – 114°]. The presence of a rather unusual hydrogen bond C(6)–H(6) \cdots O(4) with a distance of ~ 30 pm was identified.


The stereostructure of (–)-araguspongine B (**17**) was determined by X-ray crystallographic analysis. This confirmed the results of NMR investigations. The X-ray analysis elucidated that (–)-araguspongine B (**17**) contains 9*R*,9'*R* configurations. On the basis of the structural correlation among araguspongines B, D and E it was clarified that (–)-araguspongine E (**19**) has 9*R*,9'*S* configurations (98H(47)195).

B. REACTIVITY


1. Ring Opening

Treatment of 9*a*-pentylperhydropyrido[2,1-*b*][1,3]oxazin-6-one (**29**) and 5*a*-pentyl-5*a*,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzoxazin-9-one (**31**) with allyltrimethylsilane (3 equiv) in the presence of a Lewis acid (TiCl₄ and HfCl₄) gave ring-opened allylated products **30** and **32**, respectively (99SL37). In the case of tricyclic derivative **31** HfCl₄ and ZnCl₂ did not work. The TiCl₄-induced allylation reactions of diastereomeric 11-methyl-5*a*-pentyl-5*a*,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzoxazin-9-ones **33** (R = H, pentyl) and **34** in CH₂Cl₂ at 50 °C in a sealed tube afforded a 16:1 mixture of ring-opened allylated piperidones **35** and **36** (99TL739, 01OL193).






Enantiopure (*R*)-3-alkylpiperidines (38, R = Me, Et) were obtained when perhydropyrido[2,1-*b*][1,3]benzoxazin-9-ones (37, R = H, Me) were treated first with an excess of AlH₃, then with PCC, followed by a 2.5 N solution of KOH (99TL2421). Treatment of optically active perhydropyrido[2,1-*b*][1,3]benzoxazines 39 and 40 with LAH in the presence of AlCl₃ and DIBALH (if R = COOEt) yielded 3-substituted piperidines 41 (00TA2809).




Hydrolysis and subsequent oxidation of 2-methyl-4,6,7,11*b*-tetrahydro[1,3]oxazino[2,3-*a*]isoquinoline-4-one (42) afforded ring opened product 43 (99TL8269).



2. Reactivity of Ring Carbon Atoms


Neither deuterium incorporation nor double bond migration occurred when 6-cyano-2,3,4,8,9*a*-hexahydropyrido[2,1-*b*][1,3]oxazine (44) was

treated with an alkyl lithium base (BuLi, *sec*BuLi, MeLi) or LDA in THF or Et₂O at -78°C to -20°C followed by quenching with D₂O (99TL7211). However, diastereomeric mixtures of 8-hydroxy or 8-methoxy derivatives **45** (R = H, Me) were obtained when *t*-BuP₄ phosphazene base was used, followed by treatment with D₂O, or with D₂O and MeI, respectively. Diastereomeric 2:1:1:2 and 1:3:3:1 mixtures of 8-(α -hydroxybenzyl) derivatives **46** were prepared from **44** with PhCHO in the presence of LDA and *t*-BuP₄, respectively.




3. Reactivity of Substituents Attached to a Ring Carbon Atom

Reaction of 5a,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzoxazine-7,11-diones **47** (X = O, R = H, Cl) and 2-amino-6-fluorobenzamidine dihydrochloride afforded a diastereomeric mixture of spiroderivatives **48** (X = O, R = H, Cl), which were separated by flash column chromatography (00MIP1).



4. Miscellaneous

Isomerization of araguspongine E (**19**) in boiling Cl(CH₂)₂Cl over dry Al₂O₃ for 24 h gave a 58:36:6 mixture of araguspongines B (**17**), D (**18**) and E (**19**). Similar reaction mixtures were obtained from araguspongines B (**17**) and D (**18**) under the same conditions. Starting from araguspongine E (**19**) a mixture of deuterium labeled araguspongines B, D and E in positions 9 and 9' was obtained in 35:10:55 ratio under reflux for 5 h, when the reaction mixture contained D₂O (98H(47)195). The isomerization was studied in the presence of other catalysts (Scheme 5). No isomerization occurred in the



Scheme 5

cases of AlCl_3 , ZnCl_2 , BBr_3 and CuCl_2 treatment, but proceeded in the presence of $(\text{MeO})_3\text{B}$, $(i\text{-PrO})_3\text{Al}$, and $(i\text{-Pr})_4\text{Ti}$. On the basis of these results it was concluded that the isomer distribution of **17–19** is in accordance with the thermodynamic stability of the individual isomers. Because the substituents at positions 2 and 9 are in equatorial positions both in **17** and **18**, araguspongine D (**18**) having *trans*-decaline-like conformation, and in araguspongine B (**17**) having a *cis*-decaline-like conformation, it was presumed that the isomerization of the C-9 position was accompanied by inversion of the nitrogen lone-pair.


C. SYNTHESIS

1. By Formation of One Bond β to the Bridgehead Nitrogen Atom [6+0 (β)]


Intramolecular electrochemical alkoxylation of racemic 1-(3-hydroxybutyl)piperidine afforded a diastereomeric mixture of 2-methylperhydropyrido[2,1-*b*][1,3]oxazin-4-ones (00MI11).

Depending upon the structure of the substrates **49**, **52**, and **56** hexahydropyrido[1,2-*a*]-[3,1]benzoxazines **50**, **54**, 2-aminobenzaldehyde **53**, 1-substituted piperidones **51**, **55**, **57**, 3,4,5,6-tetrahydropyridinium salt **58**, or their mixture was obtained during the oxidation of 1-(2-hydroxymethyl-, 2-formyl- and 2-acetylphenyl)piperazines (**49**, **52**, **56**) with $\text{Hg}(\text{II})$ -EDTA complex (Schemes 6–8) (79AP219, 98ZN(B)37, 98ZN(B)1369).


Iodocyclization of 1,4-dihydropyridine **59** with I_2 gave a 2 : 3 mixture of 2,3,4,8,9,9*a*-hexahydropyrido[2,1-*b*][1,3]oxazine-7-carboxylates **60** and **61** (98TL5089, 99EJOC2997). When the reaction was carried out in the



Scheme 6




Scheme 7




Scheme 8

presence of NaHCO_3 only 9-iodohexahydro derivative **60** formed in 67% yield.



Treatment of 1-(2-acetoxybenzyl)- and 1-(4-chloro-2-acetoxybenzyl)-1,2,3,4-tetrahydropyridin-4-ones with aqueous LiOH in THF at room temperature gave 5*a*,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzoxazine-7,11-diones **47** ($\text{X} = \text{O}$, $\text{R} = \text{H}$, Cl) ([00MIP1](#)).

Irradiation of piperidine **62** in CH_2Cl_2 at concentration of 3 mg/ml in the presence of 1-methylimidazole using a high-pressure mercury lamp (150 w) yielded 2-phenyl-4,6,7,8,9,9*a*-hexahydropyrido[2,1-*b*][1,3]oxazin-4-one ([01S1258](#)).




The rhodium(II) acetate catalyzed reaction of 2-(3-oxo-2-diazobutyl)-1,2,3,4-tetrahydroisoquinoline in boiling toluene yielded 2-methyl-4,6,7,11b-tetra-hydro[1,3]oxazino[2,3-*a*]-isoquinoline-4-one in 72% yield ([99TL8269](#)).

By partial reduction of glutarimide **63** with Vitride[®] in toluene at -78°C followed by acid treatment (HCl) afforded pyrido[2,1-*b*][1,3]benzoxaine **33** ($\text{R} = \text{H}$) ([01OL193](#)).


2. By Formation of One Bond γ to the Bridgehead Nitrogen Atom [$6+0$ (γ)]

Radical cyclization of perhydro-1,3-benzoxazines **64**, promoted by Bu_4SnH in the presence of AIBN gave a mixture of perhydropyrido[2,1-*b*][1,3]benzoxazin-9-ones **65** and **66** and seven membered tricyclic derivatives **67** and **68**, formed in a 6-exo and 7-endo cyclization process, respectively ([99TL2421](#)). Cyclization of parent acrylamide **64** ($\text{R} = \text{R}^1 = \text{H}$) occurred with moderate regioselectivity (6-exo/7-endo ratio: 65:35) and poor stereoselectivity (**65/66** ratio: 42:43). The presence of a β -methyl group in

crotylamide **64** ($R = \text{Me}$, $R^1 = \text{H}$) disfavored the 7-endo cyclization process, but did not influence the stereoselectivity of the cyclization (**65/66** ratio: 66:34). The presence of an α -methyl group in methylacrylamide **64** ($R = \text{H}$, $R^1 = \text{Me}$) caused a retardation of the 6-exo attack, in favor of 7-endo cyclization in a higher stereoselectivity (**67/68** ratio: 75:12).




Diastereoselective 6-exo-trig radical cyclization of (–)-perhydro-1,3-benzoxazines **69**, **71**, **74** with Bu_3SnH and AIBN gave a diastereomeric mixture of perhydropyrido[2,1-*b*][1,3]-benzoxazines **39**, **70**, and **72**, **73**, and **40**, **75**, respectively (00TA2809).




Intramolecular Diels–Alder reactions of azadienes **76** afforded 6-cyano-2,3,4,8,9,9*a*-hexahydropyrido[2,1-*b*][1,3]oxazines **77** (99TL7211, 99TL7215). Cyclization was carried out smoothly at or below room temperature in

the presence of different Lewis acids [$\text{Cu}(\text{OTf})_2$, BCl_3 , TiCl_4 , AgSbF_6 , $\text{Cu}(\text{oxaz})_2(\text{OTf})_2$] (99TL7215).



3. By Formation of Two Bonds from [5+1] Atom Fragments

Cyclocondensation of 3-aminopropanol and 2-hydroxybenzylamines **78** with 5-oxodecanoic acid in boiling benzene gave 9*a*-pentylperhydropyr-ido[2,1-*b*][1,3]oxazine-6-one (**29**) and 5*a*-pentyl-5*a*,6,7,8,9,11-hexahydropyr-ido[2,1-*b*][1,3]benzoxazin-9-ones **31**, **33** ($\text{R} = \text{C}_5\text{H}_{11}$), **34** in good yields (99SL37, 99TL739). 2-Hydroxy- α -methylbenzylamine (**78**, $\text{R} = \text{Me}$) afforded a 46:1 diastereomeric mixture of 11-methylhexahydropyrido[2,1-*b*][1,3]benzoxazin-9-ones **33** ($\text{R} = \text{C}_5\text{H}_{11}$) and **34** (99TL739).



4. By formation of Two Bonds from [4+2] and [3+3] Atom Fragments

Cycloaddition of 2-styryl-4*H*-3,1-benzoxazines and malononitrile gave 1-amino-3-aryl-2-cyano-1*H*,6*H*-pyrido[1,2-*a*][3,1]benzoxazin-4-ones (99ZN(B)923). These tricyclic derivatives were also prepared in the reaction of 2-methyl-4*H*-3,1-benzoxazin-4-one and arylidenemalononitrile in AcOH in the presence of NaOAc .


3-Methyl- and 3-phenyl-4-hydroxy-2-oxo-2*H*-pyrido[2,1-*b*]oxazin-9-ones inner salts were prepared in the reaction of 2-pyridone and 2-substituted malonyl chloride, prepared *in situ* from 2-substituted malonic acid with PCl_5 in CH_2Cl_2 (00JCS(P2)2096).

5. Miscellaneous



Reaction of 3-aminopropanol with an α and β mixture of 5-bromo-5-deoxy-2-xylofuranose (**25**) and 5-*O*-tosyl-D-lyxofuranose in MeCN afforded anomeric mixtures of trihydropyrido[2,1-*b*][1,3]oxazines **20**, **21** and **22–24**, respectively (99T6759, 99T14251).


D. APPLICATIONS AND IMPORTANT COMPOUNDS

Chiral 3-alkylpiperidines were prepared through perhydropyrido[2,1-*b*][1,3]benzoxazines (99TL2421, 00TA2809). 5*a*-Pentyl-5*a*,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzoxazin-9-ones **31**, **33** ($R = C_5H_{11}$) and **34** were used in the total synthesis of racemic and natural (–)-(*R*) forms of adalinine alkaloid (99SL37, 99TL739).



The antihypertensive activity of 8-aryl-6,9*a*-dimethyl-2,3,4,8,9,9*a*-hexahydropyrido[2,1-*b*][1,3]oxazine-7,9-dicarboxylates **79** was evaluated in conscious spontaneously hypertensive rats. They resulted in potent and long-lasting antihypertensive action (97MI14).





Araguspongines B, D, C, A and other six bis-pyrido[2,1-*b*][1,3]oxazine alkaloids **17**, **18**, **80–87** were isolated from an unidentified marine sponge and they were patented as antitumor agents (97MIP1). Araguspongine C (**80**) was isolated from the marine sponge *Haliclona exigus* (96MI6). 3 β ,3 β' -Dimethylxestospongine was isolated from the Palaun-Sponge *Xestospongia* sp. (97MI3). Araguspongine/Xestospongine derivatives **17–19**, **88**, **89** are shown to be potent blockers of the inositol 1,4,5-trisphosphate receptor-mediated Ca^{2+} release from endoplasmic reticulum vesicles of rabbit cerebellum (97MI19).

III. Pyrido[2,1-*b*][1,3]thiazines and Their Benzo Derivatives

A. STRUCTURE

1. Theoretical Calculations

A molecular mechanics prediction of the conformation of *trans*-8,9*a*-H-8-phenyl-perhydropyrido[2,1-*b*][1,3]thiazin-6-one gave similar data as NMR experiments (00BAP19).

2. ^1H NMR Spectroscopy

Some coupling constants of *trans*-8,9*a*-H-8-phenyl-, -8-(2-methoxyphenyl)-, and -8-(4-methylphenyl)phenylperhydropyrido[2,1-*b*][1,3]thiazin-6-ones in CDCl_3 were measured by ^1H NMR spectroscopy (00BAP19).

B. REACTIVITY

1. Ring Opening

Treatment of *trans*-8,9*a*-H-8-(2-methoxyphenyl)perhydropyrido[2,1-*b*][1,3]thiazine-6-one with 2.5 equiv of HSnBu₃ in the presence of AIBN in boiling benzene for 1.5 h yielded 4-(2-methoxyphenyl)-1-[3-(tributylstannylthio)propyl]piperidin-2-one (01S135).


2. Hydrogenation, Reduction

Diethyl *cis*-3*H*,4*H*-3-methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4,9-dicarboxylate was obtained from the 3-methyl-6-oxo-4*H*,6*H* derivative by catalytic hydrogenation over 5% Rh on alumina in EtOH for 5 days. Catalytic reduction in a D₂ atmosphere in EtOAc overnight yielded a 2,3-dideutero-4*H*,6*H* derivative. *cis*-3*H*,4*H*-3-Methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4,9-dicarboxylate was also prepared from the 3-methyl-6-oxo-2*H*,6*H* isomer by reduction with an aqueous solution of NaBH₄ in THF at room temperature for 3 h (00JCS(P1)4373). Treatment of 4-alkoxycarbonyl-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-9-carboxylic acid first with ClCOOEt in the presence of NEt₃ in THF at 0 °C for 1 h, then with an aqueous solution of NaBH₄ at 0 °C for 1 h, then at room temperature for 3 h afforded a 9-hydroxymethyl-6-oxo-2*H*,6*H* derivative. In another experiment starting from the ethyl ester at -15 °C, ethyl 3,4-*cis*-H-9-hydroxymethyl-3-methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylate was obtained in 57% yield. The latter product was prepared in a similar yield from 4-ethoxycarbonyl-3,4-dihydro-3-methyl-6-oxo-2*H*,6*H*-pyrido-[2,1-*b*][1,3]thiazine-9-carboxylic acid using ClCOOEt and NEt₃ at -15 °C in THF, and then aqueous NaBH₄. Hydrogenation of ethyl 9-hydroxymethyl-3-methyl-6-oxo-4*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylate over Rh-Al₂O₃ in acidified MeOH at room temperature for 15 h gave a 2:1 mixture of 9-methoxymethyl-3,4-dihydro-2*H*,6*H*- and 9-hydroxymethyl-3,4-dihydro-2*H*,6*H* derivatives (00JCS(P1)4373).

3. Oxidation

Oxidation of diethyl 3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4,9-dicarboxylate and its 7,8-dihydro derivative with CF₃CO₃H in CH₂Cl₂ at room temperature gave the respective sulfone in 73% and 38% yields, respectively (99JCS(P1)3569). Sulfoxide **91** or sulfone **92** of

5-phenyl-1,2,3,6-tetrahydro[1,3]thiazino[3,2-*a*]quinolin-6-ones **90** were prepared depending on the molar ratio of oxidizing agent and substrate (97JAP(K)97/278780).



4. Reactivity of Substituents Attached to Ring Carbon Atoms


[4*R*-(4 α ,9 β ,9 $\alpha\beta$)]-9-(Benzyloxycarbonylamino)-6-oxoperhydropyrido[2,1-*b*][1,3]thiazine-4-carboxylic acid was obtained from the methyl ester by treatment with 2 N LiOH in MeOH at 0 °C for 4.5 h. The carboxyl group was coupled with amino esters. The 9-(benzyloxycarbonylamino) group was deprotected by treatment with a 1:1 mixture of TFA and CH₂Cl₂ at room temperature and the amino group was acylated with an amino acid (97MIP4, 98USP5710129).

Treatment of alkyl 9-benzyloxycarbonyl-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylates with BBr₃ in CH₂Cl₂ at -70 °C for 0.5–1 h and at room temperature for 3 h yielded 9-carboxyl derivatives. The decarboxylation of these acids was unsuccessful. Hydrolysis of diethyl *cis*-3,4-*H*-3,4-dihydro-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4,9-dicarboxylate in aqueous EtOH with KOH at room temperature for 3 days yielded 4-ethoxycarbonyl-3,4-dihydro-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-9-carboxylic acid (00JCS(P1)4373). Alkyl 9-hydroxy-methyl-3-methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylates were *O*-acylated with Ac₂O and (PhCO)₂O in pyridine at room temperature for 12–48 h.

Reaction of 5*a*,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzothiazine-7,11-dione (**47**, X = S, R = H) and 2-amino-6-fluorobenzamidine dihydrochloride in boiling EtOH yielded a diastereomeric mixture of spiro derivatives **48** (X = S, R = H), which were separated by flash column chromatography (00MIP1).

5. Ring Transformation

Irradiation of 9-substituted 6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[1,2-*b*][1,3]thiazine-4-carboxylate **93** in benzene afforded tricyclic derivatives **94**, sometimes as a diastereomeric mixture (00JCS(P1)4373).



6. Miscellaneous

Ethyl 9-ethoxycarbonyl- and 9-hydroxymethyl-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylates were isomerized into 4*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylates by treatment with KOH overnight at room temperature and by treatment with NaOEt at 0°C for 1 h and room temperature for 3 h in EtOH, respectively. In another experiment, when the 9-hydroxymethyl derivative was treated with NaOEt in EtOH at -10°C for 3 h, a 2.5:1 mixture of ethyl 3,4-*cis*-H-9-ethoxymethyl-3-methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylate and the aforementioned 4*H*,6*H*-isomer were obtained (00JCS(P1)4373).


C. SYNTHESIS

1. By Formation of One Bond β to the Bridgehead Nitrogen Atom [6+0 (β)]

Treatment of 1-(2-thioacetoxybenzoyl)-1,2,3,4-tetrahydropyridin-4-one with aqueous NaOH in MeOH yielded 5*a*,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzothiazine-7,11-dione (**47**, X = S, R = H) in 44% yield (00MIP1).


2. By Formation of One Bond γ to the Bridgehead Nitrogen Atom [6+0 (γ)]

Radical cyclization of 2-methylene-3-[3-(het)arylacroyl]perhydrothiazines **95** on the action of HSnBu₃ in the presence of AIBN in boiling benzene gave a mixture of *cis*-8,9*a*-H- and *trans*-8,9*a*-H-8-(het)aryl-6-(tributylstannyloxy)-3,4,8,9-tetrahydro-2*H*,9*aH*-pyrido[2,1-*b*][1,3]thiazines **96** and **97**, which were hydrolyzed to a 1:3 mixture of *cis*-8,9*a*-H- and *trans*-8,9*a*-H-8-(het)arylperhydropyrido[2,1-*b*][1,3]thiazin-6-ones **98** and **99** (01S135).



3. By Formation of Two Bonds from [3+3] Atom Fragments

Cyclocondensation of pyridine-2-thione **100** with cinnamitriles **101** in the presence of a catalytic amount of NEt_3 afforded 4,6-dihydropyrido[2,1-*b*][1,3]thiazine-6-ones **102** ([98MI10](#), [99MI26](#)).




5-Phenyl-1,2,3,6-tetrahydro[1,3]thiazino[3,2-*a*]quinolin-6-ones **90** were prepared in the reactions of 2-mercapto-5-phenyl-1,4-dihydroquinolin-4-ones **103** and 1,3-dihalopropane in 55–79% yields ([97JAP\(K\)97/278780](#)).

4. Rearrangement

Oxidation of 8-(1-methylethenyl)-2-oxo-7-thia-1-azabicyclo[4.3.0]octa-3,5-diene-5,8-dicarboxylate (**104**) and its 3,4-dihydro derivative in CHCl_3 with peracids (*m*-chloroperbenzoic acid and $\text{CF}_3\text{CO}_3\text{H}$) at room temperature gave diethyl 3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4,9-dicarboxylate and its 7,8-dihydro derivative in 66% and 56% yield, respectively ([99JCS\(P1\)3569](#)).

5. Miscellaneous

Cyclocondensation of D-homocystine methyl ester hydrochloride (**106**) and aldehyde **105** in the presence of Ph_3P yielded 9-(benzyloxycarbonylamino)-6-oxoperhydropyrido[2,1-*b*][1,3]thiazine-4-carboxylate (**107**) and its diastereomer ([97MIP4](#), [98USP5710129](#)).



IV. Pyrido[1,2-*a*]pyrimidine

A. STRUCTURE

1. Thermodynamic Aspects

Gas-phase basity and proton affinity values for 3,4,6,7,8,9-hexahydro-2*H*-pyrido[1,2-*a*]pyrimidine were determined and they were compared to other super bases, including its lower and higher piperidine ring homologs ([94JPO725](#), [01JPO25](#)).

Stability constants of metal complexes of 9-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one [Ni(II) , Co(II) , Zn(II) , and Cd(II)] were determined by potentiometric and polarographic investigations ([93JCC283](#)). The distribution coefficient of risperidone (**11**) in H_2O -*n*-octanol at pH 7.4 ($\log D = 2.04$) was determined by an RP-HPLC method ([01JMC2490](#)).

The chromatographic retentions (TLC, R_f values) of alkyl derivatives of 4*H*-pyrido[1,2-*a*]pyrimidin-4-one and its 6,7,8,9-tetrahydro derivatives were calculated with high accuracy by a quantitative structure-retention relationship study using quantum chemical, topological, electrical indices and physicochemical properties of molecular fragments ([92MI3](#)). Good correlations were found between H_2O -*n*-octanol partition coefficients of 4*H*-pyrido[1,2-*a*]pyrimidin-4-one and its 6 alkyl derivatives by the shake-flask technique, and TLC R_M and HPLC $\log k'$ values ([99MI10](#)). The lipophilic character of pirenperone (**9**) was characterized by R_M values using a reversed-phase TLC system, and a reversed-phase high-performance TLC.

The chromatographic parameters were compared with calculated H_2O -*n*-octanol log *P* value (2.23) (by CLOGP program) (96JC(A)135).

Sensitive HPLC methods were also developed for the determination of **11** and its active 9-hydroxy metabolite, paliperidone (**12**), in biological media (97JC(B)209, 97MI11, 99MI2, 99MI3, 99MI6, 99MI11, 00JC(B)173, 00MI13, 01MI1) and in formulations (00MI16, 00MI37). The plasma levels of **11** and **12** were monitored by a HPLC (97MI12, 00MI29). Effects of amine additives on the resolution of **11** on a cyanoalkyl HPLC column were investigated (98MI13). Risperidone was also used to evaluate the performance of new HPLC conditions (00MI28, 00MI35). Risperidone and **12** were determined in biological media by LC-MS-MS methods (00JC(B)141, 00MI20). Nortriptyline was determined in human serum in the presence of **11** by HPLC (00JC(B)233). A capillary zone electrophoresis method was developed to determine **11** and other drugs from whole blood (95MI3), and in pharmaceutical formulations (00MI1). In tablets **11** was determined by a first order derivative of its UV spectrum (01MI11). Plasma protein binding of **11** and **12** was investigated by equilibrium dialysis (94MI10).

An algorithm for an assesment of chromatographic peak purity was proposed. In this study ethyl 8-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate was also used (97MI13). Ethyl 7-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, among other compounds, was applied to show practical mathematical tools for the creation of several figures of merit of *n*th order instrumentation, namely selectivity, net analyte signal and sensitivity (96ANC1572).

2. Theoretical Calculations

Bond orders and charge densities of 4*H*-pyrido[1,2-*a*]pyrimidin-4-one and its protonated form were calculated by the semiempirical AM1 method with full optimization of geometry (97MI22).


Theoretical calculations (B3LYP/6-31G*) were reported for geometries (bond lengths and bond angles), IR, 1H and ^{13}C chemical shifts of *anhydro*-(2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxide and its 1-methyl-, 3-methyl- and 3-phenyl derivatives and 2-methoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one and its 3-methyl derivative (00JCS(P)2096). The optimized geometry of *anhydro*-(2-hydroxy-3-benzyl-1-phenyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxide in the gase phase was calculated on a semiempirical AM1 level by HyperChem Release 4 (00MI26).

Among others, **11** was included in a series of drugs to study quantitative structure-activity relationships (96KFZ(6)29, 98MI7, 99BMC2437). A statistically significant CoMFA model was developed for describing the

variation of the antiplatelet activity of 2-(substituted amino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones and their congeners in terms of molecular steric and electrostatic potential changes (00BMC751). A QSAR model was set up for prediction of drug human oral bioavailability (00JMC2575). Risperidone (10) was included in the test compounds.

Conformations of 4-oxo-1,6,7,8,9,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates and -3-carboxamides were studied by semiempirical quantum chemical calculations at the AM1 level (97H(45)2175). While 1-methyl-9*a*-unsubstituted derivatives adopt a *cis*-fused conformation, 9*a*-ethoxy-1-methyl derivatives adopt a *trans*-fused one to avoid a serious non-bonding interaction between 9*a*-ethoxy and 1-methyl groups, which would be present in an alternative *cis*-fused conformation.

Chinoin-1045 (108) was including a series of structurally divers compounds designing sedative/hypnotic derivatives from novel substructural graph-theoretical approach (98MI11).




3. UV Spectroscopy

Diorganotin(IV) complexes with 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **109** (96MI4), complexes of 2-methyl- and 2-methyl-8-nitro-9-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones with Ag(I), Cu(II), Ni(II), Co(II), and Mn(II) ions (00MI23), 2,4-dimethyl-9-hydroxypyrido[1,2-*a*]pyrimidinium perchlorate and its complexes with praseodymium, neodymium, samarium and europium (00MI24) were characterized by UV spectroscopy.

4. IR Spectroscopy

Diorganotin(IV) complexes **109**, and complexes of 2-methyl- and 2-methyl-8-nitro-9-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones with Ag(I), Cu(II), Ni(II), Co(II), and Mn(II) ions (00MI23), 2,4-dimethyl-9-hydroxypyrido[1,2-*a*]pyrimidinium perchlorate and its complexes with praseodymium, neodymium, samarium and europium (00MI24) were characterized

by IR spectroscopy (96MI4). In the IR spectra of 4-fluoroalkyl-2H-pyrido[1,2-*a*]pyrimidin-2-ones **110** the CO stretching band is shifted by 60–70 cm⁻¹ to lower wavenumbers as compared with that of 2-fluoroalkyl-4-oxo-4H isomers **111** (97JCS(P1)981).




IR spectra in conjunction with theoretical calculations (B3LYP/6-31G*) indicate that the *anhydro*-(2-hydroxy-4-oxo-4H-pyrido[1,2-*a*]pyrimidinium)-hydroxide form exists in solution and in the crystal, but the 2-hydroxy-4H-pyrido[1,2-*a*]pyrimidin-4-one tautomer dominates in the gas phase (00JCS(P2)2096).


Polymorphic forms of I and II of 3-{2-[4-(6-fluorobenzo[*d*]isoxazol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-*a*]pyrimidin-4-one was characterized by IR spectroscopy (99MIP1).

5. NMR Spectroscopy

Diorganotin(IV) complexes **109** were characterized by ¹H NMR spectroscopy (96MI4). The downfield chemical shift of 6-H in 2-fluoroalkyl-4H-pyrido[1,2-*a*]pyrimidin-4-ones **111** is attributed to the anisotropic effect of the 4-carbonyl group (97JCS(P1)981).



^1H and ^{13}C NMR investigations using D_2O showed that bicyclic diazasugar analogs of D-xylose, L-arabinose, and D-ribose exist as pure β anomer **112** ($\text{R}=\text{H}$) (98JOC391, 99T6759), a 7:3 mixture of α and β anomers **113** and **114**, and mainly as β anomer **115** (98T5097), respectively. In the latter case the minor compound was believed to be the α anomer **116**. ^1H NMR investigations of *N*(1)-methyl **117** and *N*(5)-methyl **118** derivatives of **112** ($\text{R}=\text{H}$) revealed that they adopted a similar conformation as the parent **112** ($\text{R}=\text{H}$) (99T6759). Both *N*-methyl derivatives contain the methyl group in an axial position. All of them have a *trans*-ring junction. Whereas, *cis*-2*H*,4*H*,9*aH*-dimethyl derivative **112** ($\text{R}=\text{Me}$) exists in a single conformation, its *cis*-2*H*,4*H*-*trans*-9*aH* diastereomer **119** is conformationally complex, consisting of $\alpha 1$, $\alpha 2$, and β anomers in equilibrium in D_2O (00JOC889).



Theoretical calculations (B3LYP/6-31G*) indicated that in their ^{13}C NMR spectra C(2) and C(9) carbons of *anhydro*-(2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxide mesoionic forms appeared at significantly higher field (ca. 159–160 ppm and 115–116 ppm, respectively), than in the 2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one tautomers (ca. 169–173 ppm and 130 ppm, respectively) (00JCS(P)2096). C(8) carbon of mesoions (pyridine- γ type carbon) appeared at lower field (144–146 ppm) than 6-C (140 ppm, pyridine- α type carbon), as is typical of pyridinium compounds.

A 9:1 mixture of 2,4-difluoro-4-pentafluoroethyl-3-trifluoromethyl-2*H*-, and 2,4-difluoro-2-pentafluoroethyl-3-trifluoromethyl-4*H*-, as well as 2-pentafluoroethyl-3-trifluoromethyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine were characterized by ^1H , ^{13}C , and ^{19}F NMR (00JFC105). 2-Trifluoromethyl-3-cyano-4-imino- and -4-oxo-4*H*-pyrido[1,2-*a*]pyrimidines were characterized by ^1H and ^{19}F NMR (00MI27).


Polymorphic forms I and II of 3-{2-[4-(6-fluorobenzo[*d*]isoxazol-3-yl)-3,6-dihydro-2*H*-pyridin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one were characterized by solid state ^{13}C NMR (99MIP1).

6. Mass Spectrometry

The mass spectrometric behavior of the isomeric 2-oxo-2*H*- and 4-oxo-4*H*-6,7,8,9-tetrahydropyrido[1,2-*a*]pyrimidines was studied under electron-impact induced polarization (97RCM664). The molecular ion of the 2-oxo-2*H* isomer appeared to be much more stable than that of the 4-oxo-4*H* isomer. The fragmentation of the molecular ion (M^+) of the 4-oxo-4*H* isomer is related mostly to the saturated piperidine ring, whereas that of the 2-oxo-2*H* isomer is much more selective, the only significant process is the primary loss of a CO molecule from the pyrimidinone ring via contraction of the ring. Electrospray ionization quadrupole ion-trap mass spectrometric characterization of risperidon (**11**) was presented and a possible mechanism for the observed MS^n fragmentation pattern was proposed (00JC(B)141).

7. X-ray Investigations

The structure of 2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide (**120**) was confirmed by X-ray investigations. The crystal unit cell contains one mol of $CHCl_3$ and two crystallographically independent pyrido[1,2-*a*]pyrimidines with substantially identical geometries (93JHC33). The structures of 2,4-dimethyl-9-hydroxypyrido[1,2-*a*]pyrimidinium perchlorate (00MI24), 3-acetyl-4-phenylamino- and 3-acetyl-4-methylthio-2*H*-pyrido[1,2-*a*]pyrimidin-2-ones **121** (95MI2, 96MI22), *anhydro*-(2-hydroxy-3-benzyl-1-phenyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium) hydroxide (00MI26), 2-pentafluoroethyl-3-trifluoromethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (00JFC105), 3-cyano-7-methyl-2-trifluoromethyl-4-imino-4*H*-pyrido[1,2-*a*]pyrimidine (00MI27) and 2-methyl-9-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (00MI23) were established by X-ray diffraction analysis.



The solid state structures of *anhydro*-(3-methyl- and 3-phenyl-2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxides, 2-methoxy-3-methyl-4*H*- and 2-(2-pyridylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones were established by X-ray diffraction analysis. The “amide type” N(5)–C(4)–O bonds are unusually long (144–149 pm) showing no sign of an amide type conjugation.

The C(4)=O group tilted towards the ring N(5) atom [O–C(4)–N(5) angle: 115°–118° instead of 120°], and C(2)=O groups just tilted as much towards O(1) [O–C(2)–N(1) angle: 116°–118°]. The presence of a rather unusual hydrogen bond C(6)–H(6)⋯O(4) with a distance of 22–23 pm was detected (00JCS(P2)2096).

The relative stereostructure of 9-acetyl-7-hydroxy-1,2-dimethyl-7-methoxycarbonyl-4-phenyl-6-oxo-1,4,7,8-tetrahydro-6*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate **122** was justified by an X-ray diffraction analysis (97JOC3109). The stereochemistry and solid state structure of racemic *trans*-6,9-*H*-1,6-dimethyl-9*a*-ethoxy-9-hydroxy-4-oxo-1,6,7,8,9,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate (**123**), adopting a *cis*-fused conformation, were determined by X-ray investigations (97H(45)2175).

Solid state structure of pirenperone (**9**) was determined by X-ray investigations (95AX(C)533). The pyrido[1,2-*a*]pyrimidine ring system deviates significantly from planarity with maximum deviations for C(3) and C(8) atoms [46(7) and 58(7) pm, respectively]. An analysis was carried out on the available crystal structures of 5-HT₁, 5-HT₂ (including **9** and **11**) and 5-HT₃ selective drugs to identify their similarities with the endogenous ligand serotonin (5-HT) and the stereochemical differences, which determine selectivity for the various receptor subtypes (96AX(B)509).


X-ray diffraction investigations of *cis*-8,9*a*-*H*-*trans*-7,9-*H*-7,8,9-trihydroxyperhydropyrido[1,2-*a*]pyrimidine (**112**, R = H), obtained in the reaction of D-xylose and 1,3-diaminopropane, revealed that it was the β -anomer with a *trans*-fused conformation containing all the hydroxy groups in equatorial positions (98JOC391, 98T5097). X-ray crystallography established that the bicyclic diazasugar analog of L-arabinose exists in the solid state as a single configuration and conformation of **114**, containing an axial NH bond (98T5097). Both the bicyclic diazasugar analog of D-ribose and its HCl salt have similar conformation **115**. Protonation occurred on N(1), and in the base the NH bond occupied an axial orientation (98T5097). X-ray diffraction studies justified that in the solid state both 1-methyl **117** and 5-methyl **118** derivatives of perhydropyrido[1,2-*a*]pyrimidine **112** (R = H) contain the methyl group in axial position (99T6759). 5-Methyl derivative **118** contains an axial N(1)H bond, and a much shorter N(1)–C(9*a*) bond (139.7 pm) than that of the N(5)–C(9*a*) bond (157.4 pm), suggesting the presence a very strong *exo*-anomeric effect in the molecule.

Polymorphic forms I and II of 3-{2-[4-(6-fluorobenzo[*d*]isoxazol-3-yl)-3,6-dihydro-2*H*-pyridin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one were characterized by the powder X-ray diffraction model (99MIP1).

B. REACTIVITY


1. Ring Opening

Reaction of 4-imino-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitriles **124** with NaN₃ in the presence of NH₄Cl gave 3-(2-pyridylamino)-2-(1*H*-tetrazol-5-yl)acrylonitriles **125** (93MIP3).



Flash vacuum thermolysis (FVT) of 2-substituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **126** above 800 °C afforded (2-pyridyl)iminopropadienone (**130**) (99JCS(P2)1087). These reactions were interpreted in terms of reversible ring opening of 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones to imidoalkenes **127**. A 1,5-H shift in **127** generated the N(1)H-tautomeric methylene ketene **128**, in which facile elimination of HX took place via a six-membered cyclic transition state **129** to yield **130**. In the case of 2-methoxy derivative **126** (X = OMe) another competing pathway was also identified at lower temperature, which resulted in the formation C₃O₂ and 2-methylaminopyridine via mesoionic isomer **131** (Scheme 9). The products were identified by IR spectroscopy.


For some further example see Section IV.B.8.



Scheme 9


2. Hydrogenation, Reduction

Hydrogenation of mesoionic pyrido[1,2-*a*]pyrimidin-4-ones **132** over Pd/C catalyst yielded 6,7,8,9-tetrahydro derivatives **133** (95H(40)681, 96JHC663). Catalytical hydrogenation of 2-(4-methyl-1-piperazinyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one over Raney Ni in EtOH under hydrogen pressure (45 psi) (93FES1225), and that of 2-(1-piperazinyl)- (00BMC751), 3-(2-hydroxyethyl)- (94MIP8), 3-(2-chloroethyl)- (01MIP11), 9-hydroxy-3-(2-bromoethyl)- (96MIP2), 9-methoxy-3-(2-hydroxyethyl)- (95MIP4, 96MIP2), 3-(acetamido)- and 3-(benzamido)- (98MI8, 00JHC783), and 9-dodecyloxy-3-(2-chloroethyl)-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (95MIP4) over Pd/C catalyst afforded the appropriate 6,7,8,9-tetrahydro derivative. Catalytic hydrogenation of 3-(benzyloxycarbonylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones over Pd/C gave 3-amino-6,7,8,9-tetrahydro derivatives, whereas hydrogenation over 10% Pt/C yielded 3-(benzyloxycarbonylamino)-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (00JHC783). 3-Amino-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was also obtained by the catalytic hydrogenation of 3-[(2-acetyl-2-ethoxycarbonyl-1-ethenyl)amino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one over Pd/C in EtOH (00JHC783). Catalytic hydrogenation of 3-[2-(bisbenzylamino)ethyl]-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-4-one over 10% Pd/C catalyst in EtOH gave 3-(2-aminoethyl) derivative (94MIP8).



Hydrogenation of 2-[(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)oxymethyl]-4-isopropyl-6-alkoxysaccharins **134** over 10% Pd/C catalyst at 50 psi in a Parr hydrogenator yielded 6,7,8,9-tetrahydro derivatives **135** (94EUP626378, 95JMC4687, 95USP5378720). When 6-[2-(benzyloxy)ethoxy] derivative **134** (R = CH₂CH₂OCH₂Ph) was hydrogenated

6-(2-hydroxyethoxy) derivative **135** ($R^1 = \text{CH}_2\text{CH}_2\text{OH}$) was the product ([94EUP626378](#), [95USP5378720](#)).




3-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1,2,3,6-tetrahydro-1-pyridyl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones **137** were obtained by reduction of pyridinium salts **136** with NaBH₄ ([95MIP5](#), [99MIP1](#), [00MIP10](#)). Reduction of 9-formyl-7-methyl-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one with NaBH₄ in MeOH at room temperature gave a 9-hydroxymethyl derivative ([01MIP9](#)).

Reduction of pehydropyrido[1,2-a]pyrimidine with DIBAL-H in toluene led to the formation of 1,5-diazacyclodecane in 60% yield ([99JCS\(CC\)1279](#)).

For further examples see [Section IV.B.7](#).

3. Oxidation

Oxidation of 9-(4-pyridylvinyl)-7-methyl-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one with cetyltrimethylammonium permanganate in CH₂Cl₂ at room temperature for 5 h yielded a 9-formyl derivative ([01MIP9](#)).




4. Reactivity of Ring Nitrogen Atoms

Perhydropyrido[1,2-*a*]pyrimidin-2-one was *N*-alkylated with 1,4-dibromobutane to yield a 1-(4-bromobutyl) derivative (**94MIP6**). 6-Methyl-4-oxo-4*H*-1,6,7,8,9,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate **138** was alkylated with alkyl chlorides **139** to give 1-substituted derivatives **140** (**97MIP2**).



5. Reactivity of Ring Carbon Atoms


Nitration of 2-(1-piperazinyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one with 99% HNO₃ in 96% H₂SO₄ at 0°C (**00BMC751**) and that of 2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one and its 6-, 7-, 8-, and 9-methyl derivatives with a mixture of HNO₃ and 96% H₂SO₄ in the presence of Ac₂O at 0°C (**93IJC(B)978**) gave the appropriate 3-nitro derivative. Nitration of 2-chloromethyl-7-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one in conc. H₂SO₄ with fuming HNO₃ at 0°C yielded the 3-nitro derivative (**01H(55)535**).

Chlorination of 2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one with NCS in a mixture of AcOH and TFA at room temperature for 72 h yielded a 3-chloro-2-hydroxy derivative (**95JMC4687**). Bromination of 2-chloro-4*H*-pyrido[1,2-*a*]pyrimidinone with Br₂ in a mixture of CH₂Cl₂ and pyridine at room temperature for 15 min gave a 3-bromo derivative (**00BMC751**).




Alkylation of mesoionic **132** (R=H) with 2-chloromethyl-4-(3-methylbutyl)-5-methyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide gave a mixture of C-3 and 2-*O*-alkylated products **141** and **142** (**96USP5512576**).





3-Arylsulfonyl derivatives **151** were obtained from mesoionic **150** with diaryl disulfides in the presence of K₂CO₃ when air was bubbled through the reaction mixture (99MI147). *anhydro*-(2-Hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones)hydroxide (R = H) afforded 3-dialkylaminothiocarbonylthio derivatives **152** in the reaction of tetraalkylthiuram disulfides under similar conditions.

9-Arylhydrazono-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **154** were obtained from 6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **153** with aryldiazonium chlorides in the presence of NaOAc · 3H₂O at 0 °C overnight (96JHC799, 99MI12, 00MI22).




2,7-Dichloro-3-propyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**155**) was obtained from *anhydro*-(2-hydroxy-7-chloro-3-propyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones)hydroxide in boiling POCl₃ for 88 h in 27% yield, and then the 2-chloro atom was changed for a 2-propylthio group with PrSH to give **156** (93MIP4). Treatment of 9-benzyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one with excess POCl₃ under reflux yielded a 2-chloro derivative (01MIP9). 2-Ethylamino and 2-(disubstituted amino)-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitriles were obtained in the reaction of 2-methylthio-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile with an excess of EtNH₂ and secondary amines in boiling MeCN for 48–52 h (95MI9).

In the series of reactions the chloro atom of 2-chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones was substituted by different primary and cyclic amines (93FES1225, 95EJM27, 00BMC751, 01MIP9), and by ethylenediamine and 1-aminopiperazine (00BMC751) in boiling EtOH; by an excess of Me₂NH in a mixture of CH₂Cl₂ and Et₂O at room temperature for 16 h and by Et₂NH in boiling CHCl₃ for 24 h (99JCS(P2)1087), by *i*-Bu₂NH and cyclohexylamine in HOCH₂CH₂OH at 160 °C for 2 h, and by 2-aminopyridine and its 4- and 5-methyl derivatives in a melt at 200 °C for 4 h (93FES1225, 01JCS(P2)602). The chloro atom of 2-chloro-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was also substituted by different secondary amines (96T13081).

Reaction of 9-bromo-2-morpholino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones with 4-vinylpyridine in DMF at 80 °C for 16 h in the presence of Cs₂CO₃ and PdCl₂(dppf), and with amines and phenols in boiling THF for 20 h in the presence of KO*t*-Bu and PdCl₂(dppf) yielded 9-[2-(4-pyridyl)vinyl], 9-(substituted amino), and 9-aryloxy derivatives, respectively (01MIP9). 4-Hydroxyaniline gave a 9-(4-hydroxyphenyl)amino derivative.

2-Methoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was prepared from 2-chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one with NaOMe in MeOH for 16 h, and from *anhydro*-(2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-4-yl)hydroxide with Me₂SO₄ in the presence of NaOMe in MeOH for 3 h at room temperature in 93% and 41% yields, respectively (99JCS(P2)1087). 2-(2-Hydroxyethoxy)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was prepared from the 2-chloro derivative with HOCH₂CH₂OH in the presence of K₂CO₃ at 160 °C for 1 h (00BMC751).

2-Chloro-4*H*-pyrido[1,2-*a*]pyrimidine-4-thione was obtained by the treatment of the 4-oxo derivative with Lawesson's reagent in boiling anhydrous toluene, and then the 2-chloro atom was changed for a piperazino group with piperazine in boiling EtOH (00BMC751). Treatment of 7-chloro-3-propyl-2-propoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one with (P₂S₅)₂ (93MIP4), and that of 1,3,3-trimethyl-9-phenyl-1,2,3,6,7,8-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-2,4-dione with Lawesson's reagent (96H(42)117) afforded 4-thione and 2,4-dithione derivatives, respectively.




Heating 9-ethoxycarbonylmethylene-4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate (**157**) at 250 °C yielded 6,7-dihydro derivative **158** (99T10221). Under similar conditions 9-benzylidene-6,7,8,9-tetrahydro derivatives **159** did not give the respective 9-benzyl-6,7-dihydro isomer.

For further example see Section IV.B.7.

6. Reactivity of the Substituents Attached to a Ring Nitrogen Atom

Photolytic cleavage of the substituent in position 1 of 1,2-dihydro-6*H*-pyrido[1,2-*a*]pyrimidine-2,6-dione **160** with 320 nm light gave 6*H*-pyrido[1,2-*a*]pyrimidin-6-one **161** (95MIP1, 96MIP4, 96USP5580872).




7. Reactivity of the Substituent Attached to a Ring Carbon Atom

The hydroxy group of 3-(2-hydroxyethyl)-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones was replaced by a chloro atom on treatment with SOCl₂ in CH₂Cl₂ at ambient temperature (94MIP8), or with boiling POCl₃ (95MIP4) and by a bromo atom with conc. HBr in MeOH (96MIP2). The hydroxy group of 3-(2-hydroxyethyl)-9-methoxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one and its 6,7,8,9-tetrahydro derivative was acylated with MeSO₂Cl in CH₂Cl₂ in the presence of NEt₃ (95MIP4).

The side chain chloro atom of 2-chloromethyl-4*H*- **162** (95FES69, 00BMC751), and that of 3-(2-chloroethyl)-, and 3-(3-chloropropyl)-2-substituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones and their 6,7,8,9-tetrahydro derivatives was replaced by cyclic amines (93GEP4243287, 93MIP2, 94MIP1, 94MIP4, 94MIP5, 94MIP8, 95JAP(K)95/33744, 95JAP(K)95/188215, 95MIP4, 95USP5468763, 97MIP8, 97MIP9, 98MIP5, 99MIP2, 00BMCL71, 00MIP3, 00MIP4, 00MIP7, 01MIP10, 01MIP11). Sometimes instead of 3-(2-chloroethyl) derivatives 3-(2-bromoethyl) (96MIP2) and 3-[2-(methylsulfonyloxy)ethyl] (95MIP4, 96MIP2, 98MIP5) derivatives were

also used as starting materials. The bromo atom of 1-(4-bromobutyl)perhydropyrido[1,2-*a*]pyrimidin-2-one was replaced by 3-(4-piperidyl)-1,2-benzisothiazole (94MIP6). Pyridinium salts **136** were obtained in the reaction of 3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones and 6-fluoro-3-(4-pyridinyl)-1,2-benzisoxazole in boiling MeCN (95MIP5, 00MIP10).

¹⁸F-Labeled pirenperone (**9**) was prepared with high radiochemical yield (72%) and high purity (99%) for PET studies from pirenperone using a [¹⁸F] fluoride-cryptand-oxalate system (95CL835).




Reaction of 2-chloromethyl-4*H*-pyrido[1,2-*a*]pyrimidine-4-one **162** with various nitronate anions (4 equiv) under phase-transfer conditions with Bu_4NOH in H_2O and CH_2Cl_2 under photo-stimulation gave 2-ethylenic derivatives **164** (01H(55)535). These alkenes **164** were formed by single electron transfer C-alkylation and base-promoted HNO_2 elimination from **163**. When the ethylenic derivative **164** ($\text{R} = \text{R}^1$) was unsymmetrical, only the *E* isomer was isolated. Compound **162** was treated with *S*-nucleophiles (sodium salt of benzyl mercaptan and benzenesulfinic acid) and the lithium salt of 4-hydroxycoumarin to give compounds **165–167**, respectively.

2-(Piperazinomethyl)-9-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was obtained by hydrolysis of the 2-(4-formylpiperazino)methyl derivative in boiling 10% HCl. The hydrolysis of the 2-(4-ethoxycarbonylpiperazino) derivative in NaOH solution was unsuccessful (95EJM27).

Treatment of 9-benzyloxy-2-morpholino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one with $(\text{CF}_3\text{SO}_2)_2\text{O}$ in CH_2Cl_2 overnight at room temperature gave a 9-hydroxy derivative (**01MIP9**). The 9-hydroxy group was derivatized by a copper promoted arylation using $\text{Cu}(\text{Ac})_2$ and arylboronic acids [e.g., $\text{PhB}(\text{OH})_2$] in CH_2Cl_2 in the presence of NEt_3 at room temperature, or by base catalyzed alkylation using (het)arylmethyl halides [e.g., $(2\text{-ClPh})\text{CH}_2\text{Br}$] in MeCN at 80°C in the presence of K_2CO_3 overnight to yield 9-aryloxy or 9-[(het)aryl]methoxy derivatives (**01MIP9**). The hydroxy group of 9-hydroxymethyl-7-methyl-2-morpholino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was acylated with MeSO_3Cl in the presence of NEt_3 in CH_2Cl_2 at 0°C , then the 9-(mesyloxymethyl) group was allowed to react with different anilines under reflux to give 9-(arylamino)methyl derivatives.

The hydroxy group of ethyl 9-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate was *O*-alkylated with 2-chloromethyl-4-isopropyl-1,3-thiazole in DMF at 115°C in the presence of K_2CO_3 and KI (**01MIP1**).


The hydroxy group of 2-hydroxy-3-substituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones was *O*-alkylated with alkyl bromides in boiling MeCOMe (**94BMCL183**), with alkyl iodides and allyl bromide in DMF at room temperature in the presence of K_2CO_3 (**93MIP4**), and with 2-bromomethyl-4-isopropyl-6-alkoxy-1,2-benzisothiazol-3(2*H*)-one 1,1-dioxides in DMF in the presence of NEt_3 (**01MIP8**). 2-Hydroxy-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, its 6- and 7-methyl, and their 6,7,8,9-tetrahydro derivatives were *O*-alkylated with 4-substituted benzyl bromides (**96EUP733633**).




Reaction of 2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **168** and 2-chloromethylsaccharins **169** in the presence of a base gave 2-*O*-alkylated products **170** (**94EUP626378**, **95JMC4687**, **95USP5378720**). From the reaction mixture of 3-chloro derivative **168** ($\text{R} = \text{H}$, $\text{R}^1 = \text{Cl}$) and

2-chloromethyl-4-*sec*-butylsaccharin (**172**, $R^2 = \text{Me}$, $R^3 = \text{H}$) in DMF in the presence of methyltriazabicyclodecene in addition to the 4-oxo-4*H* derivative **170** ($R^1 = \text{Cl}$, $R = R^3 = \text{H}$, $R^2 = \text{Me}$) ($\sim 47\%$), the isomeric 2-oxo-2*H* compound **171** ($\sim 4\%$) was also isolated. Treatment of triisopropylsilyloxy derivative **170** ($R^1 = \text{Cl}$, $R = R^2 = \text{H}$, $R^3 = \text{OCH}_2\text{CH}_2\text{OSi}(\text{Pr})_3$) with 2 N HCl in a mixture of MeOH and THF at ambient temperature yielded 6-(2-hydroxyethoxy) derivative **170** ($R^1 = \text{Cl}$, $R = R^2 = \text{H}$, $R^3 = -\text{OCH}_2\text{CH}_2\text{OH}$), and the hydroxy group then was acylated with 2-(dimethylamino)acetic acid in CH_2Cl_2 in the presence of 1,3-dicyclohexylcarbodiimide and 4-(dimethylamino)pyridine at room temperature (94EUP626378, 95USP5378720).

2-Hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one **168** ($R = \text{H}$, $R^1 = \text{Cl}$) was *O*-alkylated with compound **172** in DMF in the presence of KF at room temperature (97MIP3). The *tert*-butoxycarbonyl group of compound **173** was converted to a carboxyl group by treatment with TFA. The hydroxy group of 3-aryl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **174** was *O*-alkylated and *O*-acylated with BuBr and with arylsulfonyl chlorides and MeSO_3Cl , respectively (97BRP2307177). The phenylsulfonyloxy group of **175** was changed for secondary amino groups with secondary amines and for a butylthio group with BuSH (Scheme 10).




Scheme 10



The 9-hydroxy group of 9-hydroxy-2-methyl-3-(2-hydroxyethyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was alkylated with Me_2SO_4 in aqueous NaOH at room temperature for 15 min followed by heating at 95–100 °C (95MIP4, 96MIP2), and with $\text{MeOCH}_2\text{CH}_2\text{I}$ in DMF in the presence of K_2CO_3 at 60–70 °C for 1 h (95MIP4) to give 9-methoxy (42%) and 9-(2-methoxyethoxy) (66%) derivatives, respectively. 9-Hydroxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was *O*-alkylated with benzyl bromide **176** in DMF to give compound **177** (96MIP1). 9-Hydroxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was *O*-alkylated with other benzyl halogenide derivatives (98FRP2765222).

The side chain hydroxy group of 3-(2-hydroxyethyl)-2-methyl-9-methoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, and that of its 6,7,8,9-tetrahydro derivative was acylated with MeSO_2Cl in the presence of NEt_3 in CH_2Cl_2 at room temperature (95MIP4, 96MIP2). The hydroxy group of 2-[4-(4-hydroxybenzoyl)benzyloxy]-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, its 6-methyl derivative and 2-[4-(4-hydroxybenzoyl)benzylthio]-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was alkylated with 4-(2-chloroethyl)morpholine hydrochloride and 4-picolyl chloride hydrochloride (96EUP733633).

Acylation of mesoionic pyrido[1,2-*a*]pyrimidin-4-ones **150** with aroyl chlorides in the presence of NEt_3 yielded 2-aroyloxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **178** (96JHC663). None of the esters **178** could be rearranged to the 2-hydroxy-3-aroyl derivatives **179**. The hydroxy group of 9-hydroxy-2-methyl-3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was acylated with hexadecanoic acid in CH_2Cl_2 in the presence of dicyclohexylcarbodiimide and 4-pyrrolidinopyridine at room temperature for 3 days in 80% yield (97MIP7).




Scheme 11

Treatment of 9-(ethoxymethoxy)-3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl] and -1-piperidyl}ethyl}-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones with conc. HCl afforded 9-hydroxy derivatives (95MIP4, 00MIP10).


2-Mercapto-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one and its 6,7,8,9-tetrahydro derivative were *S*-alkylated with 4-substituted benzylbromides (96EUP733633).

Risperidone (**11**) was prepared starting from 3-(2-chloroethyl) **180**, via 3-(2-aminoethyl) **181**, and 3-{2-[4-(2,4-difluorobenzoyl)piperidino]ethyl} **182** derivatives of 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones as depicted in Scheme 11 (94MIP8, 95MIP7).




3-Amino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **184** were obtained from 3-(2,2-disubstituted ethenylamino) derivatives **183** with $\text{H}_2\text{NNH}_2 \cdot \text{H}_2\text{O}$ or $\text{HONH}_2 \cdot \text{HCl}$ in good yields, and from **183** ($R^1 = \text{COOCH}_2\text{Ph}$, $R^2 = \text{acetyl}$) by treatment with NaBH_4 in moderate yields (97H(45)2349,

97HCA2418, 97JHC1511, 98ACH613, 98H(47)1017, 98H(49)133, 98JHC1275, 01JHC869). 3-Amino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones were also prepared from 3-(benzyloxycarbonylamino) derivatives by catalytic transfer hydrogenation over 10% Pd/C catalyst with cyclohexene in boiling EtOH (99CCCC177), or by treatment with HBr in AcOH (00MI33). 3-Amino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **184** (R = H, 8-Me) were transformed into the stable 3-diazonium tetrafluoroborates **185** by treatment with NaNO₂ in 1:1 HCl below 0 °C, then with 50% HBF₄ or with *t*-BuNO₂ and BF₃·EtO₂ in CH₂Cl₂ at -15 °C (00H(53)1793, 00MI33).




3-Diazonium salt **185** (R = H) when coupled with different CH active compounds yielded 3-hydrazono derivatives (e.g. **186** and **187**). Hydrazono derivatives **186** and **187** were cyclized into 3-(1,4-dihydropyridazin-1-yl) **188** and 3-(pyrrolin-1-yl) derivatives **189**, respectively (00MI33).

The 3-formyl group of 8-substituted 3-formyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was reacted with (cyanomethyl)- and (*tert*-butoxycarbonylmethylene)triphenylphosphorane in THF, and with 5-aminotetrazole in boiling MeOH for 9 h to yield (*E*)-3-propenenitrile, *tert*-butyl (*E*)-3-propenoate and 3-[(2*H*-tetrazol-5-yl)imino]methyl derivatives, respectively (01MIP1).



Deprotection of 2-(*tert*-butoxycarbonylamino)-3-(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-3-yl)propionate **190** with conc. HCl afforded the amino acid **191** in quantitative yield (95TL7503, 97JCS(P1)1297).



Reaction of 3-methoxythiocarbonylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one **192** with MeI gave a mixture of 3-(1-methylthio-1-methoxymethyleneamino) **193** and 3-(dimethoxymethyleneamino) derivatives **194** after a chromatographic work-up (94JHC125).

Acidic hydrolysis of 4-imino-3-cyano-2-trifluoromethyl-4*H*-pyrido[1,2-*a*]pyrimidines in boiling EtOH with aqueous hydrochloric acid afforded 4-oxo derivatives (00MI27).

The chloro atom of 2-[4-(6-chloronicotinoyl)benzyloxy]-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, its 6-methyl derivative and 2-[4-(6-chloronicotinoyl)benzylthio]-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was replaced by a 4-piperidinopiperidino and 4-phenylpiperazino group with 4-piperidinopiperidine and 4-phenylpiperazine (96EUP733633). The carboxyl group of 2-[4-(4-carboxybenzoyl)benzyloxy]-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, prepared by hydrolysis of methyl ester in DMF with 1 N NaOH, was reacted first with diethyl pyrocarbonate in DMF at room temperature and then with 4-phenylpiperazine and 4-piperidinopiperidine to give the appropriate amide derivatives (96EUP733633).


The *N*-substituted derivatives of 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamides and -3-acetamides and 1,6-dimethyl-4-oxo-1,6,7,8-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide were prepared by treatment of the appropriate 3-carboxylic acids and acetic acid, first with an alkyl chloroformate in the presence of NEt₃ in CHCl₃ below -10 °C, then with an amine (98ACH515). *N*-Phenethyl and *N*-[2-(3,4-dimethoxyphenyl)ethyl] derivatives of 6-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetamide were obtained in the reaction of 6-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetic acid and phenethylamines in boiling xylene under a H₂O separator. Hydrazides of 4-oxo-4*H*- and 4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetic acid were prepared from the appropriate ester with H₂NNH₂·H₂O in EtOH. Heating 4-oxo-4*H*- and 6-methyl-4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetic hydrazides in EtOH in the presence of excess Raney Ni afforded the appropriate 4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetamide. In the case of the 4-oxo-4*H* derivative, in addition to N–N bond

cleavage, saturation of the pyridine moiety of 4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide also occurred. *N*-Substituted 2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamides were prepared from alkyl 2-hydroxy-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidine-3-carboxylates with (het)arylamines in boiling bromobenzene for 2–30 h (99JHC237).

An ester group in the side chain at position 9 of 4*H*-pyrido[1,2-*a*]-pyrimidin-4-one was hydrolysed and the carboxyl group was converted into an *N*-{3-[(4-cyanophenyl)carbonylamino]propyl} derivative of carboxamide group with *N*-(3-aminopropyl)-4-cyanobenzamide in the presence of [1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxy-7-azabenzotriazole and *N*-methylmorpholine in CH₂Cl₂ at ambient temperature. Treatment of a cyano group in the side-chain at position 9 of 4*H*-pyrido[1,2-*a*]-pyrimidin-4-one with HONH₂·HCl in the presence of NEt₃ in DMSO afforded an *N*-hydroxycarboxamidine derivative. Its hydroxy group was acylated with Ac₂O, and catalytic reduction of *N*-acetoxycarboxamidine over 5% Pd Lindlar catalyst in MeOH yielded a carboxamidine derivative (98FRP2765222).

2-Methylthio-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was prepared by FVT of 2-methylthio-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylic acid at 650 °C at 8×10^{-5} mbar for 4 h (99JCS(P2)1087).


Acidic and basic hydrolysis of ethyl 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-3-carboxylates gave 3-carboxylic acid derivatives (**01MIP1**). Stirring *tert*-butyl (*E*)-3-(2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-3-yl)-2-propenoate in CF₃CO₂H at room temperature yielded (*E*)-3-substituted 2-propenoic acid.




2,9-Disubstituted 3-fluoro-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylates **195** on treatment with Ti(OEt)₄ in dry benzyl alcohol yielded benzyl esters **196**. The 7-benzyl esters **196** were converted to 7-carboxylic acids by catalytic hydrogenation over 10% Pd/C catalyst at room temperature under 1–4 atm of hydrogen, or by treatment with 98% HCOOH in the presence of 10% Pd/C catalyst at ambient temperature for 20–110 min (**95MPI1**, **96JMC3070**, **96MIP4**, **96USP5580872**). When the substituent in position 2 contained a benzyloxycarbonylamino group, then 7-carboxylic acid derivatives, containing a free amino group in the side-chain at position 2 were obtained. 2,9-Disubstituted 3-fluoro-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylic acids were also prepared from 7-*tert*-butyl esters on

the action of 4 N HCl in dioxane (95MIP1, 96JMC3070, 96MIP4, 96USP5580872). When the substituent in position 2 contained a *tert*-butoxycarbonylamino group, then a 7-carboxylic acid containing a free amino group was obtained (96JMC3070).

9-(4-Fluorophenyl)-3-fluoro-2-hydroxy-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylic acid (**197**, R = 4-FPh, R¹ = H) was obtained from the 2-(4-methyl-1-piperazinyl)-7-ester derivative by the treatment with 1 N NaOH in an 1:1 mixture of H₂O and THF at room temperature for 6 h (95MIP1, 96JMC3070, 96MIP4, 96USP5580872).



2-Chloro derivatives **198** were prepared from 2-hydroxy derivatives **197** with POCl₃ (96JMC3070, 96MIP4, 96USP5580872). The chloro atom of compounds **198** was changed for a cyclic amino group by treatment with a cyclic amine in CH₂Cl₂, sometimes in the presence of NEt₃, at room temperature overnight (95MIP1, 96JMC3070, 96MIP4, 96USP5580872). The amino group of benzyl 2-(3-amino-1-pyrrolidiny)-3-fluoro-9-(2,4-difluorophenyl)-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylate was *N*-acylated with different protected dipeptide derivatives in DMF in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl and 1-hydroxybenzotriazole hydrate at 0 °C for 30 min, then at room temperature for 2 h (95MIP1, 96JMC3070, 96MIP4, 96USP5580872).




Reaction of **199** with NaN₃ or NH₄N₃ in DMF at 90–95 °C afforded a 1:4–5 mixture of **200** and ring opened **201** products. When the reactions

were carried out with $\text{Al}(\text{N}_3)_3$, prepared *in situ* from AlCl_3 and NaN_3 in boiling THF or in AcOH, 3-(1*H*-tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidine **200** resulted. Acidic hydrolysis of **200** gave 3-(1*H*-tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one **202** with high purity. Treatment of 4-imino-9-methyl-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile (**199**) first with NaN_3 , then with 10% HCl gave 9-methyl-3-(1*H*-tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**202**) (95CPB683).

The cyano group of 2-alkoxy-3-{4-[(2-cyanophenyl)phenyl]methyl}-4*H*-pyrido[1,2-*a*]pyrimidine-4-ones was converted to a 5-tetrazolyl group by treatment with NaN_3 in the presence of Bu_3SnCl in boiling xylene (94BMCL183). From the 7-iodo-2-alkoxy-3-{4-[(2-cyanophenyl)phenyl]methyl}-4*H*-pyrido[1,2-*a*]pyrimidin-4-one 7-methoxycarbonyl-, 7-vinyl-, and 7-(1-ethoxyvinyl) derivatives were prepared on the treatment with CO in the presence of $(\text{Ph}_3\text{P})_2\text{Pd}(\text{II})\text{Cl}_2$ and NEt_3 in boiling MeOH, with vinyltributyltin in the presence of $(\text{Ph}_3\text{P})_4\text{Pd}$ in toluene at 80°C , and with (2-ethoxyvinyl)tributyltin in the presence of $(\text{Ph}_3\text{P})_2\text{Pd}(\text{II})\text{Cl}_2$ in toluene at 80°C , respectively. The 7-(1-ethoxyvinyl) group was hydrolyzed into an acetyl group in a mixture of 5 N HCl and THF at ambient temperature and then the acetyl group was reduced with NaBH_4 in the presence of CeCl_3 in EtOH to a 1-hydroxyethyl group.

Reaction of 8-substituted 3-[2-(4-methoxybenzyl)-2*H*-tetrazol-5-yl]-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones with CF_3COOH for 2 days at room temperature gave 3-(2*H*-tetrazol-5-yl) derivatives (01MIP1). The cyano group of a 3-(8-substituted 2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-3-yl)-2-propenenitrile was converted into a 5-tetrazolyl group by treatment with NaN_3 in the presence of AlCl_3 in DMF at 100°C for 2 days.





Reaction of 7-bromo-2-butoxy-3-phenyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**203**, R = Bu, Ar = Ph) and $(4\text{-ClPh})\text{BH}_2$ in the presence of a 2 M solution of Na_2CO_3 and $(\text{Ph}_3\text{P})_4\text{Pd}$ afforded 7-(4-chlorophenyl) derivative



204 (97BRP2307177). The bromine atom of **203** was also replaced by a methoxy and a cyano groups with NaOMe in the presence of Cu(I)I; and with Cu(I)CN to give compounds **205** and **206**, respectively. The nitrile group of **206** was converted into a methoxycarbonyl group to give compound **207**.

8. Reactions Leading to Polycondensed Ring System


Treatment of 2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **208** with TFA furnished tricyclic derivatives **209** (99ACS901, 99MI29).




Cyclocondensation of 3-cyano-2-methylthio-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones and ethyl mercaptoacetate in boiling EtOH in the presence of NaOEt afforded 4*H*-pyrido[1,2-*a*]thieno[2,3-*d*]pyrimidin-4-ones **210** (00HC571). 2-Methylthio-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates **211** and mercaptoacetates afforded tricyclic derivatives **212** (93MIP1). Cyclocondensation of 2-methylthio-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-3-carbonitriles **213** with $\text{H}_2\text{NNH}_2 \cdot \text{H}_2\text{O}$ and with guanidine HCl afforded tricyclic derivatives **214** and **215**, respectively (96FES781).




Treatment of ethyl 9-dimethylaminomethylene-3-formyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-2-acetate with saturated NH_3 ethanolic solution in a closed ampule at 100°C for 24 h, then with 5% HCl for 1 h at room temperature gave 6-formyl-2,3,6,7,8,9-hexahydro-11*H*-dipyrido[1,2-*a*;5,6-*c'*]pyrimidine-2,11-dione (**01MI4**).



The 3-amino group of 3,4-diamino-2*H*-pyrido[1,2-*a*]pyrimidin-2-ones **216**, obtained from 3-nitroso derivatives by reduction with $\text{Na}_2\text{S}_2\text{O}_4$ in 30% NH_4OH at $70\text{--}80^\circ\text{C}$, was acylated with acyl chlorides, and the acylated products **217** were cyclized to pyrido[2,1-*b*]purin-10-ones **218** by treatment with NaOMe (**95JHC1725**).




Reaction of 2-(*N*-allylamino)-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **219** in EtOH with $\text{HONH}_2\cdot\text{HCl}$ yielded (*E*)-oximes **220** at 0°C and **221** ($\text{R} = \text{PhCH}_2$) under reflux. Heating **220** ($\text{R}^1 = \text{H}$) in a boiling solvent afforded *cis*-fused tetracyclic cycloadducts **221** ($\text{R}^1 = \text{H}$). In an aprotic solvent (e.g., benzene or MeCN) the main *cis*-fused cycloadducts **221** ($\text{R}^1 = \text{H}$) were accompanied by a mixture of *trans*-fused cycloadducts **222**, *N*-oxides **223** and tetracyclic isoxazoline **224** (**96T887**). The basicity of the 2-allylamino moiety of compounds **219** affected the rate of the conversion. Cycloadditions were also investigated in dioxane and BuOH.




Treatment of the 2-(*N*-allylamino) derivative of 4*H*-pyrido[1,2-*a*]pyrimidin-4-one **225** with a Lewis acid afforded a mixture of hetero-Diels–Alder adduct **226**, tetracyclic pyrane **227**, and tricyclic derivatives **228** and **229**. Whereas TiCl_4 (in CH_2Cl_2) and EtAlCl_2 (in HPh) gave a mixture of **226** and **227**, Et_2AlCl (in HPh) yielded a mixture of tricyclic derivatives **228** and **229**, $\text{BF}_3 \cdot \text{OEt}_2$ (in CH_2Cl_2) afforded **228** with a trace of **229**. A mixture of **226** or **227** accompanied with **228** and **229** was obtained in the presence of ZnCl_2 and ZnBr_2 , respectively. The formation of compound **228** was explained as depicted on Scheme 12 (98JCS(P1)3327).


A similar reaction of 2-(*N*-benzylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one **230** ($\text{R} = \text{R}^1 = \text{Ph}$) gave tricyclic derivative **231** ($\text{R} = \text{Ph}$) on the action of $\text{BF}_3 \cdot \text{OEt}_2$. 2-(*N*-Ethoxycarbonylmethyl-*N*-methyl), and *N*-cyanomethyl-*N*-methyl derivatives **230** ($\text{R} = \text{COOEt}$, CN ; $\text{R}^1 = \text{H}$) did not yield any tricyclic product (98JCS(P1)3327).




Scheme 12



Heating oxime **232**, prepared from the corresponding 3-formyl derivative, gave an unstable cycloadduct **233** in an *exo*-approaching manner (the *endo* one is unfavorable owing to steric crowding), which converted spontaneously into a dehydrogenated pentacyclic derivative **234** (96T887).




Reaction of 2-[*N*-(2-alkenyl)amino]-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **235** with $HONH_2 \cdot HCl$ under both acidic and basic conditions (in the absence or in the presence of NEt_3) gave tetracyclic derivatives **236** in good yields. Higher yields were achieved in the presence of NEt_3 (96T887).




Intramolecular cycloadditions of 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **235** (R=H, Me, Ph) and MeNHOH·HCl gave tetracyclic isoxazolo derivatives **237**. In the case of **235** (R=Me) a minor epimer **238** was also isolated (00JCR(S)414). Similar reaction of **235** (R=H, Me, Ph) and sarcosine ethyl ester HCl afforded an isomeric mixture of epimeric tetracyclic pyrrolo derivatives **239** and **240**. In the reaction of **235** (R=H) and PhCH₂NHCH₂COOEt only one product **241** was obtained.

The phenylhydrazones of 2-[(2-alkenyl)amino]-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **242** underwent a thermally induced intramolecular 1,3-dipolar cycloaddition leading to a mixture of tetracyclic compounds **243** and **244** at room temperature or to **244** under reflux (96T901). Derivatives **243** were not stable and converted to compounds **244** gradually on standing or on heating their ethanolic solutions in air. The (*E*)-hydrazones **245** could be isolated only in the case of 2-(*N*-allyl-*N*-phenyl-, -*N*-benzenesulfonyl-, and -*N*-ethoxycarbonylamino)-3-formyl derivatives **242** (R=Ph, PhSO₂, COOEt, R¹=H). The hydrazones **245** (R=Ph, PhSO₂, R¹=H) could be converted into a mixture of tetracyclic derivatives **243** and **244** or into pure **244** in a boiling solvent. No reaction occurred in the case of ethoxycarbonylamino derivative (**245**, R=COOEt) in EtOH, while decomposition happened in BuOH.




Reaction of 3-formyl-2-[*N*-(2-alkenyl)amino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **242** with TsNHNH₂ gave tetracyclic cyclopropanes **246** in good

yields (97S53). The yields were lower (46–47%) in EtOH or MeCN at 50 °C. *N*-Allyl- and *N*-(2-butenyl) derivatives **242** ($R^1 = \text{H, Me}$) gave intractable mixtures of unidentified products. 2-[*N*-(*E,E*)-(hexa-2,4-dienyl)-*N*-benzylamino] derivative **242** ($R = \text{Bn}$, $R^1 = \text{trans-CH=CH-Me}$) afforded two cyclopropane derivatives **246** ($R = \text{Bn}$, $R^1 = \text{trans-CH=CH-Me}$) and **247** in a 5:1 ratio.




A 14:1 mixture of (*E*)- and (*Z*)-phenylhydrazones **249** and **250** was obtained from 2-[*N*-(cyclohex-2-en-1-yl)]-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one **248** with PhNHNH_2 . Pentacyclic compound **251** was obtained from both (*E*)- and (*Z*)-phenylhydrazones **249** and **250** by heating in boiling EtOH (96T901).



27


Reaction of 3-formyl-2-[*N*-(2-alkenyl)-*N*-benzylamino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **252** and primary amines in the presence of MS (4 Å) afforded pyrido[1',2':1,2]pyrimido[4,5-*b*]azepin-6-ones **253** (96T13081).

No reaction occurred when dimethyl derivative **252** ($R^1 = R^2 = \text{Me}$) was the starting material. The reaction of **252** ($R^1 = \text{COOEt}$, $R^2 = \text{H}$) and PhNH_2 gave **253** ($R = \text{Ph}$, $R^1 = \text{COOEt}$); **254** ($R^1 = \text{COOEt}$) was also isolated from the reaction mixture. When pyrido[1,2-*a*]pyrimidin-4-ones **252** ($R^2 = \text{H}$) were heated in boiling toluene or xylene a mixture of tricyclic derivatives **254–256** was obtained. Heating **252** ($R^1 = R^2 = \text{Me}$) in toluene and xylene did not provide any changes.




Whereas heating 3-formyl-2-(*N*-allyl-*N*-phenylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one **257** ($R = \text{Ph}$) in boiling deoxygenated xylene yielded a mixture of **258** and **259**, 2-(*N*-allyl-*N*-ethoxycarbonylamino) and 2-(*N*-allyl-*N*-benzenesulfonylamino) derivatives **257** ($R = \text{COOEt}$, SO_2Ph) gave only **257** ($R = \text{H}$) ([96T13081](#)). MO calculations by the PM3 method suggested that the electron-withdrawing substituent on the amino group could be unfavorable to the 1,7-electrocyclic ring-closure process to the azepine ring.


Reactions of 3-formyl-2-[*N*-(2-alkenyl)-*N*-benzylamino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **260** with $\text{MeONH}_2 \cdot \text{HCl}$ and $\text{BnONH}_2 \cdot \text{HCl}$ or with 4-aminomorpholine gave oximes **261** (mainly as the *E* isomer) and Schiff bases **262** (as the pure *E*-isomer), respectively ([96T13097](#)). Reaction of 3-formyl derivative **260** ($R = \text{H}$) with $\text{MeONH}_2 \cdot \text{HCl}$ in MeCN and benzene for 20 h yielded a 85:15 and 66:34 mixture of *E* and *Z* isomers of oximes **261** ($R = \text{H}$, $R^1 = \text{Me}$). Heating *E*-isomers of **261** in deoxygenated *o*-dichlorobenzene for 2–24 h gave tetracyclic derivatives **263**. When the *E* isomer of compound **261** ($R = \text{H}$, $R^1 = \text{Me}$) was heated only 1 h, a 69:31 mixture of **263** ($R = \text{H}$, $R^1 = \text{Me}$) and **264** was obtained. On further heating or during chromatography compound **264** converted gradually to compound **263** ($R = \text{H}$, $R^1 = \text{Me}$). Progress of these reactions in 2-methoxyethyl ether was monitored by HPLC and revealed that only the *E* isomer of oximes **261** underwent cyclization and the *Z* isomers were unchanged. No interconversion between *E*- and *Z*-isomers of the oximes was observed. Heating hydrazone **262** in toluene afforded tricyclic derivative **265** ([96T13097](#)).



Reaction of 2-(*N*-alkyl-*N*-benzylamino)- and 2-[*N*-(*trans*-crotyl)-*N*-benzylamino]-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (**260**, R = H, Me) with tosylamine gave compounds **268** via compounds **266** and **267** (**96T13097**). The results of kinetic studies and MP3 calculations on the 3-formyl derivatives **252**, **260** and the imines **262**, **263** suggested a concerted nature for azepine-ring formation.




Reaction of 2-[*N*-(*trans*-crotyl)-*N*-benzylamino]-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**269**) with chiral primary amines **270** and **271** gave mixtures of diastereoisomers of tetracyclic compounds **273** and tricyclic **275** (96T13111). The chiral centers in **272** and **274** did not provide any stereocontrol for the formation of diastereomers **273** and **275**, respectively.



Heating optically active 4*H*-pyrido[1,2-*a*]pyrimidin-4-one **276**, prepared from 2-chloro-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one and (2'*S*,3*E*)-ethyl 4-(2-pyrrolidinyl)-but-3-enoate in THF in the presence of NEt₃ gave single isomer **277**. Reaction of **276** with (*R*)-1-phenylethylamine (**271**) in the presence of MS (4 Å) gave also a single isomer **278**, which converted to compound **279** on silica gel, or in a solution of CDCl₃. Reaction of 4*H*-pyrido[1,2-*a*]pyrimidin-4-one **276** and **271** in boiling benzene yielded also **279** (96T13111).


Heating 2-(2-alkenylamino)-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **280** (R = H, Me, Ph) in boiling toluene in the presence of BF₃·OEt₂, *p*TSA, MgCl₂·OEt₂, EtAlCl₂, or Et₂AlCl, did not give any identifiable products, only starting materials **280** could be recovered (97BCJ2201). Reaction of **280** (R¹ = CH₂Ph, R = H, Me) with *i*-BuNH₂ in the presence of the above additives or MS (3 Å) resulted in the formation of tricyclic derivatives **281** (R = H, Me). It was suggested that additives catalyzed only the formation of a Schiff-base from aldehyde **280** and *i*-BuNH₂, and did not influence azepine-ring formation. Reaction of **280** (R¹ = PhCH₂, R = Me) with PhNH₂ in the presence of MS (3 Å) gave tricyclic product **282** (R = Me). When the reaction was carried out in the presence of a Brönsted




or a Lewis acid ($\text{BF}_3 \cdot \text{OEt}_2$, $p\text{TSA}$, EtAlCl_2 , Et_2AlCl) either **283** ($R = \text{CH=CHMe}$, 2-furyl; $R^1 = \text{Me}$, CH_2Ph) or a mixture of **283** and **284** were obtained, sometimes together with tricyclic derivatives **282**. While the isolated **284** was stable under the reaction conditions, **283** partially decomposed under similar conditions. The tetraazapentaphene **283** and **284** was formed by an intramolecular [4+2] cycloaddition between the *N*-arylimine and ene moieties.

9. Ring Transformations


3-Acetyl-4-phenylamino-2*H*-pyrido[1,2-*a*]pyrimidin-2-one (**285**) isomerized into 4-oxo isomer **286** by heating in DMF at 100°C (95MI2).



Flash vacuum thermolysis of 2-dialkylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **126** ($X = \text{NMe}_2$, NEt_2) at 850°C led to the formation of 4*H*-pyrido[1,2-*a*]pyrimidin-4-one (Scheme 13). The product was identified by ^1H NMR and GC-MS (99JCS(P2)1087).



Scheme 13




2-(Het)aryl-1,4-dihydro-1,8-naphthyridin-4-ones **288** were obtained by heating 2-(het)aryl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **287** at 350°C (97JMC2266, 99JMC4081) and in Dowtherm A at $220\text{--}240^\circ\text{C}$ (00JMC2814). Not only the 6-methyl derivatives **287** ($\text{R} = 6\text{-Me}$) but also 6-unsubstituted derivatives could be rearranged into 1,8-naphthyridines (97JMC2266, 97JMC3049, 98MIP3, 99JMC4081). The 6-methyl derivatives of **287** ($\text{R} = 6\text{-Me}$) provided 1,8-naphthyridines **288** ($\text{R} = 6\text{-Me}$) at lower temperature ($\sim 240^\circ\text{C}$) in excellent yield ($>95\%$) within 2 h in a concentration 0.5–1% (w/v) (98MIP3, 00JMC2814). In the case of 6-unsubstituted derivatives of **287** tar formation was also observed, and therefore shorter reaction period was applied, and 7-unsubstituted derivatives were isolated by column chromatography in 25–45% yields (99PC1). Earlier it was reported that only 6-substituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones could be thermally transformed into 1,8-naphthyridine derivatives (75TL1019, 77JCS(P1)789, 79JHC457). In the case of 6-unsubstituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones only tar formation was observed. Probably in the case of 2-aryl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones the C(4)–N(5) bond is the weakest one and therefore tar formation is suppressed.


Whereas FVT of 3-methyl derivative of **131** at $700\text{--}830^\circ\text{C}$ (10^{-4} mbar) afforded 1,3-dimethyl-4-hydroxy-1,2-dihydro-1,8-naphthyridin-2-one, FVT

of **132** ($R = H, Me, Ph$) resulted in the formation of 2-amino-, 2-(methylamino)-, 2-(phenylamino)pyridines and C_3O_2 (**00JCS(P2)1841**).


Heating 6-bromo- and 6-chloro-2-halomethyl- (**99JHC1065**) and 6-bromo-, 6-chloro- and 6-fluoro-2-phenyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (**00JMC2814**) in phenyl ether at 220 °C for 10 min yielded the appropriate 7-halo-1,8-naphthyridin-4-ols. 6-Amino-2-trifluoromethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was transformed into 7-amino-2-trifluoromethyl-1,4-dihydro-1,8-naphthyridin-4-one in 90% yield (**98EJM383**).



Fischer indolization of 9-arylhyaazono-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **289** by heating in 85% phosphoric acid, or in PPA yielded 7,12-dihydropyrimido[1',2':1,2]pyrido[3,4-*b*]indol-4(6*H*)-ones **290** (**96JHC799**, **99MI12**, **00MI22**). From the 3-ester and 3-carboxylic acid derivatives **289** ($R^1 = COOEt, COOH$) and decarboxylated products **290** ($R^1 = H$) were obtained.



Heating 9-hydrazono-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **291** in a mixture of POCl₃ and DMF at 95 °C gave 8-chloro-7-(chloromethyl)-9-[(dimethylaminomethylene)amino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **293** via 9-hydrazino-6,7-dihydro-4*H* derivatives **292**. At lower temperature 9-[(dimethylaminomethylene)amino]-7-dimethylaminomethylene-8-chloro-6,7-dihydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **294** (R = H, D) were obtained from the 6-methyl-3-ester derivative and its 6,7,8-deuterio derivative **291** (R = Me, R¹ = COOEt, R²-R⁴ = H, D). These derivatives were transformed into **293** (R² = H, D) by heating in POCl₃. Optically active **291** (R = Me, R¹ = COOEt, R²-R⁴ = H) afforded optically active 6,7-dihydro-4*H* **294** (R² = H), but optically inactive 4*H*-pyrido[1,2-*a*]pyrimidine **293** (R = Me, R¹ = COOEt, R² = H). Similarly ethyl 9-(*N*-phenyl-*N*-methylamino)-6-methyl-4-oxo-6,7-dihydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate gave 9-[*N*-(4-formylphenyl)-*N*-methylamino]-7-dimethylaminomethylene-6-methyl-6,7-dihydro-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates in a mixture of POCl₃ and DMF at lower (20–25 °C) and higher (95–100 °C) temperatures, respectively. 9-(Ethoxycarbonylmethyl)-4-oxo-6,7-dihydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate **158** (but not 9-ethoxycarbonylmethylene-6,7,8,9-tetrahydro derivative **157**) was also transformed into ethyl 9-(ethoxycarbonylmethyl)-7-(1-chloroethyl)-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate (99T10221).




Reaction of 6-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetic acid (**295**) with phenylethylamine in boiling xylene afforded ring-transformed product **296** (98ACH515).

Heating 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-diazonium tetrafluoroborate and its 8-methyl derivative in alcohol at 60–90 °C for 15 min to 5 h gave alkyl 1-(2-pyridyl)- and 1-(4-methyl-2-pyridyl)-1*H*-1,2,3-triazole-4-carboxylates (00H(53)1793).

10. Miscellaneous

Diorganotin(IV) complexes (**109**) were prepared from 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones with Me₂SnCl₂ and Ph₂SnCl₂ in dry CHCl₃ (**96MI4**). Different complexes of 2-methyl-9-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one and its 8-nitro derivative were prepared with Cu(I)Cl, Cu(II)Cl₂, Ni(II)Cl₂, Co(II)Cl₂, Mn(II)Cl₂, and Ag(I)NO₃ in EtOH (**00MI23**). Complexes of 2,4-dimethyl-9-hydroxypyrido[1,2-*a*]pyrimidinium salt were obtained with Pr(III), Nd(III), Sm(III), and Eu(III) ions in acetone (**00MI24**).



9*a*-Ethoxy-9-hydroxy-1,6-dimethyl-1,6,7,8,9,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate **123** was isolated from a solution of rimazolium (**297**) in 2 N NaOH solution, standing for 30 min at room temperature (**97H(45)2175**).

Reaction of perhydropyrido[1,2-*a*]pyrimidine with BrCN in the presence of MgO in a 1:1 mixture of CHCl₃ and MeOH at 40°C resulted in the formation of the ten-membered 6-methoxy-3,4,7,8,9,10-hexahydro-1,5-diazecine-1,5-(2*H*,6*H*)-dicarbonitrile. Similar reaction of perhydropyrido[1,2-*a*]pyrimidin-2-one led to the nine-membered 6-methoxy-4-oxo-2,3,4,5,6,7,8,9-octahydro-1*H*-1,5-diazonine-1-carbonitrile (**99AJC1131**).


Two polymorphic forms of 3-{2-[4-(6-fluorobenzisoxazol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**137** R = H) were prepared (**99MIP1**). Racemic 9-hydroxy-2-methyl-3-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1,2,3,6-tetrahydro-1-pyridyl]ethyl}-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was resolved into its (*R*)- and (*S*)-isomers (**00MIP10**).

Free radical polymerization of *anhydro*-(2-hydroxy-3-[(3-vinylphenyl)-methyl]-1-phenyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxide in DMF at 60°C for 2 days in the presence of 2,2'-azoizobutyronitrile led to a mesoionic polymer (**00MI26**).


C. SYNTHESIS

1. By Formation of One Bond α to the Bridgehead Nitrogen Atom [6+0 (α)]

Cyclization of 3-cyano-2-[(3-hydroxypropyl)amino]-5-(4-pyridyl)pyridine-1'-oxide (**298**) in POCl_3 yielded 9-cyano-7-(4-pyridyl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]-pyrimidine 1'-oxide (**299**) ([94EJM175](#)). After heating 3-cyano-4-trifluoromethyl-6-phenyl-2-[(3-hydroxypropyl- and 3-hydroxybutyl)-amino]pyridines in boiling POCl_3 for 1 h, the product was treated with aqueous NH_4OH to yield 6-phenyl-8-trifluoromethyl-9-cyano-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidine and its 4-methyl derivative ([01CHE329](#)).




7,8,9-Trihydroxyperhydropyrido[1,2-*a*]pyrimidines **112**, **113**, **115** were obtained by the cyclization of 2-substituted perhydropyrimidines **300**–**302**, obtained in the reactions of 1,3-propanediamine and D-xylose, L-arabinose and D-ribose, respectively, with Ph_3P and CCl_4 in the presence of NEt_3 in DMF at ambient temperature in 22–40% yields ([98JOC391](#), [98T5097](#)). Perhydropyrido[1,2-*a*]pyrimidine **112** was also prepared in crude form, containing dehydrated impurity, by the cyclization of compound **303** with a saturated aqueous solution of SO_2 and with a 1:2 mixture of 1 N HCl in THF ([98JOC391](#)).




Heating diethyl (2-pyridylamino)methylenemalonates **304** ($\text{R} = \text{COOEt}$, $\text{R}^1 = \text{Me}$, OH) in AcOH afforded 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates **305** ($\text{R}^1 = \text{Me}$, OH) ([96JHC1041](#)). Flash vacuum thermolysis of 2-substituted 3-(2-pyridylamino)acrylates **304** ($\text{R} = \text{CN}$, COOEt , $\text{R}^1 = \text{H}$) through a packed silica tube (530°C , 0.01 mmHg) gave 3-substituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **306** ($\text{R} = \text{CN}$, COOEt) ([94AJC1263](#)). Ethyl 7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate (79%) was

obtained together with ethyl 6-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate (5%), when diethyl [(6-methyl-2-pyridyl)amino]methylenemalonate was pumped at a rate 14 g/min through a stainless steel coil heated in a fluidized sand bath at 380 °C (00MI14). Heating isopropylidene (2-pyridylamino)-methylenemalonates at 200 °C gave 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (00CHE754).




Cyclization of *N*-aryl-2-(ethoxycarbonyl)-3-(2-pyridylamino)acrylamides **307** in AcOH, and in PPA, or in ethylene glycol afforded *N*-aryl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylic amide **308** (94KGS629, 95KFZ(5)39).




Cyclization of ethyl 3-[(9-methyl-2-pyridyl)amino]-2-cyanoacrylate on treatment with AlCl₃ and NaN₃ gave a 2 : 1 mixture of 3-(1*H*-tetrazol-5-yl)-9-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one and ethyl 4-imino-9-methyl-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate in 48 and 24% yields, respectively (95CPB683). 3-(1*H*-Tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **310** were prepared by the cyclization of 3-(2-pyridylamino)-2-(1*H*-tetrazol-5-yl)acrylonitrile **309** in boiling conc. HCl, or in PPA at 130–140 °C (93MIP3). The 6-methyl derivative **309** (R = Me, R¹ = H) could be cyclized only by the PPA method. Treatment of ethyl 3-(3-methyl-2-pyridylamino)-2-(1*H*-tetrazol-5-yl)acrylate with 2 N KOH in boiling *i*-PrOH for 2 h gave pemirolast (**7**) in 95% yield (98H(48)775). Cyclization under acidic conditions, such as aqueous HCl or H₂SO₄ were unsuccessful.

Alkyl 3-(2-pyridylamino)-3-alkoxycarbonylacrylates cyclized into alkyl 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-2-carboxylates either spontaneously or by the action of silica gel (00TL5837).




Cyclization of methyl 2-[2-benzoyl-2-ethoxycarbonyl-1-vinylamino]-3-[(4-methyl-2-pyridyl)amino]acrylate (**311**) afforded the 3-amino-8-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one derivative **312** (97JHC1511).




Cyclization of 4-[(2-pyridylamino)methylene]-2-methoxythiazolin-5(4*H*)-one **313** (R = Me) in the presence of NaOMe gave 3-(methoxythiocarbonylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one **314**. When the reaction mixtures were subsequently treated with MeI, and the evaporated reaction mixtures with conc. HCl in EtOH, 3-amino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **315** were obtained (94JHC125).

9-Dodecyloxy-3-(2-chloroethyl)-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one **317** was obtained by cyclization of 3-[1-[(3-dodecyloxy-2-pyridyl)amino]ethylidene]-4,5-dihydro-2(3*H*)-furanone (**316**) in boiling POCl₃ (95MIP4).




Heating 1,5-di(*tert*-butoxycarbonyl)-3-[(2-pyridylamino)methylene]pyrrolidin-2-one (**318**) in boiling EtOH in the presence of K₂CO₃ gave 2-(*tert*-butoxycarbonylamino)-3-(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-3-yl)propionate (**190**) in 55% yield (95TL7503, 97JCS(P1)1297).


Cyclization of ethyl *N*-(2-pyridyl)-2-methyl- and *N*-(5-chloro-2-pyridyl)-malonamates in a mixture of POCl₃ and PPA at 130 °C gave 2-chloro-3-methyl- and 2,7-dichloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones in 26 and 61% yields, respectively (00BMC751).




Cyclization of 3-aryl-2-ethoxy-3-(5-fluoro-2-pyrimidinyl)propane-1,1-dicarboxylates **319** either in boiling toluene in the presence of DBU under a Dean-Stark condenser, or in boiling EtOH in the presence of catalytic amount of piperidine and AcOH, or in the presence of conc. H₂SO₄ gave 9-aryl-3-fluoro-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylates **320** (95MIP1, 96JMC3070, 96MIP4, 96USP5580872).



It was claimed that cyclization of ethyl 2-chloro-5-cyclopropyl-6-[[*N*-(4,5-dimethoxy-2-nitrophenyl)methoxy]carbonyl]-*N*-(2-fluoro-3-hydroxy-1-oxo-2-propen-1-yl)amino}nicotinate (**321**) in boiling aqueous dioxane in the presence of K₂CO₃ overnight yielded 1-[[[4,5-dimethoxy-2-nitrophenyl)methoxy]carbonyl]-9-cyclopropyl-3-fluoro-2-oxo-2,6-dihydropyrido[1,2-*a*]pyrimidine-7-carboxylate (**160**) (95MIP1, 96MIP4, 96USP5580872).




Heating amidoamidines **322** [obtained from 2-pyridylimino-propadienone **130** with dialkylamine] gave imidoylketenes **323**, which



Scheme 14


subsequently cyclized to 2-dialkylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **126** (X = NMe₂, NEt₂). The formation of pyrido[1,2-*a*]pyrimidin-4-ones started at 40 °C (99JCS(P2)1087). Flash vacuum thermolysis of 2-amino-pyridine derivative **324** at 500 °C gave a mixture of 2-methoxy- and 2-dimethylamino-4*H*-pyrido[1,2-*a*]pyrimidinones (**126**, X = MeO, NMe₂). 2-Pyridyliminopropadienone (**130**), obtained by FVT of **126** (X = Cl), reacted very efficiently with HCl on warm-up to yield the starting 2-chloro derivative **126** (X = Cl) (Scheme 14).

Treatment of perhydropyrimidine **325** with NaOt-Bu gave 1,2,3,4,6,7-hexahydro-8*H*-pyrido[1,2-*a*]pyrimidin-8-one **326** (00MI25).




2. By Formation of One Bond β to the Bridgehead Nitrogen Atom [6+0 (β)]

Photocyclization of *N*-(4-phenyl-4-pentenyl)monothioibarbiturate (**327**) afforded a mixture of 1,2,3-trimethyl-9-phenyl-1,2,3,6,7,8-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-2,4-dione and tricyclic nitrogen bridgehead compound **328** (96H(42)117).




Dehydrogenation of piperidine derivative **329** with Hg(II)–EDTA reagent afforded a mixture of perhydropyrido[1,2-*a*]pyrimidin-2-one **330** and pyrido[1,2-*c*][1,2,5]oxadiazine **331** (99ZN(B)632).




3. By Formation of Two Bonds from [5+1] Atom Fragments

3-Acetyl-4-phenylamino-2*H*-pyrido[1,2-*a*]pyrimidin-2-one (**285**) was obtained when *N*-(2-pyridyl)acetoacetamide **332** (R = H) was first treated with PhNCS in the presence of K₂CO₃ and BnEt₃NCl, then with MeI and NEt₃, and then the reaction mixture was heated rapidly to 80 °C (95MI2). Reaction of *N*-(2-pyridyl)acetoacetamides **332** with CS₂ in the presence of K₂CO₃ and a catalytic amount of BnEt₃NCl, then with 1 or 2 equiv of MeI afforded 3-acetyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidine-4-thiones **333** and 3-acetyl-4-methylthio-2*H*-pyrido[1,2-*a*]pyrimidin-2-one (**334**), respectively (96MI22).




4. By Formation of Two Bonds from [4+2] Atom Fragments


Reaction of 2-(arylmethyleneamino)pyridines **335** and styrenes in the presence of hydroquinone afforded 2,4-diaryl-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidines **336** by means of an inverse electron demand Diels–Alder reaction (95MI10). Reaction of 2-(benzylideneamino)pyridines **337** and chloroacetyl chloride gave 2-aryl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **338** (97JMC2266).



9-Cyclopropyl-3-fluoro-2-hydroxy-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylates **340** were obtained in the reaction of 2-cyclopropyl-2-(5-fluoro-4-hydroxy-2-pyrimidinyl)acetaldehyde (**339**) and ethyl, *tert*-butyl and dibenzyl malonates in the presence of piperidine and AcOH (95MIP1, 96JMC3070, 96MIP4, 96USP5580872).




Reaction of 2-[(benzotriazol-1-yl)alkylamino]pyridines **341** with open-chain electron-rich alkenes **342** in the presence of BF₃·Et₂O gave 4-substituted 1,2,3,4-tetrahydropyrido[1,2-*a*]pyrimidinium tetrafluoroborates **343** (98S704).




3,9-Dicyano-2,4,8-triphenyl-7-phenylsulfonyl-6*H*-pyrido[1,2-*a*]pyrimidine-6-thione was obtained in the reaction of 6-amino-1-benzoyl-5-cyano-4-phenyl-3-phenylsulfonylpyridin-2(1*H*)-one and benzylidenemalononitrile in the presence of piperidine in boiling dioxane for 4 h in 59% yields (98M1049).

5. By Formation of Two Bonds from [3+3] Atom Fragments

Cyclocondensation of 2-amino-3-hydroxypyridinium perchlorate with benzoylacetone in boiling EtOH afforded 2-methyl-4-phenylpyrido[1,2-*a*]pyrimidinium perchlorate in 23% yield (94KFZ(10)23).




Treatment of a residue, obtained after the evaporation of the reaction mixtures of 2-aminopyridines and enone Mannich bases **344** with 70% HClO_4 gave 3-aroyl-1,2,3,4-tetrahydropyrido[1,2-*a*]pyrimidinium perchlorates **345** (98SL263). Reactions in AcOH afforded a complex reaction mixture with lower overall yields.





Heating the crystalline salt 2-aminopyridinium propionate (346) at 100 °C in the solid state led to a 10:9 mixture of 2*H*-pyrido[1,2-*a*]pyrimidin-2-one and (*E*)-3-(2-imino-1,2-dihydro-1-pyridyl)acrylic acid (347). Analysis of differential scanning calorimetry data shows unambiguously that the reaction takes place in the solid state. An endothermic peak at 81.1 °C corresponds to a solid state reaction, and a peak at 122–123 °C is attributed to melting. The product ratio of 2*H*-pyrido[1,2-*a*]pyrimidin-2-one and 347 is 1:2.5 at 60 °C, and 1:1.4 at 80 °C (94MI12).

Reaction of 2-cyano-3-(4-methoxyphenyl)acryloyl chloride and 2-aminopyridine in boiling benzene in the presence of NEt₃ for 5 h gave a 2:1 mixture of 3-cyano-4-(4-methoxyphenyl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidin-2-one and 2-[[2-cyano-3-(4-methoxyphenyl)acryloyl]amino]pyridine (01SUL151).



Cyclocondensation of 2-aminopyridines and ethyl cyano(hydroxyimino)acetate in the presence of NaOEt gave 4-amino-3-nitroso-4*H*-pyrido[1,2-*a*]pyrimidin-2-ones 348 (95JHC1725).


Reaction of 2-aminopyridine and 6-chloro-1,3-dipropyl-1*H*,3*H*-pyrimidine-2,4-dione in THF in the presence of NaH at room temperature overnight gave a mixture of 4-[*N*-(propylaminocarbonyl)-*N*-propylamino]-2*H*-pyrido[1,2-*a*]pyrimidin-2-one (349) and 6-(2-pyridylamine)-1,3-dipropyl-1*H*,3*H*-pyrimidine-2,4-dione (350, R = H) (94JHC81). Only the non-cyclized product 350 (R = Cl) was obtained from 5-chloro-2-aminopyridine.



Reaction of 2 equiv of 2-aminopyridines with 2-hdropolyfluoroalk-2-anoates **351** in MeCN in the presence of NEt_3 at 90°C for 50 h afforded a mixture of the isomeric 2-oxo-2*H*- and 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidines **110** and **111**. Reaction of 3 equiv of 2-amino-pyridines and 2-hdropolyfluoroalk-2-enoates **351** in MeCN in the presence K_2CO_3 could be accelerated by ultrasonic irradiation (125 W). 2-Amino-6-methylpyridine yielded only 2-substituted 6-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **111** ($\text{R} = 6\text{-Me}$), whereas 2-amino-5-bromopyridine gave a mixture of 7-bromo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**111**, $\text{R} = 7\text{-Br}$, $\text{R}^{\text{F}} = \text{CF}_2\text{Cl}$) and 2-(chloro,difluoromethyl)-6-bromoimidazo[1,2-*a*]pyrimidine-3-carboxylate in 44 and 8% yields, respectively (**97JCS(P1)981**). Reactions in the presence of K_2CO_3 in MeCN at 90°C for 60 h afforded only imidazo[1,2-*a*]pyrimidine-3-carboxylates.

Cyclocondensation of 2-iminopiperidine and 3-aryl-2-propynylnitriles in THF or 5% MeCN/THF afforded 4-aryl-2-imino-6,7,8,9-tetrahydro-2*H*- and 2-aryl-4-imino-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidines in 70–98% and 2–30% yields, respectively (**00OL3389**). When the reactions were carried out in the presence of 2 equiv of NaHMDS the product ratio was reversed.

From the reaction mixture of 2-aminopyridine and perfluoro-2-methylpent-2-ene in MeCN a 9:1 mixture of 2,4-difluoro-2-pentafluoroethyl-3-trifluoromethyl-4*H*- and isomeric 2,4-difluoro-4-pentafluoroethyl-3-trifluoromethyl-2*H*-pyrido[1,2-*a*]pyrimidine (64%), and 2-pentafluoroethyl-3-trifluoromethyl-4*H*-pyrido[1,2-*a*]pyrimidine-4-one (20%) was isolated (**00JFC105**).




Reaction of 1 mole of amins **352** with 4 mol of methyl 3-aminocrotonate in the presence of the solid acids montmorillonite clay (K_{10}) and ZF520 zeolite as strong Brönsted acidic catalysts, gave 1,4-dihydropyridines **353** and 2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**99MI8**).


Reaction of 2-aminopyridine with dimethyl 2-methylmalonate in the presence of some drops of conc. HCl at 150°C for 1 h (**96EUP733633**), and with diethyl 2-(1-decyl)malonate at 120°C for 5 min (**94JCR(S)206**) gave 2-hydroxy-3-methyl- and 2-hydroxy-3-(1-decyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones in 2.2% and 7.5% yields, respectively. Reaction of 3-benzyl-2-aminopyridine and diethylmalonate at $190\text{--}200^\circ\text{C}$ for 4 h yielded 9-benzyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**01MIP9**). Cyclocondensation

of 2-amino-5-bromopyridine and diethyl arylmalonates at 180 °C overnight under nitrogen yielded 3-phenyl- and 3-(3-thienyl)-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (97BRP2307177). Cyclocondensation of 2-amino-pyridines with diethyl 2-{[4-(2-cyanophenyl)phenyl]methyl}malonate at 180 °C gave 2-hydroxy-3-{4-[(2-cyanophenyl)phenyl]methyl}-4*H*-pyrido[1,2-*a*]pyrimidines (94BMCL183). Reaction of 3-(2-substituted ethoxy)-2-aminopyridines and bis(2,4,6-trichlorophenyl)malonate in boiling acetone afforded 2-hydroxy-9-(2-substituted ethoxy)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (01MIP8).

Anhydro-(2-hydroxy-7-chloro-3-propyl- and -3-allyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxydes were prepared in the reaction of 5-chloro-2-aminopyridine and the appropriate diethylmalonates near at 175 °C for 3.5 h, or in boiling diethylbenzene for 1 h (93MIP4). Heating a 1 : 2 molar ratio of 2-aminopyridine and trialkyl methanetricarboxylates in boiling bromobenzene for 10 h afforded alkyl 2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates (99JHC237). When 2:1 molar ratio of 2-aminopyridine and trialkyl methanetricarboxylate was heated at 200 °C in a melt for 20 min *N*-(2-pyridyl)-2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide (354) was obtained.



Cyclocondensation of 2-(alkylamino)- and 2-(benzylamino)pyridines with bis(2,4,6-trichlorophenyl) 2-ethyl- (99BCJ503, 00BMC1917), and 2-phenylmalonates (99BCJ503) at 160–190 °C in a melt for 5–10 min, and with diethyl 2-substituted malonates (99BCJ503) in boiling tetralin for 2–6 h afforded mesoionic *anhydro*-(2-hydroxy-1,3-disubstituted 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxydes **355** in 24–90% yields. Reaction of 4-[2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-aminopyridine and bis(2,4,6-trichlorophenyl)malonate in boiling xylene for 12 h gave 8-substituted 2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (01MIP1). Cyclocondensation of 2-anilino-pyridine with 2-benzyl- and 2-[(3-vinylphenyl)methyl]malonic acids in the presence of 2 mol equiv of dicyclohexylcarbodiimide and a catalytic amount of hydroquinone monopropyl ether in CH₂Cl₂ at 0 °C, then 25 °C for 3 h gave *anhydro*-(2-hydroxy-3-benzyl- and -3-[(3-vinylphenyl)methyl]-1-phenyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxydes in 87 and 67% yields, respectively (00MI26).



Reaction of 2-aminopyridine and its 4-methyl derivative and diethyl alkylidenemalonates **356** at 175 °C for 1.5–2.5 h yielded 3-vinyl derivatives **358**, after the isomerization of the exocyclic double bond in **357** (99ACS901). Reaction of 2-amino-4-methylpyridine and bis(2,4,6-trichlorophenyl) benzylidenemalonate in the presence of NEt_3 afforded only non-cyclized product **359**. 2-Aminopyridine and its 4-methyl derivative with diethyl benzylidene- and hexylidenemalonates at 190 °C did not give cyclized products (99ACS901, 99MI29).

Cyclocondensation of 2-aminopyridines with ethyl acetoacetate at 100 °C (93JJC(B)978, 95KFZ(2)40), with ethyl (het)aroylacetates at 125 °C (97JMC2266, 97JMC3049, 98MIP3, 99JMC4081), with ethyl 4-methoxyacetoacetate at 80–85 °C (93MI2) in PPA yielded 2-methyl-, 2-hetaryl- and 2-methoxymethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, respectively. From the reaction mixture of 6-substituted 2-aminopyridines (6-Me, 6-F, 6-Cl, 6-Br) and ethyl benzoylacetate and its *o*-, and *p*-fluoro derivatives, 2-aryl-6-substituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (14–15%, Knorr product) and 1-(6-substituted-2-pyridyl)-3-aryl-4-aryl-4-hydroxy-1,2-dihydropyridin-4-ones (3–12%, Conrad-Limpach product) could be isolated (99JHC1123).

Cyclocondensation of 2-amino-6-bromopyridine and 4-chloroacetoacetate in PPA at 100 °C for 4 h afforded a mixture of 2-chloromethyl-, 2-bromomethyl-6-bromo-, and 2-chloromethyl-, 2-bromomethyl-6-chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones in 84% yield (99JHC1065). The pyrido-[1,2-*a*]pyrimidin-4-ones were separated by preparative reversed phase HPLC. The pure 2-bromomethyl-6-bromo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was prepared from 2-amino-6-bromopyridine with ethyl 4-bromoacetoacetate in 63% yield. Reaction of 2-aminomethylpyridines and ethyl 4-chloroacetoacetate in PPA at 110 °C gave 2-chloromethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (95FES69, 01H(55)535).

9-Hydroxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was prepared in the reaction of 2-amino-3-benzoyloxy pyridine and ethyl acetoacetate at 60 °C, then at 100 °C for 3 h in 22% yield (96MIP1). Reaction of 2-amino-3-hydroxypyridine and ethyl 2-methylacetoacetate in a 1:2 mixture of


PPA and AcOH at 100 °C for 4 h gave 9-hydroxy-2,3-dimethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one in 24% yield (96EUP733633). Reaction of 2-aminopyridine and ethyl 2-acetoxyacetoacetate in boiling EtOH gave 2-methyl-3-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one in 47% yield (94KFZ(10)23).

2-Methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones were also prepared in the reaction of 2-aminopyridines and ethyl 3-methoxy-2-butenate in PPA at 80–85 °C for 3 h (93MI2).

Reaction of 2-amino-3,4,5,6-tetrahydropyridine and ethyl 2-methyl-, 2-propargyl-benzoylacetates in EtOH at room temperature for 3 weeks gave 2-phenyl-3-methyl- and -3-propargyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (94EUP579425). Reaction of 2-iminopiperidine and methyl 4,4,4-trifluoro-2-methylacetoacetate in boiling CH₂Cl₂ for 3 days gave 2-trifluoromethyl-3-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (01T2689).


Reaction of 2-aminopyridine and its 3-, 4-, 5-, and 6-methyl derivatives with 3-chloro-3-trifluoromethyl-3-ethoxycarbonyl- and -2-cyanoacrylnitrils in CHCl₃, sometimes in the presence of NEt₃, afforded 4-oxo- and 4-imino derivatives of 2-trifluoromethyl-3-cyano-4*H*-pyrido[1,2-*a*]pyrimidines, respectively (00MI27).

Cyclocondensation of 4-substituted 2-aminopyridines and ethyl 3-dimethylamino-2-[2-(4-methoxybenzyl)tetrazol-5-yl]acrylate in boiling EtCOOH for 4 h afforded 8-substituted [2-(4-methoxybenzyl)-2*H*-tetrazol-5-yl]-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones (01MIP1).




Cyclocondensation of 2-aminopyridines with 2-acetylbutyrolactone (360) in PPA (94MIP8) or in xylene in the presence of *p*TSA (95MIP4, 96MIP2)

with 4-ethoxymethylene-2-(het)aryl-5(4*H*)-oxazolone (**361**) in AcOH, in boiling DMF or in boiling pyridine in the presence of NEt_3 (93H(35)955, 99H(50)315); with 4-ethoxymethylene-2-methoxy-4,5-dihydro-5-thiazolone (**362**) in Ac_2O in the presence of NEt_3 at room (94JHC125); with ethyl 2-aryl-5-oxo-2,5-dihydroisoxazole-4-carboxylates (**363**) (93JHC33), and with (*S*)-3-[(dimethylamino)methylidene]-5-(methoxycarbonyl)tetrahydrofuran-2-one (**364**) in boiling AcOH in the presence of NaOAc (00JHC703) afforded 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **365–369**, respectively. When **364** was reacted with 2-aminopyridines in boiling AcOH only condensation products were obtained (00JHC703).




Cyclocondensation of 2-aminopyridines with methyl 3-(*N,N*-dimethylamino)-2-(benzyloxycarbonylamino)acrylate in boiling AcOH for several hours gave 3-(benzyloxycarbonylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **370** (99CCCC177, 00MI33). 2-Amino-6-methylpyridine afforded only condensation product **371**.



Reaction of 2-aminopyridines and methyl 3-(*N,N*-dimethylamino)-2-acetylaminoacrylate (**372**) in boiling AcOH yielded 3-acetylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **373** (97JHC247). From 2-amino-5-nitropyridine only a condensation product **374** was obtained. Similarly 3-(pyrazinylcarbonylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was obtained in the reaction of 2-aminopyridine and methyl 3-(*N,N*-dimethylamino)-2-(pyrazinylcarbonylamino)acrylate in boiling DMSO for 4 h in 17% yield (99H(50)315). Reaction of 2-amino-pyridines and 3-(*N,N*-dimethylamino)-2-(2-pyridyl)acrylate **375** yielded 3-(2-pyridyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **376** (93JHC1253). Cyclocondensation of 2-aminopyridines and 3-(*N,N*-dimethylamino)-2-(substituted amino)acrylates **377** yielded 3-(substituted amino)-4*H*-pyrido-[1,2-*a*]pyrimidin-4-ones **378** (95JHC921, 97H(45)2349, 97HCA2418, 97JHC813, 97JHC1511, 98ACH613, 98H(47)1017, 98H(49)133, 98JHC1275). In the case of 2-amino-5-nitropyridine only the

substitution of the *N,N*-dimethylamino group occurred to give a condensation product (95JHC921).




Reaction of 2-aminopyridine with ethyl 2-cyano-3-ethoxy-3-methyl-, -3-ethyl-, -3-phenylacrylates and ethyl 2-ethoxycarbonyl-3-ethoxy-3-methyl-, -3-phenylacrylates in boiling xylene yielded 2-substituted 4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitriles and -3-carboxylates (99M17). Similar reactions of 2-aminopyridine with 2-cyano-3-ethoxyacrylonitrile and its 3-methyl, 3-ethyl, -3-phenyl derivatives in boiling MeCN afforded 4-imino-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile and its 2-substituted derivatives.

Cyclocondensation of 4-(*E*)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl)-2-aminopyridine and ethyl ethoxymethylenemalonate in boiling toluene for 2 h gave ethyl 8-substituted 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one-3-carboxylate (01M1P1). Reaction of 2-amino-4-methylpyridine and diethyl *N,N*-dimethylaminomethylenemalonate in boiling AcOH for 90 min gave ethyl 8-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate in 35% yield (96JHC1041). Cyclocondensation of 2-amino-3-methylpyridine and ethoxymethylenemalononitrile gave 9-methyl-4-imino-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile (199) in 91% yield (95CPB683). It was stated that cyclocondensation of 2-amino-3,5-dicyano-4-phenyl-6-phenylthiopyridine and ethyl ethoxymethylenecyanoacetate in boiling AcOH for 5 h gave ethyl 7,9-dicyano-4-imino-8-phenyl-6-phenylthio-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate in 70% yield (94M15).

Cyclocondensation of 2-aminopyridine and its 3-, 4-, and 5-methyl derivatives with ethyl 2-(bismethylthiomethylene)cyanoacetate in boiling BuOH for 5 h afforded 2-methylthio-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitriles in 55–87% yields (96FES781).

Cyclocondensation of 2-iminopiperidine hydrochloride with an *E-Z* isomeric mixture of ethyl 2-cyano-3-methylsulfanyl-3-(1,2,4,5-tetrahydro-3*H*-benzo[*d*]azepin-3-yl)acrylate in DMF in the presence of DBU at 100°C gave 2-substituted 6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile (01EUP1074549).


Cyclocondensation 2-[[2-cyano-2-(2-pyridyl)ethenyl]amino}-3-(dimethylamino)acrylates and 2-aminopyridines in boiling AcOH for 1–1.5 h afforded 3-[[2-cyano-2-(2-pyridyl)ethenyl]amino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones in low yields (01H(55)705, 01JHC869).



Cyclocondensation of 2-(nitromethylene)perhydropyrimidine (379) and dimethyl acetylenedicarboxylate yielded a mixture of 9-nitro-1,2,3,4-tetrahydro-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidin-8-carboxylate 380 and a pyrrolo[1,2-*a*]pyrimidine-7-ylideneacetate 381 (93BCJ2118). Their ratio depends on the reaction circumstances.

6. By Formation of Three Bonds from [3+2+1] Atom Fragments


Reaction of 2-aminopyridines with formaldehyde and electron rich styrenes 383 permitted the synthesis of 3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidines 384 (96TL2615). First imines 382 formed; they are involved in a formal aza-Diels–Alder reaction to give compounds 384.




Pemirolast (7) was prepared in 68% yield in a one pot reaction of 2-amino-3-methyl-pyridine, malononitrile and HC(OEt)₃ and NaN₃ in AcOH at 90°C for 2 h, then the reaction mixture was treated with conc. HCl at 90°C for another 2 h (98H(48)775).

7. Rearrangement

Reaction of 1,3-propanediamine and 3-cyano-4-methyl-6-methylthio-1-phenyl-2-oxo-1,2-dihydropyridine-5-carboxylate **385** yielded 7-cyano-8-methyl-6-oxo-1,2,3,4-tetrahydro-6*H*-pyrido[1,2-*a*]pyrimidine-9-carboxylate (**386**) (94JHC393).




Reaction of 5-cyano-6-methoxy-1,2,3,4-tetrahydropyridin-2-ones **387** with 1,3-propanediamine in boiling *N,N*-dimethylacetamide gave 9-cyano-1,2,3,4,7,8-hexahydro-6*H*-pyrido-[1,2-*a*]pyrimidin-6-ones **388** either via route *a* or via route *b* (95H(41)2173).



Dipolar cycloadditions of dihydropyrimidine-fused mesomeric betaines **389**, **391** and **394** with different dipolarophiles afforded 6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates **390**, **392**, **393** and **396** (97JOC3109).


Pyrido[1,2-*a*]pyrimidine-3,7-dicarboxylate **396** was also obtained in the reaction of diazo compound **395** and methyl vinyl ketone in boiling benzene in the presence of a catalytic amount of ruthenium acetate.



8. Miscellaneous


Rhodium catalyzed reaction of *N*-butenyl-1,3-propanediamines **397** with a mixture of H_2 and CO gave usually a mixture of hydroformylated **398** and **399** and carbonylated products **400** and **401** in the presence of a phosphite [PPh_3 , PBU_3 , $\text{P}(\text{C}_6\text{H}_{11})_3$, $\text{P}(o\text{-tol})_3$] (97TL4315, 97T17449). When the hindered biphosphite, BIPEPHOS, and a 9:1 or 1:1 mixture of H_2 and

CO were used only perhydropyrido[1,2-*a*]pyrimidine (**398**, R = H) formed from compound **397** (R = H).





Reaction of pyridinium-*N*-(2-pyridyl)amidine (**402**) and alkyl haloacetates in the presence of K_2CO_3 afforded a mixture of 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-2-carboxylates **407** and 2-aminopyridine derivatives **406** through intermediaries **403–405**, as depicted in Scheme 15 (00TL5837). Compound **406** could be cyclized on the action of heat or silica gel into **407**. The best yield was achieved in the case of ethyl bromoacetate.

Reaction of 1,3-propanediamine and a mixture of α and β isomers of 5-bromo-5-deoxy-D-xylofuranose in H_2O for 10 min gave 7*R*-(7 α ,8 β ,9 α)-7,8,9-trihydroxyperhydropyrido[1,2-*a*]pyrimidine (**112**, R = H) in 27% yield (99T6759). Reaction of 5-bromo-5-deoxy-D-xylofuranose and *N*-methyl-1,3-propanediamine in H_2O at room temperature afforded a 5:1 mixture of 1-methyl **117** and 5-methyl **118** derivatives of 7,8,9-trihydroxyperhydropyrido[1,2-*a*]pyrimidine **112** (R = H). When this reaction was carried out in the presence of 3 moles of NEt_3 the product ratio of **117** to **118** was 1:2. The influence of NEt_3 on the product ratio may be a consequence of it scavenging HBr and freeing the more basic and more nucleophilic methylamino group for participation in the displacement reaction.




Scheme 15




Scheme 16

Heating thioacetal **410** in the presence of dimethyl(methylthio)sulfonium tetrafluoroborate (DMTSF) yielded 1-methylperhydropyrido[1,2-*a*]pyrimidine-2,6-dione (**411**) (00JOC235).



A diastereomeric mixture of 1-alkyl-7-(1-alkylperhydropyrido[1,2-*a*]-pyrimidin-6-yl)-1,2,3,4,8,9-hexahydro-9*a*-pyrido[1,2-*a*]pyrimidines **412** was obtained in the reaction of glutaraldehyde and *N*-alkyl-1,3-propanediamines in the presence of a drop of AcOH at 0 °C, then at ambient temperature for 13 h (96H(43)2487).

Reaction of di(benzylthio)acetal **413** and 1,3-diaminopropane in the presence of a catalytic amount of NEt₃ afforded 1,2,3,4,6,7-hexahydro-8*H*-pyrido[1,2-*a*]pyrimidin-8-one **414** (00MI25).



Retro Diels–Alder reaction of nitrogen bridgehead compound **415** at 100 °C afforded 6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one and cyclobutadiene (97SC195).


D. APPLICATIONS AND IMPORTANT COMPOUNDS

Neurotropic and antistress properties of 2,4-dimethylpyrido[1,2-*a*]pyrimidinium perchlorate were compared with those of piracetam (95MI7). 4*H*-Pyrido[1,2-*a*]pyrimidin-4-one binds selectively to rat A₃ receptors with a *K_i* value of 48 μM. No affinities were observed to rat A₁ and A₂ receptors (96MI17). 4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylic acid and -3-carbonitrile did not exhibit significant antibacterial activities (97MI6).

2-(4-Methyl-1-piperazinyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one exhibited *in vitro* platelet aggregation inhibitory activities on human platelet aggregations induced by ADP, collagen and A23187 (93FES1225). 2-Piperazino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one inhibited dose-dependently aggregation both in platelet rich plasma and in washed platelets, exerting its maximal power in the presence of collagen, ADP and platelet activating factor (97MI21). The structure and antiplatelet activity relationship of a series of 2-(substituted amino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones and their congeners and isosteric analogs was analyzed by comparative molecular field analysis (COMFA) (00BMC751). Inhibitory activities of mesoionic **355** were investigated on ADP-induced human platelet aggregation (00BMC1917). The gastroprotective activities of a series of *N*-substituted 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamides were


studied. The most active derivative was 6-methyl-*N*-cyclopentyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide (92MI1). The mechanism of action of the cytoprotective effect of *trans*-6,9*a*-H-1,6-dimethyl-4-oxo-1,6,7,8,9,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide (CHINOIN-127) was investigated (92MI2). Analgetic activity of 2-(substituted amino)-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitriles was reported (95MI9). Cytotoxic activity of diorganotin(IV) complexes of 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **109** was tested (96MI4).

The antiallergic activity of pemirolast (**7**) were investigated on different *in vitro* and *in vivo* models (93MI3, 94MI2, 94MI7, 94MI9, 95MI1, 95MI12, 95MI15, 95MI16, 96MI18, 96MI21, 97MI17, 98MI12). Pemirolast did not inhibit neuronal dopamine up-take into the rat striatal synaptosomes (98MI6). Interaction of **7** and theophylline was investigated under steady-state conditions in healthy male volunteers (94MI4). The preventive effects of **7** on restenosis after percutaneous transluminal coronary angioplasty were investigated on humans (98MI15). Treatment of inflammatory bowel and liver diseases with **7** was patented (95JAP(K)95/69895, 95JAP(K)95/101863). A meta-analysis of clinical trials of antihistamines, among them **7**, was performed to access the risk–benefit ratio of this therapeutic class in asthma (97MI23). Compositions, containing **7** among others, were patented for the treatment of the common cold (97JAP(K)97/52849) and as a compound of ophthalmic compositions (01JAP(K)01/187728). Pemirolast was patented as an arteriosclerosis depressant (95MIP6). Stabilized aqueous solutions of **7** were patented (96JAP(K)96/92093, 96USP5527802). Antiallergic activity of AS-35 (**8**) was investigated on different models (94AF754, 94MI11, 94MI13, 00MI19). AS-35 (**8**) was claimed for the treatment of inflammatory intestinal diseases (94MIP2). Orally administrable compositions of antiallergic 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **416** were patented (93MIP5).



2-Alkoxy-3-{4-[2-(5-tetrazolyl)phenyl]phenylmethyl}-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **417** exhibited potential angiotensin II receptor antagonistic activities (94BMCL183).

2-[4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl]oxymethylsaccharin derivatives **418** exhibited human leukocytal elastase inhibitory activities (94EUP626378, 95USP5378720). 2-Substituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**419**) is a potent human leukocytal elastase inhibitor (K_i 1.79 μ M) (96USP5512576). The 4*H*-pyrido[1,2-*a*]pyrimidin-4-one moiety was included in leukotriene antagonist 2-ethynylthiazole derivatives (98JAP(K) 98/195063)



Biochemical and pharmacological properties of pirenperone (**9**) (94AF269, 95MI4, 95MI6, 95MI8, 96MI8, 97MI10, 97MI16, 97MI20, 99MI5, 99MI21), ocaperidone (**13**) (94AF269, 95MI14, 96MI8, 96MI23, 97MI5, 98BJP1655, 00MI2, 00MI18), and seganserine (**15**) (95MI5, 96MI8, 98MI5) were investigated. Pirenperone partially blocked (\pm)-3,4-methylenedioxymethamphetamine discrimination (00MI31). Applications of **9** and risperidone (**11**) for the treatment of circadian rhythms were patented (98MIP4). Among other serotonin antagonists, **9** and **11** were patented for use in a dermatological composition for treating sensitive skin (98MIP7). Metrenperone (**10**), a selective 5HT₂ receptor antagonist, was investigated as a possible drug to alleviate respiratory distress associated with experimentally induced *Pasteurella haemolytica* pneumonia in feedlot calves (96MI20). The effect of **10** on systematic and pulmonary hemodynamics was determined in conscious 7 to 15-day-old calves after they were intratracheally inoculated with *Pasteurella haemolytica* (96MI16). Three dosage regimens of **10** were compared to inhibit the 5-HT-induced pulmonary dysfunction in cattle (93MI1). Among other 5-HT₂ and D₂ receptor antagonists, **11** and **13** were patented for treating mental disease associated with cerebrovascular disorders (96CP2167004). The binding of **11** and **13** to D₃ receptors in the rat brain was studied (96MI19). Covalent conjugates of **11** and **13** with a fatty acid were patented for the treatment of schizophrenia (99MIP5).

Risperidone (**11**) is a new type of an atypical antipsychotic with relatively pronounced effects on negative symptoms and low extrapyramidal side

effects. Its preclinical (00MI42), animal (96MI9), and clinical pharmacology, metabolism (00MI30), pharmacokinetics (96MI9), pharmacodynamics, pharmacoeconomics (00MI12, 00MI32, 00MI34, 01MI5), pharmacogenetics (00MI15), toxicology (96MI9), clinical development and clinical applications (00MI42), extrapyramidal side effects, safety use and usage in the treatment of schizophrenia, dementia (00MI21) and in geriatric patients and its side effects were extensively reviewed (94MI1, 95MI11, 95MI13, 96MI1–96MI3, 96MI5, 96MI7, 96MI8, 96MI10–96MI15, 97MI1, 97MI2, 97MI8, 97MI9, 98MI1, 98MI3, 99MI9, 99MI16–99MI19, 99MI24, 00MI3–00MI10, 00MI17). Possible induction of mania and hypomania of olanzepine and **11** was discussed (00MI36). Cardiac safety parameters of **11** were compared with those of olanzepine (01MI6). The advantages and disadvantages of the medications of different atypical antipsychotics, including **11**, for schizophrenia (01MI15), pharmacology and toxicology of atypical antipsychotics, including **11** (01MI12), were reviewed. In the treatment of refractory schizophrenia **11** was less effective than clozapine (00MI43). Bodyweight gain after treatment with **11** (01MI7), the possible role of **11** in the treatment of autism (01MI8), its optimal dosing (01MI9), and priapism side effect of **11** (01MI10) were reviewed. A summary of the uses of **11** in the emergency treatment of psychosis (00MI44), in the treatment of bipolar disorders (00MI45), and in the treatment of psychosis and agitation in elderly patients (00MI46) has been presented.

Different pharmaceutical formulations of **11** were developed and patented (94MIP3, 95MIP2, 95MIP3, 95USP5453425, 96MIP3, 97MIP5, 97MIP6, 97USP5616587, 98EUP830864, 98MIP6, 98USP5792477, 99MI1, 99MI4, 00MIP9).

Risperidone (**11**) was also included among a α 1-adrenergic receptor antagonists to study a quantitative structure–activity relationship (99BMC2437). A pharmacophore model for atypical antipsychotics, including **11**, was established (00MI41). An increased plasma level of **11** and 9-hydroxyrisperidone (**12**) was observed in combination with paroxetine (01MI13). The effect of vanlafaxine on the pharmacokinetics of **11** was reported (99MI13).

Preparations of aqueous suspensions of submicron **12** fatty acid esters were patented (99MIP4). Risperidone was used and patented in combination therapies (99MIP8, 99MIP9, 00MIP5, 00MIP6, 01MIP7). Risperidone was applied in an ophthalmic formulation (01JAP(K)01/97865). Preparation of microparticles of **11** and **12** was patented (01MIP2, 01MIP3, 01USP6264987). Absorption, metabolism and excretion of **11** in rats, dogs (94MI6) and humans (93MI4) were studied. The long-term stability of **11** and **12** in plasma was studied (99MI20). The regional brain distribution of **11** and its 9-hydroxy main metabolite **12** was investigated

in the rat (94MI3, 98MI9). The *in vivo* pharmacological profile (94MI8) and *in vitro* and *in vivo* receptor binding (96MI5) of **12** were studied. The role of cytochromes P450 2D6 in the metabolism of **11** and **12** was investigated (99MI3, 99MI14, 99MI15, 99MI22, 99MI23). Pharmacokinetic interaction of **11** with CYP450 isoenzymes was investigated (01MI14). Risperidone drug interactions were evaluated (01MI3). Different antipsychotic drugs, including **11** and **12**, were investigated to bind to nine different receptors of postmortem human brain (00LS29).

The treatment of psychoses with enantiomers of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-9-sulfonic acid and **12** was patented (99MIP6, 99MIP7). Pamoate acid salt of **11** was prepared and patented (94MIP7).

3,4-Dihydro-2*H*-pyrido[1,2-*a*]pyrimidin-2-one was used in the synthesis of antiallergic tricyclic triazolobenzazepine derivatives (99MIP3). 8-[2-(4-*i*-Propyl-2-thienyl)ethenyl]- and 8-[(4-*i*-propyl-2-thienyl)methoxy]-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylic acids were patented for the treatment of preventing and/or treating microbial infectious diseases (01MIP1).

Potential antidepressant activity of lusaperidone (**14**) and its derivatives were investigated on $\alpha 1$, $\alpha 2A$, $\alpha 2B$ and $\alpha 2C$ receptor binding tests (00BMCL71). Hydrophilic controlled release formulations of **14** were developed and patented (00MIP8).

3,4,6,7,8,9-Hexahydro-2*H*-pyrido[1,2-*a*]pyrimidine was used as deblockable latent catalysts for Michael addition-based polyurethane coatings (97MI4), and its usage in the preparation of a fuel barrier laminate was patented (01MIP6). Its salt with trimellitic anhydride as a curing catalyst for epoxy resin compounds with good storage stability for scaling semiconductor devices (98JAP(K)98/53588), and its pyromellitic acid as a hardening accelerator in the manufacture of epoxy materials for hybrid powdered coatings (95EUP663385) were patented.

1-(Dichloroacetyl)-3,3,9*a*-trimethylperhydropyrido[1,2-*a*]pyrimidin-6-one was applied in herbicidal compositions as a safener (99EUP901752).

Among other bicyclic amidine catalysts, 3,4,6,7,8,9-hexahydro-2*H*-pyrido[1,2-*a*]pyrimidine was also applied in the preparation of β -alkoxy nitriles from α,β -unsaturated nitriles and alcohols (99GEP 19803515). The azido group could be smoothly converted into a trifluoroacetylamido group by treatment with $(CF_3CO)_2$ in the presence of Ph_3P and 2,3-dihydro-2*H*-pyrido[1,2-*a*]pyrimidin-2-one under Ar in THF (99HCA2380).

V. Benzologs of Pyrido[1,2-*a*]pyrimidine


A. STRUCTURE

1. Thermodynamic Aspects

The lipophilicity (R_M value) and specific hydrophobic surface area of 11*H*-pyrido[2,1-*b*]quinazolin-11-one and its isomeric 6*H*-pyrido[1,2-*a*]quinazolin-6-one were determined by reversed-phase thin-layer chromatography (98MI4).

2. Circular Dichroism

The absolute configuration of C-3 of the chromophore **4** of an isopyoverdin was determined as *S* from the CD spectrum (Cotton effect +242 nm, -290 nm, +358 nm) of **420** obtained from isopyoverdin by acidic hydrolysis (01T1019).



3. Theoretical Calculations

Bond orders, charges on the atoms in 11*H*-pyrido[2,1-*b*]quinazolin-11-one and its protonated form were calculated by quantum chemical calculations by the semiempirical AM1 method. According to the results, the equilibrium conformation of the ring in 11*H*-pyrido[2,1-*b*]quinazolin-11-one is planar, while 1*H*-pyrimido[1,2-*a*]quinolin-1-one adopts a conformation close to a half-chair due to the unfavorable interactions between the oxygen atom of the carbonyl group and the ring C-10 atom in the *peri*-position (97MI22).

4. Infrared Spectroscopy

IR Spectra of the hydrochloride of 6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]quinazolines and their $ZnCl_2$ complexes were investigated in the stretching vibration region of N^+H (2000–3500 cm^{-1}) (97MI18, 99MI25).

5. *NMR Spectroscopy*

Chromophore **1** of pyoverdin siderophores (99MI27, 99MI28, 00ZN(C)153, 00ZN(C)323, 00ZN(C)671, 00ZN(C)857, 01TL5849), and chromophore **4** of isopyoverdin (01T1019) were characterized by ^1H and ^{13}C NMR data.

6. *X-ray Investigations*

The structures of 5-ethyl-11-methyl-9-oxo-5,11-dihydro-9*H*-pyrido[2,1-*b*]-quinazoline-8-carboxylic acid (00K669), the chromophore **4** of isopyoverdin siderophores (01T1019), and that of 5,5*a*,6,7,8,9-hexahydro-11*H*-pyrido[2,1-*b*]-quinazoline (99SL1383) were justified by X-ray analysis.

B. REACTIVITY

1. *Hydrogenation*

Catalytic debenzoylation of 10-(dibenzylamino)-6-(4-*tert*-butylphenyl)-3,4-dihydro-2*H*-pyrimido[2,1-*a*]isoquinoline **421** ($\text{R} = \text{PhCH}_2$) over a 5% Pd/C catalyst under hydrogen at atmospheric pressure in acidified EtOH at ambient temperature afforded the 10-amino derivative **421** ($\text{R} = \text{H}$) (98JMC1050).

2. *Oxidation*

Ozonolysis of 6-(phenylmethylene)-6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]-quinazolin-11-one in CH_2Cl_2 gave 6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]-quinazoline-6,11-dione (01H(55)1555).

Ozonolysis of 5,8,9-trihydroxy-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-3-carboxylic acid (**420**), obtained from isopyoverdin isolated from *Pseudomonas putida* BTP1 by acidic hydrolysis, gave L-2,4-diaminobutyric acid, which confirmed the hypothesis that heterocyclic chromophores **1** and **4** of pyoverdine and isopyoverdin, respectively, could have the same precursor, and the configuration at C(3) should be *S* (97ZN(C)549).

3. Reactivity of Ring Carbon Atoms

Condensation of 6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]quinazolin-11-one and PhCHO in boiling Ac₂O for 48 h yielded a 6-phenylmethylene derivative (01H(55)1555).

4. Reactivity of Substituents Attached to Ring Carbon Atoms

The halogen atoms of 2-iodo- and 3-bromo-11-oxo-11*H*-pyrido[2,1-*b*]quinazoline-6-carboxamides were replaced by (het)aryl groups on treatment with (het)arylboronic acids in the presence of [Ph₃P]₄Pd and 2 M Na₂CO₃ in toluene at 120–125 °C (98MIP1, 98MIP2, 99USP5908840, 99USP5914327). Instead of (het)arylboronic acids 4-(tributylstannyl)pyridine (98MIP2, 99USP5908840) and phenyl trimethyltin (98MIP1, 99USP5914327) were also applied.

Reaction of 6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]quinazoline-6,11-dione and PhNHNH₂ in EtOH afforded 6-phenylhydrazono derivative (01H(55)1555).

N-Substituted 11-oxo-11*H*-pyrido[2,1-*b*]quinazoline-6-carboxamides were prepared from 11-oxo-11*H*-pyrido[2,1-*b*]quinazoline-6-carboxylic acids and amines in the presence of (*i*-Pr)₂EtN and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate in CH₂Cl₂ (98MIP1, 98MIP2, 99USP5908840, 99USP5914327).

(*tert*-Butyldimethylsilyl)oxy and *N-tert*-butoxycarbonylamido groups on a substituent in position 9 of 11*H*-pyrido[2,1-*b*]quinazolin-11-one were converted into hydroxy and amino groups by treatment with 3 N–6 N HCl at room temperature (99USP5914327).

A 3-amino-*N*-[2-chloro-4{[(3-hydroxyphenyl)methyl]aminocarbonyl}benzoyl-L-alanine substituted Wang resin was *N*-acylated with 2-methoxy-11-oxo-11*H*-pyrido[2,1-*b*]quinazoline-8-carboxylic acid in *N*-methylpyrrolidone in the presence of 1-hydroxy-7-azabenzotriazole and diisopropylcarbodiimide (00MIP2). The product was cleaved from the resin by treatment with 50% TFA in a mixture of CH₂Cl₂ and MeOH.

The amino group of 3,4-dihydro-2*H*-pyrimido[2,1-*a*]isoquinoline **421** (R = H) was acylated with different isocyanates and phenyl isothiocyanate (98JMC1050).


5. Miscellaneous

A pyoverdine, containing chromophore **1**, was coupled with different antibacterial fluoroquinolone-3-carboxylic acids (01JMC2139).

C. SYNTHESIS

1. By Formation of One Bond α to the Bridgehead Nitrogen Atom [6+0 (α)]


Cyclization of 2-(4-hydroxypentyl)quinazolin-4(3*H*)-ones **422** under Mitsunobu's conditions afforded only linearly fused 6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]quinazolin-11-ones **423** without angularly fused 1,2,3,4-tetrahydro-6*H*-pyrido[1,2-*a*]quinazolin-6-ones **424** (98CPB928).



3-Methyl-1*H*-pyrimido[1,2-*a*]quinolin-1-one was obtained by heating isopropylidene 2-[1-(2-quinolylamino)ethylidene]malonate in EtOH at 20 °C (00MI40).

2. By Formation of One Bond β to the Bridgehead Nitrogen Atom [6+0 (β)]

5,5a,6,7,8,9-Hexahydro-11*H*-pyrido[2,1-*b*]quinazoline alkaloid was obtained in 70% yield when 1-(2'-nitrobenzyl)-2-cyanopiperidine was reduced with Zn in acidified EtOH at 78 °C (99SL1383). 6,7,8,9-Tetrahydro-11*H*-pyrido[2,1-*b*]quinazolin-11-ones (**426**) were synthesized by azidoreductive cyclization of *N*-(2-azidobenzoyl)-2-piperidones **425** using TMSCl-NaI and bakers' yeast (01JOC997).




Oxidative cyclization of 1-[(2'-aminocarbonyl)phenyl]piperidine and its 4'-substituted derivatives with Hg(OAc)₂-EDTA reagent afforded 1,2,3,4-tetrahydro-6*H*-pyrido[2,1-*b*]quinazolin-6-one and its 3-substituted derivatives in 36–82% yields (99ZN(B)1577). Similarly, (*E*)-2-(piperidin-2-yl)benzal-doximes gave 2,3,4,4a-tetrahydro-1*H*-pyrido[1,2-*a*]quinazolin-5-oxide and

its 3-substituted derivatives, which were sometimes accompanied by over-oxidized, ring-opened (*E*)-2-(2-oxopiperidin-1-yl)benzaldoximes.


3. By Formation of Two Bonds from [5+1] Atom Fragments

Lithiation of 2-(2-alkylphenyl)-1,2,3,4-tetrahydropyrimidines **427** with 1.3 M BuLi in the presence of *N,N,N',N'*-tetramethylethylenediamine, then with 1.3 M *s*-BuLi, followed by the addition of a carboxylic acid methyl ester, and treatment of the reaction mixture with *p*TSA afforded 3,4-dihydro-2*H*-pyrimido[2,1-*a*]isoquinolines **428** after chromatographic work-up (98JMC1050).



4. By Formation of Two Bonds from [4+2] Atom Fragments

Reaction of malononitrile and quinazolinone **429** in the presence of three drops of NEt₃ yielded pyrido[2,1-*b*]quinazolinone **430** (97MI7). 9,11-Dioxo-5,9-dihydro-11*H*-pyrido[2,1-*b*]quinoline-8-carboxylates **432** were prepared in the reaction of anthranilonitrile and 2-piperidones **431** in boiling EtOH in the presence of AcOH (00JCS(P1)3686, 00PS133).




5. By Formation of Two Bonds from [3+3] Atom Fragments

Cyclocondensation of 2-chloronicotinic acid with 2-amino-5-iodobenzoic acid and methyl 2-amino-4-bromobenzoate in boiling EtOH in the presence of conc. HCl for 18 h gave the 2-iodo and 3-bromo derivatives of 11-oxo-11*H*-pyrido[2,1-*b*]quinazoline-6-carboxylic acid ([98MIP1](#), [98MIP2](#), [99USP5908840](#), [99USP5914327](#)).

Reaction of 2-aminopyridine and 2,3,4,5,6-pentafluoro- and 5-nitro-2-fluorobenzoyl chloride in CH₂Cl₂ in the presence of (*i*-Pr)₂EtN at room temperature afforded 1,2,3,4-tetrafluoro- and 8-nitro-11*H*-pyrido[2,1-*b*]quinazolin-11-ones, respectively ([01TL1851](#)).

The reaction of methyl anthranilate and 3-amino-2-chloropyridine in 1,2,4-trichlorobenzene in the presence of KO*t*-Bu at 50 °C gave 5,11-dihydro-6*H*-pyrido[2,3-*b*]benzodiazepin-6-one and 6-amino-11*H*-pyrido[2,1-*b*]quinazolin-11-one as a by-product ([99BMCL3031](#)).




Reaction of 2-amino-3-hydroxypyridine and cyclohexanone **433** in boiling AcOH yielded *N*,1-diphenyl-6-hydroxy-3-methyl-11-oxo-1,2-dihydro-11*H*-pyrido[2,1-*b*]quinazoline-2-carboxamide (**434**) ([98MI2](#), [99USP5908840](#), [99USP5914327](#)).

Cyclocondensation of 2-aminoquinoline and isopropylidene 2-(1-methylthioalkylidene)malonates on SiO₂ under microwave irradiations afforded 3-substituted (3-methylthio, 3-methyl, 3-ethyl, and 3-phenyl) 1*H*-pyrimido[1,2-*a*]quinolin-1-ones ([00MI40](#)).

6. Ring Transformation

Reaction of 1-methylene-1,2,3,4-tetrahydro-5*H*-pyrazino[2,1-*b*]quinazoline-3,6-diones (**435**) with PhLi and MeMgBr in THF at -78 °C gave a mixture of 11*H*-pyrido[2,1-*b*]quinazolin-11-ones **435-439** ([01T1987](#)).



7. Miscellaneous


11-(4-Fluorophenyl)-11-hydroxy-2,3,4,11-tetrahydro-6*H*-pyrimido[1,2-*b*]-isoquinolin-6-one was obtained in the reaction of 1-(4-fluorophenyl)-3-oxo-1,3-dihydro-2-benzofuran-1-carboxamide and 1,3-diaminopropane in boiling toluene (01BMCL339).

(3*S*)-5,8,9-Trihydroxy-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-3-carboxylic acid and (420) and its (1*S*)-1-carboxylic acid isomer were isolated from isopyoverdins (97ZN(C)549, 01T1019) and pyoverdins (99MI27), respectively, after acidic hydrolysis in 3 M HCl for 5 days at 110°C.

D. APPLICATIONS AND IMPORTANT COMPOUNDS

Different pyoverdins contain a (1*S*)-8,9-dihydroxy-5-amino-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-1-carboxylic acid **1** chromophore (99MI27, 99MI28, 99ZN(C)1021, 00MI38, 00MI39, 00MI47, 00ZN(C)146, 00ZN(C)153, 00ZN(C)323, 00ZN(C)857, 01MI2, 01MIP4, 01TL5849). 5-Amino-8,9-dihydroxy-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-3-carboxylic acid moiety **4** was also identified as a chromophoric moiety of certain

isopyoverdins (99ZN(C)1021, 01T1019, 01ZN(C)303). Chromophores **1** and **4** are formed from the same precursor (01T1019).



3,4-Dihydro-2*H*-pyrimido[2,1-*a*]isoquinolines **421** inhibited the FcεRI-mediated activation of mast cells (98JMC1050). 3-Piperazino-1*H*-pyrimido[1,2-*a*]quinolin-1-one (**440**) and 2-piperazino-4*H*-pyrimido[2,1-*a*]isoquinolin-4-one (**441**) inhibited platelet aggregation in a concentration dependent manner (97MI15). The *in vitro* platelet aggregation inhibitory activities of 3-(cyclic amino and disubstituted amino)-1*H*-pyrimido[1,2-*a*]quinolin-1-ones and 2-(cyclic amino and diethylamino)-4*H*-pyrimido[1,2-*a*]quinolin-4-ones were investigated on human platelet aggregations induced by ADP collagen, and A23187 (00BMC751). 11*H*-Pyrido[2,1-*b*]quinazolin-11-one (**442**) was screened for anticancer activity (98MI14). 6-(2-Methoxyphenyl)-3,4-dihydro-2*H*-pyrimido[2,1-*a*]isoquinoline exhibited good inhibition of melanocortin-4 receptors (01MIP5). *N*-Methyl-11-oxo-11*H*-pyrido[2,1-*b*]quinazolin-7-carboxamide did not exhibit any MAO A and B inhibitory activities (97JMC2466).

The use of 11*H*-pyrido[2,1-*b*]quinazolin-11-ones in an organic electro-luminescent device was patented (99JAP(K)99/74080). 2*H*-Pyrimido[2,1-*a*]isoquinolin-7-ols were patented as multi-functional fuel and lube additives (97USP5646098).

REFERENCES

- | | |
|----------------|--|
| 61HC(15-2)1141 | W. L. Mosby, <i>Chem. Heterocycl. Compd.</i> , 15-2 , 1141 (1961). |
| 61HC(15-2)1153 | W. L. Mosby, <i>Chem. Heterocycl. Compd.</i> , 15-2 , 1153 (1961). |
| 61HC(15-2)1160 | W. L. Mosby, <i>Chem. Heterocycl. Compd.</i> , 15-2 , 1160 (1961). |
| 75TL1019 | Z. Mészáros and I. Hermecz, <i>Tetrahedron Lett.</i> , 1019 (1995). |
| 77JCS(P1)789 | I. Hermecz, Z. Mészáros, L. Vasvári-Debreczy, Á. Horváth, G. Horváth, and M. Pongor-Csákvári, <i>J. Chem. Soc., Perkin 1</i> , 789 (1977). |
| 79AP219 | H. Möhrle and J. Gerloff, <i>Arch. Pharm. (Weinheim)</i> , 312 , 219 (1979). |
| 79JHC457 | F. Fülöp, I. Hermecz, Z. Mészáros, Gy. Dombi, and G. Bernáth, <i>J. Heterocycl. Chem.</i> , 16 , 457 (1979). |

- 83AHC(33)241 I. Hermecz and Z. Mészáros, *Adv. Heterocycl. Chem.*, **33**, 241 (1983).
 85MI1 I. Hermecz and Z. Mészáros, A kémia újabb eredményei 61". Akadémiai Kiadó, Budapest, 1985 [*CA* **105**, 24,255 (1986)].
- 86AHC(39)281 I. Hermecz and L. Vasvári Debreczy, *Adv. Heterocycl. Chem.*, **39**, 281 (1986).
- 92MI1 I. Hermecz, J. Sipos, L. Vasvári-Debreczy, K. Gyires, and Z. Kapui, *Acta Physiol. Hung.*, **80**, 225 (1992) [*CA* **121**, 57,450 (1994)].
- 92MI2 Z. Kapui, K. Boér, I. Hermecz, and K. Gyires, *Acta Physiol. Hung.*, **80**, 237 (1992) [*CA* **121**, 553 (1994)].
- 92MI3 N. Dimov, *Bulg. Chem. Commun.* **25**N. Dimov, *Bulg. Chem. Commun.*, **25** 367 (1992) [*CA* **120**, 244,034 (1994)].
- 93BCJ2118 T. Tokumitsu and S. Nagao, *Bull. Chem. Soc. Jpn.*, **66**, 2118 (1993).
- 93FES1225 G. Roma, M. Di Braccio, G. Leoncini, and B. Apride, *Farmaco*, **48**, 1225 (1993).
- 93GEP4243287 G. Steiner, L. Unger, B. Behl, H. J. Teschendorf, and R. Munschauer, *Ger. Pat.* **4**, **243**, 287 (1993) G. Steiner, L. Unger, Behl, H. J. Teschendorf, and R. Munschauer, *Ger. Pat.* **4**, **243**, 287 (1993) [*CA* **121**, 205,375 (1994)].
- 93H(35)955 V. Kepe, M. Kocivar, and S. Polanc, *Heterocycles*, **35**, 955 (1993).
- 93IJC(B)978 N. K. Satti, K. A. Suri, O. P. Suri, and A. Kapil, *Indian J. Chem. B.*, **32B**, 978 (1993).
- 93JCC283 N. Youyou, P. Decock, and D. Blondeau, *J. Coord. Chem.*, **30**, 283 (1993).
- 93JHC33 R. Bossio, S. Marcaccini, R. Pepino, and P. Paoli, *J. Heterocycl. Chem.*, **30**, 33 (1993).
- 93JHC1253 P. Kolar and M. Tišler, *J. Heterocycl. Chem.*, **30**, 1253 (1993).
- 93MI1 A. S. Linden, D. J. M. Desmecht, H. Amory, F. A. Rollin, and P. M. Lekeux, *Res. Vet. Sci.*, **55**, 25 (1993).
- 93MI2 M. T. Ayoub, R. I. Al-Bayati, and T. K. Mohammad, *Dirasat-Univ. Jordan, Ser. B*, **20B**, 79 (1993) [*CA* **120**, 23,330 (1994)].
- 93MI3 T. Kawashima, Y. Sato, T. Aibo, S. Omura, and H. Kasai, *Oyo Yakuri*, **46**, 265 (1993) [*CA* **120**, 23,330 (1994)].
- 93MI4 G. Mannens, M. L. Huang, W. Meuldermans, J. Hendrickx, R. Woestenborghs, and J. Heykants, *Drug Metab. Dispos.*, **21**, 1134 (1993).
- 93MIP1 M. Mellor and P. D. Riordan, *PCT Int. Appl.* 93/13,664 (1993) [*CA* **120**, 106,972 (1994)].
- 93MIP2 F. E. Janssens, J. E. Leenaerts, G. S. M. Diels, and F. M. Sommen, *PCT Int. Appl.*, 93/14,088 (1993) [*CA* **120**, 54,556 (1994)].
- 93MIP3 I. Hermecz, J. Sipos, L. Vasvári-Debreczy, Z. Kapui, Á. Horváth, M. Balogh, G. Keresztúri, K. Boér, and A. Pajor, *PCT Int. Appl.* 93/16,070 (1993) [*CA* **120**, 107,025 (1994)].
- 93MIP4 T. P. Selby, *PCT Int. Appl.* 93/23,398 (1993) [*CA* **120**, 217,721 (1994)].
- 93MIP5 A. Iso, K. Hayashishita, and M. Yamaguchi, *PCT Int. Appl.* 93/25,206 (1993) [*CA* **120**, 173,476 (1994)].
- 94AF269 P. A. J. Janssen and F. H. L. Awouters, *Arzneim.-Forsch.*, **44**, 269 (1994).
- 94AF754 T. Bando, M. Fujimura, H. Shintani, M. Saito, K. Kurashima, K. N. Nishi, and T. Matsuda, *Arzneim.-Forsch.*, **44**, 754 (1994).
- 94AJC1263 R. H. Prager and Y. Singh, *Aust. J. Chem.*, **47**, 1263 (1994).
- 94BMCL183 A. M. Venkatesan, J. I. Levin, J. S. Baker, P. S. Chan, T. Bailey, and J. Coupet, *Bioorg. Med. Chem. Lett.*, **4**, 183 (1994).

- 94EJM175 E. Klauschenz, V. Hagen, B. Wiesner, A. Hagen, G. Reck, and E. G. Krause, *Eur. J. Med. Chem.*, **29**, 175 (1994).
- 94EUP579425 C. M. Tice, *Eur. Pat.*, **579**, 425 (1994) [CA **120**, 245,148 (1994)].
- 94EUP626378 D. J. Hlasta, J. H. Ackerman, A. J. Mura, and R. Ch. Desai, *Eur. Pat.*, **626**, 378 (1994) [CA **122**, 239,688 (1995)].
- 94JCR(S)206 A. Gupta and J. Skarzewski, *J. Chem. Res. Synop.*, 206 (1994).
- 94JHC81 F. Gatta, M. R. Del Giudice, A. Borioni, and C. Mustazza, *J. Heterocycl. Chem.*, **31**, 81 (1994).
- 94JHC125 J. Smodiz, B. Stanovnik, and M. Tišler, *J. Heterocycl. Chem.*, **31**, 125 (1994).
- 94JHC393 D. G. Hehemann and W. Winnik, *J. Heterocycl. Chem.*, **31**, 393 (1994).
- 94JPO725 E. D. Raczyńska, P.-C. Maria, J.-F. Gal, and M. Decouzon, *J. Phys. Org. Chem.*, **7**, 725 (1994).
- 94KFZ(10)23 M. M. Kozlovskaya, S. V. Nikitin, A. Gochmuradov, and L. D. Smirnov, *Khim.-Farm. Zh.*, **28**(10), 23 [CA **125**, 48,339 (1996)].
- 94KGS579 S. V. Nikitin and L. D. Smirnov, *Khim. Geterosikl. Soedin.*, 579 (1994) [CA **122**, 239,562 (1995)].
- 94KGS629 A. I. Mikhalev, S. V. Ukhov, and M. E. Konshin, *Khim. Geterotsikl. Soedin.*, 629 (1994) [CA **123**, 83,301 (1995)].
- 94MI1 A.A.H.P. Megens, F. H. L. Awouters, S. Schotte, T. F. Meert, C. Dugovic, C. J. E. Niemegeers, and J. E. Leysen, *Psychopharmacology (Berlin)*, **114**, 9 (1994).
- 94MI2 M. Hojo, Y. Hamasaki, I. Fujita, H. Koga, S. Matsumoto, and S. Miyazaki, *Ann. Allergy*, **73**, 21 (1994).
- 94MI3 L. E. C. van Beijsterveldt, R. J. F. Geerts, J. E. Leysen, A.A.H.P. Megens, H. M. J. Van den Eynde, W. E. G. Meuldermans, and J. J. P. Heykants, *Psychopharmacology (Berlin)*, **114**, 53 (1994).
- 94MI4 T. Hasegawa, K. Takagi, M. Nadai, Y. Ogura, and T. Nabeshima, *Eur. J. Clin. Pharmacol.*, **46**, 55 (1994).
- 94MI5 A. A. El-Bahnasawy, A. Essawy, and A. M. Amer, *Aswan Sci. Techol. Bull.*, **15**, 108 (1994) [CA **122**, 105,704 (1995)].
- 94MI6 W. Meuldermans, J. Hendrickx, G. Mannens, K. Lavrijsen, C. Janssen, J. Bracke, L. Le Jeune, W. Lauwers, and J. Heykants, *Drug Metab. Dispos.*, **22**, 129 (1994).
- 94MI7 H. Fujimiya, S. Nakashima, T. Kumada, Y. Nakamura, H. Miyata, and Y. Nozawa, *Alerugi*, **43**, 142 (1994) [CA **120**, 289,656 (1994)].
- 94MI8 A.A.H.P. Megens and F. H. L. Awouter, *Drug Dev. Res.*, **33**, 399 (1994).
- 94MI9 T. Kawashima, I. Iwamoto, N. Nakagawa, H. Tomioka, and S. Yoshida, *Int. Arch. Allergy Immunol.*, **103**, 405 (1994).
- 94MI10 G. Mannens, W. Meuldermans, E. Snoeck, and J. Heykants, *Psychopharmacology (Berlin)*, **114**, 566 (1994).
- 94MI11 T. Kawashima, S. Nagaki, A. Iwakaji, Iwamoto, S. Yoshida, and H. Tomioka, *Alerugi*, **43**, 1326 (1994) [CA **122**, 177,920 (1995)].
- 94MI12 K. A. Wheeler and B. M. Foxman, *Chem. Mater.*, **6**, 1330 (1994).
- 94MI13 H. Otsuka, *Yakuri to Chiryō*, **22**, 2043 (1994) [CA **121**, 271,573 (1994)].
- 94MIP1 J. Vandenberk, L. E. J. Kennis, and A. H. Van Heertum, *PCT Int. Appl.* 94/1437 (1994) [CA **120**, 270,442 (1994)].
- 94MIP2 S. Omura, *PCT Int. Appl.* 94/3172 (1994) [CA **120**, 226,975 (1994)].
- 94MIP3 S. Kino, T. Osajima, and H. Mizuta, *PCT Int. Appl.* 94/10,982 (1994) [CA **121**, 65,597 (1994)].

- 94MIP4 F. E. Janssens, G. S. M. Diels, and J. E. Leenaerts, *PCT Int. Appl.* 94/13,680 (1994) [*CA* **121**, 157,645 (1994)].
- 94MIP5 F. E. Janssens, J. F. A. Lacrampe, and I. N. C. Pilatte, *PCT Int. Appl.* 94/13,681 (1994) [*CA* **121**, 205,360 (1994)].
- 94MIP6 Y. Fukuda, T. Sasaki, Y. Nakatani, Y. Ichimaru, and T. Imanishi, *PCT Int. Appl.* 94/18,197 (1994) [*CA* **123**, 83,356 (1995)].
- 94MIP7 J. L. Mesens and J. Peeters, *PCT Int. Appl.* 94/25,460 (1994) [*CA* **122**, 89,414 (1995)].
- 94MIP8 F. Marquillas Olondriz, A. Bosch Rovira, P. Dalmases Barjoan, and J. M. Caldero Ges, *Span. Pat.* 2,050,069 (1994) [*CA* **121**, 255,824 (1994)].
- 95AHC(63)103 I. Hermecz, *Adv. Heterocycl. Chem.*, **63**, 103 (1995).
- 95AX(C)533 N. M. Blaton, O. M. Peeters, and C. J. De Ranter, *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.*, **C51**, 533 (1995).
- 95CL835 K. Hashizume, N. Hashimoto, D. G. Cork, and Y. Miyake, *Chem. Lett.*, 835 (1995).
- 95CPB683 A. Sano, M. Ishihara, J. Yoshihara, M. Sumino, and H. Nawa, *Chem. Pharm. Bull.*, **43**, 683 (1995).
- 95EJM27 M. Di Braccio, G. Roma, and G. Leoncini, *Eur. J. Med. Chem.*, **30**, 27 (1995).
- 95EUP663385 R. Gras and E. Wolf, *Eur. Pat.* 663,385 (1995) [*CA* **123**, 288,344 (1995)].
- 95FES69 P. L. Ferrarini, C. Mori, G. Armani, and L. Rossi, *Farmaco*, **50**, 69 (1995).
- 95H(40)681 T. Kappe, W. Lube, K. Thonhofer, C. Kratky, and U. G. Wagner, *Heterocycles*, **40**, 681 (1995).
- 95H(41)2173 P. Victory, N. Busquets, J. I. Borrell, J. Teixido, C. de Alvaro, A. Arenas, A. Alvarez-Larene, and J. F. Piniella, *Heterocycles*, **41**, 2173 (1995).
- 95JAP(K)95/33744 T. Sasaki, J. Nakatani, T. Hiranum, H. Kashima, and Y. Fukuda, *Jpn. Kokai* 95/33,744 (1995) [*CA* **123**, 55,870 (1995)].
- 95JAP(K)95/69895 S. Oomura, N. Takenawa, and S. Kamyu, *Jpn. Kokai* 95/69,895 (1995) [*CA* **123**, 965 (1995)].
- 95JAP(K)95/101863 Y. Sato and T. Ogata, *Jpn. Kokai* 95/101,863 (1995) [*CA* **123**, 25,681 (1993)].
- 95JAP(K)95/188215 Y. Fukuda, J. Nakata, T. Hasegawa, T. Murase, and K. Fuji, *Jpn. Kokai* 95/188,215 (1995) [*CA* **123**, 340,149 (1995)].
- 95JHC477 W. Winnik, *J. Heterocycl. Chem.*, **32**, 477 (1995).
- 95JHC921 G. Sorsak, A. Sinur, L. Golic, and B. Stanovnik, *J. Heterocycl. Chem.*, **32**, 921 (1995).
- 95JHC1725 M. R. Del Giudice, A. Borioni, C. Mustazza, and F. Gatta, *J. Heterocycl. Chem.*, **32**, 1725 (1995).
- 95JMC4687 D. J. Hlasta, J. H. Ackerman, J. J. Court, R. P. Farrell, J. A. Johnson, J. L. Kofron, D. T. Robinson, T. G. Talomie, R. P. Dunlap, C. A. Franke, *J. Med. Chem.*, **38**, 4687 (1995).
- 95KFZ(2)40 A. I. Mikhalev, M. E. Kon'shin, L. A. Ovodenko, and A. S. Zaks, *Khim.-Farm. Zh.*, **29**(2), 40 (1995) [*CA* **124**, 117,225 (1996)].
- 95KFZ(5)39 A. I. Mikhalev, M. L. Suslina, T. M. Kon'shina, A. S. Zaks, and M. E. Kon'shin, *Khim.-Farm. Zh.*, **29**(5), 39 (1995) [*CA* **124**, 117,221 (1996)].
- 95MI1 Y. Nakamura, S. Nakashima, H. Fujimiya, T. Kumada, Y. Kato, H. Miyata, and Y. Nozawa, *Arerugi*, **44**, 34 (1995) [*CA* **122**, 306,088 (1995)].

- 95MI2 V. S. Bogdanov, K. L. Cherkasova, V. A. Dorokhov, O. V. Shishkin, and Y. T. Struchkov, *Mendeleev Commun.*, 106 (1995).
- 95MI3 J. C. Hudson, M. Golin, and M. Malcolm, *J.-Can. Soc. Forensic Sci.*, **28**, 137 (1995).
- 95MI4 G. Griebel, D. C. Blanchard, A. Jung, C. K. Masuda, and R. J. Blanchard, *Pharmacol., Biochem. Behav.*, **51**, 235 (1995).
- 95MI5 A. M. Herneth, A. Puspok, R. Steindl, and C. Yurdaydin, *Adv. Hepatic Encephalopathy Metab. Nitrogen Exch.*, 254 (1995).
- 95MI6 J.-P. Valentin, A.-M. Bessac, F. C. Colpaert, and G. W. John, *Methods Find. Exp. Clin. Pharmacol.*, **17**, 267 (1995).
- 95MI7 M. M. Kozlovskaya, A. N. Inozemtsev, S. V. Nikitin, A. G. Gochmuradov, R. A. Yakushev, and R. Chabak-Gorbach *Byull. Eksp. Biol. Med.*, **119**, 299 (1995) [*CA* **124**, 76,193 (1996)].
- 95MI8 D. Fiorella, R. A. Rabin, and J. C. Winter, *Psychopharmacology (Berlin)*, **121**, 347 (1995).
- 95MI9 S. S. Sawart, Y. S. R. Reddy, Samevenkatesh, U. Mishra, and B. Suresh, *Indian Drugs*, **32**, 458 (1995).
- 95MI10 M. A. Abdel-Rahman, *Rev. Roum. Chim.*, **40**, 535 (1995) [*CA* **124**, 260,974 (1996)].
- 95MI11 M. Murasaki, *Shinkei Seishin Yakuri*, **17**, 599 (1995) [*CA* **123**, 328,945 (1995)].
- 95MI12 Y. Nakamura, S. Nakashima, H. Fujimiya, T. Kumada, K. Ojio, H. Miyata, and Y. Nozawa, *Arerugi*, **44**, 624 (1995) [*CA* **123**, 187,986 (1995)].
- 95MI13 J. M. Kane and T. H. McGlashan, *Lancet*, **346**, 820 (1995).
- 95MI14 M. J. Millan, J.-L. Peglion, J. Vian, J.-M. Rivet, M. Brocco, A. Gobert, A. Newman-Tancredi, C. Dacquets, and K. Bervoets, *J. Pharmacol. Exp. Ther.*, **275**, 885 (1995).
- 95MI15 K. Sawa, T. Kurose, H. Ibuki, H. Mibu, K. Nakata, H. Takashina, and E. Shirasawa, *Atarashii Ganka*, **12**, 1565 (1995) [*CA* **124**, 105,909 (1996)].
- 95MI16 Y. Sakuma, *Atarashii Ganka*, **12**, 1915 (1995) [*CA* **124**, 164,612 (1996)].
- 95MIP1 D. T. Chu, Q. Li, C. S. Cooper, A. K. L. Fung, C. M. Lee, and J. J. Plattner, *PCT Int. Appl.* 95/10,519 (1995) [*CA* **123**, 313,930 (1995)].
- 95MIP2 J. M. Ramstack, P. F. Herbert, J. Strobel, T. J. Atkins, and A. M. Hazrati, *PCT Int. Appl.* 95/13,799 (1995) [*CA* **123**, 17,9481 (1995)].
- 95MIP3 J. L. Mesens, M. E. Rickey, and T. J. Atkins, *PCT Int. Appl.* 95/13,814 (1995) [*CA* **123**, 123,212 (1995)].
- 95MIP4 J. Vandenberg and L. E. J. Kennis, *PCT Int. Appl.* 95/14,691 (1995) [*CA* **123**, 340,172 (1995)].
- 95MIP5 J. M. Caldero Ges, J. Huguét Clotet, F. Marquillas Olondriz, P. Dalmases Barjoan, A. Bosch Rovira, J. Roca Acin, and N. C. del Castillo Nieto, *PCT Int. Appl.* 95/23,144 (1995) [*CA* **123**, 256,763 (1995)].
- 95MIP6 H. Tomioka, H. Ohsawa, M. Moroi, and T. Kawashima, *PCT Int. Appl.* 95/32,714 (1995) [*CA* **124**, 127,149 (1996)].
- 95MIP7 P. Dalmases Barjoan, F. Marquillas Olondriz, J. Huguét Clotet, A. Bosch Rovira, J. Del Castillo Nieto, and J. Caldero Ges, *Span. Pat.* 2,074,966 (1995) [*CA* **125**, 221,862 (1996)].

- 95TL7503 A. Dinsmore, P. M. Doyle, and D. W. Young, *Tetrahedron Lett.*, **36**, 7503 (1995).
- 95USP5378720 D. J. Hlasta, J. H. Ackerman, A. J. Mura, and R. Ch. Desai, *US. Pat.* 5,378,720 (1995) [*CA* **122**, 265,363 (1995)].
- 95USP5453425 M. K. J. Francois and W. M. A. C. Dries, *US. Pat.* 5,453,425 (1995) [*CA* **123**, 266,188 (1995)].
- 95USP5468763 F. E. Janssens, G. S. M. Diels, and J. E. Leenaerts, *US. Pat.* 5,468,763 (1995) [*CA* **124**, 202,249 (1996)].
- 96ANC1572 N. J. Messick, J. H. Kalivas, and P. M. Lang, *Anal. Chem.*, **68**, 1572 (1996).
- 96AX(B)509 A. Dalpiaz, V. Ferretti, P. Gilli, and V. Bertolasi, *Acta Crystallogr., Sect. B: Struct. Sci.*, **B52**, 509 (1996).
- 96CHC-II(8)563 I. Hermecz, L. Vasvári-Debreczy, and P. Mátyus, *Compr. Heterocycl. Chem. II.*, **8**, 563 (1996).
- 96CP2167004 E. Otomi, *Can. Pat.* 2,167,004 (1996) [*CA* **125**, 317,375 (1996)].
- 96EUP733633 T. Aono, S. Marui, F. Itoh, M. Yamaoka, and M. Nakao, *Eur. Pat.* 733,633 [*CA* **125**, 328,725 (1996)].
- 96FES781 J. Dominguez, J. Charris, L. Iarrusso, S. Lopez, G. Lobo, and F. Riggione, *Farmaco*, **51**, 781 (1996).
- 96H(42)117 H. Takechi and M. Machida, *Heterocycles*, **42**, 117 (1996).
- 96H(43)2487 T. Okawara, Y. Okamoto, S. Ehara, T. Yamasaki, and M. Furakawa, *Heterocycles*, **43**, 2487 (1996).
- 96JAP(K)96/92093 T. Yazaki and K. Taguma, *Jpn. Kokai* 96/92,093 (1996) [*CA* **125**, 96,170 (1996)].
- 96JC(A)135 G. L. Biagi, A. M. Barbaro, A. Sapone, P. A. Borea, K. Varani, and M. Recanatini, *J. Chromatogr., A*, **723**, 135 (1996).
- 96JHC663 T. Kappe and B. Schnell, *J. Heterocycl. Chem.*, **33**, 663 (1996).
- 96JHC799 I. Hermecz, P. Forgó, Zs. Böcskei, M. Fehér, J. Kökösi, and Gy. Szász, *J. Heterocycl. Chem.*, **33**, 799 (1996).
- 96JHC1041 M. Kusar, J. Svete, and B. Stanovnik, *J. Heterocycl. Chem.*, **33**, 1041 (1996).
- 96JMC3070 Q. Li, D. T. W. Chu, A. Claiborne, C. S. Cooper, C. M. Lee, K. Raye, K. B. Berst, P. Donner, W. Wang, L. Hasvold, A. Fung, Z. Ma, M. Tufano, R. Flamm, L. L. Shen, J. Baranowski, A. Nilius, J. Alder, J. Meulbroek, K. Marsh, D. Crowell, Y. Hui, L. Seif, L. M. Melcher, R. Henry, S. Spanton, R. Faghieh, L. L. Klein, S. K. Tanaka, and J. J. Plattner, *J. Med. Chem.*, **39**, 3070 (1996).
- 96KFZ(6)29 G. I. Poda, A. S. Dimoglo, V. Yu. Tanchuk, I. V. Tetko, M. I. Koshel, and A. I. Luik, *Khim. Farm. Zh.*, **30**(6) 29 (1996) [*CA* **125**, 211,839 (1996)].
- 96MI1 D. S. Aurora and M. Towle, *J. Appl. Ther.*, **1**, 1 (1996).
- 96MI2 N. A. Keks, *Acta Psychiatr. Scand.*, **389**, 18 (1996).
- 96MI3 B. Peruche and M. Schulz, *Pharm. Ztg.*, **141**, 32 (1996).
- 96MI4 T. A. K. Al-Allaf, R. I. H. Al-Bayati, L. J. Rashan, and R. F. Khuzaie, *Appl. Organomet. Chem.*, **10**, 47 (1996).
- 96MI5 S. R. Marder, *J. Clin. Psychiatry*, **57**(Suppl. 9), 57 (1996).
- 96MI6 V. Anjaneyulu, M. M. Kirshna, and P. Radhika, *Acta Cienc. Indica Chem.*, **22**, 59 (1996) [*CA* **127**, 78,731 (1997)].
- 96MI7 M. J. Byerly and C. L. DeVane, *J. Clin. Psychopharmacol.*, **16**, 177 (1996).
- 96MI8 A.A.H.P. Megens and L. E. J. Kennis, *Prog. Med. Chem.*, **33**, 185 (1996).

- 96MI9 H. Van Cauteren, A.A.H.P. Anton, A. Lampo, and W. Meuldermans, *Med. Psychiatry*, **3**, 253 (1996).
- 96MI10 E. Klieser, E. Lehmann, and H. Kurt, *Med. Psychiatry*, **3**, 331 (1996).
- 96MI11 G. Eberhard, *J. Drug Dev. Clin. Pract.*, **7**, 269 (1996).
- 96MI12 C. R. Meibach, S. L. E. Heylen, and L. E. Stef, *Med. Psychiatry*, **3**, 293 (1996).
- 96MI13 A. Mortimer and T. R. E. Barnes, *Med. Psychiatry*, **3**, 311 (1996).
- 96MI14 H.-J. Moeller, *Med. Psychiatry*, **3**, 345 (1996).
- 96MI15 T. M. Reilly and S. L. E. Heylen, *Med. Psychiatry*, **3**, 357 (1996).
- 96MI16 A. Desmecht, A. Linden, H. Armory, and P. Lekeux, *Can. J. Physiol. Pharmacol.*, **74**, 572 (1996).
- 96MI17 S. M. Siddigi, X.-D. Ji, N. Melman, M. E. Olah, R. Jain, P. Evans, M. Glashofer, W. L. Padgett, and L. A. Cohen, *Nucleosides Nucleotides*, **15**, 693 (1996).
- 96MI18 M. Kanai, *Domyaku Koka*, **23**, 707 (1996) [*CA* **125**, 75,926 (1996)].
- 96MI19 A. Schotte, P. F. M. Janssen, P. Bonaventure, and J. E. Leysen, *Histochem. J.*, **28**, 791 (1996).
- 96MI20 J. E. Hare, D. B. Tesarowski, G. E. Gail, K. Vlaminck, P. E. Shewen, and L. Viel, *Am. J. Vet. Res.*, **57**, 1034 (1996).
- 96MI21 Y. Nishizawa, T. Yamamoto, N. Terada, S. Fushiki, Y. Amakata, and Y. Nishizawa, *Anticancer Res.*, **16**, 1241 (1996).
- 96MI22 K. L. Cherkasova, V. S. Bogdanov, V. A. Dorokhov, O. V. Shishkin, and Yu. T. Struchkov, *Izv. Akad. Nauk, Ser. Khim.*, 1508 (1996) [*CA* **125**, 247,749 (1996)].
- 96MI23 J. E. Leysen, W. Gommeren, L. Heylen, W.H.M.L. Luyten, I. van de Weyer, P. Vanhoenacker, G. Haegeman, A. Schotte, and P. van Gompel, *Mol. Pharmacol.*, **50**, 1567 (1996).
- 96MIP1 T. Oku, H. Kayakiri, S. Satoh, Y. Abe, Y. Sawada, T. Inoue, and H. Tanaka, *PCT Int. Appl.* 96/13,485 (1996) [*CA* **126**, 142,578 (1996)].
- 96MIP2 J. Vanderbeck, L. E. J. Ludo, and J. C. Mertens, *PCT Int. Appl.* 96/23,784 (1996) [*CA* **125**, 221,867 (1996)].
- 96MIP3 J. L. Mesens, *PCT Int. Appl.* 96/31,201 (1996) [*CA* **125**, 339,058 (1996)].
- 96MIP4 D. T. Chu, Q. Li, C. S. Cooper, A. K. L. Fung, C. M. Lee, J. J. Plattner, Z. Ma, and W.-B. Wang, *PCT Int. Appl.* 96/39,407 (1996) [*CA* **126**, 117,990 (1997)].
- 96T887 M. Gotoh, B. Sun, K. Hirayama, and M. Noguchi, *Tetrahedron*, **52**, 887 (1996).
- 96T901 B. Sin, K. Adachi, and M. Noguchi, *Tetrahedron*, **52**, 901 (1996).
- 96T13081 M. Noguchi, T. Mizukoshi, and A. Kakehi, *Tetrahedron*, **52**, 13,081 (1996).
- 96T13097 M. Noguchi, T. Mizukoshi, T. Uchida, and Y. Kuroki, *Tetrahedron*, **52**, 13,097 (1996).
- 96T13111 M. Noguchi, T. Mizukoshi, S. Nakagawa, and A. Kakehi, *Tetrahedron*, **52**, 13,111 (1996).
- 96TL2615 J. M. Mellor, G. D. Merriman, H. Rataj, and G. Reid, *Tetrahedron Lett.*, **37**, 2615 (1996).
- 96USP5512576 R. C. Desai and D. J. Hlasta, *US Pat.* 5,512,576 (1996) [*CA* **125**, 58,526 (1996)].
- 96USP5527802 P. Parab, *US Pat.* 5,527,802 (1996) [*CA* **125**, 123,745 (1996)].

- 96USP5580872 D. T. Chu, Q. Li, C. S. Copper, A. K. L. Fung, C. M. Lee, and J. J. Plattner, *US Pat.* 5,580,872 (1996) [*CA* **126**, 101,707 (1997)].
- 97BCJ2201 M. Noguchi, T. Mizukoshi, and S. Nishimura, *Bull. Chem. Soc. Jpn.*, **70**, 2201 (1997).
- 97BRP2307177 M. J. O'Mahony, P. J. West, S. D. Lindell, and J. A. Macritchie, *Br. Pat.*, 2,307,177 (1997) [*CA* **127**, 132,274 (1997)].
- 97H(45)2175 K. Simon, L. Pusztay, M. Hanusz, Zs. Böcskei, B. Podányi, M. Fehér, and I. Hermecz, *Heterocycles*, **45**, 2175 (1997).
- 97H(45)2349 L. Selic, S. Golic Grdadolnik, and B. Stanovnik, *Heterocycles*, **45**, 2349 (1997).
- 97HCA2418 L. Selic, S. Golic Grdadolnik, and B. Stanovnik, *Helv. Chim. Acta*, **80**, 2418 (1997).
- 97JAP(K)97/52849 H. Kitajama, I. Okudaira, and K. Tsunoda, *Jpn. Kokai* 97/52,849 (1997) [*CA* **126**, 255,504 (1997)].
- 97JAP(K)97/278780 M. Tsumiki, I. Miki, S. Sato, J. Shimada, and F. Suzuki, *Jpn. Kokai* 97/278,780 (1997) [*CA* **127**, 358,857 (1997)].
- 97JC(B)209 O. V. Olesen and K. Linnet, *J. Chromatogr., B*, **698**, 209 (1997).
- 97JCS(P1)981 Y.-S. Liu and W.-Y. Huang, *J. Chem. Soc., Perkin Trans. 1*, 981 (1997).
- 97JCS(P1)1297 A. N. Bowler, A. Dinsmore, P. M. Doyle, and D. W. Young, *J. Chem. Soc., Perkin Trans. 1*, 1297 (1997).
- 97JHC247 L. Kralj, A. Hvala, J. Steve, L. Golic, and B. Stanovnik, *J. Heterocycl. Chem.*, **34**, 247 (1997).
- 97JHC813 L. Selic and B. Stanovnik, *J. Heterocycl. Chem.*, **34**, 813 (1997).
- 97JHC1511 S. Strah, A. Golobic, L. Golic, and B. Stanovnik, *J. Heterocycl. Chem.*, **34**, 1511 (1997).
- 97JMC2266 K. Chen, S.-C. Kuo, M.-C. Hsieh, A. Mauger, C. M. Lin, E. Hamel, and K.-H. Lee, *J. Med. Chem.*, **40**, 2266 (1997).
- 97JMC2466 M. Harfenist, D. M. Joseph, S. C. Spence, D. P. C. McGee, M. D. Reeves, and H. L. White, *J. Med. Chem.*, **40**, 2466 (1997).
- 97JMC3049 K. Chen, S.-C. Kuo, M.-C. Hsieh, A. Mauger, C. M. Lin, E. Hamel, and K.-H. Lee, *J. Med. Chem.*, **40**, 3049 (1997).
- 97JOC3109 C. O. Kappe, K. Peters, and E.-M. Peters, *J. Org. Chem.*, **62**, 3109 (1997).
- 97MI1 V. Kumar, *Int. J. Geriatr. Psychopharmacol.*, **1**, 15 (1997).
- 97MI2 H. Jones, *J. Serotonin Res.*, **4**, 17 (1997).
- 97MI3 M. V. R. Reddy and D. J. Faulkner, *Nat. Prod. Lett.*, **11**, 53 (1997).
- 97MI4 A. Noomen, *Prog. Org. Coat.*, **32**, 137 (1997).
- 97MI5 A. Newman-Tancredi, V. Audinot, C. Chaput, L. Verrielle, and M. J. Millan, *J. Pharmacol. Exp. Ther.*, **282**, 181 (1997).
- 97MI6 A. Belicova, M. Seman, V. Milata, D. Ilavsky, and L. Ebringer, *Folia Microbiol. (Prague)*, **42**, 193 (1997) [*CA* **127**, 63,024 (1997)].
- 97MI7 M. G. Assy and A. A. Hataba, *J. Indian Chem. Soc.*, **74**, 239 (1997).
- 97MI8 P. J. H. Tooley and P. Zuiderwijk, *Adv. Ther.*, **14**, 262 (1997).
- 97MI9 D. Taylor, *CNS Drug*, **8**, 285 (1997).
- 97MI10 M. C. Ritz and F. R. George, *Psychopharmacology (Berlin)*, **129**, 299 (1997).
- 97MI11 C.-K. Lai, T. Lee, K.-M. Au, and Y.-W. Albert, *Clin. Chem. (Washington D.C.)*, **43**, 312 (1997).
- 97MI12 M. C. Price and D. W. Hoffman, *Ther. Drug Monit.*, **19**, 333 (1997).
- 97MI13 Y.-L. Xie and J. H. Kalivas, *Anal. Lett.*, **30**, 395 (1997).

- 97MI14 A. Moran, E. Martín, C. Velasco, M. L. Martín, L. S. Roman, E. Caballero, P. Puebla, M. Medarde, and A. S. Feliciano, *J. Pharm. Pharmacol.*, **49**, 421 (1997).
- 97MI15 G. Leoncini, M. G. Signorello, G. C. Grossi, and M. Di Braccio, *Thromb. Res.*, **87**, 483 (1997).
- 97MI16 L. E. Baker, T. B. Virden, M. E. Miller, and C. L. Sullivan, *Pharmacol. Biochem. Behav.*, **58**, 505 (1997).
- 97MI17 J. M. Yanni, S. T. Miller, D. A. Gamache, J. M. Spellman, S. Xu, and N. A. Sharif, *Ann. Allergy, Asthma, Immunol.*, **79**, 541 (1997).
- 97MI18 É. L. Kristallovich, N. D. Abdullaev, A. L. D'yakovon, L. V. Molchanov, and M. V. Telezhenetskaya, *Chem. Nat. Compd.*, **33**, 667 (1997) [Pub. 1998] [*CA* **129**, 216,305 (1998)].
- 97MI19 J. Gafni, J. A. Munsch, T. H. Lam, M. C. Catlin, L. G. Costa, T. F. Molinski, and I. N. Pessah, *Neuron*, **19**, 723 (1997).
- 97MI20 G. Griebel, R. J. Rodgers, G. Perrault, and D. J. Sanger, *Pharmacol. Biochem. Behav.*, **57**, 817 (1997).
- 97MI21 G. Leoncini, M. G. Signorello, G. Roma, and M. Di Braccio, *Biochem. Pharmacol.*, **53**, 1667 (1997).
- 97MI22 A. Yu. Kovalevsky, O. V. Shishkin, I. A. Ronova, I. I. Ponomarev, S. V. Lindeman, and Yu. A. Volkova, *Russ. Chem. Bull.*, **46**, 1866 (1997).
- 97MI23 E. Van Ganse, L. Kaufman, M. P. Derde, J. C. Yernault, L. Delaunois, and W. Vincken, *Eur. Respir. J.*, **10**, 2216 (1997).
- 97MIP1 J. Tanaka, T. Higa, and D. Garcia Gravalos, *PCT Int. Appl.* 97/4,783 (1997) [*CA* **126**, 207,511 (1997)].
- 97MIP2 K. Kánai, S. Erdo, A. Szappanos, J. Bence, I. Hermecz, Gy. Szvoboda, S. Bátori, G. Héja, M. Balogh, *PCT Int. Appl.* 97/7116 (1997) [*CA* **126**, 238,661 (1996)].
- 97MIP3 M. J. Batchelor, D. Bebbington, G. W. Bemis, W. H. Fridman, R. J. Gillespie, J. M.C. Golec, Y. Gu, D. J. Laufer, D. J. Livingston, S. S. Matharu, M. D. Mullican, M. A. Murcko, R. Murdoch, P. L. Philip, and A. L.C. Robidoux, *PCT Int. Appl.* 97/22,619 (1997) [*CA* **127**, 122,000 (1997)].
- 97MIP4 B. A. Lynch and M. Weigle, *PCT Int. Appl.* 97/31,016 (1997) [*CA* **127**, 248,419 (1997)].
- 97MIP5 M. E. Rickey, J. M. Ramstack, D. H. Danny, and J. L. Mesens, *PCT Int. Appl.* 97/41,837 (1997) [*CA* **128**, 39,549 (1998)].
- 97MIP6 A. M. Morella, I. H. Pitman, and G. Heinicke, *PCT Int. Appl.* 97/41,839 (1997) [*CA* **128**, 7344 (1998)].
- 97MIP7 M. K.J. Francois, R. C.A. Embrechts, H. K. Borghijs, and J. Monbaliu, *PCT Int. Appl.* 97/41,839 (1997) [*CA* **128**, 39,539 (1998)].
- 97MIP8 L. E.J. Kennis and J. C. Mertens, *PCT Int. Appl.* 97/44,040 (1997) [*CA* **128**, 34,772 (1998)].
- 97MIP9 A. Yuan, W. Yuan, and H. Yuan, *Faming Zhuanli Shenging Gongkai Shoumingshu* 1,142,360 (1997) [*CA* **128**, 261,939 (1998)].
- 97RCM664 T. Erős-Takácsy, J. Tamás, I. Hermecz, and K. Kovács, *Rapid Commun. Mass Spectrom.*, **11**, 664 (1997).
- 97S53 B. Sun, K. Adachi, N. Kenji, and M. Noguchi, *Synthesis*, 53 (1997).
- 97SC195 F. Fülöp, M. Palkó, G. Bernáth, and P. Sohár, *Synth. Commun.*, **27**, 195 (1997).

- 97T17449 D. J. Bergmann, E. M. Campi, W. R. Jackson, Q. J. McCubbin, and A. F. Patti, *Tetrahedron*, **53**, 17,449 (1997).
- 97TL4315 D. J. Bergmann, E. M. Campi, W. R. Jackson, Q. J. McCubbin, and A. F. Patti, *Tetrahedron Lett.*, **38**, 4315 (1997).
- 97USP5616587 M. K. J. Francois and W. M. A. C. Dries, *US Pat.* 5,616,587 (1997) [*CA* **126**, 297,695 (1996)].
- 97USP5646098 S. J. Brois, *US Pat.* 5,646,098 (1997) [*CA* **127**, 164,254 (1997)].
- 97ZN(C)549 R. Michalke, K. Taraz, H. Budzikiewicz, Ph. Thonart, and Ph. Jacques, *Z. Naturforsch.*, **52C**, 549 (1997).
- 98ACH515 I. Hermecz, L. Vasvári-Debreczy, Á. Horváth, J. Sipos, M. Balogh, B. Podányi, and K. Kovács, *ACH-Models Chem.*, **135**, 519 (1998).
- 98ACH613 G. Sorsak, S. Golik Grdadolnik, and B. Stanovnik, *ACH-Models Chem.*, **135**, 613 (1998).
- 98BJP1655 A. S. Lesage, R. Wouters, P. Van Gompel, L. Heylen, P. Vanhoenacker, G. Haegeman, W.H.M.L. Luyten, and J. E. Leysen, *Br. J. Pharmacol.*, **123**, 1655 (1998).
- 98CPB928 J.-W. Chern, H.-T. Chen, N.-Y. Lai, K.-R. Wu, and Y.-C. Chern, *Chem. Pharm. Bull.*, **46**, 928 (1998).
- 98EJM383 P. L. Ferrarini, C. Mori, M. Badawneh, V. Calderone, L. Calzolari, T. Loffredo, E. Martinotti, and G. Saccomanni, *Eur. J. Med. Chem.*, **33**, 383 (1998).
- 98EUP830864 F. P. Bymaster, K. W. Perry, and G. D. Tollefson, *Eur. Pat.* 830,864 (1998) [*CA* **128**, 261,968 (1998)].
- 98FRP2765222 P. Dodey, M. Bondoux, P. Houziaux, M. Barth, and K. Ou, *Fr. Demande*, 2,765,222 (1998) [*CA* **130**, 168,650 (1999)].
- 98H(47)195 M. Kobayashi, Y. Miyamoto, S. Aoki, N. Murakami, I. Kitagawa, Y. In, and T. Ishida, *Heterocycles*, **47**, 195 (1998).
- 98H(47)1017 L. Selic, S. Strah, R. Toplak, and B. Stanovnik, *Heterocycles*, **47**, 1017 (1998).
- 98H(48)775 A. Sano and M. Ishihara, *Heterocycles*, **48**, 775 (1998).
- 98H(49)133 L. Selic, S. Golic Grdadolnik, and B. Stanovnik, *Heterocycles*, **49**, 133 (1998).
- 98JAP(K)98/53588 K. Shimizu, M. Takei, M. Eshinu, and T. Shiohara, *Jpn. Kokai* 98/53,588 [*CA* **128**, 193,323 (1998)].
- 98JAP(K)98/195063 A. Nakayama, S. Takeda, N. Machinaga, T. Ogasawara, H. Naito, M. Hasegama, and M. Haruda, *Jpn. Kokai* 98/195,063 (1998) [*CA* **129**, 189,329 (1998)].
- 98JCS(P1)3327 M. Noguchi, H. Yamada, and T. Sunagawa, *J. Chem. Soc., Perkin Trans. 1*, 3327 (1998).
- 98JHC1275 G. Soršak, S. Golic Grdadolnik, and B. Stanovnik, *J. Heterocycl. Chem.*, **35**, 1275 (1998).
- 98JMC1050 D. Scholz, H. Schmidt, E. E. Prieschl, R. Csonga, W. Scheirer, V. Weber, A. Lembachner, G. Seidl, G. Werner, P. Mayer, T. Baumruker, *J. Med. Chem.*, **41**, 1050 (1998).
- 98JOC391 D. A. Berges, M. D. Ridges, and N. K. Dalley, *J. Org. Chem.*, **63**, 391 (1998).
- 98M1049 A. W. Erian, *Monatsh. Chem.*, **129**, 1049 (1998).
- 98MI1 Collaborative Working Group on Clinical Trial Evaluations (USA), *J. Clin. Psychiatry*, **59** (Suppl 12), 3 (1998).

- 98MI2 E. M. Kandeel, M. Hammouda, E. G. Sadek, and A. M. Khalil, *Indian J. Heterocycl. Chem.*, **8**, 15 (1998).
- 98MI3 J. Arnt and T. Skarsfeldt, *Neuropsychopharmacology*, **18**, 63 (1998).
- 98MI4 T. Cserhádi, E. Forgács, and G. Hajós, *J. Planar Chromatogr.-Mod. TLC*, **11**, 64 (1998).
- 98MI5 I. Ninan and S. K. Kulkarni, *Eur. J. Pharmacol.*, **358**, 111 (1998).
- 98MI6 K. Matsugana, T. Sato, H. Shuto, Y. Tsuruta, K. Suemaru, Y. Gomita, and R. Oishi, *Eur. J. Pharmacol.*, **350**, 165 (1998).
- 98MI7 M. Montorsi, M. C. Menziani, M. Cocchi, F. Fanelli, and P. G. De Benedetti, *Methods (Orlando Fla.)*, **14**, 239 (1998).
- 98MI8 S. Recnik, R. Toplak, and B. Stanovnik, *Zb. Ref. Posvetovenja Slov. Kem. Dnevi*, 274 (1998) [*CA* **130**, 125,042 (1999)].
- 98MI9 M. Aravagiri, A. Yuwiler, and S. R. Marder, *Psychopharmacology (Berlin)*, **139**, 356 (1998).
- 98MI10 F. A. Attaby, S. M. Eldin, and M. A. A. Elneariry, *Heteroat. Chem.*, **9**, 571 (1998).
- 98MI11 E. Estrada, A. Pefia, and R. Garcia-Domenech, *J. Comput.-Aided Mol. Des.*, **12**, 583 (1998).
- 98MI12 H. Taniguchi, G. Tamura, H. Iijima, Y. Liu, and K. Shirato, *Aerugi*, **47**, 720 (1998) [*CA* **129**, 254,746 (1998)].
- 98MI13 M. Andersson, U.-K. Hultin, and A. Sokolowski, *Chromatographia*, **48**, 770 (1998).
- 98MI14 M. Alvarez, R. Robey, V. Sandor, K. Nishiyama, Y. Matsumoto, K. Paull, S. Bates, and T. Fojo, *Mol. Pharmacol.*, **54**, 802 (1998).
- 98MI15 H. Ohsawa, H. Noike, M. Kanai, M. Yoshinuma, K. Mineoka, T. Hitsumoto, K. Aoyagi, T. Sakurai, S. Sato, T. Uchi, K. Kawamura, K. Tokuhira, Y. Uchida, H. Tomioka, *Am. Heart J.*, **136**, 1081 (1998).
- 98MIP1 M. P. Trova, N. Zhang, and D. B. Kitchen, *PCT Int. Appl.* 98/23,616 (1998) [*CA* **129**, 41,144 (1998)].
- 98MIP2 M. P. Trova and N. Zhang, *PCT Int. Appl.* 98/23,617 (1998) [*CA* **129**, 54,298 (1998)].
- 98MIP3 K.-H. Lee, K. Chen, and S.-C. Kuo, *PCT Int. Appl.* 98/39,332 (1998) [*CA* **129**, 230,737 (1998)].
- 98MIP4 D. Kennaway, *PCT Int. Appl.* 98/42,331 (1998) [*CA* **129**, 286,016 (1998)].
- 98MIP5 L. E.J. Kennis, C. J. Love, and F. P. Bischoff, *PCT Int. Appl.* 98/45,297 (1998) [*CA* **129**, 302,654 (1998)].
- 98MIP6 I. Odidi and A. Odidi, *PCT Int. Appl.* 98/47,491 (1998) [*CA* **129**, 335,768 (1998)].
- 98MIP7 L. Breton, I. Nonotte, and O. De Lacharriere, *Fr. Demande*, 2,758,263 (1998) [*CA* **129**, 179,973 (1998)].
- 98S704 A. R. Katritzky, G. Qiu, and B. Yang, *Synthesis*, 704 (1998).
- 98SL263 U. Girreser, D. Heber, and M. Schuett, *Synlett*, 263 (1998).
- 98T5097 D. A. Berges, L. Hong, and N. K. Dalley, *Tetrahedron*, **54**, 5097 (1998).
- 98TL5089 R. Lavilla, O. Coll, M. Nicolás, and J. Bosch, *Tetrahedron Lett.*, **39**, 5089 (1998).
- 98USP5710129 B. A. Lynch and M. Weigele, *US Pat.* 5,710,129 (1998) [*CA* **128**, 128,290 (1998)].

- 98USP5792477 M. E. Rickey, J. M. Ramstack, D. H. Lewis, and J. Mesens, *US Pat.* 5,792,477 (1998) [*CA* **129**, 166,226 (1998)].
- 98ZN(B)37 H. Möhrle and J. Mehrens, *Z. Naturforsch.*, **53B**, 37 (1998).
- 98ZN(B)1369 H. Möhrle and J. Mehrens, *Z. Naturforsch.*, **53B**, 1369 (1998).
- 99ACS901 J. H. P. Utley, M. Elinson, M. Güllü, R. Ludwig, and M. Motevalli, *Acta Chem. Scand.*, **53**, 901 (1999).
- 99AHC(72)225 I. Hermecz, *Adv. Heterocycl. Chem.*, **72**, 225 (1999).
- 99AHC(73)178 I. Hermecz, *Adv. Heterocycl. Chem.*, **73**, 178 (1999).
- 99AJC1131 D. J. Bergmann, E. M. Campi, W. R. Jackson, and A. F. Patti, *Aust. J. Chem.*, **52**, 1131 (1999).
- 99BCJ503 Y. A. E. Issac, *Bull. Chem. Soc. Jpn.*, **72**, 503 (1999).
- 99BMC2437 M. C. Menziani, M. Montorsi, P. G. De Benedetti, and M. Karelson, *Bioorg. Med. Chem.*, **7**, 2437 (1999).
- 99BMCL3031 F. Novelli, A. Sparatore, B. Tasso, and F. Sparatore, *Bioorg. Med. Chem. Lett.*, **9**, 3031 (1999).
- 99CCC177 R. Toplak, J. Svete, S. Golic Grdadolnik, and B. Stanovnik, *Collect. Czech. Chem. Commun.*, **64**, 177 (1999).
- 99EJOC2997 R. Lavilla, O. Coll, M. Nicolàs, B.A. Sufi, J. Torrents, and J. Bosch, *Eur. J. Org. Chem.*, 2997 (1999).
- 99EUP901752 N. Fukuda, T. Kitajima, and S. Koyanagi, *Eur. Pat.* 901,752 (1999) [*CA* **130**, 219,467 (1999)].
- 99GEP19803515 W. Friedrich, H.-J. Kneuper, K. Eller, A. Henne, and R. Lebkuecher, *Ger. Offen.* 19,803,515 (1999) [*CA* **131**, 144,330 (1999)].
- 99H(50)315 V. Kepe, V. Kozjan, S. Polanc, and M. Kocevar, *Heterocycles*, **50**, 315 (1999).
- 99HCA2380 T. Storz, B. Bernet, and A. Vasella, *Helv. Chim. Acta*, **82**, 2380 (1999).
- 99JAP(K)99/74080 M. Nakatsuka and N. Kitamoto, *Jpn. Kokai* 99/74,080 (1999) [*CA* **130**, 259,333 (1999)].
- 99JCS(CC)1279 D. J. Bergmann, E. M. Campi, W. R. Jackson, and A. F. Patti, *J. Chem. Soc., Chem. Commun.*, 1279 (1999).
- 99JCS(P1)3569 N. K. Capps, G. M. Davies, R. W. McCabe, and D. W. Young, *J. Chem. Soc., Perkin Trans. 1*, 3569 (1999).
- 99JCS(P2)1087 C. Plüg, W. Frank, and C. Wentrup, *J. Chem. Soc., Perkin Trans. 2*, 1087 (1999).
- 99JHC237 A. Kutyrev and T. Kappe, *J. Heterocycl. Chem.*, **36**, 237 (1999).
- 99JHC1065 P. L. Ferrarini, C. Mori, F. Mori, G. Saccomanni, S. Barontini, M. Macchia, P. L. Barili, and M. Hamdan, *J. Heterocycl. Chem.*, **36**, 1065 (1999).
- 99JHC1123 P. L. Ferrarini, C. Moro, C. Manera, F. Mori, V. Calderone, and E. Martinotti, *J. Heterocycl. Chem.*, **36**, 1123 (1999).
- 99JMC4081 S.-X. Zhang, K. F. Bastow, Y. Tachibana, S.-C. Kuo, E. Hamel, A. Mauger, V. L. Narayanan, and K.-H. Lee, *J. Med. Chem.*, **42**, 4081 (1999).
- 99M1147 B. Schnell and T. Kappe, *Monatsh. Chem.*, **130**, 1147 (1999).
- 99MI1 J. M. Kane, *J. Clin. Psychiatry*, **60**(Suppl 5), 43 (1999).
- 99MI2 A. E. Balant-Gorgia, M. Gex-Fabry, C. Genet, and L. P. Balant, *Ther. Drug Monit.*, **21**, 105 (1999).
- 99MI3 J. Fang, M. Bourin, and G. B. Baker, *Naunyn-Schmiedeberg's Arch. Pharmacol.*, **359**, 147 (1999).
- 99MI4 N. A. Keks and C. Culhane, *Expert Opin. Invest. Drugs*, **8**, 443 (1999).

- 99MI5 J. C. Winter and D. Timineri *Pharmacol., Biochem. Behav.*, **62**, 543 (1999).
- 99MI6 T. Nagasaki, T. Ohkubo, K. Sugawara, N. Yasui, H. Furukori, and S. Kaneko, *J. Pharm. Biomed. Anal.*, **19**, 595 (1999).
- 99MI7 M. T. Kaddachi, M. B. Amor, S. Zouari, H. Cossy, and Ph. Khan, *J. Soc. Chim. Tunis.*, **4**, 537 (1999) [*CA* **133**, 120,290 (2000)].
- 99MI8 M. Balogh, A. Gerstmanns, and I. Hermecz, *Heterocycl. Commun.*, **5**, 89 (1999).
- 99MI9 H. H. Fernandez and J. H. Friedman, *CNS Drugs*, **11**, 467 (1999).
- 99MI10 J. Almási, K. Takács-Novák, J. Kökösi, and J. Vámos, *Int. J. Pharm.*, **180**, 13 (1999).
- 99MI11 H. Xiao, J. Yang, S. Zhang, and X. Zhang, *Sepu*, **17**, 395 (1999) [*CA* **131**, 266,495 (1999)].
- 99MI12 J. Kökösi, J. Almási, Á. Kiss, P. Forgó, Zs. Böcskei, M. Fehér, and I. Hermecz, *Acta Pharm. Hung.*, **69**, 135 (1999) [*CA* **131**, 299,426 (1999)].
- 99MI13 J. Amchin, W. Zarycranski, K. P. Taylor, D. Albano, and P. M. Klockowski, *J. Clin. Pharmacol.*, **39**, 297 (1999).
- 99MI14 J. A. Bork, T. Rogers, P. J. Wedlund, and J. De Leon, *J. Clin. Psychiatry*, **60**, 469 (1999).
- 99MI15 S. Ekins, G. Bravi, S. Binkley, J. S. Gillespie, B. J. Ring, J. H. Wikel, and S. A. Wrighton, *Pharmacogenetics*, **9**, 477 (1999).
- 99MI16 J. Logan and P. Finley, *CNS Drug Rev.*, **5**, 249 (1999).
- 99MI17 D. Taylor and K. J. Aitchison, *Int. J. Psychiatry Clin. Pract.*, **3**, 237 (1999).
- 99MI18 J. P. Warner, *J. Psychopharmacol. (London)*, **13**, 415 (1999).
- 99MI19 D. J. Lee, K. U. Lee, J. S. Kwon, I. J. Jang, M. J. Cho, S. G. Shin, and J. I. Woo, *Psychopharmacology (Berlin)*, **144**, 272 (1999).
- 99MI20 D. E. Moody, K. M. Monti, A. C. Spanbauer, and J. P. Hsu, *J. Anal. Toxicol.*, **23**, 535 (1999).
- 99MI21 J. C. Winter, D. J. Fiorella, S. E. Helsley, and R. A. Rabin, *Int. J. Neuropsychopharmacol.*, **2**, 165 (1999).
- 99MI22 M. G. Scordo, E. Spina, G. Facciola, A. Avenoso, I. Johansson, and M.-L. Dahl, *Psychopharmacology (Berlin)*, **147**, 300 (1999).
- 99MI23 S. Ekins, G. Bravi, S. Binkley, J. S. Gillespie, B. J. Ring, J. H. Wikel, and S. A. Wrighton, *Pharmacogenetics*, **9**, 477 (1999).
- 99MI24 A. J. M. Loonen, C. H. Doorschot, M.C.J.M. Oostelbos, and J. M. A. Sitsen, *Eur. Neuropsychopharmacol.*, **10**, 51 (1999).
- 99MI25 B. Tashkhodzhaev, K. K. Turgunov, and É. L. Kristallovich, *Chem. Nat. Compd.*, **35**, 388 (1999) [*CA* **132**, 228,849 (2000)].
- 99MI26 F. A. Attaby, S. M. Eldin, and M. A. A. Elneary, *Heteroat. Chem.*, **10**, 676 (1999) [*CA* **132**, 122,589 (2000)].
- 99MI27 W. Wossen and K. Taraz, *BioMetals*, **12**, 323 (1999).
- 99MI28 H. Beiderbeck, K. Taraz, and J.-M. Meyer, *Boi Metals*, **12**, 331 (1999).
- 99MI29 M. Güllü and J. H. P. Utley, *Commun. Fac. Sci. Univ. Ank. Series B*, **45**, 93 (1999) [*CA* **134**, 178,523 (2001)].
- 99MIP1 R. A. Bosh, I. Diez Martin, and J. Huguét Clotet, *PCT Int. Appl.* 99/9028 (1999) [*CA* **130**, 200,934 (1999)].
- 99MIP2 L. E.J. Kennis and J. C. Mertens, *PCT Int. Appl.* 99/12,926 (1999) [*CA* **130**, 237,551 (1999)].
- 99MIP3 Y. Ohtsuka, T. Nishizuka, S. Shiokawa, S. Tsutsumi, M. Kawaguchi, H. Kitagawa, H. Takata, T. Shishikura, T. Ishikura, K. Fushihara,

- Y. Okada, S. Miyamoto, and M. Shiobara, *PCT Int. Appl.* 99/16,770 [CA **130**, 282,073 (1999)].
- 99MIP4 M. K.J. Francois, W. M.A. C. Dries, and E. D.D. Basstanie, *PCT Int. Appl.* 99/25,354 (1999) [CA **130**, 357,192 (1999)].
- 99MIP5 M. O. Bradley, V. E. Shashoua, C. S. Swindell, and N. L. Webb, *PCT Int. Appl.* 99/26,661 (1999) [CA **131**, 719 (1999)].
- 99MIP6 W. E. Yelle, *PCT Int. Appl.* 99/59,589 (1999) [CA **132**, 6351 (2000)].
- 99MIP7 W. E. Yelle, *PCT Int. Appl.* 99/59,590 (1999) [CA **132**, 6352 (2000)].
- 99MIP8 G. D. Tollefson, *PCT Int. Appl.* 99/62,522 (1999) [CA **132**, 9033 (2000)].
- 99MIP9 T. J. Barberich, P. D. Rubin, and D. A. Handley, *PCT Int. Appl.* 99/61,014 (1999) [CA **132**, 6368 (2000)].
- 99PC1 K. H. Lee, personal communication.
- 99SL37 N. Yamazaki, T. Ito, and C. Kibayashi, *Synlett*, 37 (1999).
- 99SL1383 E. Le Gall, R. Malassene, L. Toupet, J.-P. Hurvois, and C. Moinet, *Synlett*, 1383 (1999).
- 99T6759 D. A. Berges, J. Fan, S. Devinct, N. Liu, and N. K. Dalley, *Tetrahedron*, **55**, 6759 (1999).
- 99T10221 I. Hermecz and Á. Horváth, *Tetrahedron*, **55**, 10,221 (1999).
- 99T14251 D. A. Berges, N. Zhang, and L. Hong, *Tetrahedron*, **55**, 14,251 (1999).
- 99TL739 N. Yamazaki, T. Ito, and C. Kibayashi, *Tetrahedron Lett.*, **40**, 739 (1999).
- 99TL2421 C. Andrés, J. P. Duque-Soladana, J. M. Iglesias, and R. Pedrosa, *Tetrahedron Lett.*, **40**, 2421 (1999).
- 99TL7211 I. A. Motorina and D. S. Grierson, *Tetrahedron Lett.*, **40**, 7211 (1999).
- 99TL7215 I. A. Motorina and D. S. Grierson, *Tetrahedron Lett.*, **40**, 7215 (1999).
- 99TL8269 G. Chelucci, N. Culeddu, A. Saba, and R. Valenti, *Tetrahedron Lett.*, **40**, 8269 (1999).
- 99USP5908840 M. P. Trova and N. Zhang, *US. Pat.* 5,908,840 [CA **131**, 19,016 (1999)].
- 99USP5914327 M. P. Trova, N. Zhang, and D. B. Kithen *US. Pat.* 5,914,327 [CA **131**, 44,842 (1999)].
- 99ZN(B)632 H. Möhrle and G. Keller, *Z. Naturforsch., B: Chem. Sci.*, **54b**, 632 (1999).
- 99ZN(B)923 I. S. Abdel Hafiz, A. A. Hassanien, and A. M. Hussein, *Z. Naturforsch., B: Chem. Sci.*, **54b**, 923 (1999).
- 99ZN(B)1577 H. Möhrle and M. Jeandree, *Z. Naturforsch., B: Chem. Sci.*, **54b**, 1577 (1999).
- 99ZN(C)1021 H. Budzikiewicz, D. U. Fernández, R. Fuchs, R. Michalke, K. Taraz, and C. Rungviriachai, *Z. Naturforsch.*, **54c**, 1021 (1999).
- 00BAP19 R. B. Nazarski and S. Leśniak, *Bull. Acad. Pol. Sci. Chim.*, **48**, 19 (2000).
- 00BMC751 G. Roma, N. Cinone, D. Di Braccio, G. Grossi, G. Leoncini, M. G. Signorello, and A. Carott, *Bioorg. Med. Chem.*, **8**, 751 (2000).
- 00BMC1917 M. Hellberg, J. F. Stubbins, and R. A. Glennon, *Bioorg. Med. Chem.*, **8**, 1917 (2000).
- 00BMCL71 L. E. J. Kennis, F. P. Bischoff, C. J. Mertens, L. J. Love, F. A. F. Van den Keybus, S. Pieters, M. Braeken, A.A.H.P. Megens, and J. E. Leysen, *Bioorg. Med. Chem. Lett.*, **10**, 71 (2000).
- 00CHE754 D. Zicane, I. Ravinya, Z. Tetere, I. Rijkure, E. Gudriniece, and U. Kalejs, *Chem. Heterocycl. Compd. (Eng. Transl.)*, **36**, 754 (2000).

- 00H(53)1793 S. Recnik, J. Svete, A. Meden, and B. Stanovnik, *Heterocycles*, **53**, 1793 (2000).
- 00HC571 J. Charris, J. Domínguez, M. Cordero, L. Orfila, F. Riggione, S. López, D. Enriz, and F. Suvire, *Heterocycl. Commun.*, **6**, 571 (2000).
- 00JC(B)141 S. McClean, E. J. O'Kane, and W. F. Smyth, *J. Chromatogr., B.: Biomed. Sci. Appl.*, **740**, 141 (2000).
- 00JC(B)173 A. Avenoso, G. Facciola, M. Salemi, and E. Spina, *J. Chromatogr., B.: Biomed. Sci. Appl.*, **746**, 173 (2000).
- 00JC(B)233 O. V. Olesen, P. Plougmann, and K. Linnet, *J. Chromatogr., B.: Biomed. Sci. Appl.*, **746**, 233 (2000).
- 00JCR(S)414 M. Noguchi, R. Akao, M. Gotoh, H. Kawamoto, and A. Kakehi, *J. Chem. Res. (S)*, 414 (2000).
- 00JCS(P1)3686 A. W. Erian, Y. A. El-sayed Issac, S. M. Sherif, and F. F. Mahmoud, *J. Chem. Soc., Perkin 1*, 3686 (2000).
- 00JCS(P1)4373 N. K. Capps, G. M. Davies, D. Loakes, and D. W. Young, *J. Chem. Soc., Perkin Trans. 1*, 4373 (2000).
- 00JCS(P2)1841 A. Fiksdahl, C. Plüg, and C. Wentrup, *J. Chem. Soc., Perkin Trans. 2*, 1841 (2000).
- 00JCS(P2)2096 C. Plüg, B. Wallfish, H. Gade Andersen, P. V. Bernhardt, L.-J. Baker, G. R. Clark, M. W. Wong, and C. Wentrup, *J. Chem. Soc., Perkin Trans. 2*, 2096 (2000).
- 00JFC105 K.-W. Chi, G. G. Furin, Y. V. Gatilov, I. Yi, Bagryanskay, and E. L. Zhuzhgov, *J. Fluorine Chem.*, **103**, 105 (2000).
- 00JHC703 M. Škof, J. Svete, and B. Stanovnik, *J. Heterocycl. Chem.*, **37**, 703 (2000).
- 00JHC783 S. Recnik, R. Toplak, J. Steve, L. Pizzioli, and B. Stanovnik, *J. Heterocycl. Chem.*, **37**, 783 (2000).
- 00JMC2575 P. Yoshida and J. G. Topliss, *J. Med. Chem.*, **43**, 2575 (2000).
- 00JMC2814 P. L. Ferrarini, C. Mori, C. Manera, A. Martinelli, F. Mori, G. Saccomanni, P. L. Barili, L. Betti, G. Giannaccini, L. Trincavelli, A. Lucacchini, *J. Med. Chem.*, **43**, 2814 (2000).
- 00JOC235 A. Padwa and A. G. Waterson, *J. Org. Chem.*, **65**, 235 (2000).
- 00JOC889 D. A. Berges, J. Fan, S. Devinck, and K. Mower, *J. Org. Chem.*, **65**, 889 (2000).
- 00K669 V. K. Reinikant, V. K. Gupta, and A. Singkh, *Kristallografiya*, **45**, 669 (2000).
- 00LS29 E. Richelson and T. Souder, *Life Sci.*, **68**, 29 (2000).
- 00MI1 V. Pucci, M. A. Raggi, and E. Kenndler, *J. Liq. Chromatogr. Relat. Technol.*, **23**, 25 (2000).
- 00MI2 M. J. Millan, A. Gobert, K. Bervoets, J.-M. Rivet, S. Veiga, and M. Brocco, *J. Pharmacol. Exp. Ther.*, **292**, 672 (2000).
- 00MI3 J. L. Defilippi and M. L. Crismon, *Pharmacotherapy*, **20**, 23 (2000).
- 00MI4 G. Remington and S. Kapur, *Psychopharmacology (Berlin)*, **148**, 3 (2000).
- 00MI5 R. R. Conley, *J. Clin. Psychiatry*, **61**(Suppl. 8), 20 (2000).
- 00MI6 A. E. Falsetti, *Am. J. Health-Syst. Pharm.*, **57**, 862 (2000).
- 00MI7 P. Odou, J. C. Levrone, M. Luyckx, C. Brunet, and H. Robert, *Clin. Drug Invest.*, **19**, 283 (2000).
- 00MI8 R. M. Procyshyn and N. B. Kennedy, *Clin. Drug Invest.*, **19**, 257 (2000).
- 00MI9 H.-Y. Lane, W.-C. Chiu, J.C.-Y. Chou, S.-T. Wu, M.-H. Su, and W.-H. Chang, *J. Clin. Psychiatry*, **61**, 209 (2000).

- 00MI10 P. E. Keck, Jr., S. M. Strakowski, and S. M. McElroy, *J. Clin. Psychiatry*, **61**(Suppl. 3), 4 (2000).
- 00MI11 T. Siu, W. Li, and A. K. Yudin, *J. Comb. Chem.*, **2**, 545 (2000).
- 00MI12 R. M. Procyshyn, D. Thompson, and G. Tse, *CNS Drugs*, **13**, 47 (2000).
- 00MI13 G. Casamenti, R. Mandrioli, C. Sabbioni, F. Bugamelli, V. Volterra, and M. A. Raggi, *J. Liq. Chromatogr. Relat. Technol.*, **23**.
- 00MI14 T. Cablewski, P. A. Gurr, P. J. Pajalic, and C. R. Strauss, *Green Chem.*, **2**, 25 (2000).
- 00MI15 K. Otani and T. Aoshima, *Ther. Drug. Monit.*, **22**, 118 (2000).
- 00MI16 M. A. Raggi, G. Casamenti, R. Mandrioli, C. Sabbioni, and V. Volterra, *J. Pharm. Biomed. Anal.*, **23**, 161 (2000).
- 00MI17 B. Green, *Curr. Med. Res. Opin.*, **16**, 57 (2000).
- 00MI18 R. Brys, K. Jossen, M. P. Castelli, M. Jurzak, P. Lijnen, W. Gommeren, and J. E. Leysen, *Mol. Pharmacol.*, **57**, 1132 (2000).
- 00MI19 Y. Hamasaki, M. Zaitu, K. Tsuji, M. Miyazaki, R. Hayasaki, E. Muro, S. Yamamoto, I. Kobayashi, M. Matsuo, T. Ichimaru, S. Miyazaki, *Int. J. Immunopharmacol.*, **22**, 483 (2000).
- 00MI20 M. Aravagiri and S. R. Marder, *J. Mass Spectrom.*, **35**, 718 (2000).
- 00MI21 N. Bhana and C. M. Spencer, *Drugs Aging*, **16**, 451 (2000).
- 00MI22 J. Kőkösi, Á. Kiss, P. Forgó, Zs. Böcskei, M. Fehér, and I. Hermecz, *Magy. Kém. Foly.*, **106**, 297 (2000) [*CA* **133**, 362,746 (2000)].
- 00MI23 O. V. Kovalchukova, S. B. Strashnova, B. E. Zaitsev, O. V. Goncharov, P. de Souza Almeida, S. N. Nikitin, V. K. Bel'skii, and A. I. Stash, *Russ. J. Coord. Chem.*, **26**, 587 (2000).
- 00MI24 O. V. Kovalchukova, S. B. Strashnova, B. E. Zaitsev, V. K. Bel'skii, A. I. Stash, S. V. Nikitin, O. V. Goncharov, and R. N. Shchelokov, *Russ. J. Coord. Chem.*, **26**, 310 (2000).
- 00MI25 M. X. Zhao, Q. Liu, Y. L. Hu, and D. L. Li, *Chin. Chem. Lett.*, **11**, 283 (2000) [*CA* **133**, 17,436 (2000)].
- 00MI26 T. Deutschmann and H. Ritter, *Macromol. Chem. Phys.*, **201**, 1200 (2000).
- 00MI27 A. F. Shidlovskii, A. Yu. Sizov, L. N. Kuleshova, V. V. Nesterov, M. Yu. Antipin, A. S. Peregodov, and N. D. Chkanikov, *Russ. Chem. Bull.*, **49**, 1257 (2000).
- 00MI28 Y.-F. Cheng, T. H. Walter, Z. Lu, P. Iraneta, B. A. Alden, C. Gendreau, U. D. Neue, J. M. Grassi, J. L. Carmody, J. E. O'Gara, R. P. Fisk, *LC-GC*, **18**, 1162 (2000).
- 00MI29 E. Spina, A. Avenoso, G. Facciola, M. Salemi, M. G. Scordo, T. Giacobello, A. G. Madia, and E. Perucca, *Ther. Drug Monit.*, **22**, 481 (2000).
- 00MI30 W. N. Wu and L. A. McKown, *Curr. Drug Metab.*, **1**, 255 (2000).
- 00MI31 A. K. Goodwin and L. E. Baker, *Exp. Clin. Psychopharmacol.*, **8**, 415 (2000).
- 00MI32 M. Zaudig, *Drug Saf.*, **23**, 183 (2000).
- 00MI33 S. Recnik, J. Svete, and B. Stanovnik, *Zb. Ref. Povetovanja Slov. Kem. Dnevi* (Pt1), 131 (2000) [*CA* **134**, 222,683 (2000)].
- 00MI34 N. Bhana and C. M. Spencer, *Drugs Aging*, **16**, 451 (2000).
- 00MI35 M. Hanna, V. de Biasi, B. Bond, P. Camilleri, and A. J. Hutt, *Chromatographia*, **52**, 710 (2000).

- 00MI36 J.-M. Aubry, A. E. Simon, and G. Bertschy, *J. Clin. Psychiatry*, **61**, 649 (2000).
- 00MI37 C.-M. Fu, J. Meng, X.-Y. Liu, and G.-F. Zhao, *Zhongguo Yiyao Gongye Zazhi*, **31**, 307 (2000) [*CA* **134**, 300,885 (2001)].
- 00MI38 R. Sultana, B. S. Siddiqui, K. Taraz, H. Budzikiewicz, and J.-M. Meyer, *Biometals*, **13**, 147 (2000).
- 00MI39 R. Fusch and H. Budzikiewicz, *Spectroscopy*, **14**, 229 (2000).
- 00MI40 L.-L. Wu, W.-M. Xu, and X. Huang, *Gaodeng Xuexiao Huaxue Xuebao*, **21**, 1867 (2000) [*CA* **134**, 326,490 (2001)].
- 00MI41 B. G. Tehan, M. G. Wong, G. J. Cross, and E. J. Lloyd, *Mol. Model. Predict. Bioact.*, [*Proc. Eur. Symp. Quant. Struct.-Act. Relat.*], 12th 1998 (Pub 2000) 448 [*CA* **135**, 144 (2001)].
- 00MI42 R. C. Love and M. W. Nelson, *Expert Opin. Pharmacother.*, **1**, 1441 (2000).
- 00MI43 D. M. Taylor and D. Duncan-McConnell, *J. Phycho pharmacol. (London)*, **14**, 409 (2000).
- 00MI44 G. W. Currier, *J. Clin. Psychiatry*, **61**(Suppl. 14), 21 (2000).
- 00MI45 S. N. Ghaemi, *J. Clin. Psychiatry*, **61**(Suppl. 14), 33 (2000).
- 00MI46 D. G. Daniel, *J. Clin. Psychiatry*, **61**(Suppl. 14), 49 (2000).
- 00MI47 M. Weber, K. Taraz, H. Budzikiewicz, V. Geoffroy, and J.-M. Meyer, *BioMetals*, **13**, 301 (2000).
- 00MIP1 P. Hamley and A. Tinker, *PCT Int. Appl.* 00/6576 (2000) [*CA* **132**, 137,406 (2000)].
- 00MIP2 N. Fotouhi, P. Gillespie, R. W. Guthrie, S. L. Pietranico-Cole, and W. Yun, *PCT Int. Appl.* 00/21,920 (2000) [*CA* **132**, 294,010 (2000)].
- 00MIP3 L. E. J. Kennis, F. M. A. Van den Keybus, and J. C. Mertens, *PCT Int. Appl.* 00/20,421 (2000) [*CA* **132**, 265,187 (2000)].
- 00MIP4 L. E. J. Kennis, S. M. A. Pieters, and F. P. Bischoff, *PCT Int. Appl.* 00/20,422 (2000) [*CA* **132**, 265,188 (2000)].
- 00MIP5 T. J. Barberich, P. D. Rubin, and D. A. Handley, *PCT Int. Appl.* 00/24,399 (2000) [*CA* **132**, 303,503 (2000)].
- 00MIP6 P. L. I. De Nijs and W. L. J. Parys, *PCT Int. Appl.* 00/23,057 (2000) [*CA* **132**, 298,845 (2000)].
- 00MIP7 F. E. Janssens and J. E. Leenaerts, *PCT Int. Appl.* 00/37,470 (2000) [*CA* **133**, 74,016 (2000)].
- 00MIP8 R. P. G. Vandecruys and E. M. J. Jans, *PCT Int. Appl.* 00/59,477 (2000) [*CA* **133**, 301,173 (2000)].
- 00MIP9 R. S. Obach, *PCT Int. Appl.* 00/59,486 (2000) [*CA* **133**, 301,178 (2000)].
- 00MIP10 J. Huguet Clotet, J. Roca Acin, A. Bosch Rovira, and M. Canovas Bonet Span. 2,141,671 (2000) [*CA* **134**, 311,216 (2001)].
- 00OL3389 J. A. McCauley, C. R. Theberge, and N. J. Liverton, *Org. Lett.*, **2**, 3389 (2000).
- 00PS133 F. F. Mahmoud, N. R. Mohamed, S. M. Sherif, and A. W. Erian Phosphorus, *Sulfur Silicon Relat. Elem.*, **167**, 133 (2001).
- 00TA2809 R. Pedrosa, C. Andrés, J. P. Dugue-Soladana, and C. D. Rosón, *Tetrahedron: Asymmetry*, **11**, 2809 (2000).
- 00TL5837 R. de la Rosa, V. Martínez-Barrasa, C. Burgos, and J. Alvarez-Builla, *Tetrahedron Lett.*, **41**, 5837 (2000).
- 00ZN(C)146 C. Lenz, C. Amann, G. Briskot, K. Taraz, and H. Budzikiewicz, *Z. Naturforsch. C*, **556**, 146 (2000).

- 00ZN(C)153 W. Vossen, R. Fuchs, K. Taraz, and H. Budzikiewicz, *Z. Naturforsch. C*, **55b**, 153 (2000).
- 00ZN(C)323 C. Ruangviriyachai, I. Barelmann, R. Fuchs, and H. Budzikiewicz, *Z. Naturforsch. C*, **55b**, 323 (2000).
- 00ZN(C)671 C. Amann, K. Taraz, H. Budzikiewicz, and J.-M. Meyer, *Z. Naturforsch. C*, **55c**, 671 (2000).
- 00ZN(C)857 R. Sultana, R. Fuchs, H. Schmickler, K. Schlegel, H. Budzikiewicz, B. S. Siddiqui, V. Geoffrey, and J.-M. Meyer, *Z. Naturforsch. C*, **55c**, 857 (2000).
- 01BMCL339 H. Elokda, S.-Y. Chai, D. Ho, and T. Sulkowski, *Bioorg. Med. Chem. Lett.*, **11**, 339 (2001).
- 01CHE329 E. Suloeva, M. Yure, E. Gudriniece, S. Belyakov, M. Petrova, and I. Kalnite, *Chem. Heterocycl. Compd. (Engl. Transl.)*, **37**, 329 (2001).
- 01EUP1074549 G. Adam, A. Binggeli, H.-P. Maerki, V. Mutel, M. Wilhelm, and W. Wostl, *Eur. Pat. Appl.*, 1,074,549 (2001) [*CA* **134**, 147,611 (2001)].
- 01H(55)535 S. Djekou, A. Gellis, J. Maldonado, M. P. Crozet, and P. Vanelle, *Heterocycles*, **55**, 535 (2001).
- 01H(55)705 L. Jukić, J. Svete, and S. Stanovnik, *Heterocycles*, **55**, 705 (2001).
- 01H(55)1555 S. H. Lee, S. I. Kim, J. G. Park, E. S. Lee, and Y. Jahng, *Heterocycles*, **55**, 1555 (2001).
- 01JAP(K)01/97865 T. Suzuki, *Jpn. Kokai Tokkyo Koho* 01/97,865 (2001) [*CA* **134**, 256,908 (2001)].
- 01JAP(K)01/187728 R. Ishii and M. Koide, *Jpn. Kokai Tokkyo Koho* 01/187728 (2001) [*CA* **135**, 97,453 (2001)].
- 01JCS(P2)602 H. G. Andersen, U. Mitschke, and C. Wentrup, *J. Chem. Soc., Perkin Trans. 2*, 602 (2001).
- 01JHC869 L. Jukić, J. Svete, and B. Stanovnik, *J. Heterocycl. Chem.*, **38**, 869 (2001).
- 01JMC2139 C. Hennard, Q. C. Truong, J.-F. Desnottes, J.-M. Paris, N. J. Moreau, and M. A. Abdallah, *J. Med. Chem.*, **44**, 2139 (2001).
- 01JMC2490 F. Lombardo, M. Y. Shalaeva, K. A. Tupper, and F. Gao, *J. Med. Chem.*, **44**, 2490 (2001).
- 01JOC997 A. Kamal, K. V. Ramana, and M. V. Rao, *J. Org. Chem.*, **66**, 997 (2001).
- 01JPO25 E. D. Raczynska, M. Decouzon, J.-F. Gal, P.-C. Maria, G. Gelbard, and F. Vielfaure-Joly, *J. Phys. Org. Chem.*, **14**, 25 (2001).
- 01MI1 E. Spina, A. Avenoso, G. Facciola, M. Salemi, M. G. Scordo, M. Ancione, A. G. Madia, and E. Perucca, *Psychopharmacology (Berlin)*, **153**, 238 (2001).
- 01MI2 D. U. Fernandez, R. Fuchs, K. Taraz, H. Budzikiewicz, P. Munsch, and J.-M. Meyer, *BioMetals*, **14**, 81 (2001).
- 01MI3 C. L. DeVane and C. B. Nemeroff, *J. Clin. Psychopharmacol.*, **21**, 408 (2001).
- 01MI4 J. Kökösi, Zs. Likó, Á. Kiss, B. Podányi, and I. Hermecz, *Magy. Kem. Foly.*, **107**, 181 (2001) [*CA* **135**, 122,655 (2001)].
- 01MI5 D. A. Revicki, *Curr. Opin. Invest. Drugs (PharmaPress Ltd.)*, **2**, 110 (2001).
- 01MI6 J. Czekalla, S. Kollack-Walker, and C. M. Beasley, Jr., *J. Clin. Psychiatry*, **62**(Suppl. 2), 35 (2001).

- 01MI7 T. Wetterling, *Drug Saf.*, **24**, 59 (2001).
- 01MI8 D. J. Posey and C. J. McDougale, *Expert Opin. Pharmacother.*, **2**, 587 (2001).
- 01MI9 R. Williams, *J. Clin. Psychiatry*, **62**, 282 (2001).
- 01MI10 M. T. Compton and A. H. Miller, *J. Clin. Psychiatry*, **62**, 362 (2001).
- 01MI11 X. Li, C. Fu, L. Li, and X. Wang, *Zhongguo Yiyao Gongye Zazhi*, **32**, 174 (2001) [*CA* **135**, 278,110 (2001)].
- 01MI12 M. J. Burns, *J. Toxicol., Clin. Toxicol.*, **39**, 1 (2001).
- 01MI13 E. Spina, A. Avenoso, G. Facciola, M. G. Scordo, M. Ancione, and A. Madia, *Ther. Drug Monit.*, **23**, 223 (2001).
- 01MI14 C. B. Eap, G. Bondolfi, D. Zullino, C. Bryois, M. Fuciec, L. Savary, M. Jonzier-Perey, and P. Baumann, *Ther. Drug Monit.*, **23**, 228 (2001).
- 01MI15 A. Kennedy, S. Jain, and S. Vinogradov, *Formulary*, **36**, 500 (2001).
- 01MIP1 R. Leger, W. J. Watkins, J. Z. Zhang, T. E. Renau, V. J. Lee, T. Ohta, K. Nakayama, Y. Ishida, M. Ohtsuka, and H. Kawato, *PCT Int. Appl.* 01/30,757 (2001) [*CA* **134**, 336,205 (2001)].
- 01MIP2 S. L. Lyons and S. G. Wright, *PCT Int. Appl.* 01/34,113 (2001) [*CA* **134**, 371,768 (2001)].
- 01MIP3 S. L. Lyons and S. G. Wright, *PCT Int. Appl.* 01/34,120 (2001) [*CA* **134**, 371,770 (2001)].
- 01MIP4 A. R. Gorringe, M. J. Hudson, M. A. Matheson, A. Robinson, and D. M. West, *PCT Int. Appl.* 01/73,080 (2001) [*CA* **135**, 283,965 (2001)].
- 01MIP5 M. P. Maguire, M. Dai, and T. J. Vos, *PCT Int. Appl.* 01/10,842 (2001) [*CA* **134**, 178,566 (2001)].
- 01MIP6 N. R. Benham, *PCT Int. Appl.* 01/36,556 (2001) [*CA* **135**, 6531 (2001)].
- 01MIP7 M. Dib and C. Leperlier, *PCT Int. Appl.* 01/41,769 (2001) [*CA* **135**, 14,348 (2001)].
- 01MIP8 P. Arányi, S. Batori, S. Desilla, I. Hermecz, Z. Kapui, F. Lévai, E. Mikus, M. Pascal, L. T. Nagy, B. Simonot, K. Urbán-Szabó, M. Varga, and L. Vasvári-Debreczy, *PCT Int. Appl.* 01/44,245 (2001) [*CA* **135**, 46,198 (2001)].
- 01MIP9 A. D. Robertson, S. Jackson, V. Kenche, C. Yaip, H. Parbaharan, and P. Thompson, *PCT Int. Appl.* 01/53,266 (2001) [*CA* **135**, 122,509 (2001)].
- 01MIP10 Y. K. Hamied and V. M. Kulkarni, *PCT Int. Appl.* 01/79,188 (2001) [*CA* **135**, 331,441 (2001)].
- 01MIP11 T. V. Radhákrisnan, D. G. Sathe, and C. V. Suryavanshi, *PCT Int. Appl.* 01/85,731 (2001) [*CA* **135**, 357,942 (2001)].
- 01OL193 N. Yamazaki, W. Dokoshi, and C. Kibayashi, *Org. Lett.*, **3**, 193 (2001).
- 01S135 S. Lesniak and J. Flisinska, *Synthesis*, 135 (2001).
- 01S1258 P. Wessig, J. Schwarz, V. Lindemann, and M. C. Holthausen, *Synthesis*, 1258 (2001).
- 01SUL151 H. M. F. Madkour, S. A. Shiba, H. M. Sayed, and A. A. Hamed, *Sulfur Lett.*, **24**, 151 (2001).
- 01T1019 R. Sultana, B. S. Siddiqui, K. Taraz, H. Budzikiewicz, and J.-M. Meyer, *Tetrahedron*, **57**, 1019 (2001).
- 01T1987 M. L. Heredia, E. de la Cuesta, and C. Avendano, *Tetrahedron*, **57**, 2001 (1987).

- 01T2689 C. M. Tice and L. M. Bryman, *Tetrahedron*, **57**, 2689 (2001).
01TL1851 M. J. Deetz, J. P. Malerich, A. M. Beatty, and B. D. Smith, *Tetrahedron Lett.*, **42**, 2001 (1851).
01TL5849 M. Ongena, P. Jacques, P. Thonart, I. Gwose, D. U. Fernández, M. Schäfer, and H. Budzikiewicz, *Tetrahedron Lett.*, **42**, 5849 (2001).
01USP6264987 S. G. Wright, M. E. Rickey, J. M. Ramstack, S. L. Lyons, and J. M. Hotz, *US Pat.* 6,264,987 [*CA* **135**, 112,020 (2001)].
01ZN(C)303 R. Sultana, B. S. Siddiqui, S. Bina, K. Taraz, H. Budzikiewicz, and J.-M. Meyer, *Z. Naturforsch. C*, **56**, 303 (2001); 1039 (2000).
03AHC(84)219 I. Hermecz, *Adv. Heterocycl. Chem.*, **84**, 219 (2003).

Cumulative Index of Authors, Volumes 1–85

- Abarca-Gonzalez, B., see Sepúlveda-Arques, J., **63**, 339.
- Abbound, J. L. M., see Catalan, J., **41**, 187.
- Abdallah, M. A., see Shawali, A. S., **63**, 277.
- Abramovitch, R. A., Saha, J. G.,
Substitution in the Pyridine Series: Effect of Substituents, **6**, 229.
- Abramovitch, R. A., Spenser, I. D., *The Carbolines*, **3**, 79.
- Abu-Shanab, F. A., Wakefield, B. J., Elnagdi, M. H., *Methylpyridines and Other Methylazines as Precursors to Bicycles and Polycycles*, **68**, 181.
- Acheson, R. M., *1-Hydroxypyrrroles, 1-Hydroxyindoles, and 9-Hydroxycarbazoles*, **51**, 105; *Reactions of Acetylenecarboxylic Acids and Their Esters with Nitrogen-Containing Heterocyclic Compounds*, **1**, 125.
- Acheson, R. M., Elmore, N. F., *Reactions of Acetylenecarboxylic Esters with Nitrogen-Containing Heterocycles*, **23**, 263.
- Adam, W., *The Chemistry of 1,2-Dioxetanes*, **21**, 437.
- Ahmad, N. M., Li, J. J., *Palladium in Quinoline Synthesis*, **84**, 1.
- Aiello, E., see Cirrincione, G., **48**, 65.
- Aitken, A. R., Thomas, A. W., *Heterocyclic Acyl and Formyl Anion Equivalents*, **79**, 89.
- Akibe, K.-A., see Ohkata, K., **65**, 283.
- Albert, A., *4-Amino-1,2,3-triazoles*, **40**, 129; *The Chemistry of 8-Azapurines (1,2,3-Triazolo[4,5-d]pyrimidines)*, **39**, 117; *Annulation of a Pyrimidine Ring to an Existing Ring*, **32**, 1; *Covalent Hydration in Nitrogen Heterocycles*, **20**, 117.
- Albert, A., Armarego, W. L. F., *Covalent Hydration in Nitrogen-Containing Heteroaromatic Compounds. I. Qualitative Aspects*, **4**, 1.
- Albert, A., Yamamoto, H., *Heterocyclic Oligomers*, **15**, 1.
- Alcalde, E., *Heterocyclic Betaines: Pyridinium (Imidazolium) Azolate Inner Salts with Several Interannular Linkages*, **60**, 197.
- Alexeev, S. G., see Charushin, V. N., **46**, 73.
- Almerico, A. M., see Cirrincione, G., **48**, 65.
- Anastassiou, A. G., Kasmai, H. S., *Medium-Large and Large π -Excessive Heteroannulenes*, **23**, 55.
- Anders, E., Wermann, K., Eynde, J. J. V., *Chemistry of N-(1-Haloalkyl) Heteroarylium Salts*, **77**, 183.
- Anderson, P. S., see Lyle, R. L., **6**, 45.
- ApSimon, J. W., See Paré, J. R. J., **42**, 335.
- Arai, S., Hida, M., *Polycyclic Aromatic Nitrogen Cations*, **55**, 261.
- Arán, V. J., Goya, P., Ochoa, C., *Heterocycles Containing the Sulfamide Moiety*, **44**, 81.
- Arbuzov, B. A., Nikonov, G. N., *Phosphorus Heterocycles from α -Hydroxyalkylphosphines and Vinylphosphines*, **61**, 59.
- Armarego, W. L. F., *Quinazolines*, **1**, 253; **24**, 1.
- Armarego, W. L. F., see Albert, A., **4**, 1.
- Ashby, J., Cook, C. C., *Recent Advances in the Chemistry of Dibenzothiophenes*, **16**, 181.
- Assafir, H., see El Ashry, E. S. H., **75**, 79.
- Avendaño López, C., González Trigo, G., *The Chemistry of Hydantoins*, **38**, 177.
- Badger, G. M., Sasse, W. H. F., *The Action of Metal Catalysts on Pyridines*, **2**, 179.
- Balaban, A. T., see Kuznetsov, E. V., **50**, 157.
- Balaban, A. T., Dinculescu, A., Dorofeenko, G. N., Fischer, G., Koblik, A. V., *Pyrylium Salts: Syntheses, Reactions and Physical Properties*, **S2**.
- Balaban, A. T., Schroth, W., Fischer, G., *Pyrylium Salts, Part I. Syntheses*, **10**, 241.
- Banister, A. J., see Rawson, J. M., **62**, 137.
- Bapat, J. B., Black, D. StC., Brown, R. F. C., *Cyclic Hydroxamic Acids*, **10**, 199.

- Baram, S. G., see Mamaev, V. P., **42**, 1.
- Barker, J. M., *gem-Dithienylalkanes and Their Derivatives*, **32**, 83; *The Thienopyridines*, **21**, 65.
- Barluenga, J., Tomas, M., *Synthesis of Heterocycles from Azadienes*, **57**, 1.
- Barton, H. J., see Bojarski, J. T., **38**, 229.
- Barton, J. W., *Benzo[c]cinnolines*, **24**, 151.
- Becher, J., see Bryce, M. R., **55**, 1.
- Beckert, R., *Syntheses and Properties of Azafulvalenes*, **77**, 115.
- Beke, D., *Heterocyclic Pseudobases*, **1**, 167.
- Belen'kii, L. I., *The Literature of Heterocyclic Chemistry, Part III*, **44**, 269.
- Belen'kii, L. I., Kruchkovskaya, N. D., *The Literature of Heterocyclic Chemistry, Part IV*, **55**, 31.
- Belen'kii, L. I., Kruchkovskaya, N. D., *The Literature of Heterocyclic Chemistry, Part V*, **71**, 291.
- Belen'kii, L. I., Kruchkovskaya, N. D., Gramenitskaya, V. N., *The Literature of Heterocyclic Chemistry, Part VI*, **73**, 295.
- Belen'kii, L. I., Kruchkovskaya, N. D., Gramenitskaya, V. N., *The Literature of Heterocyclic Chemistry, Part VII: 1997-1999*, **79**, 201.
- Benassi, R., Folli, U., Schenetti, L., Taddei, F., *The Conformations of Acyl Groups in Heterocyclic Compounds*, **41**, 75.
- Benneche, T., see Undheim, K. **62**, 305.
- Berg, U., see Gallo, R., **43**, 173.
- Bergman, J., Janosik, T., Wahlstrom, N., *Indolocarbazoles*, **80**, 1.
- Bernáth, G., see Fülöp, F., **69**, 349.
- Bhatt, M. V., see Shirwaiker, G. S., **37**, 67.
- Bhushan, V., see Lohray, B. B., **68**, 89.
- Black, D. StC., Doyle, J. E., *1-Azabicyclo[3.1.0]hexanes and Analogs with Further Heteroatom Substitution*, **27**, 1.
- Black, D. StC., see Bapat, J. B., **10**, 199.
- Blackman, A., *Reactions of Coordinated Ligands*, **58**, 123.
- Blaha, K., Červinka, O., *Cyclic Enamines and Imines*, **6**, 147.
- Bobbitt, J. M., *The Chemistry of 4-Oxy- and 4-Keto-1,2,3,4-tetrahydroisoquinolines*, **15**, 99.
- Bodea, C., Silberg, I., *Recent Advances in the Chemistry of Phenothiazines*, **9**, 321.
- Bohle, M., Liebscher, J., *Ring Contraction of Heterocycles by Sulfur Extrusion*, **65**, 39.
- Böhm, S., see Kuthan, J., **59**, 179.
- Böhm, S., see Kuthan, J., **62**, 19.
- Bojarski, J. T., Mokrosz, J. L., Barton, H. J., Paluchowska, M. H., *Recent Progress in Barbituric Acid Chemistry*, **38**, 229.
- Bönnemann, H., Brijoux, W., *Organocobalt-Catalysed Synthesis of Pyridines*, **48**, 177.
- Bonnett, R., North, S. A., *The Chemistry of the Isoindoles*, **29**, 341.
- Bosshard, P., Eugster, C. H., *The Development of the Chemistry of Furans, 1952-1963*, **7**, 377.
- Boulton, A. J., Ghosh, P. B., *Benzo[*f*]uroxans*, **10**, 1.
- Boulton, A. J., see Gasco, A., **29**, 251; Wünsch, K. H., **8**, 277.
- Bradsher, C. K., *Cationic Polar Cycloaddition*, **16**, 289; **19**, xi.
- Brijoux, W., see Bönnemann, H., **48**, 177.
- Brown, C., Davidson, R. M., *1,4-Benzothiazines, Dihydro-1,4-benzothiazines, and Related Compounds*, **38**, 135.
- Brown, R. F. C., see Bapat, J. B., **10**, 199.
- Broy, W., see Mayer, R., **8**, 219.
- Brunner, E., see Burger, K., **60**, 1.
- Bryce, M. R., Becher, J., Fält-Hansen, B., *Heterocyclic Synthesis using new Heterodienophiles*, **55**, 1.
- Bryce, M. R., Vernon, J. M., *Reactions of Benzyne with Heterocyclic Compounds*, **28**, 183.
- Bulka, E., *The Present State of Selenazole Chemistry*, **2**, 343.
- Bunting, J. W., *Heterocyclic Pseudobases*, **25**, 1.
- Burger, K., Wucherpfennig, U., Brunner, E., *Fluoro Heterocycles with Five-membered Rings*, **60**, 1.
- Busby, R. E., *Thiadiazines with Adjacent Sulfur and Nitrogen Ring Atoms*, **50**, 255.
- Busecni, S., see Vivona, N., **56**, 49.
- Butler, R. N., *Recent Advances in Tetrazole Chemistry*, **21**, 323.

- Cagniant, P., Cagniant, D., *Recent Advances in the Chemistry of Benzo[b]furan and Its Derivatives. Part I. Occurrence and Synthesis*, **18**, 337.
- Calf, G. E., Garnett, J. L., *Isotopic Hydrogen Labeling of Heterocyclic Compounds by One-Step Methods*, **15**, 137.
- Catala Noble, A., see Popp, F. D., **8**, 21.
- Catalan, J., Abboud, J. L. M., Elguero, J., *Basicity and Acidity of Azoles*, **41**, 187.
- Červinka, O., see Blaha, K., **6**, 147.
- Chambers, R. D., Sargent, C. R., *Polyfluoroheteroaromatic Compounds*, **28**, 1.
- Chandra, R., see Kumar, R., **78**, 269.
- Charushin, V. N., Alexeev, S. G., Chupakhin, O. N., van der Plas, H. C., *Behavior of Monocyclic 1,2,4-Triazines in Reactions with C-, N-, O-, and S-Nucleophiles*, **46**, 73.
- Charushin, V. N., Chupakhin, O. N., van der Plas, H. C., *Reactions of Azines with Bifunctional Nucleophiles: Cyclizations and Ring Transformations*, **43**, 301.
- Cheeseman, G. W. H., *Recent Advances in Quinoxaline Chemistry*, **2**, 203.
- Cheeseman, G. W. H., Werstiuk, E. S. G., *Quinoxaline Chemistry: Developments 1963-1975*, **22**, 367; *Recent Advances in Pyrazine Chemistry*, **14**, 99.
- Chimirri, A., Gitto, R., Grasso, S., Montforte, A. M., Zappalà, M., *Annelated 1,5-Benzothiazepines*, **63**, 61.
- Chupakhin, O. N., see Charushin, V. N., **43**, 301; **46**, 73.
- Chupakhin, O. N., see Kozhevnikov, D. N., **82**, 261.
- Cirrinzione, G., Almerico, A. M., Aiello, E., Dattolo, G., *Diazoazoles*, **48**, 65.
- Clapp, L. B., *1,2,4-Oxadiazoles*, **20**, 65.
- Claramunt, R. M., see Elguero, J., **22**, 183.
- Claramunt, R. M., Elguero, J., Katritzky, A. R., *Tautomerism Involving Other Than Five- and Six-Membered Rings*, **77**, 1.
- Cleghorn, H. P., see Lloyd, D., **17**, 27.
- Clerici, F., *Thiazole and Thiadiazole S-oxides*, **83**, 71.
- Comins, D. L., O'Connor, S., *Regioselective Substitution in Aromatic Six-Membered Nitrogen Heterocycles*, **44**, 199.
- Cook, C. C., see Ashby, J., **16**, 181.
- Cook, M. J., Katritzky, A. R., Linda, P., *Aromaticity of Heterocycles*, **17**, 255.
- Costero, A. M., *The Chemistry of Unsaturated Nitrogen Heterocyclic Compounds Containing Carbonyl Groups*, **58**, 171.
- Crabb, T. A., Katritzky, A. R., *Conformational Equilibria in Nitrogen-Containing Saturated Six-Membered Rings*, **36**, 1.
- Crabb, T. A., Jackson, D., Patel, A. V., *Saturated Bicyclic 6/5 Ring-Fused Systems with Bridgehead Nitrogen and a Single Additional Heteroatom*, **49**, 193.
- Cusmano, G., see Vivona, N., **56**, 49.
- D., Auria, M., *Photochemical Isomerization of Pentaatomic Heterocycles*, **79**, 41.
- Daltrozzo, E., see Scheibe, G., **7**, 153.
- Dattolo, G., see Cirrinzione, G., **48**, 65.
- Davidson, J. L., Preston, P. N., *Use of Transition Organometallic Compounds in Heterocyclic Synthesis*, **30**, 319.
- Davidson, R. M., see Brown, C., **38**, 135.
- Davis, M., *Benzisothiazoles*, **14**, 43; *Recent Advances in the Chemistry of Benzisothiazoles and Other Polycyclic Isothiazoles*, **38**, 105; *Sulfur Transfer Reagents in Heterocyclic Synthesis*, **30**, 47.
- Deady, L. W., see Zoltewicz, J. A., **22**, 71.
- Dean, F. M., *Recent Advances in Furan Chemistry, Part I*, **30**, 167; *Part II*, **31**, 237.
- Denisko, O. V., see Elguero, J., **76**, 1.
- Denisko, O. V., see Minkin, V. I., **76**, 159.
- Denisko, O. V., see Stanovnik, B., **81**, 253.
- den Hertog, H. J., van der Plas, H. C., *Hetarynes*, **4**, 121.
- Dinculescu, A., see Balaban, A. T., **S2**.
- Doddi, G., Ercolani, G., *Thiopyrylium, Selenopyrylium, and Telluropirylium Salts*, **60**, 65.
- Donald, D. S., Webster, O. W., *Synthesis of Heterocycles from Hydrogen Cyanide Derivatives*, **41**, 1.

- Dorofeenko, G. N., see Balaban, A. T., **S2**.
Dou, H. J. M., see Gallo, R. J., **36**, 175.
Doyle, J. E., see Black, D. StC., **27**, 1.
Drum, C., see Katritzky, A. R., **40**, 1.
Duffin, G. F., *The Quaternization of Heterocyclic Compounds*, **3**, 1.
Dyke, S. F., *1,2-Dihydroisoquinolines*, **14**, 279.
Dzenis, J., see Wamhoff, H., **55**, 129.
- Easton, C. J., Hughes, C. M. M., Savage, G. P., Simpson, G. P., *Cycloaddition Reactions of Nitrile Oxides with Alkenes*, **60**, 261.
Eckstein, Z., Urbański, T., *1,3-Oxazine Derivatives*, **2**, 311; **23**, 1.
Eisch, J. J., *Halogenation of Heterocyclic Compounds*, **7**, 1.
El Ashry, E. S. H., Rashed, N., Taha, M., Ramadan, E., *Condensed 1,2,4-Triazines: I. Fused to Heterocycles with Three-, Four- and Five-membered Rings*, **59**, 39.
El Ashry, E. S. H., Rashed, N., Mousaad, A., Ramadan, E., *Condensed 1,2,4-Triazines: II. Fused to Heterocycles with Six- and Seven-Membered Rings and Fused to Two Heterocyclic Rings*, **61**, 207.
El Ashry, E. S. H., Kilany, Y. E., *Acyclonucleosides: Part 1. Seco-Nucleosides*, **67**, 391.
El Ashry, E. S. H., Kilany, Y. E., *Acyclonucleosides: Part 2. Diseco-Nucleosides*, **68**, 1.
El Ashry, E. S. H., Kilany, Y. E., *Acyclonucleosides: Part 3. Tri-, Tetra-, and Penta-Seco-Nucleosides (Two, Three, and Four Bonds Disconnections)*, **69**, 129.
El Ashry, E. S. H., Rashed, N., *1,2,3-Triazolo[x, y-z]pyrimidines*, **71**, 57.
El Ashry, E. S. H., Rashed, N., *1,2,4-Triazolo- and Tetrazolo[x, y-z]pyrimidines*, **72**, 127.
El Ashry, E. S. H., El Kilany, Y., Assafir, H., Rashed, N., *Dimroth Rearrangement: Translocation of Heteroatoms in Heterocyclic Rings and Its Role in Ring Transformations of Heterocycles*, **75**, 79.
El-Ashry, E. S. H., Ibrahim, E. S. I., *Fused Heterocyclo-Quinolines Containing One Nitrogen Atom at Ring Junction: Part I. Four and Five Membered Heterocyclo-Quinolines*, **84**, 71.
Elgemeie, G. E. H., see Elnagdi, M. H., **41**, 319.
Elguero, J., see Catalan, J., **41**, 187.
Elguero, J., Claramunt, R. M., Summers, A. J. H., *The Chemistry of Aromatic Azapentalenes*, **22**, 183.
Elguero, J., Katritzky, A. R., Denisko, O. V., *Phototropic Tautomerism of Heterocycles: Heteroaromatic Tautomerism—General Overview and Methodology*, **76**, 1.
Elguero, J., Marzin, C., Katritzky, A. R., Linda, P., *The Tautomerism of Heterocycles*, **S1**.
Elguero, J., see Friedrichsen, W., **76**, 85.
Elguero, J., see Minkin, V. I., **76**, 159.
Elguero, J., see Claramunt, R. M., **77**, 1.
Elguero, J., see Shcherbakova, I., **77**, 51.
Elguero, J., see Vasilevsky, S. F., **82**, 1.
El Kilany, Y., see El Ashry, E. S. H., **75**, 79.
Elmoghayar, M. R. H., see Elnagdi, M. H., **41**, 319; **48**, 223.
Elmore, N. F., see Acheson, R. M., **23**, 263.
Elnagdi, M. H., Elgemeie, G. E. H., Elmoghayar, M. R. H., *Chemistry of Pyrazolopyrimidines*, **41**, 319.
Elnagdi, M. H., Elmoghayar, M. R. H., Sadek, K. U., *Chemistry of Pyrazoles Condensed to Heteroaromatic Five- and Six-Membered Rings*, **48**, 223.
Elnagdi, M. H., see Abu-Shanab, F. A., **68**, 181.
El'tsov, A. V., see Timpe, H. J., **33**, 185.
Elvidge, J. A., Jones, J. R., O'Brien, C., Evans, E. A., Sheppard, H. C., *Base-Catalyzed Hydrogen Exchange*, **16**, 1.
Elwahy, A. H., see Ibrahim, Y. A., **65**, 235.
Epszajn, J., see Quéguiner, G., **52**, 187.
Ercolani, G., see Doddi, G., **60**, 65.
Esker, J. L., Newcomb, M., *The Generation of Nitrogen Radicals and their Cyclizations for the Construction of the Pyrrolidine Nucleus*, **58**, 1.
Eugster, C. H., see Bosshard, P., **7**, 377.
Evans, E. A., see Elvidge, J. A., **16**, 1.
Eynde, J. J. V., see Anders, E., **77**, 183.
- Fält-Hansen, B., see Bryce, M. R., **55**, 1.
Fedrick, J. L., see Shepherd, R. G., **4**, 145.

- Fetles, M., Pliml, J., *3-Piperidineines (1,2,3,6-Tetrahydropyridines)*, **12**, 43.
- Fiamegos, Y., see Varvounis, G., **80**, 73.
- Filler, R., *Recent Advances in Oxazolone Chemistry*, **4**, 75.
- Filler, R., Rao, Y. S., *New Developments in the Chemistry of Oxazolones*, **21**, 175.
- Fischer, G., *1,2,4-Triazolo[1,5-a]pyrimidines*, **57**, 81.
- Fischer, G., *Tropones, Tropolones, and Tropylium Salts with Fused Heterocyclic Rings Part 1: Synthesis*, **64**, 81.
- Fischer, G., *Tropones, Tropolones, and Tropylium Salts with Fused Heterocyclic Rings Part 2: Synthesis, Reactivity, and Application*, **66**, 285.
- Fischer, G. W., see Balaban, A. T., **10**, 241; **S2**.
- Fletcher, I. J., Siegrist, A. E., *Olefin Synthesis with Anils*, **23**, 171.
- Flitsch, W., *The Chemistry of 4 Azaamlenes*, **43**, 35; *Hydrogenated Porphyrin Derivatives: Hydroporphyrins*, **43**, 73.
- Flitsch, W., Jones, G., *The Chemistry of Pyrrolizines*, **37**, 1.
- Flitsch, W., Kraemer, U., *Cyclazines and Related N-Bridged Annulenes*, **22**, 321.
- Folli, U., see Benassi, R., **41**, 75.
- Fowler, F. W., *Synthesis and Reactions of 1-Azirines*, **13**, 45.
- Freeman, F., *The Chemistry of 1-Pyridines*, **15**, 187.
- Frenna, V., see Vivona, N., **56**, 49.
- Friedrichsen, W., Traulsen, T., Elguero, J., Katritzky, A. R., *Tautomerism of Heterocycles: Five-Membered Rings with One Heteroatom*, **76**, 85.
- Friedrichsen, W., see Sheremetev, A. B., **78**, 65.
- Fujita, E., Nagao, Y., *Chiral Induction Using Heterocycles*, **45**, 1.
- Fülöp, F., see Valters, R. E., **64**, 251.
- Fülöp, F., see Valters, R. E., **66**, 1.
- Fülöp, F., Beneáth, G., Pihlaja, K., *Synthesis, Stereochemistry and Transformations of Cyclopentane-, Cyclohexane-, Cycloheptane-, and Cyclooctane-Fused 1, 3-Oxazines 1, 3-Thiazines, and Pyrinridines*, **69**, 349.
- Furukawa, N., see Oae, S., **48**, 1.
- Furusaki, F., see Takeuchi, Y., **21**, 207.
- Gallo, R. J., Makosza, M., Dou, H. J. M., Hassanaly, P., *Applications of Phase Transfer Catalysts in Heterocyclic Chemistry*, **36**, 175.
- Gallo, R. J., Roussel, C., Berg, U., *The Quantitative Analysis of Steric Effects in Heteroaromatics*, **43**, 173.
- Gardini, G. P., *The Oxidation of Monocyclic Pyrroles*, **15**, 67.
- Garin, J., *The Reactivity of Tetrathia- and Tetraselenafulvalenes*, **62**, 249.
- Gamett, J. L., see Calf, G. E., **15**, 137.
- Gamovskii, A. D., Sadimenko, A. P., *Five- and Six-Membered Heteroaromatic Compounds as σ and π Ligands*, **72**, 1.
- Gamovskii, A. D., see Minkin, V. I., **76**, 159.
- Gasco, A., Boulton, A. J., *Furoxans and Benzofuroxans*, **29**, 251.
- Gelbin, A., see Henning, H. G., **57**, 139.
- George, M. V., Khetan, S. K., Gupta, R. K., *Synthesis of Heterocycles through Nucleophilic Addition to Acetylenic Esters*, **19**, 279.
- Ghosh, P. B., see Boulton, A. J., **10**, 1.
- Giannopoulos, T., see Varvounis, G., **66**, 193.
- Gilchrist, T. L., *Ring-Opening of Five-Membered Heteroaromatic Anions*, **41**, 41.
- Gilchrist, T. L., Gymer, G. E., *1,2,3-Triazoles*, **16**, 33.
- Gitto, R., see Chimirri, A., **63**, 61.
- Glukhovtseev, M. N., see Simkin, B. Ya., **56**, 303.
- Glushkov, R. G., Granik, V. G., *The Chemistry of Lactim Ethers*, **12**, 185.
- Gol'dfarb, Ya. L., see Litvinov, V. P., **19**, 123.
- Gompper, R., *The Reactions of Diazomethane with Heterocyclic Compounds*, **2**, 245.
- González Trigo, G., see Avendaño Lopez, C., **38**, 177.
- Goya, P., see Arán V. J., **44**, 81.
- Gramenitskaya, V. N., see Belen'kii, L. I., **73**, 295.
- Gramenitskaya, V. N., see Belen'kii, L. I., **79**, 201.
- Granik, V. G., see Glushkov, R. G., **12**, 185.

- Granik, V. G., Kadushkin, A. V., Liebscher, J., *Synthesis of Amino Derivatives of Five-Membered Heterocycles by Thorpe-Ziegler Cyclization*, **72**, 79.
- Granik, V. G., Makarov, V. A., Pákányi, C., *Enamines as Synthons in the Synthesis of Heterocycles*, **72**, 283.
- Grandberg, I. I., see Kost, A. N., **6**, 347.
- Grasso, S., see Chimirri, A., **63**, 61.
- Greenhill, J. V., see Lue, P., **67**, 209.
- Grimfin, T. S., Woods, T. S., and Klayman, D. L., *Thioureas in the Synthesis of Heterocycles*, **18**, 99.
- Grimmett, M. R., *Advances in Imidazole Chemistry*, **12**, 103; **27**, 241; *Electrophilic Substitution in the Azines*, **47**, 325; *Halogenation of Heterocycles: I. Five-membered Rings*, **57**, 291; *II. Six and Seven-numbered Rings*, 58, 271; *III. Heterocycles Fused to Other Aromatic and Heteroaromatic Rings*, **59**, 245.
- Grimmett, M. R., Keene, B. R. T., *Reactions of Annular Nitrogens of Azines with Electrophiles*, **43**, 127.
- Gronowitz, S., *Recent Advances in the Chemistry of Thiophenes*, **1**, 1.
- Groundwater, P. W., Munawar, M. A., *Heterocycle-Fused Acridines*, **70**, 89.
- Groundwater, P. W., Nyerges, M., *1,7-Electrocyclizations of $\alpha,\beta,\gamma,\delta$ -Unsaturated 1,3-Dipoles*, **73**, 97.
- Guilloton, O., see Quiniou, H., **50**, 85.
- Gupta, R. K., see George, M. V., **19**, 279.
- Gut, J., *Aza Analogs of Pyrimidine and Purine Bases of Nucleic Acids*, **1**, 189.
- Gymer, G. E., see Gilchrist, T. L., **16**, 33.
- Haas, A., *Some Recent Developments in Chalcogen Heterocyclic Chemistry*, **71**, 115.
- Hanson, P., *Heteroaromatic Radicals, Part II: General Properties; Radicals with Group V Ring Heteroatoms*, **25**, 205; *Part III: Radicals with Group VI and Groups V and VI Ring Heteroatoms*, **27**, 31.
- Hardy, C. R., *The Chemistry of Pyrazolopyridines*, **36**, 343.
- Hashem, A., Senning, A., *Reactions of 2(3H)-Furanones*, **73**, 275.
- Hashem, A., Kleinpeter, E., *The Chemistry of 2(5H)-Furanones*, **81**, 107.
- Hazai, L., *3(2H)-Isoquinolinones and Their Saturated Derivatives*, **52**, 155.
- Heacock, R. A., *The Aminochromes*, **5**, 245.
- Heacock, R. A., Kasperek, S., *The Indole Grignard Reagents*, **10**, 43.
- Heinz, B., see Ried, W., **35**, 199.
- Henning, H. G., Gelbin, A., *Advances in Tetramic Acid Chemistry*, **57**, 139.
- Hermecz, I., *Chemistry of Diazabicycloundecene (DBU) and Other Pyrimidoazepines*, **42**, 83.
- Hermecz, I., Kerestűri, G., Vasvári-Debrecezy, L., *Aminomethylenemalonates and Their Use in Heterocyclic Synthesis*, **54**.
- Hermecz, I., Meszaros, Z., *Chemistry of Pyrido[1,2-a]pyrimidines*, **33**, 241.
- Hermecz, I., Vasvári-Debrecezy, L., *Tricyclic Compounds with a Central Pyrimidine Ring and One Bridgehead Nitrogen*, **39**, 281.
- Hermecz, I., *Recent Developments in the Chemistry of Pyrido[1,2-a]pyrimidines*, **63**, 103.
- Hermecz, I., *Chemistry of Pyrido[1,2-b][1,2]oxazines, Pyrido[1,2-b][1,2]thiazines, Pyrido[1,2-b]pyridazines and Their Benzologs: Part I*, **69**, 89.
- Hermecz, I., *Chemistry of Pyrido[1,2-c][1,3]oxazines, Pyrido[1,2-c][1,3]thiazines, Pyrido[1,2-c]pyrimidines, and Their Benzologs: Part II*, **70**, 1.
- Hermecz, I., *Chemistry of Pyrido[2,1-c][1,4]oxazines, Pyrido[1,2-c][1,4]thiazines, Pyrido[1,2-a]pyrazines and Their Benzologues*, **71**, 145.
- Hermecz, I., *Chemistry of Pyrido[2,1-b][1,3]oxazines, Pyrido[2,1-b][1,3]thiazines, and Their Benzologs, Part IV*, **72**, 225.
- Hermecz, I., *Chemistry of Benzologs of Pyrido[1,2-a]pyrimidines: Part V of Series on Pyrido-oxazines, -diazines, and -thiazines*, **73**, 177.
- Hermecz, I., *Recent Development in the Chemistry of Pyrido-oxazines, Pyrido-thiazines, Pyrido-diazines and Their Benzologs: Part I*, **84**, 221.
- Hermecz, I., *Recent Development in the Chemistry of Pyrido-oxazines, Pyrido-thiazines, Pyrido-diazines and Their Benzologs. Part 2*, **85**, 175.

- Hettler, H., 3-Oxo-2,3-dihydrobenz[d]isothiazole-1, 1-dioxide (Saccharin) and Derivatives, **15**, 233.
- Hetzheim, A., Moeckel, K., *Recent Advances in 1,3,4-Oxadiazole Chemistry*, **7**, 183.
- Hewitt, D., *The Chemistry of Azaphosphorines*, **43**, 1.
- Hibino, S., see Kametani, T, **42**, 245.
- Hida, M., see Arai, S., **55**, 261.
- Hiremath, S. P., Hosmane, R. S., *Applications of Nuclear Magnetic Spectroscopy to Heterocyclic Chemistry: Indole and Its Derivatives*, **15**, 277.
- Hiremath, S. P., Hooper, M., *Isatogens and Indolones*, **22**, 123.
- Hirota, K., see Wamhoff, H., **55**, 129.
- Holm, A., 1,2,3,4-Thiatriazoles, **20**, 145.
- Honda, T., see Kametani, T., **39**, 181.
- Hooper, M., see Hiremath, S. P., **22**, 123.
- Hörnfeldt, A. B., Selenophenes, **30**, 127.
- Hosmane, R. S., see Hiremath, S. P., **15**, 277.
- Hughes, C. M. M., see Easton, C. J., **60**, 261.
- Hunt, J. H., see Swinbourne, F. J., **23**, 103.
- Hurst, D. T., *The Nitration of Phenyl-substituted Heterocycles*, **58**, 215.
- Ibrahim, Y. A., Elwahy, A. H., Kadry, A. M., *Thienopyrimidines: Synthesis, Reactions, and Biological Activity*, **65**, 235.
- Ibrahim, E. S. I., see El-Ashry, E. S. H., **84**, 71.
- Iddon, B., *Benzo[c]thiophenes*, **14**, 331.
- Iddon, B., Scrowston, R. M., *Recent Advances in the Chemistry of Benzo[b]-thiophenes*, **11**, 177.
- Ikeda, M., see Tamura, Y., **29**, 71.
- Illuminati, G., *Nucleophilic Heteroaromatic Substitution*, **3**, 285.
- Illuminati, G., Stegel, F., *The Formation of Anionic σ -Adducts from Heteroaromatic Compounds: Structures, Rates, and Equilibria*, **34**, 305.
- Ishikura, M., see Terashima, M., **46**, 143.
- Ionescu, M., Mantsch, H., *Phenoxazines*, **8**, 83.
- Irwin, W. J., Wibberley, D. G., *Pyridopyrimidines: 1,3,5-, 1,3,6-, 1,3,7-, and 1,3,8-Triazanaphthalenes*, **10**, 149.
- Ishii, A., see Nakayama, J., **77**, 221.
- Jackson, D., see Crabb, T. A., **49**, 193.
- Jaffé, H. H., Jones, H. L., *Applications of the Hammett Equation to Heterocyclic Compounds*, **3**, 249.
- Jankowski, K., see Paré, J. R. J., **42**, 335.
- Jankowski, K., Paré, J. R. J., Wightman, R. H., *Mass Spectrometry of Nucleic Acids*, **39**, 79.
- Janosik, T., see Bergman, J., **80**, 1.
- Jensen, K. A., Pedersen, C., 1,2,3,4-Thiatriazoles, **3**, 263.
- Johnson, C. D., see Tomasik, P., **20**, 1.
- Johnson, F., Madroñero, R., *Heterocyclic Syntheses Involving Nitrilium Salts and Nitriles under Acidic Conditions*, **6**, 95.
- Jones, G., *Aromatic Quinolizines*, **31**, 1.
- Jones, G., Sliskovic, D. R., *The Chemistry of the Triazolopyridines*, **34**, 79.
- Jones, G., see Flitsch, W., **37**, 1.
- Jones, G., *The Chemistry of the Triazolopyridines: an Update*, **83**, 1.
- Jones, H. L., see Jaffé, H. H., **3**, 209.
- Jones, J. R., see Elvidge, J. A., **16**, 1.
- Jones, P. M., see Katritzky, A. R., **25**, 303.
- Jones, R. A., *Physicochemical Properties of Pyrroles*, **11**, 383.
- Joule, J. A., *Recent Advances in the Chemistry of 9H-Carbazoles*, **35**, 83; *Thianthrenes*, **48**, 301.
- Kadaba, P. K., Δ^3 - and Δ^4 -1,2,3-Triazolines, **37**, 351; 1,2,4-Triazolines, **46**, 169.
- Kadaba, P. K., Stanovnik, B., Tišler, M., Δ^2 -1,2,3-Triazolines, **37**, 217.
- Kadry, A. M., see Ibrahim, Y. A., **65**, 235.
- Kadushkin, A. V., see Granik, V. G., **72**, 79.
- Kametani, T., Hibino, S., *The Synthesis of Natural Heterocyclic Products by Hetero Diels-Alder Cycloaddition Reactions*, **42**, 245.
- Kametani, T., Honda, T., *The Application of Aziridines to the Synthesis of Natural Products*, **39**, 181.
- Kanemasa, S., see Tsuge, O., **45**, 231.
- Kappe, T., Stadlbauer, W., *Isatoic Anhydrides and Their Uses in Heterocyclic Synthesis*, **28**, 127.
- Kasmai, H. S., see Anastassiou, A. G., **23**, 55.
- Kasperek, S., 1-, 2- and 3-Benzazepines, **17**, 45.
- Kasperek, S., see Heacock, R. A., **10**, 43.

- Katritzky, A. R., Drum, C., *Advances in Heterocyclic Chemistry: Prospect and Retrospect*, **40**, 1.
- Katritzky, A. R., Jones, P. M., *The Literature of Heterocyclic Chemistry, Part II*, **25**, 303.
- Katritzky, A. R., Lagowski, J. M., *Prototropic Tautomerism of Heteroaromatic Compounds. I. General Discussion and Methods of Study*, **1**, 311; *II. Six-Membered Rings*, **1**, 339; *III. Five-Membered Rings and One Hetero Atom*, **2**, 1; *IV. Five-Membered Rings with Two or More Hetero Atoms*, **2**, 27.
- Katritzky, A. R., Taylor, R., *Electrophilic Substitution of Heterocycles: Quantitative Aspects*, **47**, 1.
- Katritzky, A. R., Weeds, S. M., *The Literature of Heterocyclic Chemistry*, **7**, 225.
- Katritzky, A. R., see Cook, M. J., **17**, 255; Crabb, T. A., **36**, 1; Elguero, J., **S1**; Sammes, M. P., **32**, 233; **34**, 1, 53; **35**, 375, 413.
- Katritzky, A. R., see Rewcastle, G. W., **56**, 155.
- Katritzky, A. R., see Elguero, J., **76**, 1.
- Katritzky, A. R., see Friedrichsen, W., **76**, 85.
- Katritzky, A. R., see Mirnkin, V. I., **76**, 159.
- Katritzky, A. R., see Claramunt, R. M., **77**, 1.
- Katritzky, A. R., see Shcherbakova, I., **77**, 51.
- Katritzky, A. R., see Stanovnik, B., **81**, 253.
- Keay, J. G., *The Reduction of Nitrogen Heterocycles with Complex Metal Hydrides*, **39**, 1.
- Keene, B. R. T., see Grimmett, M. R., **43**, 127.
- Keene, B. R. T., Tissington, P., *Recent Developments in Phenanthridine Chemistry*, **13**, 315.
- Kerestüri, G., see Hermecz, I., **54**.
- Khetan, S. K., see George, M. V., **19**, 279.
- Khlebnikov, A. F., Novikov, M. S., Kostikov, R. R., *Carbines and Carbenoids in Synthesis of Heterocycles*, **65**, 93.
- Kilany, Y. E., see El Asbry, E. S. H., **67**, 391.
- Kilany, Y. E., see El Ashry, E. S. H., **68**, 1.
- Kilany, Y. E., see El Ashry, E. S. H., **69**, 129.
- Kirschke, K., see Schulz, M., **8**, 165.
- Kiselyov, A. S., see Strekowski, L., **62**, 1.
- Klayman, D. L., see Griffin, T. S., **18**, 99.
- Kleinpeter, E., *Conformational Analysis of Saturated Six-Membered Oxygen-Containing Heterocyclic Rings*, **69**, 217.
- Kleinpeter, E., see Hashem, A., **81**, 107.
- Klemm, L. H., *Syntheses of Tetracyclic and Pentacyclic Condensed Thiophene Systems*, **32**, 127.
- Klinkert, G., see Swinbourne, F. J., **23**, 103.
- Knabe, J., *1,2-Dihydroisoquinolines and Related Compounds*, **40**, 105.
- Kobayashi, Y., Kumadaki, I., *Dewar Heterocycles and Related Compounds*, **31**, 169.
- Koblik, A. V., see Balaban, A. T., **S2**.
- Kobylecki, R. J., McKillop, A., *1,2,3-Triazines*, **19**, 215.
- Kochetkov, N. K., Likhoshervostov, A. M., *Advances in Pyrrolizidine Chemistry*, **5**, 315.
- Kochetkov, N. K., Sokolov, S. D., *Recent Developments in Isoxazole Chemistry*, **2**, 365.
- Kolar, P., see Tišler, M., **64**, 1.
- Kolar, P., Tišler, M., *Recent Advances in the Chemistry of Pyridazines*, **75**, 167.
- Korbonits, D., see Valters, R. E., **64**, 251.
- Korbonits, D., see Valters, R. E., **66**, 1.
- Konhavina, O. B., see Ryabukhin, Y. I., **66**, 131.
- Kost, A. N., Grandberg, I. I., *Progress in Pyrazole Chemistry*, **6**, 347.
- Kostikov, R. R., see Khlebnikov, A. F., **65**, 93.
- Koutecký, J., see Zahradnik, R., **5**, 69.
- Kozhevnikov, D. N., Rusinov, V. L., Chupakhin, O. N., *1,2,4-Triazine N-Oxides*, **82**, 261.
- Kraemer, U., see Flitsch, W., **22**, 321.
- Kress, T. J., see Paudler, W. W., **11**, 123.
- Kricka, L. J., Vernon, J. M., *Nitrogen-Bridged Six-Membered Ring Systems: 7-Azabicyclo-22.1 hepta-2,5-dienes, Naphthalen-1,4-imines, and Anthracen-9,10-imines*, **16**, 87.
- Kruchkovskaya, N. D., see Belen'kii, L. I., **55**, 31.
- Kruchkovskaya, N. D., see Belen'kii, L. I., **71**, 291.
- Kruchkovskaya, N. D., see Belen'kii, L. I., **73**, 295.

- Kruchkovskaya, N. D., see Belen'kii, L. I., **79**, 201.
- Kuhla, D. E., Lombardino, J. G., *Pyrrrolidiazines with a Bridgehead Nitrogen*, **21**, 1.
- Kuhla, D. E., see Lombardino, J. G., **28**, 73.
- Kumadaki, I., see Kobayashi, Y., **31**, 169.
- Kumar, R., Chandra, R., *Stereocontrolled Additions to Dihydropyridines and Tetrahydropyridines: Access to N-Heterocyclic Compounds Related to Natural Products*, **78**, 269.
- Kurzer, F., *1,2,4-Thiadiazoles*, **32**, 285.
- Kuthan, J., *Pyrans, Thiopyrans, and Selenopyrans*, **34**, 145.
- Kuthan, J., Šebek, P., Böhm, S., *Developments to the Chemistry of Thiopyrans, Selenopyrans, and Telluopyrans*, **59**, 179.
- Kuthan, J., Šebek, P., Böhm, S., *New Developments to the Chemistry of Pyrans*, **62**, 19.
- Kuzmenko, V. V., Pozharskii, A. F., *N-Aminoazoles*, **53**, 85.
- Kuznetsov, E. V., Shcherbakova, I. V., Balaban, A. T., *Benzo[c]pyrylium Salts: Syntheses, Reactions, and Physical Properties*, **50**, 157.
- Lagowski, J. M., see Katritzky, A. R., **1**, 311, 339; **2**, 1, 27.
- Lakhan, R., Ternai, B., *Advances in Oxazole Chemistry*, **17**, 99.
- Lalezari, I., Shafiee, A., Yalpani, M., *Selenium-Nitrogen Heterocycles*, **24**, 109.
- Lavender, I., see Rawson, J. M., **62**, 137.
- Li, J. J., see Ahmad, **84**, 1.
- Liebscher, J., see Bohle, M., **65**, 39.
- Liebscher, J., see Granik, V. G., **72**, 79.
- Likhosherstov, A. M., see Kochetkov, N. K., **5**, 315.
- Linda, P., see Cook, M. J., **17**, 255; Elguero, J., **S1**.
- Lindner, E., *Metallacyclo-alkanes and -alkenes*, **39**, 237.
- Lister, J. H., *Current Views on Some Physicochemical Aspects of Purines*, **24**, 215; *Physicochemical Aspects of the Chemistry of Purines*, **6**, 1.
- Litvinov, V. P., Gol'dfarb, Ya. L., *The Chemistry of Thienothiophenes and Related Systems*, **19**, 123.
- Lloyd, D., Cleghorn, H. P., *1,5-Benzodiazepines*, **17**, 27.
- Lloyd, D., Cleghorn, H. P., Marshall, D. R., *2,3-Dihydro-1,4-diazepines*, **17**, 1.
- Lloyd, D., McNab, H., *2,3-Dihydro-1,4-diazepines and 2,3-Dihydro-1,4-diazepinium Salts*, **56**, 1.
- Lloyd, D., McNab, H., *1,5-Benzodiazepines and 1,5-Benzodiazepinium Salts*, **71**, 1.
- Lohray, B. B., Bhushan, V., *1,3,2-Dioxathiolane Oxides: Epoxide Equivalents and Versatile Synthons*, **68**, 89.
- Lombardino, J. G., Kuhla, D. E., *1,2- and 2,1-Benzothiazines and Related Compounds*, **28**, 73.
- Lombardino, J. G., see Kuhla, D. E., **21**, 1.
- Lozac'h, N., *1,6,6aS^{IV}-Trithiapentalenes and Related Structures*, **13**, 161.
- Lozac'h, N., Stavaux, M., *The 1,2- and 1,3-Dithiolium Ions*, **27**, 151.
- Lue, P., Greenhill, J. V., *Enaminones in Heterocyclic Synthesis*, **67**, 209.
- Lukyanov, S. M., *1,3-Oxazinium and 3-Azapyrylium Salts*, **64**, 341.
- Lund, H., *Electrolysis of N-Heterocyclic Compounds*, **12**, 213.
- Lund, H., Tabakovic, I., *Electrolysis of N-Heterocyclic Compounds, Part II*, **36**, 235.
- Lüpfert, S., Friedrichsen, W., *Heteropentalenes with a Fused Imidazole or 1,2,4-Triazole Ring and One Bridgehead Nitrogen Atom*, **69**, 271.
- Lyle, R. E., Anderson, P. S., *The Reduction of Nitrogen Heterocycles with Complex Metal Hydrides*, **6**, 45.
- Lythgoe, D. J., Ramsden, C. A., *4-Unsubstituted, 5-Amino and 5-Unsubstituted, 4-Aminoimidazoles*, **61**, 1.
- Mackay, S. P., Meth-Cohn, O., Waigh, R. D., *Synthesis of Quaternary Benzo[c]phenanthridine Alkaloids and Their Analogues*, **67**, 345.
- Madroñero, R., see Johnson, F., **6**, 95.

- Magdesieva, N. N., *Advances in Selenophene Chemistry*, **12**, 1.
- Makarov, V. A., see Granik, V. G., **72**, 283.
- Makhova, N. N., see Sheremetev, A. B., **78**, 65.
- Mamaev, V. P., Shkurko, O. P., Baram, S. G., *Electron Effects of Heteroaromatic and Substituted Heteroaromatic Groups*, **42**, 1.
- Mann, M. E., see White, J. D., **10**, 113.
- Mantsch, H., see Ionescu, M., **8**, 83.
- Maretina, I. A., Trofimov, B. A., *Diacetylene and Its Derivatives in Heterocyclization Reactions*, **82**, 157.
- Marino, G., *Electrophilic Substitutions of Five-Membered Rings*, **13**, 235.
- Marino, G., see Fringuelli, F., **21**, 119.
- Marsais, F., see Quéguiner, G., **52**, 187.
- Marshall, D. R., see Lloyd, D., **17**, 1.
- Marzin, C., see Elguero, J., **S1**.
- Mayer, R., Broy, W., Zahradnik, R., *Monocyclic Sulfur-Containing Pyrones*, **8**, 219.
- McGill, C. K., Rappa, A., *Advances in the Chichibabin Reaction*, **44**, 1.
- McKillop, A., see Kobylecki, R. J., **19**, 215.
- McNab, H., see Lloyd, D., **56**, 1.
- McNab, H., see Lloyd, D., **71**, 1.
- McNaught, A., *The Nomenclature of Heterocycles*, **20**, 175.
- Medio-Simon, M., see Sepúlveda-Arques, J., **63**, 339.
- Merlini, L., *Advances in the Chemistry of Chrom-3-enes*, **18**, 159.
- Meszaros, Z., see Hermecz, I., **33**, 241.
- Meth-Cohn, O., Suschitzky, H., *Heterocycles by Ring-Closure of Ortho-Substituted t-Anilines—The t-Amino Effect*, **14**, 211.
- Meth-Cohn, O., Tarnowski, B., *Cyclizations under Vilsmeier Conditions*, **31**, 207; *Thiocoumarins*, **26**, 115.
- Meth-Cohn, O., *The t-Amino Effect: Heterocycles Formed by Ring Closure of ortho-Substituted t-Anilines*, **65**, 1.
- Meth-Cohn, O., see Mackay, S. P., **67**, 345.
- Mezheritskii, V. V., Tkachenko, V. V., *Synthesis of Peri-Annulated Heterocyclic Systems*, **51**, 1.
- Mezheritskii, V. V., see Balaban, A. T., **S2**.
- Milata, V., *Tricyclic Azoloquinolines*, **78**, 189.
- Minisci, F., Porta, O., *Advances in Homolytic Substitution of Heteroaromatic Compounds*, **16**, 123.
- Minkin, V. I., see Simkin, B. Ya., **56**, 303; see Sadekov, I. D., **58**, 47; **63**, 1; **79**, 1.
- Minkin, V. I., Garnovskii, A. D., Elguero, J., Katritzky, A. R., Denisko, O., *Tautomerism of Heterocycles: Five-Membered Rings with Two or More Heteroatoms*, **76**, 159.
- Moeckel, K., see Hetzheim, A., **7**, 183.
- Mokrosz, J. L., see Bojarski, J. T., **38**, 229.
- Monforte, A. M., see Chimirri, A., **63**, 61.
- Moody, C. J., *Azodicarbonyl Compounds in Heterocyclic Synthesis*, **30**, 1; *Claisen Rearrangements in Heteroaromatic Systems*, **42**, 203.
- Moreno-Mañas, M., Pleixats, R., *Dehydroacetic Acid, Triacetic acid Lactone, and Related Pyrones*, **53**, 1.
- Moreno-Mañas, M., Pleixats, R., *Palladium (0)-Catalyzed Allylation of Ambident Nucleophilic Aromatic Heterocycles*, **66**, 73.
- Morgaan, A. E. A., see Shaban, M. A. E., **73**, 131.
- Morgaan, A. E. A., see Shaban, M. A. E., **75**, 243.
- Morgaan, Ali E. A. see Shaban, M. E. A., **77**, 345.
- Moriarty, R. M., Prakash, O., *Synthesis of Heterocyclic Compounds Using Organohypervalent Iodine Reagents*, **69**, 1.
- Mousaad, A., see El Ashry, E. S. H., **53**, 233.
- Mousaad, A., see El Ashry, E. S. H., **61**, 207.
- Moynahan, E. B., see Popp, F. D., **13**, 1.
- Munawar, M. A., see Groundwater, P. W., **70**, 89.
- Nagao, Y., see Fujita, E., **45**, 1.
- Nair, M. D., see Rajappa, S., **25**, 113.
- Nakayama, J., Ishii, A., *Chemistry of Dithiiranes, 1,2-Dithietanes, and 1,2-Dithietes*, **77**, 221.
- Nasr, A. Z., see Shaban, M. A. E., **49**, 277; see Shaban, M. A. E., **68**, 225.
- Natekar, M. V., see Rajappa, S., **57**, 187.

- Nayak, A., see Newkome, G. R., **25**, 83.
 Newcomb, M., see Esker, J. L., **58**, 1.
 Newkome, G. R., Nayak, A.,
4-Thiazolidinones, **25**, 1.
 Nikonov, G. N., see Arbuzov, B. A., **61**, 59.
 Novikov, M. S., see Khlebnikov, A. F., **65**, 93.
 Norman, R. O. C., Radda, G. K., *Free-Radical Substitution of Heteroaromatic Compounds*, **2**, 131.
 North, S. A., see Bonnett, R., **29**, 341.
 Nyerges, M., see Groundwater, P. W., **73**, 97.
 Oae, S., Furukawa, N., *Heteroaromatic Sulfoxides and Sulfones: Ligand Exchange and Coupling in Sulfuranes and Ipso-Substitutions*, **48**, 1.
 O'Brien, C., see Elvidge, J. A., **16**, 1.
 Ochoa, C., see Arán, V. J., **44**, 81.
 O'Connor, S., see Comins, D. L., **44**, 199.
 Ohkata, K., Akiba, K.-A., *Cycloadditions and Reactions of Oxa-Aromatics with Nucleophiles*, **65**, 283.
 Ollis, W. D., Ramsden, C. A., *Meso-ionic Compounds*, **19**, 1.
 Paluchowska, M. H., see Bojarski, J. T., **38**, 229.
 Paré, J. R. J., see Jankowski, K., **39**, 79.
 Paré, J. R. J., Jankowski, K., ApSimon, J. W., *Mass Spectral Techniques in Heterocyclic Chemistry: Applications and Stereochemical Considerations in Carbohydrates and Other Oxygen Heterocycles*, **42**, 335.
 Párkányi, C., see Granik, V. G., **72**, 283.
 Patel, A. V., see Crabb, T. A., **49**, 193.
 Paudler, W. W., Kress, T. J., *The Naphthyridines*, **11**, 123.
 Paudler, W. W., Sheets, R. M., *Recent Developments in Naphthyridine Chemistry*, **33**, 147.
 Pedersen, C., see Jensen, K. A., **3**, 263.
 Pedersen, C. Th., *1,2-Dithiole-3-thiones and 1,2-Dithiol-3-ones*, **31**, 63.
 Perlmutter, H. D., *1,4-Diazocines*, **45**, 185;
1,5-Diazocines, **46**, 1; *1,2-Diazocines*,
1,3-Diazocines, *Triazocines*, and
Tetrazocines, **50**, 1.
 Perlmutter, H. D., Trattner, R. B., *Azocines*,
31, 115.
 Perrin, D. D., *Covalent Hydration in Nitrogen Heteroaromatic Compounds. II Quantitative Aspects*, **4**, 43.
 Pevzner, M. S., *Aromatic N-Halozoles*, **75**, 1.
 Pihlaja, K., see Fülöp, F., **69**, 349.
 Pilidis, G., see Varvounis, G., **80**, 73.
 Plas, H. van der, see Woźniak, M., **77**, 285.
 Plas, H. van der, *Pyrimidine-pyridine Ring Interconversion*, **84**, 31.
 Pleixats, R., see Moreno-Mañas, M., **53**, 1;
 see Moreno-Mañas, M., **66**, 73.
 Pliml, J., Prystaš, M., *The Hilbert-Johnson Reaction of 2,4-Dialkoxy-pyrimidines with Halogenoses*, **8**, 115.
 Pliml, J., see Ferles, M., **12**, 43.
 Popp, F. D., *Developments in the Chemistry of Reissert Compounds, 1968-1978*, **24**,
 187; *Reissert Compounds*, **9**, 1; *The Chemistry of Isatin*, **18**, 1.
 Popp, F. D., Catala Noble, A., *The Chemistry of Diazepines*, **8**, 21.
 Popp, F. D., Moynahan, E. B., *Heterocyclic Ferrocenes*, **13**, 1.
 Porta, O., see Minisci, F., **16**, 123.
 Porter, A. E. A., *The Chemistry of Thiophenium Salts and Thiophenium Ylids*,
45, 151.
 Pozharskii, A. F., see Kuzmenko, V. V., **53**, 85.
 Prakash, O., see Moriarty, R. M., **69**, 1.
 Preston, P. N., see Davidson, J. L., **30**, 321.
 Prinzbach, H., Futterer, E., *The 1,2- and 1,3-Dithiolium Ions*, **7**, 39.
 Prystaš, M., see Pliml, J., **8**, 115.
 Pullman, A., Pullman, B., *Electronic Aspects of Purine Tautomerism*, **13**, 77.
 Pullman, B., see Kwiatkowski, J. S., **18**, 199.
 Pujari, H. K., *Condensed 4-Thiazolidinones*,
49, 1.
 Quéguiner, G., Marsais, F., Snieckus, V.,
 Epszajn, J., *Directed Metalation of π -Deficient Azaaromatics: Strategies of Functionalization of Pyridines, Quinolines, and Diazines*, **52**, 187.
 Quiniou, H., Guilloton, O., *1,3-Thiazines*,
50, 85.
 Radda, G. K., see Norman, R. O. C., **2**, 131.
 Rademacher, P., *Fragmentations of Five-Membered Rings*, **72**, 361.

- Rádl, S., *Mono- and Diazaquinones*, **61**, 141.
Rádl, S., *1,2,4-Triazoline-3,5-Diones*, **66**, 119.
Rádl, S., *Aromatic Nucleophilic Denitrocyclization Reactions*, **83**, 189.
Rajappa, S., Nair, M. D., *Ring Synthesis of Heteroaromatic Nitro Compounds*, **25**, 113.
Rajappa, S., Natekar, M. V., *Piperazine-2,5-diones and Related Lactim Ethers*, **57**, 187.
Ramadan, E., see El Ashry, E. S. H., **59**, 39.
Ramadan, E., see El Ashry, E. S. H., **61**, 207.
Ramsden, C. A., *Heterocyclic Betaine Derivatives of Alternant Hydrocarbons*, **26**, 1.
Ramsden, C. A., see Ollis, W. D., **19**, 1.
Ramsden, C. A., see Lythgoe, D. J., **61**, 1.
Rao, Y. S., see Filler, R., **21**, 175.
Rappa, A., see McGill, C. K., **44**, 1.
Rashed, N., see El Ashry, E. S. H., **53**, 233; **59**, 39.
Rashed, N., see El Ashry, E. S. H., **61**, 207.
Rashed, N., see El Ashry, E. S. H., **71**, 57.
Rashed, N., see El Ashry, E. S. H., **72**, 127.
Rashed, N., see El Ashry, E. S. H., **75**, 79.
Rauhut, G., *Recent Advances in Computing Heteroatom-Rich Five- and Six-Membered Ring Systems*, **81**, 1.
Rawson, J. M., Banister, A. J., Lavender, I., *The Chemistry of Dithiadiazolium and Dithiadiazolyl Rings*, **62**, 137.
Rees, C. W., Smithen, C. E., *The Reactions of Heterocyclic Compounds with Carbenes*, **3**, 57.
Reid, S. T., *The Photochemistry of Heterocycles*, **11**, 1; *The Photochemistry of Oxygen- and Sulfur-Containing Heterocycles*, **33**, 1; *Photochemistry of Nitrogen-Containing Heterocycles*, **30**, 239.
Reinhoudt, D. N., *(2+2)-Cycloaddition and (2+2)-Cycloreversion Reactions of Heterocyclic Compounds*, **21**, 253.
Rewcastle, G. W., Katritzky, A. R., *Generation and Reactions of sp^2 -Carbanionic Centers in the Vicinity of Heterocyclic Nitrogen Atoms*, **56**, 155.
Richardt, G., see Wamhoff, H., **64**, 159.
Ried, W., Heinz, B., *Four-Membered Rings Containing One Sulfur Atom*, **35**, 199.
Robins, D. J., *Advances in Pyrrolizidine Chemistry*, **24**, 247.
Roussel, C., see Gallo, R., **43**, 173.
Ruccia, M., Vivona, N., Spinelli, D., *Mononuclear Heterocyclic Rearrangements*, **29**, 141.
Rusinov, V. L., see Kozhevnikov, D. N., **82**, 261.
Ryabukhin, Y. I., Korzhavina, O. B., Suzdalev, K. F., *Chemistry of 1,3-Thiazin-4-ones and Their Derivatives*, **66**, 131.
Sadek, K. U., see Elnagdi, M. H., **48**, 223.
Sadekov, I. D., Minkin, V. I., *Tellurium-containing Heterocycles with Two Heteroatoms*, **58**, 47.
Sadekov, I. D., Minkin, V. I., *Six-Membered Heterocycles with a Tellurium Atom*, **63**, 1.
Sadekov, I. D., Minkin, V. I., *Tellurium-Nitrogen-Containing Heterocycles*, **79**, 1.
Sadimenko, A. P., see Garnovskii, A. D., **72**, 1.
Sadiminko, A. P., *Organometallic Compounds of Furan, Thiophene, and Their Benzannulated Derivatives*, **78**, 1.
Sadimenko, A. P., *Organometallic Compounds of Pyrrole, Indole, Carbazole, Phospholes, Siloles, and Boroles*, **79**, 115.
Sadimenko, A. P., *Organometallic Complexes of Pyrazoles*, **80**, 157.
Sadimenko, A. P., *Organometallic Complexes of Pyrazolylborates and Related Ligands*, **81**, 167.
Sadimenko, A. P., *Organometallic Complexes of Polyheteroatom Azoles Other than Pyrazole*, **83**, 117.
Sadimenko, A. P., *Organometallic Compounds of Chalcogenoazoles and Their Benzannulated Derivatives*, **84**, 91.
Sadimenko, A. P., *Organometallic Complexes of Boron, Silicon, and Phosphorus Analogues of Azoles*, **85**, 1.
Saha, J. G., see Abramovitch, R. A., **6**, 229.
Sammes, M. P., Katritzky, A. R., *The 2H-Imidazoles*, **35**, 375; *The 4H-Imidazoles*, **35**, 413; *The 3H-Pyrazoles*, **34**, 1; *The 4H-Pyrazoles*, **34**, 53; *The 2H- and 3H-Pyrroles*, **32**, 233.

- Sandström, J., *Recent Advances in the Chemistry of 1,3,4-Thiadiazoles*, **9**, 165.
- Sargent, C. R., see Chambers, R. D., **28**, 1.
- Sargent, M. V., Stransky, P. O., *Dibenzofurans*, **35**, 1.
- Sasaki, T., *Heteroadamantanes*, **30**, 79.
- Sasse, W. H. F., see Badger, G. M., **2**, 179.
- Savage, G. P., see Easton, C. J., **60**, 261.
- Scheibe, G., Daltrozzo, E., *Diquinolymethane and Its Analogs*, **7**, 153.
- Schenetti, L., see Benassi, R., **41**, 75.
- Schmidt, A., *Heterocyclic Mesomeric Betaines and Analogues in Natural Chemistry. Betainic Alkaloids and Nucleobases*, **85**, 67.
- Schmitz, E., *Three-Membered Rings with Two Hetero Atoms*, **2**, 83; **24**, 63.
- Schneller, S. W., *Thiochromanones and Related Compounds*, **18**, 59.
- Schroth, W., see Balaban, A. T., **10**, 241; **S2**.
- Schulz, M., Kirschke, K., *Cyclic Peroxides*, **8**, 165.
- Scrowston, R. M., *Recent Advances in the Chemistry of Benzof[b]thiophenes*, **29**, 171.
- Scrowston, R. M., see Iddon, B., **11**, 177.
- Šebek, P., see Kuthan, J., **59**, 179.
- Šebek, P., see Kuthan, J., **62**, 19.
- Senning, A., see Hashem, A., **73**, 275.
- Sepúlveda-Arques, J., Abarca-Gonzalez, B., Medio-Simon, M., *Cycloaddition Reactions with Vinyl Heterocycles*, **63**, 339.
- Shaban, M. A. E., Nasr, A. Z., *Synthesis of Condensed 1,2,4-Triazolo[3,4-x] Heterocycles*, **49**, 277.
- Shaban, M. A. E., Taha, M. A. M., Sharshira, E. M., *Synthesis and Biological Activities of Condensed Heterocyclic [n,m-a, b, or c]quinazolines*, **52**, 1.
- Shaban, M. A. E., Nasr, A. Z., *The Chemistry of C-Nucleosides and Their Analogs I: C-Nucleosides of Hetero Monocyclic Bases*, **68**, 225.
- Shaban, M. A. E., *The Chemistry of C-Nucleosides and Their Analogs II: C-Nucleosides of Condensed Heterocyclic Bases*, **70**, 163.
- Shaban, M. A. E., Morgaan, A. E. A., *The Chemistry of 1,2,4-Triazolopyrimidines I: 1,2,4-Triazolo[4,3-a]Pyrimidines*, **73**, 131.
- Shaban, M. A. E., Morgaan, A. E. A., *The Chemistry of 1,2,4-Triazolopyrimidines II: 1,2,4-Triazolo[4,3-c]Pyrimidines*, **75**, 243.
- Shaban, M. A. E., Morgaan, Ali E. A., *Chemistry of 1,2,4-Triazolopyrimidines III: 1,2,4-Triazolo[1,5-c]Pyrimidines*, **77**, 345.
- Shafiee, A., see Lalezari, I., **24**, 109.
- Sharshira, E. M., see Shaban, M. A. E., **52**, 1.
- Shawali, A. S., Abdallah, M. A., *The Chemistry of Heterocyclic Hydrazonoyl Halides*, **63**, 277.
- Shcherbakova, I. V., see Kuznetsov, E. V., **50**, 157.
- Shcherbakova, I., Elguero, J., Katritzky, A. R., *Tautomerism of Heterocycles: Condensed Five-Six, Five-Five, and Six-Six Ring Systems with Heteroatoms in Both Rings*, **77**, 51.
- Shepherd, R. G., Fedrick, J. L., *Reactivity of Azine, Benzoazine, and Azinoazine Derivatives with Simple Nucleophiles*, **4**, 145.
- Sheppard, H. C., see Elvidge, J. A., **16**, 1.
- Sheremetev, A. B., Makhova, N. N., Friedrichsen, W., *Monocyclic Furazans and Furoxans*, **78**, 65.
- Shirwaiker, G. S., Bhatt, M. V., *Chemistry of Arene Oxides*, **37**, 67.
- Shkurko, O. P., see Mamaev, V. P., **42**, 1.
- Siegrist, A. E., see Fletcher, I. J., **23**, 171.
- Silberg, I., see Bodea, C., **9**, 321.
- Silvester, M. J., *Recent Advances in Fluoroheterocyclic Chemistry*, **59**, 1.
- Simkin, B. Ya., Minkin, V. I., Glukhovtsev, M. N., *The Concept of Aromaticity in Heterocyclic Chemistry*, **56**, 303.
- Simpson, G. P., see Easton, C. J., **60**, 261.
- Slack, R., Wooldridge, K. R. H., *Isothiazoles*, **4**, 107.
- Sliskovic, D. R., see Jones, G., **34**, 79.
- Smalley, R. K., *The Chemistry of Indoxazenes and Anthranils, 1966-1979*, **29**, 1.
- Smith, G. F., *The Acid-Catalyzed Polymerization of Pyrroles and Indoles*, **2**, 287.
- Smithen, C. E., see Rees, C. W., **3**, 57.

- Snieckus, V., see Quéguiner, G., **52**, 187.
- Somei, M., *Recent Advances in the Chemistry of 1-Hydroxyindoles, 1-Hydroxytryptophans, and 1-Hydroxytryptamines*, **82**, 101.
- Spenser, I. D., see Abramovitch, R. A., **3**, 79.
- Speranza, M., *The Reactivity of Heteroaromatic Compounds in the Gas Phase*, **40**, 25.
- Spinelli, D., see Ruccia, M., **29**, 141.
- Spiteller, G., *Mass Spectrometry of Heterocyclic Compounds*, **7**, 301.
- Stadlbauer, W., see Kappe, T., **28**, 127.
- Stanovnik, B., see Kadaba, P. K., **37**, 217; Tišler, M., **9**, 211; **24**, 363; **49**, 385.
- Stanovnik, B., Tišler, M., Katritzky, A. R., Denisko, O. V., *The Tautomerism of Heterocycles, Six-Membered Heterocycles: Part 1, Annular Tautomerism*, **81**, 253.
- Stavaux, M., see Lozac'h, N., **27**, 151.
- Steel, P. J., *Aromatic Biheterocycles: Syntheses, Structures, and Properties*, **67**, 1.
- Stegel, F., see Illuminati, G., **34**, 305.
- Strekowski, L., Kiselyov, A. S., *N-Fluoropyridinium Salts*, **62**, 1.
- Stölben, S., see Wamhoff, H., **64**, 159.
- Stoodley, R. J., *1,4-Thiazines and Their Dihydro Derivatives*, **24**, 293.
- Stransky, P. O., see Sargent, M. V., **35**, 1.
- Summers, A. J. H., see Elguero, J., **22**, 183.
- Summers, L. A., *The Bipyridines*, **35**, 281; *The Phenanthrolines*, **22**, 1.
- Suschitzky, H., see Meth-Cohn, O., **14**, 211.
- Suzdalev, K. F., see Ryabukhin, Y. I., **66**, 131.
- Swinbourne, F. J., Hunt, J. H., Klinkert, G., *Advances in Indolizine Chemistry*, **23**, 103.
- Tabakovic, I., see Lund, H., **36**, 235.
- Taddei, F., see Benassi, R., **41**, 75.
- Taha, M., see El Ashry, E. S. H., **59**, 39.
- Taha, M. A. M., see Shaban, M. A. E., **52**, 1.
- Takeuchi, Y., Furusaki, F., *The Chemistry of Isoxazolidines*, **21**, 207.
- Tamura, Y., Ikeda, M., *Advances in the Chemistry of Heteroaromatic N-Imines and N-Aminoazonium Salts*, **29**, 71.
- Tarnowski, B., see Meth-Cohn, O., **26**, 115; **31**, 207.
- Taticchi, A., see Fringuelli, F., **21**, 119.
- Taylor, R., see Katritzky, A. R., **47**, 1.
- Tedder, J. M., *Heterocyclic Diazo Compounds*, **8**, 1.
- Terashima, M., Ishikura, M., *Boron-substituted Heteroaromatic Compounds*, **46**, 143.
- Ternai, B., see Lakhan, R., **17**, 99.
- Thomas, A. W., see Aitken, A. R., **79**, 89.
- Thyagarajan, B. S., *Aromatic Quinolizines*, **5**, 291; *Claisen Rearrangements in Nitrogen Heterocyclic Systems*, **8**, 143.
- Timpe, H. J., *Heteroaromatic N-Imines*, **17**, 213.
- Timpe, H. J., El'tsov, A. V., *Pseudoazulenes*, **33**, 185.
- Tišler, M., *Heterocyclic Quinones*, **45**, 37.
- Tišler, M., see Kadaba, P. K., **37**, 217.
- Tišler, M., Stanovnik, B., *Pyridazines*, **9**, 211; *Recent Advances in Pyridazine Chemistry*, **24**, 363; *Advances in Pyridazine Chemistry*, **49**, 385.
- Tišler, M., Kolar, P., *Amino Acids as Synthons for Heterocyclic Compounds*, **64**, 1.
- Tišler, M., see Kolar, P., **75**, 167.
- Tišler, M., see Stanovnik, B., **81**, 253.
- Tissington, P., see Keene, B. R. T., **13**, 315.
- Tkachenko, V. V., see Mezheritskii, V. V., **51**, 1.
- Tomas, M., see Barluenga, J., **57**, 1.
- Tomasik, P., Johnson, C. D., *Applications of the Hammett Equation to Heterocyclic Compounds*, **20**, 1.
- Toomey, J. E., Jr., *Synthesis of Pyridines by Electrochemical Methods*, **37**, 167.
- Trattner, R. B., see Perlmutter, H. D., **31**, 115.
- Traulsen, T., see Friedrichsen, W., **76**, 85.
- Tretyakov, E. V., see Vasilevsky, S. F., **82**, 1.
- Trofimov, B. A., *Preparations of Pyrroles from Ketoximes and Acetylenes*, **51**, 177.
- Trofimov, B. A., see Maretina, I. A., **82**, 157.
- Tsuge, O., Kanemasa, S., *Recent Advances in Azomethine Ylide Chemistry*, **45**, 231.
- Ugi, I., *Pentazoles*, **3**, 373.
- Umemoto, T., *S-, Se-, and Te-(Perfluoroalkyl)dibenzothiophenium, -selenophenium, and -tellurophenium Salts*, **64**, 323.

- Undheim, K., Benneche, T., *Organometallics in Coupling Reactions in π -Deficient Azaheterocycles*, **62**, 305.
- Urbański, T., see Eckstein, Z., **2**, 311; **23**, 1.
- Valters, R. E., Fülöp, F., Korbonits, D., *Recent Developments in Ring-Chain Tautomerism I. Intramolecular Reversible Addition Reaction of the C=O Group*, **64**, 251.
- Valters, R. E., Fülöp, F., Korbonits, D., *Recent Developments in Ring-Chain Tautomerism II. Intramolecular Reversible Addition Reactions to the C=N, C \equiv N, and C \equiv C Groups*, **66**, 1.
- Varvounis, G., Fiamegos, Y., Pilidis, G., *Pyrazol-3-ones Part 1: Synthesis and Applications*, **80**, 73.
- Vasilevsky, S. F., Tretyakov, E. V., Elguero, J., *Synthesis and Properties of Acetylenic Derivatives of Pyrazoles*, **82**, 1.
- Wahlström, N., see Bergman, J., **80**, 1.
- Waigh, R. D., see Mackay, S. P., **67**, 345.
- Wakefield, B. J., Wright, D. J., *Isoxazole Chemistry since 1963*, **25**, 147.
- Wakefield, B. J., see Abu-Shanab, F. A., **68**, 181.
- Wamhoff, H., *Heterocyclic β -Enamino Esters, Versatile Synthons in Heterocyclic Synthesis*, **38**, 299.
- Wamhoff, H., Dzenis, J., Hirota, K., *Uracils: Versatile Starting Materials in Heterocyclic Synthesis*, **55**, 129.
- Wamhoff, H., Richardt, G., Stölben, S., *Iminophosphoranes: Versatile Tools in Heterocyclic Synthesis*, **64**, 159.
- Weber, H., *Oxidative Transformations of Heteroaromatic Iminium Salts*, **41**, 275.
- Weeds, S. M., see Katritzky, A. R., **7**, 225.
- Weinstock, L. M., Pollak, P. I., *The 1,2,5-Thiadiazoles*, **9**, 107.
- Weis, A. L., *Recent Advances in the Chemistry of Dihydroazines*, **38**, 1.
- Wentrup, C., *Carbenes and Nitrenes in Heterocyclic Chemistry: Intramolecular Reactions*, **28**, 231.
- Wermann, K., see Anders, E., **77**, 183.
- Werstiuk, E. S. G., see Cheeseman, G. W. H., **14**, 99; **22**, 367.
- White, J. D., Mann, M. E., *Isoindoles*, **10**, 113.
- Wightman, R. H., see Jankowski, K., **39**, 79.
- Willette, R. E., *Monoazaindoles: The Pyrrolopyridines*, **9**, 27.
- Woods, T. S., see Griffin, T. S., **18**, 99.
- Wooldridge, K. R. H., *Recent Advances in the Chemistry of Mononuclear Isothiazoles*, **14**, 1.
- Wooldridge, K. R. H., see Slack, R., **4**, 107.
- Wozniak, M., see van der Plas, H. C., **33**, 95.
- Wozniak, M., Plas, H. van der, *Chemistry of Nitronaphthyridines*, **77**, 285.
- Wright, D. J., see Wakefield, B. J., **25**, 147.
- Wucherpennig, U., see Burger, K., **60**, 1.
- Wünsch, K. H., Boulton, A. J., *Indoxazenes and Anthranils*, **8**, 277.
- Yakhontov, L. N., *Quinuclidine Chemistry*, **11**, 473.
- Yalpani, M., see Lalezari, I., **24**, 109.
- Zahradnik, R., *Electronic Structure of Heterocyclic Sulfur Compounds*, **5**, 1.
- Zahradnik, R., Koutecký, J., *Theoretical Studies of Physico-chemical Properties and Reactivity of Azines*, **5**, 69.
- Zahradnik, R., see Mayer, R., **8**, 219.
- Zoltewicz, J. A., Deady, L. W., *Quaternization of Heteroaromatic Compounds: Quantitative Aspects*, **22**, 71.
- Zappalà, M., see Chimirri, A., **63**, 61.

Cumulative Index of Titles, Volumes 1–85

A

- Acetylenecarboxylic acids and esters, reactions with *N*-heterocyclic compounds, **1**, 125
- Acetylenecarboxylic esters, reactions with nitrogen-containing heterocycles, **23**, 263
- Acetylenic derivatives of pyrazoles, synthesis and properties of, **82**, 1
- Acetylenic esters, synthesis of heterocycles through nucleophilic additions to, **19**, 297
- Acid-catalyzed polymerization of pyrroles and indoles, **2**, 287
- Acidity of azoles, basicity and, **41**, 187
- Acridines, heterocycle-fused, **70**, 89
- Acyl groups in heterocyclic compounds, conformations of, **41**, 75
- Acyclonucleosides, *seco*-nucleosides, **67**, 391
diseco-nucleosides, **68**, 1
tri-, tetra-, and penta-*seco*-nucleosides, **69**, 129
- Advances
in amination of nitrogen heterocycles, **49**, 117
in the Chichibabin reaction, **44**, 1
in chrom-3-ene chemistry, **18**, 159
in heterocyclic chemistry, prospect and retrospect, **40**, 1
in homolytic substitution of heteroaromatic compounds, **16**, 123
in imidazole chemistry, **12**, 103; **27**, 241
in indolizine chemistry, **23**, 103
in oxazole chemistry, **17**, 99
in pyridazine chemistry, **49**, 385
in pyrrolizidine chemistry, **5**, 315; **24**, 247
in selenophene chemistry, **12**, 1
in tetramic acid chemistry, **57**, 139
- Amination of nitrogen heterocycles, advances in, **49**, 117
- Amino acids as synthons for heterocyclic compounds, **64**, 1
- t*-Amino effect, **14**, 211, 65, 1
- N*-Aminoazoles, **53**, 85
- N*-Aminoazonium salts, *N*-imines and, **29**, 71
- Aminochromes, **5**, 205
- Aminomethylenemalonates and their use in heterocyclic synthesis, **54**
- Aminoimidazoles, **61**, 1
- 4-Amino-1,2,3-triazoles, **40**, 129
- Anils, olefin synthesis with, **23**, 171
- Anionic σ -adducts of heterocycles, **34**, 305
- Anions, ring-opening of five-membered heteroaromatic, **41**, 41
- Annelated 1,5-benzothiazepines, **63**, 61
- Annelation of a pyrimidine ring to an existing ring, **32**, 1
- Annular nitrogens of azines with electrophiles, reactions of, **43**, 127
- Annulenes, *N*-bridged, cyclazines and, **22**, 321
- Anthracen-1,4-imines, **16**, 87
- Anthranils, **8**, 277; **29**, 1
- Applications
of the Hammett equation to heterocyclic compounds, **3**, 209; **20**, 1
of mass spectral techniques and stereochemical considerations in carbohydrates and other oxygen heterocycles, **42**, 335
of NMR spectroscopy to indole and its derivatives, **15**, 277
of phase-transfer catalysis to heterocyclic chemistry, **36**, 175
- Arene oxides, chemistry of, **37**, 67
- Aromatic azapentalenes, **22**, 183
- Aromatic biheterocycles, **67**, 1
- Aromatic nitrogen cations, polycyclic, **55**, 261
- Aromatic nucleophilic denitrocyclization reactions, **83**, 189
- Aromatic quinolizines, **5**, 291; **31**, 1
- Aromatic six-membered nitrogen heterocycles, regioselective substitution in, **44**, 199
- Aromaticity
concept of in heterocyclic chemistry, **56**, 303
of heterocycles, **17**, 255

Aza analogs of pyrimidine and purine bases, **1**, 189
4-Azaazulenes, chemistry of, **43**, 35
7-Azabicyclo[2.2.1]hepta-2,5-dienes, **16**, 87
1-Azabicyclo[3.1.0]hexanes and analogs with further heteroatom substitution, **27**, 1
Azadienes, synthesis of heterocycles from, **57**, 1
Azapentalenes, aromatic, chemistry of, **22**, 183
Azaphosphorines, chemistry of, **43**, 1
8-Azapurines, chemistry of, **39**, 117
Azines
 reactions of annular nitrogens of, with electrophiles, **43**, 127
 reactivity with nucleophiles, **4**, 145
 theoretical studies of, physicochemical properties and reactivity of, **5**, 69
Azinoazines, reactivity with nucleophiles, **4**, 145
Aziridine intermediates, synthesis of natural products via, **39**, 181
1-Azirines, synthesis and reactions of, **13**, 45
Azocines, **31**, 115
Azodicarbonyl compounds in heterocyclic synthesis, **30**, 1
Azoles, basicity and acidity of, **41**, 187
Azomethine ylide chemistry, recent advances in, **45**, 231

B

Barbituric acid, recent progress in chemistry of, **38**, 229
Base-catalyzed hydrogen exchange, **16**, 1
Basicity and acidity of azoles, **41**, 187
Behavior of monocyclic 1,2,4-triazines in reactions with C-, N-, O-, and S-nucleophiles, **46**, 73
1-, 2-, and 3-Benzazepines, **17**, 45
Benzisothiazoles, **14**, 43; **38**, 105
Benzisoxazoles, **8**, 277; **29**, 1
Benzoazines, reactivity with nucleophiles, **4**, 145
Benzo[c]cinnolines, **24**, 151
1,5-Benzodiazepines, **17**, 27
1,5-Benzodiazepines and
 1,5-benzodiazepinium salts, **71**, 1

Benzo[b]furan and derivatives, recent advances in chemistry of, Part 1, occurrence and synthesis, **18**, 337
Benzo[c]furans, **26**, 135
 recent advances in the chemistry of, and related compounds, **73**, 1
Benzofuroxans, **10**, 1; **29**, 251
2*H*-1-Benzopyrans (chrom-3-enes), **18**, 159
Benzo[c] pyrylium salts: syntheses, reactions, and physical properties, **50**, 157
1,2-and 2,1-Benzothiazines and related compounds, **28**, 73
1,4-Benzothiazines and related compounds, **38**, 135
Benzo[b]thiophene chemistry, recent advances in, **11**, 177; **29**, 171
Benzo[c]thiophenes, **14**, 331
1,2,3-Benzotriazines, **19**, 215
Benzynes, reactions with heterocyclic compounds, **28**, 183
Betaines, heterocyclic derivatives of alternant hydrocarbons, **26**, 1
 pyridinium and imidazolium azolate inner salts, **60**, 197
Betainic alkaloids and nucleobases, **85**, 67
Bicyclic 6/5 ring-fused systems with bridgehead nitrogen, **49**, 193
Bifunctional nucleophiles: cyclizations and ring transformations on reaction of azines with, **43**, 301
Biological pyrimidines, tautomerism and electronic structure of, **18**, 199
Bipyridines, **35**, 281
Boron-substituted heteroaromatic compounds, **46**, 143
Bridgehead nitrogen
 saturated bicyclic 6/5 ring-fused systems with, **49**, 193
 Tricyclic compounds with a central pyrimidine ring and, **39**, 281

C

sp²-Carbanionic centers in the vicinity of heterocyclic nitrogen atoms, generation and reactions, **56**, 155
9*H*-Carbazoles, recent advances in, **35**, 83
Carbazoles, 9-hydroxy-, **51**, 168

- Carbenes
and nitrenes, intramolecular reactions, **28**, 231
reactions with heterocyclic compounds, **3**, 57
- Carbohydrates and other oxygen
heterocycles, applications of mass
spectral techniques and stereochemical
considerations in, **42**, 335
- Carbolines, **3**, 79
- Cationic polar cycloaddition, **16**, 289 (19, xi)
- Cations, polycyclic aromatic nitrogen, **55**, 261
- Chalcogen heterocyclic chemistry, some
recent developments in, **71**, 115
- Chemistry
and rearrangements of
1,2-dihydroisoquinolines, **40**, 105
of arene oxides, **37**, 67
of aromatic azapentalenes, **22**, 183
of 4-azaazulenes, **43**, 35
of azaphosphorines, **43**, 1
of 8-azapurines, **39**, 117
of azomethine ylides, recent advances in, **45**, 231
of barbituric acid, recent progress in, **38**, 229
of benzo[*b*]furan, Part I, occurrence and
synthesis, **18**, 337
of benzo[*b*]thiophenes, **11**, 177; **29**, 171
of chrom-3-enes, **18**, 159
of C-nucleosides of hetero monocyclic
bases and their analogs, **68**, 225
of C-nucleosides of condensed heterocyclic
bases and their analogs, **70**, 163
of diazabicycloundecene (DBU) and other
pyrimidoazepines, **42**, 83
of diazepines, **8**, 21
of dibenzothiophenes, **16**, 181
of dihydroazines, **38**, 1
of 1,2-dioxetanes, **21**, 437
of dithiiranes, 1,2-dithietanes, and
1,2-dithietes, **77**, 221
of 2(*5H*)-furanones, **81**, 107
of furans, **7**, 377
of hydantoins, **38**, 177
of isatin, **18**, 1
of isoindoles, **29**, 341
of isoxazolidines, **21**, 207
of lactim ethers, **12**, 185
of mononuclear isothiazoles, **14**, 1
of *N*-(1-haloalkyl)heteroarylium salts, **77**, 183
of nitronaphthyridines, **77**, 285
of 4-oxy-and 4-keto-1,2,3,4-tetra-
hydroisoquinolines, **15**, 99
of phenanthridines, **13**, 315
of phenothiazines, **9**, 321
of polycyclic isothiazoles, **38**, 1
of pyrazoles condensed to heteroaromatic
five- and six-membered rings, **48**, 223
of pyrazolopyridines, **36**, 343
of pyrazolopyrimidines, **41**, 319
of pyrido-oxazines, pyrido-thiazines,
pyrido-diazines and their benzologs, **84**,
221; **85**, 175
of pyrido[1,2-*b*][1,2]oxazines, **69**, 89
of pyrido[1,2-*c*][1,3]oxazines, **70**, 1
of pyrido[1,2-*b*]pyridazines, **69**, 89
of pyrido[1,2-*a*]pyrimidines, **33**, 241
of pyrido[1,2-*c*]pyrimidines, **70**, 1
of pyrido[1,2-*b*][1,2]thiazines, **69**, 89
of pyrido[1,2-*c*][1,3]thiazines, **70**, 1
of 1-pyridines, **15**, 197
of pyrrolizines, **37**, 1
of tetrazoles, **21**, 323
of 1,3,4-thiadiazoles, **9**, 165
of thienothiophenes, **19**, 123
of thiophenes, **1**, 1
of thiophenium salts and thiophenium
ylids, **45**, 151
of triazolopyridines, **34**, 79; **83**, 1.
of 1,2,4-triazolopyrimidines III:
1,2,4-triazolo [1,5-*c*] pyrimidines, **77**, 345
of unsaturated nitrogen heterocyclic
compounds containing carbonyl
groups, **58**, 171
- Chichibabin reaction, advances in, **44**, 1
- Chiral induction using heterocycles, **45**, 1
- Chrom-3-ene chemistry, advances in, **18**, 159
- Claisen rearrangements
in heteroaromatic systems, **42**, 203
in nitrogen heterocyclic systems, **8**, 143
- Complex metal hydrides, reduction of
nitrogen heterocycles with, **6**, 45; **39**, 1
- Concept of aromaticity in heterocyclic
chemistry, **56**, 303
- Condensed heterocyclo[*n,m-a, b*,
or *c*]quinazolines, **52**, 1
- Condensed 4-thiazolidinones, **49**, 1

- Condensed thiophene systems, tetra- and pentacyclic, **32**, 127
- Condensed 1,2,4-triazines: I. Fused to heterocycles with three-, four-, and five-membered rings, **59**, 39
- Condensed 1,2,4-triazolo[3,4-*z*] heterocycles, synthesis, **49**, 277
- Conformational equilibria in nitrogen-containing saturated six-membered rings, **36**, 1
- Conformations of acyl groups in heterocyclic compounds, **41**, 75
- Coordinated ligands, reactions of, **58**, 123
- Covalent hydration
in heteroaromatic compounds, **4**, 1, 43
in nitrogen heterocycles, **20**, 117
- Current views on some physicochemical aspects of purines, **24**, 215
- Cyclazines and related N-bridged annulenes, **22**, 321
- Cyclic enamines and imines, **6**, 147
- Cyclic hydroxamic acids, **10**, 199
- Cyclic peroxides, **8**, 165
- Cyclizations
and ring transformations on reaction of azines with bifunctional nucleophiles, **43**, 301
of nitrogen radicals in pyrrolidine synthesis, **58**, 1
under Vilsmeier conditions, **31**, 207
- Cycloaddition reactions
cationic polar, **16**, 289 (**19**, xi)
of nitrile oxides with alkenes, **60**, 261
- (2+2)-Cycloaddition and (2+2)-cycloreversion reactions of heterocyclic compounds, **21**, 253
- D**
- Dehydroacetic acid, triacetic acid lactone, and related pyrones, **53**, 1
- Developments in the chemistry
of furans (1952-1963), **7**, 377
of Reissert compounds (1968-1978), **24**, 187
of thiopyrans, selenopyrans, and telluropyrans, **59**, 179
- Dewar heterocycles and related compounds, **31**, 169
- Diacyetylene and its derivatives in heterocyclization reactions, **82**, 157
- 2,4-Dialkoxypyrimidines, Hilbert-Johnson reaction of, **8**, 115
- Diazabicycloundecene (DBU) and other pyrimidoazepines, chemistry of, **42**, 83
- Diazaquinones, **61**, 59
- Diazepines, chemistry of, **8**, 21
- 1,4-Diazepines, 2,3-dihydro-, **17**, 1; **56**, 1
- Diazines, functionalization by directed metalation, **52**, 187
- Diazirines, diaziridines, **2**, 83; **24**, 63
- Diazoazoles, **48**, 65
- 1,2-Diazocines, 1,3-diazocines, triazocines, and tetrazocines, **50**, 1
- 1,4-Diazocines, **45**, 185
- 1,5-Diazocines, **46**, 1
- Diazo compounds, heterocyclic, **8**, 1
- Diazomethane, reactions with heterocyclic compounds, **2**, 245
- Dibenzofurans, **35**, 1
- Dibenzothiophenes, chemistry of, **16**, 181
- Dihydroazines, recent advances in chemistry of, **38**, 1
- Dihydro-1,4-benzothiazines, and related compounds, **38**, 135
- 2,3-Dihydro-1,4-diazepines, **17**, 1
- 2,3-Dihydro-1,4-diazepines and 2,3-dihydro-1,4-diazepinium salts, **56**, 1
- 1,2-Dihydroisoquinolines and related compounds, **14**, 279; **40**, 105
- 1,3,2-Dioxathiolane oxides, epoxide equivalents and versatile synthons, **68**, 89
- 1,2-Dioxetanes, chemistry of, **21**, 437
- Diquinolylmethane and its analogs, **7**, 153
- Directed metalation of π -deficient azaaromatics: strategies of functionalization of pyridines, quinolines, and diazines, **52**, 187
- gem*-Dithienylalkanes and their derivatives, **32**, 83
- 1,2-Dithiole-3-thiones and 1,2-dithiol-3-ones, **31**, 63
- 1,2- and 1,3-Dithiolium ions, **7**, 39; **27**, 151
- Dithiadiazolylum, **62**, 139
- Dithiadiazolyl rings, **62**, 139

E

- Electrochemical synthesis of
pyridines, **37**, 167
1,7-Electrocyclizations of
 $\alpha,\beta,\gamma,\delta$ -unsaturated 1,3-dipoles, **73**, 97
Electrolysis of *N*-heterocyclic compounds
Part I, **12**, 213
Part II, **36**, 235
Electronic aspects of purine tautomerism,
13, 77
Electronic effects of heteroaromatic and
substituted heteroaromatic groups,
42, 1
Electronic structure
of biological pyrimidines, tautomerism and,
18, 199
of heterocyclic sulfur compounds, **5**, 1
Electrophiles, reactions of annular nitrogens
of azines with, **43**, 127
Electrophilic substitution of heterocycles:
quantitative aspects, **47**
Electrophilic substitutions of five-membered
rings, **13**, 235
Enamines and imines, cyclic, **6**, 147
Enamines as synthons in the synthesis of
heterocycles, **72**, 283
 β -Enamino esters, heterocyclic, as
heterocyclic synthons, **38**, 299
 π -Excessive heteroannulenes, medium-large
and large, **23**, 55

F

- Ferrocenes, heterocyclic, **13**, 1
Five-membered heteroaromatic anions,
ring-opening of, **41**, 41
Five-membered heterocycles, ring
transformations of, **56**, 49
synthesis of amino derivatives of, by
Thrope-Ziegler cyclization, **72**, 79
Five-membered ring fluoro-heterocycles, **60**, 1
Five-membered rings, electrophilic
substitutions of, **13**, 235
fragmentations of **72**, 361
Five- and six-membered rings with two or
more heteroatoms, **81**, 1
Fluoro heterocycles with five-membered
rings, **60**, 1

- Fluoroheterocyclic chemistry, recent
advances in, **59**, 1
Formation of anionic σ -adducts from
heteroaromatic compounds, **34**, 305
Four-membered rings containing one sulfur
atom, **35**, 199
Free radical substitutions of heteroaromatic
compounds, **2**, 131
Furan chemistry, recent advances in, Part I,
30, 167; Part II, **31**, 237
Furans, developments of the chemistry of
(1952-1963), **7**, 377
Furans, dibenzo-, **35**, 1
2,3,4-Furantriones, **53**, 233
2(3*H*)-Furanones, reactions of, **73**, 275
2(5*H*)-Furanones, **81**, 107
Furoxans, **29**, 251
Fused heterocyclo-quinolines containing one
nitrogen atom at ring junction, **84**, 71

G

- Gas phase reactivity of heteroaromatic
compounds, **40**, 25
Generation
of nitrogen radicals and their cyclizations
for the construction of the pyrrolidine
nucleus, **58**, 1
and reactions of sp^2 -carbanionic centers in
the vicinity of heterocyclic nitrogen
atoms, **56**, 155
Grignard reagents, indole, **10**, 43

H

- Halogenation
of heterocycles
five-membered rings, **57**, 291
fused to other aromatic and
heteroaromatic rings, **59**, 245
six- and seven-membered rings, **58**, 271
of heterocyclic compounds, **7**, 1
Hammett equation, applications to
heterocyclic compounds, **3**, 209; **20**, 1
Hetarynes, **4**, 121
Heteroadamantanes, **30**, 79
Heteroannulenes, medium-large and large
 π -excessive, **23**, 55

- Heteroaromatic *N*-aminoazonium salts, **29**, 71
- Heteroaromatic compounds
five- and six-membered, as σ and π ligands, **72**, 1
free-radical substitutions of, **2**, 131
homolytic substitution of, **16**, 123
nitrogen, covalent hydration in, **4**, 1, 43
prototropic tautomerism of, **1**, 311, 339; **2**, 1, 27; **SI**
quaternization of, **22**, 71
reactivity of, in gas phase, **40**, 25
- Heteroaromatic *N*-imines, **17**, 213; **29**, 71
- Heteroaromatic nitro compounds, ring synthesis of, **25**, 113
- Heteroaromatic radicals, Part I, general properties; radicals with Group V ring heteroatoms, **25**, 205; Part II, radicals with Group VI and Groups V and VI ring heteroatoms, **27**, 31
- Heteroaromatic and substituted heteroaromatic groups, electronic effects, **42**, 1
- Heteroaromatic substitution, nucleophilic, **3**, 283
- Heteroaromatic sulfoxides and sulfones: ligand exchange and coupling in sulfuranes and *ipso*-substitutions, **49**, 1
- Heteroaromatic systems, Claisen rearrangements in, **42**, 203
- Heteroaromatics, quantitative analysis of steric effects in, **43**, 173
- Heterocycles
aromaticity of, **17**, 255
chiral induction using, **45**, 1
containing the sulfamide moiety, **44**, 81
contraction of, by sulfur extrusion, **65**, 39
halogenation of, **7**, 1; **57**, 291; **58**, 271; **59**, 245
nomenclature of, **20**, 175
phosphorus, from
 α -hydroxyalkylphosphines and vinylphosphines, **61**, 59
photochemistry of, **11**, 1
quantitative aspects of electrophilic substitution of, **47**
synthesis from azadienes, **57**, 1
by ring closure of ortho-substituted *t*-anilines, **14**, 211, **65**, 1
- Heterocycles, phenyl-substituted, nitration of, **58**, 215
- Heterocyclic betaine derivatives of alternant hydrocarbons, **26**, 1
- Heterocyclic acyl and formyl anion equivalents, **79**, 89
- Heterocyclic betaines: pyridinium (imidazolium) azolate inner salts with several interannular linkages, **60**, 197
- Heterocyclic chemistry
applications of phase-transfer catalysis in **36**, 175
literature of, **7**, 225; **25**, 303; **44**, 269; **55**, 31; **71**, 291; **73**, 295
- Heterocyclic compounds
application of Hammett equation to, **3**, 209; **20**, 1
(2 + 2)-cycloaddition and (2 + 2)-cycloreversion reactions of, **21**, 253
degenerate ring transformations of, **74**
halogenation of, **7**, 1
isotopic hydrogen labeling of, **15**, 137
mass spectrometry of, **7**, 301
quaternization of, **3**, 1; **22**, 71
reactions of, with carbenes, **3**, 57
reactions of diazomethane with, **2**, 245
reactions with benzyne, **28**, 183
- N*-Heterocyclic compounds (*see also* Nitrogen heterocycles)
containing carbonyl groups, chemistry of, **58**, 171
electrolysis of, **12**, 213
photochemistry of, **30**, 239
reaction of acetylenecarboxylic acids and esters with, **1**, 125; **23**, 263
- Heterocyclic diazo compounds, **8**, 1
- Heterocyclic ferrocenes, **13**, 1
- Heterocyclic hydrazoneyl halides, chemistry of, **63**, 277
- Heterocyclic iminium salts, oxidative transformation, **41**, 275
- Heterocyclic mesomeric betaines and analogs in natural product chemistry, **85**, 67
- Heterocyclic oligomers, **15**, 1
- Heterocyclic products, natural, synthesis of by hetero Diels-Alder cycloaddition reactions, **42**, 245
- Heterocyclic pseudobases, **1**, 167; **25**, 1
- Heterocyclic quinones, **45**, 37

Heterocyclic sulphur compounds, electronic structure of, **5**, 1
Heterocyclic synthesis, *see also* Synthesis
azodicarbonyl compounds and,
30, 1
carbines and carbenoids in, **65**, 93
enaminones in, **67**, 209
heterocyclic β -enamino esters and,
38, 299
iminophosphoranes, **64**, 159
involving nitrilium salts and nitriles under acidic conditions, **6**, 95
through nucleophilic additions to acetylenic ester, **19**, 279
sulfur transfer reagents in, **30**, 47
thioureas in, **18**, 99
uses of isatoic anhydrides in, **28**, 73
using aminomethylenemalonates, **54**
using new heterodienophiles,
55, 1
using organohypervalent iodine reagents,
69, 1
uracils in, **55**, 129
Heterocyco-quinoline, four and five membered, **84**, 71
Hetero Diels-Alder cycloaddition reactions, synthesis of natural heterocyclic products by, **42**, 245
Heterodienophiles, new, heterocyclic synthesis using, **55**, 1
Heteropentalenes, **69**, 271
Hilbert-Johnson reaction of
2,4-dialkoxypyrimidines with
halogenoses, **8**, 115
Homolytic substitution of heteroaromatic compounds, **16**, 123
Hydantoin, chemistry of, **38**, 177
Hydrogen cyanide derivatives, synthesis of heterocycles from, **41**, 1
Hydrogen exchange
base-catalyzed, **16**, 1
one-step (labeling) methods, **15**, 137
Hydrogenated porphyrin derivatives:
hydroporphyrins, **43**, 73
Hydroxamic acids, cyclic, **10**, 199
1-Hydroxyindoles, 1-hydroxytryptophans, and 1-hydroxytryptamines,
82, 101
1-Hydroxypyrroles, 1-hydroxyindoles, and 9-hydroxycarbazoles, **51**, 105

I

Imidazole chemistry, advances in, **12**, 103;
27, 241
2*H*-Imidazoles, **35**, 375
4*H*-Imidazoles, **35**, 413
Imidazolium azolate inner salts, **60**, 197
N-Imines, heteroaromatic, **17**, 213;
29, 71
Iminium salts, oxidative transformation of heterocyclic, **41**, 275
Indole Grignard reagents, **10**, 43
Indole(s)
acid-catalyzed polymerization, **2**, 287
and derivatives, application of NMR spectroscopy to, **15**, 277
1-hydroxy-, **51**, 119
Indolizine chemistry, advances in, **23**, 103
Indolones, isatogens and, **22**, 123
Indolocarbazoles, **80**, 1
Indoxazenes, **8**, 277; **29**, 1
Isatin, chemistry of, **18**, 1
Isatogens and indolones, **22**, 123
Isatoic anhydrides, uses in heterocyclic synthesis, **28**, 127
Isoindoles, **10**, 113; **29**, 341
Isoquinolines
1,2-dihydro-, **14**, 279
4-oxy- and 4-keto-1,2,3,4-tetrahydro-,
15, 99
3(2*H*)-Isoquinolinones and their saturated derivatives, **52**, 155
Isothiazoles, **4**, 107
recent advances in the chemistry of monocyclic, **14**, 1
polycyclic, recent advances in chemistry of,
38, 105
Isotopic hydrogen labeling of heterocyclic compounds, one-step methods,
15, 137
Isoxazole chemistry, recent developments in,
2, 365; since 1963; **25**, 147
Isoxazolidines, chemistry of, **21**, 207

L

Lactim ethers, chemistry of, **12**, 185
Ligand exchange and coupling in sulfuranes and *ipso*-substitutions, **48**, 1

Ligands, coordinated, reactions of, **58**, 123
Literature of heterocyclic chemistry, **7**, 225;
25, 303; **44**, 269; **55**, 31; Part VII:
1997-1999, **79**, 201

M

Mass spectral techniques in heterocyclic chemistry: applications and stereochemical considerations in carbohydrates and other oxygen heterocycles, **42**, 335
Mass spectrometry
of heterocyclic compounds, **7**, 301
of nucleic acids, **39**, 79
Medium-large and large π -excessive heteroannulenes, **23**, 55
Meso-ionic compounds, **19**, 1
Metal catalysts, action on pyridines, **2**, 179
Metalation, directed, of pyridines, quinolines, and diazines, **52**, 187
Metallacycloalkanes and -alkenes, **39**, 237
Methylazines, **68**, 181
Methylpyridines, **68**, 181
Monoazaindoles, **9**, 27
Monocyclic pyrroles, oxidation of, **15**, 67
Monocyclic sulfur-containing pyrones, **8**, 219
Monocyclic furazans and furoxens, **78**, 65
Mononuclear heterocyclic rearrangements, **29**, 141
Mononuclear isothiazoles, recent advances in chemistry of, **14**, 1
Monoquinones, **61**, 59

N

Naphthalen-1,4-imines, **16**, 87
Naphthyridines, **11**, 124
reactivity of, toward nitrogen nucleophiles, **33**, 95
recent developments in chemistry of, **33**, 147
Natural heterocyclic products by hetero Diels-Alder cycloaddition reactions, synthesis of, **42**, 245
Natural products, synthesis via aziridine intermediates, **39**, 181

New developments in the chemistry of oxazolones, **21**, 175
N-Fluoropyridinium salts, **62**, 1
Nitration of phenyl-substituted heterocycles, **58**, 215
Nitrenes, carbenes and, intramolecular reactions of, **28**, 231
Nitrile oxides, cycloadditions with alkenes, **60**, 261
Nitriles and nitrilium salts, heterocyclic synthesis involving, **6**, 95
Nitro-compounds, heteroaromatic, ring synthesis of, **25**, 113
Nitrogen-bridged six-membered ring systems, **16**, 87
Nitrogen heterocycles (*see also N-Heterocyclic compounds*)
advances in amination of, **49**, 117
aromatic six-membered, regioselective substitution in, **44**, 199
conformational equilibria in saturated six-membered rings, **36**, 1
covalent hydration in, **20**, 117
photochemistry of, **30**, 239
reactions of acetylenecarboxylic esters with, **23**, 263
reduction of, with complex metal hydrides, **6**, 45; **39**, 1
Nitrogen heterocyclic systems, Claisen rearrangements in, **8**, 143
Nitrogen radicals, generation and cyclization, **58**, 1
Nomenclature of heterocycles, **20**, 175
Nuclear magnetic resonance spectroscopy, application to indoles, **15**, 277
Nucleic acids, mass spectrometry of, **39**, 79
Nucleophiles,
bifunctional, cyclisations and ring transformations on reactions of azines with, **43**, 301
cycloadditions and reactions of oxa-aromatics with, **65**, 283
reactivity of azine derivatives with, **4**, 145
Nucleophilic additions to acetylenic esters, synthesis of heterocycles through, **19**, 299

- Nucleophilic aromatic heterocycles,
 ambident palladium (0)-catalyzed
 allylation, **66**, 73
Nucleophilic heteroaromatic substitution,
 3, 285

O

- Olefin synthesis with anils, **23**, 171
Oligomers, heterocyclic, **15**, 1
Organocobalt-catalyzed synthesis of
 pyridines, **48**, 177
Organometallic compounds, transition metal,
 use in heterocyclic synthesis,
 30, 321
 coupling reactions in π -deficient
 azaheterocycles, **62**, 305
 of furan, thiophene, and their
 benzannulated derivatives, **78**, 1
 of pyrrole, indole, carbazole, phospholes,
 siloles, and boroles, **79**, 115
Organometallic complexes
 of boron, silicon and phosphorus analogues
 of azoles, **85**, 1
 of polyheteroatom azoles (other than
 pyrazole), **83**, 117
 of pyrazoles, **80**, 157
 of pyrazolyborates and related ligands,
 81, 167
Oxa-aromatics, cycloadditions and reactions
 with nucleophiles, **65**, 283
1,3,4-Oxadiazole chemistry, recent advances
 in, **7**, 183
1,2,4-Oxadiazoles, **20**, 65
1,2,5-Oxadiazoles, **29**, 251
1,3-Oxazine derivatives, **2**, 311; **23**, 1
 synthesis and stereochemistry of, **69**, 349
Oxaziridines, **2**, 83; **24**, 63
Oxazole chemistry, advances in, **17**, 99
Oxazolone chemistry
 new developments in, **21**, 175
 recent advances in, **4**, 75
Oxidation of monocyclic pyrroles,
 15, 67
Oxidative transformations of heteroaromatic
 iminium salts, **41**, 275
3-Oxo-2,3-dihydrobenz[*d*]isothiazole
 1,1-dioxide (saccharin) and derivatives,
 15, 233

- Oxygen heterocycles, applications of mass
 spectral techniques and stereochemical
 considerations in carbohydrates and
 others, **42**, 335
4-Oxy- and 4-keto-1,2,3,4-
 tetrahydroisoquinolines, chemistry of,
 15, 99

P

- Palladium in quinoline synthesis, **84**, 1
Pentazoles, **3**, 373
Peri-annellated heterocyclic systems,
 synthesis, **51**, 1
Peroxides, cyclic, **8**, 165 (*see also*
 1,2-Dioxetanes)
Phase transfer catalysis, applications in
 heterocyclic chemistry, **36**, 175
Phenanthridine chemistry, recent
 developments in, **13**, 315
Phenanthrolines, **22**, 1
Phenothiazines, chemistry of, **9**, 321
Phenoxazines, **8**, 83
Photochemistry
 of heterocycles, **11**, 1
 of nitrogen-containing heterocycles,
 30, 239
 of oxygen- and sulfur-containing
 heterocycles, **33**, 1
Photochemical isomerization of pentaatomic
 heterocycles, **79**, 41
Physicochemical aspects of purines, **6**, 1;
 24, 215
Physicochemical properties
 of azines, **5**, 69
 of pyrroles, **11**, 383
Piperazine-2,5-diones and related lactim
 ethers, **57**, 187
3-Piperidineins, **12**, 43
Polycyclic aromatic nitrogen cations, **55**, 261
Polyfluoroheteroaromatic compounds, **28**, 1
Polymerization of pyrroles and indoles,
 acid-catalyzed, **2**, 1
Porphyrin derivatives, hydrogenated:
 hydroporphyrins, **43**, 73
Preparation of pyrroles from ketoximes and
 acetylenes, **51**, 177
Present state of selenazole chemistry, **2**, 343
Progress in pyrazole chemistry, **6**, 347

- Prototropic tautomerism of heteroaromatic compounds, **1**, 311, 339; **2**, 1, 27; **S1**
heteroaromatic tautomerism—general overview and methodology, **76**, 1
- Pseudoazulenes, **33**, 185
- Pseudobases, heterocyclic, **1**, 167; **25**, 1
- Purine bases, aza analogs of, **1**, 189
- Purines
physicochemical aspects of, **6**, 1;
24, 215
tautomerism, electronic aspects of, **13**, 77
- Pyrans, new developments, **62**, 19
thiopyrans, and selenopyrans, **34**, 145
- Pyrazine chemistry, recent advances in, **14**, 99;
see also Piperazinediones
- Pyrazole chemistry, progress in, **6**, 347
- 3*H*-Pyrazoles, **34**, 1
- 4*H*-Pyrazoles, **34**, 53
- Pyrazol-3-one, synthesis and applications,
80, 73
- Pyrazoles condensed to heteroaromatic five- and six-membered rings, **48**, 223
- Pyrazoles, synthesis and properties of acetylenic derivatives of, **82**, 1
- Pyrazolopyridines, **36**, 343
- Pyrazolopyrimidines, chemistry of, **41**, 319
- Pyridazine chemistry, advances in, **49**, 385
- Pyridazines, **9**, 211; **24**, 363; **49**, 385
- Pyridine(s)
action of metal catalysts on, **2**, 179
effect of substituents on substitution in,
6, 229
functionalization by directed metalation,
52, 187
organocobalt-catalyzed synthesis, **48**, 177
synthesis by electrochemical methods,
37, 167
1,2,3,6-tetrahydro-, **12**, 43
- Pyridinium azolate inner salts, **60**, 197
- Pyridoindoles (the carbolines), **3**, 79
- Pyrido-diazines, recent developments in the chemistry of, **84**, 221; **85**, 175
- Pyridopyrimidines, **10**, 149
- Pyrido[1,2-*a*]pyrimidines, chemistry of, **33**, 241; **73**, 177
recent developments, **63**, 103
- Pyrido-oxazines, recent developments in the chemistry of, **84**, 221; **85**, 175
- Pyrido[2,1-*c*] [1,4]oxazines, pyrido[2,1-*c*] [1,4]thiazines, Pyrido[1,2-*a*]pyrazines and their benzologues, chemistry of,
71, 145
- Pyrido[2,1-*b*] [1,3]oxazines, Pyrido[2,1-*b*] [1,3]thiazines, and their benzologs, chemistry of, **72**, 225
- Pyrido-thiazines, recent developments in the chemistry of, **84**, 221; **85**, 175
- Pyrimidine bases, aza analogs of, **1**, 189
- Pyrimidine-pyridine ring interconversion,
84, 31
- Pyrimidine ring annelation to an existing ring, **32**, 1
- Pyrimidine ring, tricyclic compounds with a central, **39**, 281
- Pyrimidines
2,4-dialkoxy-, Hilbert-Johnson reaction of,
8, 115
fused tricyclic, **39**, 281
synthesis and stereochemistry of,
69, 349
tautomerism and electronic structure of biological, **18**, 199
- Pyrimidoazepines, chemistry of diazabicycloundecene (DBU) and other,
42, 83
- 1-Pyridines, chemistry of, **15**, 197
- Pyrones, inonocyclic sulfur-containing,
8, 219
- 2-Pyrones, 4-oxy-substituted, dehydroacetic acid and related systems, **53**, 1
- Pyrroles
acid-catalyzed polymerization of,
2, 287
1-hydroxy-, **51**, 105
from ketoximes and acetylenes, preparations, **51**, 177
oxidation of monocyclic, **15**, 67
physicochemical properties of, **11**, 383
- 2*H*- and 3*H*-Pyrroles, **32**, 233
- Pyrrolidines, generation by radical cyclizations, **58**, 1
- Pyrrolizidine chemistry, **5**, 315; **24**, 247
- Pyrrolizines, chemistry of, **37**, 1
- Pyrrolodiazines with a bridgehead nitrogen,
21, 1
- Pyrrolopyridines, **9**, 27
- Prylium salts
syntheses, **10**, 241
syntheses, reactions, and physical properties, **S2**

Q

- Quantitative analysis of steric effects in heteroaromatics, **43**, 173
- Quaternization
of heteroaromatic compounds, **22**, 71
of heterocyclic compounds, **3**, 1
- Quinazolines, **1**, 253; **24**, 1
- Quinazolines, fused, **52**, 1
- Quinoline synthesis, palladium in, **84**, 1
- Quinolines, functionalization by directed metalation, **52**, 187
- Quinolizines, aromatic, **5**, 291; **31**, 1
- Quinones, heterocyclic, **45**, 37
- Quinoxaline chemistry
developments 1963–1975, **22**, 367
recent advances in, **2**, 203
- Quinuclidine chemistry, **11**, 473

R

- Radicals, *see also* Substitution, free-radical and homolytic
heteroaromatic, **25**, 205; **27**, 31
nitrogen, cyclization of, **58**, 1
- Reactions
of annular nitrogens of azines with electrophiles, **43**, 127
of azines with bifunctional nucleophiles: cyclizations and ring transformations, **43**, 301
of sp^2 -carbanionic centers in the vicinity of heterocyclic nitrogen atoms, **56**, 155
of coordinated ligands, **58**, 123
- Reactivity
of heteroaromatic compounds in the gas phase, **40**, 25
of naphthyridines toward nitrogen nucleophiles, **33**, 95
- Rearrangements, mononuclear heterocyclic, **29**, 141
- Recent advances
azomethine ylide chemistry, **45**, 231
in benzo[*b*]thiophene chemistry, **11**, 177
in computing heteroatom-rich five- and six-membered ring systems, **81**, 1
in fluoroheterocyclic chemistry, **59**, 1
in furan chemistry, **30**, 168; **31**, 237
in 1,3,4-oxadiazole chemistry, **7**, 183

- in oxazolone chemistry, **4**, 75
in pyrazine chemistry, **14**, 99
in pyridazine chemistry, **24**, 363
in quinoxaline chemistry, **2**, 203
in tetrazole chemistry, **21**, 323
in the chemistry
of benzisothiazoles and other polycyclic isothiazoles, **38**, 105
of benzo[*b*]furans, occurrence and synthesis, **18**, 337
of benzo[*b*]thiophenes, **29**, 171
of 9*H*-carbazoles, **35**, 83
of dibenzothiophenes, **16**, 181
of dihydroazines, **38**, 1
of 1-hydroxyindoles,
1-hydroxytryptophans, and
1-hydroxytryptamines, **82**, 101
of mononuclear isothiazoles, **14**, 1
of phenothiazines, **9**, 321
of 1,3,4-thiadiazoles, **9**, 165
of thiophenes, **1**, 1
- Recent developments
in naphthyridine chemistry, **33**, 147
in isoxazole chemistry, **2**, 365
in phenanthridine chemistry, **13**, 315
- Recent progress in barbituric acid chemistry, **38**, 229
- Reduction of nitrogen heterocycles with complex metal hydrides, **6**, 45; **39**, 1
- Regioselective substitution in aromatic six-membered nitrogen heterocycles, **44**, 199
- Reisert compounds, **9**, 1; **24**, 187
- Ring closure of *ortho*-substituted *t*-anilines, heterocycles by, **14**, 211, **65**, 1
- Ring-opening of five-membered heteroaromatic anions, **41**, 41
- Ring synthesis of heteroaromatic nitro compounds, **25**, 113
- Ring transformations
and cyclizations on reaction of azines with bifunctional nucleophiles, **43**, 301
of five-membered heterocycles, **56**, 49

S

- Saccharin and derivatives, **15**, 233
- Salts
1,3-Oxazinium and 3-Azapyrylium, **64**, 341

Salts (*cont.*)

S-, Se-, and

Te(perfluoroalkyl)dibenzothiophenium,
-selenophenium, and -tellurophenium,
64, 223Saturated bicyclic 6/5 ring-fused systems
with bridgehead nitrogen and a single
additional heteroatom, **49**, 193Selenazole chemistry, present state of, **2**, 343Selenium-nitrogen heterocycles, **24**, 109Selenophene chemistry, advances in, **12**, 1Selenophenes, **30**, 127Selenopyrans, **34**, 145; **59**, 179Selenopyrylium salts, **60**, 65Six-membered oxygen-containing rings,
saturated, analysis of, **69**, 217Six-membered ring systems, nitrogen
bridged, **16**, 87Stereocontrolled additions to
dihydropyridines and
tetrahydropyridines: access to
N-heterocyclic compounds related to
natural products, **78**, 269Steric effects in heteroaromatics, quantitative
analysis of, **43**, 173

Substitution(s)

electrophilic, of five-membered rings, **13**, 235
free radical, of heteroaromatic compounds,
2, 131homolytic, of heteroaromatic compounds,
16, 123nucleophilic heteroaromatic, **3**, 285
in pyridines, effect of substituents, **6**, 229
regioselective, in aromatic six-membered
nitrogen heterocycles, **44**, 199Sulfamide moiety, heterocycles containing
the, **44**, 81Sulfoxides and sulfones: heteroaromatic, **48**, 1

Sulfur compounds

electronic structure of heterocyclic, **5**, 1
four-membered rings, **35**, 199Sulfur transfer reagents in heterocyclic
synthesis, **30**, 47Sulfuranes, ligand exchange in, **48**, 1Synthesis, *see also* Heterocyclic synthesis
and biological activities of condensed
heterocyclo[n,m-*a*, *b*, or *c*]quinazolines,
52, 1of condensed 1,2,4-triazolo[3,4-*z*]
heterocycles, **49**, 277from hydrogen cyanide derivatives, **41**, 1of heterocycles from azadienes, **57**, 1from nitrilium salts and nitriles under
acidic conditions, **6**, 95of natural heterocyclic products by hetero
Diels-Alder cycloaddition reactions,
42, 245of peri-annellated heterocyclic systems, **51**, 1and properties of acetylenic derivatives of
pyrazoles, **82**, 1and properties of azafulvalenes, **77**, 115
of pyridines by electrochemical methods,
37, 167of pyrrolidines by nitrogen radical
cyclization, **58**, 1of quaternary benzo[*c*]phenanthridine
alkaloids, **67**, 345and reaction of 1-azirines, **13**, 45
by ring-closure of *o*-substituted *t*-anilines,
14, 211of tetracyclic and pentacyclic condensed
thiophene systems, **32**, 127thienopyrimidines, **65**, 235thioureas in, **18**, 99through nucleophilic additions to acetylenic
esters, **19**, 279

T

Tautomeric

intramolecular reversible addition
reaction to,C=O group, **64**, 251C=N group, **66**, 1C≡N group, **66**, 1C=C group, **66**, 1C≡C group, **66**, 1

Tautomerism

electronic aspects of purine, **13**, 77and electronic structure of biological
pyrimidines, **18**, 99heteroaromatic tautomerism—general
overview and methodology, **76**, 1of heterocycles: five-membered rings with
one heteroatom, **76**, 85of heterocycles: five-membered rings with
two or more heteroatoms, **76**, 159involving other than five and six-membered
rings, **77**, 1

- Tautomerism (*cont.*)
 of heterocycles: condensed five-six, five-five, and six-six ring systems with heteroatoms in both rings, **77**, 51
 of heterocycles: six-membered heterocycles, annular tautomerism, **81**, 253
 prototropic, of heteroaromatic compounds, **1**, 311, 339; **2**, 1, 27; **S1**
- Tellurium atom, 6-membered heterocycles with a, **63**, 1
- Tellurium-containing heterocycles with two heteroatoms, **58**, 47
- Tellurium-nitrogen-containing heterocycles, **79**, 1
- Tellurophene and related compounds, **21**, 119
- Telluropyrans, **59**, 179
- Telluropyrilium salts, **60**, 65
- 1,2,3,4-Tetrahydroisoquinolines, 4-oxy- and 4-keto-, **15**, 99
- 1,2,3,6-Tetrahydropyridines, **12**, 43
- Tetramic acid chemistry, advances in, **57**, 139
- Tetrathia- and tetraselenafulvalenes, reactivity, **62**, 249
- Tetrazocines, **50**, 1
- Tetrazolechemistry, recent advances in, **21**, 323
- Theoretical studies of physicochemical properties and reactivity of azines, **5**, 69
- Thiadiazines with adjacent sulfur and nitrogen ring atoms, **50**, 255
- 1,2,4-Thiadiazoles, **5**, 119; **32**, 285
- 1,2,5-Thiadiazoles, chemistry of, **9**, 107
- 1,3,4-Thiadiazoles, recent advances in the chemistry of, **9**, 165
- Thianthrenes, **48**, 301
- Thiathiophthenes
 (1,6,6a^{IV}-trithiapentalenes), **13**, 161
- 1,2,3,4-Thiatriazoles, **3**, 263; **20**, 145
- 1,3-Thiazin-4-ones,
 chemistry of, and their derivatives, **66**, 131
- 1,3-Thiazines, **50**, 85
 synthesis and stereochemistry of, **69**, 349
- 1,4-Thiazines and their dihydro derivatives, **24**, 293
- Thiazole and thiadiazole *S*-oxides, **83**, 71
- 4-Thiazolidinones, **25**, 83
- 4-Thiazolidinones, condensed, **49**, 1
- Thienopyridines, **21**, 65
- Thienopyrimidines,
 synthesis, chemistry, and biological properties, **66**, 193
- synthesis, reactions, biological activity, **65**, 235
- Thienothiophenes and related systems,
 chemistry of, **19**, 123
- Thiochromanones and related compounds, **18**, 59
- Thiocoumarins, **26**, 115
- Thiophenes, recent advances in the chemistry of, **1**, 1
- Thiophenium salts and thiophenium ylids,
 chemistry of, **45**, 151
- Thiopyrans, **34**, 145; **59**, 179
- Thiopyrones (monocyclic sulfur-containing pyrones), **8**, 219
- Thiopyrylium, selenopyrylium, and telluropyrilium salts, **60**, 65
- Thioureas in synthesis of heterocycles, **18**, 99
- Three-membered rings with two heteroatoms, **2**, 83; **24**, 63
- Transition organometallic compounds in heterocyclic synthesis, use of, **30**, 321
- Triacetic acid lactone and related pyrones, **53**, 1
- 1,3,5-, 1,3,6-, 1,3,7-, and
 1,3,8-Triazanaphthalenes, **10**, 149
- 1,2,3-Triazines, **19**, 215
- 1,2,4-Triazine *N*-oxides, **82**, 261
- 1,2,4-Triazines,
 fused to two heterocyclic rings, **61**, 209
 fused to heterocycles with 6- and
 7-membered rings, **61**, 209
 reactions with C-, N-, O-, and
 S-nucleophiles, **46**, 73
- Triazocines, **50**, 1
- 1,2,3-Triazoles, **16**, 33
- 1,2,3-Triazoles, 4-amino-, **40**, 129
- Δ^2 -1,2,3-Triazolines, **37**, 217
- Δ^3 - and Δ^4 -1,2,3-Triazolines, **37**, 351
- 1,2,4-Triazolines, **46**, 169
- 1,2,4-Triazolines-3,5-diones, **67**, 119
- 1,2,4-Triazolo[3,4-*z*]heterocycles, synthesis, **49**, 277
- Triazolopyridines, **34**, 79; **83**, 1
- 1,2,3-Triazolo[4,5-*d*]pyrimidines
 (8-azapurines), chemistry of, **39**, 117
- 1,2,3-Triazolo[*x,y,-z*]pyrimidines, **71**, 57
- 1,2,4-Triazolo[1,5-*a*]pyrimidines, **57**, 81
- 1,2,4-Triazolo- and tetrazolo[*x,y,-z*]
 pyrimidines, **72**, 127

1,2,4-Triazolopyrimidines I:
1,2,4-triazolo[4,3-*a*]pyrimidines,
chemistry of, **73**, 131
Tricyclic compounds with a central
pyrimidine ring and one bridgehead
nitrogen, **39**, 281
1,6,6a^{IV}-Trithiapentalenes, **13**, 161
Tricyclic azoloquinolines, **78**, 189
Tropones with fused heterocyclic rings,
synthesis, **64**, 81
structure, reactivity, and application,
66, 285
Tropolones with fused heterocyclic rings,
synthesis, **64**, 81
structure, reactivity, and application, **66**, 285
Tropylum salts with fused heterocyclic rings
synthesis, **64**, 81
structure, reactivity, and application, **66**, 285

U

Unsaturated nitrogen heterocyclic
compounds containing carbonyl groups,
chemistry of, **58**, 171
Uracils: versatile starting materials in
heterocyclic synthesis, **55**, 129
Use of transition organometallic
compounds in heterocyclic synthesis,
30, 321

V

Vinyl heterocycles, cycloaddition reactions
with, **63**, 339
Vilsmeier conditions, cyclization under,
31, 207

Cumulative Subject Index, Volumes 81–85

- α -Acetamidoacrylate, reaction with iodoquinolines, **84**, 22
- 4-Acetoacetyl-1,3,5-trimethylpyrazole, conversion to butadiynylpyrazole, **82**, 17
- (-)-Acetomycin, synthesis, **81**, 130
- 8-Acetonilydihydroberberine, **85**, 89
- 1-(2-Acetoxybenzoyl)-1,2,3,4-tetrahydro-pyridin-4-ones, **85**, 186
- 5-Acetoxy-3,4-diethoxyfuranones, formation, **81**, 109
- 5-Acetoxy-2(5*H*)-furanone, formation, **81**, 108
- reaction with aryl nitrile oxides, **81**, 146
- (+)-(S)-5-Acetoxy-2(5*H*)-furanone, hydrogenation, **81**, 130
- 13-Acetoxyoxoberberine, **85**, 91
- Acetylacetone, reaction with 1,3-diaminopropane, **82**, 162
- 3(5-)-(N-Acetylamino)-4-alkynylpyrazoles, **82**, 28
- (N-Acetylamino)iodopyrazoles, coupling with copper acetylides, **82**, 25
- 3-Acetylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 247
- 7-Acetylaminotriazolopyridine, formation, **83**, 3
- N-Acetylarylnitrenium ions, unimolecular rearrangement, **81**, 20
- Acetylated indol-1-yl glucosides, **82**, 110
- 1-Acetyl-3*a*-(4-chlorobutoxy)-1,2,3,3*a*,8,8*a*-hexahydropyrrolo[2,3-*b*]indole, **82**, 111
- (\pm)-*Nb*-Acetyl-5-chlorotryptophan methyl ester, **82**, 132
- Nb*-Acetyl-2,3-dihydro-2-oxotryptamine, **82**, 111
- 1-Acetyl-2,3-dihydropyrrolo[2,3-*b*]pyridine, **84**, 57
- Nb*-Acetyl-2,3-dihydrotryptamine, in preparation of hydroxy-melatonin, **82**, 106
- 2-Acetyl-3-dimethylamino-4,4-diphenylcyclobut-2-en-1-one, **82**, 247
- 2-Acetyl-1,9-dimethylcarbazole, **82**, 235
- 4-Acetyl-3,5-dimethylpyrazole, reaction with phosphorus pentachloride, **82**, 14
- 3-Acetyl-2,4(6)-dimethylpyridine, **82**, 197
- Acetylene, insertion into molybdenum carbonyls, **81**, 182
- reaction with diazopropyne, **82**, 3
- 4-Acetylenenylpyrazoles, acidity, **82**, 77
- 3-Acetylenyl-1,5-dimethylpyrazole-4-carboxylic acids, isomerisation, **82**, 59
- 4-Acetylenyl-1-methylpyrazole-5-carboxylic acids, isomerisation, **82**, 58
- heterocyclisations, **82**, 59
- 5-Acetylenylpyrazoles, **82**, 9
- Acetylenylpyrazolo[3,4-*d*]pyrimidines, in oligonucleotides, **82**, 24
- 1-Acetyl-3-ethoxycarbonylpyrrolo[2,1-*a*]isoquinoline, **82**, 236
- Acetylferrocene, reaction with butyllithium, **81**, 185
- 9-Acetyl-7-hydroxy-1,2-dimethyl-7-methoxycarbonyl-4-phenyl-6-oxo-1,4,7,8-tetrahydro-6*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, X-ray diffraction analysis of structure, **85**, 201
- 1-Acetyl-6-hydroxyindole, **82**, 123
- 3-Acetyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidine-4-thione, formation, **85**, 239
- Nb*Acetyl-1-hydroxytryptamine, reaction with methyl acrylate, **82**, 109
- reaction with mesyl chloride, **82**, 111
- 1-Acetylindolizine, **82**, 236
- 1-Acetylindolizino-3-carboxylate, **82**, 236
- N*-Acetyl-4-iodopyridazoles, reaction with acetylenes, **82**, 30
- Nb*-Acetyl-6-mesyloxytryptamine, **82**, 111
- 3-Acetyl-2-methoxychromo-3-ene, **82**, 228
- 2-Acetyl-3-methoxy-1,9-dimethyl-2,3-dihydrocarbazole, **82**, 235
- 3-Acetyl-1-methoxyindole, **82**, 118, 124
- 2-Acetylmethyl-1,3-benzothiazole, **82**, 241
- 2-Acetylmethyl-1,3-benzoxazole, **82**, 241
- Acetylmethyldioxolanes, **82**, 227
- 2-(Acetylmethyl)-1,3-imidazolines, **82**, 239
- 5-Acetyl-3-methylisoxazole, **82**, 233

- 2-(Acetylmethyl)-1,3-oxazolines, **82**, 239
3-Acetyl-4-methylpyridine, **82**, 211
5-Acetyl-2-methylpyridine, **82**, 211
3-Acetyl-4-methyl-2(1*H*)-pyridones, **82**, 229
3-Acetyl-4-methylthio-2*H*-pyrido[1,2-*a*]
pyrimidine-2-one, formation, **85**, 239
1-Acetyl-6-nitroindole, **82**, 123
3-Acetyl-4-(3-oxo-1-buten-1-yl)-1-phenyl-
5-diethylaminopyrazole, **82**, 247
3-Acetyl-2-(2-oxoethyl)-3,4-dihydro-
2*H*-1,2-benzothiazin-4-ones, ring
closure, **84**, 232
1-Acetyl-3-(perhydropyrido[1,2-*a*]pyrazin-
2-yl)-1*H*-indole, **84**, 308
1-Acetyl-2-(4'-phenylbenzoyl)-4-methyl-
6-ethyl-pyrrolo[2,3-*c*]pyrazole, **82**, 28
3-Acetyl-4-phenylamino-2-*H*-pyrido[1,2-*a*]
pyrimidin-2-one, isomerisation, **85**, 229
formation, **85**, 239
1-Acetyl-2-phenylimidazole, formation of
complexes, **83**, 138
1-(2-Acetylphenyl)piperazines, oxidation,
85, 184
3-Acetyl-4-(2-propoxy)-2*H*-1,2-
benzothiazine-2-acetaldehyde
1,1-dioxide, **84**, 232
4-Acetylpyrazoles, **82**, 233
1-Acetylpyrazolo[1,5-*a*]pyridine, **82**, 236
1-Acetyl-2-pyridone, addition of hydrazine,
83, 18
2-Acetylquinoline, formation, **84**, 15
3-Acetylquinoline-4-carboxylic acid, **82**, 214
1-Acetyl-1,2,3,8-tetrahydropyrrolo[2,3-*b*]
indole, **82**, 111
N-Acetyltetrazole, conversion to
1,3,4-oxadiazole, **81**, 33
3-Acetyl-2-thiomethyl-1-methoxyindole,
82, 127
1-Acetyl-[1,2,3]triazolo[4,5-*b*]pyridine, use as
acylating agents, **83**, 51
4-Acetyl-1,3,5-trimethylpyrazole, reaction
with phosphorus pentachloride, **82**, 16
Nb-Acetyltryptamine, **82**, 111
3-Acryloyl-1,3-oxazolidin-2-one, **81**, 21
Actisomide, **84**, 225
Acylaminothiadiazoles, study of rotational
barriers in, **81**, 84
5-Acyl-2,3-dihydropyrrolo[2,1-*b*]oxazoles,
83, 194
Acylimidotungsten(IV) species, **81**, 174
2-Acyl-5-nitropyrrole, reaction with ethylene
oxide, **83**, 194
4-Acylsubstituted fulvene, cycloaddition
reactions, **84**, 123
(-)(*R*)-Adalinine alkaloid, **85**, 189
Adenine, tautomerism, **81**, 61
base pair with thymine and uracil, **81**, 63
hydrogen peroxide complexes, pairing
properties, **81**, 64
Adenine-2,4-difluorotoluene complexes,
calculations on, **81**, 63
Adenine-thymine radical cations, proton
transfer in, **81**, 67
Adenosine monophosphate, in cation
binding, **81**, 65
Aeruginosine A and B, **85**, 138
Aflatoxins M₁ and M₂, synthesis, **81**, 130
Afrocurarine, **85**, 149
Alkenecarbonitrile *N*-oxides, **82**, 180
2-(*N*-Alkenylamino)-3-formyl-4*H*-
pyrido[1,2-*a*]pyrimidin-4-one, reaction
with hydroxylamine, **85**, 223
reaction with tosylhydrazides, **85**, 224
affect of heat, **85**, 228
Alkenylbenzoxazine, flash vacuum
pyrolysis, 96
2-Alkoxy-3-acylpyridines, partial
hydrogenation, **81**, 260
3-Alkoxy-2-(4-biphenyl)perhydro-
pyrido[1,2-*c*][1,4]oxazines, **84**, 276
1-Alkoxybut-1-en-3-yne, hydrolysis,
82, 193, 195
4-Alkoxy-carbonyl-3-methyl-6-oxo-
2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-
9-carboxylic acid, reaction with ethyl
chloroformate, **85**, 191
1-Alkoxy-carbonyl-2-pyridones, in formation
of triazolopyridin-3-ones, **83**, 18
10-Alkoxy-9-fluoro-2,3-dihydro-3-methyl-
7-oxo-7*H*-pyrido[1,2,3-*de*]-1,4-
benzoxazine-6-carboxylic acid, **84**, 292
 γ -Alkoxyfuranones, reaction with lithiodi-
phenylphosphide, **81**, 137
5-Alkoxy-2(5*H*)-furanone, reaction with
arylnitrile oxides, **81**, 145
3-Alkoxy-2-hydroxy-ketones, in preparation
of furanones, **81**, 114
Alkoxy-lactones, synthesis, **81**, 125
2-Alkoxy-3-{4-[2-(5-tetrazolyl)phenyl]
phenylmethyl}-4*H*-pyrido[1,2-*a*]

- pyrimidin-4-one, angiotensin II receptor antagonist activity, **85**, 256
- 3-Alkoxy-1,2,4-triazine 1-oxides, **82**, 298
- 1-Alkoxytryptamines, reaction with aqueous HCl, **82**, 130
- Alkoxyvinylacetylenic alcohols, cyclodehydration, **82**, 205
- 1-Alkyl-7-(1-alkylperhydropyrido[1,2-*a*]pyrimidin-6-yl)-1,2,3,4,8,9-hexahydro-9*a*-pyrido[1,2-*a*]pyrimidines, **85**, 254
- 4-Alkylaminobut-3-en-2-ones, **82**, 210
- 2-(Alkylamino)nicotinic acids, **84**, 35
- 4-Alkylaminopyridin-2-ones, formation, **84**, 38
- 4-Alkyl-4-aryl-substituted-4*H*-pyrans, aryl group migration, **81**, 258
- N*-Alkylated 3-oxo- β -sultams, reaction with sodium hydride, **83**, 93
- N*-Alkylated isoquinolinium-4-olates, **85**, 85
- N*-Alkylbenzoxazolin-2-ones, in the Turpin reaction, **83**, 213
- Alkyl 9-benzoyloxycarbonyl-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylates, **85**, 192
- Alkyl 2,3-dihydrodiboroles, reaction with nickel compounds, **85**, 18
- 2-Alkyl-2,3-dihydro- γ -pyrones, **82**, 206
- 1-Alkyl-2-(ethoxycarbonylmethyl)pyrimidinium iodides, rearrangements, **84**, 35
- 1-Alkyl(aryl)-5-ethynyl-1,2,3-triazoles, **82**, 181
- Alkyl 9-hydroxymethyl-3-methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylates, *O*-alkylation, **85**, 192
- Alkyl 2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **85**, 244
- 2-Alkylindoles, **82**, 115
- 5-Alkylisothiuronium salts, reaction with aminobutenones, **82**, 223
- 3(5)-Alkylisoxazoles, **82**, 190
- 3-Alkyl(aryl)-5-isoxazolecarboxylic acids, **82**, 181
- 1-Alkyl-5-methylpyrazoles, **82**, 165
- 2-(2-Alkylphenyl)-1,2,3,4-tetrahydro-pyrimidines, **85**, 263
- 3-Alkylpiperidines, preparation of chiral forms, **85**, 189
- (*R*)-3-Alkylpiperidines, preparation, **85**, 182
- 1-Alkyl-3-propynyl-5-methylpyrazoles, **82**, 13
- Alkyl 3-(2-pyridylamino)-3-alkoxycarbonylacrylates, cyclisation, **85**, 236
- 4-Alkylpyrimidines, **82**, 199
- Alkylthiobuten-3-ynones-1, reaction with diphenylnitrilimines, **82**, 9
- 2-Alkylthio-4-methylpyrimidines, **82**, 223
- 1-Alkyl-1,2,3-triazolium salts, ring expansion, **81**, 281
- 3-Alkyltriazolo[1,5-*a*]quinolines, **84**, 162
- Alkyne substitution in metal complexes, **81**, 184
- 4-Alkynyl-5-amino-3-methyl-1-alkylpyrazoles, diazotisation, **82**, 65
- 4-Alkynyl-3-aminopyrazoles, diazotisation, **82**, 67
- 7-Alkynylated 8-aza-7-deazadenine 2'-deoxyribonucleosides, biological activities, **82**, 86
- 7-Alkynylated 7-deazadenine, fluorescence, **82**, 73
- 3(5)-Alkynylpyrazoles, **82**, 7
- 4-Alkynylpyrazoles, formation, **82**, 4, 7
- 5-Alkynylpyrazoles, **82**, 179
- 4-Alkynylpyrazole-3-carboxylic esters, **82**, 4
- 3-Alkynylpyrazole-4(3)-diazonium salts, cyclisation, **82**, 68
- 5-Alkynylpyrazole-4-diazonium chlorides, cyclisation, **82**, 65
- 2-Allenylindoles, **82**, 115
- Allopurinol, tautomers, **81**, 61
- Alloyohimbane, synthesis, **85**, 79
- 2-(*N*-Allylamino)-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with hydroxylamine, **85**, 221
- (1-Allylbenzotriazole)tricarboxyliron, structure, **83**, 156
- 2-Allyl-1-*tert*-butoxycarbonylpiperidine, **84**, 246
- 1-Allyl-7-formylindole, **84**, 110
- 4-Allyloxy-2-methylquinolines, thermal rearrangements, **84**, 88
- 2-Allyloxyquinolines, cyclisation on treatment with bromine, **84**, 147
- 2-(2-Allylphenoxy)pyrimidines, **84**, 58
- 2-Allylthioquinolines, **84**, 152
- Alstoniline, **85**, 154
- Alstonine, **85**, 144
- Amiloride, complex with cytosine, **81**, 49
- 4-Amino-5-acetylenylpyrazole, intramolecular cyclisation, **82**, 54

- β -Aminoacroleins, reactions with diaminoethane, **82**, 212
- 3-(ω -Aminoalkyl)-9,10-dimethoxy-2-(arylimino)-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one, **84**, 252
- 2-Amino-4-alkylpyrimidines, **82**, 168, 201
- 1-Amino-3-aryl-2-cyano-1*H*,6*H*-pyrido[1,2-*a*][3,1]benzoxazin-4-ones, **85**, 188
- 3-Amino-4-arylisothiazole dioxides, functionalization, **83**, 78
- (3*S*,8'*S*,10-(8-Amino-6-azaspiro[3,4]octan-6-yl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 269
- o*-Aminobenzaldehyde, reaction with butenones, **82**, 215
- 2-*p*-Aminobenzenesulfamido-4-methylpyrimidine, **82**, 201
- 2-Aminobenzothiazole, with ruthenium complexes, **84**, 197
- 3-Amino-1,2,4-benzotriazine 1-oxides, **82**, 293
reaction with α -halocarbonyl compounds, **82**, 270
- 3-Amino-1,2,4-benzotriazine 4-oxides, **82**, 296
- 6-Amino-1-benzoyl-5-cyano-4-phenylsulfonylpyridin-2(1*H*)-one, **85**, 241
- 2(4-Aminobenzoyl)-1,2,3,6,11*a*-hexahydro-4*H*-pyrazino[2,1-*a*]isoquinoline-4-one, **84**, 314
- 2-Amino-3-benzylidene-2,3-dihydroisindol-1-one, **82**, 63
- 4-Amino-2-benzyl-1,2,5-thiadiazolin-3-one *S,S*-dioxide, hydrolysis, **83**, 102
- 4-Amino-2,2'-bipyridyl, basicity, **81**, 294
- 2-Amino-5-bromopyridine, **85**, 243
- 2-Amino-6-bromopyridine, reaction with 4-chloroacetoacetate, **85**, 245
- 4-Amino-2-bromopyridine, **84**, 64
- 2-Amino-5-*n*-butyl-3-ethyl-6-methyl-4(3*H*)-pyrimidinone, tautomerisation, **81**, 45
- 5-Amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-ethynylpyrazole, hydration, **82**, 43
- 5-Amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(prop-1-yn-1-yl)pyrazole, hydration, **82**, 43
- 5-Amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trimethylsilylethynylpyrazole, **82**, 47
- 3-Amino-4-cyano-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-ones, **84**, 255
- 2-Amino-3-cyanopyridines, formation, **84**, 36
- 6-Amino-7-cyanopyrido[2,3-*b*]pyrazine, **84**, 41
- 2-Amino-3-cyanoquinoline, **84**, 40
- 1-Amino-2-cyanoquinolinium perchlorate, reaction with triethyl orthoformate, **84**, 168
- 7-Amino-2-cycloalkyl-8-hydroxy-2,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, **84**, 314
- 6-Amino-1,3-dialkyluracil, **84**, 47
- 2-Amino-8,9-difluoro-5-methyl-6,7-dihydro-5*H*-pyrido[3,2,1-*ij*]quinazoline-1,3-dione, **84**, 253
- 4-Amino-2,3-dihydroisothiazole *S,S*-dioxides, synthesis, **83**, 80
- 5-Amino-2,3-dihydro-1,2,4-oxadiazol-3-one, tautomers, **81**, 33
- 2-Amino-9,10-dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one, **84**, 254
- 2-Amino-5,7-dimethylimidazo[4,5-*e*]pyrimidine-4,6(5*H*,7*H*)-diones, **82**, 286
- 2-Amino-4,6-dimethyl-3-pyridinecarbo-nitrile, **84**, 37
- 4-Amino-2,6-dimethylpyrimidine, site of protonation, **81**, 295
- 4-Amino-5,6-dimethylpyrimidine, site of protonation, **81**, 295
- 2-Amino-3(ethoxycarbonyl)pyridines, formation, **84**, 36
- 3-(2-Aminoethyl)indole, reaction with methoxybutenone, **82**, 217
- 2-[¹⁴C]-4-Amino-2-ethylpyridine, **82**, 183
- 2-Amino-6-fluorobenzamidine dihydrochloride, reaction with pyridobenzox-azinediones, **85**, 183
reaction with pyridobenzothiazinediones, **85**, 192
- 5-Amino-4-formyltriazoles, reaction with acetone, **83**, 22
- 3-Amino-6,6*a*,7,8,9,10-hexahydropyrido[2,1-*c*][1,4]benzoxazine, **84**, 275
- 1-Amino-4,4*a*,5,6,7,8-hexahydropyrido[1,2-*c*]pyrimidine, **84**, 252

- 1-Amino-2-hydroxymethyltetrahydroquino-
line, reaction with benzaldehyde, **84**, 128
- 2-Amino-3-hydroxypyridine, reaction with
2-chloro-3-nitropyridine, **83**, 211
- 3-Amino-4-hydroxypyridine, reaction with
2,4,6-trinitrochlorobenzene, **83**, 211
- 5-Aminoimidazole-4-imides, computation
on, **81**, 8
- 1-Aminoindoles, **82**, 104
- Amino-4-iodopyrazoles, coupling with
acetylenes, **82**, 26
- 4-Amino-3-iodoquinoline, **84**, 25
- 4-Amino-isothiazoline 1,1-dioxides, **83**, 85
- β -Aminolactones, formation of enantio-
merically pure forms from menthloxy-
2(5*H*)-furanone, **81**, 153
- 1-Amino-2-mercaptobenzene, reaction with
enynes, **82**, 185
- 5-Amino-4-mercaptopyrimidine, reaction
with 2-mercaptoaniline, **83**, 228
- 6-Amino-methylenehydrazino-
5-nitrosouracil, **82**, 287
- 5-Aminomethyl-4-ethynyl-1,3-dimethyl-
pyrazole, **82**, 48
- 3-Amino-5-methyl-6-phenyl-1,2,4-triazine
4-oxide, **82**, 294
- 4-Amino-2-methylpyrimidine, **84**, 63
- 2-Amino-4-methylpyrimidine, **82**, 223,
83, 201
- 4-Amino-6-methylpyrimidine, site of
protonation, **81**, 295
- 7-Aminomethyl-2-substituted
perhydro[1,2-*a*]pyrazines, **84**, 312
- 2-Aminomethyltetrahydroquinolines,
reaction with urea, **84**, 136
- 3-Amino-4-methyl-1,2,4-thiadiazoline
S,S-dioxide, synthesis, **83**, 99
- 4-Amino-3-methyl-5-thione-1,2,4-triazole,
formation of mercury complexes,
83, 163
- 1-Amino-2-methylthiopyridinium iodides,
reaction with aryl isothiocyanates, **83**, 9
- 2-Amino-5-nitrophenol, reaction with
2,4,6-trinitrochlorobenzene, **83**, 210
- 2-Amino-5-nitro-3-*R*-pyridines, **84**, 42
- 3-Amino-4-nitrosopyrazoles, **82**, 284
- 4-Amino-3-nitroso-4*H*-pyrido[1,2-*a*]
pyrimidin-2-one, **85**, 242
- 3-Amino-5-nitro-1,2,4-triazole, relative
stabilities of tautomers, **81**, 28
- 2-Amino-2-oxazoline, tautomerism, **81**, 21
- 5-Amino-3-oxo-thiadiazines, hydrolysis,
83, 104
- 4-Amino-3-oxo-1,2,5-thiadiazoline
S,S-dioxides, **83**, 104
- o*-Aminophenol, reaction with butynones,
82, 241
- 2-Amino-5-*R*-3-phenylpyridines, **84**, 43
- 3-Amino-5-phenyl-1,2,4-triazine 1-oxide,
formation, **82**, 273
- 5-Amino-6-phenyl-1,2,4-triazine 1-oxide,
82, 275
- 3-Amino-1-propanol, reaction with
furanoxylase, **85**, 180
- 2-Aminopurine, calculated dipole moments,
81, 61
- 4-Amino-1*H*-pyrazino[2,3-*c*]-1,2,6-
thiadiazine 2,2-dioxides,
tautomerism, **81**, 83
- 2-Aminopyridine/acetic acid 2-aminopyrimi-
dinium acetate, equilibrium, **81**, 294
- 2(4)-Aminopyridines, basicity and acidity,
81, 294
- formation of tricyclics, **83**, 200, 201
- reaction with pyrimidine-diones, **85**, 242
- 3-Aminopyridine-2-thiol, reaction with
4-chloro-5-nitropyrimidine, **83**, 227
- 2-Aminopyridinium propionate, effect of
heating, **85**, 242
- 1-Amino-2-pyridone, in formation of [1,2,4]
triazolo[1,5-*a*]pyridines, **83**, 9
- 2-Amino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones,
Mannich reactions, **85**, 206
- 3-Amino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one,
preparation, **85**, 214
- 6-Amino-11*H*-pyrido[2,1-*b*]quinazoline-
11-one, **85**, 264
- Aminopyridothiadiazine 2,2-dioxides,
tautomerism, **81**, 288
- Aminopyrido[2,3-*c*]-1,2,6-thiadiazine
2,2-dioxides, protonation, **81**, 295
- 3-Aminopyrido[4,3-*e*]-1,2,4-triazines, **82**, 267
- 3-Aminopyrido[3,4-*e*]-1,2,4-triazine 1-oxides,
82, 292
- 3-Aminopyrido[4,3-*e*]-1,2,4-triazine 1-oxides,
UV irradiation, **82**, 267
- 4(2)-Aminopyrimidine, computational
studies, **81**, 44
- 4-Aminopyrimidinium radicals,
computational studies, **81**, 44

- 6-Aminopyrimidin-4(3*H*)-one, **84**, 61
8-Aminoquinoline, **84**, 143
 reaction with osmium complexes, **85**, 23
1-Aminoquinoline salts, **84**, 162
1-Aminoquinolinium iodide, reaction with
 cyclopentadienones, **84**, 128
1-Amino-2-quinolone, reaction with ethyl
 benzoylacetate, **84**, 128
2-Amino-4-quinolones, chloracetylation,
 84, 132
3-Amino-5-substituted-isothiazole
 S,S-dioxides, formation, **83**, 83
2-Amino-2-[*N*-substituted-sulfamoylimino]
 acetic acid salts, formation, **83**, 102
Amino-substituted 1,2,6-thiadiazine
 1,1-dioxides, tautomerisation, **81**, 288
2-Amino-3,4,5,6-tetrahydropyridine, **85**, 246
3-Amino-6,7,8,9-tetrahydro-4*H*-pyrido
 [1,2-*a*]pyrimidin-4-one, **85**, 203
3-Amino-1,2,4-thiadiazoline *S,S*-dioxide,
 synthesis, **83**, 98, 102, 105
 reaction with amines, **83**, 102
3-Amino-2-thiopyridine, in formation of
 diazaphenothiazines, **83**, 226
3-Amino(alkylamino)-1,2,4-triazine
 1-oxides, halogenation, **82**, 268
3-Amino(alkylamino)-1,2,4-triazine
 2-oxides, halogenation, **82**, 268
3-Amino-1,2,4-triazine 2-oxide, oxidation,
 82, 266
 formation, **82**, 272
 reaction with alcohols, **82**, 280
 reaction with HCl, **82**, 280
3-Amino-1,2,4-triazine 4-oxides, **82**, 283
 oxidation, **82**, 298
5-Amino-1,2,4-triazine 4-oxides, **82**, 275
3-Amino-1,2,4-triazino[6,5-*c*]quinoline
 4-oxides, **82**, 292
3-Amino-1,2,4-triazole, relative stabilities of
 tautomers, **81**, 28
1-Aminotriazolopyridine, reaction with lead
 tetraacetate, **83**, 46
3-Aminotriazolopyridines, **83**, 15
 reaction with acid, **83**, 45
7-Aminotriazolopyridines, formation,
 83, 19
2-Amino[1,2,4]triazolo[1,5-*a*]pyridine, **83**, 6
8-Amino[1,2,4]triazolo[1,5-*a*]pyridine,
 stomach secretion inhibition, **83**, 29
 ,formation, **83**, 30
7-Amino-2-trifluoromethyl-1,4-dihydro-
 1,8-naphthyridin-4-one, formation,
 85, 231
6-Amino-2-trifluoromethyl-4*H*-pyrido[1,2-*a*]
 pyrimidin-4-one, thermolysis,
 85, 231
2-Amino-4,6,6-trimethyldihydropyrimidine,
 effect of bases, **81**, 269
1-Amino-3-trimethylsiloxybuta-1,3-dienes,
 82, 234
Amphimedine, synthesis, **84**, 17
Analgesic activity, in thiazole derivatives,
 83, 96
Anhydro-1-hydroxythiazolo[3,2-*a*]
 quinolinium hydroxide, **84**, 159
3-Anilinoferrenulin 4-oxides, formation,
 82, 296
3-Anilinoquinoline, **84**, 25
6-Anilino-1,3,5-triazines, acid-induced
 decomposition, **81**, 282
5-(*p*-Anisyl)-2-(1,1-dicyanopentynyl)pyrimi-
 dines, conversions, **84**, 56
ANRORC mechanism, **84**, 32
Anti-bacterial activity, in thiazole
 derivatives, **83**, 96
Anti-convulsant activity, in thiazole
 derivatives, **83**, 96
Anti-inflammatory activity, in thiazole
 derivatives, **83**, 96
Anti-psychotic activity, in thiazole
 derivatives, **83**, 96
Anti-tussive activity, in thiazole derivatives,
 83, 96
Anxiolytic activity, in thiazole derivatives,
 83, 96
Apicidin, synthesis, **82**, 145
Aplidiamin, **85**, 70
9-β-Arabinofuranosyladenine, vibrational
 spectra, **81**, 62
Aragupetrosine alkaloids, **85**, 175,
Araguspongine B, **85**, 177, 179, 190
Araguspongine C, **85**, 189
Araguspongine D, **85**, 177, 179, 190
Araguspongine E, **85**, 177, 178, 179, 190
 isomerisation, **85**, 183
Arcyriacyanin A, synthesis, **82**, 144
Arenes in triple-decker cobalt complexes,
 85, 10
Arenesulfonyl chlorides, reaction with
 anionic metal complexes, **81**, 185

- Arene thiolates, reaction with halogen substituted metal complexes, **81**, 186
- Argemonine, **85**, 94
- Argon, complexes with oxazoles investigated by theoretical calculations, **81**, 18
- Aromatic diazonium salts, reaction with pipercolic acid, **83**, 5
- Aroylhydrazines, reaction with pyridine-2-thione, **83**, 19
- 3-(Aroyloxymethylene)-4-(3-aroxyloxypropynyl-1)pyrazoles, **82**, 5
- 2-Aroyloxy-4-*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 213
- 3-Aroyl-1,2,3,4-tetrahydro[1,2-*a*]pyridinium perchlorate, **85**, 241
- Arsenic analogues of azaphospholes, in metal complexes, **85**, 26
- Artemisinin, **81**, 82
- 4-Arylamino-8-iodoquinoline, **84**, 105
- 1-Arylamino-1-*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates, **84**, 260
- N*-Arylazides, reaction with isothiazole *S,S*-dioxide, **83**, 74
- N*-Arylbenzoxazolin-2-one, formation, **83**, 213
- 1-Aryl-4,6-diamino-1,3,5-triazines, base catalysed Dimroth rearrangements, **81**, 282
- 4-Aryl-2,3-dihydro-1-*H*-pyrido[1,2-*c*]pyrimidine-1,3-diones, **84**, 259
- 3-Aryl-5,7-dihydro-5,5,7,7-tetramethylfuran[3,4-*e*]-1,2,4-triazine 4-oxides, **82**, 295
- 3-Aryl-5,8-dihydro-6,6,8-trimethyl-5,8-ethanopyrano[4,3-*e*]1,2,4-triazine 4-oxides, **82**, 295
- 8-Aryl-6,9a-dimethyl-2,3,4,8,9,9a-hexahydropyrido[2,1-*b*][1,3]oxazine-7,9-dicarboxylates, antihypertensive activity, **85**, 189
- 10-Aryl-3,6-dinitroacridones, formation, **83**, 236
- N*-Aryl-2-(ethoxycarbonyl)-3-(2-pyridylamino)acrylamides, cyclization, **85**, 235
- 3-Aryl-2-ethoxy-3-(5-fluoro-2-pyrimidinyl)propane-1,1-dicarboxylates, cyclization, **85**, 237
- 4-Arylethynyl-3(5)-acylpyrazoles, **82**, 6
- 1-Aryl-4-ethynyl-5-*N*-morpholino- Δ^2 -triazolines, **82**, 203
- 1-Aryl-4-ethynyltriazoles, **82**, 203
- 9-Aryl-3-fluoro-6-oxo-6-*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylates, formation, **85**, 237
- 3(4)-Arylfuran-2(5*H*)-ones, formation, **81**, 134
- 4-Aryl-2(5*H*)-furanone, formation, **81**, 123
- 4-Aryl-2,3,5,6,7,8-hexahydro-1-*H*-pyrido[1,2-*c*]pyrimidine-1,3-diones, **84**, 248
- 9-Arylhydrazono-6,7,8,9-tetrahydro-4-*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 207
- Fischer indolization, **85**, 231
- 5-Aryl-4-hydroxy-3(2*H*)-isothiazolone, formation, **83**, 79
- 1-Aryl-9-hydroxy-1,3,4,8-tetrahydropyrido[2,1-*c*][1,4]oxazin-8-ones, **84**, 281
- 4-Aryl-2-imino-6,7,8,9-tetrahydro-2-*H*-pyrido[1,2-*a*]pyrimidines, **85**, 243
- Aryl isothiocyanates, reaction with 1-amino-2-methylthiopyridinium iodides, **83**, 9
- 5-Arylmercapto-1,2,4-triazines, **82**, 281
- 2-Aryl-1-methoxyindoles, **82**, 115
- 5-Aryl-2-methoxypyrimidines, heat with ammonia, **84**, 34
- 2-(Arylmethyleneamino)pyridines, **85**, 240
- 4-(Arylmethylene)-2,3-(4*H*,5*H*)-furanones, production, **81**, 128
- Z*-Arylmethylenefuranones, **81**, 124
- Arylnitrile oxides, 1,3-dipolar cycloaddition to furanones, **81**, 145
- 1-Aryl-4-nitroindazoles, **83**, 200
- 3-Aryl-4-oxo-6-alkoxy-3a,4,6,6a-tetrahydrofuro[3,4-*d*]isoxazoles, formation, **81**, 145
- 7-Aryl-5-oxo-2,3-dihydro-5-*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxamide, **84**, 294
- 7-Aryl-5-oxo-2,3-dihydro-5-*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylate, **84**, 293
- 7-Aryl-5-oxo-2,3-dihydro-5-*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 277
- N*-Aryl-4-oxo-4-*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylic amide, formation, **85**, 235
- 7-Aryl-5-oxo-1,2,3,5-tetrahydropyrido[1,2,3-*de*]quinoxaline-6-carboxamides, **84**, 307, 310
- 2-Aryloxy-9,10-dimethoxy-6,7-dihydro-4-*H*-pyrimido[6,1-*a*]isoquinolin-4-one, **84**, 254

- N*-Arylphenoxazine, formation, **83**, 213
- 3-Aryl-2-propynynitriles, **85**, 243
- 2-Aryl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, formation, **85**, 240
- α -Aryl-2-pyridylacetamides, **84**, 259
- 3-Arylquinolines, formation, **84**, 25
- N*-Aryl substituted isothiazol-3(2*H*)one *S,S*-dioxides, formation, **83**, 79
- 6-Aryl-substituted 2-methoxyquinolines, **84**, 11
- 2-Aryl-6-substituted-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 245
- 4-Arylsulfonyl-3-diphenylmethoxy-2,5-dihydro-2-furanones, thermal rearrangement, **81**, 156
- 4-Arylsulfonyl-4-diphenylmethyl tetrahydrofuran-2,3-diones, **81**, 156
- 1-Arylsulfonyl-2-(1-iodoalkyl)piperidines, reaction with tin hydrides, **84**, 233
- 1-Arylsulfonylpipecolinamides, **84**, 233
- 6-Aryl-1,2,4-triazine 4-oxide, reaction with amines, **82**, 282, 284
- 1-Aryl[1,2,3]triazolo[1,5-*a*]pyridinium salts, **83**, 4
- 3(5)-Aryl-5(3)-trimethylsilylethynylpyrazoles, **82**, 10
- AS-35, **85**, 176
- Aspergillilic acid, **85**, 120
- Aspidospermine alkaloids, **84**, 102
- Aurachin A, **85**, 123
- Avicine, **85**, 68
- 6-Azabicyclo[3.1.0]hexane, production from pyridinium-3-olates, **85**, 80
- 2*H*-1,2,3-Azadiphosphole, in tungsten complexes, **85**, 26
- Azalactones, conversion to furanones, **81**, 118
- 1-Azaphenoxaselenines, preparation, **83**, 233
- Azaphenoxathiins, **83**, 219
- Azaphenoxathiin *N*-oxides, **83**, 219
- Azaphospha heterocycles, tautomerism, **81**, 293
- 2*H*-Azaphosphirene complexes of tungsten, thermolysis, **85**, 26
- complexes with tungsten, **85**, 29
- Azaphospholes, in formation of metal complexes, **85**, 49
- 2*H*-1,2-Azaphosphole complexes of tungsten, **85**, 26
- complexes of nickel, **85**, 27
- 1,3-Azaphospholes, in metal complexes, **85**, 26
- as ligands in organometallic compounds, **85**, 28
- 2-Azathianthrene, **83**, 231
- Azavinylidene species, of tungsten, **81**, 187
- Azetidin-3-one, derivatives with isothiazolidin-3-one *S*-oxide and *S,S*-dioxides, **83**, 80
- 2-Azidobenzaldehyde, **84**, 175
- 2-Azidobenzonitrile, reaction with ethyl acetonedicarboxylate, **84**, 162
- 3-Azido-1,2,4-benzotriazine 1-oxides, tautomerism, **82**, 266
- 4-Azido-2-chloroquinoline, **84**, 175
- o*-Azidocinnamionitriles, thermal cyclisation, **84**, 175
- 6-Azido-1,2-dihydropyrrolo[3,2,1-*ij*]quinoline, **84**, 114
- 2-Azido-1-ethylpyridinium fluoroborate, reaction with 2-pyridylacetoneitrile, **83**, 5
- 6-Azido-5-hydroxyimidazo[5,4,1-*ij*]quinolin-2-one, **84**, 144
- 8-Azidomethylperhydropyrido[1,2-*c*]pyrimidin-1-one, **84**, 254
- 5-Azidoquinoline, photolysis, **84**, 5
- 6-Azido-1,2,3,4-tetrazolo[1,5-*f*]quinoline, **84**, 175
- 2-Azidothiazole, transformation into thiazolo[3,2-*d*]tetrazole, **81**, 32
- trans*-2-Azidothiazole, stability relative to *cis*-isomer, **81**, 22
- 3-Azido-1,2,4-triazine 1-oxides, **82**, 266, 290
- 3-Azido-1,2,4-triazine 2-oxide, formation, **82**, 272
- B3-LYP exchange-correlation functional, in calculating structural parameters of heterocycles, **81**, 5
- reliability of calculated relative energies, **81**, 6
- in determination of vibrational spectra, **81**, 6
- B97, exchange-correlation functionals, in calculating structural parameters of heterocycles, **81**, 5
- Basis sets, in determining structural parameters of heterocycles, **81**, 4

- Benzaldehyde, reaction with metal complexes, **81**, 184
- 1,3-Benzazaphospholes, lithiation, **85**, 28
with tungsten complexes, **85**, 28
- Benzimidazole, calculated infrared spectra, **81**, 9
formation of complexes, **83**, 128
reaction with chromium and osmium complexes, **83**, 144
- Benzimidazole-2-thione, reaction with ruthenium carbonyls, **83**, 144
reaction with nickel complexes, **83**, 148
- Benzindolizines, **84**, 87
- Benzisoxazoles, formation from oximes of nitrophenyl ketones, **83**, 191
- Benzisoxazole-3-carboxylic acids, formation, **83**, 191
- Benzobis(1,3,2-dithiazole), structure, **81**, 39
- Benzocarbaephems, **84**, 73
- 2,1,3-Benzochalcogenodiazoles, reaction with metal carbonyls, **84**, 194
- 1,2-Benzodiazepine, **84**, 171
- 1,3-Benzodithiol-2-ones, formation, **83**, 197
- Benzofurazan *N*-oxide, reaction with diethylamine, **82**, 298
- Benzofuroxan, formation from 2-nitrophenyl azide, **81**, 35
- Benzo-fused 1,3,4-oxadiazines, tautomerism, **81**, 285
- Benzo-fused 1,4-oxazines, lack of tautomerism, **81**, 278
- Benzo[4,5]imidazo[1,2-*a*]pyridines, **83**, 201
- Benzo[4,5]imidazo[1,2-*a*]pyrimidines, **83**, 201
- Benzo[*a*]indolizine, **83**, 208
- 2-(Benzo[*d*]isoxazol-3-yl)perhydro-pyrido[1,2-*a*]pyrazines, **84**, 307
- Benzo[2,3]naphthalene[5,6,7-*i,j*]dithiepin, **83**, 243
- Benzonitrile, reaction with tungsten complexes, **85**, 27
- 3*H*-Benzo[1,2,5]oxathiazole, **83**, 229
- Benzo-2*H*-pyrans, isomerisation to 4*H*-isomer, **81**, 255
- Benzoquinoline, **83**, 238
- Benzoselenadiazole, computed ionisation potentials, **81**, 38
reaction with metal carbonyls, **84**, 200
- Benzotellurazoles, organoiron chemistry, **84**, 196
- 1,2-Benzothiaborole, in formation of ruthenium complexes, **85**, 19
- Benzo-1,3-thiaborolide, as ligand in metal complexes, **85**, 19
- 1,2,4-Benzothiadiazine 1,1-dioxide, tautomerism, **81**, 284
- 1,2,6-Benzothiadiazine 1,1-dioxide, tautomerism, **81**, 288
- 1*H*-2,1,4-Benzothiadiazines, **81**, 284
- 1,2,5-Benzothiadiborolene, reaction with iron carbonyls, **85**, 19
- Benzothiazine *S,S*-dioxide, **83**, 83
- Benzothiazole, infrared spectra, **81**, 21
reaction with metal carbonyls, **84**, 200
- 1,2,4-Benzotriazin-3(4*H*)-one 1-oxide, reaction with acetobromoglucose, **82**, 269
- 1,2,4-Benzotriazin-3(2*H*)-thione 1-oxides, **82**, 292
- Benzotriazolate anion, in complexes, **83**, 156
- Benzotriazole, reaction with molybdenum carbonyls, **83**, 156
reaction with rhodium and iridium carbonyls, **83**, 158
reaction with gold compounds, **83**, 159
- 1(2)-*H*-Benzotriazole, stability of tautomers, **81**, 29
- 2-[(Benzotriazol-1-yl)alkylamino]pyridines, reaction with electron-rich alkenes, **85**, 240
- 1*H*-2,1,4-Benzoxadiazines, **81**, 284
- Benzoxadiazole, computed ionisation potentials, **81**, 38
- Benzoxazolinone, reaction with chloro-dinitrobenzene, **83**, 213
- Benzoxazoloquinolines, **84**, 152
- 4-Benzoylamino-5-oxo-2,5-dihydrofuran-2-yl acetates, formation, **81**, 118
- (1*S*,4*aS*,7*R*)-1-Benzoyl-7-(*tert*-butyldimethylsilyloxy)perhydropyrido[1,2-*c*][1,3]oxazine, **84**, 244
- N'*-(Benzoyl-*N*-(2,4-dinitrophenyl)-*N*-phenylhydrazine, denitrocyclisation, **83**, 214
- 3(5)-Benzoylethynylpyrazole, **82**, 5
- 5-Benzoyloxy-2(5*H*)-furanone, reaction with aryl nitrile oxides, **81**, 146
- 3-(Benzoyloxymethyl)-4-(benzoyloxypropen-1-yl-1)pyrazoles, **82**, 5
- 1-Benzoylperhydropyrido[1,2-*c*][1,3]oxazine, **84**, 242

- 4-(3-Benzoylpropionyl)-1,4-morpholine, irradiation, **84**, 280
- 1-Benzoyl-2-pyridinethione, formation of 3-substituted triazolopyridines, **83**, 18
- 3-Benzoylpyridin-2(1*H*)-one, **84**, 37
- N*-Benzoyl-(*R*)-thiazolidin-4-carboxylic acid *S,S*-dioxide, cyclisation, **83**, 86
- Benzylamine, reaction with diphenylbutadiyne, **82**, 160
- 3-Benzylamino-5-alkylidene-2(5*H*)-furanone, formation, **81**, 118
- 2-(*N*-Benzylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 222
- Benzyl 2-(3-amino-1-pyrrolidinyl)-3-fluoro-9-(2,4-difluorophenyl)-6-oxo-6-*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylates, *N*-acylation, **85**, 218
- 4-Benzylated 1,4-dihydroquinoline, formation, **81**, 262
- Benzyl azides, reaction with diacetylenes, **82**, 182
- 2-Benzylbenzothiazole, cyclopalladation, **84**, 207
- 2-[*N*-Benzyl-*N*-(*t*-butoxycarbonyl)amino-methylene]-1-(2-chloroacetyl)-1,2,3,4-tetrahydroquinolines, **84**, 319
- (4*aS,R*)-2-Benzyl-5-{*N*-[(*t*-butoxycarbonyl)-1-tryptophyl]amino}perhydro[1,2-*c*]pyrimidine-1,3-dione, **84**, 262
- N*-Benzyl-3,3-dialkyl-thiazolidine-2-thione *S,S*-dioxides, **83**, 91
- 1-Benzyl-2,5-diphenylpyrrole, **82**, 160
- 3-Benzyl-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrazino[1,2-*a*]quinolin-1-ones, **84**, 318
- 4-Benzyl-3-hydroxy-2(5*H*)-furanone, formation, **81**, 129
- 9-Benzyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 243
- 1-(2-Benzylideneamino-3',5'-di-*tert*-butylbenzyl)-3-*tert*-butylimidazolium bromide, formation of silver complexes, **83**, 139
- 1-Benzylimidazole, complexes with organotin compounds, **83**, 122
- 1-Benzyl-2-imidazolylidiphenylphosphine, formation of iridium complexes, **83**, 133
- Benzylmercaptan, reaction with diacetylene, **82**, 174
- 1-Benzyl-4-methylaminotriazolo[4,5-*c*]pyridine, **83**, 20
- 1-Benzyl-4-nitroindazole, **83**, 200
- 1-Benzyl-3-nitrophenoxazine, preparation, **83**, 212
- 3-(Benzzyloxy)-6-bromo-2-methoxybenzaldehyde, **85**, 108
- 2*β*,4*αβ*,5*α*,7*β*,8*β*-*H*-5-Benzzyloxy-7-(*tert*-butyldiphenylsilyloxy)-2-[2-(methoxymethoxy)ethyl]-8-methylperhydropyrido[1,2-*b*][1,2]oxazine, ring opening, **84**, 226
- 2*α*,4*αβ*,5*α*,7*β*,8*β*-*H*-5-Benzzyloxy-7-(*tert*-butyldiphenylsilyloxy)-2-[2-(methoxymethoxy)ethyl]-8-methylperhydropyrido[1,2-*b*][1,2]oxazine, **84**, 228
- [4*R*-(4*α*,9*β*,9*αβ*)]-9-(Benzzyloxy-carbonylamino)-6-oxo-perhydropyrido[2,1-*b*][1,3]thiazine-4-carboxylic acid, **85**, 192
- 9-(Benzzyloxy-carbonylamino)-6-oxo-perhydropyrido[2,1-*b*][1,3]thiazine-4-carboxylate, **85**, 195
- 3-(Benzzyloxy-carbonylamino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **85**, 247
- catalytic hydrogenation, **85**, 203
- 3-(Benzzyloxy-carbonylamino)-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 203
- 1-(2-Benzzyloxyethyl)-6-fluoro-1,4-dihydroquinoline-2-carboxylic acid, **84**, 271
- 5-Benzzyloxyindole, in synthesis of criasbetaine, **85**, 101
- 5-Benzzyloxytryptamine, **82**, 140
- 2-(4-Benzylphenyl)-6-oxo-6,7-dihydro-4*H*-pyrido[6,1-*a*]isoquinolin-4-thione, **84**, 259
- 3-Benzyl-5-phenylpyrazole, **82**, 165
- μ - η^5 : η^5 -(2-Benzyl-1,3,4,5-tetramethyl-2,3-dihydro-1,3-diborolyl)(η^3 -allyl)(η^4 -1,5-hexadiene)dicnickel, **85**, 18
- 2-Benzyl-1,4,6-trimethylpyrimidinium salts, rearrangements, **84**, 35
- Berberidic acid, **85**, 131
- Berberine, **85**, 88
- irradiation, **85**, 92
- oxidation, **85**, 131
- Beryllium complexes, **81**, 225
- Betalaines, **85**, 70

- 2,2'-Bibenzimidazole, reaction with rhenium complexes, **83**, 149
reaction with palladium complexes, **83**, 153
- Bicyclic mesoionic thiazolo-oxazolium *S,S*-dioxides, formation, **83**, 86
- Biimidazole, as chelators, **83**, 148
reaction with molybdenum complexes, **83**, 149
reaction with osmium complexes, **83**, 150
reaction with palladium complexes, **83**, 153
- 2,2'-Biindolyis, **82**, 135
- Bioactive peptides, containing 1,2,5-thiadiazolidines, **83**, 106
- 3-[(4-Biphenyl)perhydropyrido[1,2-*c*][1,4]oxazin-3-yl]propyl nitrate, **84**, 276
- Bipyrazole, **82**, 3
- 1,3-Bis(1-adamantyl)imidazol-2-ylidene, complexes with diethyl magnesium and zinc, **83**, 121
- Bis(1-alkyl-5-tetrazolate)nickel(II), formation, **83**, 166
- 4,5-Bis(alkynyl)-1*H*-pyrazoles, **82**, 7
- 1,3-Bis(arylmethyl)imidazol-2-ylidene, complexes with tungsten hexacarbonyl, **83**, 124
formation of rhodium complexes, **83**, 133
- Bis(1,2-azaborolyl)complexes of metals, **85**, 21
- 1,6-Bis(2'-benzimidazolyl)-2,5-dithiahexane, reaction with rhodium complexes, **83**, 147
- 2,6-Bis(2-benzimidazolyl)pyridine, reaction with rhenium, **83**, 149
- 1-(3,4-Bisbenzoyloxy-5-benzoyloxymethyl-tetrahydrofuran-2-yl)-4-trimethylsilanylethynyl-1*H*-pyrazole-3-carboxylic acid methyl ester, **82**, 27
- 3,3-Bis(*tert*-butoxycarbonyl)-4,5-difluoro-1-methyl-7-oxo-2,3-dihydro-1*H*,7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, **84**, 235
- [4-(1,3-Bis-{6-[bis-*tert*-butoxycarbonylmethylamino)methyl]pyridin-2-yl}-1*H*-pyrazol-4-ylethynyl)phenoxy]acetic acid methyl ester, hydrogenation, **82**, 40
- 2-[Bis(chloroacetyl)amino-4-(chloroacetoxy)-3-phenylquinoline, **84**, 132
- 1,6-Bis-deacetylevonine, **85**, 133
- 1,4-Bis(2,6-diethylphenyl)-1,4-diazabuta-1,3-diene, reaction with gallium complexes, **85**, 21
- Bis(η^5 -2,3-dihydro-1,3-diborolyl)platinum, reaction with ferrocenes, **85**, 18
- Bis(dimethylamino)chloroborane, formation of complexes with imidazolylenes, **83**, 121
- 4-(Bis(dimethylaminotrimethylsilyl)imino)(phosphorano)-2,5-dimethyl-2*H*-1,2,3-diazaphosphole, reaction with titanium complexes, **85**, 29
- 1,3-Bis(2,6-dimethyl-4-bromo)imidazol-2-ylidene, reaction with nickelocene, **83**, 135
- Bis(dimethylphosphino)ethane, as a ligand in iridium complexes, **81**, 210
- 2,2'-Bis(3,5-dimethylpyrazol-1-yl)ethanol, in niobium complexes, **81**, 173
- Bis(3,5-dimethylpyrazol-1-yl)methane, reaction with molybdenum hexacarbonyls, **81**, 194
- Bis(3,5-dimethylpyrazol-1-yl)phenylmethane, in rhodium complexes, **81**, 216
- Bis(1,3-diphenylimidazol-2-ylidene) mercury (II) carbene complexes, **83**, 142
- 1,3-Bis(diphenylmethyl)imidazolium bromide, formation of rhodium complexes, **83**, 133
- 1,4-Bis(diphenylphosphino)butane, in formation of furanones, **81**, 112
- 1,1'-Bis(diphenylphosphino)ferrocene- η^2 -etheneplatinum, **84**, 205
- 1,4-Bis(2,6-di-*iso*-propylphenyl)-1,4-diazabuta-1,3-diene, reaction with gallium complexes, **85**, 21
- Bis-1,3-dithiole polymethine dyes, computed polarizabilities, **81**, 27
- 9,10-Bis(1,3-dithiol-2-ylidene)-9,10-dihydroanthracene, computed geometries, **81**, 27
- 1,3-Bis(mesityl)imidazol-2-ylidene, complex with alanes, **83**, 121
- 1,3-Bis(methylimidazol-2-ylidene)methylene, formation of metal complexes, **83**, 124
- Bis(1-methylimidazol-2-yl)methane, formation of rhodium complexes, **83**, 135
- 1,5-Bis(*N*-methylimidazol-2-yl)pentane, reaction with palladium acetate, **83**, 138

- 2,6-Bis(1-methylimidazolium-3-yl)pyridine dihexafluorophosphate, reaction with mercury (II), **83**, 142
- Bisoxazolines, calculated vertical ionisation energies, **81**, 21
- Bis(1,1,4,7,7-pentamethyldiethylenetriamine)lithiumbiimidazole, in titanium complexes, **83**, 149
- Bis(pentane-2,4-dionato)nickel (II), reaction with carborane dianions **85**, 13
- 1,3-Bis(phenylmethyl)imidazol-2-ylidene, formation of nickel complexes, **83**, 135
- Bis(pyrazol-1-yl)borates, as ligands, **81**, 168
- Bis(pyrazol-1-yl)methanes, formation of niobium complexes, **81**, 172
- reaction with molybdenum hexacarbonyls, **81**, 194
- reaction with iron complexes, **81**, 198
- Bis(pyrazol-1-yl)phenylmethane, in organorhodium complexes, **81**, 216
- 1,3-Bis(2'-pyridyl)imidazolium bromide, reaction with palladium acetate, **83**, 136
- 3,6-Bis(2-pyridyl)-*s*-tetrazine, electronic transitions in, **81**, 79
- 3,3-Bis-quinoline, **84**, 27
- Bis(thiadiborole)iron carbonyl complexes, **85**, 20
- Bis-1,2,4-triazines, study of ground state structure, **81**, 78
- 2,3,-Bis(tributylstannyl)acrylate, formation, **81**, 113
- 3,4-Bis(tributylstannyl)-2(5*H*)-furanone, formation, **81**, 113
- 2,4-Bis(trimethylstannyl)quinoline, formation, **84**, 8
- 2,2'-Bithiazoles, **84**, 210
- Bleekerine, **85**, 144
- Borane-tetrahydrofuran, reaction with ruthenium complexes, **85**, 4
- Boulton-Katritzky rearrangements, computational studies, **81**, 37
- Brassicinal A, formation, **82**, 127
- 6-Bromo-5-aminoquinoline, **84**, 5
- 3-Bromo-1,2,4-benzotriazine, **82**, 271
- 3-Bromo-1,2,4-benzotriazine 1-oxides, **82**, 289
- 3-Bromo-1,2,4-benzotriazine 4-oxides, reduction, **82**, 271
- 4-Bromo-5-(bromomethylene)-2(5*H*)-furanones, preparation, **81**, 115
- 7-Bromo-2-butoxy-3-phenyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reactions, **85**, 219
- 1-(4-Bromobutyl)perhydropyrido[1,2-*a*]pyrimidin-2-one, **85**, 210
- Bromochelonin B, isolation, **82**, 143
- 5-Bromo-6-chloroquinoline, **84**, 4
- 6-Bromo-2-chloroquinoline, formation, **84**, 3
- 7-Bromo-8-[(4-cyanophenyl)methoxy]-2-cyclopentyl-2,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, **84**, 309
- 1-Bromocycloocta-2,4-diene, reaction with molybdenum hexacarbonyl, **81**, 192
- 5-Bromo-5-deoxy-D-furanoxylase, **85**, 180
- 5-Bromo-5-deoxy-2-xylofuranose, reaction with 3-aminopropanol, **85**, 188
- 1-Bromo-2,5-di-*tert*-butyl-1,3-diazaborole, complexes with imidazolylidenes, **83**, 120
- 7-Bromo-4-(2,6-dichlorophenyl)-1,2-dihydro-3*H*pyrido[1,2-*c*]pyrimidin-3-one, **84**, 253
- 1-(4-Bromo-3,3-dimethylbutyl)-3-dimethylbutyl)-3-methyl-6-phenylthiouracil, reaction with tin hydrides, **84**, 257
- 2-Bromo-1-(2-ethylpiperidin-1-yl)-3-(2-phenylpyrazolo[1,5-*a*]pyridin-3-yl)pro-penone, reaction with hydroxide, **82**, 18
- 4-Bromo-5-ethylthio-2(5*H*)-furanone, **81**, 137
- 4-Bromoethynyl-1,3-dimethylpyrazole, **82**, 53
- 4-Bromoethynylpyrazoles, **82**, 38
- 5-Bromo-6-fluoro-2-methylquinoline, **84**, 4
- 5-Bromoisothiazole dioxides, formation and reaction, **83**, 76
- (±)-5-Bromo-*Nb*-methoxycarbonyltryptophan methylamide, **82**, 132
- 6-Bromo-2-methoxyquinoline, formation, **84**, 3
- 3-Bromo-5-methoxy[1,2,4] triazolo[4,3-*a*]pyridine, **83**, 30
- 2-Bromomethyl-6-bromo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 245
- 3-Bromomethyl-2,3-dihydropyrido[1,2,3-*de*]-1,4-benzothiazinium bromide, **84**, 295
- 3-Bromo-5-methylene-2(5*H*)-furanone, formation, **81**, 131
- cycloaddition with butadiene, **81**, 144
- 5-(Bromomethylene)-2(5*H*)-furanone, formation, **81**, 115

- (3*S*)-10-Bromo-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylate, synthesis, **84**, 296
- 2-Bromo-8-methylquinoline, coupling with boronic esters, **84**, 12
- 9-Bromo-2-morpholino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with 4-vinylpyridine, **85**, 208
- 2-Bromo-1,5-naphthyridine, **84**, 65
- 2-Bromo-3-nitroanthraquinone, reaction with 2-aminopyridine, **83**, 201
- 2-Bromo-1-(2-nitrophenyl)-ethanone, reaction with 2-cyanophenol, **83**, 203
- 5-Bromo-4(3*H*)-oxo-7*H*-pyrazolo[3,4-*d*]pyrimidines, reaction with acetylenes, **82**, 29
- 3-Bromo-11-oxo-11*H*-pyrido[1,2-*a*]quinazoline-6-carboxamides, **85**, 261
- 3-Bromo-11-oxo-11*H*-pyrido[2,1-*b*]quinazoline-6-carboxylic acid, **85**, 264
- 8-Bromo-1,7-phenanthroline, **84**, 64
- 4-Bromo-5-phenylthio-2(5*H*)-furanone, **81**, 137
- 1-(2'-Bromophenyl)triazolo[4,3-*a*]quinolines, **84**, 168
- 1-Bromo-2-(pyrazol-3-yl)acetylenes, **82**, 18
- 4-Bromopyridine, coupling with phenylboronic acids, **84**, 12
- 7-Bromo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 243
- 2-Bromoquinoline, **84**, 3
from 2-methoxyquinoline, **84**, 4
- 4-Bromoquinoline, **84**, 4
- 3-Bromo-1,2,4-triazine 2-oxide, reaction with alkoxides, **82**, 272
- 5-Bromotriazolopyridine, formation, **83**, 3
- 7-Bromo[1,2,3]triazolo[1,5-*a*]pyridine, nucleophilic displacement reactions, **83**, 38
- 10-Bromo-*N*-1,3-trimethyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]quinoxaline-3-carboxamide, **84**, 320
- 10-Bromo-*N*-1,3-trimethyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]quinoxaline-6-carboxamide, **84**, 309
- 5-Bromotryptamines, preparation, **82**, 132
- Bufofbutanoic acid, **82**, 140
- Bufofthionine, **85**, 70
- 4-Butadiynyl-1,3,5-trimethylpyrazole, p*K*_a, **82**, 78
- Butenolides, *see* furanones
- 2-(*tert*-Butoxycarbonylamino)-3-(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-3-yl)propionate, **85**, 236
- (4*aR*,5*S*)-5-[(*t*Butoxycarbonyl)amino]perhydropyrido[1,2-*c*]pyrimidine-1,3-dione, acid hydrolysis, **84**, 254
- 3-*t*-Butoxycarbonylaminopyrrolidine, **84**, 80
- (9*aS*)-2-*t*-Butoxycarbonyl-1,6,7,8,9,9*a*-hexahydro-2*H*-pyrido[1,2-*a*]pyrazine, **84**, 301
- 1-(*tert*-Butoxycarbonyl)-2-(2-hydroxyalkyl)piperidines, cyclisation, **84**, 243
- (9*aS*)-2-*t*-Butoxycarbonylperhydropyrido[1,2-*a*]pyrazin-4-one, **84**, 318
- 2-*tert*-Butyl-1*H*-1,3-benzazaphosphole, lithiation, **85**, 28
- 11*b*-Butyl-1,3,4,6,7,11*b*-hexahydro[1,4]oxazino[3,4-*a*]isoquinolin-4-one, **84**, 287
- tert*-Butylisocyanide, reaction with ruthenium complexes, **85**, 4
- t*-Butylmercaptan, reaction with diacetylene, **82**, 174
- 3-Butyl-9-methoxyperhydropyrido[1,2-*c*][1,3]oxazin-1-one, **84**, 243
- 3-(2'-Butyl)-4-(*p*methoxyphenylamino)-1,2,5-thiadiazole *S,S*-dioxide, formation, **83**, 100
- 1-*tert*-Butyl-2-methyl-1,2-azaborolanyl ligand, in nickel complexes, **85**, 23
- 1-*tert*-Butyl-3-methyl-2-phenyl- Δ^3 -azaboroline, reaction with iron carbonyls, **85**, 22
- tert*-Butylphosphaethyne, reaction with metallic iridium vapour, **85**, 31
- 3-*tert*-Butyl-1-(2'-pyridylmethyl)imidazolium bromide, reaction with silver oxide, **83**, 139
- 3-*t*-Butyl-8-(1'-pyrrolo) [1,2,4]triazolo[4,3-*a*]pyridine, **83**, 18
- 3-*t*-Butyltriazolopyridine, formation, **83**, 3
- 2-(But-3-ynyloxy)pyrimidine, effect of heating, **84**, 57
- 2-(3-Butynylsulfanyl)-4,6-dimethylpyrimidinium salt, **84**, 58
- 2-(3-Butynylsulfanyl)pyrimidine, rearrangement, **84**, 57

- 2-(But-3-ynylsulfonyl)pyrimidine, effect of heating, **84**, 57
- 2-(But-3-ynylthio)pyrimidine, effect of heating, **84**, 57
- 5-(Butynylthio)pyrimidines, **84**, 58
- γ -Butyrolactones, synthesis, **81**, 152
- Cadmium complexes, **81**, 225
- Calcium antagonists, in thiazole derivatives, **83**, 96
- Camptothecin, synthesis, **84**, 10
- (S)-Camptothecin, synthesis, **84**, 24
- Carbacephem, **84**, 73
- Carbamide, reaction with aminobutenones, **82**, 222
- 5-(2-Carbamoylvinyl)-1,3-dialkyluracil, reaction with sodium ethoxide, **84**, 49
- Carbimazole, conformational equilibrium, **81**, 11
- 10-Carboethoxy-9-oxo-9*H*-pyrimido[1',2':1,5][1,2,4]triazolo[4,3-*a*]quinoline, **84**, 168
- C-Carboethoxy-*N*-phenylnitrilimine, reaction with diacetylene, **82**, 181
- Carbometallation of phenylpropargyl alcohol, **81**, 114
- 3-Carbomethoxyindole-1-propionic acid, cyclisation, **84**, 106
- 3-Carbomethoxy-[1,2,3]triazolo[1,5-*a*]pyridine, photolysis, **83**, 47
- Carbon monoxide, reaction with rhodium complexes, **81**, 210
- Carbonotropy, in pyrans, **81**, 255
- Carborane anionic sandwiches of cobalt, **85**, 12
- Carborane dianion, reaction with nickel complexes, **85**, 13
- 2-[4-(4-Carboxybenzoyl)benzyloxy]-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction of carboxyl group, **85**, 216
- 3-Carboxybutyl-substituted isoxazolidines, conversion to furanones, **81**, 116
- 1-Carboxymethylnicotinic acid, **85**, 127
- 7-Carboxy[1,2,4] triazolo[4,3-*a*]pyridine, **83**, 31
- Caryophenols, structure, **82**, 4
- Casadinium chloride, **85**, 139
- CASPT2, of heterocycles, **81**, 2
- in calculation of excited states, **81**, 7
- Castro cross-couplings, **82**, 31
- C-coordinated oxazole, in metal complexes, **84**, 195
- CEBE, calculated, **81**, 18
- Chelidonine, oxidation, **85**, 154
- Chimonanthine, **82**, 136
- Chlorinated 5-hydroxy-4-methyl-2(5*H*)-furanones, formation, **81**, 120
- 4-Chloroacetoacetate, reaction with aminopyridines, **85**, 245
- 1-(4-Chloro-2-acetoxybenzoyl)-1,2,3,4-tetrahydropyridin-4-ones, **85**, 186
- 3-Chloroacetyl-1-methoxyindole, **82**, 118, 124
- 2-(2-Chloroacetyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate, **84**, 320
- 4-Chloro-1-alkyl-1*H*-pyrazolo[3,4-*c*]pyridazines, formation, **82**, 65
- 2-Chloroalkylthioquinolines, **84**, 78
- 6-Chloro(bromo)-3-amino-1,2,4-triazines, **82**, 280
- 2-Chlorobenzothiazole, **84**, 210
- reaction with iridium carbonyls, **84**, 200
- 3-Chloro-1,2,4-benzotriazine 1-oxide, reaction with amines, **82**, 273
- 2-Chlorobenzoxazole, reaction with iridium carbonyls, **84**, 200
- N*-(4-Chlorobenzyl)-9-iodo-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxamide, **84**, 274
- 2-Chloro-6-bromoimidazo[1,2-*a*]pyrimidine-3-carboxylate, **85**, 243
- Chlorocarbene complexes of molybdenum and tungsten, **81**, 183
- 8-Chloro-7-(chloromethyl)-9-[(dimethylaminomethylene)amino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 232
- 4-Chloro-5-(2-chloro-5-nitrophenylethynyl)-1,3-dimethyl-1*H*-pyrazole, **82**, 44
- 2-Chloro-3-cyano-4-methylquinoline, coupling with stannanes, **84**, 16
- 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5*H*)-furanone, mutagenicity, **81**, 120
- 2-Chloro-3,4-dihydroimidazo[5,4,1-*ij*]quinoline, **84**, 144
- 2-Chloro-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one, reaction with ammonia, **84**, 253
- 2-Chloro-9,10-dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one, **84**, 258

- 2-Chloro-3,4-dimethylthiazolium tetrafluoroborate, reaction with chromium carbonyls, **84**, 193
reaction with metal carbonyl anions, **84**, 194
reaction with iron carbonyl anions, **84**, 196
reaction with iridium complexes, **84**, 201
reaction with osmium carbonyls, **84**, 198
in nickel complexes, **84**, 205
- 2-Chloro-3,5-dinitrobenzophenone, cyclisation, **83**, 225
- 6-Chloro-2,4-diphenylquinoline, **84**, 23
- 6-Chloro-1,3-dipropyl-1*H*,3*H*-pyrimidine-2,4-dione, reaction with 2-aminopyridines, **85**, 242
- 1-(2-Chloroethyl)-6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate, **84**, 283
- 4-Chloroethynyl-1,3-dimethylpyrazole, **82**, 50
- 4-Chloroethynyl-1,5-dimethylpyrazole, **82**, 49
- 4- β -Chloroethynyl-3,5-dimethylpyrazole, **82**, 14
- 4(3)-Chloroethynyl-1-methylpyrazole, isomerisation, **82**, 50
- 4-Chloroethynyl-1,3,5-trimethylpyrazole, reaction with sodium amide, **82**, 48
- 7-Chloro-6-formyl-2,3-dihydro-1*H*,5*H*-pyrido[3,2,1-*ij*]quinazoline-1,3,-dione, **84**, 250
- 2-Chloro-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction of chloro atom, **85**, 208
- 4-Chloro-2(5*H*)-furanone, formation, **81**, 131
- 8-Chloro-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrazino[1,2-*a*]quinoline, **84**, 304
- 8-Chloro-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrazino[1,2-*a*]quinolin-2-one, **84**, 318
- 3-Chloro-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 205
- 2-Chloro-3-methylbenzothiazolium tetrafluoroborate, reaction with platinum complexes, **84**, 205
- 2-Chloromethyl-7-methyl-4*H*-[1,2-*a*]pyrimidin-4-one, nitration, **85**, 205
- 5-Chloro-1-methyl-4-nitroimidazole, reaction with 2-aminophenol, **83**, 212
- 2-Chloro-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 237
- 2-Chloromethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 245
reaction with nitronate ions, **85**, 210
- 2-Chloro-5-methylthiazole, reaction with iridium carbonyls, **84**, 200
- Chloronitrile oxide, dimerisation, **81**, 34
- 1-Chloro-2-nitroanthraquinone, reaction with 2-aminopyridine, **83**, 201
- 4-Chloro-3-nitrocoumarin, reaction with 2-mercaptophenol, **83**, 218
reaction with 2-mercaptoaniline, **83**, 228
- 2-Chloro-3-nitropyridine, **83**, 226, 231
reaction with 2-amino-3-hydroxypyridine, **83**, 211
- 3-Chloro-4-nitropyridine-1-oxide, **83**, 231
reaction with mercaptopyridinols, **83**, 219
- 4-Chloro-5-nitropyrimidine, reaction with aminopyridinethiols, **83**, 227
- 2-(4-Chlorophenyl)-imidazo[1,2-*q*]quinoline-1-acetamide, **84**, 134
- 5-(1-Chloro-1-phenylmethyl)-1,2,4-triazine, **82**, 277
- 5-Chloro-6-phenyl-1,2,4-triazine, **82**, 280
- 7-Chloro-3-propyl-2-propoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with Lawesson's reagent, **85**, 208
- 5-Chloro-4-(1-propynyl)-1,3-dimethylpyrazole, **82**, 39
- Chloropyrazines, computational studies of electronic effects, **81**, 41
- 2-Chloropyridine, reaction with semicarbazide, **83**, 19
- 2-Chloropyridine-3-carboxylic acid chloride, **84**, 168
- 2-Chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 208
- 2-Chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-thione, **85**, 208
- 6-Chloropyrimidine, effect of hydrogen bonding on aminolysis, **81**, 45
- 2-Chloroquinolines, **84**, 2
in Stille coupling, **84**, 5
- 4-Chloroquinolines, **84**, 2
- 6-Chloroquinoline, **84**, 4
- Chlorosulfonyl isocyanate, reaction with aminoacids, **83**, 105
- 2-Chlorothiazolium tetrafluoroborates, reaction with metal carbonyls, **84**, 201
- 5-Chloro[1,2,3]triazolo[1,5-*a*]pyridine, lack of displacement reactions, **83**, 38
- 7-Chloro[1,2,3]triazolo[4,5-*b*]pyridine, glycosylation, **83**, 37
- 5-Chlorotryptamine, preparation, **82**, 130

- Chrysotricine, **85**, 145
- Cinchomeric acid, formation and decarboxylation, **82**, 212
- Cinnolines, formation, **83**, 235
- Circumdatin, **85**, 98
- Clathridin zinc salt, **85**, 69
- Cobalt anionic sandwich complexes, reaction with boryl anions, **85**, 10
- Cobalt carbonyls, reaction with tin complexes, **81**, 204
reaction with diboroles, **85**, 7
- Cobalt (II) chloride, reaction with triple-decker metal complexes, **85**, 5
- Cobalt-iron triple-decker complexes, **85**, 10
- Cobalt neutral and charged triple-decker complexes, synthesis **85**, 10
- Cobalt-osmium triple decker complexes, **85**, 5
- Cobalt-ruthenium triple-decker complexes, **85**, 9
- Cobalt-tantalum triple-decker complexes, **85**, 9
- Codamine, **85**, 94
- (-)Coerulescine, isolation, **82**, 138
- Computational chemistry, of heterocycles, **81**, 2
- Configuration-interaction methods, applied to heterocycles, **81**, 2
- Conjugated nitrile ylides, cyclisation, **81**, 19
- Copper, organometallic complexes, **81**, 227
complex of 3-phenyltriazolopyridine, X-ray structure, **83**, 27
- Copper phenylacetylide, reaction with iodopyrazoles, **82**, 59
- Copper *p*-phenylbenzoylacetylide, reaction with iodopyrazoles, **82**, 58
- Copper (I) triflate, reaction with imidazolidenes, **83**, 138
- Copper zinc superoxide dismutase, calculations on, **81**, 14
- Core-electron binding energies, *see*, CEBE
- Cortamidine Oxide, **85**, 119
- Corunnine, **85**, 108, 110
- Coumarins, synthesis, **83**, 223
- Counterpoise method, in calculations of heterocycles, **81**, 6
- Creutz-Taube ion, computational studies, **81**, 41
- Criabetaïne, **85**, 100
- 2-[*N*-(*trans*-Crotlyl)-*N*-benzylamino]-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with tosylamine, **85**, 227
reaction with chiral primary amines, **85**, 228
- Cryptaustoline, **85**, 68
- Cryptolepine, **85**, 152
- Cyanacetamide, cyclisation with 1,3-enynes, **82**, 199
- 2-Cyanamino-4-alkylpyrimidine, **82**, 168
- 6-(Cyanamino)-2-*t*-butylpyridine, **84**, 49
- 6-(Cyanoamino)pyridines, **84**, 48
- 5-Cyanamino-1,2,4-triazines, **82**, 279
- Cyanoic acid, reaction with diacetylene, **82**, 180
- Cyanoalkylsulfonamides, in formation of isothiazole *S,S*-dioxides, **83**, 80
- N*-(α -Cyano- α -aryl)-methylanilines, cycloaddition with sulfinylanilines, **83**, 105
- 5-Cyano-2,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyridine, **83**, 14
- 3-Cyano-4,6-dioxypyridin-2-thione, reaction with cinnamionitriles, **85**, 194
- 4-Cyano-1,2,3,4,11*a*-hexahydro-6*H*-pyrazino[1,2-*b*]isoquinoline, **84**, 323
- 6-Cyano-2,3,4,8,9,9*a*-hexahydropyrido[2,1-*b*][1,3]oxazine, **85**, 182, 187
- 9-Cyano-1,2,3,4,7,8-hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one, **85**, 250
- 3-Cyano-4-hydroxy-1,2-dihydropyrido[1,2-*b*]pyridazinium inner salt, **84**, 234
- 3-Cyano-1-hydroxyindoles, **82**, 107
- 3-Cyano-2-[(3-hydroxypropyl)amino]-5-(4-pyridyl)pyridine-1'-oxide, cyclisation, **85**, 234
- 3-Cyano-4-hydroxypyridazino[1,6-*a*]quinolinium betaine, **84**, 239
- 4-Cyano-3-imino-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one, **84**, 255
- 2-(*N*-Cyanoimino)-thiazolidine, oxidation, **83**, 87
- 2-[[2-Cyano-3-(4-methoxyphenyl)acroyl]amino]pyridine, **85**, 242
- 2-Cyano-3-(4-methoxyphenyl)acroyl chloride, reaction with 2-aminopyridine, **85**, 242
- 3-Cyano-4-(4-methoxyphenyl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidin-2-one, **85**, 242

- 5-Cyano-6-methoxy-1,2,3,4-tetrahydropyridin-2-ones, **85**, 250
- 7-Cyanomethylated indole, **82**, 129
- 7-Cyano-8-methyl-6-oxo-1,2,3,4-tetrahydro-6*H*-pyrido[1,2-*a*]pyrimidine-9-carboxylate, **85**, 250
- 3-Cyano-6-methyl-2-pyridones, **82**, 199
- 2-Cyanomethylthiazole, **84**, 160
- 3-Cyano-2-methylthio-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with ethyl mercaptoacetate, **85**, 220
- 3-Cyanomethylthiazole, condensation with ethyl acetoacetate, **83**, 12
- 7-Cyano-6-nitroindole, **82**, 127
- 8-Cyano-2-oxo-2,3,4,4*a*,7,8-hexahydropyrido[1,2-*b*][1,2]oxazine-8-carbonitrile, **84**, 227
- 8-[(4-Cyanophenyl)methoxy-7-formyl-2-cyclopentyl-2,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, **84**, 314
- 3-Cyano-1*H*-pyridin-2-one, **82**, 226
- 9-Cyano-7-(4-pyridyl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidine-1'-oxide, formation, **85**, 234
- 3-[[2-Cyano-2-(2-pyridyl)ethenyl]amino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 249
- 2-Cyanoquinolines, chlorination, **84**, 137
- 3-Cyanoquinoline, formation, **84**, 26
- 5-Cyano-1,2,4-triazines, replacement of cyano group, **82**, 278
- 3-Cyano[1,2,3]triazolo[1,5-*a*]pyridine, **83**, 5
- 3-Cyano-4-trifluoromethyl-6-phenyl-2-[(3-hydroxypropyl)amino]pyridine, heating with phosphorous oxychloride, **85**, 234
- Cyclic sulfoximines, formation, **83**, 82
- 2-Cycloalkyl-8-hydroxy-2,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-diones, **84**, 308
- (11*aR*)-2-Cycloalkyl-8-hydroxy-2,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, **84**, 320
- 8,14-Cycloberberine, **85**, 90
- 1-Cyclohepta-2,4,6-trienyl)phosphine, reaction with rhodium complexes, **81**, 206
- 2-(*N*-Cyclohex-2-en-1-yl)-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with phenylhydrazine, **85**, 225
- 4-Cyclohexylcarbonyl-1-phenethyl-2-oxo-1,2,3,4-tetrahydropyrazine, **84**, 318
- Cyclohexyl isocyanide, reaction with rhodium complexes, **81**, 210
- Cyclooctane-1,5-diylbis(pyrazol-1-yl)borate, as a ligand in molybdenum complexes, **81**, 192
- reaction with cobalt, nickel and zinc nitrates, **81**, 204
- Cyclooctatetraene, displaced from iron complexes, **85**, 5
- Cycloocteno-1,2,3-selenadiazole, reaction with platinum complexes, **84**, 208
- Cyclopentadienyl groups in triple-decker cobalt complexes, **85**, 10
- Cyclopentenone, irradiation, **81**, 157
- 9-Cyclopropyl-3-fluoro-2-hydroxy-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylates, formation, **85**, 240
- 2-Cyclopropyl-2-(5-fluoro-4-hydroxy-2-pyrimidinyl)acetaldehyde, **85**, 240
- Cyclotelletamine, **85**, 69
- Cylindricines, **84**, 120
- (+)-Cylindricines A and B, synthesis, **84**, 121
- epi*-Cylindricine D, **84**, 123
- Cytidyl-3,5'-adenosine, reaction with ribonuclease A, **81**, 65
- Cytosine, computational studies, **81**, 46
- computational studies of hydration, **81**, 47
- Watson-Crick pair with isocytosine, **81**, 48
- Watson-Crick pair with guanine, **81**, 49
- deamination to uracil, **81**, 50
- Dapiprazole, **83**, 55
- Deca-2,4,6,8-tetrayne, reaction with sodium disulfide, **82**, 173
- Dehydrobufotenine, **85**, 70
- Dehydrocorydalmine, **85**, 94
- Dehydrodiscretamine, **85**, 94
- 5',6'-Dehydroguaiachrysine, **85**, 147
- 5',6'-Dehydroguiaflavine, **85**, 147
- 1-Dehydroimidazolyl radical, formation, **81**, 10
- Dehydronorhydrastine methyl ester, **85**, 91
- 8-*O*-Demethylvasconine, **85**, 99
- Density functional theory, *see*, DFT
- 1,1-Deoxycylindricine, **84**, 120
- Deoxypyridinoline, **85**, 81
- 4-Deuterio-2,4,6-triphenylthiopyran, conversion to 2-deuterated product, **81**, 257

- DFT, in calculating geometries of
heterocycles, **81**, 5
limitations, **81**, 5
insensitivity with respect to multireference
effects, **81**, 6
- Diacetylene, reaction with diazomethane,
82, 3
reaction with amines, **82**, 159
reaction with diamines, **82**, 160
reaction with hydrazines, **82**, 163
reaction with guanidines, **82**, 168
reaction with diols, **82**, 169
reaction with thiols, **82**, 171
reaction with phosphines, **82**, 178
reaction with arsines, **82**, 178
reaction with diazomethane, **82**, 179
reaction with azides, **82**, 182
- 3,5-Diacetyl-1-methylpyrazole, reaction with
phosphorus pentachloride, **82**, 17
- Diacylpyrazopyridines, **84**, 132
- 4,6-Dialkoxydihydropyrimidines, **81**, 265
- 3-Dialkylamino-2*H*-azirines, in formation of
1,2,5-thiadiazoline *S,S*-dioxides, **83**, 104
- Dialkylaminobis(trifluoromethyl)boranes,
reaction with methoxybutenone, **82**, 235
- 4-Dialkylamino(alkoxy)but-3-en-2-one,
reaction with nitrile oxides, **82**, 233
- 4-Dialkylaminobut-3-en-2-one, **82**, 183, 210
- 1-Dialkylaminobut-1-en-3-yne, reaction
with 1,2-diaminoethane, **82**, 183
protonation, **82**, 192
reaction with thiourea, **82**, 202
- 4-Dialkylaminobut-3-yn-2-ones, formation,
82, 237
- 7(8)-*R*-2-Dialkylamino-4-methyl-3*H*-1,5-
benzodiazepines, **82**, 240
- 2-Dialkylamino-4-methyl-5*H*-1,5-dihydro-
1,5-benzothiazepines, **82**, 185
- 7-Dialkylamino-5-methyl-7*H*-2,3-dihydro-
1,4-dithiepins, **82**, 184
- 2-Dialkylamino-4-methyl-8*H*-6,7-dihydro-
1,5-dithiocins, **82**, 185
- 3(5)-Dialkylamino-5(3)-methylpyrazoles,
82, 243
- 2-Dialkylamino-4*H*-pyrido[1,2-*a*]pyrimidin-
4-one, flash vacuum thermolysis, **85**, 229
- 3,3-Dialkyldiaziridine, reaction with dipro-
pynylketone, **82**, 13
- 1,3-Dialkyl-4,5-dimethylimidazol-2-ylidene,
complexes, **83**, 120
reaction with 1,2-dichloroethane, **83**, 120
reaction with diazaboroles, **85**, 21
- Dialkylhydrazines, reaction with enyne
ethers, **82**, 196
- 5,6-Dialkylindanone, **84**, 177
- 5,5-Dialkyl-3-methylamino-2(5*H*)-furanone,
formation, **81**, 117
- 2,3-Dialkyl-1,8-naphthyridines, **84**, 40
- 1,2-Dialkylpyrazo[1,5-*a*]quinolines, **84**, 129
- 6-*R*-1,3-Dialkylpyrido[2,3-*c*]pyrimidine-
2,4,7-(1*H*,3*H*,8*H*)trione, **84**, 47
- Dialkylthallium bromide, reaction with
borates, **81**, 170
- 1,2-Diaminobenzene, reaction with
butenones, **82**, 215
reaction with ynaminoketones, **82**, 241
- 3,6-Diamino-1,2-dithiin, structure
determination, **81**, 71
- 1,2-Diaminoethane, reaction with
diacetylene, **82**, 160
- 5,6-Diamino-3-methylsulfinyl-1,2,4-triazine
1-oxides, formation, **82**, 299
- 3,5-Diamino-4-nitroso-2*H*-1,2,6-
thiadiazines, hydrolysis, **83**, 104
- 1,3-Diaminopropane, reaction with
diacetylene, **82**, 161
reaction with acetylacetone, **82**, 162
- 1,2-Diaminopyridines, in synthesis of [1,2,4]
triazolo[1,5-*a*]pyridines, **83**, 7
- 2,3-Diaminopyridines, diazotization, **83**, 20
- 3,4-Diaminopyridines, diazotization to give
triazolo[4,5-*c*]pyridines, **83**, 20
- 3,4-Diamino-2*H*-pyrido[1,2-*a*]pyrimidin-2-
one, **85**, 221
- 3,6-Diamino-substituted dithiins, stability,
81, 72
- 3,4-Diamino-1,2,5-thiadiazole *S,S*-dioxide,
transamination reactions, **83**, 100
- 2,4-Diaryl-3,4-dihydro-2*H*-pyrido[1,2-*a*]
pyrimidines, formation, **85**, 240
- 3,4-Diaryl-2(5*H*)-furanone, reduction,
81, 129
- 3,5-Diarylpyridines, **84**, 34
- 2,5-Diaryl-substituted 1,3,4-oxadiazines,
tautomerism, **81**, 285
- 3,4-Diaryl-thiazolidin-4-one *S,S*-dioxides,
formation, **83**, 93
antibacterial and anticancer activity,
83, 96
- 3,5-Diaryl-1,2,4-triazines, oxidation, **82**, 298

- 2*H*-1,4,2-Diazaazaphosphole, in tungsten complexes, **85**, 26
- 1,3,2-Diazaboroles, reaction with chromium carbonyls, **85**, 23
- 1,3-Diazanes, conformational studies, **81**, 72
- 1(3),6-Diazaphenothiazines, **83**, 226
- 1,9(6)-Diazaphenoxaselenine, formation, **83**, 233
- 1,9-Diazaphenoxazine, **83**, 211
- 2*H*-1,2,4-Diazaphosphole, in metal complexes, **85**, 26
- complexes with tungsten, **85**, 29
- 2*H*-1,3,2-Diazaphosphole, in tungsten complexes, **85**, 26
- 1,2,4-Diazaphospholide ligand, in iron complexes, **85**, 29
- 3,4-Diaza-1,6,6aλ⁴-trithiapentalene, computational study of molecular geometry, **81**, 38
- 1,2-Diazepines, **82**, 245
- 5,5-Diazido-1,2-dihydropyrrolo[3,2,1-*ij*]quinolin-4,6-dione, **84**, 113
- 2-Diazo-2*H*-imidazole, calculated bond lengths, **81**, 11
- Diazomethane, study of reactions with olefines, **81**, 24
- reaction with diacetylene, **82**, 3, 179
- 3-Diazo-7-methyl-1,2,4-benzotriazine 1-oxide, **82**, 290
- 2-Diazopropane, reaction with diphenyldiacetylene, **82**, 6
- dipolar cyclisations, **82**, 204
- Diazopropyne, reaction with acetylene, **82**, 3
- Dibenz[*b,f*]azepines, synthesis, **83**, 240
- Dibenz[*b,f*][1,4]thiepins, **83**, 225
- 1,4-Dibenzoyl-1,3-butadiyne, reaction with diazomethane, **82**, 5
- 10-(Dibenzylamino)-6-(4-*tert*-butylphenyl)-3,4-dihydro-2*H*-pyrimido[2,1-*a*]isquinoline, catalytic debenzylation, **85**, 260
- 1,4-Dibenzyl-1,4-dihydropyrazines, benzylic migration in, **81**, 276
- 1,4-Dibenzylpiperazine, formation, **83**, 221
- Z,Z*-1,4-Di-(benzylthio)buta-1,3-dienes, **82**, 174
- Diborolyl ligands, in formation of metal sandwich complexes, **85**, 48
- 1,3-Diborolyl sandwich complexes of rhodium, **85**, 7
- 3,5-Dibromolevulinic acid, conversion to furanones, **81**, 115
- 5-(Dibromomethylene)-2(5*H*)-furanone, formation, **81**, 115
- 2,4-Dibromo-6-nitroquinoline, **84**, 17
- 2,6-Dibromo(chloro)pyridine, amination, **84**, 63
- 1,5-Di(*tert*-butoxycarbonyl)-3-[(2-pyridylamino)methylene]pyrrolidin-2-one, effect of boiling ethanol, **85**, 236
- 1,4-Di-*tert*-butyl-1,4-diazabuta-1,3-diene, reaction with gallium complexes, **85**, 21
- 1,3-Di-*tert*-butyl-1,3,2-diazasilol-2-ylidene, reaction with chromium carbonyls, **85**, 25
- 3,6-Di-*tert*-butyl 4,5-dihydropyridazines, structure, **81**, 263
- 1,4-Di(*t*-butylthio)buta-1,3-dienes, **82**, 174
- 1,6-Dicarbyloxy-1,6-hexadiynes, reaction with diazomethane, **82**, 5
- 3,3'-Dicarbomethoxy-5,5'-diisoxazoles, **82**, 180
- 4,5-Dicarboxy-1,2,3-triazole, formation of rhodium and iridium complexes, **83**, 155
- Dichlorobenzaldazine, reaction with sodium azide, **81**, 80
- 1,3-Dichloro-4,6-dinitrobenzene, reaction with 2-mercaptopyridin-3-ol, **83**, 219
- 3,4-Dichloro-2,5-diphenylthiophene, **82**, 175
- 3,4-Dichlorodithiazolium chloride, **84**, 143
- 3,4-Dichloro-5-hydroxy-2(5*H*)-furanone, formation, **81**, 120
- 3,4-Dichloro-1,2,5-oxadiazole-2-oxide, from chloronitrile oxide, **81**, 34
- 2,7-Dichloro-3-propyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 207
- 2,6-Dichloropyrazine, calculated geometric parameters, **81**, 40
- 3,6-Dichloropyridazine, calculated geometric parameters, **81**, 40, 43
- 4,5-Dichloropyridazin-6(1*H*)-one, reaction with 2-mercaptophenol, **83**, 218
- 2,7-Dichloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 237
- 2,4-Dichloropyrimidine, reaction with pinacolone enolate, **84**, 49
- 4,6-Dichloropyrimidine, calculated geometric parameters, **81**, 40
- 2,4-Dichloroquinoline, **84**, 7
- reaction with azides, **84**, 175

- 2,4-Dichloroquinoline-3-carboxaldehyde, formation, **84**, 7
- 3,4-Dichloro-1,2,5-thiadiazole *S,S*-dioxide, reaction with amines, **83**, 100
- 3,5-Dichloro-2,4,6-trimethylbenzenenitrile-oxide, **84**, 171
- 2,2-Dichlorotrioxane, predicted stability, **81**, 81
- 4- α,β -Dichlorovinyl-5-chloromethyl-1,3-dimethylpyrazole, **82**, 16
- 4-(1,2-Dichlorovinyl)-3,5-dimethyl-1*H*-pyrazole, **82**, 14
- Dicyanodiamide, reaction with diacetylene, **82**, 168
- 7,7-Dicyano-6,7-dihydro-5*H*-1-pyridines, **84**, 54
- 3,6-Dicyano-1,2-dithiin, structure determination, **81**, 71
- 5-*R*-2-(1,1-Dicyanohex-5-yn-1-yl)pyrimidine, intramolecular cycloadditions, **84**, 56
- 5-*R*-2-(1,1-Dicyanopent-4-yn-1-yl)pyrimidines, **84**, 54
- 8,8-Dicyano-5,6,7,8-tetrahydroquinolines, formation, **84**, 56
- 2,2-Dicyanotriazolopyridin-5-one, **83**, 8
- 3,9-Dicyano-2,4,8-triphenyl-7-phenylsulfonyl-6*H*-pyrido[1,2-*a*]pyrimidine-6-thione, **85**, 241
- 1,3-Dicyclohexylimidazol-2-ylidene, formation of iridium complexes, **83**, 133
- 6*a*,7-Didehydroisothebaine, **85**, 114
- 2,3-Didehydropyrazine, as an intermediate in pyrolysis of pyrazine-2,3-dicarboxylic anhydride, **81**, 42
- ion complex, **81**, 43
- 4,4-Dideutero-1-ethoxybut-1-en-3-one, **82**, 194
- 3,3-Dideutero-5(3)-methylpyrazole, **82**, 194
- Diels-Alder reaction of oxazole with ethylene, **81**, 19
- 2,3-Dienoic acids, formation and cyclisation, **81**, 113
- Diethoxy diketone, formation of hydroxycyclobutenones, **81**, 108
- 4-Diethylaminobut-3-en-2-ones, reaction with hydrazines, **82**, 221
- 6-Diethylaminohex-3-en-5-yn-2-one, cyclisation with hydrazines, **82**, 245
- 3-Diethylamino-4-(4-methoxyphenyl)-isothiazole *S,S*-dioxide, **83**, 73
- reaction with *N*-aryl- and *N*-aralkylazides, **83**, 74
- reaction with bromine, **83**, 76
- 3-Diethylamino-4-(4-methoxyphenyl)-5-vinyl-isothiazole 1,1-dioxide, synthesis and reaction with 1,3-dipoles, **83**, 78
- 3-Diethylamino-7-methyl-5*H*-1,2-diazepine, **82**, 245
- 1-(*N,N*-Diethylaminomethyl)-3-ethynylpyrazole, reaction with paraformaldehyde, **82**, 37
- 3-Diethylamino-4-methylpyridine, **84**, 53
- 1-*R*-3-(*N,N*-Diethylcarbamoylmethyl)imidazolium bromide, formation of silver complexes, **83**, 139
- Diethylcarbonate, **82**, 188
- 1,3-Diethyl-4,5-dimethylimidazol-2-ylidene, complexes with tungsten, **83**, 125
- 3,4-Diethyl-2,5-dimethyl-1,2,5-thiadiborolene, reaction with iron carbonyls, **85**, 20
- Diethyl 2-(indol-3-yl)methylmalonate, **82**, 115
- Diethylmagnesium complexes with imidazolylenes, **83**, 121
- Diethyl *cis*-3*H*,4*H*-3-methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4,9-dicarboxylate, **85**, 191
- Diethyl 3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4,9-dicarboxylate, **85**, 194
- oxidation, **85**, 191
- Diethyl 2-(6-nitroindol-3-yl)methylmalonate, **82**, 115
- N*-Diethylthioamide-1,2-thiazole, conformation, **81**, 22
- Diethylzinc, complexes with imidazolylenes, **83**, 121
- Diethylzinc 1,3-bis(1-adamantyl)imidazol-2-ylidene adduct, **83**, 142
- 3,5-Diethynyl-1-methylpyrazole, **82**, 17
- dehydrocondensation, **82**, 35
- aminomethylation, **82**, 38
- Di-(2-ethynylvinyl)sulfide, **82**, 171
- 1,3-Diferrocenylimidazolium tetraphenylborate, reaction with silver oxide, **83**, 139
- 8,9-Difluoro-5-methyl-6,7-dihydro-5*H*-pyrido[3,2,1-*ij*]quinazoline-1,3-dione, **84**, 251, 261

- 9,10-Difluoro-3-methyl-8-nitro-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 275
- 9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylate, **84**, 273, 289
- 4,5-Difluoro-1-methyl-7-oxo-2,3-dihydro-1*H*,7*H*-pyrido[3,2,1-*ij*]cinnoline-3,8-dicarboxylic acid, **84**, 236
- 9,10-Difluoro-3-methyl-7-oxo-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 288
- 6,8-Difluoro-7-(4-methyl-1-piperazinyl)-1-[1-(acetoxymethyl)ethyl]-4-oxo-1,4-dihydroquinoline-3-carboxylate, cyclisation, **84**, 283
- 2,5-Difluoronitrobenzene, in preparation of substituted dioxins, **83**, 217
- 2,4-Difluoro-2-pentafluoroethyl-3-trifluoromethyl-4*H*-pyrido[1,2-*a*]pyrimidine, **85**, 243
- 4-(Difluorophosphino)-2,5-dimethyl-2*H*-1,2,3-diazaphosphole, reaction with ruthenium complexes, **85**, 29
- 3,4-Difluoropyrazole, stability, **81**, 16
- 2,6-Difluoropyridine, failure to rearrange, **84**, 63
- 3,3'-Diformyl-5,5'-diisoxazoldioxime, **82**, 180
- Dihydroazeto[1,2-*a*]quinoline-1,4(2*H*)-dione, **84**, 75
- Dihydroberberine, **85**, 89
- Dihydrobis(3-*tert*-butylpyrazol-1-yl)borate, as ligand in nickel complexes, **81**, 218
- Dihydrobis(3,5-di(trifluoromethyl)pyrazol-1-yl)borato complexes, structure, **81**, 199
- Dihydrobis(3-ferrocenylpyrazolyl)borate, in palladium complexes, **81**, 221
- Dihydrobis(3(5)-phenylpyrazol-1-yl)methane, reaction with molybdenum hexacarbonyls, **81**, 195
- Dihydrobis(pyrazol-1-yl)borate, reaction with iron complexes, **81**, 197
- Dihydrobis(pyrazol-1-yl)methane, derivatives of tin, **81**, 171
- Dihydrocaralayne, photooxidation, **85**, 103
- Dihydrocinnolines, tautomerism, **81**, 264
- 2,3-Dihydro-1*H*-1,3,2-diazaboroles, reaction with imidazolylenes, **85**, 21
- 1,2-Dihydro[1,3,2]diazaborolo[1,5-*a*]pyridines, as ligands in chromium complexes, **85**, 23
- 2,3-Dihydro-1,3-diborole, reaction with ferrocenes, **85**, 3
- reaction with rhodium complexes, **85**, 7
- 2,3-Dihydro-4,5-diethyl-1,3-borole, reaction with ruthenium complexes **85**, 3
- 2,3-Dihydro-1,4-dioxin, conformations, **81**, 70
- 3,4(6)-Dihydro-1,2-dioxin, conformations, **81**, 70
- calculation of tautomers, **81**, 258
- 3a,8b-Dihydro-4*H*-1,3-dioxolo[4,5-*b*]indoles, **82**, 113
- 1*H*-2,3-Dihydro-2,9-dioxo-10-phenylimidazo[1,2-*a*]quinoline, **84**, 132
- 3,4(6)-Dihydro-1,2-dithiin, conformations, **81**, 72
- 2,3-Dihydro-1,4-dithiin, conformations, **81**, 72
- 5,6-Dihydroflavopereirine, **85**, 150
- 2,3-Dihydrofuro[2,3-*b*]pyridine, **84**, 57
- 5,7-Dihydrofuro[3,4-*b*]pyridine, **84**, 58
- 1,3-Dihydrofuro[3,4-*c*]pyridines, **84**, 58
- Dihydrofuro[3,4-*a*]quinoline, **84**, 164
- Dihydroharmalol, *see*- 4,9-dihydro-1-methyl-3*H*-pyrido[3,4-*b*]indol-7-ol
- 2,3-Dihydro-3-hydroxy-3-aryl-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-5-one, **84**, 271
- 2,3-Dihydro-3-hydroxy-3-methyl-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-5-one, **84**, 285
- 4,5-Dihydro-1*H*imidazoles, in reaction with 1-chloro-2-nitrobenzenes, **83**, 242
- 2-(4,5-Dihydro-1*H*-imidazol-2-yl)-7-hydroxy-8-methyl-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-5-one, **84**, 278
- 2,3-Dihydroimidazol-2-ylidene, formation, **81**, 11
- 2,3-Dihydroimidazo[2,1-*b*]oxazoles, **83**, 194
- 2,3-Dihydroindoles, preparation from indoles, **82**, 104
- nitration, **82**, 123
- 6,12-Dihydroindolo[2,3-*a*]quinolizines, **85**, 154
- 2-(3,4-Dihydroisoquinolin-yl)acetamide, **84**, 259

- 5,8-Dihydro-5,8-methanoquinoxaline, bromination, **81**, 41
- 7,12-Dihydro-2-methyl-6*H*-indolo[2,3-*a*]quinolizinium chloride, deprotonation, **85**, 130
- 2,3-Dihydro-1-methyl-5-nitropyrolo[2,3-*b*]pyridine, **84**, 52
- 2,3-Dihydro-6-methyl-1-oxothieno[2,3-*b*]pyridine, **84**, 58
- 4,9-Dihydro-1-methyl-3*H*-pyrido[3,4-*b*]indol-7-ol, **85**, 143
- 5,6-Dihydro-2-methyl-1-[2-substitutedpiperazinyl]-4,4*H*-pyrrolo[3,2,1-*ij*]quinoline, **84**, 119
- 5,6-Dihydro-4*H*-1,2,5-oxadiazines, tautomerism, **81**, 283
- 2,3-Dihydro-5-oxaisothiazole[5,4-*b*]pyridine, **82**, 232
- 5,6-Dihydro-2(4)*H*-1,2-oxazines, tautomerism, **81**, 277
- Dihydrooxazolopyridyl cations, **81**, 24
- 5,6-Dihydrooxazolo[3,2-*b*][1,2,4]triazole, formation, **83**, 195
- 1,2-Dihydro-2-oxonicotinic esters, **84**, 36
- 1,2-Dihydro-6-oxo-6*H*-pyrrolo[3,2,1-*ij*]quinoline-5-carboxylic acids, **84**, 109
- 2,3-Dihydro-pentamethyl-1,3-diboroles, reaction with ruthenium complexes **85**, 3
- 5,6-Dihydro-2*H*-pyrans, conversion to 3,4-isomer, **81**, 256
- Dihydropyran-4-ones, formation, **82**, 205
- 3,6-Dihydropyrazines, isomerisation, **81**, 275
- 1,7(5)-Dihydropyrazolo[3,4-*d*]pyrimidines, formation, **83**, 207
- 1,4-Dihydropyridazine, stability of structure, **81**, 262
- isomerisation, **81**, 275
- Dihydropyridines, tautomerism, **81**, 259
- 1,4-Dihydropyridines, **82**, 227
- iodocyclisation, **85**, 184
- 5,11-Dihydro-6*H*-pyrido[2,3-*b*]benzodiazepin-6-one, **85**, 264
- 2,3-Dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-5-one, **84**, 286
- 2,3-Dihydro-1*H*,7*H*-pyrido[3,2,1-*ij*]cinnoline-3,3,8-tricarboxylate, **84**, 236, 240
- 1,2-Dihydro-6*H*-pyrido[1,2-*a*]pyrimidin-2,6-dione, photolytic cleavage, **85**, 209
- 3,4-Dihydro-2*H*-pyrido[1,2-*a*]pyrimidines, **85**, 249
- Dihydropyrimidine, structure, **81**, 45
- tautomerism, **81**, 264
- 1,2-Dihydropyrimidines, tautomerism, **81**, 264
- 1,4-Dihydropyrimidines, tautomerism, **81**, 266
- by desulfurization of pyrimidine-2-thiones, **81**, 269
- 1,6-Dihydropyrimidines, tautomerism, **81**, 266
- 2,5-Dihydropyrimidines, tautomerism, **81**, 264
- 6,7-Dihydro-4*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione, **84**, 259
- 7,12-Dihydropyrimido-[1',2':1,2]pyrido[3,4-*b*]indol-4(6*H*)-ones, formation, **85**, 231
- 3,4-Dihydro-2*H*-pyrimido[1,2-*d*][1,4]thiazepines, **83**, 242
- 6,7-Dihydro-5*H*-pyrindines, **84**, 54
- cis*-Dihydropyrones, **82**, 230
- 1,2-Dihydropyrrolo[3,2,1-*ij*]quinolin-4-one, **84**, 118
- 1,2-Dihydroquinolines, **84**, 138
- disproportionation reaction, **81**, 261
- formation, **81**, 262
- Dihydro-1,2,4,5-tetrazines, structure determination, **81**, 291
- 4,5-Dihydro[5,1-*a*]tetrazoloquinoline, **84**, 176
- 5,6-Dihydro-4*H*-1,2,5-thiadiazines, **81**, 284
- 5,6-Dihydro-2(4)*H*-1,2-thiazines, tautomerism, **81**, 277
- 4,5-Dihydro-1,3-thiazoles, oxidation, **83**, 90
- 4,5-Dihydro-1,3-thiazole *S,S*-dioxides, **83**, 90
- 1,3-Dihydrothiazolo[3,4-*a*]quinoline, **84**, 160
- Dihydrothiazolo[3,2-*a*]quinolinium halides, **84**, 154
- 1,2-Dihydrothiazolo[3,2-*a*]quinolinium-4-olate, **84**, 155
- 2,3-Dihydrothieno[2,3-*b*]pyridine, **84**, 57
- 5-*R*-2,3-Dihydrothieno[2,3-*c*]pyridines, **84**, 58
- 3,4-Dihydro-2*H*-1,2,4,3-triazaboroles, reaction with imidazolyldenes, **85**, 21
- Dihydro-1,2,3-triazines, preparation and tautomerism, **81**, 279
- Dihydro-1,2,4-triazines, stability, **81**, 78
- tautomerism, **81**, 280
- 2,5-Dihydro-1,2,4-triazine, energies of isomers, **81**, 79

- 2,3-Dihydro-1,2,4-triazines, production, **81**, 281
- 1,2-Dihydro-1,3,5-triazines, formation, **81**, 282
- 1,4-Dihydrotriazine tris(THF)solvate lithium salt, formation, **81**, 281
- Dihydrotriazinium cations, **81**, 78
- 1,4-Dihydro-1,3,5-triazinyl anions, potassium salt monosolvate, **81**, 281
- 6,7-Dihydro-5*H*-[1,2,4]triazolo[5,1-*b*][1,3]oxazine, formation, **83**, 196
- 5,6-Dihydrotriazolopyridine, **83**, 12
- 2,3-Dihydro-1,2,4-triazolo[4,3-*a*]quinolines, **84**, 168
- 4,5-Dihydro-1*H*-[1,2,4]triazolo[5,1-*c*][1,2,4]triazepine, formation, **83**, 243
- 6,7-Dihydro-4-vinyl-1-methylpyrazolo[3,4-*d*]pyridazine-7, formation, **82**, 64
- (1*S*)-8,9-Dihydroxy-5-amino-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-1-carboxylic acid, **85**, 176
- (1*S*)-8,9-Dihydroxy-5-amino-5,6-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-1-carboxylic acid, **85**, 176
- (3*S*)-8,9-Dihydroxy-5-amino-2,3-dihydro-1*H*-pyrimido[1,2*a*]quinoline-3-carboxylic acid, **85**, 176
- (1*S*)-8,9-Dihydroxy-5-amino-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-7-sulfonic acid, **85**, 176
- 5,6-Dihydroxycytosine, tautomerisation, **81**, 48
- 2-(3,4-Dihydroxyphenyl)ethylamine hydrobromide, reaction with butenones, **82**, 216
- 2,3-Dihydroxypyrazine, computational studies of tautomers, **81**, 41
- 3-*R*-5-*R*¹-2,6-Dihydroxypyridines, formation, **84**, 45
- 4,6-Dihydroxypyrido[2,1-*b*][1,3]thiazine-6-ones, **85**, 194
- Dihydrovincarpin, **85**, 137
- 2 β (α),7 β (α)-Dihydroyohimbine, **82**, 106
- Diiodine adducts of 1,3-dithiacyclohexane-2-thione, calculated structures, **81**, 27
- Diiodo rhodium(III) complexes, **81**, 217
- Dilithium octaphenyltetraphosphafulvalene, reaction with iron complexes, **85**, 47
- 1,2-Dimercaptobenzene, reaction with 1-chloro-8-nitronaphthalene, **83**, 243
- 1,2-Dimercaptoethane, reaction with enynes, **82**, 184
- 1,3-Dimesitylimidazolium chloride, reaction with chromocene, **83**, 125
- reaction with ruthenium complexes, **83**, 128
- complexes with nickelocene, **83**, 135
- 1,3-Dimesitylimidazolium hexafluorophosphate, adduct with 1,3-dimesitylimidazol-2-ylidene, **83**, 120
- 1,3-Dimesitylimidazol-2-ylidene, stable adducts, **83**, 120
- complex formed with PhPF₄, **83**, 120
- complex with indinium compounds, **83**, 121
- reaction with chromocene, **83**, 125
- formation of rhodium complexes, **83**, 134
- formation of nickel and platinum complexes, **83**, 137
- formation of copper and zinc complexes, **83**, 138
- 1,1'-Dimesityl-3,3'-methylenediimidazolium dibromide, reaction with palladium acetate, **83**, 136
- 9,10-Dimethoxy-2-(arylimino)-2,3,6,7-tetrahydro-4*H*-pyrido[6,1-*a*]isoquinolin-4-one, alkylation, **84**, 251
- Dimethoxyborinium ion, calculations on reactions with thiazolidine, **81**, 23
- 3,6-Di(methoxycarbonyl) 4,5-dihydropyridazines, structure, **81**, 263
- 5,8-Dimethoxy-2-chloroquinoline-3-carboxaldehyde, formation, **84**, 6
- 7,9-Dimethoxy-1,2-diphenylpyrrolo[3,2,1-*ij*]quinoline derivatives, **84**, 111
- 9,10-Dimethoxy-2,3,4,6,7,11*b*-hexahydro-1*H*-pyrimido[6,1-*a*]isoquinolin-2-ones, mass spectra, **84**, 248
- 9,10-Dimethoxy-2-(2-hydroxymethylphenylamino)-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one, **84**, 256
- 4,5-Dimethoxy-2-iodobenzaldehyde, in synthesis of Corunnine, **85**, 112
- 1-[(4,5-Dimethoxy-2-nitrophenyl)methoxy]carbonyl-9-cyclopropyl-3-fluoro-2-oxo-2,6-dihydropyrido[1,2-*a*]pyrimidine-7-carboxylate, formation, **85**, 237
- N*[2-(3,4-Dimethoxyphenyl)ethyl]barbituric acid, cyclisation, **84**, 258

- 3-[(2,6-Dimethoxy-4-pyrimidinyl)hydroxymethyl]perhydropyrido[1,2-*c*]pyrimidin-1-iminium salts, **84**, 255
- 1,2-Dimethyl-6-acetoxoxazolo[3,2-*a*]quinolines, **84**, 150
- 2,4-Dimethyl-3-acetylpyridine, **82**, 163
- Dimethyl 2(3-acylindol-2-yl)malonates, **82**, 127
- 4,4-Dimethyl-5-(alkylthioethenylmethylene)-1,3-dioxolan-2-ones, **82**, 209
- N,N*-Dimethylaminoacetylenes, study of reaction with 6-nitroindolizine, **81**, 69
- 4-Dimethylaminobenzenediazonium cation, reaction with molybdenum complexes, **81**, 181
- 4-Dimethylaminobut-3-en-2-one, reaction with azides, **82**, 233
- 1-Dimethylaminobut-1-en-3-yne, **82**, 189
- 3-Dimethylaminocarboxamido-[1,2,3]triazolo[1,5-*a*]pyridine, formation, **83**, 41
- 1-Dimethylamino-3-formylimidazo[1,5-*a*]quinoline, **84**, 137
- 5-Dimethylaminoimidazo[1,5-*a*]quinolin-2-one, **84**, 138
- 9-[(Dimethylaminomethylene)amino]-7-dimethylaminomethylene-8-chloro-6,7-dihydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 232
- 2-Dimethylaminomethylene-1,2-dihydroimidazo[1,2-*a*]quinoline-1-one, **84**, 132
- 2-Dimethylamino-nitro-1,3,4-oxadiazoles, non-linear optical properties, **81**, 33
- 5-[(2-Dimethylamino)-1-propenyl]-6-methyl-1,2,4-triazine 4-oxide, **82**, 289
- 6-[(2-Dimethylamino)-1-propenyl]-3-phenyl-1,2,4-triazine 4-oxide, **82**, 289
- 3-Dimethylamino-1,2,4-triazine 4-oxide, reaction with potassium cyanide, **82**, 284
- 6-[2-(Dimethylamino)vinyl]-1,3-dimethyluracil, **84**, 62
reaction with dimethyl acetylene dicarboxylate, **84**, 39
- 6-[2-(Dimethylamino)vinyl]uracils, hydrolysis, **84**, 38
- 1,3-Dimethylbenzimidazolium iodide, reaction with rhodium complexes, **83**, 145
- Dimethylbis(pyrazol-1-yl)gallate, reaction with rhodium complexes, **81**, 217
- reaction with 2-mercapto-1-methylimidazole and rhenium complexes, **81**, 197
- Dimethyl-2-(bromomethyl)fumarate, conversion to furanones, **81**, 116
- 2,3-Dimethylbutadiene, reaction with borates and butadiene, **81**, 215
- 1,3-Dimethyl-7-chloro-1*H*-pyrazolo[4,3-*c*]pyridazines, **82**, 65
- 3,5-Dimethyl-4-chloropyrazol-1-yl, in tungsten and molybdenum complexes, **81**, 180
- 3,8-Dimethyldibenzfuran, **83**, 192
- Dimethyl 1,2-dihydropyridazine-3,6-dicarboxylate, rearrangement, **81**, 263
- 6,6-Dimethyl-6,7-dihydropyrido[1,2-*c*]quinazolinium salts, **84**, 249, 260
- 1,4-Dimethyl-1,2-dihydroquinoline, lack of isomerisation, **81**, 261
- 1,3-Dimethyl-2,4-dioxypyrimidin-6-yl hydrazone, reaction with potassium nitrate, **82**, 295
- 2,5-Dimethyl-3,4-diphenyl cyclopentadienone, reaction with aminoquinolines, **84**, 128
- 4,4-Dimethyl-3,6-diphenyl-1,4-dihydropyridazine, tautomerisation, **81**, 262
- 3,6-Dimethyl-1,2-dithiin, structure determination, **81**, 71
- trans*-6,9-*H*-1,6-Dimethyl-9*a*-ethoxy-9-hydroxy-4-oxo-1,6,7,8,9,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, structure, **85**, 201
- 1,3-Dimethyl-4-ethynylpyrazoles, acidity, **82**, 77
- 3,5-Dimethyl-4-ethynylpyrazole, **82**, 15
- 3,3-Dimethyl-5-ethynylpyrazole, **82**, 179
- 1,3-Dimethyl-5-ethynylpyrazoles, synthesis, **82**, 45
- Dimethylgallium pyrazol-1-yl-*o*-aminophenolate, reaction with rhenium complexes, **81**, 197
- Dimethylgold(II) nitrate, reaction with borates, **81**, 223
- 1,2-Dimethylguanine, tautomers, **81**, 66
- 2,7-Dimethylguanosine, **85**, 116
- (10*aR*,11*S*)-2,11-Dimethyl-7,8,9,10,10*a*,11-hexahydropyrido[1,2-*b*][1,2]benzothiazine, **84**, 234

- 2,11-Dimethyl-7,8,9,10,10*a*,11-hexahydro-pyrido[1,2-*b*][1,2]benzothiazine 5,5-dioxide, **84**, 231
- 2,2-Dimethylhexahydropyrimidine, **82**, 161
- 1,3-Dimethyl-4-hydroxy-1,2-dihydro-1,8-naphthyridin-2-one, production, **85**, 230
- 2,4-Dimethyl-9-hydroxypyrido[1,2-*a*]pyrimidinium perchlorate, complexes with transition metals, **85**, 197
- 1,3-Dimethylimidazolium-4-carboxylate, **85**, 129
- 1,3-Dimethylimidazol-2-ylidene, σ -donor properties in beryllium complexes, **83**, 121
- complexes with molybdenum and tungsten, **83**, 126
- reaction with iron carbonyls, **83**, 127
- ruthenium complexes, **83**, 129
- rhodium and iridium complexes, **83**, 132
- formation of copper complexes, **83**, 139
- 1,3-Dimethylimidazolium iodide, formation of bis-carbenes, **83**, 124
- reaction with nickel acetates, **83**, 135
- reaction with palladium acetate, **83**, 136
- 1,3-Dimethylimidazolium perchlorate, reaction with mercury (II) chloride, **83**, 142
- 1,3-Dimethyl-5-imino-6-isonitrosouracil, **82**, 286
- N,O*-Dimethyliriodendronine, **85**, 108, 115
- 3,3-Dimethyl-5-(2-methoxyvinyl)pyrazole, **82**, 204
- 4,6-Dimethyl-2-methylamino-3-phenylpyridine, **84**, 35
- 3,3'-Dimethyl-1,1'-methylenebis(imidazolium) diiodide, reaction with palladium acetate, **83**, 136
- 1,3-Dimethyl-4-nitro-5-phenylethynylpyrazole, cyclisation, **82**, 55
- 1,3-Dimethyl-5-nitroso-6-(ethen-1-ylhydrazino)uracils, **82**, 287
- 1,3-Dimethyl-5-nitroso-6-hydrazinouracil, **82**, 287
- 2,7-Dimethyloctadiyne-2,7-diol, reaction with diazomethane, **82**, 5
- reaction with 3-bromoquinoline, **84**, 21
- 2,5-Dimethyl-1,3,4-oxadiazole, formation, **81**, 34
- 3,8-Dimethylperhydropyrido[1,2-*c*][1,3]oxazin-1-one, **84**, 240
- 1,3-Dimethyl-5-phenylethynylpyrazole-4-diazonium salts, cyclisation, **82**, 65
- Dimethylphenylphosphines, reaction with molybdenum complexes, **81**, 183
- 3,4-Dimethyl-1-phenylphosphole, complex with 1-vinylimidazole, **83**, 137
- 3,5-Dimethyl-1-phenyl-4-prop-1-ynyl-1*H*-pyrazole, **82**, 18
- 1,3-Dimethyl-5-phenylpyrrolo[3,2-*c*]pyrazole, **82**, 54
- 5,6-Dimethyl-3-phenyl-1,2,4-triazine 4-oxide, **82**, 293
- 5,5-Dimethyl-3-(2-propoxy)-4-(4-methanesulfonylphenyl)-2(5*H*)-furanone, formation, **81**, 126
- 2,6-Dimethylpyrazine, rotational barriers, **81**, 41
- 1,5-Dimethylpyrazole, **82**, 189
- 1,3(5)-Dimethylpyrazoles, **82**, 187
- 3,5-Dimethylpyrazole, **82**, 164
- Dimethyl(pyrazol-1-yl)(2-methoxypyridyl) derivatives of dimethylbis(pyrazol-1-yl)gallate, **81**, 194
- 3,5-Dimethylpyrazol-1-ylmethane, in rhodium complexes, **81**, 216
- (+)-*cis*-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride, **83**, 92
- Dimethylpyrrolo[1,2-*a*]quinolines, **84**, 84
- 1,3-Dimethyl-5- β -D-ribofuranosyluracil, reaction with malonamide, **84**, 46
- 2,6-Dimethyl-3-substituted pyridines, **82**, 213
- 3,5-Dimethyl-substituted thiopyrans, irradiation, **81**, 258
- 6,7-Dimethyl-3,4,4*a*,5-tetrahydro-8*H*-pyrido[1,2-*b*]pyridazines, **84**, 238
- 4,5-Dimethyl-1,2,2,3-tetramethyl- Δ^3 -1,2,5-azasilaboroline, reaction with iron carbonyls, **85**, 24
- Dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate, Diels-Alder condensations, **81**, 263
- 2,5-Dimethyl-1,3-thiazolidine, effect of complexation with zinc ions on ^1H and ^{15}N chemical shifts, **81**, 23
- 2,3-Dimethylthiazolium iodide, reaction with platinum species, **84**, 205
- N*-Dimethylthioamide-1,2-thiazole, conformation, **81**, 22
- 2,3-Dimethylthio-6-nitroindole, **82**, 115

- Dimethyltin oxide, complexes with
imidazole-2-carbaldehyde thiosemicarbazone, **83**, 123
- 3,6-Dimethyl-1,2,4-triazine 4-oxide, **82**, 283
- 1,4-Dimethyl-1,2,4-triazolium iodide,
reaction with nickel acetate, **83**, 161
reaction with palladium acetate, **83**, 162
- 5-R-1,3-Dimethyluracil, **84**, 47
reaction with acetamides, **84**, 45
- 3 β ,3 β' -Dimethylxestopongine, **85**, 190
- Dimethyl zinc, reaction with cobalt
complexes, **85**, 9
- Dimethylzirconocene, reaction with
imidazole, **83**, 123
- 3,4-(4,5)-Di-(3-*N*-morpholinopropyn-1-yl)-
1-methylpyrazoles, **82**, 22
- 2,3-Dinitroacetanilide, reaction with sodium
ethoxide, **83**, 191
- Dinitroanilines, reaction with carbon
disulfide, **83**, 197
- 2,6-Dinitrobenzaldehyde hydrazones,
formation of 3-unsubstituted indazoles,
83, 199
- 5,7-Dinitrobenzodithiine, formation, **83**, 230
- 2',6'-Dinitrobiphenyl-2,6-dicarboxylic acid,
cyclisation, **83**, 221
- 2,4-Dinitrochlorobenzene, reaction with
2-aminopyridine, **83**, 200
- 3,5-Dinitro-4-chloropyridine, reaction with
2-aminopyridine, **83**, 201
- 2,4-Dinitro-6,6-diphenylacridine, formation,
83, 238
- 2,4-Dinitrofluorobenzene, reaction with
N-benzoylphenylhydrazine, **83**, 215
reaction with hydrazides of thiobenzoic
acid, **83**, 231
- 2,4-(4,5)Dinitroimidazole, reaction with
oxiranes, **83**, 194
- 4,6-Dinitroindole, **83**, 205
- 2,6-Dinitro-3-methyl-2'-hydroxydiphenyl-
amines, denitrocyclisation, **83**, 210
- 2,6-Dinitrophenyl dithiocarbamates,
formation, **83**, 197
- 1-(2,4-Dinitrophenyl)-3-propynyl-
5-methylpyrazole, **82**, 12
- 3,5-Dinitropyridine, from 5-nitropyrimidine,
84, 34
- 1,3-Dinitroselenazine, formation, **83**, 233
- Dinitrosobenzene, as intermediate in
reaction of benzofuroxan, **81**, 35
- 1,2-Dinitrosofuroxans, tautomerism, **81**, 36
- 3,5-Dinitro-1,2,4-triazole, reaction with
oxiranes, **83**, 195
- 1,3-Dinitro-1,2,4-trichlorobenzene, reaction
with 2-mercaptopyridin-3-ol, **83**, 219
- 3,6-Dinitroxanthene-9-one, formation, **83**, 220
- Diorganopalladium(II) complexes of
tris(pyrazol-1-yl)borate, in reduction of
water, **81**, 17
- Dioscorine, **85**, 127
- 1,3-Dioxane, studies on protonation, **81**, 73
- Dioxins, synthesis, **83**, 215
- 4*H*-1,3-Dioxin, stability of conformations,
81, 70
- Dioxiranyl radicals, **81**, 40
- 9,11-Dioxo-5,9-dihydro-11*H*-pyrido[2,1-*b*]
quinoline-8-carboxylates, **85**, 263
- 1,1-Dioxo-2,3-dihydrothieno[2,3-*b*]pyridine,
84, 57
- Dioxolane, calculations of core-electron
binding energies, **81**, 23
- 1,3-Dioxolanylium ions, **81**, 24
- Diphenylacetylene, reaction with iron
complexes, **85**, 39
- 2,3-Diphenylbenzofuran, formation, **83**, 193
- 3,6-Diphenyl-5-benzoylmethyl-1,2,4-triazine,
82, 279
- Diphenylbutadiyne, reaction with amines,
82, 160
reaction with hydroxylamine, **82**, 168
- Diphenylchlorophosphine, complexes with
imidazolyldenes, **83**, 120
- Diphenyldiacetylene, reaction with diazo
compounds, **82**, 5, 6
reaction with hydrazine hydrate, **82**, 164
- 2,6-Diphenyl-4-diethylphosphonylthiopyran,
lithiation, **81**, 257
- 3,6-Diphenyldihydropyridazine, stability of
isomers, **81**, 263
- 4,6-Diphenyldihydropyrimidine,
tautomerism, **81**, 265
- 1,3-Diphenyldinitriliimine, dipolar
cyclisations, **82**, 204
- 3,4-Diphenylfuranone, synthesis, **81**, 114
- Diphenylglyoxal mono-2-ethoxymethylene-
hydrazone, reaction with
hydroxylamine, **82**, 294
- N*,1-Diphenyl-6-hydroxy-3-methyl-11-oxo-
1,2-dihydro-11*H*-pyrido[2,1-*b*]
quinazoline-2-carboxamide, **85**, 264

- 3,4-Diphenyl-9-hydroxyperhydropyrido
[2,1-*c*][1,4]oxazine-1-one, **84**, 279
- 4,5-Diphenylimidazole, reaction with
palladium acetate, **83**, 138
- E,Z*-1,3-Diphenyl-4(5)-(2-methoxyvinyl)pyr-
azole, **82**, 204
- 2-(Diphenylmethyl)diphenylamine,
cyclisation, **83**, 238
- 4*a*,5-Diphenyl-9-methyl-1,2,3,4-tetrahydro-
4*aH*-pyrido[1,2-*a*]quinoxaline, **84**, 321
- 1,3-Diphenylnitrilimine, reactions with
diacetylene, **82**, 9
- 2-Diphenylphosphino-4,5-diphenyl-1,3-
diphospholide, reaction with iron
complexes, **85**, 33
- 2-Diphenylphosphinomethyl-1-methylimida-
zole, complexes with molybdenum,
83, 126
- 2-(Diphenylphosphino)thiazole, with iron
pentacarbonyl, **84**, 197
- 1,3-Diphenyl-5-*R*-2-pyrazolenines, **82**, 9
- 3,5-Diphenylpyridone-4, **84**, 44
- 2,3-Diphenylpyrido[1,2-*a*]pyridazinium salts,
84, 237
- 2,3-Diphenylpyrido[1,2-*b*]pyridazinium salt,
84, 236
- Diphenylthallium azide, reaction with
benzonitrile, **83**, 164
- 1-Diphenylthallium-5-phenyltetrazole,
formation, **83**, 164
- 3,5-Diphenyl-1,2,4-triazine 1-oxide, **82**, 298
- 3,6-Diphenyl-1,2,4-triazine 4-oxide, reaction
with indole, **82**, 277
- reaction with benzoylacetone, **82**, 279
- 5,6-Diphenyl-1,2,4-triazine 4-oxide,
formation, **82**, 294
- 4,4'-Di(1-phenyl-1,2,3-triazoles), **82**, 182
- 1,3-Diphenyl[1,2,4]triazolo[4,3-*a*]pyridine,
one-electron anodic oxidation, **83**, 28
- 3,4-Diphosphacyclopentadienone ligand in
tungsten complexes, **85**, 31
- Diphosphaferrocene, **85**, 34
- 2,4-Diphosphastibolyl, reaction with
rhodium complexes, **85**, 40
- 1,4,2-Diphosphastibolyl anions, reaction
with ruthenium complexes, **85**, 38
- 1,3-Dipolar cycloadditions, in formation of
acetylenylpyrazoles, **82**, 3
- N,N*-Di-*iso*-propyl-3-amino-1,3-thiaborolide,
as ligand in metal complexes, **85**, 19
- 1,3-Di-*iso*-propyl-4,5-dimethylimidazol-2-
ylidene, complexes with diazaboroles
and sulfur dichloride, **83**, 120
- complexes with trimethyl alane and
gallane, **83**, 121
- complexes with tungsten, **83**, 125
- 1,4-Di-*iso*-propyl-2,3-dimethylimidazol-2-
ylidene, reaction with samarium and
ytterbium complexes, **83**, 142
- 3,3-[Di-(2-propyl)]perhydropyrido[1,2-*c*][1,3]
oxazin-1-one, lithiation, **84**, 241
- 3-(2'',4'',6''-Di-*iso*-propylphenyl)-1-(2'-pyri-
dylmethyl)imidazolium bromide,
reaction with silver oxide, **83**, 139
- Dipyrido[1,2-*a*;4',3'-*d*]imidazole, formation,
83, 201
- Di-(2-pyridyl) ketone hydrazone, cyclisation,
83, 3
- Dirhodium complexes, **83**, 160
- Disodium salt of 2-(dimercaptomethylene)-
malonodinitrile, reaction with chloroni-
trobenzochromanone, **83**, 199
- 8,17-Disubstituted 1,10-diaza-9,20-
dioxakabutanes, **82**, 135
- 3,6-Disubstituted 4,5-dihydropyridazines,
rearrangements, **81**, 263
- 5,5-Disubstituted 2,5-dihydro-1,2,3-triazines,
mild hydrolysis to dihydro-1,2,3-
triazines, **81**, 279
- 3,3'-Disubstituted 5,5'-diisoxazoles, **82**, 181
- 2,9-Disubstituted 3-fluoro-6-oxo-6-*H*-
pyrido[1,2-*a*]pyrimidine-7-carboxylates,
esterification, **85**, 217
- 5,5-Disubstituted 2(5*H*)-furanones, cyclo-
carbonylation of terminal propargyl
alcohols, **81**, 112
- 2,6-Disubstituted pyridines, formation from
[1,2,3]triazolo[1,5-*a*]pyridine, **83**, 43
- 4,5-Disubstituted 1,2,3-selenadiazoles,
reaction with metal carbonyls, **84**, 194
- 2,5-Disubstituted tellurophenes, **82**, 177
- α,γ -Disubstituted tetrone acids, Michael
reactions, **81**, 140
- 4,4-Disubstituted 1,2,5-thiadiazolidin-3-one
S,S-dioxides, synthesis, **83**, 105
- 4,5-Disulfanyl-1,3-dithiole-2-thionate, **85**, 48
- 2,6-Dithiacyclo[3.1.0]hexane, formation,
81, 71
- 1,3-Dithiacyclohexane-2-thione, adducts
with diiodine, **81**, 27

- 1,2,3,5-Dithiadiazole, iron cluster complexes, **84**, 197
- 1,3-Dithiane, enthalpies of formation, **81**, 75
- 1,4-Dithiane, computational studies of conformations, **81**, 75
- 3,3'-Di[1,3-thiazolidin-4-one] derivatives, quantum chemical calculations and X-ray studies on, **83**, 86
- 1,3,2-Dithiazolium cation, formation, **81**, 39
- Dithiazolyl radicals, computed hyperfine coupling constants, **81**, 39
- 1,4-Dithienylbuta-1,3-diyne, reaction with hydrogen sulfide, **82**, 173
- 2,5-Di(2-thienyl)thiophene, **82**, 173
- 1,2-Dithiins, **82**, 174
structure determination, **81**, 71
- 4*H*-1,3-Dithiin, conformations, **81**, 72
- 1,4-Dithiin, structure, **81**, 72
- Dithiocarbamates, reaction with 2,6-dinitrochlorobenzenes, **83**, 197
- 1,2-Dithiolane, investigation of nature of sulfur-sulfur bond, **81**, 26
- 1,2-Dithiolan-3-one 1-oxides, as model compounds, **81**, 26
- 1,3-Dithiolanylium ions, **81**, 24
- 1,2-Dithiole-3-thione, calculated vibrational spectra, **81**, 25
- 1,3-Dithiole-2-thione-4,5-dithiolate anion, vibration frequencies, **81**, 27
- 1,3-Dithiolium tungsten complexes, **85**, 48
- 1,2-Dithiol-3-one, calculated vibrational spectra, **81**, 25
- 2,8-Di-(trifluoromethyl)-4-quinolinyl triflate, **84**, 17
- 3,5-Di(trifluoromethyl)-1,2,4,6-thiatriazine, structure, **81**, 293
- 2,8-Di-(trifluoromethyl)-4-(*N*-tosylindol-3-yl)quinoline, **84**, 17
- 1,4-Di(trimethylsilyl)buta-1,3-diyne, reaction with sodium telluride, **82**, 177
- 9-Dodecyloxy-3-(2-chloromethyl)-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 236
- 3-{1-[(3-Dodecyloxy-2-pyridyl)amino]ethylidene}-4,5-dihydro-2(3*H*)-furanone, **85**, 236
- Dunning's cc-pVDZ, as a basis set in calculating structural parameters of heterocycles, **81**, 4
- Emeheterone, **85**, 122
- EOM-CCSD(T), of heterocycles, **81**, 2
- (+)-9-Epi-6-epipinidinol, **84**, 240
- 6-Epi-6-epipinidinol, **84**, 247
- Erythromycin derivatives, **84**, 21
- Equation-of-motion coupled-cluster theory, *see*, EOM-CCSD(T)
- Equilibrium constants, calculation, **81**, 254
- Ethene, calculations on reaction with nitrosoethylene, **81**, 70
- 2-Ethoxy-3-acetylpyridine, hydrogenation, **81**, 260
- 1-Ethoxycarbonyl-4-acetyl-5-dimethylaminotriazole, **82**, 246
- 4-Ethoxycarbonyl-3,4-dihydro-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-9-carboxylic acid, **85**, 191, 192
- 3-Ethoxycarbonyl-5-hydroxypyrazole, hydrogen transfer reactions, tautomerism, **81**, 16
- 9-Ethoxycarbonylmethylene-4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, effect of heat, **85**, 209
- 3-Ethoxycarbonyl-2-methylpyridine, **84**, 47
- 4-(Ethoxycarbonylmethylthio)-4-methoxybutan-2-one, **82**, 231
- 2-Ethoxycarbonyl-3-methylthiophene, **82**, 231
- 3-Ethoxycarbonylpyridin-6(1*H*)-one, **84**, 49
- 3-Ethoxycarbonyl-4-trimethylsilylthynyl-5-trimethylsilylpyrazole, **82**, 7
- 9*a*-Ethoxy-9-hydroxy-1,6-dimethyl-1,6,7,8,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, preparation, **85**, 233
- 6-Ethoxy-2-iodo-1-methoxyindole, **82**, 123
- 9-(Ethoxymethoxy)-3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]ethyl}-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **85**, 214
- 6-Ethoxy-1-methoxyindole, **82**, 123
- Ethoxymethylenecyanoacetate, reaction with hydrazones, **83**, 19
- 4-Ethoxy-3-phenyl-3-cyclobutene-1,2-dione, formation, **81**, 110
- 1-Ethoxy-2-phenylindole, irradiation, **82**, 103, 122
- 6-Ethoxy-2-phenylindole, **82**, 123
- 6-Ethoxy-2-phenyl-1-methoxyindole, **82**, 123
- 2-Ethoxy-3,4,5,6-tetrahydropyridine, reaction with ethyl carbazate, **83**, 19

- Ethoxythiazolo[3,2-*a*]quinolinium perchlorate, **84**, 156
- 6-Ethoxy-2-trifluoromethyl-4*H*-pyran-4-one, **82**, 230
- 7-Ethoxyvinyl-2-alkoxy-3-{4-[2-cyanophenyl]-phenyl}methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, preparation, **85**, 219
- Ethyl β -aminocrotonate, reaction with dialkylaminoalk-1-en-3-yne, **82**, 197
- Ethyl (3*S*)-8-amino-3-methyl-10-(2,6-dimethyl-4-pyridyl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylate, **84**, 293
- 2 α ,4 $\alpha\alpha$,8 α ,5 β -*H*-2-Ethyl-5-benzyloxy-8-propylperhydropyrido[1,2-*b*][1,2]oxazine, conformation in solution, **84**, 226
- Ethyl (3*S*)-10-bromo-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylate, **84**, 283
- Ethyl 2-chloro-5-cyclopropyl-6-[(*N*-(4,5-dimethoxy-2-nitrophenyl)methoxy)carbonyl]-*N*-(2-fluoro-3-hydroxy-1-oxo-2-propen-1-yl)amino}nicotinate, cyclization, **85**, 237
- Ethyl 7-chloro-5-oxo-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylate-1,1-dioxide, **84**, 294
- Ethyl 2-cyano-3-methylsulfanyl-3-(1,2,4,5-tetrahydro-3*H*-benzo[*d*]azepin-3-yl)acrylate, **85**, 249
- Ethyl 7,9-dicyano-4-imino-8-phenyl-6-phenylthio-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **85**, 248
- Ethyl 9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylate, **84**, 268
- Ethyl 9,10-difluoro-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylate, **84**, 294
- N*-Ethyl-1,3-dihydrofuro[3,4-*c*]pyridinium tetrafluoroborate, **84**, 59
- 1-Ethyl-6,7-dihydro-3-phenyl-5*H*-1-pyridinium salt, **84**, 57
- Ethyl 9-dimethylaminomethylene-3-formyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-2-acetate, reaction with ammonia, **85**, 221
- Ethyl 2,4-dimethyl-3-nicotinate, **82**, 163
- Ethylene, Diels-Alder reaction with oxazoles, **81**, 19
- 1,1'-Ethylenebis(3-*tert*-butylimidazol-2-ylidene), formation of nickel complexes, **83**, 136
- 4,5-Ethylenedithio-1,3-dithiole-2-thione, with diiodine, **81**, 27
- Ethyleneglycol, reaction with diacetylene, **82**, 169
- 1,1'-(1,2-Ethylene)-3,3'-imidazol-2,2'-diylidene, formation of dinuclear species, **83**, 133
- Ethyl 9-ethoxycarbonyl-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylates, **85**, 193
- Ethyl 3,4-*cis*-*H*-9-ethoxymethyl-3-methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylate, **85**, 193
- Ethyl 9-fluoro-10-(4-methylpiperazino)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylate, hydrolysis, **84**, 294
- 2-Ethylhydrazinoquinolines, reaction with aromatic aldehydes, **84**, 168
- Ethyl 3,4-*cis*-*H*-9-hydroxymethyl-3-methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylate, **85**, 191
- Ethyl 9-hydroxymethyl-3-methyl-6-oxo-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4-carboxylates, **85**, 193
- Ethyl 9-hydroxymethyl-3-methyl-6-oxo-4*H*,6*H*-pyrido-[2,1-*b*][1,3]thiazine-4-carboxylate, hydrogenation, **85**, 191
- Ethyl 7-hydroxy-3-methyl-5-oxo-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylate, **84**, 286
- Ethyl 9-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, *O*-alkylation, **85**, 211
- (*Z*)-5-Ethylidenefuranones, formation, **81**, 110
- Ethylimidazole, calculations on hyperfine coupling constants, **81**, 13
- 4-Ethylimidazole, calculations on addition of water to protonated form, **81**, 9
- Ethyl 6-imino-1,2,3,4-tetrahydro-6*H*-pyrido[1,2-*a*]pyrimidine-9-carboxylate, **85**, 253
- 2-Ethylindole, **82**, 115

- Ethyl 2-mercapto-4-hydroxy-6,7,8-trifluoroquinoline-3-carboxylate, **84**, 157
- Ethyl 2-methyl-4(6)-alkyl-3-nicotinate, **82**, 197
- Ethyl (3*S*)-3-methyl-10-(2,6-dimethyl-4-pyridyl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylate, oxidation, **84**, 293
- Ethyl 7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate, **85**, 234
- 5-Ethyl-11-methyl-9-oxo-5,11-dihydro-9*H*-pyrido[2,1-*b*]quinazoline-8-carboxylic acid, **85**, 260
- 5-Ethyl-2-methylpyridine, from pyrimidines, **84**, 33
- 5-Ethyl-2-methyl-11*H*-pyrido[3,4-*a*]cabazolium, **85**, 152
- Ethyl 3-[(9-methyl-2-pyridyl)amino]-2-cyanoacrylate, cyclisation, **85**, 235
- Ethyl 10-methylthio-9-fluoro-3-methyl-2,3-dihydro-7-oxo-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylate, **84**, 273
- Ethyl 7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylate, synthesis, **84**, 295
- Ethyl 7-oxo-2,3,6,7-tetrahydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-2-carboxylate, **84**, 273
- 1-Ethyl-2-(pent-4-yn-1-yl)-5-phenylpyridinium tetrafluoroborate, heating, **84**, 57
- Ethyl *cis*-4*a*,7-*H*-phenyl-8-cyano-2-oxo-2,3,4,4*a*,7,8-hexahydropyrido[1,2-*b*]oxazine-8-carboxylate, stereostructure, **84**, 226
- Ethyl 9-(*N*-phenyl-*N*-methylamino)-6-methyl-4-oxo-6,7-dihydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **85**, 232
- 3-Ethylpyrazole, **82**, 164
- Ethyl 3(5)-pyrazolecarboxylates, **82**, 189
- 3-Ethylpyridine-*N*-oxide, in synthesis of Flavocarpine, **85**, 136
- 8-Ethylquinoline, formation, **84**, 18
- Ethyl 8-substituted 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one-3-carboxylate, **85**, 248
- 1-Ethylthiobut-1-en-3-one, **82**, 195
- 1-Ethylthiobut-1-en-3-yne, hydrolysis, **82**, 195
- 5-Ethylthio-2(5*H*)-furanone, formation and reactions of anions, **81**, 137
- 5-Ethylthio-4-methyl-2(5*H*)-furanone, formation of anion and alkylation, **81**, 132
- 5-Ethylthio-4-pyrrolidin-1-yl-2(5*H*)-furanone, reaction with aldehydes, **81**, 134
- Ethyne, 1,3-dipolar cycloaddition to fulminic acid, **81**, 19
- 4-Ethynyl-5-aminomethyl-1,3-dimethylpyrazole, failure to cyclise, **82**, 55
- 4-Ethynyl-5-aminomethyl-1-methylpyrazole, **82**, 49
- Ethynylated 7*H*-pyrazolo[3,4-*d*]pyrimidines, **82**, 29
- 5-Ethynyl-4-chloro-1,3-dimethylpyrazole, coupling with 3-iodo-4-chloronitrobenzene, **82**, 35
- 4-Ethynyl-5-chloro-1,3-dimethylpyrazole, **82**, 50
- 3-Ethynyl-5-chloro-1-methylpyrazole, formation, **82**, 50
- 4-Ethynyl-1,3-dimethyl-5-(acetyl)amino-methylpyrazole, **82**, 35
- 4-Ethynyl-1,3-dimethyl-5-aminomethylpyrazole, reaction with iodobenzene, **82**, 35
- 1-Ethynyl-3,5-dimethylpyrazole, infrared spectrum, **82**, 70
- 4-Ethynyl-1,3-dimethylpyrazole, **82**, 49, 50
- reaction with bromine, **82**, 40
- formation of dehydrodimers, **82**, 34
- methylation, **82**, 39
- 4-Ethynyl-5-methyl-1-phenyl-1*H*-pyrazole, **82**, 20
- 1-Ethynyl-3(5)-methylpyrazole, hydrogenation, **82**, 40
- 3-Ethynyl-1-methylpyrazole, **82**, 19, 50
- formation of dehydrodimers, **82**, 34
- 3(4)-Ethynyl-1-methylpyrazole, chlorination, **82**, 38
- NMR spectra, **82**, 73
- acidity, **82**, 76
- 3(5)-Ethynyl-1-methylpyrazole, formation of, **82**, 3
- 5-Ethynyl-1-methylpyrazole, infrared spectrum, **82**, 70
- 5-Ethynyl-3-methyl-1*H*-pyrazole, **82**, 7
- Ethynylpyrazoles, acidity, **82**, 75
- 3(5)-Ethynylpyrazole, **82**, 3, 32
- infrared spectrum, **82**, 70
- 4-Ethynylpyrazole, formation, **82**, 47

- 5-Ethynylpyrazole, **82**, 179
- 5-Ethynyl-1*H*-pyrazole-3-carboxylic acid methyl ester, **82**, 7
- 5-Ethynyl-1*H*-pyrazole-3,4-dicarboxylic acid dimethyl ester, **82**, 7
- 4-Ethynyl-1- β -D-ribofuranosylpyrazole-3-carboxamide, **82**, 47
- 4(5)-Ethynyl-1,2,3-triazoles, **82**, 181, 182
- 4-Ethynyl-1,3,5-trimethylpyrazole, amino-methylation, **82**, 37
- halogenation, **82**, 38
- Euxylophorine A, **85**, 154
- Exchange-correlation functional, in density functional theory, **81**, 3
- Excited states, calculation of, **81**, 7
- Fagaridine, **85**, 107
- Fagaronine, synthesis, **85**, 155
- Fangchinoline, **85**, 96
- Fascaplysine, **85**, 152
- Fasicularin, **84**, 120
- Fenfangjines, **85**, 96
- Fervenuins, **82**, 271
- Fervenuin 4-oxides, thermal deoxygenation, **82**, 267
- reduction, **82**, 271
- formation, **82**, 295
- Fimbrolide, from red algae, **81**, 120
- Fissisaine, **85**, 94
- Flavocarpine, isolation, **85**, 136
- Flavocoryline, **85**, 149
- Flavocorynanthrone, **85**, 149
- Flavocristamide A, **83**, 97
- Flavopereirine, **85**, 149
- 4-Fluoroalkyl-2*H*-pyrido[1,2-*a*]pyrimidin-2-ones, IR spectra, **85**, 198
- 2-Fluoroalkyl-2*H*-pyrido[1,2-*a*]pyrimidin-4-ones, NMR spectra, **85**, 198
- 3-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1,2,3,6-tetrahydro-1-pyridyl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, formation, **85**, 204
- 3-{2-[4-(6-Fluorobenzo[*d*]isoxazol-3-yl)-3,6-dihydro-2*H*-pyridin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, solid state NMR, **85**, 199
- 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-pyrido[1,2,3-*de*]-1,4-benzoxazine-7-one, **84**, 278
- 8-Fluoro-1,2-dihydro-4*H*,6*H*-[1,4]oxazino[4,3-*a*]quinoline-4,6-dione, **84**, 271, 283
- 3-Fluoro-2-iodoquinoline, formation, **84**, 6
- 3-Fluoro-4-iodoquinoline, rearrangement, **84**, 6
- 9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-7-one, **84**, 268
- (-)-9-Fluoro-3-methyl-7-oxo-10-[(3*S*)-3-(*t*-butoxycarbonylamino)pyrrolidino]-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 276
- (3*S*)-(-)-9-Fluoro-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 277
- 6-Fluoro-2-methylquinoline, **84**, 4
- 9-(4-Fluorophenyl)-3-fluoro-2-hydroxy-6-oxo-6-*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylic acid, formation, **85**, 218
- 6-[(4-Fluorophenyl)hydroxymethyl]-7-hydroxy-1,3,4,8-tetrahydropyrido[2,1-*c*][1,4]oxazine-1,8-dione, **84**, 281
- 11-(4-Fluorophenyl)-11-hydroxy-2,3,4,11-tetrahydro-6*H*-pyrimido[1,2-*b*]isoquinolin-6-one, **85**, 265
- 9-Fluoro-10-piperazino-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 277
- 3(5)-Fluoropyrazole, stability, hydrogen transfer reactions, **81**, 16
- Folicanthine, **82**, 136
- Formamide, methanolysis, **81**, 13
- 3-Formyl-2-[*N*-(2-alkenyl)-*N*-benzylamino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with primary amines, **85**, 225
- reaction with hydroxylamine, **85**, 226
- 3-Formyl-2-[*N*-2-allyl-*N*-phenylamino]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, effect of heating, **85**, 226
- N*-Formylarylhydrazine, reaction with carbamates, **83**, 18
- N*-Formyl-4-bromo-6-nitroquipazine, **84**, 17
- 7-Formyl-8-[(4-cyanophenyl)methoxy]-1,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, reduction, **84**, 302

- 3-Formyl-2,3-dihydro-1,3-oxazole, theoretical conformational studies, **81**, 20
- 3-Formyl-4,5-dihydro-1,3-oxazole, theoretical conformational studies, **81**, 20
- 3-Formyl-5,5'-diisoxazol-3'-aldoxime, **82**, 180
- 6-Formyl-2,3,6,7,8,9-hexahydro-11*H*-dipyrido[1,2-*a*:5,6-*c*]pyrimidine-2,11-dione, **85**, 221
- 3-Formyl-2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 206
- 1-Formylimidazole, reaction with iron carbonyls, **83**, 127
- 4-Formylimidazole, **84**, 137
- 1-Formylmelatonin, **82**, 137
- 9-Formyl-7-methyl-2-morpholino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reduction, **85**, 204
- 7-Formyloxazoloquinolines, **84**, 151
- 1-(2-Formylphenyl)piperazines, oxidation, **85**, 184
- 2-Formyl-5-(prop-1-ynyl)thiophene, **82**, 175
- 7-Formyl[1,2,4] triazolo[4,3-*a*]pyridine, **83**, 32
- Fulminic acid, 1,3-dipolar cycloaddition to ethyne, **81**, 19
- Fumonisin, **85**, 82
- 3-Functionalised 5-alkoxymethyl-2(5*H*)-furanones, preparation, **81**, 114
- 3-Functionalised 5-phenoxyethyl-2(5*H*)-furanones, preparation, **81**, 114
- 2(5*H*)-Furanones, **81**, 107, 111
- photochemical transformations, **81**, 157
- 2-(5*H*)-Furano-3-ylmethanesulfonate, reaction with benzylamine, **81**, 156
- Furfural, oxidation, **81**, 116
- Furo[3,4-*b*]indole, calculations, **81**, 20
- Furo[3,4-*d*]isoxazole, calculations, **81**, 20
- Furo[3,4-*b*]-pyrid-7(5*H*)-one, **84**, 60
- Furo[3,4-*b*]oxazole, calculations, **81**, 20
- Furo[3,4-*d*]oxazole, Diels-Alder reactions, **81**, 20
- Furo[3,4-*d*]thiazole, calculations, **81**, 20
- Furoxans, computational studies, **81**, 34
- ring-chain tautomerism, **81**, 36
- Furylbenzindolizines, **84**, 86
- Gambirtannine, **85**, 87
- Geometry optimization, in producing geometries of heterocycles, **81**, 5
- (+)-Gephyran, **84**, 93
- (+/-)-Gephyrotoxin, **84**, 94
- Glaucon, **85**, 112
- 3-Glucosylaminopyrimidines, **84**, 61
- Gold complexes with imidazolato groups, **83**, 140
- Gramine, **82**, 115
- Group IIa metal ion complexes, effect on base pairs, **81**, 64
- Guanidine, reaction with diacetylene, **82**, 168
- reaction with 1-methoxyalk-1-en-3-yne, **82**, 201
- reaction with aminobutenones, **82**, 222
- Guanine, Watson-Crick pair with cytosine, **81**, 49
- tautomerism, **81**, 65
- complexes with pentahydrated zinc ions, **81**, 68
- Guanine-adenine radical cations, proton transfer in, **81**, 67
- Guanine-cytosine base pairs, **81**, 64, 67
- Guanine-guanine base pairs, **81**, 64
- Guanin-7-oxide, **85**, 124
- 1-Guanyl-3-methylpyrazole, **82**, 167
- Guianensine, **85**, 149
- Haeme peroxidases, reaction of, **81**, 13
- 3-Halogen-1,2,4-triazine 2-oxides, **82**, 289
- 2-Halo-6-nitro-2'-hydroxydiphenylamines, in formation of nitrophenoxazines, **83**, 210
- Halonitrouacils, **83**, 207
- 4-Halo-1*H*-pyrazolo[3,4-*c*]pyridazines, Richter reactions, **82**, 69
- 4-Halo-1*H*-pyrazolo[4,3-*c*]pyridazines, Richter reactions, **82**, 69
- 6-Halo-1,2,4-triazine 1-oxides, **82**, 268
- 6-Halo-1,2,4-triazine 2-oxides, **82**, 268
- Hamabiwalactone B, total synthesis, **81**, 128
- Hammick reaction of pyridine- and quinoline-2-carboxylic acids, **85**, 132
- Hartree-Fock calculations of heterocycles, **81**, 2
- HCTH functionals, in calculating structural parameters of heterocycles, **81**, 5
- Herbicides, in thiazole derivatives, **83**, 96
- Hetarenes in triple-decker cobalt complexes, **85**, 10
- 7-(Hetarylmino)methyl-2-substituted perhydro[1,2-*a*]pyrazines, **84**, 311
- 2-(Het)aryl-1,4-dihydro-1,8-naphthyridin-4-ones, preparation, **85**, 230

- trans*-8,9*a*-*H*-8-(Het)aryl-6-(tributylstannyloxy)-3,4,8,9-tetrahydro-2*H*,9*a*-*H*-pyrido[2,1-*b*][1,3]-thiazines, **85**, 193
- 1-Heteroalk-1-en-3-yne, reaction with formamide, **82**, 199
- Heterobimetallic cobalt – iridium complexes, **85**, 11
- Hetero Diels-Alder cycloaddition reactions, **84**, 33
- Hexadecker cobalt-metal complexes, **85**, 14
- Hexa-2,4-dien-1-al, reaction with mercaptoacetaldehyde, **82**, 175
- 2,3,5,6,7,8-Hexahydro-1,2,4-benzotriazine 4-oxides, formation, **82**, 297
- 1,2,3,4,4*a*,9*a*-Hexahydro- β -carboline, in preparation of carbolines, **82**, 104
- cis*(*trans*)-6,11*b*-Hexahydro-1*H*-6-methyl-2,3,4,6,7,11*b*-hexahydro-1*H*-pyrimido[6,1-*a*]isoquinolin-2-one, conformational analysis, **84**, 247
- 1,3,4,4*a*,5,6-Hexahydroperhydropyrido[1,2-*c*][1,3]oxazin-1,6-dione, **84**, 245
- 1,3,4,6,11,11*a*-Hexahydro-2*H*-pyrazino[2,1-*b*]isoquinoline-1,4-dione, **84**, 320
- 2,3,4,6,11,11*a*-Hexahydro-1*H*-pyrazino[1,2-*b*]isoquinolin-1-one, **84**, 319
- 1,2,3,5,6,11*a*-Hexahydro-4*H*-pyrazino[2,1-*a*]isoquinolin-4-ones, **84**, 322
- 5*a*,6,7,8,9,11-Hexahydropyrido[2,1*b*][1,3]benzothiazine-7,11-diones, **85**, 192, 3
- 7,8,9,10,10*a*,11-Hexahydropyrido[1,2-*b*][1,2]benzothiazine-10,11-dione 5,5-dioxide, catalytic hydrogenation, **84**, 232
- 7,8,9,10,10*a*,11-Hexahydropyrido[1,2-*b*][1,2]benzothiazine 5,5-dioxides, **84**, 233
- 5*a*,6,7,8,9,11-Hexahydropyrido[2,1*b*][1,3]benzoxazine-7,11-diones, **85**, 183, 186
- Hexahydropyrido[1,2-*d*]-1,3,4-oxadiazines, conformations, **81**, 83
- 2,3,4,8,9,9*a*-Hexahydropyrido[2,1-*b*][1,3]oxazine-7-carboxylates, **85**, 184
- 1,3,4,6,9,9*a*-Hexahydropyrido[2,1-*c*]oxazine-1,4-diones, **84**, 284
- Hexahydropyrido[1,2-*b*][1,2]oxazin-2-ones, **84**, 230
- 2,4*a*,5,6,7,8-Hexahydropyrido[1,2-*b*][1,2]oxazin-8-one, hydrogenation, **84**, 227
- 3,4,6,7,8,9-Hexahydro-2*H*-pyrido[1,2-*a*]pyrimidine, gas phase basicity values, **85**, 195
- 2,3,5,6,7,8-Hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1,3-dione, **84**, 247, 258
- 1,2,3,4,6,7-Hexahydro-8*H*-pyrido[1,2-*a*]pyrimidin-8-one, **85**, 254
- 5,5*a*,6,7,8,9-Hexahydro-11*H*-pyrido[2,1-*b*]quinazoline alkaloid, **85**, 262
- 6,6*a*,7,8,9,10-Hexahydro-5*H*-pyrido[1,2-*a*]quinoxalines, **84**, 302
- 1,2,3,5,6,7-Hexahydropyrido[1,2,3-*de*]quinoxaline-2,5-dione, **84**, 318
- Hexahydro-1*H*-pyrimido[6,1-*a*]isoquinolin-2,4-diones, mass spectra, **84**, 248
- 1,2,3,5,6,7-Hexahydropyrimido[3,2,1-*ij*]quinazoline-1,3,7-trione, **84**, 259
- Hexahydro-1,3,5-triazine, computational studies, **81**, 77
- Hexahydro-1,3,5-trinitro-1,3,5-triazine, studies on conformations, **81**, 77
- Hierarchy, of computational methods of determining energies of heterocycles, **81**, 6
- Histamine, calculations, **81**, 15
- Histamine H₃ receptor, activation mechanism, **81**, 15
- Histidine, calculations on, **81**, 12
- ¹H NMR line-shape analysis, in determining kinetics of tautomeric equilibrium, **81**, 272
- Homarine, **85**, 75
- Hurd-Mori synthesis of 1,2,3-thiadiazoles, **83**, 98
- Hydrazine hydrate, reaction with diacetylene, **82**, 163
- 2-Hydrazinocinnamic acid, **84**, 175
- 6-Hydrazino-1,3-dimethyl-5-nitrosouracil, formation of fervenulin 4-oxides, **82**, 295
- 1-Hydrazino-1-hydroxy-4-phenyl-1,2-dihydro-3*H*pyrido[1,2-*c*]pyrimidin-3-one hydrazone, **84**, 263
- 3-Hydrazino-3-methylbutan-2-one oxime, reaction with aldehydes, **82**, 297
- 2-Hydrazino-4-methylquinoline derivatives of sugars, cyclisation, **84**, 166
- 3-Hydrazino-5-phenyl-1,2,4-triazine 1-oxide, formation, **82**, 273
- 3-Hydrazinopyrido[2,3-*c*]-1,2,4-triazine 1-oxide, reaction with orthoformates, **82**, 270
- 2-Hydrazinoquinoline, **84**, 165

- 3-Hydrazino-1,2,4-triazine 1-oxide, reaction with orthoformates, **82**, 270
diazotisation, **82**, 290
- α -Hydrazonooximes, reaction with ortho-carboxylates, **82**, 294
- 9-Hydrazono-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, effect of heating, **85**, 232
- Hydrobis(3-isopropylpyrazol-1-yl)(5-methylpyrazol-1-yl)borate, complex with tungsten, **81**, 174
- Hydrobis(2-mercapto-1-methylimidazol-3-yl)(pyrazol-1-yl)borate, as a ligand, **81**, 226
- Hydrogen molecular, reaction with ruthenium complexes, **81**, 204
- Hydrolilolidine, **84**, 102
- 2-Hydropolyfluoroalk-2-anoates, reaction with 2-aminopyridines, **85**, 243
- Hydrotris(3-*p*-anisylpyrazol-1-yl)borate ligands, in rhodium complexes, **81**, 205
- Hydrotris(3-*tert*-butyl-5-isopropylpyrazol-1-yl)borate, in copper complexes, **81**, 223
- Hydrotris(3-*tert*-butyl-5-methylpyrazol-1-yl)borate, in copper complexes, **81**, 223
- Hydrotris(3-*tert*-butylpyrazol-1-yl)borate, aluminum complexes, **81**, 169
in copper complexes, **81**, 223
- Hydrotris(3,5-di-*tert*-butylpyrazol-1-yl)borate, aluminum complexes, **81**, 169
- Hydrotris(3,5-diisopropylpyrazol-1-yl)borate, in copper complexes, **81**, 223
- Hydrotris(3,5-dimethyl-1,2,4-triazol-1-yl)borate, in molybdenum complexes, **81**, 174
- Hydrotris(3,5-diphenylpyrazol-1-yl)borate, in copper complexes, **81**, 223
- Hydrotris(indazol-1-yl)borate, reaction with palladium complexes, **81**, 220
- Hydrotris(3-isopropylpyrazol-1-yl)borate, in tungsten complexes, **81**, 186
- Hydrotris(2-mercapto-1-methylimidazol-3-yl)borate, zinc complexes, **81**, 170
- Hydrotris(3-phenyl-5-isopropylpyrazol-1-yl)borate, in copper complexes, **81**, 223
- Hydrotris(3-phenylpyrazol-1-yl)borate ligands, in rhodium complexes, **81**, 205
- Hydrotris(pyrazol-1-yl)borate ligands, **81**, 168
reaction with iron complexes, **81**, 197
cyclopalladated complexes, **81**, 220
- Hydrotris(3-trifluoromethyl-5-methylpyrazol-1-yl)borate, in iridium complexes, **81**, 211
reaction with rhodium complexes, **81**, 212
- Hydrotris(3,5-trifluoromethylpyrazol-1-yl)borate, in copper complexes, **81**, 223
- 1-Hydroxy-8-(acetylamino)naphthalene, conversion to 2-methyl naphtho[1,8-*d,e*]1,3-oxazines, **81**, 69
- 2-Hydroxyadenine, pairing properties, **81**, 64
- Hydroxy-1-alkynonoates, catalysed addition to alkenes, **81**, 111
- 2-[4-(4-Hydroxybenzoyl)benzyloxy]-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, alkylation, **85**, 213
- 2-[4-(4-Hydroxybenzoyl)benzylthio]-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, alkylation, **85**, 213
- anhydro*(2-Hydroxy-3-benzyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxides, **85**, 244
- 1-Hydroxy-2,2'-biindolyis, **82**, 135
- 3-Hydroxy-3-(4-biphenyl)perhydro-pyrido[1,2-*c*][1,4]oxazine, **84**, 285
- 2-Hydroxy-5-bromopyrimidine, complexes with water, **81**, 44
- 4-(4-Hydroxybutyn-1-yl)pyrazole, **82**, 31
- 1-(3-Hydroxybutyl)piperidine, intramolecular electrochemical alkoxylation, **85**, 184
- 11-Hydroxycanthin-6-one-*N*-oxide, **85**, 123
- anhydro*(2-Hydroxy-7-chloro-3-propyl-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxides, **85**, 244
- 2-Hydroxy-3-{4-[(2-cyanophenyl)phenyl]methyl}-4*H*-pyrido[1,2-*a*]pyrimidine, **85**, 244
- 8-Hydroxy-2-cycloalkyl-2,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, **84**, 313
- Hydroxycyclobutenones, formation from diethoxy diketone, **81**, 108
- 4-Hydroxy-2-cyclobutenones, ring enlargement, **81**, 109
- 5-Hydroxycyclohepta[1,2-*d*]isoxazole-4(7*H*)-one, calculations of hydrogen transfer in, **81**, 20
- 5-Hydroxycytosine, tautomerisation, **81**, 48

- 4-Hydroxy-3,4-dihydro-1,2,4-triazine, open chain tautomerism, **82**, 282, 283
- 3-Hydroxy-2,5-diisobutylpyrazine-4-oxide, **85**, 120
- 3-[(4-Hydroxy-2,6-dimethylphenyl)methyl]-2,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, **84**, 300
- 9-Hydroxy-2,3-dimethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 246
- 2'-Hydroxy-2,4-dinitrodiphenylamine, denitrocyclisation, **83**, 209
- 2'-Hydroxy-2,6-dinitrodiphenylamine, denitrocyclisation, **83**, 209
- anhydro*(2-Hydroxy-1,3-disubstituted 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxides, **85**, 244
- 3-Hydroxy-5-ethoxycarbonylpyrazole, tautomerism, **81**, 16
- 4-(2-Hydroxyethoxymethyl)-1,2,4-benzotriazine, **82**, 269
- 2-(2-Hydroxyethoxy)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, preparation, **85**, 208
- 2-Hydroxyethylamine, reaction with diacetylene, **82**, 162
- 1-(2-Hydroxyethyl)-2-(1-aryl-1-hydroxymethyl)-3-benzoyloxy-1,4-dihydropyridin-4-ones, **84**, 281
- 1-(2-Hydroxyethyl)-2-cyanopiperidine, **84**, 283
- 3-(2'-Hydroxyethyl-6-fluoro-7-(2'-dimethyl-carbamidoethyl)indole, **84**, 112
- 2-Hydroxyethylhydrazine, reaction with diacetylene, **82**, 165
- 2-[2-(2-Hydroxyethyl)iminopropyl]-1,3-oxazolidine, **82**, 162
- 3-(2-Hydroxyethyl)-9-methoxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, 209
- acylation, **85**, 213
- 1-(2-Hydroxyethyl)-5-methylpyrazole, **82**, 165
- 3-(2-Hydroxyethyl)-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 209
- 8-(1-Hydroxyethyl)-1,2,3,4,5,6,7,8-octahydroquinoline-2-one, reaction with benzaldehyde, **84**, 245
- 1-(2-Hydroxyethyl)-2-[(phenyl)hydroxymethyl]piperidine, **84**, 282
- 7-Hydroxyethyl-2-(2-pyrimidinyl)perhydropyrido[1,2-*a*]pyrazines, **84**, 305
- 5-Hydroxyfuranone, formation, **81**, 137
- 11*b*-Hydroxy-1,3,4,6,7,11*b*,hexahydropyrido[1,4]oxazino[3,4-*a*]isoquinolin-4-one, **84**, 276, 281
- 3-Hydroxyiminomethyl-1,2,5-oxadiazole, rearrangement, **81**, 34
- 1-Hydroxyindoles, **82**, 103
- acidity, **82**, 108
- methylation, **82**, 109
- rearrangement, **82**, 119
- 5-Hydroxyindole, **85**, 100
- (3*S*,6*S*)-(-)-6-(1-Hydroxyindol-3-ylmethyl)-3-isobutyl-2,5-piperazinedione, **82**, 121
- 8-Hydroxy-11-isopropoxy-7,8,9,10-tetrahydropyrido[1,2-*b*][1,2]benzothiazin-10-ones, reaction with acid, **84**, 232
- 4-Hydroxy-isothiazoline 1,1-dioxides, **83**, 85
- Hydroxylamine, reaction with diphenylbuta-1,3-diyne, **82**, 168
- 5-Hydroxylamino-1,2,4-triazines, formation, **82**, 285
- 1-Hydroxymelatonin, reaction with formic acid, **82**, 136
- 2-Hydroxy-10-methoxy-2-(2,6-dimethyl-4-methoxymethylphenyl)imino-3-methyl-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-4-one, **84**, 256
- 10-Hydroxy-9-methoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-4-one, **84**, 256
- 4-Hydroxymethylbenzothiazolone *S,S*-dioxide, **83**, 73
- 7-Hydroxymethyl-8-[(4-cyanophenyl)-methoxy]-1,3,4,6,11,11*a*-hexahydro-1*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, reduction, **84**, 302
- 1-Hydroxy-8-methylene-4-phenylperhydropyrido[2,1-*c*][1,4]oxazine, oxidation, **84**, 273
- 4-[3-(1-Hydroxy-1-methylethyl)-1*H*-pyrazol-4-yl]-2-methylbut-3-yn-2-ol, **82**, 5
- 9-Hydroxy-2-methyl-3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, acylation, **85**, 213
- 9-Hydroxy-2-methyl-3-{2-[4-(6-fluorobenzo[*a*]isoxazol-3-yl)-1,2,3,6-tetrahydro-1-pyridyl]ethyl}-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-4-one, resolution, **85**, 233

- 5-Hydroxymethyl-2(5*H*)-furanone, reaction with benzylamine, **81**, 156
- R-(+)-5-Hydroxymethyl-2(5*H*)-furanone, dialkylation, **81**, 132
- 9-Hydroxy-2-methyl-3-(2-hydroxyethyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, alkylation, **85**, 213
- 4-Hydroxy-2-methylisoquinolinium iodide, **85**, 86
- 3-Hydroxymethyl-6-methyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-one, **84**, 251
- 9-Hydroxymethyl-7-methyl-2-morpholino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, acylation, **85**, 211
- 4-Hydroxymethyl-1-methyl[1,2,3]triazolo[4,5-*c*]pyridine, formation, **83**, 43
- 7-Hydroxy-1-methyl-5-oxo-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]quinoxaline, **84**, 321
- 7,9*a*-*cis*-H-7-Hydroxymethylperhydropyrido[1,2-*a*]pyrazine, **84**, 304
- 1-(2-Hydroxymethyl)piperazines, oxidation, **85**, 184
- (-)-(2*R*)-[(2*S*-Hydroxymethyl)piperidin-1-yl]-2-phenylethanol, **84**, 270
- 3-Hydroxy-2-(2-methyl-4-prop-1-ynyl-1*H*-pyrazol-3-yl)acrylic acid methyl esters, **82**, 18
- 5-Hydroxymethyl-2-prop-1-ynylthiophene, **82**, 173
- 3-Hydroxy-1-methylpyridine, basicity, **85**, 80
- 3-Hydroxy-1-methylpyridinium iodide, NMR spectra, **85**, 80
- 2-Hydroxy-3-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 243
- 9-Hydroxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 245
- Mannich reaction, **85**, 206
- alkylation, **85**, 213
- 1-Hydroxymethyl-2-*p*-tolylimidazo[1,2-*a*]quinoline, **84**, 135
- 2-Hydroxy-2'-nitrodiphenylsulfones, base-catalysed cyclisation, **83**, 218
- 1-Hydroxy-4-nitroindole, formation of active esters, **82**, 122
- 7-Hydroxy-5-oxo-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 275
- 2-Hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide, structure determination, **85**, 200
- anhydro*-(2-Hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxide, geometries, **85**, 196
- 2(3-Hydroxypentyl)piperidine, **84**, 226
- 2-(4-Hydroxypentyl)quinazolin-4(3*H*)ones, cyclisation, **85**, 262
- 2-(2'-Hydroxyphenyl)benzimidazole, excited state proton transfer, **81**, 22
- 2-(2'-Hydroxyphenyl)benzothiazole, excited state proton transfer, **81**, 22
- 2-(2'-Hydroxyphenyl)benzoxazole, excited state proton transfer, **81**, 19, 22
- 5-Hydroxyphenyl-4-hydroxy-4,5-dihydro-1,2,4-triazines, **82**, 276
- 2-(2'-Hydroxyphenyl)imidazole, calculations on intramolecular hydrogen bonding in, **81**, 8
- tautomerism, **81**, 9
- 3-[(4-Hydroxyphenyl)methyl]-1,2,3,4,11,11*a*-hexahydro-6*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, **84**, 317
- 9-Hydroxy-9-phenylperhydropyrido[2,1-*c*][1,4]oxazine-6-one, **84**, 280
- 5-Hydroxyphenyl-1,2,4-triazine 4-oxides, **82**, 276
- 9-(3-Hydroxy-1-propynyl)-*N*-(4-chlorobenzyl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxamide, **84**, 273
- 4-(3-Hydroxypropyn-1-yl)pyrazole, **82**, 31
- 8-Hydroxypseudoptisine chloride, **85**, 138
- 2-Hydroxypyrazine, computational studies of tautomers, **81**, 41
- 1-Hydroxypyrazole, proton transfer to pyrazole-*N*-oxide, **81**, 15
- Hydroxypyridazine *N*-oxides, tautomers, **81**, 43
- 6-Hydroxypyridazine 1-oxide, tautomers, **81**, 43
- 3-Hydroxypyridine, isolation and structure, **85**, 79
- 3-Hydroxypyridine-2-selol, **83**, 233
- 2-Hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 211, 212
- 9-Hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, complexes with metals, **85**, 195

- 2-Hydroxypyrimidine, complexes with water, **81**, 44
- 8-Hydroxypyrroloquinoline, **84**, 103
- 7-Hydroxyquinoline, allylation, **84**, 103
- 4-Hydroxyquinoline-2-one, reaction with oxalyl chloride, **84**, 148
- 8-Hydroxyquinolin-2-one, reaction with ethyl 3-chloroacrylate, **84**, 151
- 3-Hydroxyquinoline-2(1*H*)-thiones, **84**, 155
- Hydroxysanguinarinebetaine, formation from Chelidonine, **85**, 154
- 2-Hydroxy-9-(2-substituted ethoxy)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 244
- 2-Hydroxy-3-substituted-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, *O*-alkylation, **85**, 211
- 8-Hydroxy-7,8,9,10-tetrahydropyrido[1,2-*b*][1,2]benzothiazine-10-one 5,5-dioxides, catalytic hydrogenation, **84**, 232
- 7-Hydroxy-2,3,6,7-tetrahydro-1*H*,5*H*-pyrido[3,2,1-*ij*]quinazoline-1,3-dione, Vilsmeier-Haack formylation, **84**, 253
- 4-Hydroxy-2,3,4,5-tetrahydro-1,2,4-triazines, oxidation, **82**, 297
- 13-Hydroxy-2,3,10,11-tetramethoxydibenzo[*a,g*]quinolinium chloride, **85**, 104
- 1-Hydroxythiazolo[3,2-*a*]quinolinium perchlorate, **84**, 156
- 1-Hydroxy-1,4,5-triazahexatrienes, **82**, 283
- 3-Hydroxy-1,2,4-triazine, **82**, 280
- 5-Hydroxy-1,2,4-triazine 4-oxides, **82**, 268
- 1-Hydroxy-1,2,3-triazole, stability of tautomers, **81**, 28
- 3-Hydroxy[1,2,3]triazolo[4,5-*b*]pyridine, **83**, 22
- X-ray structure, **83**, 27
- 3-Hydroxytriazolopyridine, used as peptide coupling catalysts, **83**, 53
- 8-Hydroxy[1,2,4]triazolo[1,5-*a*]pyridine, **83**, 8
- 1-Hydroxy-*Nb*-trifluoroacetyltryptamine, reaction with mesylchloride, **82**, 139
- 1-Hydroxytryptamines, **82**, 103
- reaction with *p*toluenesulfonyl chloride, **82**, 112
- 1-Hydroxytryptophans, **82**, 103
- anhydro*(2-Hydroxy-3-[(3-vinylphenyl)-methyl]-1-phenyl- 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium)hydroxides, **85**, 233, 244
- 1-Hydroxyyohimbine, **82**, 107
- rearrangement, **82**, 120
- Hyperaspine alkaloid, **84**, 225, 246
- Hypoxanthine, tautomers, **81**, 61
- Imidazo[2,1-*cj*]-1,2,4-benzotriazine 1-oxides, **82**, 270
- Imidazo-fused pyrimidines, tautomerism, **81**, 270
- Imidazolate anion ligand, **83**, 118
- Imidazoles, calculations of, **81**, 8
- complexes with water, calculations on, **81**, 8
- calculations on electronic spectra, **81**, 12
- aromaticity in, **81**, 15
- electronic structure, **83**, 118
- complex with dimethylzirconocene, **83**, 123
- complex with rhenium carbonyls, **83**, 126
- complex with iron carbonyls, **83**, 127
- complex with osmium carbonyls, **83**, 130
- rhodium complexes, **83**, 132
- Imidazole cation π -complexes, calculations on, **81**, 9
- Imidazole-2-carbaldehyde thiosemicarbazone, complex with dimethyltin oxide, **83**, 123
- 1-*H*-Imidazole-2-carboxylic acid, decarboxylation, **81**, 11
- Imidazole-fused thiadiazines, tautomerism, **81**, 290
- Imidazole-tetramethylammonium complex, calculations on, **81**, 9
- 2(4)-*H*-Imidazol-2(4)-ylidene, calculated bond lengths, **81**, 11
- carbene ligands, **83**, 118
- Imidazol-4-ylzinc reagent, **84**, 10
- Imidazo[1,2-*a*]pyridine, reaction with osmium carbonyls, **83**, 144
- Imidazo[1,5-*a*]quinolines, **84**, 137
- Imidazoquinoline-2-carboxylate, formation, **84**, 133
- Imidazoquinoline-2-thiols, reaction with 2-chloromethylpyridine, **84**, 144
- Imidazo[5,4,1-*ij*]quinolin-2-one, **84**, 144
- 4-Imino-3-cyano-2-trifluoromethyl-4*H*-pyrido[1,2-*a*]pyrimidine, acid hydrolysis, **85**, 216
- Iminodiazomethane, spontaneous 1,5-cyclisation, **81**, 30
- 1-Iminoperhydropyrido[1,2-*c*]pyrimidines, **84**, 258
- 2-Iminopiperidine, reaction with propynyl-nitriles, **85**, 243

- 4-Imino-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile, **85**, 248
reaction with azides, **85**, 202
Indene, use of CCSD(T), **81**, 3
2-(1-*H*-Inden-2-yl)-1-methyl-naphthalene dianion, **85**, 86
Indolo[2',3':3,4]pyrido[1,2-*b*]isoquinolinium-14-olate, **85**, 86
Indolopyridocoline, **85**, 149
5-(Indol-2'-yl)dihydropyridazine, tautomerism, **81**, 263
Interaction energies, requirement for corrections, **81**, 6
Indole-3-methanol, **82**, 143
11*H*-Indolo[3,2-*c*]quinolines, **84**, 14
5-(Indol-3-yl)-3,6-diphenyl 4-oxide, **82**, 276
5-Indolyl-4-hydroxy-4,5-dihydro-1,2,4-triazines, **82**, 275
1-(Indol-3-yl)indoles, **82**, 124
2-(Indol-1-yl)indole-3-carbaldehyde, **82**, 127
6-Indol-3-yl-methylenedihydrazino-5-nitrosouracil, **82**, 287
Iodinine, *see* 1,6-phenazindiol-5,10-dioxide
7-Iodo-2-alkoxy-3-[4-[2-cyanophenyl]-phenyl]methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 219
Iodoaminopyrazoles, reactions with electron-rich alk-1-ynes, **82**, 25
2-Iodo-1,3-dimesitylimidazolium iodide, complex with 1,3-dimesitylimidazol-2-ylidene, **83**, 120
5-Iodo-1,3-dimethylpyrazole-4-carboxylic acid, **82**, 57
4-Iodo-1,3-dimethylpyrazole-5-carboxylic acid, **82**, 57
4-Iodoethynyl-1,3-dimethylpyrazole, **82**, 53
4-Iodoethynylpyrazoles, **82**, 38
2-Iodo-6-methoxyquinoline, **84**, 6
3-Iodomethyl-8-chloro-2,3-dihydropyrido[1,2,3-*de*]-1,4-benzoxazinium salts, **84**, 280
3-Iodomethyl-2,3-dihydro-1*H*-pyrido[1,2,3-*de*]quinoxalium iodides, **84**, 318
3-Iodomethylperhydropyrido[1,2-*c*][1,3]oxazin-1-one, **84**, 244
5-Iodo-1-methylpyrazole, reaction with alk-1-ynes, **82**, 21
3-Iodo-1-methylpyrazole-4-carboxylic acid, reaction with copper acetylides, **82**, 57
4-Iodo-1-methylpyrazole-5(3)-carboxylic acid, cyclocondensation with copper phenylacetylide, **82**, 59
5-Iodo-4-nitro-1,3-dimethylpyrazole, reaction with phenylacetylene, **82**, 23
9-Iodo-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 288
2-Iodo-11-oxo-11*H*-pyrido[1,2-*a*]quinazoline-6-carboxamides, **85**, 261
2-Iodo-11-oxo-11*H*-pyrido[2,1-*b*]quinazoline-6-carboxylic acid, **85**, 264
4-Iodopyrazole-3(5)-carboxylic acid, cyclisation, **82**, 57
2-Iodoquinoline, **84**, 6
4-Iodoquinoline, Heck reactions of, **84**, 22
Ipohardine, **85**, 84
Iridapyrrole complexes, **81**, 209
Iron-cobalt-triple-decker complexes, **85**, 5
Iron complexes, **81**, 226
Isoamyl nitrite, in nitrosation of metal complexes, **81**, 190
Isocytosine, computational studies, **81**, 46
Watson-Crick pair with cytosine, **81**, 48
tautomeric equilibria, **81**, 270
Isogagaridine, **85**, 108
Isonitrosoacetophenone hydrazones, reaction with aldehydes, **82**, 283
Isonitrosopropiophenone, formation of triazine oxides, **82**, 294
4-Isonitroso-2,2,5,5-tetramethyltetrahydrofuran-3-one hydrazones, reaction with orthobenzoates, **82**, 295
5-Isonitroso-1,3,3-trimethyl-2-oxabicyclo-[2,3,3]octan-6-one hydrazone, reaction with orthobenzoates, **82**, 295
Isopropylidene (2-pyridylamino)-methylene-malonates, thermolysis, **85**, 235
2-Isopropylimidazole, complexes with organotin compounds, **83**, 122
(11*aS*)-3-Isopropyl-11*a*-methyl-4-phenyl-1,6,11,11*a*-tetrahydro[1,4]oxazino[4,3-*b*]isoquinolin-1-one, **84**, 271
4-{2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl}-2-aminopyridine, **85**, 244
Isoquino[3,2-*a*]isoquinolinium-13-olate, **85**, 86
Isoquinolinium-4-olate, preparation, **85**, 86
Isoregecoline, **85**, 139
Isoregelinone, **85**, 139

- Isothebaine, **85**, 114
Isothiadiazole *S,S*-dioxide, heteroaromaticity, **83**, 72
Isothiazole, in gold complexes, **84**, 210
Isothiazole *S,S*-dioxide, heteroaromaticity, **83**, 72
Isothiazolidine *S,S*-dioxides, formation, **83**, 83
3-Isothiazolidinone *S*-oxide moiety found in Leinamycin, **83**, 85
spiro-Isothiazolines, formation, **83**, 81
Isothiazolo[5,4-*d*]isoxazolines, formation, **83**, 74
Isothiazol-3-one *S,S*-dioxide, Diels Alder reactions, **83**, 72
Isoxazolidines, conversion to furanones, **81**, 117
Isoxazolidinium salts, conversion to furanones, **81**, 118
Isoxazoline-5-spirocyclopropanes, thermal rearrangements, **84**, 96
Javacarboline, **85**, 70
2-Keto-4,5-dimethyltetrahydrocarbazole, **82**, 219
Kost-Sagitullin rearrangements, **84**, 35
Lavendamycin, synthesis, **84**, 17
Leinamycin, sulfur-oxygen interaction in, **81**, 26
83, 85
Lepadiformine, **84**, 120
(-)-Lepadins A,B,C, **84**, 231
Leptopinine, **85**, 97
Levofloxacin, **84**, 225
Liriodendronine, **85**, 115
 α -Lithiated 2,6-diphenyl-2*H*-thiopyrans, rearrangement, **81**, 257
Lithiated imidazol-2-ylidenes, as dimers or tetramers, **83**, 121
Lithiodiphenylphosphide, reaction with alkoxyfuranones, **81**, 137
2-Lithio-1-methoxyindole, reactions, **82**, 114
2-Lithio-4-methylthiazolate, in gold complexes, **84**, 209
2-Lithio-1,3-oxazole, calculated structure, **81**, 18
2-Lithio-2-phenyl-1,3-dithianetetrahydrofuran tetramethylethylenediamine, reaction with carbon dioxide, **81**, 76
7-Lithiotriazolopyridine, reaction with pyridine-2-carboxaldehyde, **83**, 28
Lithium benzothiazolate, reaction with metal carbonyls, **84**, 194
 reaction with iron carbonyls, **84**, 196
 reaction with gold complexes, **84**, 209
Lithium benzothiazole-2-thiolate, rhenium complexes, **84**, 202
 reaction with iridium complexes, **84**, 203
Lithium 1-benzylimidazolate, rhodium complexes, **83**, 132
Lithium 1-*tert*-butyl-2-methyl-1,2-azaboroliny, reaction with iron(II) and cobalt(II) bromides, **85**, 22
Lithium 1,2-diphospholide reaction with iron complexes, **85**, 33
Lithium 1,3-diphospholides, reaction with iron complexes, **85**, 33
Lithium hydrate of bis(3,5-dimethylpyrazol-1-yl)acetate, reaction with niobium complexes, **81**, 173
Lithium hydrobis(2-mercapto-1-methylimidazol-3-yl)(pyrazol-1-yl)borate, reaction with alkylthalliums, **81**, 170
Lithium 4-methylthiazolate, reaction with iron carbonyls, **84**, 196
 reaction with gold complexes, **84**, 209
Lithium pentamethylcyclopentadienyl, reaction with ferrous chloride, **85**, 8, 38
Lithium salts of cobalt complexes, reaction with boranyl anions, **85**, 11
Lithium salt of 2-(di-*iso*-propylamino)-1,2-thiaborolide, reaction with ruthenium and zinc complexes, **85**, 19
Lithium salt of *N*-*ortho*-hydroxybenzylidene-2-thiazolylimine, reaction with metal carbonyls, **84**, 195
Lithium salt of 2-methyl-1-trimethylsilyl-1,2-azaboroliny, reaction with iron(II) and cobalt (II)bromides, **85**, 22
Lithium tetrazolate, complexes with rhodium complexes, **83**, 165
Lithium 2-thiolatobenzothiazole, reaction with palladium complexes, **84**, 208
Lithium 1,2,4-triazolate, reaction with rhodium complexes, **83**, 161
Lithium tris(3-*tert*-butylpyrazol-1-yl)methanesulfonate, in copper complexes, **81**, 223
Local correlation approach, in calculations of heterocycles, **81**, 3

- Lomefloxacin, **84**, 106
Lusaperidone, **85**, 177
 antidepressant activity, **85**, 258
Magnesidine, **85**, 70
Magnesium complexes, **81**, 225
Malloapeltine, **85**, 74, 119
Matrix-isolated imidazoles, calculated
 infrared spectra, **81**, 9
Melatonin, in preparation of 1-hydroxy-
 melatonin, **82**, 106
Melinonine E, isolation and synthesis, **85**, 146
5-Methyloxy-2(5*H*)-furanone, **81**, 142
 reaction with amines, **81**, 153
 in preparation of β -lactams, **81**, 155
(5*S*)-5-(*d*-Methyloxy)-4-(phenylsulfonyl)-
 2(5*H*)-furanone, reaction with cyclo-
 pentadiene, **81**, 143
2-Mercapto-4-alkylpyrimidines, **82**, 202
2-Mercaptobenzimidazole, reaction with
 coumarins, **83**, 202
2-Mercaptobenzothiazole, in metal
 complexes, **84**, 195
 reaction with ruthenium carbonyls, **84**, 199
 reaction with rhenium complexes, **84**, 202
 reaction with iridium complexes, **84**, 204
2-Mercapto-1-methylimidazole, reaction
 with dimethylbis(pyrazol-1-yl)gallate,
 81, 197
2-Mercapto-3-methyl-4*H*-pyrido[1,2-*a*]
 pyrimidin-4-one, *S*-alkylation, **85**, 214
2-Mercapto-4-methylpyrimidine, **82**, 222
2-Mercapto-5-[4'-methylquinolinyl-2-
 oxymethyl]-1,3,4-oxadiazole, in mercury
 complexes, **84**, 211
2-Mercapto-5-methyl-1,3,4-thiadiazole, in
 mercury complexes, **84**, 211
2-Mercaptophenol, reaction with 4-chloro-
 3-nitrocoumarin, **83**, 218
2-Mercapto-5-phenyl-1,4-dihydroquinolin-
 4-ones, **85**, 194
2-Mercaptoquinoline, reaction with
 bromoacetic acid, **84**, 159
8-Mercaptoquinoline, reaction with
 methylene diiodide, **84**, 160
2-Mercaptoquinoline-3-carboxylates,
 reaction with bromoacetal, **84**, 157
3-Mercapto-[1,2,4]triazolo[4,3-*a*]pyridine,
 reaction with methyl acrylate, **83**, 49
2-Mercaptotriazolo[4,5-*a*]quinolines,
 84, 167
Mercury (II) chloride, reaction with
 imidazolium perchlorates, **83**, 142
7-Mesyloxyethyl-2-substituted
 perhydo[1,2-*a*]pyrazines, **84**, 311
Metal dithiolenes, computed molecular
 properties, **81**, 27
1-Methoxy-2-allenylindole, reaction with
 diethyl acetylenedicarboxylate, **82**, 117
3-Methoxy-1,2,4-benzotriazine 1-oxide,
 formation, **82**, 274
Methoxybutenones, reaction with
 carboxamide oximes, **82**, 224
4-Methoxybut-3-en-2-one, formation, **82**, 210
Methoxybutenyne, **82**, 201
 reaction with diethyl carbonate, **82**, 188
1-Methoxybut-1-en-3-yne, as stable
 derivative of diacetylene, **82**, 159
 formation of pyridazines, **82**, 204
9-Methoxycanthin-6-one *N*-oxide, **85**, 122
7-Methoxycarbonyl-2-alkoxy-
 3-{4-[2-cyanophenyl]-phenyl}methyl]-
 4*H*-pyrido[1,2-*a*]pyrimidin-4-one,
 preparation, **85**, 219
1-(2-Methoxycarbonyl)ethoxytryptamine,
 82, 110
1-Methoxycarbonyl-2-ethylquinoline, **84**, 75
4-Methoxycarbonyl-2(5*H*)-furanone,
 formation, **81**, 116
2-Methoxycarbonyl-1,2,3,4,4*a*,9*a*-
 hexahydro- β -carboline, **82**, 106
2-Methoxycarbonyl-9-hydroxy- β -carboline,
 82, 106
2-Methoxycarbonylmethylbenzothiazole,
 82, 249
2-Methoxycarbonylmethylbenzoxazole,
 82, 249
1-(2-Methoxycarbonyl-1-methyl)ethoxytryp-
 tamine, **82**, 110
6(3-Methoxycarbonylpropionyl)-1,1-dioxo-
 1,2-thiazine, **84**, 239
2-(3-Methoxycarbonylpropyl)-3,4-dihydro-
 2*H*-1,2-benzothiazin-4-one 1,1-dioxide,
 cyclisation, **84**, 232
3-Methoxycarbonyl-1*H*-pyridin-2-one,
 82, 226
8-Methoxydihydroberberine, **85**, 92
5-Methoxy-1,3-dioxane, conformational
 study, **81**, 73
5-Methoxy-2(5*H*)-furanone, **81**, 142
 reaction with phenylazides, **81**, 151

- reaction with amines, **81**, 153
- 6-Methoxy-3,4,7,8,9,10-hexahydro-1,5-diazecine-1,5-(2*H*,6*H*)-dicarbonitrile, formation, **85**, 233
- Methoxyimino-(2-methyl-4-prop-1-ynyl-2*H*-pyrazol-3-yl)acetic acid methyl ester, **82**, 18
- 1-Methoxyindole, **82**, 114
- 1-Methoxyindole-3-carbaldehyde, **82**, 124
iodination, **82**, 119
reduction, **82**, 143
- 1-Methoxy-4-iodo-3-carbaldehyde, **82**, 119
- 1-Methoxy-*Nb*-methoxycarbonyltryptamine, **82**, 140
- 2-Methoxy-1-[1-(1-methylcyclooctyl)-4-piperazinyl]-1*H*-benzimidazole, **84**, 306
- 3-Methoxy-5-methylene-2(5*H*)-furanone, cycloaddition with butadiene, **81**, 144
- 1-Methoxy-6-nitroindole, **82**, 127
reaction with diethyl malonate, **82**, 115
- 2-(2-Methoxy-5-nitrophenyl)perhydro-pyrido[1,2-*a*]pyrazin-3-one, **84**, 319
- 4-Methoxy-3-nitropyridines, reaction with guanidine, **82**, 292
- 6-Methoxy-4-oxo-2,3,4,5,6,7,8,9-octahydro-1*H*-1,5-diazonine-1-carbonitrile, formation, **85**, 233
- 1-(*p*-Methoxyphenyl)-4-acetyltriazole, **82**, 233
- p*-Methoxyphenyl azide, cycloaddition with furanones, **81**, 151
- 6-(2-Methoxyphenyl)-3,4-dihydro-2*H*-pyrimido[2,1-*a*]isoquinoline, inhibition of melanocortin-4 receptors, **85**, 266
- 4-(4-Methoxyphenyl)perhydropyrido[1,2-*c*]pyrimidine, **84**, 248
- trans*-8,9*a*-*H*-8-(2-Methoxyphenyl)perhydropyrido[2,1-*b*][1,3]thiazin-6-ones, **85**, 190
reaction with tributyltin hydride, **85**, 191
- 3-Methoxy-5-phenylsulfonyl-1,2,4-triazine 4-oxides, **82**, 277
- 3-Methoxy-5-phenyl-1,2,4-triazine 1-oxide, reaction with ammonia, **82**, 273
- 4-(2-Methoxyphenyl)-1-[3-(tributylsilylthio)propyl]piperidin-2-one, **85**, 191
- 2-Methoxypyridine, reaction with tetrazoles, **83**, 20
- 2-Methoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, preparation, **85**, 208
- 5-Methoxy-4-pyrrolidin-1-yl-2(5*H*)-furanone, reaction with aldehydes, **81**, 134
- 1-Methoxy-6,7-secoagroclavine, **82**, 147
- 10-Methoxy-3,4,5,6-tetradehydrocorynantheol, **85**, 144
- 10-(Methoxy-3,4,5,6-tetradehydro-18,19-dihydrocorynantheol, **85**, 143
- 2-Methoxytetrahydropyrrole, **84**, 96
- 2-Methoxy-8,4,5,5,-tetramethyl-[1,3,2]dioxaborolylquinoline, **84**, 10
- 3-Methoxythiocarbonylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 216, 236
- 2-Methoxy-1,2,4-triazin-3(2*H*)-one, **82**, 291
- 3-Methoxy-1,2,4-triazine 1-oxides, halogenation, **82**, 268
- 3-Methoxy-1,2,4-triazine 2-oxide, halogenation, **82**, 268
formation, **82**, 272
- 5-Methoxy[1,2,4] triazolo[4,3-*a*]pyridine, bromination, **83**, 31
- 1-Methoxy-3-trimethylsilyloxybuta-1,3-diene, **82**, 234
- 5-Methoxy-5-(2,3,5-tris-*O*-benzoyl- β -D-ribofuranosyl)- 2(5*H*)-furanone, reaction with hydrazine hydrate, **81**, 153
- 1-Methyl-4-acyl-1,2,5,6-tetrahydropyridines, relative thermodynamic stability, **81**, 259
- 7(9)-Methyladenine, electronic spectra, **81**, 62
- 4-Methyl-2-alkylthiopyrimidines, **82**, 202
- 3-Methylamino-2(5*H*)-furanones, **81**, 116
- 2-Methylamino-5-nitro-3-phenylpyridine, **84**, 35
- 1-(*N*-Methylamino)quinolines, reaction with acrylates, **84**, 124
- 2-(Methylamino)thiazole, in metal complexes, **84**, 195
- 2-Methyl-4-amino-1,3,5-triazanaphthalene, **84**, 65
- 7-Methylamino[1,2,3]triazolo[1,5-*a*]pyridine, **83**, 38
- Methyl anhydroberberilate, **85**, 91
- Methylated guanines, vibrational spectra, **81**, 66
- Methylated triazoles and tetrazoles, computed nitrogen NMR shieldings, **81**, 31
- 2-Methyl-1*H*-1,3-benzazaphosphole, lithiation, **85**, 28

- 1-Methylbenzimidazole, calculated infrared spectra, **81**, 9
- 2-Methylbenzimidazole, **84**, 144
- 2-Methylbenzotellurazole, reaction with iron carbonyls, **84**, 196
- 2-Methylbenzothiazole, **82**, 249
- 3-Methyl-1,2,4-benzotriazine 1-oxide, reaction with phenylmagnesium bromide, **82**, 286
- 3-Methyl-1,2,4-benzotriazine 4-oxide, **82**, 298
- 7-Methyl-1,2,4-benzotriazin-3(4*H*)-one 1-oxide, **82**, 290
- 2-Methylbenzoxazole, **82**, 249
- Methyl 2-[2-benzoyl-2-ethoxycarbonyl-1-vinylamino]-3-[(4-methyl-2-pyridyl)amino]acrylate, cyclization, **85**, 236
- trans*- and *cis*-Methyl-*N*-benzyl-2-hydroxymethylaziridine-2-carboxylates, formation, **81**, 156
- 1-Methyl-2-benzyl-5-nitropyrimidinium salts, rearrangements, **84**, 36
- Methyl *N*-[2-(benzyloxycarbonylamino)acetyl]-4-substituted pipercolinates, **84**, 319
- 1-Methyl-3(5)-butadiynylpyrazole, synthesis, **82**, 46
- 2-Methylbut-2-ene, Diels-Alder reactions, **81**, 24
- Methyl-2-butyl-2,3-pentadienoate, in synthesis of fimbrolide, **81**, 120
- 2-Methylcarbazole, **82**, 219
- 1-Methyl-2-chlorobenzothiazolium tetrafluoroborate, reaction with iron carbonyl anions, **84**, 196
- 3-Methyl-2-chlorobenzothiazolium tetrafluoroborate, reaction with osmium carbonyls, **84**, 198
- 3-Methyl-4-chloropyrazol-1-yl, in tungsten complexes, **81**, 180
- 1-Methyl-4-chloro[1,2,3]triazolo[4,5-*c*]pyridine, reaction with secondary amines, **83**, 40
- 4-Methyl-5-cinnamyloxy-2(5*H*)-furanone, photoreactivity, **81**, 157
- Methyl cyanate, in formation of triazines, **81**, 77
- 1-Methylcytosine, tautomerisation, **81**, 47
modelling of cytosine methylation, **81**, 50
- Methyldiacetylene, reaction with hydrazine hydrate, **82**, 164
- 5-*R*-3-Methyl-4-diethylaminopyridine, **84**, 53
- 2-Methyl-8,9-difluoro-1,2-dihydropyrrolo[3,2,1-*ij*]quinolin-6-one-5-carboxylic acid, **84**, 107
- 5-Methyl-2,3-dihydro-1,4-diazepine, **82**, 160, 183
- 1-Methyl-1,4-dihydropyridine, calculated stability relative to 1,2-isomer, **81**, 259
- 1-Methyl-1,2-dihydroquinoline, formation, **81**, 261
- 6-Methyl-9,10-dimethoxy-4-phenyl-2,3,4,6,7,11*b*-hexahydro-1*H*-pyrimido[6,1-*a*]isoquinolin-2-one, **84**, 249
- 2-Methyl-4-(dimethylamino)pyrimidines, **82**, 288
- Methyl-3-([(1,1-dimethylethyl)diphenylsilyl]oxy)-4-(chloromethoxyphosphinyl)butyrate, reaction with lithium pyrazolyl-alkynide, **82**, 39
- 1-Methyl-3,5-dinitro-1,4-dihydropyridin-4-one, conversion to furo[3,2-*b*]pyridine, **83**, 194
- 2-Methyl-1,3-dioxolane, reaction with 2-pyridyl cations, **81**, 24
- N*-(3-Methyl-2,4-dioxypyrimidin-6-yl) *N*-methylhydrazone, reaction with potassium nitrate, **82**, 295
- 6-Methyl-2,4-diphenyldihydropyrimidine, tautomeric equilibrium, **81**, 267, 272
- 1,1'-Methylenebis(4-alkyl-1,2,4-triazolium)-diiodides, reaction with palladium acetate, **83**, 162
- 1,1'-Methylenebis(3-*tert*-butylimidazol-2-ylidene), formation of nickel complexes, **83**, 136
- 1,1'-Methylenebis(3-methylbenzimidazolium) diiodide, reaction with palladium chloride, **83**, 148
- 1,1'-Methylene-3,3'-dimethylbis(imidazolium) diiodide, formation of palladium complexes, **83**, 136
- 5-Methylene-1,3-dioxane-4,6-dione, cycloaddition reactions, **81**, 73
- 5-Methylene-2(5*H*)-furanone, formation, **81**, 108
as a dienophile, **81**, 144
- 2-Methylene-3-[3-(het)arylacroyl]perhydrothiazines, radical cyclisation, **85**, 193
- Methyleneketene, cycloadditions, **81**, 73

- 1-Methylene-1,2,3,4-tetrahydro-5*H*-pyrazino[2,1-*b*]quinazoline-3,6-diones, **85**, 264
- 8-(1-Methylethenyl)-2-oxo-7-thia-1-azabicyclo[4.3.0]octa-3,5-diene-5,8-dicarboxylate, oxidation, **85**, 194
- 1(2)-Methyl-3-ethynylindazole, **82**, 48
- 1-Methyl-3(4)-ethynylpyrazoles, synthesis, **82**, 45
reaction with base in acetone, **82**, 32
- 1-Methyl-3-ferrocenylbenzimidazolium iodide, reaction with palladium acetate, **83**, 148
- 1-Methyl-3-ferrocenylimidazolium tetrafluorborate, formation of anion and reaction with tungsten carbonyls, **83**, 143
reaction with mercury (II) acetate, **83**, 148
- 7-Methylguanine, **85**, 116
- 7-Methylguanosine, **85**, 116
- 2-Methyl-1,2,3,4,4*a*,9*a*-hexahydro- β -carboline, **82**, 106
- 4*a*-Methyl-1,2,3,4,4*a*,5-hexahydro-10*H*-pyrazino[1,2-*b*]isoquinolin-10-one, acylation, **84**, 307
- 11-Methylhexahydropyrido[2,1-*b*][1,3]benzoxazin-9-ones, **85**, 188
- 6-Methyl- 2,3,4,6,7,11*b*-hexahydro-1*H*-pyrido[6,1-*a*]isoquinolin-2-ones, **84**, 248
- 2-Methylhexahydropyrimidine, **82**, 161
- 2-Methyl-9-hydroxy- β -carboline, **82**, 106
- Methyl 1-hydroxyindole-3-acetate, **82**, 135
- 2-Methyl-7-hydroxyisoquinolinium iodide, **85**, 93
- 2-Methylhydroxyisoquinolinium chlorides, pK_a values, **85**, 86
- 3-Methyl-4-hydroxy-2-oxo-2*H*-pyrido[2,1-*b*][1,3]oxazinium inner salts, **85**, 179, 180, 188
- anhydro*-(3-Methyl-2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyridinium)hydroxides, solid state structure, **85**, 200
- 2-Methyl-3-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 246
- 2-Methyl-4-hydroxypyrimidin-6-one, **84**, 61
- Methylidene rhodanine, calculations on structure, **81**, 23
- 4-Methylimidazole, spectra of tautomers, **81**, 9
- 1(2)(4)-Methylimidazole, complexes with organotin compounds, **83**, 122
- 2-Methylimidazole, complexes with osmium, **83**, 130
- 1-Methylimidazole-2-thiol, mercury complexes, **83**, 142
- 1-Methylimidazol-2-ylidene, palladium complex, **83**, 137
- Methyl 2-(imidazol-1-yl)indole-3-carboxylate, **82**, 127
- Methyl 2-(imidazol-1-yl)-5-iodoindole-3-carboxylate, **82**, 127
- 1-Methylimidazol-2-yllithium, reaction with cuprous compounds, **83**, 138
reaction with gold complexes, **83**, 141
- 9-Methyl-4-imino-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile, **85**, 248
- β -(1-Methyl-3-indazolyl)- α -bromoacrylic acid, conversion to propynic acids, **82**, 17
- β -(2-Methyl-3-indazolyl)- α -bromoacrylic acid, conversion to propynic acids, **82**, 17
- 1-(1-Methyl-3-indazolyl)-3-methylbutyne-1-ol-3, **82**, 33
- 1(2-)-Methyl-3-indazolyl-propynoic acids, **82**, 18
- Methyl 2-(indol-1-yl)indole-3-carboxylate, **82**, 127
- Methyl iodide, reaction with rhodium complexes, **81**, 209
- Methyl 5(6,7)-iodo-1-methoxyindole-3-carboxylate, **82**, 118
- 1-Methylisoquinolinium 2-carboxylate, **85**, 133
- 2-Methylisoquinolinium-6-olates, **85**, 86
- 5-Methylisoxazole, **82**, 190, 221
- N*-Methyliriodendronine, **85**, 108, 115
- Methylolithium, alkylation of iridium complexes, **81**, 215
- Methyl 1-methoxyindole-3-carboxylate, **82**, 138
- 4-Methyl-7-methoxyquinoline, **82**, 214
- N*-Methyl-(2-methylamino)troponimate germanium chloride, formation of silver-germanium complex, **81**, 223
- Methyl 2-methylthioindole-3-carboxylate, **82**, 126
- 2-Methyl naphtho[1,8-*d,e*]1,3-oxazine, formation from 1-hydroxy-8-(acetyl-amino)naphthalene, **81**, 69
- 2-Methyl-5,6-naphtho-(1,2)-pyrylium ferrochlorate, **82**, 226

- 5-Methyl-4-nitrobenzofuroxan, rearrangement, **81**, 37
- 2-Methyl-7-nitrobenzoxazole, **83**, 191
- 2-Methyl-8-nitro-9-hydroxy-4H-pyrido[1,2-*a*]pyrimidin-4-ones, organotin complexes, **85**, 197
- 1-Methyl-4-nitroindazole, **83**, 200
- 1-Methyl-3-nitro-4-iodopyrazole, reaction with copper phenylacetylide, **82**, 21
- 3-Methyl-5-nitropyrimidin-4-(3*H*)-one, reaction with enolate anions, **84**, 45
- 4-Methyl-9-nitro-pyrrolidino[1,2-*a*]quinoline, **84**, 92
- 1-Methyl-5-nitrotriazol-2-one, reaction with epichlorohydrine, **83**, 195
- 2-Methyloxazoline, calculated vertical ionisation energies, **81**, 21
- cis*-3*H*,4*H*-3-Methyl-6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[2,1-*b*][1,3]thiazine-4,9-dicarboxylate, **85**, 191
- 6-Methyl-4-oxo-4*H*-1,6,7,8,9,9*a*-hexahydro-4*H*pyrido[1,2-*a*]pyrimidine-3-carboxylate, alkylation, **85**, 205
- 2-(4-Methyl-2-oxo-3-pentenyl)-1,3-dioxacyclanes, **82**, 208
- 2-Methyl-7-oxo-5-phenylpyrano[3,4-*c*]pyrazole, **82**, 59
- 6-Methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetic acid, reaction with phenylethylamine, **85**, 232
- 1-Methyl-4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-1-ium-2-olate, reaction with tetracyanoethylene, **85**, 206
- 5-Methyl-(2-penta-2,4-diynyl)thiophene, **82**, 173
- 11-Methyl-5*a*-pentyl-5*a*,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzoxazin-9-ones, **85**, 181
- 3-Methylperhydropyrido[1,2-*c*][1,3]oxazine, **84**, 240, 244
- 8-Methylperhydropyrido[1,2-*c*][1,3]oxazine-1,3-dione, reaction with benzylamine, **84**, 241
- 2-Methylperhydropyrido[2,1-*b*][1,3]oxazin-4-ones, **85**, 184
- 1-Methylperhydropyrido[1,2-*a*]pyrimidine-2,6-dione, **85**, 253
- trans*-8,9*a*-*H*-8-(4-Methylperhydropyrido[2,1-*b*][1,3]thiazin-6-ones, **85**, 190
- Methylphenylacetylene, in reaction with metal complexes, **81**, 171
- 1-Methyl-4-phenylacetylpyrazole, **82**, 42
- 2-(4-Methylphenyl)benzothiazole, cyclopalladation, **84**, 207
- 3-Methyl- α -(2-phenylethyl)-1,4-dioxo-1,3,4,6,11,11*a*-hexahydro-2*H*-pyrazino[1,2-*b*]isoquinoline-2-acetic acid, **84**, 300
- 1-Methyl-4-phenylethynylpyrazole-3-carboxylic acid, **82**, 59
- 1-Methyl-4-phenylethynyl-1*H*-pyrazole-3-carboxylic acid amide, cyclisation, **82**, 61
- (7-Methyl-8-phenylethynylpyrazolo[5,1-*c*][1,2,4]triazin-3-yl)phosphonic acid dialkyl ester, **82**, 26
- 1-Methyl-3-phenyl-6,7,8,9,10,10*a*-1*H*,5*H*-hexahydropyrido[3,2,1-*ij*][3,1]benzoxazin-5-one, **84**, 245
- 1-Methyl-2-phenylnaphthalene anion, **85**, 86
- cis*- and *trans*-2-Methyl-4-phenyloxazoline-5-methylcarboxylate, reaction with azide ions, **81**, 20
- (+/-)-(3*R*,4*R*,9*a**S*)-4-Methyl-3-phenylperhydropyrido[2,1-*c*][1,4]oxazin-3-ol, reduction, **84**, 270
- (+/-)-(3*R*,9*a**R*)-4-Methyl-3-phenylperhydropyrido[2,1-*c*][1,4]oxazin-3-ol, **84**, 285
- N*-Methyl-3-phenyl-propanesulfonamide, cyclisation, **83**, 83
- 2-Methyl-4-phenylpyrido[1,2-*a*]pyridinium perchlorate, **85**, 241
- (2*R*,1'*S*)-1-[(4-Methylphenyl)sulfonyl]-2-(iodoethyl)piperidine, **84**, 234
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, oxidation processes, **81**, 294
- 3-Methyl-6-phenyl-1,2,4-triazine 4-oxide, **82**, 293
- reaction with nitrobenzaldehyde, **82**, 289
- 6-Methyl-3-phenyl-1,2,4-triazine-4-oxide, reaction with 1-(dimethylamino)-1-ethoxyethylene, **82**, 288
- 2-(4-Methyl-1-piperazinyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, catalytic hydrogenation, **85**, 203
- Vilsmeier-Haack formylation, **85**, 206
- anti-platelet aggregation activity, **85**, 254
- 5-Methyl-3-(1-propynyl)pyrazole, **82**, 11, 12
- Methylpseudolycorine, **85**, 101
- 3(5)-Methylpyrazole, **82**, 163, 186

- 3-Methyl-pyrazole-1-carboxamide, **82**, 167
1-Methyl-1*H*-pyrazolo[3,4-*d*]pyrimidinium salts, **84**, 40
Methylpyrazolylketones, reaction with phosphorus pentachloride, **82**, 16
4-[3-(1-Methyl-1*H*-pyrazol-3-yl)-prop-2-ynyl]morpholine hydrochloride, hypoxic activity, **82**, 83
2-Methyl-5-pyridinecarboxylic acid, **82**, 212
1-Methylpyridinium-2-carboxylate, **85**, 74
isolation from lobster, **85**, 131
1-Methylpyridinium-3-olate, **85**, 74
1-Methyl-3-(pyridin-2-yl)-1,2,4-triazole, reaction with ruthenium complexes, **83**, 159
1-Methyl-9*H*-pyrido[3,4-*b*]indole, **85**, 142
2-Methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 246
3-Methyl-7-(2'-pyridyl) [1,2,4]triazolo[4,3-*a*]pyridine, **83**, 17
1-Methylpyrimidinium iodide, reaction with crotonates, **84**, 47
3-Methyl-1*H*-pyrimido[1,2-*a*]quinolin-1-one, **85**, 262
2-Methylquinazoline, **84**, 64
2-Methylquinoline, **82**, 214
reaction with benzenesulfonyl azide, **84**, 164
4-Methylquinolines, **82**, 223
2-Methylquinoline-3-carbaldehyde dimethylacetal, **82**, 215
1-Methylquinolinium salt, reduction with tributylstannyl hydride, **81**, 261
Methyl 2-quinolylacetate, **84**, 87
nitrosation, **84**, 137
2-Methyl-6-substituted-pyrimidine-1-oxides, **82**, 225
10-Methylsulfonyl-9-(4-methylpiperazinyl)-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 274
3-Methylsydnone, computed nitrogen NMR shieldings, **81**, 33
3-Methyl-4,5,6,7-tetrahydroindazolate complexes of rhodium, **81**, 206
3-Methyl-1,2,3,4-tetrahydroisoquinoline-1-acetamides, **84**, 260
(3*S*)-3-Methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, **84**, 271
2-Methyl-4,6,7,11*b*-tetrahydro[1,3]oxazino-[2,3-*a*]isoquinoline-4-one, **85**, 182, 186
1-Methyl-1,2,5,6-tetrahydropyridine, isomerisation, **81**, 259
1-Methyl-1,4,5,6-tetrahydropyridine, formation, **81**, 259
6-Methyl-3,4,4*a*,5-tetrahydro-8*H*-pyrido[1,2-*b*]pyridazines, **84**, 238
6-Methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetic acid, reaction with amines, **85**, 216
2-Methyl-Δ¹-tetrahydropyrimidine, **82**, 161
(3*S*,8*R*,9*aR*)-2-(3-Methyl-1,2,3,4-tetrahydro-8-quinolinylsulfonyl)-3-[3-(*N*³-4-methoxy-2,3,6-trimethylbenzene-sulfonyl)guanidinopropyl]perhydropyrido[1,2-*a*]pyrazine-1,4-dione, **84**, 320
1-(5-Methyltetrazol-2-yl)ethanone, in formation of 2,5-dimethyl-1,3,4-oxadiazole, **81**, 34
4-Methylthiazole, reaction with osmium complexes, **84**, 198
1-Methylthiazolidine-2,4-dione, calculations on structure, **81**, 23
3-Methylthiazolium tetrafluoroborate, reaction with platinum complexes, **84**, 205
N-Methylthioamide-1,2-thiazole, conformation, **81**, 22
3-Methylthio-1,2,4-benzotriazine 1-oxide, reaction with amines, **82**, 273
2-Methylthio-6,7-difluorobenzothiazin-4-one, **84**, 79
3-Methylthiomethyl-6-nitroindole, **82**, 115
2-Methylthio-3-methylthiomethyl-6-nitroindole, **82**, 115
3-Methylthio-6-nitroindole, **82**, 115
2-Methylthio-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile, **85**, 207, 248
reaction with guanidine, **85**, 220
4-Methylthiophenylmagnesium chloride, reaction with propargyl alcohols, **81**, 114
7-(4-Methylthiophenyl)-5-oxo-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-3-carboxamide, **84**, 273
2-Methylthio-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, preparation, **85**, 217
3-Methylthio-1*H*-pyrimido[1,2-*a*]quinolin-1-one, **85**, 264

- s-Methylthiosemicarbazide, formation of triazine oxides, **82**, 294
- 8-Methyl-3-(tosyloxymethyl)perhydropyrido[1,2-*c*][1,3]oxazin-1-one, **84**, 242
- 4-Methyl-1,1,3-trialkyl-2,3-diaza-1,4-nonadien-7-yn-6-ones, **82**, 12
- 2-Methyl-1,3,5-triazanaphthalene, **84**, 65
- 2-Methyl-1,3,5-triazaphenanthrene, **84**, 64
- 5-Methyl-1,2,4-triazines, **82**, 288
- 1-Methyl[1,2,3]triazolo[4,5-*c*]pyridine, reaction with radicals, **83**, 42
- 3-Methyl[1,2,3]triazolo[1,5-*a*]pyridine, X-ray powder diffraction, **83**, 28
reaction with LDA, **83**, 32
by photochemical reaction, **83**, 47
- 5-Methyl[1,2,4]triazolo[1,5-*a*]pyridine, **83**, 34
- 8-Methyl[1,2,4]triazolo[1,5-*a*]pyridine, **83**, 6
- (5*S*)-Methyl-3-tributylstannyl-2(5*H*)-furanone, in synthesis of hamabiwalactones, **81**, 128
- 3-Methyl-4-trifluoroacetylaminopyrrolidine, **84**, 81
- 2-Methyl-1-trimethylsilyl- Δ^3 -1,2-azaboroline, reaction with vanadium, **85**, 22
- N*-Methyl-1,3,5,2-trioxazinane, thermal decomposition, **81**, 81
- Methyltris(3,5-dimethylpyrazol-1-yl)silane, reaction with molybdenum carbonyls, **81**, 174
- 4-Methyl-1-vinyl-2-quinolone, bromination, **84**, 147
- Metrenperone, **85**, 176
- Mitragynine, **85**, 145
- Mitrasulgynine, structure, **85**, 147
- Molecular cluster, calculations of, **81**, 3
- Molybdenum carbonyl, **81**, 173
- Molybdenum-cobalt triple-decker complexes, **85**, 8
- Molybdenum hexacarbonyl, reaction with sodium methyl tris(pyrazol-1-yl)gallate, **81**, 190
reaction with 1-bromocycloocta-2,4-diene, **81**, 192
reaction with tetraethylammonium dimethylbis(pyrazol-1-yl)gallate, **81**, 194
reaction with tetraethylammonium dimethylbis(pyrazol-1-yl)gallate, **81**, 194
- reaction with dihydrobis(3(5)-phenylpyrazol-1-yl)methane, **81**, 195
- Molybdenum(II)-molybdenum(VI) species formation, **81**, 184
- 3-Monoheteroaryl amino thiadiazole *S,S*-dioxides, **83**, 101
- Montelukast, **84**, 2
- Morpholine, computational studies, **81**, 70
- 3-Morpholino-1,2,4-benzotriazine 4-oxide, reduction, **82**, 271
- 1-Morpholino-6-iminocyclohexene, reaction with hydrazine hydrate, **82**, 297
- 9-(4-Morpholinomethyl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylate, **84**, 283
- 2-Morpholino-5-nitropyridine, **84**, 51
- 1-Morpholybut-1-en-3-ynes, reaction with azides, **82**, 203
- MP2 calculations of heterocycles, **81**, 4
unreliability of calculations of transition states, **81**, 6
in vibrational spectra, **81**, 6
- Multifunctional (lactone-annulated) isoxazolines, synthesis, **81**, 147
- Multireference perturbation theory, *see*, CASPT2
- Myxin, **85**, 122
- Nandazurine, **85**, 108, 113
- Naphthisoazole, with ruthenium complexes, **84**, 197
- 2-Naphthole, reaction with methoxybutenone, **82**, 226
- 2-Naphthylbenzothiazole, reaction with iridium chloride, **84**, 202
- 7-[2-Naphthylsulfonyl]aminomethyl]perhydropyrido[1,2-*a*]pyrazine, **84**, 306
- Narcotine, **85**, 140
- Narcotoline, **85**, 140
- Neoscorbigen, synthesis, **82**, 143
- Neoxyberberine, **85**, 87, 88
- Neoxygambirtannine, **85**, 86
- Nickelocene, in formation of imidazolyldene complexes, **83**, 135
- Nicotine, in synthesis of Trigollenine, **85**, 127
- Nigellidine, **85**, 71, 140
- Niobium trichloride, reaction with borates, **81**, 172
- 2-Nitro-6-acetamidophenol, **83**, 191
- 2-Nitro-2'-aminobiphenyl, diazotisation, **83**, 192

- o*-Nitroaniline, in formation of
 hydroxyindoles, **82**, 103
 reaction with cyanamide, **82**, 293
- 8-Nitro-*N*-arylquinolones, **83**, 214
- 2-Nitrobenzaldehyde, in formation of
 coumarin derivatives, **83**, 222
 reaction with malonic acids, **83**, 223
- 4-Nitrobenzaldehyde hydrazone, in denitro-
 cyclisation reactions, **83**, 205
- 2-Nitrobenzamide, reaction with sodium
 ethoxide, **83**, 206
- 2-Nitrobenzenesulphenanilides, thermal
 reactions, **83**, 228
- 4-Nitrobenzofuroxans, tautomerism/
 rearrangements, **81**, 37
- 4-Nitro-3*H*-benzothiazole-2-thiones, **83**, 197
- 5-Nitro-6-chlorouracil, reaction with
 2-mercaptoaniline, **83**, 227
- Nitro-2*H*-chromenes, reaction with
 enamines, **83**, 204
- 8-Nitro-10-(2,6-dimethyl-4-pyridyl)-7-oxo-
 2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-
 benzoxazine-2-carboxylate, **84**, 273
- 8-Nitro-ethyl (3*S*)-3-methyl-10-(2,6-
 dimethyl-4-pyridyl)-7-oxo-2,3-dihydro-
 7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-
 6-carboxylate, **84**, 293
- 4-Nitrofurylmethylquinolinium bromide,
 cycloaddition reactions, **84**, 86
- 8-Nitro-1,3,4,6,11,11*a*-hexahydro[1,4]
 oxazino[4,3-*b*]isoquinoline, **84**, 272
- 8-Nitro-1,3,4,6,11,11*a*-hexahydro[1,4]
 oxazino[4,3-*b*]isoquinolin-4-one,
 hydrogenation, **84**, 272
- 8-Nitro-2,3,4,6,11,11*a*-hexahydro-1*H*-
 pyrazino[1,2-*b*]isoquinoline-1,4-dione,
 84, 320
- 8-Nitro-1,2,3,4,4*a*,6-hexahydropyrido[1,2-*a*]
 [3,1]benzoxazine, conformation, **85**, 180
- 3-Nitro-6,6*a*,7,8,9,10-hexahydropyrido[2,1-*c*]
 [1,4]benzoxazine, reduction, **84**, 273, 285
- 6-Nitro-2'-hydroxybiphenyl-2-carboxylic
 acid, thermal cyclisation, **83**, 192
- Nitroimidazoles, conformational studies,
 81, 10
- 6-Nitroindole, **82**, 115
- 6-Nitroindolizine, study of reaction with
 N,N-dimethylaminoacetylenes, **81**, 69
- 3-Nitro-5-methoxy[1,2,4]triazolo[1,5-*a*]
 pyridine, reduction, **83**, 30
- 3-Nitro-1,6-naphthyridine, **84**, 53
- 1-Nitrophenoxazine, formation,
 83, 209
- N*-(2-Nitrophenyl)aminophenols, in
 formation of phenoxazines, **83**, 208
- 2-Nitrophenyl azide, in formation of
 benzofuroxan, **81**, 35
- 4-Nitrophenyl azide, reaction with
 diethylketal of *N*-methylpiperidone,
 83, 21
- N*-(2-Nitrophenyl)-*N'*-benzoylthiourea,
 cyclisation, **82**, 292
- 2-(3-Nitrophenyl)-5-(*t*-butoxycarbonylami-
 no)perhydropyrido[1,2-*c*]pyrimidine-
 1,3-dione, **84**, 250
- 4-Nitrophenylhydrazones of arylaldehydes,
 anodic oxidation, **83**, 17
- 3-(4'-Nitrophenyl)indazole, **83**, 205
- ortho*-Nitrophenyl ketone oximes, denitro-
 cyclisations, **83**, 191
- 2-(4-Nitrophenyl)pyrido[1,2,3-*de*]-1,4-
 benzothiazinium bromide, **84**, 297
- 2(4-Nitrophenyl)-1*H*-pyrido[1,2,3-*de*]
 quinoxalinium bromide, **84**, 278, 322
- 3-(Nitrophenylvinyl)-1,2,4-triazine 4-oxides,
 82, 289
- 4-Nitrophthalodinitrile, reaction with
 dimedone, **83**, 194
- 8-Nitro-11*H*-pyrido[2,1-*b*]quinazolin-11-one,
 85, 264
- 5-Nitropyrimidine, ring transformation,
 84, 34
 reaction with active methylene groups,
 84, 42
 reaction with enamines, **84**, 51
- 6-Nitroquinoline, cyclocondensation with
 hydrazones, **83**, 205
- Nitrosoethylene, calculations on reaction
 with ethene, **81**, 70
- 2-Nitrosophenols, reaction with amino-
 guanidines, **82**, 296
- 2-Nitrosopyridine, reaction with nitrile
 oxides, **83**, 9
- 3-Nitro-5,6,7,8-tetrahydro-1,6-
 naphthyridine, **84**, 53
- 9-Nitro-1,2,3,4-tetrahydro-6-oxo-6*H*-
 pyrido[1,2-*a*]pyrimidin-8-carboxylate,
 85, 249
- Nitrotetrazolo[1,5-*a*]pyridines, ring
 structure, **81**, 32

- 8-Nitrotheophyllin, reaction with oxiranes, **83**, 195
- 6-Nitro-[1,2,4]triazolo[1,5-*a*]pyridine, reaction with 2-diazopropane, **83**, 49
- 8-Nitro[1,2,4]triazolo[1,5-*a*]pyridine, from 8-nitro[1,2,4]triazolo[4,3-*a*]pyridine, **83**, 10
- reduction, **83**, 30
- 8-Nitro[1,2,4]triazolo[4,3-*a*]pyridine, **83**, 17
- rearrangement to 8-nitro[1,2,4]triazolo[1,5-*a*]pyridine, **83**, 10
- 6-Nitro-1,2,4-triazolo[1,5-*a*]pyrimidine, reaction with labelled active methylene compounds, **84**, 43
- 2-R'-6-Nitro-1,3,7*a*-triazolo[1,5-*a*]pyrimidines, effect of heating, **84**, 43
- 2-Nitro-6-trifluoromethyltoluene, in formation of indanes, **83**, 207
- Nizofenone fumarate, **84**, 136
- Norcoralyne, reduction, **85**, 104
- Normelinonine F, **85**, 143
- Norpapaverinium chloride, **85**, 94, 138
- Norzooanemonine, *see*-1,3-dimethylimidazolium-4-carboxylate
- Nuclear-independent chemical shifts, as a measure of aromaticity, **81**, 15
- Nuclear quadrupole coupling in imidazoles, **81**, 12
- Ocaperidone, **85**, 177
- Octa-2,4,6-triyn-1-ol, reaction with hydrogen sulfide, **82**, 173
- Ofloxacin, **84**, 225
- acid-base properties, **84**, 263
- determination in biological fluids, **84**, 265
- Ophiocarpine, **85**, 91, 92
- Ophiorine, **85**, 144
- Orellanine, **85**, 119
- Organoiridium complexes, **81**, 226
- Organo-iron complexes of pyrazol-1-ylborates, **81**, 198
- Organonickel complexes, **81**, 227
- Organorhodium complexes, **81**, 226
- Organotin derivatives of imidazoles, **83**, 122
- Orouparine, **85**, 154
- Osmium complexes, **81**, 226
- Otonecine, **85**, 70
- 1,3,4-Oxadiazines, tautomerism, **81**, 284
- 1,2,6-Oxadiazines, tautomerism, **81**, 286
- 1,3,4-Oxadiazin-5(2)-ones, tautomerism, **81**, 285
- 1,2,5-Oxadiazoles, **81**, 33
- 1,3,4-Oxadiazole, from *N*-acetyltetrazole, **81**, 33
- 1,2,5-Oxadiazole-2-oxides, calculated bond lengths, **81**, 10
- tautomerisation, **81**, 36
- Oxadiazolopyridinium ylide, rearrangement, **83**, 10
- 1,4-Oxathiin, structure, **81**, 72
- 1,3-Oxathiolanylium ions, **81**, 24
- Oxazines, computational studies on properties of, **81**, 69
- 1,3-Oxazines, structure, **81**, 278
- 1,4-Oxazines, tautomerism, **81**, 278
- 2*H*-1,2-Oxazino[2,3-*a*]indole, **82**, 114
- [1,2]Oxazino[3,2-*f*]quinolines, **84**, 227
- 1,2(3)-Oxazole, structural parameters, **81**, 17
- proton affinity, **81**, 18
- Diels-Alder cyclisation with ethylene, **81**, 19
- Oxazolidine-3-carbaldehydes, rotational barriers, **81**, 21
- Oxazolo[3,2-*a*]quinoline, **84**, 148
- Oxazolo[5,4,3-*i*]quinolines, **84**, 151
- Oxazolyl radicals, reaction with oxygen, **81**, 21
- N*-Oxides of oxadiazoles, computational studies, **81**, 33
- 2-Oxindole, **82**, 119
- 8-Oxoadenine, pairing properties, **81**, 64
- Oxobenzocarbazoles, **82**, 218
- 4-(3-Oxobut-1-en-1-yl)-3-phenyl-5-diethylaminoisoxazole, **82**, 247
- N*-(3-Oxobuten-1-yl)-1,2,3,4-tetrahydrocarbazole, heterocyclization, **82**, 219
- 9(2-Oxobutyl)perhydropyrido[1,2-*c*][1,3]oxazin-1-ones, reduction, **84**, 242
- 2-Oxo-1,2-dihydro-3-pyridinecarboxylate, **84**, 37
- 7-Oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzothiazine-6-carboxylic acid, **84**, 294
- 7-Oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid, **84**, 278, 288
- 2-Oxo-2,3-dihydropyrido[1,2,3-*de*]-1,4-benzoxazinium chloride, **84**, 284
- 1-Oxo-2,3-dihydrothieno[2,3-*b*]pyridine, **84**, 57
- 8-Oxoguanine, tautomers, **81**, 65

- 4-Oxo-1,6,7,8,9,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamides, conformations, **85**, 197
- 4-Oxo-1,6,7,8,9,9*a*-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates, conformations, **85**, 197
- 1-Oxo-1*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates, **84**, 260
- 4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates, formation, **85**, 234
- 6-Oxo-6*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates, **85**, 250
- 4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-diazonium tetrafluoroborate, effect of heat, **85**, 232
- 2-[(4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)oxymethyl]-4-isopropyl-6-alkoxy-saccharins, hydrogenation, **85**, 203
- 7-Oxo-2,3,6,7-tetrahydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-2-carboxylate, **84**, 284
- 4-Oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetamide, formation, **85**, 216
- 2-Oxo-1,2,3,4-tetrahydropyrido[1,2-*a*]pyridazine, **84**, 239
- 4-Oxo-4*H*-6,7,8,9-tetrahydropyrido[1,2-*a*]pyrimidines, mass spectra, **85**, 200
- 6-*R*-3-*R*¹-4-Oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidines, rearrangement, **84**, 50
- 1-Oxycarbonyl-[1,2,3]triazolo[4,5-*b*]pyridine, use as acylating agents, **83**, 51
- Paliperidone, **85**, 177
- HPLC analysis, **85**, 196
- Papaverinium chloride, **85**, 94
- Paramagnetic cobalt complexes, **85**, 15
- Pazufloxacin, **84**, 225
- assay, **84**, 267
- Pemirolast, **85**, 176
- synthesis, **85**, 249
- anti-allergic activity, **85**, 255
- Pentaarsacyclopentadienyl-containing triple decker metal complexes, **85**, 44
- Pentadecker cobalt-nickel species, **85**, 13
- 2-Pentafluoroethyl-3-trifluoromethyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine, NMR spectra, **85**, 199
- 2-Pentafluoroethyl-3-trifluoromethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 243
- Pentafluoropyridine, complexes with imidazolyldienes, **83**, 120
- Pentamethylcyclopentadienyl ferrocenes, **85**, 37
- Pentamethylcyclopentadienyl groups in triple-decker cobalt complexes, **85**, 10
- Pentaphosphacyclopentadienyl lithium, reaction with iron(II) chloride, **85**, 46
- Pentaphosphacyclopentadienyl rings, reaction with chromium carbonyls, **85**, 43
- 2(5)-Pentenyl-pyrimidin-5-ones, thermolysis, **84**, 62
- 5*a*-Pentyl-5*a*,6,7,8,9,11-hexahydropyrido[2,1-*b*][1,3]benzoxazin-9-one, **85**, 181, 188, 189
- 9*a*-Pentylperhydropyrido[2,1-*b*][1,3]oxazin-6-one, **85**, 181, 188
- 2-(Pent-4-yn-1-yl)pyrimidines, rearrangements, **84**, 54
- Perhydro-1,3-benzoxazines, radical cyclisation, **85**, 186
- Perhydropyrido[2,1-*b*][1,3]benzoxazines, ring opening, **85**, 182
- Perhydropyrido[2,1-*b*][1,3]benzoxazin-9-ones, **85**, 182, 186
- Perhydropyrido[1,2-*b*][1,2]oxazine, **84**, 226
- Perhydropyrido[2,1-*c*][1,4]oxazine-3,6-dione, **84**, 279
- 84**, 270
- Perhydropyrido[1,2-*c*][1,3]oxazin-1-one, **84**, 243
- Perhydropyrido[2,1-*c*][1,4]oxazin-1-ones, **84**, 283
- catalytic hydrogenation, **84**, 269
- reaction with vinyl chloroformate, **84**, 271
- Perhydropyrido[1,2-*c*][1,3]oxazin-1,3,5-triones, **84**, 243
- Perimidine, prototropic tautomerism, **81**, 274
- 2-Phenacylaminoquinoline, **84**, 133
- N*-Phenacyl-4-iodopyridazoles, reaction with acetylenes, **82**, 30
- 1,6-Phenazindiol-5,10-dioxide, **85**, 122
- Phenoxathiine 10,10-dioxides, **83**, 218
- Phenoxathiins, synthesis, **83**, 217
- Phenoxy-2,4-hexadiyn-6-oles, reaction with diazomethane, **82**, 5
- Phenylacetylene, reaction with ruthenium complexes, **81**, 200
- 3-Phenyl-4-acetylisoazole, **82**, 233

- 2-Phenyl-3-alkyl-1,8-naphthyridines, **84**, 40
2-Phenylaminodiphenylsulfides, **83**, 225
2-[2-(4-Phenyl-3-amino)pyridyl]quinoline, **84**, 17
N'-Phenyl-4-anilino-2-quinoline-*N*-acetamide, **84**, 151
Phenylarsine, reaction with diacetylenes, **82**, 178
Phenyl azide, dipolar additions, **81**, 29
 reaction with diacetylene, **82**, 182
2-Phenylazoacetanilide, **82**, 286
2-Phenyl-1,3-benzazaphosphole-*P*, in chromium complexes, **85**, 28
3-Phenyl-1,4-benzothiazine, tautomerism, **81**, 278
2-Phenylbenzothiazole, reaction with iridium chloride, **84**, 202
2-Phenyl-1,2,4-benzotriazin-3(2*H*)-one 1-oxide, tautomerism, **82**, 267
3-Phenyl-1,2,4-benzotriazine 1(2)-oxide, **82**, 300
2-Phenyl-5-benzylisoxazole, **82**, 168
3-Phenyl-5-benzylpyrazole, **82**, 164
Phenyl-bis(3,5-dimethylpyrazol-1-yl)methane, reaction with palladium complexes, **81**, 221
Phenylboronic acid, coupling with heterocyclics, **84**, 12
1-Phenyl-3-carboethoxy-5-(1-alkynyl)pyrazoles, **82**, 181
1-Phenyl-3(5)-dialkylamino-5(3)-methylpyrazoles, **82**, 244
3-Phenyl-6,7-dichloroisoflavone, **83**, 223
3-Phenyl-5,6-dihydro-1*H*,7*H*-pyrido[3,2,1-*ij*]quinoline-1,7-dione, **84**, 260
3-Phenyl-5,6-dihydro-1*H*,7*H*-pyrido[3,2,1-*ij*]quinoline-7-one, **84**, 260
2-Phenyldihydropyrimidine, tautomerism, **81**, 267
3-Phenyl-5,6-dihydro-4*H*-1,2-oxazine, conversion to 2-phenylpyrrole, **81**, 277
2-Phenyl-4,5-dihydro-1,3-thiazoles, oxidation, **83**, 90
1-Phenyl-4,5-dihydro-1*H*-1,2,3-triazoles, formation, **81**, 29
1,2-Phenylenediamine, **82**, 183
3,3'-*R*₂-1,1'-*o*-Phenylene-dimethylenebisimidazolium dibromides, formation of silver complexes, **83**, 139
2-Phenylethylpyrazoles, **82**, 187
Phenylethyne, coupling with 3-bromoquinoline, **84**, 20
4-Phenylethynyl-5-aminomethyl-1,3-dimethylpyrazole, failure to cyclise, **82**, 55
Phenylethynyl-3*H*-pyrazoles, ¹³CNMR spectra, **82**, 74
4-Phenylethynylpyrazole, **82**, 6
 hydration, **82**, 42
5-Phenylethynylpyrazoles, **82**, 11
4-Phenylethynylpyrazole-3(5)-carboxylic acid, heterocyclisation, **82**, 60
1-Phenyl-4(5)-ethynyl-1,2,3-triazoles, **82**, 182
Phenylglycine *o*-carboxylic acids, double cyclisation, **84**, 149
2-Phenyl-4,6,7,8,9,9*a*hexahydropyrido[2,1-*b*][1,3]oxazin-4-one, **85**, 186
3-Phenyl-4-hydroxy-2-oxo-2*H*-pyrido[2,1-*b*][1,3]oxazinium inner salts, **85**, 179, 180, 188
anhydro-(3-Phenyl-2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyridinium)hydroxides, solid state structure, **85**, 200
3-Phenyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 243
4-Phenylimidazole, complexes with organotin compounds, **83**, 122
2-Phenylindole, cyanoethylation, **84**, 111
Phenylodonium dichloride, reaction with palladium complexes, **81**, 219
3-Phenylisoxazol-5(4*H*)-one, in Vilsmeier-Haack reaction, **84**, 7
Phenylmagnesium chloride, reaction with phenylpropargyl alcohol, **81**, 114
4-Phenyl-8-methyleneperhydropyrido[2,1-*c*][1,4]oxazin-1-ones, hydrogenation, **84**, 272
6-(Phenylmethylene)-6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]quinazolin-11-one, ozonolysis, **85**, 260
3-Phenyl-*N*-methyl-isothiazolidine *S,S*-dioxide, formation, **83**, 83
2-Phenyl-4-methylpyrimidine, **82**, 223
1-Phenyl-5-methylpyrazole, **82**, 186
2-Phenyl-3-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 246
2-Phenyl-7-methyl[1,2,4]triazolo[1,5-*a*]pyridine, **83**, 6
3-Phenyl-7-nitrobenzoxadiazine, **83**, 214

- 1-Phenyl-6-nitroindazole-3-carboxylic acid, formation, **83**, 199
- 2-Phenyloxazolones, in metal complexes, **84**, 205
- 1-Phenylpentazole, and metal complexes, **83**, 167
- N*-(4-Phenyl-4-pentenyl)monothioibarbiturate, photocyclization, **85**, 238
- 1-Phenylperhydropyrido[2,1-*c*][1,4]oxazine, **84**, 282
- 4 β ,($\alpha\alpha$ -H-4-Phenylperhydropyrido[2,1-*c*][1,4]oxazin-1,8-diones, hydrogenation, **84**, 272
- 4-Phenylperhydropyrido[2,1-*c*][1,4]oxazin-1-one, **84**, 289
- trans*-8,9 α -H-8-Phenyl-perhydropyrido[2,1-*b*][1,3]thiazin-6-ones, **85**, 190
- 4-Phenyl-3(5)-phenylethynylpyrazole, **82**, 5
- 3(5)-Phenyl-5(3)-phenylethynylpyrazole, **82**, 43
- Phenylphosphine, reaction with diacetylene, **82**, 178
- Phenylpropargyl alcohol, carbometallation, **81**, 114
- 4-Phenyl-9-(2-propoxycarbonylamino)perhydropyrido[2,1-*c*][1,4]oxazin-1-one, **84**, 277
- catalytic hydrogenation, **84**, 270
- (4*S*,6*R*,9*aS*)-4-Phenyl-6-propylperhydro[2,1-*c*][1,4]oxazin-1-one, **84**, 287
- 1-Phenyl-3(5)-propylpyrazoles, **82**, 186
- 1-Phenyl-5-prop-1-ynyl-1*H*-pyrazole-3-carboxylic acid ethyl ester, **82**, 9
- 5-Phenyl-2-[2-(1-prop-2-ynyl)pyrrolidin-2-yl]pyrimidine, **84**, 58
- 1-[3-(2-Phenylpyrazolo[1,5-*a*]pyridin-3-yl)propynoyl]-2-ethylpiperidine, hydrogenation, **82**, 41
- 5-(2-Phenylpyrazolo[1,5-*a*]pyridin-3-yl)-2*H*-pyrazol-3-ol, **82**, 44
- 2-Phenyl-1-(4-pyrazolyl)ethanone, **82**, 42
- 3-Phenylpyrido[3,2-*c*]pyrrolizine, **84**, 58
- 1-Phenyl-pyrimidin-2(1*H*)-one, reaction with active methylene compounds, **84**, 37
- 2-Phenylpyrrole, from oxazines, **81**, 277
- 2-Phenylquinoline, **84**, 22
- 3-Phenylquinoline, **84**, 13
- 4-Phenyl-7(8)-substituted perhydropyrido[2,1-*c*][1,4]oxazin-1-ones, **84**, 270
- 1-Phenylsulfonyl-4-acetyl-5-dimethylamino-triazole, **82**, 246
- 2-Phenylsulfonylmethyl lactam, cyclisation, **84**, 73
- 5-Phenyl-1,2,3,6-tetrahydro[1,3]thiazino[3,2-*a*]quinolin-6-ones, **85**, 194
- sulfoxide and sulfone, **85**, 192
- 5-Phenyl-2*H*-tetrazole, computed barrier of rotation, **81**, 31
- complexes with aluminium compounds, **83**, 163
- tin chemistry, **83**, 164
- Phenylthiobutenone, aldol condensations, **82**, 230
- 7-Phenylthio-4-(2,6-dichlorophenyl)-1,2-dihydro-3*H*]pyrido[1,2-*c*]pyrimidin-3-one, **84**, 253
- 5-Phenylthio-2(5*H*)-furanone, formation and reactions of anions, **81**, 137
- 3-Phenyltriazolopyridine, formation, **83**, 3
- 2-Phenyl[1,2,4]triazolo[1,5-*a*]pyridine-3-mono-*N*-oxide, **83**, 9
- 3-Phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine, **84**, 54
- 6-Phenyl-8-trifluoromethyl-9-cyano-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidine, **85**, 234
- 2-Phenyl-4,4,6-trimethyldihydropyrimidine, tautomerism, **81**, 266
- (4*R*,9*S*,9*aR*)-4-Phenyl-1-trimethylsilyloxy-9-vinylperhydropyrido[2,1-*c*][1,4]oxazine, asymmetric synthesis, **84**, 268
- (4*R*,8*aR*)-*trans*-4*H*,9*aH*-4-Phenyl-9-vinylidenperhydropyrido[2,1-*c*][1,4]oxazin-1-one, **84**, 269
- 2-Phosphaindolizine, in chromium complexes, **85**, 29
- Phospharinane, structures, **81**, 296
- Phosphinatocarbyne complexes of molybdenum and tungsten, **81**, 183
- Phosphorus P₄, reaction with sodium, **85**, 43
- reaction with chromium complexes, **85**, 44
- reaction with iron complexes, **85**, 45
- Photosystem II, structure, **81**, 13
- 3-[(4-Phthalimidobutyl)-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrazino[1,2-*a*]quinoline, **84**, 306
- Picrasidine F, **85**, 144
- Piericidine B₁*N*-oxide, **85**, 119

- 2-(Piperazinomethyl)-9-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, formation, **85**, 210
- 2-Piperazino- 4*H*-pyrido[1,2-*a*]pyrimidin-4-one, platelet aggregation activity, **85**, 254
- 3-Piperazino-1*H*-pyrimido[1,2-*a*]quinolin-1-one, inhibition of platelet aggregation, **85**, 266
- 2-(1-Piperazinyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, nitration, **85**, 205
- 1-(*N*-Piperidino)methyl-3-ethynylpyrazole, reaction with base in acetone, **82**, 32
- 1-Piperidinonitrile, in metal complexes, **85**, 26
- 2-Piperidino-5-nitropyridine, **84**, 51
- Pirenperone, **85**, 176
- lipophilic character, **85**, 195
- solid state structure, **85**, 201
- formation of ¹⁸F, **85**, 210
- biochemical and pharmacological properties, **85**, 256
- 2-Pivaloylpyridine hydrazone, cyclisation, **83**, 3
- Platelet activating factors, in thiazole derivatives, **83**, 96
- Platinated guanine-guanine-cytosine triplet, geometry, **81**, 67
- Pluviine, **85**, 142
- Polychlorinated dibenzo-*p*-dioxins, **81**, 70
- synthesis, **83**, 217
- Polyvinine, **85**, 154
- Pontevedrine, **85**, 112, 155
- Pople's 6-31G**, as a basis set in calculating structural parameters of heterocycles, **81**, 4
- Population analyses, in understanding the electronic properties of molecules, **81**, 7
- Potassium bis(3,5-dimethylpyrazol-1-yl)borate, reaction with rhodium complexes in presence of 2,3-dimethylbutadiene, **81**, 215
- Potassium dihydrobis(pyrazol-1-yl)borate, reaction with tungsten complexes, **81**, 192
- reaction with ruthenium complexes, **81**, 203
- reaction with palladium complexes, **81**, 221
- Potassium dimethylbis(pyrazol-1-yl)borates, reaction with ruthenium complexes, **81**, 203
- Potassium 4,5-diphenylimidazolate, with ruthenium complexes, **83**, 130
- Potassium hydrotris(3,5-dimethylpyrazol-1-yl)borate, reaction with rhenium complexes, **81**, 195
- reaction with trimethylplatinum iodide, **81**, 219
- Potassium hydrotris(3-neopentylpyrazol-1-yl)borate, reaction with molybdenum complexes, **81**, 189
- Potassium hydrotris(3-phenyl-5-methylpyrazol-1-yl)borate, reaction with rhodium complexes, **81**, 207
- Potassium hydrotris(pyrazol-1-yl)borate, reaction with methyltin chlorides, **81**, 170
- reaction with molybdenum and chromium complexes, **81**, 177
- reaction with molybdenum complexes, **81**, 189
- reaction with ruthenium complexes, **81**, 198
- reaction with chloroiridium complexes, **81**, 217
- reaction with nickel complexes, **81**, 218
- Potassium salt of 1,2,4-triphospholyl, reaction with scandium iodides, **85**, 43
- Potassium tetrakis(pyrazol-1-yl)borate, reaction with gold complexes, **81**, 223
- reaction with palladium complexes, **81**, 219
- Potassium tris(3-*tert*-butylpyrazol-1-yl)borate, reaction with tungsten carbonyls, **81**, 173
- Potassium tris(pyrazol-1-yl)borate, reaction with tungsten complexes, **81**, 186
- Potassium tris(3,5-trifluoromethylpyrazol-1-yl)borate, reaction with platinum complexes, **81**, 219
- Praziquantel, **84**, 225
- Progesterone receptor binding agents, in thiazole derivatives, **83**, 96
- 2-(Propa-1,2-dienyl)-1,3-dioxane, **82**, 170
- 2-(Propa-1,2-dienyl)-1,3-dioxolane, **82**, 169
- Propane-1,3-diols, reaction with diacetylene, **82**, 170
- Propargyl alcohols, cyclocarbonylation reactions, **81**, 112
- (2*R*,3*S*)-3-(2-Propoxycarbonylamino)-pipercolinic acid, **84**, 270
- 4-[*N*-(Propylaminocarbonyl)-*N*-propylamino]-2*H*-pyrido[1,2-*a*]pyrimidin-2-one, **85**, 242
- 1-Propynolpyrazoles, pyrolysis, **82**, 31

- 4-(1-Propynyl)-1,3-dimethylpyrazole, **82**, 39
2-(Prop-1-ynyl)-1,3-dioxane, **82**, 170
2-(Prop-2-ynyl)-1,3-dioxane, **82**, 170
2-(Prop-1-ynyl)-1,3-dioxolane, **82**, 169
2-(Prop-2-ynyl)-1,3-dioxolane, **82**, 169
3(5)-Propynyl-5(3)-methylpyrazole, **82**, 13
2-(Prop-2-ynyloxycarbonyl)pyrimidine, **84**, 60
5-(Prop-2-ynyloxycarbonyl)pyrimidine, **84**, 60
5-Propynyloxycycloalkanepyrimidines, **84**, 60
2-(2-Propynyloxymethyl)pyrimidines, **84**, 58
5-Propynyloxymethylpyrimidines, **84**, 58
Protopapaverinium betaine, **85**, 94, 138
Pseudocytidine, tautomeric equilibria, **81**, 270
Pseudolaudanine, **85**, 94
Pseudopericyclic one-step mechanism, for rearrangements, **81**, 37
(-)-Pumiliotoxin C, **84**, 231
5-*epi*-Pumiliotoxin C, **84**, 231
Pyocyanine, **85**, 141
Pyrano[3,4-*b*]indol-3-one, **82**, 235
4(2)-*H*-Pyrans **81**, 255, 256
Pyrazine, singlet and triplet valence excited states, **81**, 40
as a ligand in organometallic chemistry, **81**, 41
Pyrazine-2,3-dicarboxylic anhydride, pyrolysis, **81**, 42
Pyrazine-*diN*-oxides, protonation, **81**, 295
Pyrazine-*N*-oxides, protonation, **81**, 295
2*H*-Pyrazino[1',2':1,5]pyrrolo[2,3-*b*]indoles, **82**, 121
4(2)-*H*-Pyrazole, aromaticity in, **81**, 15
Diels-Alder reaction, **81**, 16
Pyrazole-*N*-oxide, formation from 1-hydroxypyrazole, **81**, 15
Pyrazolo[4,3-*c*]pyridine carbaribo-*C*-nucleoside, calculations on pseudo-rotational equilibrium of cyclopentane ring, **81**, 17
Pyrazolo[1,5-*a*]pyridin-5-ol, **82**, 31
Pyrazolo[3,4-*d*]pyrimidines, **83**, 207
Pyrazolo[3,4-*f*]quinolines, **83**, 205
Pyrazolo[3,4-*c*]-1,2,4-triazine 6-oxides, **82**, 270
Pyrazolyethynylphenylnitroxides, **82**, 79
Pyrazol-1-ylgallate, reaction with rhenium complexes, **81**, 197
3-(Pyrazol-4-yl)propargyl alcohol, molecular structure, **82**, 69
Pyrazo[1,5-*a*]pyridine-3-carboxylate, **84**, 131
Pyrazo[1,5-*a*]quinolines, synthesis, **84**, 124
Pyridazine, computational studies, **81**, 43
Pyridazino[1,2-*a*]indazolium-11-carboxylate, **85**, 134
Pyridinebetaine A and B, **85**, 129
Pyridine-2,3-dithiol, reaction with 1-chloro-2-nitrobenzene, **83**, 231
Pyridine-*N*-oxide, oxidation of rhenium(V) complexes, **81**, 196
Pyridine-2-thiones, formation, **85**, 132
Pyridinium-3-olates, photostability, **85**, 80
Pyridinoline, **85**, 81
2-Pyridin-1-yl-1*H*-benzimidazole, geometric parameters, **81**, 13
Pyridin-1-yl-bis(3,5-dimethylpyrazol-1-yl)methane, reaction with palladium complexes, **81**, 221
4-Pyridinylmethane, tautomerism, **81**, 267
Pyrido[1,2-*b*][1,2]benzothiazine 5,5-dioxides, **84**, 233
2-Pyridone, vibrational spectra, **81**, 75
1*H*,8*H*-Pyrido[2,1-*c*][1,4]oxazine-7,9-carboxylate, **84**, 279
Pyrido[3,2,1-*k*]phenoxazines, **83**, 214
Pyrido[1,2-*b*]pyridazinium inner salts, **84**, 236
Pyrido[1,2-*a*]pyrimidine betaines, **84**, 257
Pyrido[2,3-*d*]pyrimidine 3-oxide, reaction with alkylphenylketones, **84**, 40
6-*H*-Pyrido[1,2-*a*]pyrimidin-6-one, **85**, 209
11*H*-Pyrido[1,2-*a*]quinazolin-11-one, quantum chemical calculations, **85**, 259
in organic electroluminescent devices, **85**, 266
6*H*-Pyrido[1,2-*c*]quinazoline-6-thione, **84**, 260
Pyridoxamine, structure, **85**, 80
Pyridoxaminephosphate, structures, **85**, 80
2-Pyridylacetonitrile, reaction with 2-azido-1-ethylpyridinium fluoroborate, **83**, 5
2-Pyridylamidines, oxidative cyclisations to [1,2,4]triazolo[1,5-*a*]pyridines, **83**, 6
3-(4'-Pyridylamino)amino-6-nitrobenzisoxazole, **83**, 191
6-(2-Pyridylamino)-1,3-dipropyl-1*H*3*H*-pyrimidine-2,4-dione, **85**, 242
4-[(2-Pyridylamino)methylene]-2-methoxythiazolin-5(4*H*)-one, cyclization, **85**, 236

- 3-(2-Pyridylamino)-2-(1*H*-tetrazol-5-yl)acrylonitriles, preparation, **85**, 202
- 2-(2'-Pyridyl)benzimidazole, in heteronuclear metal complexes, **83**, 148
- 2-(2'-Pyridyl)benzothiazole, reaction with metal carbonyls, **84**, 194
- 2-Pyridylboronic ester, **84**, 12
- 2-Pyridylcarboxaldehyde hydrazones, in synthesis of [1,2,3]triazolo[1,5-*a*]pyridines, **83**, 3
- 2-Pyridyl cations, reaction with 2-methyl-1,3-dioxolane, **81**, 24
- 2-Pyridylcyanamides, formation from quaternary salts of triazolopyridines, **83**, 45
- 2-Pyridylhydrazides, cyclisation by PPA, **83**, 16
- 2-Pyridylhydrazine, reaction with *ortho*-formates, **83**, 17
- 2-Pyridylhydrazones, anodic oxidation, **83**, 16
- oxidative cyclisation, **83**, 15
- N*-(2-Pyridyl)-2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide, **85**, 244
- 7-[(2-Pyridylmethylene)amino]-2,3,11,11*a*-tetrahydro-6*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione, 303
- 2-(2-Pyridyl)-8-methylquinoline, **84**, 12
- (2-Pyridyl)propionic acids, **84**, 227
- 3-(2-Pyridyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 247
- 2-(4-Pyridyl)quinoline, **84**, 16
- 3-(2-Pyridyl)quinoline, **84**, 16, 17
- 3-(3-Pyridyl)quinoline, formation, **84**, 13
- N*-(2-Pyridyl)tetrazoles, cyclisation to [1,2,4]triazolo[1,5-*a*]pyridines, **83**, 6
- 3-(2-Pyridyl)triazolopyridine copper complex, **83**, 4
- 3-(2'-Pyridyl)[1,2,3]triazolo[1,5-*a*]pyridine, X-ray structure, **83**, 27
- 3-2'-Pyridyl[1,2,4]triazolo[4,3-*a*]pyridine, **83**, 4
- 9-(4-Pyridylvinyl)-7-methyl-2-morpholino-4*a*]pyrimidin-4-one, oxidation, **85**, 204
- 3,4-Pyridyne, formation, **83**, 47
- Pyrimidines, reduction by lithium aluminum hydride, **81**, 265
- Pyrimidine-*N*-oxides, **82**, 225
- Pyrimidine-2-thiones, desulfurization, **81**, 269
- Pyrimido[1,2-*a*][1,8]naphthyridine, isomerisation, **84**, 50
- Pyrimido[4,5-*g*]pteridin *N*-oxide, **83**, 236
- γ -Pyrone, **82**, 228
- Pyrroles, from reaction of diacetylene and amines, **82**, 159
- Pyrrolidine-2,4-dione, **84**, 94
- Pyrrolidino[1,2-*a*]quinolinone-4-carboxylate, **84**, 91
- 3-Pyrrolidino-1,2,4-triazine 4-oxide, reaction with amines, **82**, 282
- Pyrrolo[2,3-*c*]pyrazole, **82**, 54
- Pyrrolo[3,4-*c*]pyridine, **84**, 40
- Pyrrolo[1,2-*a*]pyrimidine-7-ylideneacetate, **85**, 249
- Pyrroloquinoline, **84**, 75, 83
- 4-*H*-Pyrrolo[3,2,1-*ij*]quinoline, **84**, 105
- Pyrroloquinoline 2-carboxylate esters, reaction with ethylene diamine, **84**, 119
- Pyrroloquinoline-3-carboxylic acid, **84**, 106
- Pyrrolo[1,2-*a*]quinoxaline, **83**, 238
- 2-Pyrrolylbenzoic acid derivatives, **84**, 90
- Pyrroxazinone, **84**, 96
- Quinazoline 3-oxide, reaction with active methylene compounds, **84**, 40
- Quindoline, **84**, 25
- Quinine, **84**, 2
- Quinolines, **84**, 2
- reaction with ethylmagnesium bromide, **84**, 75
- hydrogenation, **81**, 261
- Quinoline-4-arylboronic esters, formation, **84**, 9
- 2-Quinolincarboxaldehyde, **84**, 87
- Quinoline 3-carboxylate, **84**, 151
- Quinoline-2-carboxylic acid, decarboxylation, **85**, 132
- Quinoline 1-oxide, reaction with 3-amino-crotononitrile, **84**, 136
- Quinoline 2-thiols, in preparation of thiazolo[3,2-*a*]quinolones, **84**, 152
- reaction with bromoacetaldehyde diethyl acetal, **84**, 156
- Quinoliny-4-arylboronic ester, formation, **84**, 14
- Quinoliny-8-diphenylphosphine, formation, **84**, 27
- 4-(4'-Quinoliny)imidazole, **84**, 10
- Quinoliny-8-triflate, in preparation of quinolinyphosphines, **84**, 27

- 2(1*H*)-Quinolone, **84**, 3
Quinolylacetates, **84**, 83
2-Quinolylacetyl azide, thermolysis, **84**, 137
2-Quinolylglycinates, **84**, 137
Quinolyl iminodithiazole, **84**, 143
2-(2-Quinolylthio)acetaldehyde
 diethylacetal, **84**, 156
2-(Quinolylthio)acetic acid, reaction with
 benzoxazolium iodide, **84**, 159
Quinoxaline di-*N*-oxides, protonation,
 81, 295
Quinoxaline-2,3-dithiol, infra-red spectra,
 81, 42
Quinoxaline-2,3-dithiolate dianion, as a
 ligand, **81**, 42
Ramastine, **85**, 177
Regecoline, **85**, 139
Regelinone, **85**, 139
Reisert compounds, **84**, 86
Rhenium(V) oxophenyl species, **81**, 196
5- β -D-Ribofuranosyl-2,6-dihydroxynico-
 tinamide, **84**, 46
4-(β -D-Ribofuranosyl)-1,2,4-triazin-3(4*H*)-
 one 1-oxide, **82**, 269
Ribonuclease A, reaction with cytidyl-
 3,5'-adenosine, **81**, 65
Risperidone, **85**, 177
 HPLC analysis, **85**, 196
 preparation, **85**, 214
 antipsychotic activity, **85**, 256
Rofecoxib, synthesis, **81**, 125
Rubrolides A-F, antibiotics, **81**, 120
 synthesis, **81**, 123
Rufloxacin, **84**, 225
Ruthenium complexes, **81**, 226; **85**, 3
Ruthenium complex catalysts, in addition of
 alkenes to hydroxy-1-alkynoates, **81**, 111
Ruthenium-osmium triple decker complexes,
 85, 5
Salicylaldehyde, reaction with 2,4,6-trinitro-
 toluene, **83**, 240
Schoberidine, **85**, 144
(+)-Sedridine, **84**, 244
Seganserine, **85**, 177
1,2,3-Selenadiazoles, reaction with cobalt
 carbonyls, **84**, 200
1,2,4-Selenadiphosphole, formation of metal
 complexes, **85**, 47
Selenium, adducts with imidazolylenes,
 83, 120
Selenophene, **82**, 177
Self-consistent reaction field approach to
 modelling solvent effects, **81**, 7
Sempervirine, **85**, 135, 149
Serine hydrolase-catalyzed ester hydrolysis,
 modelling, **81**, 14
Serpenticine, **85**, 144
Shihunine, isolation, **85**, 133
Silicon analogues of imidazol-2-ylidenes,
 85, 24
 in formation of metal complexes, **85**, 49
Silver triflate reactions with rhenium
 complexes, **81**, 196
 reaction with imidazolylenes, **83**, 138
Sodium, reaction with phosphorus, **85**, 43
Sodium alkyl thiolates, reaction with
 halogen substituted metal complexes,
 81, 186
Sodium amalgam reduction of rhenium
 complexes, **81**, 196
Sodium cyclopentadienyl, reaction with
 triple-decker metal complexes, **85**, 5
 reaction with rhodium complexes, **85**, 8
Sodium dimethylbis(pyrazol-1-yl)gallate,
 reaction with nickel and palladium
 complexes, **81**, 218
Sodium 1-methyl-5-mercaptotetrazolate,
 reaction with gold complexes, **83**, 167
Sodium methyl tris(pyrazol-1-yl)gallate,
 reaction with molybdenum
 hexacarbonyl, **81**, 190
Sodium tetraazidoaurates(III), reaction with
 isocyanides, **83**, 166
Sodium tetrakis(1-*tert*-butyltetrazol-5-
 ato)aurate(III), **83**, 166
Sodium tetrakis(pyrazol-1-yl)borate,
 reaction with alkylthalliums, **81**, 170
Sodium tetrazolates, in manganese
 complexes, **83**, 164
Solvent effects, simulation of, **81**, 7
Sonogashira-Heck reaction, **82**, 23
Spirobenzylisoquinoline, **85**, 90
Spiroketal, formation, **82**, 207
SQM method, in calculating vibrational
 spectra, **81**, 6
Stepharanine, **85**, 94
Sternbergine, **85**, 103
Streptonigrin, synthesis, **84**, 17
Strychnoxanthine, isolation and synthesis,
 85, 146

- 2-Styrylazetidinone, cyclisation, **84**, 73
2-Styryl-4*H*-3,1-benzoxazines, cycloaddition with malononitrile, **85**, 188
Styrylpyrazoles, cyclisation, **84**, 131
4-Substituted-*N*-alkyl-1,2,5-thiadiazolidin-3-ones, formation and MHC class-II inhibitor activity, **83**, 107
3-Substituted 5-alkynylisoxazoles, **82**, 181
5(3)-Substituted 3(5)-alkynylpyrazoles, **82**, 10
2-(Substituted amino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, antiplatelet activity, **85**, 197
3-(Substituted amino)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 247
2-(Substituted amino)-3-(substituted imino)-3*H*-pyrido[1,2-*b*]pyridazine, **84**, 239
2-Substituted 4-aryl-1-oxo-1,2-dihydropyrazino[1,2-*b*]isoquinolinium salts, **84**, 317
3-Substituted 2-aryl-4,5,6,7-tetrahydroindazoles, phytotoxicity, **82**, 87
1-Substituted 1*H*-benzotriazoles, calculated vertical ionisation potentials, **81**, 29
(4*aR*(*S*))-2-Substituted 5-{[*N*-(*t*-butoxycarbonyl)-1-tryptophyl]amino}-perhydropyrido[1,2-*c*]pyrimidine-1,3-diones, NMR data, **84**, 248
3(5)-Substituted dialkylvinylpyrazoles, **82**, 188
N-Substituted 5,6-dihydro-2*H*-1,2-oxazines, tautomerism, **81**, 277
*N*¹-Substituted dihydro-1,2,3-triazines, structure, **81**, 279
1-Substituted 1,2-dihydro-1,3,5-triazines, formation, **81**, 282
6-Substituted 2,3-dimethyl-4-oxopyrano[4,3-*c*]pyrazoles, **82**, 59
7-Substituted 2,4-diphenyl-6,7-dihydroxy-pyrido[2,1-*a*]phthalazinium perchlorates, irradiation, **84**, 237
8-Substituted 3-formyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction of formyl group, **85**, 215
2-Substituted 3,4,4*a*,5,6,7-hexahydro-8*H*-pyrido[1,2-*b*]pyridazin-8-ones, **84**, 235
2-Substituted hexahydropyrimidines, tautomerism, **81**, 274
5-Substituted-4-hydroxy-2-methyl-2*H*-pyrazolo[3,4-*c*]pyridazines, **82**, 67
1-Substituted 3-hydroxypyridines, as components of fungal toxins, **85**, 82
4-Substituted 2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 244
2-Substituted isoquinolinium-olates, structure, **85**, 84
N-Substituted 1,2-isothiazolin-3-one *S*-oxides, **83**, 75
1-Substituted methyl 2,3-dihydro-3-oxo-5*H*-pyrido[4,3-*b*]indole-4-carboxylates, **82**, 142
5(7)-Substituted 4-nitrobenzofuroxans, calculated geometric parameters, **81**, 37
9-Substituted 6-oxo-3,4-dihydro-2*H*,6*H*-pyrido[1,2-*b*][1,3]thiazine-4-carboxylate, irradiation, **85**, 192
N-Substituted 11-oxo-11*H*-pyrido[2,1-*b*]quinazoline-6-carboxamides, **85**, 261
1(2)-Substituted perimidine salts, ¹³C NMR spectra, **81**, 295
2-Substituted-7-phenyl-1,8-dioxo-1*H*,8*H*-pyrido[1,2-*c*]pyrimidine-5,6-dicarboxylates, **84**, 261
1-Substituted pyridinium-2-carboxylates, loss of carbon dioxide, **85**, 132
2-Substituted 4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitriles, **85**, 248
2-Substituted 3-(2-pyridylamino)acrylates, flash vacuum thermolysis, **85**, 234
1-(6-Substituted-2-pyridyl)-3-aryl-4-aryl-4-hydroxy-1,2-dihydropyridin-4-ones, **85**, 245
2-Substituted-5-(substituted amino)perhydropyrido[1,2-*a*]pyrimidine-1,3-diones, **84**, 258
4-Substituted 1,2,3,4-tetrahydropyrido[1,2-*a*]pyridinium tetrafluoroborates, **85**, 240
2-Substituted 6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-carbonitrile, **85**, 69
4-Substituted 2*H*-1,2,4-thiadiazin-3(4*H*)ones, **83**, 87
5-Substituted 1,2,4-triazine 4-oxides, **82**, 277
7-Substituted [1,2,3]triazolo[1,5-*a*]pyridines, fluorescence properties, **83**, 22
Sulfobacin A (B), **83**, 96
3(5)-Sulfonyl-1-methyl-4-acetylenylpyrazoles, **82**, 8
Sulfur dichloride, adducts with imidazolyldenes, **83**, 120
Sunepitron, **84**, 225
Tarkonine, **85**, 140

- Tautomerism, methods of investigation, **81**, 254
- TD-DFT, of heterocycles, **81**, 2, 7
- Teliglazine, **85**, 108, 110
- 1,2,4-Telluradiphosphole, formation of metal complexes, **85**, 47
- Tellurium, adducts with imidazolyldienes, **83**, 120
- Tellurophene, **82**, 177
- 1-(2,3,4,6-Tetra-*O*-acetyl- α -D-glucopyranosyl)oxy-*Nb*-methoxycarbonyltryptamine, reaction with HCl, **82**, 132
- 1,3,5,7-Tetraazadecalins, conformational studies, **81**, 72
- Tetra-*tert*-butylantimony, reaction with molybdenum carbonyls, **85**, 45
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, decomposition pathway, **81**, 71
- 2,3,5,6-Tetrachloronitrobenzene, reaction with 1,2-diamines, **83**, 237
- 4,4',5,5'-Tetracyano-2,2'-biimidazole, complexes, **83**, 134
- reaction with rhodium and iridium complexes, **83**, 152
- Tetracyclic 2,3-dihydroimidazo[1,2-*d*][1,4]thiazepines, formation, **83**, 242
- Tetraeder cobalt complexes, synthesis, **85**, 12, 13, 14
- 3,4,5,6-Tetrahydro-18,19-dihydrocorynantheol, **85**, 143
- 3,4,5,6-Tetrahydro-17-hydroxycorynanium, **85**, 146
- 3',4',5',6'-Tetrahydrolongicaudatine, **85**, 144
- 3,4,5,6-Tetrahydroditsirikine, **85**, 144
- 3,4,5,6-Tetrahydro- β -yohimbine, **85**, 147
- Tetraethylammonium dimethylbis(pyrazol-1-yl)gallate, reaction with molybdenum and tungsten hexacarbonyls, **81**, 194
- 1,3,4,5-Tetraethyldiborole, reaction with cobalt carbonyls, **85**, 7
- 1,3,4,5-Tetraethyl-1*H*-2,3-dihydro-2-methyl-1,3-diborole, reaction with cobalt complexes, **85**, 13
- 3,4,5,6-Tetrahydrobenzo[*h*]quinazoline, tautomerism, **81**, 274
- 1,2,3,6-Tetrahydro-3,6-dimethyl-1,2,4,5-tetrazine, calculations on thermolysis, **81**, 80
- 1,2,3,4-Tetrahydro-9-hydroxy- β -carboline, **82**, 104
- 1,2,5,6-Tetrahydro-2-methyl-6-fluoropyrrolo[3,2,1-*ij*]quinolin-4-one, **84**, 119
- 8-[(2,3,4,5-Tetrahydro-4-methylidene-5-oxo-2-furanyl)-methoxy]quinolin-2(1*H*)-ones, **84**, 271
- 5,6,7,8-Tetrahydro-9-methyl-3-nitropyrido[2,3-*b*]azepine, **84**, 52
- 3,4,5,6-Tetrahydromitragynine, **85**, 145
- 7-*R*-3-*R*¹-5,6,7,8-Tetrahydro-1,8-naphthyridin-4-ones, **84**, 50
- 1,2,3,4-Tetrahydro-6-nitro[2,3-*d*]pyrimidine-2,4-dione, **84**, 43
- 6,7,8,9-Tetrahydro-11-oxo-pyrido[2,1-*a*]quinazoline, **85**, 176
- Tetrahydropapaverine, synthesis, **85**, 79
- 1-Tetrahydropyranyl-3-carboxyethyl-4-[2-(trimethylsilyl)ethynyl]pyrazole, deprotection, **82**, 48
- 3,4,5,6-Tetrahydropyridine-1-oxide, cycloaddition with furanones, **81**, 147
- 7,10,10*a*,11-Tetrahydropyrido[1,2-*b*][1,2]benzothiazin-9,10-diones, catalytic hydrogenation, **84**, 232
- 7,10,10*a*,11-Tetrahydropyrido[1,2-*b*][1,2]benzothiazine-10,11-dione 5,5-dioxides, catalytic hydrogenation, **84**, 232
- 1,3,4,8-Tetrahydropyrido[2,1-*c*][1,4]oxazine-7,9-dicarboxylate, **84**, 272
- 3,4,9,9*a*-Tetrahydro-6*H*-pyrido[1,2-*a*]pyrazin-4-one, **84**, 321
- 6,7,8,9-Tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 207, 254
- 6,7,8,9-Tetrahydro-11*H*-pyrido[2,1-*a*]quinazoline, **85**, 176,
- 6,7,8,9-Tetrahydro-11*H*-pyrido[2,1-*b*]quinazolines, **85**, 259
- 6,7,8,9-Tetrahydro-11*H*-pyrido[2,1-*b*]quinazoline-6,11-dione, reaction with phenylhydrazine, **85**, 261
- 2,3,6,7-Tetrahydro-1*H*,5*H*-pyrido[3,2,1-*ij*]quinazoline-1,3-diones, **84**, 258
- 2,3,6,7-Tetrahydro-1*H*,5*H*-pyrido[3,2,1-*ij*]quinazoline-1,3,7-trione, **84**, 250, 257
- 1,2,3,4-Tetrahydro-6*H*-pyrido[2,1-*b*]quinazolin-6-one, **85**, 262
- 6,7,8,9-Tetrahydro-11*H*-pyrido[2,1-*b*]quinazolin-11-one, **85**, 262
- reaction with benzaldehyde, **85**, 261

- 2,3,4,4a-Tetrahydro-1*H*-pyrido[1,2-*a*]quinazolin-5-oxide, **85**, 262
- 1,2,3,5-Tetrahydropyrido[1,2,3-*de*]quinoline-2,5-dione, **319**
- Δ^1 -Tetrahydropyrimidine, **82**, 161
- 1,4,5,6-Tetrahydropyrimidines, in synthesis of polycyclic compounds, **83**, 242
- 1,2,5,6-Tetrahydropyrrolo[3,2,1-*ij*]quinoline, **84**, 102
- 1,2,3,4-Tetrahydroquinolines, **84**, 100
- reaction with 1-chloro-4-phenoxybut-2-yne, **84**, 105
- 5,6,7,8-Tetrahydroquinolin-4-one, reaction with phenacyl bromides, **84**, 101
- Tetrahydro-*s*-tetrazine, conformations, **81**, 80
- Tetrahydrotetrazines, tautomerism, **81**, 291
- 1,2,3,6-Tetrahydro-1,2,4-triazine 4-oxides, ring-chain tautomerism, **82**, 266
- Tetrahydrotriazolopyridinium-3-oxides, formation, **83**, 5
- 1,3,4,6-Tetrahydro-1,2,4-triazine 4-oxides, formation, **82**, 297
- Tetrakis(3,5-bis(trifluoromethyl)phenyl)boric acid, reaction with tungsten complexes, **81**, 188
- Tetrakis(camphorpyrazol-1-yl)borate, in copper complexes, **81**, 223
- Tetrakis(pyrazol-1-yl)borate, reaction with binuclear metal complexes, **81**, 189
- cyclopalladated complexes, **81**, 220
- in copper complexes, **81**, 223
- in rhodium complexes, **81**, 215
- Tetramethylammonium hydrotris(pyrazol-1-yl)borate, in preparation of titanium complexes, **81**, 171
- 4,4',5,5'-Tetramethyl-2,2'-biimidazole, reaction with rhenium complexes, **83**, 149
- 1,3,4,5-Tetramethyl-2,3-dihydro-1,3-diborole, formation of rhodium complexes, **85**, 7
- 2,4,6,6-Tetramethyldihydropyrimidine, effect of bases, **81**, 269
- 4,4,5,5-Tetramethylimidazoline-3-oxide-1-oxyl radicals, **82**, 79
- 4,4,5,5-Tetramethylimidazoline-1-oxyl radicals, **82**, 79
- 1,3,4,5-Tetramethylimidazol-2-ylidene, complexes with diazaboroles, **83**, 120
- complexes with chromium, molybdenum and tungsten, **83**, 125
- reaction with chromocene, **83**, 125
- complexes with nickelocene, **83**, 135
- reaction with samarium complexes, **83**, 142
- 3,3,6,6-Tetramethyl-1,2,4,5-tetroxane, conformations, **81**, 82
- 1,2,4,5-Tetranitroimidazole, calculated bond lengths, **81**, 10
- 1,3,6,8-Tetranitronaphthalene, reaction with *N*-methyl phenylacetamidines, **83**, 239
- Tetraphenylarsonium tetraazidoaurate (III), reaction with cyclohexyl isonitrile, **83**, 166
- 2,4,6,6-Tetraphenyldihydropyrimidine, tautomerism, **81**, 266
- 2,2,4,6-Tetraphenyldihydro-1,3,5-triazine, photochemical behaviour, **81**, 282
- 1,2,3,5-Tetraphenylpyrimidiniumolate, **81**, 40
- 3,4,5,6-Tetrasubstituted 4,5-dihydropyridazines, structure, **81**, 263
- 1,1',2,2',3,3'-Tetrathiadiazafulvalene, calculated structure, **81**, 39
- Tetrathiadiazafulvalene/tetracyanoethylene complexes, interaction energies, **81**, 27
- 1,2,4,5-Tetrazines, computational studies, **81**, 79
- 1*H*-Tetrazole, computational study of formation, **81**, 30
- metal complexes, **83**, 163
- rhodium complexes, **83**, 165
- Tetrazolopyridazine, ring structure, **81**, 32
- 1,2,3,4-Tetrazolo[1,5-*a*]quinolines, **84**, 173
- 3-(1*H*-Tetrazol-5-yl)-9-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, formation, **85**, 235
- 3-(1*H*-Tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidine, **85**, 219
- 1,3,5,7-Tetroxane, formation, **81**, 82
- Thallium benzotriazolate, reaction with iridium carbonyls, **83**, 158
- Thallium bis(3-*tert*-butyl-5-methylpyrazol-1-yl)borate, complex with aluminum and gallium alkyls, **81**, 168, 169
- Thallium cyclopentadienyl, reaction with cobalt complexes, **85**, 7
- Thallium (η^5 -cyclopentadienyl), reaction with iron complexes, **85**, 22
- Thallium 2,3-di-*tert*-butyl-1,4,2-diphosphatibolyl, reaction with ytterbium, **85**, 43

- Thallium hydrotris(3-*tert*-butylpyrazol-1-yl)borate, reaction with nickel complexes, **81**, 218
- Thallium hydrotris(3-mesitylpyrazolyl)borate, reaction with molybdenum complexes, **81**, 189
- Thallium hydrotris(pyrazol-1-yl)borate, reaction with molybdenum complexes, **81**, 181
- Thallium phenyltris(3-*tert*-butylpyrazol-1-yl)borate, in metal complexes, **81**, 169
- Thallium salts of cyclooctane-1,5-diylbis(pyrazol-1-yl)borate, reaction with palladium complexes, **81**, 221
- Thallium salt of 2,3-di-*tert*-1,2,4-triphosphole, reaction with samarium complexes, **85**, 41
- Thallium tris(3-*tert*-butylpyrazol-1-yl)borate, complex with magnesium alkyls, **81**, 168, 169
- Thallium tris(3-*tert*-butylpyrazol-1-yl)methanesulfonate, in copper complexes, **81**, 223
- Thallium tris(3-mesitylpyrazol-1-yl)borate, reaction with rhodium complexes, **81**, 204
- Thalidastine, **85**, 94, 103
- Thalifendine, **85**, 94
- Thiadiazabicyclo[3.1.0]hexenes, formation, **83**, 74
- 2*H*-1,3,5-Thiadiazine, from 1,2,4-thiadiazole, **81**, 83
- 1,2,6-Thiadiazines, tautomerism, **81**, 286
- 1,3,4,-Thiadiazines, tautomerism, **81**, 285
- Thiadiazine dioxides, formation, **83**, 74
- Thiadiazoles, computational studies, **81**, 37
- reaction with metal carbonyls, **84**, 192
- 1,2,4-Thiadiazole, ring expansion, **81**, 83
- 1,2,5-Thiadiazole *S,S*-dioxides, electrochemistry, **83**, 101
- 1,2,5-Thiadiazole *S*-oxide, **83**, 103
- theoretical studies of conformation, **83**, 98
- electrochemistry, **83**, 101
- 1,2,5-Thiadiazolidine *S,S*-dioxides, reaction with HBr, 102
- oxidation, **83**, 103
- synthesis, **83**, 105
- 1,2,4-Thiadiazolidin-3-one *S,S*-dioxides, isolated as by-products in synthesis of sulfonopeptides, **83**, 99
- 1,2,5-Thiadiazolidine-3-one *S,S*-dioxides, reaction with oxygen nucleophiles, **83**, 103
- synthesis of chiral analogs, **83**, 107
- in *N*-arylsulfonylarginine amides as bioisosteric replacement of guanidine/arginine, **83**, 108
- in pseudonucleosidases, **83**, 108
- Thiadiazoloquinolines, **84**, 173
- 1,2,5-Thiadiborolene, reaction with iron, zinc complexes, **85**, 20
- reaction with manganese carbonyls, **85**, 20
- Thianthrene cation radical, in oxidation of pyridylhydrazones, **83**, 16
- 1,2,4,5(6)-Thiatriazine, thermodynamic stabilities of tautomers, **81**, 292
- 1,2,4,6-Thiatriazine 1,1-dioxides, tautomers, **81**, 292
- Thiazete dioxides, formation, **83**, 74
- Thiazetoquinolines, **84**, 78, 80
- Thiazetoquinoline 3-carboxylic acid derivatives, **84**, 82
- 1,3-Thiazines, structure, **81**, 278
- 1,2-Thiazole, vibrational spectra, **81**, 18, 21
- heteroaromaticity, **83**, 72
- reaction with metal carbonyls, **84**, 192
- Thiazolidine, calculations on reaction with dimethoxyborinium ion, **81**, 23
- Thiazolidine methylidenemalonate, cyclisation, **84**, 160
- Thiazolidine-4-carboxylate *S,S*-dioxide, base-induced cyclization, **83**, 88
- Thiazolidine *S,S*-dioxides, reduction, **83**, 87
- Thiazolidine-2-one *S,S*-dioxides, thermolysis, 89
- formation of chiral, **83**, 94
- Thiazolidin-4-one *S,S*-dioxides, conversion to β -lactams, **83**, 89
- 2-Thiazoline *S,S*-dioxides, formation, **83**, 91
- Thiazolo[3,2-*a*]tetrazole, from 2-azidothiazole, **81**, 32
- Thienobenzothiazole, formation, **83**, 227
- 3-(3-Thienyl)-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 243
- 3-(3-Thienyl)quinoline, **84**, 14
- 1-(2-Thioacetoxybenzoyl)-1,2,3,4-tetrahydropyridin-4-one, hydrolysis, **85**, 193
- Thiocarbamide, reaction with aminobutenones, **82**, 222
- Thiophene, from diacetylene, **82**, 171

- Thiourea, reaction with methoxybutenynes, **82**, 201
reaction with dialkylaminobutenynes, **82**, 202
- 2*H*-Thiopyrans, electroreductions, **81**, 257
- 4*H*-Thiopyrans, lack of tautomeric inter-conversion, **81**, 255
photochemistry, **81**, 257
- 2-Thioxo-4-oxopyrimidines, reaction with 2,4,6-trinitrochlorobenzene, **83**, 201
- 1-Thioxo-1*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates, **84**, 260
- Time-dependent density functional theory, *see* TD-DFT
- Titanium complexes, **81**, 226
- Transition states, calculation of geometries, **81**, 5
- 2-Tolylquinoline, **84**, 12
- 1-*p*-Tolylsulfonyl-3-alkynylpyrazoles, **82**, 12
- 2(*R*),1'(*S*)-1-Tosyl-2-(1'-iodoethyl)piperidine, reaction with tin hydrides, **84**, 231
- 1-Tosyl-4-iodoindole, **82**, 144
- N*-Tosyl-4-iodopyridazoles, reaction with acetylenes, **82**, 30
- Toxoflavine 4-oxides, formation, **82**, 295
- Transmission coefficients, determination of, **81**, 7
- Trazadone, **83**, 54
- Trequinsin, **84**, 225
demethylation, **84**, 255
- 3,5,5-Trialkyl-2(5*H*)furanone, formation, **81**, 113
- 2,4,6-Triamino-1,3,5-triazine, fragmentation, **81**, 77
- 2,3,5-Triaryl-4-imino-substituted 1,2,5-thiadiazolidin *S*-oxides, formation, **83**, 105
- 1,2,3,4-Triazaphospholes, in metal complexes, **85**, 26
- 1,2,3-Triazines, reduction, **81**, 279
- 1,3,6-Triazine dication, calculated multiplicity, **81**, 77
- 1,2,4-Triazine 1,4-dioxides, **82**, 268
- 1,2,4-Triazine mono-*N*-oxides, **82**, 262
mass spectra, **82**, 265
- 1,2,4-Triazine 4-oxides, reduction, **82**, 271
reaction with phenols, **82**, 276
- [1,2,4]Triazino[6,5-*b*]quinolines, **83**, 205
- 1,2,3-Triazoles, computed stability, **81**, 28
flash vacuum photolysis, **81**, 261
formation from 1,2,4-triazine 4-oxides, **82**, 286
- 1*H*-1,2,3-Triazole, from iminodiazomethane, **81**, 30
reaction with osmium carbonyls, **83**, 155
- 1*H*-1,2,4-Triazole, crystal structure, **81**, 29
in carbene complexes, **83**, 159, 161
reaction with gold complexes, **83**, 163
- 1,2,3(4)-Triazole anions, tautomers, **81**, 28
- 1,2,3-Triazole-5-carboxylic acids, **82**, 182
- 1,2,4-Triazole-3,5-diylidene, computational study, **81**, 30
- 1,2,4-Triazole-3-thiol, reaction with chloronitrobenzocoumarins, **83**, 202
- 1,2,4-Triazoline-2,5-dione, ene reaction with isobutene, **81**, 30
- 1,2,4-Triazolium-5-ylidene, computational study, **81**, 30
- [1,2,4]Triazolo[5,1-*c*][1,4]benzoxazines, formation, **83**, 203
- Triazolo-fused pyrimidines, tautomerism, **81**, 270
- 2-*spiro*-Triazolopyridines, **83**, 8
- [1,2,3]-Triazolo[1,5-*a*]pyridine, ¹³*C*-NMR-spectra, **83**, 24
¹⁵*N*-NMR-spectra, **83**, 25
theoretical calculations on site of alkylation, **83**, 26
directed lithiation, **83**, 31
ring opening of the five membered ring, **83**, 43
- [1,2,4]-Triazolo[1,5-*a*]pyridine, ¹³*C*-NMR-spectra, **83**, 24
¹⁵*N*-NMR-spectra, **83**, 25
theoretical calculations on site of alkylation, **83**, 26
directed lithiation, **83**, 34
alkylation, **83**, 35
- [1,2,4]-Triazolo[4,3-*a*]pyridine, ¹³*C*-NMR-spectra, **83**, 24
¹⁵*N*-NMR-spectra, **83**, 25
theoretical calculations on site of alkylation, **83**, 26
alkylation, **83**, 36
- Triazolo[4,5-*b*]pyridines, formation, **83**, 20
- [1,2,3]Triazolo[4,5-*b*]pyridine, alkylation, **83**, 37
- [1,2,3]Triazolo[4,5-*c*]pyridine, arylation, **83**, 37
- Triazoloquinoliny ketoximes, **84**, 170

- 2-[1,2,4-Triazolyl(pyrazolyl)amino]-5-nitropyridine, **84**, 43
- 2-(5- R^1 -1,2,4-Triazolylamino)-3- R^2 -5-nitropyridines, formation, **84**, 43
- 1-[1,2,4-Triazol-3-yl](pyrazol-3-yl)-3- R^2 -5-nitropyridine, **84**, 43
- Triborolyl ligands, in formation of metal sandwich complexes, **85**, 48
- 4-Tributylstannyl-2(5*H*)-furanone, in production of bromofuranones, **81**, 131
- (Tributylstannyl)trimethylsilane, in formation of acrylates from dienoid acids, **81**, 113
- 2,4,5-Trichlorophenol, formation of dioxins, **81**, 71
- 3,4,5-Trichloropyridazine, computational studies, **81**, 43
- 2,4,6-Tri[1-[4-(dimethylamino)pyridinium]]-1,3,5-triazine trichloride, computational studies, **81**, 77
- Triethyl aluminum, complexes with borates, **81**, 169
- 3-Triethylstannyldiacetylene, in 1,3-dipolar cycloadditions, **82**, 4
- 3(5)-Triethylstannylethynylpyrazole, destannylation, **82**, 48
- 3,4,5-Triethynyl-1-methylpyrazole, synthesis, **82**, 45
- 2-*N*-Trifluoroacetyl-amino-5-bromo-4-oxonorvaline methyl ester, **84**, 87
- 1-Trifluoroacetyl-1,2,3,8-tetrahydropyrrolo[2,3-*b*]indole, **82**, 139
- 2-Trifluoromethyl-3-cyano-4-imino-4*H*-pyrido[1,2-*a*]pyrimidines, NMR spectra, **85**, 199
- 2-Trifluoromethyl-3-cyano-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 246
- 2-Trifluoromethyl-3-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **85**, 246
- 11-Trifluoromethyl-1,2,3,4,4*a*,5,8,9-octahydropyrido[1',2':4,5][1,4]oxazino[3,2-*a*]quinolin-9-one, **84**, 275
- 4-Trifluoromethylphenothiazine, **83**, 224
- 2,3,4-Trifluoronitrobenzene, **84**, 107
- Trigollenine, **85**, 75, 124–5, 133
synthesis, **85**, 126
- 5,8,9-Trihydroxy-2,3-dihydro-1*H*-pyrimido[1,2-*a*]quinoline-3-carboxylic acid, **85**, 265
ozonolysis, **85**, 260
- Trihydroxypyrido[2,1-*b*][1,3]oxazines, **85**, 188
- (7*R*)-7 α ,8 β ,9 α -Trihydroxyperhydropyrido[2,1-*b*][1,3]oxazine, **85**, 179
- (7*R*)-7 α ,8 β ,9 β -Trihydroxyperhydropyrido[2,1-*b*][1,3]oxazine, **85**, 179
- 7,8,9-Trihydroxyperhydropyrido[1,2-*a*]pyrazines, **84**, 322
- 7,8,9-Trihydroxyperhydropyrido[1,2-*a*]pyrimidines, **85**, 234
- 1,9,10-Trihydroxy-1,6,7,11*b*-tetrahydro-2*H*,4*H*-[1,3]oxazino[4,3-*a*]isoquinoline-4-one, **84**, 245
- 8,9,10-Trimethoxy-5,13*a*-dihydro-6*H*-[1,3]dioxolo[4,5-*g*]isoquino[3,2-*a*]isoquinolinium-13-olate, **85**, 91
- 2,4,6-Trimethoxy-1,3,5-triazine, formation, **81**, 77
- Trimethyl aluminum, in complexes with borates, **81**, 169
- Trimethyl alane, complexes with imidazolylidenes, **83**, 121
- Trimethyl aluminium, reaction with cobalt complexes, **85**, 9
- 3-(2,4,6-Trimethylbenzoyl)-1,2-dihydro-4*H*-pyrrolo[2,1-*c*][1,4]benzoxazine-1,2,4-trione, **84**, 286
- μ - η^5 : η^5 [2-(2,4,6-Trimethylbenzyl)-1,3,4,5-tetramethyl-2,3-dihydro-1,3-diborolyl](η^3 -allyl)(η^4 -1,5-hexadiene)dinickel, **85**, 18
- 1,4,5-Trimethyl-3-boraneimidazole, formation of anionic carbenes, **83**, 121
- 3,4,5-Trimethyl-4-chloropyrazol-1-yl, in tungsten complexes, **81**, 180
- 1,2,3-Trimethyl-4,5-diethyl-1,3-diboroles, reaction with ruthenium complexes, **85**, 3
- 1,3,5-Trimethyl-4-ethynylpyrazoles, synthesis, **82**, 45
- Trimethyl gallane, complexes with imidazolylidenes, **83**, 121
- 2,2,7-Trimethylguanosine, **85**, 116
- 1,7,9-Trimethylhypoxanthinium, **85**, 130

- 1,3,3-Trimethyl-9-phenyl-1,2,3,6,7,8-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidin-2,4-dione, reaction with Lawesson's reagent, **85**, 208
- 1,2,3-Trimethyl-9-phenyl-1,2,3,6,7,8-hexahydro-4*H*-pyrido[1,2-*a*]pyrimidine-2,4-dione, **85**, 238
- 2-[(2,4,6-Trimethylphenyl)imino]-3-methyl-9-methoxy-10-hydroxy-3,4,6,7-tetrahydro-2*H*-pyrido[6,1-*a*]isoquinolin-4-one, oxidation, **84**, 251
- 3-(2'',4'',6''-Trimethylphenyl)-1-(2'-pyridylmethyl)imidazolium bromide, reaction with silver oxide, **83**, 139
- Trimethylphosphine, reaction with rhodium complexes, **81**, 207
- Trimethylplatinum iodide, reaction with potassium hydrotris(3,5-dimethylpyrazol-1-yl)borate, **81**, 219
- 2-Trimethylsiloxyphenyl isocyanide, reaction with platinum complexes, **84**, 206
- Trimethylsilylacetylene, reaction with lanthanide complexes, **81**, 224
- 2-(2-Trimethylsilylethynylphenoxy)-pyrimidines, **84**, 58
- 4-Trimethylsilylethynylpyrazole, deprotection, **82**, 48
- 3[(Trimethylsilyl)methyl]perhydro-pyrido[1,2-*c*][1,3]oxazin-1-one, **84**, 246
- 2-Trimethylsilyloxy-1,3-butadiene, reaction with furanones, **81**, 142
- (4*S*,9*aS*)-1-Trimethylsilyloxy-4-phenyl-3,4,6,7-tetrahydro-1*H*-pyrido[2,1-*c*][1,4]oxazine, **84**, 280
- hydrogenation, **84**, 272
- 7-Trimethylsilyl[1,2,4] triazolo[4,3-*a*]pyridine, **83**, 31
- 5-Trimethylstannylethynyl-1*H*-pyrazole-3-carboxylic acid ethyl ester, molecular dimensions, **82**, 69
- 2-Trimethylstannyl-6-methylpyridine, in coupling reactions, **84**, 6
- 2(4,5)-Trimethylstannylquinoline, **84**, 8
- 3-Trimethylstannyl quinoline, Stille coupling, **84**, 17
- 8-Trimethylstannylquinoline, formation, **84**, 9
- 1,2,4-Trimethyltriazolium ditriflate, reaction with silver acetate, **83**, 163
- 3,4,5-Tri-(3-*N*-morpholinopropyn-1-yl)-1-methylpyrazoles, **82**, 22
- 1,3,6-Trinitrobenzene, reaction with phenyl acetamidines, **83**, 205
- N*-(2,4,6-Trinitrobenzyl)pyrimidinium salts, reaction with sodium hydroxide, **83**, 207
- 2,4,6-Trinitrochlorobenzene, formation of benzo[*a*]indolizine derivatives, **83**, 208
- reaction with 1,3-propanedithiole, **83**, 242
- 1,2,5-Trinitroimidazole, calculated bond lengths, **81**, 10
- 1,3,6-Trinitroselenazines, formation, **83**, 233
- Trinuclear rhodium (III) complexes, **83**, 160
- 1,2,4-Trioxane, model system for artemisinin, **81**, 82
- 1,3,5-Trioxane, thermal decomposition, **81**, 81
- reaction with formaldehyde, **81**, 82
- 6,8,10-Trioxo-9,10-dihydro-6*H*-pyrido[1,2-*b*]quinoxaline-7,9-dicarboxylate, **84**, 321
- 1,2,5-Triphenylarsole, **82**, 179
- 3,5,6-Triphenyl-1,4-dihydropyridazine, **81**, 262
- 2,4,6-Triphenyl-4-methyl-3,4-dihydropyrimidine, thermolysis, **84**, 34
- 6-(Triphenylphosphoranylidene)amino-1,3-dimethyluracil, **84**, 62
- reaction with dimethyl acetylene dicarboxylate, **84**, 39
- 2,4,6-Triphenylpyridine, **84**, 35
- 1-Triphenylstannyl-3,5-di(*tert*-butyl)-1,2,4-triphosphole, reaction with manganese carbonyls, **85**, 32
- reaction with cobalt carbonyls, **85**, 40
- reaction with nickel compounds, **85**, 41
- 3,5,6,-Triphenyl-1,2,4-triazine, reduction, **81**, 280
- Triphosphacymantrene manganese complexes, **85**, 32
- 1,2,4-Triphosphole anion, reaction with cobalt (II) chloride, **85**, 39
- 1,3,4-Triphosphole metal complexes, **85**, 32
- Triphospholyl anions, formation of ruthenium cyclopentadienyl complexes, **85**, 37
- 1,2,4-Triphospholyl anions, reaction with ruthenium complexes, **85**, 38

- Triple decker complexes of ruthenium, **85**, 9
- Triple-decker cobalt-metal complexes, synthesis, **85**, 11
- 3,5,5-Tris-aryl-2(*SH*)-furanones, reduction, **81**, 129
- Tris(4-benzyl-3,5-dimethylpyrazol-1-yl)borate, in molybdenum complexes, **81**, 175
- Tris(2-cyanophenyl)-1,3,5-triazine, structure, **81**, 77
- Tris(3,5-dimethylpyrazol-1-yl)methane, reaction with niobium complexes, **81**, 172
- Tris(1-ethoxymethylimidazol-2-yl)methanol, ruthenium complexes, **83**, 131
- Tris(imidazol-1-yl)borate, reaction with iron chloride, **83**, 128
- Tris(3-methyl-5-*tert*-butylpyrazol-1-yl)borate, in metal complexes, **81**, 169
- Tris(1-methylimidazol-2-yl)methanol, ruthenium complexes, **83**, 131
- Tris(3-phenylpyrazol-1-yl)borate, complexes, **81**, 169
- Tris(pyrazol-1-yl)borates, as ligands, **81**, 168
- Tris(pyrazol-1-yl)borate anion, complex with molybdenum carbonyls, **81**, 173
- Tris(pyrazol-1-yl)methane, reaction with niobium complexes, **81**, 172
- reaction with iron complexes, **81**, 198
- as a ligand in rhodium and iridium complexes, **81**, 217
- with platinum complexes, **81**, 222
- Tris(3-*p*-tolyl)pyrazol-1-yl)borate, complexes, **81**, 169
- 2,4,6-Trisubstituted dihydropyrimidines, tautomerism, **81**, 266
- 1,6,6a λ^4 -Trithiapentalene, computational study in comparison with 3,4-diaza-1,6,6a λ^4 -trithiapentalene, **81**, 38
- 1-Trityl-4-iodoimidazole, **84**, 10
- Trityl tetrakis(pentafluorophenyl)borate, reaction with tungsten complexes, **81**, 188
- Tryptophan-histidine adducts, calculations on, **81**, 14
- Tubacurarine, **85**, 69
- Tungsten carbonyls, reaction with borates, **81**, 173
- Tungsten complexes, **85**, 9
- Tungsten hexacarbonyl, complexes with imidazolylidenes, **83**, 124
- Turpin synthesis, **83**, 208
- Tyrosine, proton transfer to histidine in enzymes, **81**, 13
- radicals, in photosystem II, **81**, 13
- (R)-(+)-Umbelactone, isolation from plants, **81**, 120
- Ungeremine, **85**, 99
- synthesis, **85**, 100
- 4-Unsubstituted 3,5-diamino-1,2,6-thiadiazine 1,1-dioxide, **81**, 287
- 3,5-Unsubstituted-4*H*-pyrans, **81**, 258
- N*-Unsubstituted 1,2,6-thiadiazine 1,1-dioxides, **81**, 286
- Urocanic acid, calculations on intramolecular hydrogen bonding in, **81**, 8, 14
- δ -Valerolactones, in formation of spiroketals, **82**, 206
- Vallesamidine, synthesis, **85**, 79
- Vanadium, reaction with azaborolines, **85**, 22
- Vanadium complexes, **81**, 226
- Villagorgin B, **85**, 153
- Vilsmeier-Haack formylation of pyridopyrimidones, **85**, 206
- Vincarpin, **85**, 137
- 7-Vinyl-2-alkoxy-3-{4-[2-cyanophenyl]phenyl}methyl}-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, preparation, **85**, 219
- 2-Vinyl-*N,N*-dialkylanilines, thermal cyclisation, **84**, 92
- 2-Vinyl-1,4-dithiins, **82**, 176
- 1-Vinyl-6-fluoro-1,4-dihydroquinoline-2-carboxylic acid, **84**, 271
- 1-Vinylimidazole, complexes with osmium, **83**, 130
- reaction with palladium complexes, **83**, 137
- 1-Vinylpyrroloquinolines, **84**, 103
- 2-Vinylthioquinolines, **84**, 152
- Vitamin B₁, site of protonation, **81**, 295
- Wasabi phytoalexin, reaction with thiolates, **82**, 126
- Xanthine, tautomerism, **81**, 61
- Xestospongine/araguspongine alkaloids, **85**, 175, 190
- Xylyl-bridged bis(triple-decker) cobalt complexes, **85**, 16

5-Ylidenefuranones, formation,
81, 109

Ynaminocarboxylates, reaction with diami-
nobenzene, **82**, 249

Ynaminoketones, reaction with diamines,
82, 241

Ytterbium, reaction with diphosphastiboyls,
85, 43

Zefbetaine, **85**, 102

Zinc complexes, **81**, 225

2-ZnCl-1,3-oxazole, calculated structure,
81, 18